[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSaq9-JBGu9DUi4ayOZPVnRnzGOZx5otUgDfV84uKpYA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Assistance Publique - Hôpitaux de Paris",[4],3482,false,930,460,44677738,354,2494,[14,17,19,22,25,28,31,34],{"name":15,"count":16},"COVID-19",33,{"name":18,"count":16},"Obesity",{"name":20,"count":21},"Sickle Cell Disease",30,{"name":23,"count":24},"Cystic Fibrosis",28,{"name":26,"count":27},"Covid19",24,{"name":29,"count":30},"Breast Cancer",23,{"name":32,"count":33},"Rheumatoid Arthritis",21,{"name":35,"count":36},"Hepatocellular Carcinoma",20,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02716233","A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents","2022-04","pegaspargase 1250 IU\u002Fm2 x 2",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05213104","Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia","2024-02-28","Flecainide",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05195645","AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS","2024-03-05","Abatacept 250 MG",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05458492","Sirolimus in Cutaneous Sarcoidosis","2024-05","Sirolimus",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05054478","Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation","2024-06","Daratumumab",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03274375","Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis","2024-07","IA session",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05232006","PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers","2024-09","Niraparib",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04888221","Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement","2025-01-29","Tocilizumab",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05044611","AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium","2025-03-03","Anhydrous Amiloride Hydrochloride",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05113004","New Clinical End-points in Patients With Primary Sjögren's Syndrome","2025-04-01","Hydroxychloroquine 400mg\u002Fd",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,183,428,472,548,573,591,612,639,657,686,704,722,740,767,785,811,829,854,881,899,925,1070,1233,1297,1360,1419,1482,1540,1596,1636,1658,1696,1794,1840,1888,1915,1956,1993,2031,2069,2098,2137,2170,2207,2235,2274,2300,2327,2345,2370,2388,2406,2424,2442,2468,2492,2520,2538,2556,2574,2592,2615,2638,2656,2681,2699,2720,2746,2764,2787,2814,2832,2858,2876,2902,2920,2943,2961,2987,3014,3032,3050,3068,3096,3114,3132,3157,3175,3202,3220,3242,3260,3284,3307,3334,3352,3379,3405,3423,3441,3459,3484,3510,3528,3554,3572,3598,3616,3634,3660,3685,3703,3727,3755,3773,3791,3809,3835,3853,3878,3906,3929,3952,3975,4001,4019,4037,4055,4082,4100,4125,4143,4161,4187,4212,4230,4255,4279,4304,4328,4346,4364,4388,4416,4442,4466,4484,4511,4529,4556,4574,4599,4617,4643,4661,4687,4705,4723,4753,4771,4789,4815,4839,4863,4889,4907,4932,4959,4977,5002,5020,5038,5056,5074,5096,5121,5209,5273,5316,5359,5392,5445,5500,5533,5583,5618,5671,5712,5758,5790,5825,5860,5887,5921,5950,5972,5995,6019,6044,6062,6080,6104,6128,6152,6174,6192,6210,6235,6253,6280,6300,6323,6346,6371,6397,6415,6433,6451,6474,6497,6515,6539,6565,6590,6608,6633,6651,6677,6695,6718,6742,6760,6782,6804,6826,6851,6873,6898,6916,6939,6962,6980,7006,7024,7042,7060,7083,7101,7119,7139,7163,7181,7205,7232,7256,7281,7299,7317,7335,7353,7371,7389,7407,7425,7443,7461,7479,7497,7522,7540,7558,7582,7602,7624,7647,7713,7738,7756,7779,7803,7920,8097,8173,8195,8283,8354,8398,8433,8454,8479,8497,8523,8541,8566,8589,8611,8635,8653,8680,8698,8722,8747,8765,8788,8813,8831,8849,8873,8897,8915,8940,8964,8988,9006,9029,9056,9074,9092,9118,9136,9154,9172,9190,9214,9232,9257,9279,9305,9323,9341,9366,9384,9412,9430,9448,9466,9484,9502,9520,9538,9564,9587,9610,9637,9661,9684,9709,9727,9752,9770,9792,9810,9828,9852,9897,9940,9969,10004,10039,10074,10099,10117,10141,10165,10183,10201,10219,10243,10266,10289,10312,10335,10361,10379,10402,10420,10445,10471,10489,10515,10539,10557,10582,10600,10623,10641,10663,10686,10704,10728,10746,10770,10788,10815,10837,10855,10880,10898,10923,10946,10970,10994,11012,11030,11054,11077,11104,11122,11140,11158,11180,11203,11227,11245,11269,11297,11315,11337,11363,11381,11399,11423,11448,11466,11491,11509,11532,11550,11575,11601,11624,11649,11667,11691,11709,11733,11751,11774,11796,11820,11842,11865,11891,11909,11932,11958,11976,11994,12018,12036,12061,12079,12127,12182,12226,12278,12325,12351,12388,12416,12438,12480,12502,12524,12546,12568,12600,12634,12669,12708,12740,12774,12814,12846,12874,12896,12932,12959,12982,13006,13024,13048,13074,13092,13110,13128,13146,13164,13182,13205,13223,13246,13274,13292,13317,13335,13353,13371,13396,13414,13438,13462,13488,13506,13530,13548,13571,13594,13617,13641,13659,13677,13700,13727,13745,13770,13788,13811,13834,13857,13886,13904,13928,13952,13977,13995,14018,14044,14062,14080,14098,14123,14141,14166,14184,14202,14225,14249,14267,14288,14313,14331,14349,14372,14390,14408,14426,14448,14473,14497,14515,14540,14566,14584,14611,14635,14653,14676,14699,14722,14746,14764,14789,14813,14836,14861,14879,14901,14925,14943,14968,14991,15009,15027,15045,15063,15090,15117,15135,15158,15176,15200,15224,15251,15269,15287,15309,15335,15353,15371,15389,15411,15435,15460,15478,15506,15524,15542,15564,15591,15609,15633,15651,15675,15698,15716,15744,15762,15780,15805,15823,15847,15872,15893,15911,15929,15954,15972,15996,16023,16041,16059,16084,16109,16127,16151,16169,16194,16212,16234,16258,16282,16300,16318,16336,16354,16381,16399,16421,16442,16467,16494,16512,16530,16554,16580,16598,16621,16644,16662,16689,16707,16725,16743,16768,16786,16809,16827,16852,16870,16893,16916,16939,16965,16983,17006,17024,17042,17064,17087,17109,17132,17154,17181,17199,17223,17247,17265,17283,17305,17331,17349,17373,17395,17419,17444,17462,17487,17505,17530,17548,17573,17599,17624,17649,17667,17692,17710,17731,17753,17777,17801,17823,17848,17866,17884,17902,17920,17938,17956,17981,18005,18028,18046,18069,18087,18105,18128,18152,18176,18204,18222,18249,18272,18297,18315,18339,18361,18386,18404,18427,18445,18471,18489,18515,18538,18561,18582,18606,18631,18649,18672,18690,18714,18739,18761,18786,18804,18828,18846,18864,18886,18913,18936,18959,18985,19041,19076,19113,19138,19173,19209,19243,19274,19305,19327,19351,19376,19402,19428,19446,19464,19482,19500,19525,19547,19574,19592,19616,19640,19658,19676,19699,19732,19754,19772,19790,19808,19826,19850,19872,19890,19915,19937,19955,19973,19996,20021,20042,20064,20088,20109,20130,20148,20166,20184,20202,20220,20243,20265,20291,20309,20327,20349,20371,20394,20417,20440,20458,20484,20502,20520,20544,20570,20588,20606,20629,20651,20675,20699,20721,20746,20771,20793,20817,20840,20858,20876,20894,20918,20941,20964,20986,21011,21029,21047,21069,21091,21118,21136,21159,21186,21204,21230,21248,21275,21293,21317,21341,21364,21391,21409,21427,21445,21468,21493,21519,21537,21559,21584,21602,21620,21638,21663,21686,21707,21729,21753,21776,21801,21819,21844,21862,21884,21907,21933,21956,21978,21996,22014,22032,22056,22074,22098,22116,22140,22165,22183,22208,22232,22255,22273,22294,22316,22339,22365,22383,22401,22423,22446,22469,22493,22516,22534,22556,22578,22601,22622,22646,22664,22682,22705,22728,22753,22771,22794,22815,22837,22858,22884,22902,22920,22942,22964,22986,23007,23025,23047,23070,23094,23117,23142,23160,23183,23205,23227,23245,23268,23291,23309,23330,23354,23377,23400,23423,23450,23468,23486,23504,23522,23540,23558,23579,23601,23623,23645,23706,23742,23781,23829,23864,23898,23927,23961,23994,24021,24056,24085,24115,24141,24170,24198,24223,24247,24265,24283,24305,24323,24341,24364,24385,24403,24428,24452,24470,24491,24515,24539,24563,24581,24602,24626,24652,24674,24697,24722,24746,24764,24782,24808,24831,24857,24875,24900,24922,24945,24966,24988,25009,25030,25057,25075,25093,25111,25136,25158,25181,25204,25227,25253,25276,25298,25321,25345,25369,25387,25405,25428,25446,25464,25487,25505,25530,25552,25575,25601,25619,25637,25662,25687,25705,25728,25754,25772,25795,25817,25841,25859,25877,25898,25923,25941,25964,25988,26006,26028,26050,26074,26095,26118,26139,26162,26188,26206,26224,26248,26271,26298,26327,26345,26363,26381,26399,26417,26435,26458,26476,26500,26521,26546,26567,26590,26612,26634,26658,26680,26704,26727,26745,26770,26794,26817,26835,26859,26881,26904,26928,26946,26968,26992,27015,27038,27060,27083,27105,27123,27145,27169,27187,27211,27229,27247,27269,27296,27319,27341,27364,27388,27414,27437,27458,27480,27502,27523,27546,27564,27589,27612,27630,27653,27671,27689,27712,27735,27759,27777,27801,27823,27849,27873,27895,27919,27937,27958,27983,28006,28029,28054,28077,28100,28124,28150,28173,28191,28213,28235,28257,28282,28304,28329,28351,28369,28392,28417,28439,28465,28483,28507,28525,28543,28561,28579,28597,28615,28633,28651,28669,28687,28705,28723,28741,28759,28777,28795,28813,28831,28849,28867,28885,28903,28926,28948,28970,28995,29013],{"intervention":97,"totalTrials":98,"cells":99},"Standard of care",5,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":121,"PHASE4":164,"NA":181},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT06602557","\" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA).\"","UNKNOWN",[91],"2025-05-15","2026-05-15","2024-11-15",26,[117,118],"Pneumonia, Bacterial","Extracorporeal Membrane Oxygenation",[120,97],"Amikacin",{"trials":122,"activeCount":163,"soonestReadout":154},[123,136,149],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT06859671","A Randomized Study of a Short Duration Therapy for Candidemia","NOT_YET_RECRUITING",[92],"2027-09-01","2025-07-01",362,[132],"CANDIDEMIA",[134,135],"Standard of Care","Shortened duration of antifungal therapy",{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":147},"NCT02664649","Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis","COMPLETED",[92],"2020-10-15","2016-08-26",1510,[145,146],"Symptomatic Aortic Stenosis","Eligible for Transcatheter Aortic Valve Replacement",[148,97],"Apixaban",{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT05545384","Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial","RECRUITING",[92],"2027-04","2030-04","2025-04",86,[159],"Acute Demyelinating Syndrome",[161,162,97],"Immediate Azathioprine","Immediate Rituximab",2,{"trials":165,"activeCount":180,"soonestReadout":171},[166],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":178},"NCT04951856","Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI","ACTIVE_NOT_RECRUITING",[93],"2026-05-22","2028-05-22","2021-09-29",2166,[176,177],"STEMI - ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation MI",[179,97],"Evolocumab 140 MG\u002FML",1,{"trials":182,"activeCount":102},[],{"intervention":184,"totalTrials":33,"cells":185},"Rituximab",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":272,"PHASE4":392,"NA":405},{"trials":187,"activeCount":102},[],{"trials":189,"activeCount":102},[],{"trials":191,"activeCount":180,"soonestReadout":66},[192,199,212,222,238,252,262],{"nctId":64,"briefTitle":65,"status":152,"phases":193,"primaryCompletion":66,"completion":194,"start":195,"enrollment":36,"conditions":196,"interventions":198},[91],"2026-06","2021-06-23",[197],"Anti-NMDAR Encephalitis",[67,184],{"nctId":200,"briefTitle":201,"status":139,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT03069703","Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy",[91],"2020-11-24","2021-11-21","2018-02-05",96,[208],"Invasive Pneumococcal Infection",[210,211,184],"PCV13","PPV23",{"nctId":213,"briefTitle":214,"status":139,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":21,"conditions":218,"interventions":221},"NCT00774462","Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis",[91],"2011-12","2008-01",[219,220],"Myositis","Myasthenia Gravis",[184],{"nctId":223,"briefTitle":224,"status":139,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":232},"NCT03651518","Personalized Therapies in Inflammatory Complex Disease",[91],"2025-11-20","2020-10-20",32,[230,231],"Inflammatory Disease","Autoimmune Diseases",[233,234,235,236,237,184],"Kineret","Humira","Stelara","Cosentyx","Roactemra",{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},"NCT02556866","Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis","TERMINATED",[91],"2018-05-31","2015-07-17",14,[247,248],"Cryoglobulinemia","Systemic Vasculitis",[250,251],"rituximab","Prednisone",{"nctId":253,"briefTitle":254,"status":110,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT03970577","RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome",[91],"2023-11-29","2020-07-29",148,[260],"Minimal Change Nephrotic Syndrome (MCNS)",[184,251],{"nctId":263,"briefTitle":264,"status":139,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT00907751","Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura",[91],"2013-08","2010-05",12,[270],"Thrombotic Thrombocytopenic Purpura",[250],{"trials":273,"activeCount":180,"soonestReadout":288},[274,284,297,307,317,327,338,348,359,370,381],{"nctId":275,"briefTitle":276,"status":139,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT03920722","Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis",[92],"2023-09-06","2020-10-24",8,[282],"Microscopic Polyangiitis (MPA)",[184],{"nctId":285,"briefTitle":286,"status":152,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":295},"NCT04871191","Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis",[92],"2028-10","2029-03","2025-06-06",42,[293,294],"Granulomatosis With Polyangiitis","Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis",[184,77,296],"Tofacitinib",{"nctId":298,"briefTitle":299,"status":139,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT00259974","RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy",[92],"2010-01","2006-04",60,[305],"Polyneuropathy",[184],{"nctId":308,"briefTitle":309,"status":139,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":228,"conditions":314,"interventions":316},"NCT01181154","Rituximab in Auto-Immune Hemolytic Anemia",[92],"2015-01-08","2016-01-08","2011-03-03",[315],"Warm Autoimmune Hemolytic Anemia",[250],{"nctId":318,"briefTitle":319,"status":139,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT01748084","Rituximab in Systemic Sclerosis",[91,92],"2016-04-18","2013-04-09",22,[325],"Systemic Sclerosis",[184],{"nctId":328,"briefTitle":329,"status":139,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":337},"NCT01731561","Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis",[92],"2016-04-05","2012-11-16",166,[293,335,336],"Microscopic Polyangiitis","Renal Limited Forms",[184,184],{"nctId":339,"briefTitle":340,"status":139,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT02433522","Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab",[92],"2018-08-16","2015-03-31",97,[346],"ANCA-associated Vasculitides",[250],{"nctId":349,"briefTitle":350,"status":139,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT02807103","Rituximab in Eosinophilic Granulomatosis With Polyangiitis",[92],"2020-10-21","2016-12-05",107,[356],"Eosinophilic Granulomatosis With Polyangiitis (EGPA)",[184,358],"Cyclophosphamide",{"nctId":360,"briefTitle":361,"status":139,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT03164473","Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.",[92],"2024-09-23","2018-03-07",98,[367],"Eosinophilic Granulomatosis With Polyangiitis",[184,369],"Azathioprine",{"nctId":371,"briefTitle":372,"status":139,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT00327678","Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults",[92],"2014-04","2006-05",1080,[378],"Leukemia, Lymphocytic",[184,380],"Imatinib Mesylate",{"nctId":382,"briefTitle":383,"status":139,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},"NCT00748644","Efficacy Study of Two Treatments in the Remission of Vasculitis",[92],"2013-03","2013-06","2008-10",117,[390,335],"Wegener Granulomatosis",[184,369],{"trials":393,"activeCount":180,"soonestReadout":398},[394],{"nctId":395,"briefTitle":396,"status":126,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":404},"NCT07451847","Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.",[93],"2030-02","2026-02",70,[402,403,282],"ANCA Associated Vasculitis (AAV)","Polyangiitis (GPA)",[184],{"trials":406,"activeCount":102},[407,417],{"nctId":408,"briefTitle":409,"status":139,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":416},"NCT03154385","Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia",[94],"2019-11-13","2017-03-13",15,[415],"Immune Thrombocytopenia",[184],{"nctId":418,"briefTitle":419,"status":139,"phases":420,"completion":421,"start":422,"enrollment":36,"conditions":423,"interventions":426},"NCT00307593","RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides",[94],"2007-06","2004-05",[424,425,335],"Wegener's Granulomatosis","Churg-Strauss Syndrome",[427,184],"Infliximab",{"intervention":148,"totalTrials":429,"cells":430},3,{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":453,"NA":470},{"trials":432,"activeCount":102},[],{"trials":434,"activeCount":102},[],{"trials":436,"activeCount":102},[],{"trials":438,"activeCount":180,"soonestReadout":443},[439,449],{"nctId":440,"briefTitle":441,"status":169,"phases":442,"primaryCompletion":443,"completion":444,"start":445,"enrollment":333,"conditions":446,"interventions":448},"NCT04007289","Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension",[92],"2026-07-31","2026-12-31","2019-06-24",[447],"Intrahepatic Non Cirrhotic Portal Hypertension",[148],{"nctId":137,"briefTitle":138,"status":139,"phases":450,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":451,"interventions":452},[92],[145,146],[148,97],{"trials":454,"activeCount":180,"soonestReadout":459},[455],{"nctId":456,"briefTitle":457,"status":126,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":468},"NCT06486792","Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation",[93],"2025-09-01","2028-03-01","2024-09-01",1148,[464,465,466,467],"Stroke","Ischemic Stroke","Cerebral Infarction","Atrial Fibrillation",[148,469],"Aspirin",{"trials":471,"activeCount":102},[],{"intervention":469,"totalTrials":473,"cells":474},6,{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":516,"NA":546},{"trials":476,"activeCount":102},[],{"trials":478,"activeCount":102},[],{"trials":480,"activeCount":102},[],{"trials":482,"activeCount":102},[483,493,507],{"nctId":484,"briefTitle":485,"status":241,"phases":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":492},"NCT00224679","APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence",[92],"1999-03","1997-03",300,[491],"Colon Adenomas",[469],{"nctId":494,"briefTitle":495,"status":139,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":504},"NCT00562289","Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence",[92],"2016-12","2007-12",664,[465,501,502,503],"Patent Foramen Ovale","Atrial Septal Aneurysm","Migraine",[505,506],"aspirin","Antivitamins K or rivaroxaban or dabigatran or apixaban",{"nctId":508,"briefTitle":509,"status":139,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":27,"conditions":513,"interventions":515},"NCT02906761","Aspirin for Uncontrolled Asthma",[92],"2021-06-17","2019-01-15",[514],"Uncontrolled Asthma",[469],{"trials":517,"activeCount":180,"soonestReadout":459},[518,531,542],{"nctId":519,"briefTitle":520,"status":139,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":529},"NCT00822536","Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation",[93],"2014-09","2009-01",1798,[526,527,528],"Coronary Artery Disease","Stent Thrombosis","Myocardial Ischemia",[530,469],"Aspirin and Clopidogrel",{"nctId":532,"briefTitle":533,"status":139,"phases":534,"primaryCompletion":535,"completion":536,"start":523,"enrollment":537,"conditions":538,"interventions":540},"NCT00827411","Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy",[93],"2012-03","2013-01",2500,[526,539],"Acute Coronary Syndrome",[541,541,541,469],"Aspirin and clopidogrel \u002F Prasugrel",{"nctId":456,"briefTitle":457,"status":126,"phases":543,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":544,"interventions":545},[93],[464,465,466,467],[148,469],{"trials":547,"activeCount":102},[],{"intervention":549,"totalTrials":180,"cells":550},"Continuation of OMA treatment",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":571},{"trials":552,"activeCount":102},[],{"trials":554,"activeCount":102},[],{"trials":556,"activeCount":102},[],{"trials":558,"activeCount":102},[],{"trials":560,"activeCount":180,"soonestReadout":565},[561],{"nctId":562,"briefTitle":563,"status":152,"phases":564,"primaryCompletion":565,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},"NCT04763447","Short Treatment with Omalizumab for Severe Asthma",[93],"2027-05-20","2021-05-20",234,[569],"Asthma",[549],{"trials":572,"activeCount":102},[],{"intervention":179,"totalTrials":180,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":589},{"trials":576,"activeCount":102},[],{"trials":578,"activeCount":102},[],{"trials":580,"activeCount":102},[],{"trials":582,"activeCount":102},[],{"trials":584,"activeCount":180,"soonestReadout":171},[585],{"nctId":167,"briefTitle":168,"status":169,"phases":586,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":587,"interventions":588},[93],[176,177],[179,97],{"trials":590,"activeCount":102},[],{"intervention":82,"totalTrials":180,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":610},{"trials":594,"activeCount":102},[],{"trials":596,"activeCount":102},[],{"trials":598,"activeCount":102},[],{"trials":600,"activeCount":102},[],{"trials":602,"activeCount":180,"soonestReadout":81},[603],{"nctId":79,"briefTitle":80,"status":169,"phases":604,"primaryCompletion":81,"completion":605,"start":606,"enrollment":258,"conditions":607,"interventions":609},[93],"2026-01-11","2023-01-11",[608],"Bipolar Disorder",[82],{"trials":611,"activeCount":102},[],{"intervention":613,"totalTrials":180,"cells":614},"14-day antibiotic therapy",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":623,"NA":637},{"trials":616,"activeCount":102},[],{"trials":618,"activeCount":102},[],{"trials":620,"activeCount":102},[],{"trials":622,"activeCount":102},[],{"trials":624,"activeCount":180,"soonestReadout":629},[625],{"nctId":626,"briefTitle":627,"status":126,"phases":628,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT06203769","Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads",[93],"2028-01-30","2028-06-30","2024-06-30",500,[634],"Cardiac Devices Infection",[613,636],"28-day antibiotic therapy",{"trials":638,"activeCount":102},[],{"intervention":636,"totalTrials":180,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":655},{"trials":642,"activeCount":102},[],{"trials":644,"activeCount":102},[],{"trials":646,"activeCount":102},[],{"trials":648,"activeCount":102},[],{"trials":650,"activeCount":180,"soonestReadout":629},[651],{"nctId":626,"briefTitle":627,"status":126,"phases":652,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":653,"interventions":654},[93],[634],[613,636],{"trials":656,"activeCount":102},[],{"intervention":658,"totalTrials":180,"cells":659},"continuous pivotal βL-AB",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":684},{"trials":661,"activeCount":102},[],{"trials":663,"activeCount":102},[],{"trials":665,"activeCount":102},[],{"trials":667,"activeCount":102},[],{"trials":669,"activeCount":180,"soonestReadout":674},[670],{"nctId":671,"briefTitle":672,"status":152,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":680},"NCT05681442","Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis",[93],"2027-01-04","2027-06-04","2023-11-13",600,[679],"Sepsis",[658,681,682,683],"intermittent pivotal βL-AB","AG infusion most 1 dose","AG infusion for 5 days",{"trials":685,"activeCount":102},[],{"intervention":681,"totalTrials":180,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":702},{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[],{"trials":693,"activeCount":102},[],{"trials":695,"activeCount":102},[],{"trials":697,"activeCount":180,"soonestReadout":674},[698],{"nctId":671,"briefTitle":672,"status":152,"phases":699,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":700,"interventions":701},[93],[679],[658,681,682,683],{"trials":703,"activeCount":102},[],{"intervention":682,"totalTrials":180,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":720},{"trials":707,"activeCount":102},[],{"trials":709,"activeCount":102},[],{"trials":711,"activeCount":102},[],{"trials":713,"activeCount":102},[],{"trials":715,"activeCount":180,"soonestReadout":674},[716],{"nctId":671,"briefTitle":672,"status":152,"phases":717,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":718,"interventions":719},[93],[679],[658,681,682,683],{"trials":721,"activeCount":102},[],{"intervention":683,"totalTrials":180,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":738},{"trials":725,"activeCount":102},[],{"trials":727,"activeCount":102},[],{"trials":729,"activeCount":102},[],{"trials":731,"activeCount":102},[],{"trials":733,"activeCount":180,"soonestReadout":674},[734],{"nctId":671,"briefTitle":672,"status":152,"phases":735,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":736,"interventions":737},[93],[679],[658,681,682,683],{"trials":739,"activeCount":102},[],{"intervention":741,"totalTrials":180,"cells":742},"Ferric carboxymaltose IV",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":765},{"trials":744,"activeCount":102},[],{"trials":746,"activeCount":102},[],{"trials":748,"activeCount":102},[],{"trials":750,"activeCount":102},[],{"trials":752,"activeCount":180,"soonestReadout":757},[753],{"nctId":754,"briefTitle":755,"status":152,"phases":756,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":763},"NCT06833788","Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression",[93],"2028-06-22","2028-10-30","2025-10-22",2860,[762],"Postpartum Depression (PPD)",[741,764],"TIMOFÉROL®",{"trials":766,"activeCount":102},[],{"intervention":764,"totalTrials":180,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":783},{"trials":770,"activeCount":102},[],{"trials":772,"activeCount":102},[],{"trials":774,"activeCount":102},[],{"trials":776,"activeCount":102},[],{"trials":778,"activeCount":180,"soonestReadout":757},[779],{"nctId":754,"briefTitle":755,"status":152,"phases":780,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":781,"interventions":782},[93],[762],[741,764],{"trials":784,"activeCount":102},[],{"intervention":786,"totalTrials":180,"cells":787},"IV Antibacterial Agents",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":809},{"trials":789,"activeCount":102},[],{"trials":791,"activeCount":102},[],{"trials":793,"activeCount":102},[],{"trials":795,"activeCount":102},[],{"trials":797,"activeCount":180,"soonestReadout":802},[798],{"nctId":799,"briefTitle":800,"status":152,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT05544565","3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children",[93],"2028-01","2023-03-22",480,[806],"Pyelonephritis Acute",[786,808],"Orally antibacterial agents",{"trials":810,"activeCount":102},[],{"intervention":808,"totalTrials":180,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":827},{"trials":814,"activeCount":102},[],{"trials":816,"activeCount":102},[],{"trials":818,"activeCount":102},[],{"trials":820,"activeCount":102},[],{"trials":822,"activeCount":180,"soonestReadout":802},[823],{"nctId":799,"briefTitle":800,"status":152,"phases":824,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":825,"interventions":826},[93],[806],[786,808],{"trials":828,"activeCount":102},[],{"intervention":830,"totalTrials":180,"cells":831},"Rivaroxaban group",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":852},{"trials":833,"activeCount":102},[],{"trials":835,"activeCount":102},[],{"trials":837,"activeCount":102},[],{"trials":839,"activeCount":102},[],{"trials":841,"activeCount":180,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":126,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT05487950","Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk",[93],"2027-04-05","2023-04-05",550,[850],"Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)",[830],{"trials":853,"activeCount":102},[],{"intervention":855,"totalTrials":180,"cells":856},"Experimental group",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":879},{"trials":858,"activeCount":102},[],{"trials":860,"activeCount":102},[],{"trials":862,"activeCount":102},[],{"trials":864,"activeCount":102},[],{"trials":866,"activeCount":180,"soonestReadout":871},[867],{"nctId":868,"briefTitle":869,"status":126,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":877},"NCT05784051","Prophylactic Frequent Premature Ventricular complexeS sUPPression on Left ventriculaR Function impairmEnt in aSymptomatic patientS",[93],"2027-06-01","2023-10-01",298,[875,876],"Premature Ventricular Contractions","Ventricular Dysfunction, Left",[855,878],"Control group",{"trials":880,"activeCount":102},[],{"intervention":878,"totalTrials":180,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":897},{"trials":884,"activeCount":102},[],{"trials":886,"activeCount":102},[],{"trials":888,"activeCount":102},[],{"trials":890,"activeCount":102},[],{"trials":892,"activeCount":180,"soonestReadout":871},[893],{"nctId":868,"briefTitle":869,"status":126,"phases":894,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":895,"interventions":896},[93],[875,876],[855,878],{"trials":898,"activeCount":102},[],{"intervention":900,"totalTrials":180,"cells":901},"Course of amoxicillin",{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":908,"PHASE4":910,"NA":923},{"trials":903,"activeCount":102},[],{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":102},[],{"trials":909,"activeCount":102},[],{"trials":911,"activeCount":180,"soonestReadout":916},[912],{"nctId":913,"briefTitle":914,"status":126,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":922},"NCT07104552","Comparing Short to Standard Amoxicillin Course for Erysipelas",[93],"2029-01-12","2029-02-01","2026-01-01",656,[921],"Erysipelas",[900],{"trials":924,"activeCount":102},[],{"intervention":251,"totalTrials":268,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":970,"PHASE4":1020,"NA":1044},{"trials":928,"activeCount":102},[],{"trials":930,"activeCount":102},[],{"trials":932,"activeCount":102},[933,948,952,966],{"nctId":934,"briefTitle":935,"status":936,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":946},"NCT04844814","Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4\u002F5 or Renal Transplantation","SUSPENDED",[91],"2025-02-12","2026-08-31","2022-06-02",204,[943,944,945],"Gout","Chronic Kidney Disease","Renal Transplantation",[947,251],"Anakinra 100Mg\u002F0.67Ml Inj Syringe",{"nctId":239,"briefTitle":240,"status":241,"phases":949,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":950,"interventions":951},[91],[247,248],[250,251],{"nctId":953,"briefTitle":954,"status":139,"phases":955,"primaryCompletion":956,"completion":536,"start":957,"enrollment":958,"conditions":959,"interventions":963},"NCT00508040","Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a",[91],"2011-10","2007-09",58,[960,961,962],"Birdshot Chorioretinopathy","Cystoid Macular Edema","Transient Partial Visual Loss",[964,965],"interferon alpha 2a","prednisone",{"nctId":253,"briefTitle":254,"status":110,"phases":967,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":968,"interventions":969},[91],[260],[184,251],{"trials":971,"activeCount":102},[972,984,995,1008],{"nctId":973,"briefTitle":974,"status":110,"phases":975,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":982},"NCT02627417","Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia",[92],"2019-05","2015-12",216,[980,981],"Adult Immune Thrombocytopenia (ITP)","Dapsone",[981,983,251],"Prednisone (Cortancyl®) alone followed by monitoring and \"standard of care\"",{"nctId":985,"briefTitle":986,"status":139,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":388,"conditions":991,"interventions":993},"NCT01197040","Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome",[92],"2014-07","2015-06","2009-10",[992],"Nephrotic Syndrome",[251,994],"acid mycophenolic",{"nctId":996,"briefTitle":997,"status":241,"phases":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1006},"NCT00307645","IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis",[92],"2009-08","2003-05",160,[1003,1004,1005],"ANCA Associated Systemic Vasculitis Including Wegener's","Granulomatosis and Microscopic Polyangiitis and","Renal Limited Vasculitis",[358,1007,369,251],"Mycophenolate mofetil",{"nctId":1009,"briefTitle":1010,"status":110,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1018},"NCT05247554","Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis",[92],"2023-03-01","2024-03-01","2022-03-01",200,[1017],"Pulmonary Sarcoidosis",[1019,251],"Hydroxychloroquine + low-dose prednisone",{"trials":1021,"activeCount":180,"soonestReadout":1026},[1022,1033],{"nctId":1023,"briefTitle":1024,"status":152,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},"NCT05428826","Early Discontinuation of Steroid Treatment in Negative FDG-PET\u002FCT Patients With Idiopathic Retroperitoneal Fibrosis",[93],"2026-11-25","2028-11-25","2022-11-25",41,[1031],"Idiopathic Retroperitoneal Fibrosis",[251],{"nctId":1034,"briefTitle":1035,"status":139,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1043},"NCT02330952","Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD",[93],"2017-05-23","2015-02-10",189,[1041,1042],"Pulmonary Disease","Chronic Obstructive (MeSH)",[251],{"trials":1045,"activeCount":102},[1046,1058],{"nctId":1047,"briefTitle":1048,"status":110,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT01987076","Comparison Between Corticosteroid and Topical Steroids in the DRESS",[94],"2015-10","2016-10","2013-10",112,[1055],"Drug Rash With Eosinophilia and Systemic Symptoms",[251,1057],"Clobetasol",{"nctId":1059,"briefTitle":1060,"status":139,"phases":1061,"primaryCompletion":1062,"completion":1062,"start":1063,"enrollment":1015,"conditions":1064,"interventions":1069},"NCT01407484","Male Infertility Related With Post Infection Inflammatory Syndrome",[94],"2015-05-14","2011-03-02",[1065,1066,1067,1068],"Male Infertility","Leukopenia","Postinfection Inflammation","Oxidative Stress",[251],{"intervention":77,"totalTrials":268,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1176,"PHASE4":1229,"NA":1231},{"trials":1073,"activeCount":102},[],{"trials":1075,"activeCount":102},[],{"trials":1077,"activeCount":429,"soonestReadout":1105},[1078,1091,1101,1112,1123,1134,1153],{"nctId":1079,"briefTitle":1080,"status":139,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1053,"conditions":1085,"interventions":1088},"NCT02929251","Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis",[91],"2021-10-29","2022-01-29","2017-06-29",[1086,1087],"Uveitis","Biotherapy",[1089,77,1090],"Anakinra","Adalimumab",{"nctId":1092,"briefTitle":1093,"status":126,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":303,"conditions":1098,"interventions":1100},"NCT05874505","\"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease\"",[91],"2026-11","2027-07","2023-07",[1099],"Behcet's Uveitis",[1090,77],{"nctId":1102,"briefTitle":1103,"status":126,"phases":1104,"primaryCompletion":1105,"completion":1106,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1111},"NCT07254637","Tocilizumab in Chronic Inflammatory CPPD Disease",[91],"2026-10","2029-11","2026-04",80,[1110],"Calcium Pyrophosphate Deposition Disease",[77],{"nctId":1113,"briefTitle":1114,"status":139,"phases":1115,"primaryCompletion":1116,"completion":1117,"start":1118,"enrollment":1119,"conditions":1120,"interventions":1122},"NCT04331808","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)",[91],"2020-05-04","2020-11-09","2020-03-30",228,[1121],"Corona Virus Infection",[77],{"nctId":1124,"briefTitle":1125,"status":110,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1133},"NCT04564001","Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis",[91],"2021-02","2023-09","2020-09",50,[1132],"Takayasu Arteritis",[427,77],{"nctId":1135,"briefTitle":1136,"status":139,"phases":1137,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1151},"NCT04476979","Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19",[91],"2021-06-01","2021-08-11","2020-07-16",453,[1143,1144,1145,1146,1147,1148,1149,1150],"Coronavirus Infection","SARS (Severe Acute Respiratory Syndrome)","Virus Diseases","Coronaviridae Infections","Nidovirales Infections","RNA Virus Infections","Respiratory Tract Infections","Respiratory Tract Disease",[77,1152],"Dexamethasone",{"nctId":1154,"briefTitle":1155,"status":126,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1162},"NCT06381661","Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial",[91],"2028-06-01","2031-05-01","2026-05-01",2000,[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],"Baricitinib","Hydrocortisone","Hydrocortisone and fludrocortisone","Heparin","Low molecular weight heparin","Recombinant humanThrombomodulin","Sivelestat","G-CSF filgrastim","Interferon gamma-1b","Fludrocortisone","Prophylactic unfractionated heparin","Octaplas LG","Plasminogen",{"trials":1177,"activeCount":163,"soonestReadout":76},[1178,1182,1195,1209,1218],{"nctId":285,"briefTitle":286,"status":152,"phases":1179,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":1180,"interventions":1181},[92],[293,294],[184,77,296],{"nctId":1183,"briefTitle":1184,"status":139,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT02477059","Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis",[92],"2018-12-26","2019-02","2015-11-20",104,[1191],"Hand Osteoarthritis",[1193,1194],"tocilizumab","saline solution",{"nctId":1196,"briefTitle":1197,"status":139,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT02840175","Treatment Tapering in JIA With Inactive Disease",[92],"2019-10-29","2020-10-01","2017-05-18",62,[1204],"Juvenile Idiopathic Arthritis",[1206,1207,1208,77],"etanercept","adalimumab","Abatacept",{"nctId":74,"briefTitle":75,"status":169,"phases":1210,"primaryCompletion":76,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1217},[92],"2025-08-13","2021-09-24",66,[1215,1216],"Giant Cell Arteritis","Neurovascular Disorder",[77],{"nctId":1219,"briefTitle":1220,"status":139,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1228},"NCT02101333","Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis",[92],"2018-12-10","2019-02-01","2014-06-10",18,[1227],"TAKAYASU ARTERITIS",[77],{"trials":1230,"activeCount":102},[],{"trials":1232,"activeCount":102},[],{"intervention":1163,"totalTrials":98,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1282,"PHASE4":1293,"NA":1295},{"trials":1236,"activeCount":102},[],{"trials":1238,"activeCount":102},[],{"trials":1240,"activeCount":429,"soonestReadout":1157},[1241,1251,1266,1270],{"nctId":1242,"briefTitle":1243,"status":152,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1250},"NCT06490757","A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas",[91],"2028-09-02","2024-10-02",25,[1249],"Inflammatory Hepatocellular Adenoma",[1163],{"nctId":1252,"briefTitle":1253,"status":139,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1261},"NCT05524311","Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)",[91],"2025-05-13","2026-01-02","2022-11-10",16,[1260],"Juvenile Dermatomyositis",[1163,1262,1263,1264,1265],"pharmacokinetics study","dosage of cytokines","transcriptomic analysis","Pregnancy test",{"nctId":1154,"briefTitle":1155,"status":126,"phases":1267,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1268,"interventions":1269},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"nctId":1271,"briefTitle":1272,"status":126,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":1278,"interventions":1280},"NCT07268534","Biologics in Folliculitis Decalvans : an Adaptative Trial Research",[91],"2029-11-01","2030-04-01","2026-04-01",120,[1279],"Folliculitis Decalvans (FD)",[1090,1281,1163],"Ustekinumab",{"trials":1283,"activeCount":180,"soonestReadout":1288},[1284],{"nctId":1285,"briefTitle":1286,"status":152,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":1202,"conditions":1290,"interventions":1292},"NCT04972760","Baricitinib in Patients With Relapsing or naïve Dermatomyositis",[92],"2028-02-28","2022-08-31",[1291],"Dermatomyositis",[1163],{"trials":1294,"activeCount":102},[],{"trials":1296,"activeCount":102},[],{"intervention":1298,"totalTrials":1299,"cells":1300},"Fecal Microbiota Transplantation",4,{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1321,"PHASE4":1356,"NA":1358},{"trials":1302,"activeCount":102},[],{"trials":1304,"activeCount":102},[],{"trials":1306,"activeCount":180,"soonestReadout":1311},[1307],{"nctId":1308,"briefTitle":1309,"status":126,"phases":1310,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1318},"NCT07477782","Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation",[91],"2029-04","2030-05","2026-05",72,[1316,1317],"Primary Sclerosing Cholangitis (PSC)","Inflammatory Bowel Disease (IBD)",[1319,1320],"Fecal microbiota transplantation","Sham-transplantation",{"trials":1322,"activeCount":429,"soonestReadout":1349},[1323,1334,1345],{"nctId":1324,"briefTitle":1325,"status":152,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1333},"NCT04997733","Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal",[92],"2027-05-22","2029-07-22","2021-09-22",150,[1332],"Crohn Disease",[1298,1320],{"nctId":1335,"briefTitle":1336,"status":152,"phases":1337,"primaryCompletion":1313,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1343},"NCT05035342","Fecal Transplantation to Eradicate Colonizing Emergent Superbugs",[92],"2028-04","2024-01-11",214,[1342,1298],"Enterobacteriaceae Infections",[1344],"Fecal Microbiota Transplantation (FMT)",{"nctId":1346,"briefTitle":1347,"status":169,"phases":1348,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1330,"conditions":1352,"interventions":1354},"NCT03483246","Impact of Fecal Microbiota Transplantation in Ulcerative Colitis",[92],"2025-09-16","2027-03-27","2018-09-17",[1353],"Ulcerative Colitis",[1298,1355],"Sham-transplantation Placebo",{"trials":1357,"activeCount":102},[],{"trials":1359,"activeCount":102},[],{"intervention":1090,"totalTrials":1361,"cells":1362},7,{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1392,"PHASE4":1415,"NA":1417},{"trials":1364,"activeCount":102},[],{"trials":1366,"activeCount":102},[],{"trials":1368,"activeCount":163,"soonestReadout":1095},[1369,1373,1377,1388],{"nctId":1079,"briefTitle":1080,"status":139,"phases":1370,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1053,"conditions":1371,"interventions":1372},[91],[1086,1087],[1089,77,1090],{"nctId":1092,"briefTitle":1093,"status":126,"phases":1374,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":303,"conditions":1375,"interventions":1376},[91],[1099],[1090,77],{"nctId":1378,"briefTitle":1379,"status":139,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT02113904","Clinical Trial Using Humira in Netherton Syndrome",[91],"2016-12-20","2017-09-21","2014-01-27",11,[1386],"Netherton Syndrome",[1090],{"nctId":1271,"briefTitle":1272,"status":126,"phases":1389,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":1390,"interventions":1391},[91],[1279],[1090,1281,1163],{"trials":1393,"activeCount":180,"soonestReadout":871},[1394,1398,1406],{"nctId":1196,"briefTitle":1197,"status":139,"phases":1395,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1396,"interventions":1397},[92],[1204],[1206,1207,1208,77],{"nctId":1399,"briefTitle":1400,"status":139,"phases":1401,"primaryCompletion":1402,"completion":1402,"start":375,"enrollment":1403,"conditions":1404,"interventions":1405},"NCT00305539","HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis",[92],"2011-05",69,[1215],[1207],{"nctId":1407,"briefTitle":1408,"status":126,"phases":1409,"primaryCompletion":871,"completion":1410,"start":1013,"enrollment":1277,"conditions":1411,"interventions":1413},"NCT06258915","Treatment FOr Corticosteroid Dependent UveitiS",[92],"2027-11-01",[1412],"Non Infectious Uveitis",[1090,1414],"Mycophenolate Mofetil",{"trials":1416,"activeCount":102},[],{"trials":1418,"activeCount":102},[],{"intervention":1089,"totalTrials":473,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1456,"PHASE4":1478,"NA":1480},{"trials":1422,"activeCount":102},[],{"trials":1424,"activeCount":102},[],{"trials":1426,"activeCount":180,"soonestReadout":1157},[1427,1431,1441,1452],{"nctId":1079,"briefTitle":1080,"status":139,"phases":1428,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1053,"conditions":1429,"interventions":1430},[91],[1086,1087],[1089,77,1090],{"nctId":1432,"briefTitle":1433,"status":139,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1440},"NCT04341584","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection",[91],"2020-05-10","2020-07-25","2020-04-08",161,[1121],[1089],{"nctId":1442,"briefTitle":1443,"status":139,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1258,"conditions":1448,"interventions":1451},"NCT02390596","Anakinra and Kawasaki Disease",[91],"2019-01-21","2019-02-18","2016-02-05",[1449,1450],"Kawasaki Disease","Children",[1089],{"nctId":1154,"briefTitle":1155,"status":126,"phases":1453,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":1454,"interventions":1455},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":1457,"activeCount":163,"soonestReadout":1462},[1458,1468],{"nctId":1459,"briefTitle":1460,"status":152,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1130,"conditions":1464,"interventions":1466},"NCT06336733","Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy",[92],"2026-12-04","2024-06-04",[1465],"FMF",[1467],"ANAKINRA",{"nctId":1469,"briefTitle":1470,"status":152,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1476},"NCT04656184","A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment",[92],"2027-03","2023-10-20",84,[1449],[1467,1477],"Intravenous immunoglobulin",{"trials":1479,"activeCount":102},[],{"trials":1481,"activeCount":102},[],{"intervention":1483,"totalTrials":1299,"cells":1484},"Metformin",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1503,"PHASE4":1536,"NA":1538},{"trials":1486,"activeCount":102},[],{"trials":1488,"activeCount":102},[],{"trials":1490,"activeCount":180,"soonestReadout":1495},[1491],{"nctId":1492,"briefTitle":1493,"status":152,"phases":1494,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1502},"NCT06687265","Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension",[91],"2027-03-30","2027-07-31","2025-03-10",76,[1500,1501],"Cirrhosis","Portal Hypertension Related to Cirrhosis",[1483],{"trials":1504,"activeCount":163,"soonestReadout":1529},[1505,1513,1525],{"nctId":1506,"briefTitle":1507,"status":241,"phases":1508,"primaryCompletion":1509,"completion":1509,"start":989,"enrollment":1384,"conditions":1510,"interventions":1512},"NCT02319200","Primary Prevention Hepatocellular Carcinoma by Metformin",[92],"2016-04",[35,1511,1500],"Hepatitis C, Chronic",[1483],{"nctId":1514,"briefTitle":1515,"status":169,"phases":1516,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1524},"NCT04583462","Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes",[92],"2027-09-29","2027-10-29","2021-06-02",230,[1522,1523],"Type 1 Diabetes","Peripheral Arterial Calcification",[1483],{"nctId":1526,"briefTitle":1527,"status":152,"phases":1528,"primaryCompletion":1529,"completion":1095,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1535},"NCT04581447","Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care",[92],"2026-07","2021-01-07",126,[1533,1534,1483],"Diabetes","Bariatric Surgery",[1483],{"trials":1537,"activeCount":102},[],{"trials":1539,"activeCount":102},[],{"intervention":1541,"totalTrials":1299,"cells":1542},"Chemotherapy",{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1557,"PHASE3":1559,"PHASE4":1592,"NA":1594},{"trials":1544,"activeCount":102},[],{"trials":1546,"activeCount":180,"soonestReadout":1551},[1547],{"nctId":1548,"briefTitle":1549,"status":126,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":268,"conditions":1553,"interventions":1555},"NCT04062721","Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases",[90],"2028-11","2025-08",[1554],"Unresectable Colorectal Liver Metastases",[1541,1556],"In situ immunotherapy",{"trials":1558,"activeCount":102},[],{"trials":1560,"activeCount":180,"soonestReadout":1565},[1561,1573,1583],{"nctId":1562,"briefTitle":1563,"status":152,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1571},"NCT03875781","Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer",[92],"2026-12-05","2019-06-05",540,[1569,1570],"Rectal Cancer","Advanced Cancer",[1541,1572],"Radiochemotherapy",{"nctId":1574,"briefTitle":1575,"status":110,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":988,"enrollment":1578,"conditions":1579,"interventions":1582},"NCT02363049","Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer",[92],"2018-07",278,[1580,1581],"Malignant Neoplasm of Large Intestine","Colon Cancer Liver Metastasis",[1541],{"nctId":1584,"briefTitle":1585,"status":139,"phases":1586,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":1015,"conditions":1589,"interventions":1591},"NCT00428558","Timed-Sequential Induction in CBF-AML",[92],"2011-06","2007-07",[1590],"Acute Myeloid Leukemia",[1541,1541],{"trials":1593,"activeCount":102},[],{"trials":1595,"activeCount":102},[],{"intervention":1597,"totalTrials":163,"cells":1598},"standard antibiotic therapy",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1605,"PHASE4":1632,"NA":1634},{"trials":1600,"activeCount":102},[],{"trials":1602,"activeCount":102},[],{"trials":1604,"activeCount":102},[],{"trials":1606,"activeCount":163,"soonestReadout":1622},[1607,1618],{"nctId":1608,"briefTitle":1609,"status":152,"phases":1610,"primaryCompletion":1611,"completion":444,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1616},"NCT05696093","Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit",[92],"2026-10-31","2023-10-19",628,[1615],"Ventilator Associated Pneumonia",[1617,1597],"cotrimoxazole",{"nctId":1619,"briefTitle":1620,"status":152,"phases":1621,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1629},"NCT05117398","Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus",[92],"2025-09-23","2026-09-23","2023-06-23",406,[1627,1628],"Catheter Bacteremia","Staphylococcus Aureus Infection",[1630,1631],"Dalbavancin administration","Standard antibiotic therapy",{"trials":1633,"activeCount":102},[],{"trials":1635,"activeCount":102},[],{"intervention":1320,"totalTrials":163,"cells":1637},{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1648,"PHASE4":1654,"NA":1656},{"trials":1639,"activeCount":102},[],{"trials":1641,"activeCount":102},[],{"trials":1643,"activeCount":180,"soonestReadout":1311},[1644],{"nctId":1308,"briefTitle":1309,"status":126,"phases":1645,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":1646,"interventions":1647},[91],[1316,1317],[1319,1320],{"trials":1649,"activeCount":180,"soonestReadout":1327},[1650],{"nctId":1324,"briefTitle":1325,"status":152,"phases":1651,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1652,"interventions":1653},[92],[1332],[1298,1320],{"trials":1655,"activeCount":102},[],{"trials":1657,"activeCount":102},[],{"intervention":1659,"totalTrials":163,"cells":1660},"Tadalafil",{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1692,"NA":1694},{"trials":1662,"activeCount":102},[],{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":163,"soonestReadout":1673},[1669,1679],{"nctId":1670,"briefTitle":1671,"status":152,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":1015,"conditions":1675,"interventions":1678},"NCT05844462","Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease",[92],"2027-09","2024-02-01",[1676,1677],"Pulmonary Hypertension","Chronic Obstructive Pulmonary Disease",[1659],{"nctId":1680,"briefTitle":1681,"status":152,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1690},"NCT07245680","COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities",[92],"2029-02-14","2026-04-28",186,[1687,1688,1689],"Pulmonary Arterial Hypertension (PAH)","Comorbidities","Cardiovascular Disease (CVD)",[1659,1691],"Ambrisentan",{"trials":1693,"activeCount":102},[],{"trials":1695,"activeCount":102},[],{"intervention":1152,"totalTrials":1361,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1724,"PHASE4":1781,"NA":1783},{"trials":1699,"activeCount":102},[],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[1704,1720],{"nctId":1705,"briefTitle":1706,"status":139,"phases":1707,"primaryCompletion":1708,"completion":301,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1716},"NCT00763763","Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",[91],"2007-10","2004-12",55,[1712,1713,1714,1715],"Leukemia, Lymphocytic, Acute","Philadelphia Chromosome","Blast Crisis","Leukemia, Myeloid, Chronic",[1717,1718,1719,1152],"Imatinib mesylate","Interferon","Vincristine",{"nctId":1135,"briefTitle":1136,"status":139,"phases":1721,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":1141,"conditions":1722,"interventions":1723},[91],[1143,1144,1145,1146,1147,1148,1149,1150],[77,1152],{"trials":1725,"activeCount":163,"soonestReadout":1775},[1726,1743,1760,1771],{"nctId":1727,"briefTitle":1728,"status":110,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT02611492","A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults",[92],"2020-12","2025-12",265,[1734],"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia",[1736,1737,1738,1739,1740,1152,1719,1741,1742],"Nilotinib","Methotrexate","Aracytine","Granulocyte Colony-Stimulating Factor","Depomedrol","Imatinib","6 Mercaptopurine",{"nctId":1744,"briefTitle":1745,"status":139,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1758},"NCT03555929","Impact on Sensitivity and Motor Block Duration of an Intravenous Dexamethasone an Axillary Block With Mepivacaine.",[92],"2018-10-15","2018-10-16","2018-04-04",52,[1752,1753,1754,1755,1756,1757],"Hand Wound","Wrist Wound","Forearm Wound","Hand Fracture","Wrist Fracture","Forearm Fracture",[1152,1759],"Normal saline",{"nctId":1761,"briefTitle":1762,"status":152,"phases":1763,"primaryCompletion":1764,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1770},"NCT06561854","Study Comparing Therapy for Advanced Relapsed\u002FRefractory Multiple Myeloma With and Without Dexamethasone",[92],"2028-12","2024-12-12",318,[1768,1769],"Multiple Myeloma","Relapse Multiple Myeloma",[1152],{"nctId":1772,"briefTitle":1773,"status":126,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":400,"conditions":1778,"interventions":1780},"NCT07084285","Cervical Facet Injection of Corticosteroids for the Management of Cervicobrachialgia",[92],"2028-02","2028-05","2026-01",[1779],"Cervicobrachial Neuralgia",[1152],{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":102},[1785],{"nctId":1786,"briefTitle":1787,"status":110,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":848,"conditions":1791,"interventions":1793},"NCT04344730","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia",[94],"2021-12-31","2020-04-10",[1792,15],"Acute Hypoxemic Respiratory Failure",[1152],{"intervention":1795,"totalTrials":429,"cells":1796},"Morphine",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1825,"NA":1827},{"trials":1798,"activeCount":102},[],{"trials":1800,"activeCount":102},[],{"trials":1802,"activeCount":102},[],{"trials":1804,"activeCount":163,"soonestReadout":1775},[1805,1814],{"nctId":1806,"briefTitle":1807,"status":126,"phases":1808,"primaryCompletion":1809,"completion":1809,"start":194,"enrollment":1810,"conditions":1811,"interventions":1812},"NCT07445737","Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction",[92],"2029-06",700,[176],[1813,1795],"Methoxyflurane",{"nctId":1815,"briefTitle":1816,"status":152,"phases":1817,"primaryCompletion":1775,"completion":1775,"start":1818,"enrollment":489,"conditions":1819,"interventions":1821},"NCT06464146","Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine",[92],"2025-02-26",[1820],"Limb Injury",[1795,1822,1823,1824],"IN fentanyl","IN ketamine","NaCl 0,9 %",{"trials":1826,"activeCount":102},[],{"trials":1828,"activeCount":102},[1829],{"nctId":1830,"briefTitle":1831,"status":139,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1225,"conditions":1835,"interventions":1837},"NCT00797264","Ketamine Associated With Morphine PCA After Total Hip Arthroplasty",[94],"2010-10","2008-11",[1836],"Arthroplasty, Replacement, Hip",[1838,1795,1839],"Ketamine-Morphine","Postoperative PCA of Ketamine and morphine",{"intervention":1841,"totalTrials":429,"cells":1842},"Letermovir",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1873,"NA":1875},{"trials":1844,"activeCount":102},[],{"trials":1846,"activeCount":102},[],{"trials":1848,"activeCount":102},[],{"trials":1850,"activeCount":163,"soonestReadout":1673},[1851,1862],{"nctId":1852,"briefTitle":1853,"status":152,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1473,"enrollment":1856,"conditions":1857,"interventions":1860},"NCT05446571","Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir",[92],"2029-08",46,[1858,1859],"Pregnant Women","CMV Infected Fetuses",[1841,1861],"Valacyclovir",{"nctId":1863,"briefTitle":1864,"status":152,"phases":1865,"primaryCompletion":1673,"completion":1866,"start":1867,"enrollment":1108,"conditions":1868,"interventions":1870},"NCT06334497","Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections",[92],"2027-11","2024-08-14",[1869],"Cytomegalovirus Infection",[1841,1871,1872],"Valganciclovir","Letermovir placebo",{"trials":1874,"activeCount":102},[],{"trials":1876,"activeCount":102},[1877],{"nctId":1878,"briefTitle":1879,"status":139,"phases":1880,"primaryCompletion":1881,"completion":1882,"start":1883,"enrollment":1361,"conditions":1884,"interventions":1887},"NCT04732260","Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1",[94],"2021-11-05","2021-11-12","2021-06-11",[1885,1886],"Pregnant Women Undergoing TOP","TOP - Failed Attempted Termination of Pregnancy",[1841],{"intervention":1861,"totalTrials":163,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1902,"NA":1913},{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":102},[],{"trials":1897,"activeCount":180,"soonestReadout":1855},[1898],{"nctId":1852,"briefTitle":1853,"status":152,"phases":1899,"primaryCompletion":1855,"completion":1855,"start":1473,"enrollment":1856,"conditions":1900,"interventions":1901},[92],[1858,1859],[1841,1861],{"trials":1903,"activeCount":102},[1904],{"nctId":1905,"briefTitle":1906,"status":241,"phases":1907,"primaryCompletion":1908,"completion":1587,"start":1909,"enrollment":473,"conditions":1910,"interventions":1912},"NCT01037712","In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir",[93],"2011-03","2009-09",[1911,1869],"Viral Disease",[1861],{"trials":1914,"activeCount":102},[],{"intervention":1414,"totalTrials":1299,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1923,"PHASE4":1952,"NA":1954},{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"trials":1922,"activeCount":102},[],{"trials":1924,"activeCount":180,"soonestReadout":871},[1925,1935,1944,1948],{"nctId":1926,"briefTitle":1927,"status":139,"phases":1928,"primaryCompletion":1929,"completion":1929,"start":1930,"enrollment":1931,"conditions":1932,"interventions":1934},"NCT02494505","Interest of Mycophenolate for CIDP Weaning",[92],"2018-05-09","2013-11-18",40,[1933],"Chronic Inflammatory Demyelinating Polyradiculopathy",[1414],{"nctId":1936,"briefTitle":1937,"status":139,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":400,"conditions":1941,"interventions":1943},"NCT01092962","Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children",[92],"2015-02","2010-09",[1942],"Idiopathic Nephrotic Syndrome",[358,1007],{"nctId":1407,"briefTitle":1408,"status":126,"phases":1945,"primaryCompletion":871,"completion":1410,"start":1013,"enrollment":1277,"conditions":1946,"interventions":1947},[92],[1412],[1090,1414],{"nctId":996,"briefTitle":997,"status":241,"phases":1949,"completion":999,"start":1000,"enrollment":1001,"conditions":1950,"interventions":1951},[92],[1003,1004,1005],[358,1007,369,251],{"trials":1953,"activeCount":102},[],{"trials":1955,"activeCount":102},[],{"intervention":1957,"totalTrials":163,"cells":1958},"etoposide",{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1977,"PHASE4":1989,"NA":1991},{"trials":1960,"activeCount":102},[],{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":102},[1965],{"nctId":1966,"briefTitle":1967,"status":139,"phases":1968,"primaryCompletion":301,"completion":301,"start":1969,"enrollment":1130,"conditions":1970,"interventions":1972},"NCT00231582","High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II",[91],"2004-09",[1971],"Testicular Neoplasms",[1973,1974,1957,1975,1976],"epirubicin","paclitaxel","ifosfamide","carboplatin",{"trials":1978,"activeCount":180,"soonestReadout":1983},[1979],{"nctId":1980,"briefTitle":1981,"status":126,"phases":1982,"primaryCompletion":1983,"completion":398,"start":1107,"enrollment":1984,"conditions":1985,"interventions":1987},"NCT07497438","Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis",[92],"2029-12",176,[1986],"Hemophagocytic Lymphohistiocytosis",[1988,1988],"Etoposide",{"trials":1990,"activeCount":102},[],{"trials":1992,"activeCount":102},[],{"intervention":1994,"totalTrials":163,"cells":1995},"Midazolam",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2027,"NA":2029},{"trials":1997,"activeCount":102},[],{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":102},[],{"trials":2003,"activeCount":180,"soonestReadout":2017},[2004,2013],{"nctId":2005,"briefTitle":2006,"status":139,"phases":2007,"primaryCompletion":1834,"completion":2008,"start":2009,"enrollment":303,"conditions":2010,"interventions":2012},"NCT00416039","Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture",[92],"2009-02","2007-01",[2011],"Fractures",[1994],{"nctId":2014,"briefTitle":2015,"status":152,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2025},"NCT06878703","Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants",[92],"2027-12-30","2029-10-16","2025-10-16",380,[2022,2023,2024],"PreTerm Neonate","Sedation for Invasive Mechanical Ventilation","Very Preterm Neonates With Sedation for Invasive Mechanical Ventilation",[1994,2026],"Dexmedetomidine",{"trials":2028,"activeCount":102},[],{"trials":2030,"activeCount":102},[],{"intervention":2032,"totalTrials":163,"cells":2033},"Intravenous immunoglobulins",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2065,"NA":2067},{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":180,"soonestReadout":2057},[2042,2053],{"nctId":2043,"briefTitle":2044,"status":241,"phases":2045,"completion":2046,"start":2047,"enrollment":1931,"conditions":2048,"interventions":2052},"NCT00307658","Intravenous Immunoglobulin After Relapse in Vasculitis",[92],"2006-07","2001-03",[2049,2050,2051],"ANCA + Vasculitides Relapsing Either Under Corticosteroid","and Immunosuppressant Therapies or After One Year","Post Treatment.",[2032],{"nctId":2054,"briefTitle":2055,"status":152,"phases":2056,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":2060,"conditions":2061,"interventions":2063},"NCT04968899","IgIV Plus Prednisone vs High-dose Dexamethasone for ITP",[92],"2025-04-09","2026-10-09","2022-04-07",272,[2062],"Immune Thrombocytopenia (ITP)",[2064,2032],"Neofordex®",{"trials":2066,"activeCount":102},[],{"trials":2068,"activeCount":102},[],{"intervention":1759,"totalTrials":163,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2094,"NA":2096},{"trials":2072,"activeCount":102},[],{"trials":2074,"activeCount":102},[],{"trials":2076,"activeCount":102},[],{"trials":2078,"activeCount":180,"soonestReadout":2087},[2079,2083],{"nctId":1744,"briefTitle":1745,"status":139,"phases":2080,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":2081,"interventions":2082},[92],[1752,1753,1754,1755,1756,1757],[1152,1759],{"nctId":2084,"briefTitle":2085,"status":152,"phases":2086,"primaryCompletion":2087,"completion":1551,"start":2088,"enrollment":1277,"conditions":2089,"interventions":2092},"NCT06902805","Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.",[91,92],"2027-05","2025-12-03",[2090,2091],"Base-of-thumb Osteoarthritis","Osteoarthritis",[2093,1759],"OnabotulinumtoxinA",{"trials":2095,"activeCount":102},[],{"trials":2097,"activeCount":102},[],{"intervention":2099,"totalTrials":163,"cells":2100},"Norepinephrine",{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2107,"PHASE4":2133,"NA":2135},{"trials":2102,"activeCount":102},[],{"trials":2104,"activeCount":102},[],{"trials":2106,"activeCount":102},[],{"trials":2108,"activeCount":180,"soonestReadout":2113},[2109,2121],{"nctId":2110,"briefTitle":2111,"status":152,"phases":2112,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2119},"NCT06344442","Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)",[92],"2025-05-16","2027-05-16","2025-04-16",304,[2118],"Acute Kidney Injury Post Liver Transplantation",[2120,2099],"Arginine vasopressin",{"nctId":2122,"briefTitle":2123,"status":139,"phases":2124,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":2127,"conditions":2128,"interventions":2130},"NCT02473263","Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and\u002For Septic Shock",[92],"2019-02-09","2016-05-09",398,[2129],"Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit",[2131,2132,2099,1164],"Ceftriaxone","Piperacillin tazobactam",{"trials":2134,"activeCount":102},[],{"trials":2136,"activeCount":102},[],{"intervention":2138,"totalTrials":163,"cells":2139},"Gentamicin",{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2154,"PHASE4":2166,"NA":2168},{"trials":2141,"activeCount":102},[],{"trials":2143,"activeCount":102},[],{"trials":2145,"activeCount":102},[2146],{"nctId":2147,"briefTitle":2148,"status":241,"phases":2149,"completion":2150,"start":2151,"enrollment":36,"conditions":2152,"interventions":2153},"NCT00376428","Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients",[91],"2005-06","2003-01",[23],[2138],{"trials":2155,"activeCount":180,"soonestReadout":1410},[2156],{"nctId":2157,"briefTitle":2158,"status":152,"phases":2159,"primaryCompletion":1410,"completion":1410,"start":2160,"enrollment":2161,"conditions":2162,"interventions":2164},"NCT06387147","ORal Antibiotics in Acute Mesenteric Ischemia",[92],"2025-01-31",196,[2163],"Acute Mesenteric Ischemia",[2138,2165],"Metronidazole",{"trials":2167,"activeCount":102},[],{"trials":2169,"activeCount":102},[],{"intervention":2171,"totalTrials":163,"cells":2172},"Apixaban 5 MG Oral",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2203,"NA":2205},{"trials":2174,"activeCount":102},[],{"trials":2176,"activeCount":102},[],{"trials":2178,"activeCount":102},[],{"trials":2180,"activeCount":180,"soonestReadout":2185},[2181,2191],{"nctId":2182,"briefTitle":2183,"status":126,"phases":2184,"primaryCompletion":2185,"completion":289,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2189},"NCT05687448","DIrect Oral Anticoagulation and Bioprothesis Aortic Valve",[92],"2025-09",1500,[2188],"Aortic Valve Disease",[2171,2190],"Aspirin 75 to 100mg once a day",{"nctId":2192,"briefTitle":2193,"status":139,"phases":2194,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":2199,"interventions":2201},"NCT03692065","API-CAT STUDY for APIxaban Cancer Associated Thrombosis",[92],"2024-09-06","2024-10-20","2018-10-11",1766,[2200],"Cancer-associated Thrombosis",[2202],"Apixaban 5 MG",{"trials":2204,"activeCount":102},[],{"trials":2206,"activeCount":102},[],{"intervention":1871,"totalTrials":163,"cells":2208},{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2231,"NA":2233},{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[],{"trials":2214,"activeCount":102},[],{"trials":2216,"activeCount":180,"soonestReadout":1673},[2217,2221],{"nctId":1863,"briefTitle":1864,"status":152,"phases":2218,"primaryCompletion":1673,"completion":1866,"start":1867,"enrollment":1108,"conditions":2219,"interventions":2220},[92],[1869],[1841,1871,1872],{"nctId":2222,"briefTitle":2223,"status":241,"phases":2224,"primaryCompletion":2225,"completion":2226,"start":2227,"enrollment":180,"conditions":2228,"interventions":2230},"NCT02606266","Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance",[91,92],"2018-07-11","2018-12-11","2017-07-11",[2229],"Congenital Cytomegalovirus (CMV)",[1871],{"trials":2232,"activeCount":102},[],{"trials":2234,"activeCount":102},[],{"intervention":2236,"totalTrials":163,"cells":2237},"oral placebo",{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2244,"PHASE4":2270,"NA":2272},{"trials":2239,"activeCount":102},[],{"trials":2241,"activeCount":102},[],{"trials":2243,"activeCount":102},[],{"trials":2245,"activeCount":180,"soonestReadout":871},[2246,2258],{"nctId":2247,"briefTitle":2248,"status":139,"phases":2249,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2256},"NCT02905799","Resveratrol in Knee Osteoarthritis",[92],"2022-02-09","2022-05-12","2017-11-09",142,[2255],"Knee Osteoarthritis",[2257,2236],"oral resveratrol",{"nctId":2259,"briefTitle":2260,"status":126,"phases":2261,"primaryCompletion":871,"completion":1410,"start":2262,"enrollment":206,"conditions":2263,"interventions":2265},"NCT06266221","Severe Erythema Multiforme - CORTICO",[92],"2024-05-01",[2264],"Erythema Multiforme",[2266,2267,2268,2269],"Prednisone 20 Mg","Oral Placebo","Methylprednisolone 120 Mg","IV Placebo",{"trials":2271,"activeCount":102},[],{"trials":2273,"activeCount":102},[],{"intervention":2275,"totalTrials":180,"cells":2276},"Antagonization of heparin with protamine sulfate",{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2296,"NA":2298},{"trials":2278,"activeCount":102},[],{"trials":2280,"activeCount":102},[],{"trials":2282,"activeCount":102},[],{"trials":2284,"activeCount":180,"soonestReadout":2289},[2285],{"nctId":2286,"briefTitle":2287,"status":152,"phases":2288,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2295},"NCT06215378","Antagonization of Heparin With Protamine Sulfate After TAVI",[92],"2027-03-01","2025-05-25",940,[2293,2294],"Aortic Valve Stenosis","Heart Valve Diseases",[2275],{"trials":2297,"activeCount":102},[],{"trials":2299,"activeCount":102},[],{"intervention":2301,"totalTrials":180,"cells":2302},"Acetylsalicylic acid lysinate 300 mg",{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2309,"PHASE4":2323,"NA":2325},{"trials":2304,"activeCount":102},[],{"trials":2306,"activeCount":102},[],{"trials":2308,"activeCount":102},[],{"trials":2310,"activeCount":180,"soonestReadout":2315},[2311],{"nctId":2312,"briefTitle":2313,"status":169,"phases":2314,"primaryCompletion":2315,"completion":2316,"start":2317,"enrollment":2318,"conditions":2319,"interventions":2321},"NCT02813824","Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome",[92],"2026-06-15","2027-12-15","2017-11-14",852,[2320],"Lynch Syndrome",[2301,2322],"Acetylsalicylic acid lysinate 100 mg",{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"intervention":2322,"totalTrials":180,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2341,"NA":2343},{"trials":2330,"activeCount":102},[],{"trials":2332,"activeCount":102},[],{"trials":2334,"activeCount":102},[],{"trials":2336,"activeCount":180,"soonestReadout":2315},[2337],{"nctId":2312,"briefTitle":2313,"status":169,"phases":2338,"primaryCompletion":2315,"completion":2316,"start":2317,"enrollment":2318,"conditions":2339,"interventions":2340},[92],[2320],[2301,2322],{"trials":2342,"activeCount":102},[],{"trials":2344,"activeCount":102},[],{"intervention":2346,"totalTrials":180,"cells":2347},"Dapagliflozin 10 MG Oral Tablet [Farxiga]",{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2366,"NA":2368},{"trials":2349,"activeCount":102},[],{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":180,"soonestReadout":2360},[2356],{"nctId":2357,"briefTitle":2358,"status":152,"phases":2359,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":677,"conditions":2362,"interventions":2364},"NCT07025629","Dapagliflozin for Cardio-renal Protection After ICU Discharge",[92],"2029-01-15","2025-12-02",[2363],"Heart Failure and Chronic Kidney Disease Post-ICU",[2346,2365],"One tablet of placebo of dapagliflozin 10 mg",{"trials":2367,"activeCount":102},[],{"trials":2369,"activeCount":102},[],{"intervention":2365,"totalTrials":180,"cells":2371},{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2384,"NA":2386},{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[],{"trials":2377,"activeCount":102},[],{"trials":2379,"activeCount":180,"soonestReadout":2360},[2380],{"nctId":2357,"briefTitle":2358,"status":152,"phases":2381,"primaryCompletion":2360,"completion":2360,"start":2361,"enrollment":677,"conditions":2382,"interventions":2383},[92],[2363],[2346,2365],{"trials":2385,"activeCount":102},[],{"trials":2387,"activeCount":102},[],{"intervention":1617,"totalTrials":180,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2402,"NA":2404},{"trials":2391,"activeCount":102},[],{"trials":2393,"activeCount":102},[],{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":180,"soonestReadout":1611},[2398],{"nctId":1608,"briefTitle":1609,"status":152,"phases":2399,"primaryCompletion":1611,"completion":444,"start":1612,"enrollment":1613,"conditions":2400,"interventions":2401},[92],[1615],[1617,1597],{"trials":2403,"activeCount":102},[],{"trials":2405,"activeCount":102},[],{"intervention":296,"totalTrials":180,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2420,"NA":2422},{"trials":2409,"activeCount":102},[],{"trials":2411,"activeCount":102},[],{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":180,"soonestReadout":288},[2416],{"nctId":285,"briefTitle":286,"status":152,"phases":2417,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":2418,"interventions":2419},[92],[293,294],[184,77,296],{"trials":2421,"activeCount":102},[],{"trials":2423,"activeCount":102},[],{"intervention":1813,"totalTrials":180,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2438,"NA":2440},{"trials":2427,"activeCount":102},[],{"trials":2429,"activeCount":102},[],{"trials":2431,"activeCount":102},[],{"trials":2433,"activeCount":180,"soonestReadout":1809},[2434],{"nctId":1806,"briefTitle":1807,"status":126,"phases":2435,"primaryCompletion":1809,"completion":1809,"start":194,"enrollment":1810,"conditions":2436,"interventions":2437},[92],[176],[1813,1795],{"trials":2439,"activeCount":102},[],{"trials":2441,"activeCount":102},[],{"intervention":2443,"totalTrials":180,"cells":2444},"Ivabradine",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2464,"NA":2466},{"trials":2446,"activeCount":102},[],{"trials":2448,"activeCount":102},[],{"trials":2450,"activeCount":102},[],{"trials":2452,"activeCount":180,"soonestReadout":2457},[2453],{"nctId":2454,"briefTitle":2455,"status":169,"phases":2456,"primaryCompletion":2457,"completion":2458,"start":2459,"enrollment":2460,"conditions":2461,"interventions":2463},"NCT04031573","Ivabradine for Heart Rate Control In Septic Shock",[92],"2026-02-19","2026-04-22","2021-02-26",429,[2462],"Septic Shock",[2443,2443],{"trials":2465,"activeCount":102},[],{"trials":2467,"activeCount":102},[],{"intervention":2469,"totalTrials":180,"cells":2470},"Investigational products administration",{"EARLY_PHASE1":2471,"PHASE1":2473,"PHASE2":2475,"PHASE3":2477,"PHASE4":2488,"NA":2490},{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[],{"trials":2476,"activeCount":102},[],{"trials":2478,"activeCount":180,"soonestReadout":399},[2479],{"nctId":2480,"briefTitle":2481,"status":152,"phases":2482,"primaryCompletion":399,"completion":399,"start":2483,"enrollment":2484,"conditions":2485,"interventions":2487},"NCT04404400","Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency",[92],"2022-02-17",1092,[2486],"Critical Illness Related Corticosteroids Insufficiency",[2469],{"trials":2489,"activeCount":102},[],{"trials":2491,"activeCount":102},[],{"intervention":2493,"totalTrials":180,"cells":2494},"Intravenous administration of Methylprednisolone",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2516,"NA":2518},{"trials":2496,"activeCount":102},[],{"trials":2498,"activeCount":102},[],{"trials":2500,"activeCount":102},[],{"trials":2502,"activeCount":180,"soonestReadout":2507},[2503],{"nctId":2504,"briefTitle":2505,"status":126,"phases":2506,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT06522100","Corticoid Therapy in Acute Myocarditis",[92],"2028-08-16","2025-02-01",420,[2511],"Acute Myocarditis",[2493,2513,2514,2515],"Oral Prednisone","Perfusion of placebo","Oral Prednisone placebo",{"trials":2517,"activeCount":102},[],{"trials":2519,"activeCount":102},[],{"intervention":2513,"totalTrials":180,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2534,"NA":2536},{"trials":2523,"activeCount":102},[],{"trials":2525,"activeCount":102},[],{"trials":2527,"activeCount":102},[],{"trials":2529,"activeCount":180,"soonestReadout":2507},[2530],{"nctId":2504,"briefTitle":2505,"status":126,"phases":2531,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2532,"interventions":2533},[92],[2511],[2493,2513,2514,2515],{"trials":2535,"activeCount":102},[],{"trials":2537,"activeCount":102},[],{"intervention":2514,"totalTrials":180,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2552,"NA":2554},{"trials":2541,"activeCount":102},[],{"trials":2543,"activeCount":102},[],{"trials":2545,"activeCount":102},[],{"trials":2547,"activeCount":180,"soonestReadout":2507},[2548],{"nctId":2504,"briefTitle":2505,"status":126,"phases":2549,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2550,"interventions":2551},[92],[2511],[2493,2513,2514,2515],{"trials":2553,"activeCount":102},[],{"trials":2555,"activeCount":102},[],{"intervention":2515,"totalTrials":180,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2562,"PHASE3":2564,"PHASE4":2570,"NA":2572},{"trials":2559,"activeCount":102},[],{"trials":2561,"activeCount":102},[],{"trials":2563,"activeCount":102},[],{"trials":2565,"activeCount":180,"soonestReadout":2507},[2566],{"nctId":2504,"briefTitle":2505,"status":126,"phases":2567,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":2509,"conditions":2568,"interventions":2569},[92],[2511],[2493,2513,2514,2515],{"trials":2571,"activeCount":102},[],{"trials":2573,"activeCount":102},[],{"intervention":1572,"totalTrials":180,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":102},[],{"trials":2579,"activeCount":102},[],{"trials":2581,"activeCount":102},[],{"trials":2583,"activeCount":180,"soonestReadout":1565},[2584],{"nctId":1562,"briefTitle":1563,"status":152,"phases":2585,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":2586,"interventions":2587},[92],[1569,1570],[1541,1572],{"trials":2589,"activeCount":102},[],{"trials":2591,"activeCount":102},[],{"intervention":2593,"totalTrials":180,"cells":2594},"Intravenous administration",{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2601,"PHASE4":2611,"NA":2613},{"trials":2596,"activeCount":102},[],{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":102},[],{"trials":2602,"activeCount":180,"soonestReadout":2607},[2603],{"nctId":2604,"briefTitle":2605,"status":126,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":2315,"enrollment":2608,"conditions":2609,"interventions":2610},"NCT07603440","Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)",[92],"2029-07-01",486,[464],[2593],{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"intervention":2616,"totalTrials":180,"cells":2617},"Certolizumab",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2634,"NA":2636},{"trials":2619,"activeCount":102},[],{"trials":2621,"activeCount":102},[],{"trials":2623,"activeCount":102},[],{"trials":2625,"activeCount":180,"soonestReadout":1311},[2626],{"nctId":2627,"briefTitle":2628,"status":152,"phases":2629,"primaryCompletion":1311,"completion":1311,"start":2630,"enrollment":1438,"conditions":2631,"interventions":2633},"NCT05930613","Certolizumab in Recurrent Implantation Failure (RIF)",[92],"2023-11-30",[2632],"Recurrent Unexplained Implantation Failure",[2616],{"trials":2635,"activeCount":102},[],{"trials":2637,"activeCount":102},[],{"intervention":2120,"totalTrials":180,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2652,"NA":2654},{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[],{"trials":2645,"activeCount":102},[],{"trials":2647,"activeCount":180,"soonestReadout":2113},[2648],{"nctId":2110,"briefTitle":2111,"status":152,"phases":2649,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":2116,"conditions":2650,"interventions":2651},[92],[2118],[2120,2099],{"trials":2653,"activeCount":102},[],{"trials":2655,"activeCount":102},[],{"intervention":2657,"totalTrials":180,"cells":2658},"Donepezil",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2677,"NA":2679},{"trials":2660,"activeCount":102},[],{"trials":2662,"activeCount":102},[],{"trials":2664,"activeCount":102},[],{"trials":2666,"activeCount":180,"soonestReadout":2671},[2667],{"nctId":2668,"briefTitle":2669,"status":152,"phases":2670,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2673,"conditions":2674,"interventions":2676},"NCT04661280","Donepezil Versus Non-drug Treatment in Alzheimer's Disease.",[92],"2026-08","2022-02-10",240,[2675],"Alzheimer Disease, Early Onset",[2657],{"trials":2678,"activeCount":102},[],{"trials":2680,"activeCount":102},[],{"intervention":2165,"totalTrials":180,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":102},[],{"trials":2686,"activeCount":102},[],{"trials":2688,"activeCount":102},[],{"trials":2690,"activeCount":180,"soonestReadout":1410},[2691],{"nctId":2157,"briefTitle":2158,"status":152,"phases":2692,"primaryCompletion":1410,"completion":1410,"start":2160,"enrollment":2161,"conditions":2693,"interventions":2694},[92],[2163],[2138,2165],{"trials":2696,"activeCount":102},[],{"trials":2698,"activeCount":102},[],{"intervention":47,"totalTrials":180,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2707,"PHASE4":2716,"NA":2718},{"trials":2702,"activeCount":102},[],{"trials":2704,"activeCount":102},[],{"trials":2706,"activeCount":102},[],{"trials":2708,"activeCount":180,"soonestReadout":46},[2709],{"nctId":44,"briefTitle":45,"status":169,"phases":2710,"primaryCompletion":46,"completion":1529,"start":2711,"enrollment":1685,"conditions":2712,"interventions":2715},[92],"2022-03-23",[501,2713,2714],"Atrial Arrhythmia","Cryptogenic Stroke",[47,47],{"trials":2717,"activeCount":102},[],{"trials":2719,"activeCount":102},[],{"intervention":2721,"totalTrials":180,"cells":2722},"Soliris®",{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2742,"NA":2744},{"trials":2724,"activeCount":102},[],{"trials":2726,"activeCount":102},[],{"trials":2728,"activeCount":102},[],{"trials":2730,"activeCount":180,"soonestReadout":2735},[2731],{"nctId":2732,"briefTitle":2733,"status":152,"phases":2734,"primaryCompletion":2735,"completion":2736,"start":2737,"enrollment":1213,"conditions":2738,"interventions":2740},"NCT05726916","Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome",[92],"2026-05-09","2027-11-09","2023-11-09",[2739],"Hypertensive Emergency-associated Hemolytic Uremic Syndrome",[2721,2741],"Renin angiotensin system blockers",{"trials":2743,"activeCount":102},[],{"trials":2745,"activeCount":102},[],{"intervention":2741,"totalTrials":180,"cells":2747},{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2754,"PHASE4":2760,"NA":2762},{"trials":2749,"activeCount":102},[],{"trials":2751,"activeCount":102},[],{"trials":2753,"activeCount":102},[],{"trials":2755,"activeCount":180,"soonestReadout":2735},[2756],{"nctId":2732,"briefTitle":2733,"status":152,"phases":2757,"primaryCompletion":2735,"completion":2736,"start":2737,"enrollment":1213,"conditions":2758,"interventions":2759},[92],[2739],[2721,2741],{"trials":2761,"activeCount":102},[],{"trials":2763,"activeCount":102},[],{"intervention":2765,"totalTrials":180,"cells":2766},"Anakinra, KINERET®",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2773,"PHASE4":2783,"NA":2785},{"trials":2768,"activeCount":102},[],{"trials":2770,"activeCount":102},[],{"trials":2772,"activeCount":102},[],{"trials":2774,"activeCount":180,"soonestReadout":1983},[2775],{"nctId":2776,"briefTitle":2777,"status":126,"phases":2778,"primaryCompletion":1983,"completion":1983,"start":399,"enrollment":2779,"conditions":2780,"interventions":2782},"NCT07371689","ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS",[92],110,[2781],"PEDIATRIC ACUTE MYOCARDITIS",[2765],{"trials":2784,"activeCount":102},[],{"trials":2786,"activeCount":102},[],{"intervention":2788,"totalTrials":180,"cells":2789},"Bezafibrate 400 mg in addition to UDCA therapy",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2810,"NA":2812},{"trials":2791,"activeCount":102},[],{"trials":2793,"activeCount":102},[],{"trials":2795,"activeCount":102},[],{"trials":2797,"activeCount":180,"soonestReadout":2017},[2798],{"nctId":2799,"briefTitle":2800,"status":152,"phases":2801,"primaryCompletion":2017,"completion":2802,"start":2803,"enrollment":2804,"conditions":2805,"interventions":2808},"NCT06443606","Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy",[92],"2029-06-01","2025-03-27",108,[2806,2807],"BPC","Non Optimal Response to UDCA",[2788,2809],"Bezafibrate 200 mg in addition to UDCA therapy",{"trials":2811,"activeCount":102},[],{"trials":2813,"activeCount":102},[],{"intervention":2809,"totalTrials":180,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2828,"NA":2830},{"trials":2817,"activeCount":102},[],{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[],{"trials":2823,"activeCount":180,"soonestReadout":2017},[2824],{"nctId":2799,"briefTitle":2800,"status":152,"phases":2825,"primaryCompletion":2017,"completion":2802,"start":2803,"enrollment":2804,"conditions":2826,"interventions":2827},[92],[2806,2807],[2788,2809],{"trials":2829,"activeCount":102},[],{"trials":2831,"activeCount":102},[],{"intervention":2833,"totalTrials":180,"cells":2834},"Inahled Isoflurane",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2854,"NA":2856},{"trials":2836,"activeCount":102},[],{"trials":2838,"activeCount":102},[],{"trials":2840,"activeCount":102},[],{"trials":2842,"activeCount":180,"soonestReadout":2847},[2843],{"nctId":2844,"briefTitle":2845,"status":126,"phases":2846,"primaryCompletion":2847,"completion":2848,"start":2849,"enrollment":489,"conditions":2850,"interventions":2852},"NCT07099014","Inhaled Isoflurane for Sedation of Invasively Ventilated Patients With Cardiogenic Shock on Extracorporeal Membrane Oxygenation",[92],"2028-10-13","2029-04-13","2025-09-15",[2851],"Cardiogenic Shock, ECMO",[2833,2853],"Propofol, midazolam",{"trials":2855,"activeCount":102},[],{"trials":2857,"activeCount":102},[],{"intervention":2853,"totalTrials":180,"cells":2859},{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2872,"NA":2874},{"trials":2861,"activeCount":102},[],{"trials":2863,"activeCount":102},[],{"trials":2865,"activeCount":102},[],{"trials":2867,"activeCount":180,"soonestReadout":2847},[2868],{"nctId":2844,"briefTitle":2845,"status":126,"phases":2869,"primaryCompletion":2847,"completion":2848,"start":2849,"enrollment":489,"conditions":2870,"interventions":2871},[92],[2851],[2833,2853],{"trials":2873,"activeCount":102},[],{"trials":2875,"activeCount":102},[],{"intervention":2877,"totalTrials":180,"cells":2878},"Oral Anticoagulant, Direct-Acting",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2898,"NA":2900},{"trials":2880,"activeCount":102},[],{"trials":2882,"activeCount":102},[],{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":180,"soonestReadout":2891},[2887],{"nctId":2888,"briefTitle":2889,"status":152,"phases":2890,"primaryCompletion":2891,"completion":2891,"start":2892,"enrollment":2893,"conditions":2894,"interventions":2896},"NCT05387954","PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years",[92],"2031-07-07","2023-07-07",792,[2895,501],"Cryptogenic Ischemic Stroke",[2877,2897],"Antiplatelet therapy",{"trials":2899,"activeCount":102},[],{"trials":2901,"activeCount":102},[],{"intervention":2897,"totalTrials":180,"cells":2903},{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2910,"PHASE4":2916,"NA":2918},{"trials":2905,"activeCount":102},[],{"trials":2907,"activeCount":102},[],{"trials":2909,"activeCount":102},[],{"trials":2911,"activeCount":180,"soonestReadout":2891},[2912],{"nctId":2888,"briefTitle":2889,"status":152,"phases":2913,"primaryCompletion":2891,"completion":2891,"start":2892,"enrollment":2893,"conditions":2914,"interventions":2915},[92],[2895,501],[2877,2897],{"trials":2917,"activeCount":102},[],{"trials":2919,"activeCount":102},[],{"intervention":2921,"totalTrials":180,"cells":2922},"Piperacillin\u002Ftazobactam or temocillin",{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2929,"PHASE4":2939,"NA":2941},{"trials":2924,"activeCount":102},[],{"trials":2926,"activeCount":102},[],{"trials":2928,"activeCount":102},[],{"trials":2930,"activeCount":180,"soonestReadout":1107},[2931],{"nctId":2932,"briefTitle":2933,"status":152,"phases":2934,"primaryCompletion":1107,"completion":194,"start":2935,"enrollment":677,"conditions":2936,"interventions":2937},"NCT05565222","Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit",[92],"2023-03-11",[679,2462],[2921,2938],"Meropenem",{"trials":2940,"activeCount":102},[],{"trials":2942,"activeCount":102},[],{"intervention":2938,"totalTrials":180,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2957,"NA":2959},{"trials":2946,"activeCount":102},[],{"trials":2948,"activeCount":102},[],{"trials":2950,"activeCount":102},[],{"trials":2952,"activeCount":180,"soonestReadout":1107},[2953],{"nctId":2932,"briefTitle":2933,"status":152,"phases":2954,"primaryCompletion":1107,"completion":194,"start":2935,"enrollment":677,"conditions":2955,"interventions":2956},[92],[679,2462],[2921,2938],{"trials":2958,"activeCount":102},[],{"trials":2960,"activeCount":102},[],{"intervention":2962,"totalTrials":180,"cells":2963},"active intervention",{"EARLY_PHASE1":2964,"PHASE1":2966,"PHASE2":2968,"PHASE3":2970,"PHASE4":2983,"NA":2985},{"trials":2965,"activeCount":102},[],{"trials":2967,"activeCount":102},[],{"trials":2969,"activeCount":102},[],{"trials":2971,"activeCount":180,"soonestReadout":2976},[2972],{"nctId":2973,"briefTitle":2974,"status":152,"phases":2975,"primaryCompletion":2976,"completion":2977,"start":2978,"enrollment":2979,"conditions":2980,"interventions":2982},"NCT04292054","Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)",[92],"2026-04-18","2026-07-09","2020-10-11",506,[2981],"Burns Surgery",[2962],{"trials":2984,"activeCount":102},[],{"trials":2986,"activeCount":102},[],{"intervention":2988,"totalTrials":180,"cells":2989},"Obinutuzumab administration",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":3010,"NA":3012},{"trials":2991,"activeCount":102},[],{"trials":2993,"activeCount":102},[],{"trials":2995,"activeCount":102},[],{"trials":2997,"activeCount":180,"soonestReadout":3002},[2998],{"nctId":2999,"briefTitle":3000,"status":152,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":2161,"conditions":3004,"interventions":3007},"NCT04702256","Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF",[92],"2031-12","2021-12-09",[3005,3006],"Lupus Nephritis","Systemic Lupus Erythematosus (SLE)",[2988,3008,3009],"Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil","Administration of methylprednisolone, paracetamol and dexchlorpheniramine",{"trials":3011,"activeCount":102},[],{"trials":3013,"activeCount":102},[],{"intervention":3008,"totalTrials":180,"cells":3015},{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3028,"NA":3030},{"trials":3017,"activeCount":102},[],{"trials":3019,"activeCount":102},[],{"trials":3021,"activeCount":102},[],{"trials":3023,"activeCount":180,"soonestReadout":3002},[3024],{"nctId":2999,"briefTitle":3000,"status":152,"phases":3025,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":2161,"conditions":3026,"interventions":3027},[92],[3005,3006],[2988,3008,3009],{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":102},[],{"intervention":3009,"totalTrials":180,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3040,"PHASE4":3046,"NA":3048},{"trials":3035,"activeCount":102},[],{"trials":3037,"activeCount":102},[],{"trials":3039,"activeCount":102},[],{"trials":3041,"activeCount":180,"soonestReadout":3002},[3042],{"nctId":2999,"briefTitle":3000,"status":152,"phases":3043,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":2161,"conditions":3044,"interventions":3045},[92],[3005,3006],[2988,3008,3009],{"trials":3047,"activeCount":102},[],{"trials":3049,"activeCount":102},[],{"intervention":2190,"totalTrials":180,"cells":3051},{"EARLY_PHASE1":3052,"PHASE1":3054,"PHASE2":3056,"PHASE3":3058,"PHASE4":3064,"NA":3066},{"trials":3053,"activeCount":102},[],{"trials":3055,"activeCount":102},[],{"trials":3057,"activeCount":102},[],{"trials":3059,"activeCount":180,"soonestReadout":2185},[3060],{"nctId":2182,"briefTitle":2183,"status":126,"phases":3061,"primaryCompletion":2185,"completion":289,"start":2185,"enrollment":2186,"conditions":3062,"interventions":3063},[92],[2188],[2171,2190],{"trials":3065,"activeCount":102},[],{"trials":3067,"activeCount":102},[],{"intervention":3069,"totalTrials":180,"cells":3070},"single infusion of Rituximab",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3077,"PHASE4":3092,"NA":3094},{"trials":3072,"activeCount":102},[],{"trials":3074,"activeCount":102},[],{"trials":3076,"activeCount":102},[],{"trials":3078,"activeCount":180,"soonestReadout":3083},[3079],{"nctId":3080,"briefTitle":3081,"status":152,"phases":3082,"primaryCompletion":3083,"completion":3084,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3090},"NCT05786768","Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome",[91,92],"2027-10-18","2027-12-31","2023-10-18",88,[3088,3089],"Steroid-Dependent Nephrotic Syndrome","Steroid-Sensitive Nephrotic Syndrome",[3069,3091],"single infusion of Obinutuzumab",{"trials":3093,"activeCount":102},[],{"trials":3095,"activeCount":102},[],{"intervention":3091,"totalTrials":180,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3104,"PHASE4":3110,"NA":3112},{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[],{"trials":3103,"activeCount":102},[],{"trials":3105,"activeCount":180,"soonestReadout":3083},[3106],{"nctId":3080,"briefTitle":3081,"status":152,"phases":3107,"primaryCompletion":3083,"completion":3084,"start":3085,"enrollment":3086,"conditions":3108,"interventions":3109},[91,92],[3088,3089],[3069,3091],{"trials":3111,"activeCount":102},[],{"trials":3113,"activeCount":102},[],{"intervention":2093,"totalTrials":180,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3120,"PHASE3":3122,"PHASE4":3128,"NA":3130},{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":180,"soonestReadout":2087},[3124],{"nctId":2084,"briefTitle":2085,"status":152,"phases":3125,"primaryCompletion":2087,"completion":1551,"start":2088,"enrollment":1277,"conditions":3126,"interventions":3127},[91,92],[2090,2091],[2093,1759],{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[],{"intervention":3133,"totalTrials":180,"cells":3134},"Mepolizumab",{"EARLY_PHASE1":3135,"PHASE1":3137,"PHASE2":3139,"PHASE3":3141,"PHASE4":3153,"NA":3155},{"trials":3136,"activeCount":102},[],{"trials":3138,"activeCount":102},[],{"trials":3140,"activeCount":102},[],{"trials":3142,"activeCount":180,"soonestReadout":3147},[3143],{"nctId":3144,"briefTitle":3145,"status":169,"phases":3146,"primaryCompletion":3147,"completion":3147,"start":3148,"enrollment":3149,"conditions":3150,"interventions":3151},"NCT05030155","Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)",[92],"2025-11","2022-05-30",100,[367],[3133,3152],"cyclophosphamide\u002Fazathioprine",{"trials":3154,"activeCount":102},[],{"trials":3156,"activeCount":102},[],{"intervention":3152,"totalTrials":180,"cells":3158},{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3165,"PHASE4":3171,"NA":3173},{"trials":3160,"activeCount":102},[],{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":102},[],{"trials":3166,"activeCount":180,"soonestReadout":3147},[3167],{"nctId":3144,"briefTitle":3145,"status":169,"phases":3168,"primaryCompletion":3147,"completion":3147,"start":3148,"enrollment":3149,"conditions":3169,"interventions":3170},[92],[367],[3133,3152],{"trials":3172,"activeCount":102},[],{"trials":3174,"activeCount":102},[],{"intervention":3176,"totalTrials":180,"cells":3177},"DDAVP",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3198,"NA":3200},{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":180,"soonestReadout":3190},[3186],{"nctId":3187,"briefTitle":3188,"status":152,"phases":3189,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":3193,"conditions":3194,"interventions":3196},"NCT06020495","Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia",[92],"2026-09-30","2026-11-30","2024-12-17",260,[3195],"Hyponatremia",[3176,3197],"Standard hyponatremia treatment",{"trials":3199,"activeCount":102},[],{"trials":3201,"activeCount":102},[],{"intervention":3197,"totalTrials":180,"cells":3203},{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3216,"NA":3218},{"trials":3205,"activeCount":102},[],{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"trials":3211,"activeCount":180,"soonestReadout":3190},[3212],{"nctId":3187,"briefTitle":3188,"status":152,"phases":3213,"primaryCompletion":3190,"completion":3191,"start":3192,"enrollment":3193,"conditions":3214,"interventions":3215},[92],[3195],[3176,3197],{"trials":3217,"activeCount":102},[],{"trials":3219,"activeCount":102},[],{"intervention":42,"totalTrials":180,"cells":3221},{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3228,"PHASE4":3238,"NA":3240},{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"trials":3229,"activeCount":180,"soonestReadout":41},[3230],{"nctId":39,"briefTitle":40,"status":169,"phases":3231,"primaryCompletion":41,"completion":1472,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},[92],"2016-09-19",2044,[3235],"Acute Lymphoblastic Leukemia",[42,3237],"pegaspargase 2500 IU\u002Fm2 x 1",{"trials":3239,"activeCount":102},[],{"trials":3241,"activeCount":102},[],{"intervention":3237,"totalTrials":180,"cells":3243},{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3256,"NA":3258},{"trials":3245,"activeCount":102},[],{"trials":3247,"activeCount":102},[],{"trials":3249,"activeCount":102},[],{"trials":3251,"activeCount":180,"soonestReadout":41},[3252],{"nctId":39,"briefTitle":40,"status":169,"phases":3253,"primaryCompletion":41,"completion":1472,"start":3232,"enrollment":3233,"conditions":3254,"interventions":3255},[92],[3235],[42,3237],{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[],{"intervention":3261,"totalTrials":180,"cells":3262},"Prednisolone",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3280,"NA":3282},{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[],{"trials":3268,"activeCount":102},[],{"trials":3270,"activeCount":180,"soonestReadout":3275},[3271],{"nctId":3272,"briefTitle":3273,"status":126,"phases":3274,"primaryCompletion":3275,"completion":3275,"start":3276,"enrollment":1277,"conditions":3277,"interventions":3279},"NCT07210008","\"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis\"",[92],"2028-12-01","2026-06-01",[3278],"Hypersensitivity Pneumonitis",[3261],{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[],{"intervention":3285,"totalTrials":180,"cells":3286},"Tocilizumab (RoActemra®, 20 mg\u002FmL).",{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3293,"PHASE4":3303,"NA":3305},{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[],{"trials":3292,"activeCount":102},[],{"trials":3294,"activeCount":180,"soonestReadout":154},[3295],{"nctId":3296,"briefTitle":3297,"status":126,"phases":3298,"primaryCompletion":154,"completion":1096,"start":156,"enrollment":3299,"conditions":3300,"interventions":3302},"NCT06818266","Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease",[92],130,[20,3301],"Acute Chest Syndrome",[3285],{"trials":3304,"activeCount":102},[],{"trials":3306,"activeCount":102},[],{"intervention":3308,"totalTrials":180,"cells":3309},"Ovulation induction with hCG + Luteal phase support with vaginal progesterone",{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3316,"PHASE4":3330,"NA":3332},{"trials":3311,"activeCount":102},[],{"trials":3313,"activeCount":102},[],{"trials":3315,"activeCount":102},[],{"trials":3317,"activeCount":180,"soonestReadout":1673},[3318],{"nctId":3319,"briefTitle":3320,"status":152,"phases":3321,"primaryCompletion":1673,"completion":3322,"start":3323,"enrollment":3324,"conditions":3325,"interventions":3328},"NCT06150703","Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF\u002FICSI Cycles",[92],"2027-09-27","2024-06-27",652,[3326,3327],"In Vitro Fertilization","ICSI Intracytoplasmic Spermatozoid Injection",[3308,3329],"Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin",{"trials":3331,"activeCount":102},[],{"trials":3333,"activeCount":102},[],{"intervention":3329,"totalTrials":180,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3348,"NA":3350},{"trials":3337,"activeCount":102},[],{"trials":3339,"activeCount":102},[],{"trials":3341,"activeCount":102},[],{"trials":3343,"activeCount":180,"soonestReadout":1673},[3344],{"nctId":3319,"briefTitle":3320,"status":152,"phases":3345,"primaryCompletion":1673,"completion":3322,"start":3323,"enrollment":3324,"conditions":3346,"interventions":3347},[92],[3326,3327],[3308,3329],{"trials":3349,"activeCount":102},[],{"trials":3351,"activeCount":102},[],{"intervention":3353,"totalTrials":180,"cells":3354},"Bedaquiline Oral",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3361,"PHASE4":3375,"NA":3377},{"trials":3356,"activeCount":102},[],{"trials":3358,"activeCount":102},[],{"trials":3360,"activeCount":102},[],{"trials":3362,"activeCount":180,"soonestReadout":3367},[3363],{"nctId":3364,"briefTitle":3365,"status":126,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":1107,"enrollment":1710,"conditions":3369,"interventions":3374},"NCT07486024","Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)",[92],"2030-08","2032-02",[3370,3371,3372,3373],"MDR-TB","Tuberculosis Multi Drug Resistant Active","Antibiotic Resistance","Mycobacterium Tuberculosis",[3353,3353],{"trials":3376,"activeCount":102},[],{"trials":3378,"activeCount":102},[],{"intervention":3380,"totalTrials":180,"cells":3381},"Administration of AVP",{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3386,"PHASE3":3388,"PHASE4":3401,"NA":3403},{"trials":3383,"activeCount":102},[],{"trials":3385,"activeCount":102},[],{"trials":3387,"activeCount":102},[],{"trials":3389,"activeCount":180,"soonestReadout":1731},[3390],{"nctId":3391,"briefTitle":3392,"status":152,"phases":3393,"primaryCompletion":1731,"completion":1731,"start":3394,"enrollment":2020,"conditions":3395,"interventions":3397},"NCT04591990","HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome",[92],"2021-05-27",[3396],"Postresuscitation Syndrome",[3380,3398,3399,3400],"Administration of placebo AVP","Administration of placebo hydrocortisone","Administration of hydrocortisone",{"trials":3402,"activeCount":102},[],{"trials":3404,"activeCount":102},[],{"intervention":3398,"totalTrials":180,"cells":3406},{"EARLY_PHASE1":3407,"PHASE1":3409,"PHASE2":3411,"PHASE3":3413,"PHASE4":3419,"NA":3421},{"trials":3408,"activeCount":102},[],{"trials":3410,"activeCount":102},[],{"trials":3412,"activeCount":102},[],{"trials":3414,"activeCount":180,"soonestReadout":1731},[3415],{"nctId":3391,"briefTitle":3392,"status":152,"phases":3416,"primaryCompletion":1731,"completion":1731,"start":3394,"enrollment":2020,"conditions":3417,"interventions":3418},[92],[3396],[3380,3398,3399,3400],{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":102},[],{"intervention":3399,"totalTrials":180,"cells":3424},{"EARLY_PHASE1":3425,"PHASE1":3427,"PHASE2":3429,"PHASE3":3431,"PHASE4":3437,"NA":3439},{"trials":3426,"activeCount":102},[],{"trials":3428,"activeCount":102},[],{"trials":3430,"activeCount":102},[],{"trials":3432,"activeCount":180,"soonestReadout":1731},[3433],{"nctId":3391,"briefTitle":3392,"status":152,"phases":3434,"primaryCompletion":1731,"completion":1731,"start":3394,"enrollment":2020,"conditions":3435,"interventions":3436},[92],[3396],[3380,3398,3399,3400],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"intervention":3400,"totalTrials":180,"cells":3442},{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3447,"PHASE3":3449,"PHASE4":3455,"NA":3457},{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[],{"trials":3450,"activeCount":180,"soonestReadout":1731},[3451],{"nctId":3391,"briefTitle":3392,"status":152,"phases":3452,"primaryCompletion":1731,"completion":1731,"start":3394,"enrollment":2020,"conditions":3453,"interventions":3454},[92],[3396],[3380,3398,3399,3400],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"intervention":3460,"totalTrials":180,"cells":3461},"Treatment taken",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3480,"NA":3482},{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":102},[],{"trials":3469,"activeCount":180,"soonestReadout":1095},[3470],{"nctId":3471,"briefTitle":3472,"status":152,"phases":3473,"primaryCompletion":1095,"completion":3474,"start":3475,"enrollment":2253,"conditions":3476,"interventions":3479},"NCT05532813","Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)",[92],"2026-12","2024-11-29",[3477,3478,1483],"Steinert's Disease","Myotonic Dystrophy 1",[3460],{"trials":3481,"activeCount":102},[],{"trials":3483,"activeCount":102},[],{"intervention":3485,"totalTrials":180,"cells":3486},"Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution",{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3491,"PHASE3":3493,"PHASE4":3506,"NA":3508},{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[],{"trials":3492,"activeCount":102},[],{"trials":3494,"activeCount":180,"soonestReadout":3499},[3495],{"nctId":3496,"briefTitle":3497,"status":152,"phases":3498,"primaryCompletion":3499,"completion":3499,"start":3500,"enrollment":3501,"conditions":3502,"interventions":3504},"NCT06192693","Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery",[92],"2029-02","2024-01-21",54,[1534,3503],"Type 2 Diabetes",[3485,3505],"Capsulized placebo transfer containing dilution solution",{"trials":3507,"activeCount":102},[],{"trials":3509,"activeCount":102},[],{"intervention":3505,"totalTrials":180,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3518,"PHASE4":3524,"NA":3526},{"trials":3513,"activeCount":102},[],{"trials":3515,"activeCount":102},[],{"trials":3517,"activeCount":102},[],{"trials":3519,"activeCount":180,"soonestReadout":3499},[3520],{"nctId":3496,"briefTitle":3497,"status":152,"phases":3521,"primaryCompletion":3499,"completion":3499,"start":3500,"enrollment":3501,"conditions":3522,"interventions":3523},[92],[1534,3503],[3485,3505],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"intervention":3529,"totalTrials":180,"cells":3530},"Glenzocimab",{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3550,"NA":3552},{"trials":3532,"activeCount":102},[],{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":180,"soonestReadout":3543},[3539],{"nctId":3540,"briefTitle":3541,"status":126,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":3545,"enrollment":3193,"conditions":3546,"interventions":3549},"NCT05559398","Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study",[91,92],"2025-10-10","2026-10-10","2022-10-10",[3547,3548],"Stroke, Acute","Stroke, Ischemic",[3529],{"trials":3551,"activeCount":102},[],{"trials":3553,"activeCount":102},[],{"intervention":1872,"totalTrials":180,"cells":3555},{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3562,"PHASE4":3568,"NA":3570},{"trials":3557,"activeCount":102},[],{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[],{"trials":3563,"activeCount":180,"soonestReadout":1673},[3564],{"nctId":1863,"briefTitle":1864,"status":152,"phases":3565,"primaryCompletion":1673,"completion":1866,"start":1867,"enrollment":1108,"conditions":3566,"interventions":3567},[92],[1869],[1841,1871,1872],{"trials":3569,"activeCount":102},[],{"trials":3571,"activeCount":102},[],{"intervention":3573,"totalTrials":180,"cells":3574},"Randomization + Blinatumomab + chemotherapy",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3594,"NA":3596},{"trials":3576,"activeCount":102},[],{"trials":3578,"activeCount":102},[],{"trials":3580,"activeCount":102},[],{"trials":3582,"activeCount":180,"soonestReadout":3587},[3583],{"nctId":3584,"briefTitle":3585,"status":152,"phases":3586,"primaryCompletion":3587,"completion":3587,"start":3588,"enrollment":3589,"conditions":3590,"interventions":3591},"NCT06860269","A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia",[91,92],"2035-03-15","2025-05-06",1200,[3235],[3573,3592,3593],"Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone","Randomization + Blinatumomab + Ponatinib + chemotherapy",{"trials":3595,"activeCount":102},[],{"trials":3597,"activeCount":102},[],{"intervention":3592,"totalTrials":180,"cells":3599},{"EARLY_PHASE1":3600,"PHASE1":3602,"PHASE2":3604,"PHASE3":3606,"PHASE4":3612,"NA":3614},{"trials":3601,"activeCount":102},[],{"trials":3603,"activeCount":102},[],{"trials":3605,"activeCount":102},[],{"trials":3607,"activeCount":180,"soonestReadout":3587},[3608],{"nctId":3584,"briefTitle":3585,"status":152,"phases":3609,"primaryCompletion":3587,"completion":3587,"start":3588,"enrollment":3589,"conditions":3610,"interventions":3611},[91,92],[3235],[3573,3592,3593],{"trials":3613,"activeCount":102},[],{"trials":3615,"activeCount":102},[],{"intervention":3593,"totalTrials":180,"cells":3617},{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3624,"PHASE4":3630,"NA":3632},{"trials":3619,"activeCount":102},[],{"trials":3621,"activeCount":102},[],{"trials":3623,"activeCount":102},[],{"trials":3625,"activeCount":180,"soonestReadout":3587},[3626],{"nctId":3584,"briefTitle":3585,"status":152,"phases":3627,"primaryCompletion":3587,"completion":3587,"start":3588,"enrollment":3589,"conditions":3628,"interventions":3629},[91,92],[3235],[3573,3592,3593],{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"intervention":3635,"totalTrials":180,"cells":3636},"IRBESARTAN, tablet, 150 mg",{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3643,"PHASE4":3656,"NA":3658},{"trials":3638,"activeCount":102},[],{"trials":3640,"activeCount":102},[],{"trials":3642,"activeCount":102},[],{"trials":3644,"activeCount":180,"soonestReadout":3649},[3645],{"nctId":3646,"briefTitle":3647,"status":169,"phases":3648,"primaryCompletion":3649,"completion":3650,"start":3651,"enrollment":3652,"conditions":3653,"interventions":3655},"NCT05272878","Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.",[92],"2025-06-27","2026-06-27","2022-11-22",508,[3654],"Acute Kidney Injury",[3635],{"trials":3657,"activeCount":102},[],{"trials":3659,"activeCount":102},[],{"intervention":3661,"totalTrials":180,"cells":3662},"Daratumumab\u002FLenalidomide\u002FDexamethasone for 24 months",{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3667,"PHASE3":3669,"PHASE4":3681,"NA":3683},{"trials":3664,"activeCount":102},[],{"trials":3666,"activeCount":102},[],{"trials":3668,"activeCount":102},[],{"trials":3670,"activeCount":180,"soonestReadout":1529},[3671],{"nctId":3672,"briefTitle":3673,"status":169,"phases":3674,"primaryCompletion":1529,"completion":1529,"start":3675,"enrollment":3676,"conditions":3677,"interventions":3679},"NCT03836014","Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma",[92],"2019-07-25",436,[3678],"Multiple Myeloma in Relapse",[3661,3680],"Daratumumab\u002FLenalidomide\u002FDexamethasone until progression",{"trials":3682,"activeCount":102},[],{"trials":3684,"activeCount":102},[],{"intervention":3680,"totalTrials":180,"cells":3686},{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3693,"PHASE4":3699,"NA":3701},{"trials":3688,"activeCount":102},[],{"trials":3690,"activeCount":102},[],{"trials":3692,"activeCount":102},[],{"trials":3694,"activeCount":180,"soonestReadout":1529},[3695],{"nctId":3672,"briefTitle":3673,"status":169,"phases":3696,"primaryCompletion":1529,"completion":1529,"start":3675,"enrollment":3676,"conditions":3697,"interventions":3698},[92],[3678],[3661,3680],{"trials":3700,"activeCount":102},[],{"trials":3702,"activeCount":102},[],{"intervention":3704,"totalTrials":180,"cells":3705},"STOP arm",{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3712,"PHASE4":3723,"NA":3725},{"trials":3707,"activeCount":102},[],{"trials":3709,"activeCount":102},[],{"trials":3711,"activeCount":102},[],{"trials":3713,"activeCount":180,"soonestReadout":3718},[3714],{"nctId":3715,"briefTitle":3716,"status":169,"phases":3717,"primaryCompletion":3718,"completion":3718,"start":3719,"enrollment":228,"conditions":3720,"interventions":3722},"NCT05689879","Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis",[92],"2027-01-12","2023-03-23",[3721],"Sarcoidosis",[3704],{"trials":3724,"activeCount":102},[],{"trials":3726,"activeCount":102},[],{"intervention":3728,"totalTrials":180,"cells":3729},"Electronic cigarette without nicotine (ECwN) plus active varenicline",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3736,"PHASE4":3751,"NA":3753},{"trials":3731,"activeCount":102},[],{"trials":3733,"activeCount":102},[],{"trials":3735,"activeCount":102},[],{"trials":3737,"activeCount":180,"soonestReadout":3499},[3738],{"nctId":3739,"briefTitle":3740,"status":169,"phases":3741,"primaryCompletion":3499,"completion":1983,"start":3742,"enrollment":3743,"conditions":3744,"interventions":3748},"NCT03630614","Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation.",[92],"2018-10-17",650,[3745,3746,3747],"Smoking Cessation","Smoking, Cigarette","Electronic Cigarette",[3728,3749,3750],"Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline","Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline",{"trials":3752,"activeCount":102},[],{"trials":3754,"activeCount":102},[],{"intervention":3749,"totalTrials":180,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3763,"PHASE4":3769,"NA":3771},{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":102},[],{"trials":3764,"activeCount":180,"soonestReadout":3499},[3765],{"nctId":3739,"briefTitle":3740,"status":169,"phases":3766,"primaryCompletion":3499,"completion":1983,"start":3742,"enrollment":3743,"conditions":3767,"interventions":3768},[92],[3745,3746,3747],[3728,3749,3750],{"trials":3770,"activeCount":102},[],{"trials":3772,"activeCount":102},[],{"intervention":3750,"totalTrials":180,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3787,"NA":3789},{"trials":3776,"activeCount":102},[],{"trials":3778,"activeCount":102},[],{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":180,"soonestReadout":3499},[3783],{"nctId":3739,"briefTitle":3740,"status":169,"phases":3784,"primaryCompletion":3499,"completion":1983,"start":3742,"enrollment":3743,"conditions":3785,"interventions":3786},[92],[3745,3746,3747],[3728,3749,3750],{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":102},[],{"intervention":135,"totalTrials":180,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3799,"PHASE4":3805,"NA":3807},{"trials":3794,"activeCount":102},[],{"trials":3796,"activeCount":102},[],{"trials":3798,"activeCount":102},[],{"trials":3800,"activeCount":180,"soonestReadout":128},[3801],{"nctId":124,"briefTitle":125,"status":126,"phases":3802,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":3803,"interventions":3804},[92],[132],[134,135],{"trials":3806,"activeCount":102},[],{"trials":3808,"activeCount":102},[],{"intervention":3810,"totalTrials":180,"cells":3811},"Interferon Gamma 1-b",{"EARLY_PHASE1":3812,"PHASE1":3814,"PHASE2":3816,"PHASE3":3818,"PHASE4":3831,"NA":3833},{"trials":3813,"activeCount":102},[],{"trials":3815,"activeCount":102},[],{"trials":3817,"activeCount":102},[],{"trials":3819,"activeCount":180,"soonestReadout":1775},[3820],{"nctId":3821,"briefTitle":3822,"status":152,"phases":3823,"primaryCompletion":1775,"completion":1338,"start":3824,"enrollment":3825,"conditions":3826,"interventions":3830},"NCT06694740","Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo",[91,92],"2026-01-12",170,[3827,3828,3829],"Post-aggressive Immunosuppression","Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6","Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB\u002FC",[3810],{"trials":3832,"activeCount":102},[],{"trials":3834,"activeCount":102},[],{"intervention":1355,"totalTrials":180,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3843,"PHASE4":3849,"NA":3851},{"trials":3838,"activeCount":102},[],{"trials":3840,"activeCount":102},[],{"trials":3842,"activeCount":102},[],{"trials":3844,"activeCount":180,"soonestReadout":1349},[3845],{"nctId":1346,"briefTitle":1347,"status":169,"phases":3846,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1330,"conditions":3847,"interventions":3848},[92],[1353],[1298,1355],{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":102},[],{"intervention":3854,"totalTrials":180,"cells":3855},"BTA group",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3862,"PHASE4":3874,"NA":3876},{"trials":3857,"activeCount":102},[],{"trials":3859,"activeCount":102},[],{"trials":3861,"activeCount":102},[],{"trials":3863,"activeCount":180,"soonestReadout":3868},[3864],{"nctId":3865,"briefTitle":3866,"status":152,"phases":3867,"primaryCompletion":3868,"completion":3869,"start":3870,"enrollment":3193,"conditions":3871,"interventions":3873},"NCT06499324","Surgery with Botulinum Toxin a for Incisional Hernia",[92],"2028-08-04","2029-03-04","2025-01-17",[3872],"Incisional Hernia",[3854],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"intervention":3879,"totalTrials":180,"cells":3880},"Dapagliflozin propanediol",{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3902,"NA":3904},{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":102},[],{"trials":3886,"activeCount":102},[],{"trials":3888,"activeCount":180,"soonestReadout":3893},[3889],{"nctId":3890,"briefTitle":3891,"status":152,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":3895,"conditions":3896,"interventions":3901},"NCT05764057","DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction",[92],"2026-10-12","2023-06-12",450,[3897,3898,3899,3900],"AMI","STEMI","NSTEMI","Left Ventricular Dysfunction",[3879],{"trials":3903,"activeCount":102},[],{"trials":3905,"activeCount":102},[],{"intervention":3907,"totalTrials":180,"cells":3908},"Landiolol",{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3925,"NA":3927},{"trials":3910,"activeCount":102},[],{"trials":3912,"activeCount":102},[],{"trials":3914,"activeCount":102},[],{"trials":3916,"activeCount":180,"soonestReadout":1529},[3917],{"nctId":3918,"briefTitle":3919,"status":152,"phases":3920,"primaryCompletion":1529,"completion":1529,"start":3921,"enrollment":3922,"conditions":3923,"interventions":3924},"NCT04931225","LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)",[92],"2022-07-18",44,[2462],[3907],{"trials":3926,"activeCount":102},[],{"trials":3928,"activeCount":102},[],{"intervention":3930,"totalTrials":180,"cells":3931},"active FMT",{"EARLY_PHASE1":3932,"PHASE1":3934,"PHASE2":3936,"PHASE3":3938,"PHASE4":3948,"NA":3950},{"trials":3933,"activeCount":102},[],{"trials":3935,"activeCount":102},[],{"trials":3937,"activeCount":102},[],{"trials":3939,"activeCount":180,"soonestReadout":1673},[3940],{"nctId":3941,"briefTitle":3942,"status":152,"phases":3943,"primaryCompletion":1673,"completion":1673,"start":3944,"enrollment":36,"conditions":3945,"interventions":3947},"NCT05654753","The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment",[91,92],"2024-03-28",[3946],"Axial Spondyloarthritis",[3930],{"trials":3949,"activeCount":102},[],{"trials":3951,"activeCount":102},[],{"intervention":3953,"totalTrials":180,"cells":3954},"Pembrolizumab, 25 mg\u002Fml solution for intravenous (IV)",{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3971,"NA":3973},{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[],{"trials":3960,"activeCount":102},[],{"trials":3962,"activeCount":180,"soonestReadout":1338},[3963],{"nctId":3964,"briefTitle":3965,"status":126,"phases":3966,"primaryCompletion":1338,"completion":1338,"start":3967,"enrollment":16,"conditions":3968,"interventions":3970},"NCT06276504","Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection",[91,92],"2024-04",[3969],"Progressive Multifocal Leukoencephalopathy",[3953],{"trials":3972,"activeCount":102},[],{"trials":3974,"activeCount":102},[],{"intervention":3976,"totalTrials":180,"cells":3977},"Vaccination",{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3982,"PHASE3":3984,"PHASE4":3997,"NA":3999},{"trials":3979,"activeCount":102},[],{"trials":3981,"activeCount":102},[],{"trials":3983,"activeCount":102},[],{"trials":3985,"activeCount":180,"soonestReadout":3990},[3986],{"nctId":3987,"briefTitle":3988,"status":152,"phases":3989,"primaryCompletion":3990,"completion":3991,"start":3992,"enrollment":3993,"conditions":3994,"interventions":3996},"NCT04814446","Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts",[92],"2025-06-29","2026-06-29","2022-06-29",146,[3995],"Palmar or Plantar Warts",[3976],{"trials":3998,"activeCount":102},[],{"trials":4000,"activeCount":102},[],{"intervention":1822,"totalTrials":180,"cells":4002},{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4007,"PHASE3":4009,"PHASE4":4015,"NA":4017},{"trials":4004,"activeCount":102},[],{"trials":4006,"activeCount":102},[],{"trials":4008,"activeCount":102},[],{"trials":4010,"activeCount":180,"soonestReadout":1775},[4011],{"nctId":1815,"briefTitle":1816,"status":152,"phases":4012,"primaryCompletion":1775,"completion":1775,"start":1818,"enrollment":489,"conditions":4013,"interventions":4014},[92],[1820],[1795,1822,1823,1824],{"trials":4016,"activeCount":102},[],{"trials":4018,"activeCount":102},[],{"intervention":1823,"totalTrials":180,"cells":4020},{"EARLY_PHASE1":4021,"PHASE1":4023,"PHASE2":4025,"PHASE3":4027,"PHASE4":4033,"NA":4035},{"trials":4022,"activeCount":102},[],{"trials":4024,"activeCount":102},[],{"trials":4026,"activeCount":102},[],{"trials":4028,"activeCount":180,"soonestReadout":1775},[4029],{"nctId":1815,"briefTitle":1816,"status":152,"phases":4030,"primaryCompletion":1775,"completion":1775,"start":1818,"enrollment":489,"conditions":4031,"interventions":4032},[92],[1820],[1795,1822,1823,1824],{"trials":4034,"activeCount":102},[],{"trials":4036,"activeCount":102},[],{"intervention":1824,"totalTrials":180,"cells":4038},{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4045,"PHASE4":4051,"NA":4053},{"trials":4040,"activeCount":102},[],{"trials":4042,"activeCount":102},[],{"trials":4044,"activeCount":102},[],{"trials":4046,"activeCount":180,"soonestReadout":1775},[4047],{"nctId":1815,"briefTitle":1816,"status":152,"phases":4048,"primaryCompletion":1775,"completion":1775,"start":1818,"enrollment":489,"conditions":4049,"interventions":4050},[92],[1820],[1795,1822,1823,1824],{"trials":4052,"activeCount":102},[],{"trials":4054,"activeCount":102},[],{"intervention":4056,"totalTrials":180,"cells":4057},"Combination of Rituximab with subcutaneous belimumab",{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4064,"PHASE4":4078,"NA":4080},{"trials":4059,"activeCount":102},[],{"trials":4061,"activeCount":102},[],{"trials":4063,"activeCount":102},[],{"trials":4065,"activeCount":180,"soonestReadout":4070},[4066],{"nctId":4067,"briefTitle":4068,"status":152,"phases":4069,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":4073,"conditions":4074,"interventions":4076},"NCT05338190","Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia",[92],"2026-11-14","2027-11-14","2022-11-14",132,[4075],"Primary Immune Thrombocytopenia (ITP)",[4056,4077],"Combination of Rituximab with subcutaneous placebo",{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":102},[],{"intervention":4077,"totalTrials":180,"cells":4083},{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4090,"PHASE4":4096,"NA":4098},{"trials":4085,"activeCount":102},[],{"trials":4087,"activeCount":102},[],{"trials":4089,"activeCount":102},[],{"trials":4091,"activeCount":180,"soonestReadout":4070},[4092],{"nctId":4067,"briefTitle":4068,"status":152,"phases":4093,"primaryCompletion":4070,"completion":4071,"start":4072,"enrollment":4073,"conditions":4094,"interventions":4095},[92],[4075],[4056,4077],{"trials":4097,"activeCount":102},[],{"trials":4099,"activeCount":102},[],{"intervention":4101,"totalTrials":180,"cells":4102},"Trumenba®",{"EARLY_PHASE1":4103,"PHASE1":4105,"PHASE2":4107,"PHASE3":4109,"PHASE4":4121,"NA":4123},{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":180,"soonestReadout":4115},[4111],{"nctId":4112,"briefTitle":4113,"status":152,"phases":4114,"primaryCompletion":4115,"completion":288,"start":4116,"enrollment":1474,"conditions":4117,"interventions":4119},"NCT04166656","Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.",[92],"2028-09","2022-09-15",[4118],"Splenectomy",[4101,4120],"Bexsero®",{"trials":4122,"activeCount":102},[],{"trials":4124,"activeCount":102},[],{"intervention":4120,"totalTrials":180,"cells":4126},{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4133,"PHASE4":4139,"NA":4141},{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[],{"trials":4132,"activeCount":102},[],{"trials":4134,"activeCount":180,"soonestReadout":4115},[4135],{"nctId":4112,"briefTitle":4113,"status":152,"phases":4136,"primaryCompletion":4115,"completion":288,"start":4116,"enrollment":1474,"conditions":4137,"interventions":4138},[92],[4118],[4101,4120],{"trials":4140,"activeCount":102},[],{"trials":4142,"activeCount":102},[],{"intervention":1691,"totalTrials":180,"cells":4144},{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4151,"PHASE4":4157,"NA":4159},{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":180,"soonestReadout":1683},[4153],{"nctId":1680,"briefTitle":1681,"status":152,"phases":4154,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":4155,"interventions":4156},[92],[1687,1688,1689],[1659,1691],{"trials":4158,"activeCount":102},[],{"trials":4160,"activeCount":102},[],{"intervention":4162,"totalTrials":180,"cells":4163},"Dexamethasone IV",{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4183,"NA":4185},{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"trials":4171,"activeCount":180,"soonestReadout":4176},[4172],{"nctId":4173,"briefTitle":4174,"status":126,"phases":4175,"primaryCompletion":4176,"completion":4177,"start":4178,"enrollment":4179,"conditions":4180,"interventions":4182},"NCT06722118","Corticosteroids Before Extubation in Pediatric Intensive Care Unit",[92],"2028-06","2028-07","2025-06-15",348,[4181],"Intensive Care Pediatric",[4162],{"trials":4184,"activeCount":102},[],{"trials":4186,"activeCount":102},[],{"intervention":4188,"totalTrials":180,"cells":4189},"Lenalidomide",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4196,"PHASE4":4208,"NA":4210},{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[],{"trials":4197,"activeCount":180,"soonestReadout":917},[4198],{"nctId":4199,"briefTitle":4200,"status":126,"phases":4201,"primaryCompletion":917,"completion":4202,"start":4203,"enrollment":4204,"conditions":4205,"interventions":4207},"NCT06965244","Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus",[92],"2029-04-01","2025-10-01",122,[4206],"Cutaneous Lupus Erythematosus (CLE)",[4188,1737],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[],{"intervention":2064,"totalTrials":180,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4220,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[],{"trials":4221,"activeCount":180,"soonestReadout":2057},[4222],{"nctId":2054,"briefTitle":2055,"status":152,"phases":4223,"primaryCompletion":2057,"completion":2058,"start":2059,"enrollment":2060,"conditions":4224,"interventions":4225},[92],[2062],[2064,2032],{"trials":4227,"activeCount":102},[],{"trials":4229,"activeCount":102},[],{"intervention":4231,"totalTrials":180,"cells":4232},"Βeta-Blockers discontinued",{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4251,"NA":4253},{"trials":4234,"activeCount":102},[],{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":180,"soonestReadout":4245},[4241],{"nctId":4242,"briefTitle":4243,"status":152,"phases":4244,"primaryCompletion":4245,"completion":4245,"start":4246,"enrollment":4247,"conditions":4248,"interventions":4250},"NCT06518694","Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction",[92],"2027-10","2025-02-11",1300,[4249],"Heart Failure",[4231],{"trials":4252,"activeCount":102},[],{"trials":4254,"activeCount":102},[],{"intervention":4256,"totalTrials":180,"cells":4257},"Ethiodized Oil-based emulsion",{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4264,"PHASE4":4275,"NA":4277},{"trials":4259,"activeCount":102},[],{"trials":4261,"activeCount":102},[],{"trials":4263,"activeCount":102},[],{"trials":4265,"activeCount":180,"soonestReadout":4270},[4266],{"nctId":4267,"briefTitle":4268,"status":152,"phases":4269,"primaryCompletion":4270,"completion":4271,"start":4272,"enrollment":3299,"conditions":4273,"interventions":4274},"NCT06497140","Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2",[92],"2028-01-01","2028-10-01","2024-09-30",[2255],[4256],{"trials":4276,"activeCount":102},[],{"trials":4278,"activeCount":102},[],{"intervention":4280,"totalTrials":180,"cells":4281},"Nifedipine",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4300,"NA":4302},{"trials":4283,"activeCount":102},[],{"trials":4285,"activeCount":102},[],{"trials":4287,"activeCount":102},[],{"trials":4289,"activeCount":180,"soonestReadout":1095},[4290],{"nctId":4291,"briefTitle":4292,"status":169,"phases":4293,"primaryCompletion":1095,"completion":4294,"start":4295,"enrollment":4296,"conditions":4297,"interventions":4299},"NCT03976063","Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation",[92],"2031-11","2019-10-07",857,[4298],"Preterm Premature Rupture of Membrane",[4280],{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"intervention":4305,"totalTrials":180,"cells":4306},"Levetiracetam IV",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4324,"NA":4326},{"trials":4308,"activeCount":102},[],{"trials":4310,"activeCount":102},[],{"trials":4312,"activeCount":102},[],{"trials":4314,"activeCount":180,"soonestReadout":4319},[4315],{"nctId":4316,"briefTitle":4317,"status":126,"phases":4318,"primaryCompletion":4319,"completion":4319,"start":4320,"enrollment":4321,"conditions":4322,"interventions":4323},"NCT06851078","Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial",[92],"2027-06-15","2025-03-15",280,[2462],[4305],{"trials":4325,"activeCount":102},[],{"trials":4327,"activeCount":102},[],{"intervention":161,"totalTrials":180,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4336,"PHASE4":4342,"NA":4344},{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"trials":4335,"activeCount":102},[],{"trials":4337,"activeCount":180,"soonestReadout":154},[4338],{"nctId":150,"briefTitle":151,"status":152,"phases":4339,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":4340,"interventions":4341},[92],[159],[161,162,97],{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"intervention":162,"totalTrials":180,"cells":4347},{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4354,"PHASE4":4360,"NA":4362},{"trials":4349,"activeCount":102},[],{"trials":4351,"activeCount":102},[],{"trials":4353,"activeCount":102},[],{"trials":4355,"activeCount":180,"soonestReadout":154},[4356],{"nctId":150,"briefTitle":151,"status":152,"phases":4357,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":4358,"interventions":4359},[92],[159],[161,162,97],{"trials":4361,"activeCount":102},[],{"trials":4363,"activeCount":102},[],{"intervention":4365,"totalTrials":180,"cells":4366},"Continue the antimicrobial treatment",{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4373,"PHASE4":4384,"NA":4386},{"trials":4368,"activeCount":102},[],{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":180,"soonestReadout":2087},[4375],{"nctId":4376,"briefTitle":4377,"status":152,"phases":4378,"primaryCompletion":2087,"completion":2087,"start":4379,"enrollment":4380,"conditions":4381,"interventions":4383},"NCT05903352","Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia",[92],"2024-02-05",328,[4382],"Community-Acquired Pneumonia",[4365],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"intervention":4389,"totalTrials":180,"cells":4390},"Cyclic peptide Fertiline",{"EARLY_PHASE1":4391,"PHASE1":4393,"PHASE2":4395,"PHASE3":4397,"PHASE4":4412,"NA":4414},{"trials":4392,"activeCount":102},[],{"trials":4394,"activeCount":102},[],{"trials":4396,"activeCount":102},[],{"trials":4398,"activeCount":180,"soonestReadout":4403},[4399],{"nctId":4400,"briefTitle":4401,"status":169,"phases":4402,"primaryCompletion":4403,"completion":4404,"start":4405,"enrollment":4406,"conditions":4407,"interventions":4411},"NCT04954274","Improvement of Live Babies Rates After ICSI, Using cpFT",[92],"2026-07-29","2027-07-29","2021-07-29",366,[4408,4409,4410],"Infertility","Oocyte","Pregnancy",[4389],{"trials":4413,"activeCount":102},[],{"trials":4415,"activeCount":102},[],{"intervention":4417,"totalTrials":180,"cells":4418},"Intervention Group",{"EARLY_PHASE1":4419,"PHASE1":4421,"PHASE2":4423,"PHASE3":4425,"PHASE4":4438,"NA":4440},{"trials":4420,"activeCount":102},[],{"trials":4422,"activeCount":102},[],{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":180,"soonestReadout":4431},[4427],{"nctId":4428,"briefTitle":4429,"status":126,"phases":4430,"primaryCompletion":4431,"completion":4432,"start":4433,"enrollment":4434,"conditions":4435,"interventions":4437},"NCT07590687","KetAmine and Recovery After Mechanical VentilAtion ( KARMA )",[92],"2029-12-19","2030-01-19","2026-10-19",640,[4436],"Critical Illness",[4417],{"trials":4439,"activeCount":102},[],{"trials":4441,"activeCount":102},[],{"intervention":4443,"totalTrials":180,"cells":4444},"Brentuximab Vedotin",{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4462,"NA":4464},{"trials":4446,"activeCount":102},[],{"trials":4448,"activeCount":102},[],{"trials":4450,"activeCount":102},[],{"trials":4452,"activeCount":180,"soonestReadout":4457},[4453],{"nctId":4454,"briefTitle":4455,"status":126,"phases":4456,"primaryCompletion":4457,"completion":4457,"start":4458,"enrollment":1474,"conditions":4459,"interventions":4461},"NCT07178457","Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance",[92],"2032-11-01","2025-11-01",[4460,4443],"Cutaneous T Cell Lymphoma (CTCL)",[4443],{"trials":4463,"activeCount":102},[],{"trials":4465,"activeCount":102},[],{"intervention":1477,"totalTrials":180,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4474,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":102},[],{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":180,"soonestReadout":1472},[4476],{"nctId":1469,"briefTitle":1470,"status":152,"phases":4477,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":1474,"conditions":4478,"interventions":4479},[92],[1449],[1467,1477],{"trials":4481,"activeCount":102},[],{"trials":4483,"activeCount":102},[],{"intervention":4485,"totalTrials":180,"cells":4486},"Short antibiotic treatment",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4493,"PHASE4":4507,"NA":4509},{"trials":4488,"activeCount":102},[],{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":180,"soonestReadout":4499},[4495],{"nctId":4496,"briefTitle":4497,"status":152,"phases":4498,"primaryCompletion":4499,"completion":4500,"start":4501,"enrollment":4502,"conditions":4503,"interventions":4505},"NCT05597540","Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.",[92],"2027-03-22","2027-08-22","2024-02-22",470,[806,4504],"Kidney Transplant Infection",[4485,4506],"Usual antibiotic treatment",{"trials":4508,"activeCount":102},[],{"trials":4510,"activeCount":102},[],{"intervention":4506,"totalTrials":180,"cells":4512},{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4517,"PHASE3":4519,"PHASE4":4525,"NA":4527},{"trials":4514,"activeCount":102},[],{"trials":4516,"activeCount":102},[],{"trials":4518,"activeCount":102},[],{"trials":4520,"activeCount":180,"soonestReadout":4499},[4521],{"nctId":4496,"briefTitle":4497,"status":152,"phases":4522,"primaryCompletion":4499,"completion":4500,"start":4501,"enrollment":4502,"conditions":4523,"interventions":4524},[92],[806,4504],[4485,4506],{"trials":4526,"activeCount":102},[],{"trials":4528,"activeCount":102},[],{"intervention":4530,"totalTrials":180,"cells":4531},"Corticosteroids + Rivaroxaban",{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4538,"PHASE4":4552,"NA":4554},{"trials":4533,"activeCount":102},[],{"trials":4535,"activeCount":102},[],{"trials":4537,"activeCount":102},[],{"trials":4539,"activeCount":180,"soonestReadout":4544},[4540],{"nctId":4541,"briefTitle":4542,"status":152,"phases":4543,"primaryCompletion":4544,"completion":4545,"start":4546,"enrollment":4547,"conditions":4548,"interventions":4550},"NCT06780462","Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome",[92],"2027-12-24","2028-06-24","2025-06-24",134,[4549],"Behcet Syndrome",[4530,4551],"Corticosteroids alone",{"trials":4553,"activeCount":102},[],{"trials":4555,"activeCount":102},[],{"intervention":4551,"totalTrials":180,"cells":4557},{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4564,"PHASE4":4570,"NA":4572},{"trials":4559,"activeCount":102},[],{"trials":4561,"activeCount":102},[],{"trials":4563,"activeCount":102},[],{"trials":4565,"activeCount":180,"soonestReadout":4544},[4566],{"nctId":4541,"briefTitle":4542,"status":152,"phases":4567,"primaryCompletion":4544,"completion":4545,"start":4546,"enrollment":4547,"conditions":4568,"interventions":4569},[92],[4549],[4530,4551],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[],{"intervention":4575,"totalTrials":180,"cells":4576},"Combination of antibiotics",{"EARLY_PHASE1":4577,"PHASE1":4579,"PHASE2":4581,"PHASE3":4583,"PHASE4":4595,"NA":4597},{"trials":4578,"activeCount":102},[],{"trials":4580,"activeCount":102},[],{"trials":4582,"activeCount":102},[],{"trials":4584,"activeCount":180,"soonestReadout":1312},[4585],{"nctId":4586,"briefTitle":4587,"status":126,"phases":4588,"primaryCompletion":1312,"completion":1312,"start":4589,"enrollment":4590,"conditions":4591,"interventions":4593},"NCT06572761","A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor",[92],"2026-09",350,[4592],"Previable Labour With Intact Membranes",[4575,4594],"Vaginal progesterone",{"trials":4596,"activeCount":102},[],{"trials":4598,"activeCount":102},[],{"intervention":4594,"totalTrials":180,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4607,"PHASE4":4613,"NA":4615},{"trials":4602,"activeCount":102},[],{"trials":4604,"activeCount":102},[],{"trials":4606,"activeCount":102},[],{"trials":4608,"activeCount":180,"soonestReadout":1312},[4609],{"nctId":4586,"briefTitle":4587,"status":126,"phases":4610,"primaryCompletion":1312,"completion":1312,"start":4589,"enrollment":4590,"conditions":4611,"interventions":4612},[92],[4592],[4575,4594],{"trials":4614,"activeCount":102},[],{"trials":4616,"activeCount":102},[],{"intervention":4618,"totalTrials":180,"cells":4619},"Grafalon",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4639,"NA":4641},{"trials":4621,"activeCount":102},[],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[],{"trials":4627,"activeCount":180,"soonestReadout":4632},[4628],{"nctId":4629,"briefTitle":4630,"status":152,"phases":4631,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":4634,"conditions":4635,"interventions":4637},"NCT06083129","Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10\u002F10 HLA Matched Unrelated Donor",[92],"2028-11-28","2023-11-28",324,[4636],"GVHD",[4618,4638],"Thymoglobulin",{"trials":4640,"activeCount":102},[],{"trials":4642,"activeCount":102},[],{"intervention":4638,"totalTrials":180,"cells":4644},{"EARLY_PHASE1":4645,"PHASE1":4647,"PHASE2":4649,"PHASE3":4651,"PHASE4":4657,"NA":4659},{"trials":4646,"activeCount":102},[],{"trials":4648,"activeCount":102},[],{"trials":4650,"activeCount":102},[],{"trials":4652,"activeCount":180,"soonestReadout":4632},[4653],{"nctId":4629,"briefTitle":4630,"status":152,"phases":4654,"primaryCompletion":4632,"completion":4632,"start":4633,"enrollment":4634,"conditions":4655,"interventions":4656},[92],[4636],[4618,4638],{"trials":4658,"activeCount":102},[],{"trials":4660,"activeCount":102},[],{"intervention":4662,"totalTrials":180,"cells":4663},"hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +\u002F- 6 months",{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4683,"NA":4685},{"trials":4665,"activeCount":102},[],{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[],{"trials":4671,"activeCount":180,"soonestReadout":4676},[4672],{"nctId":4673,"briefTitle":4674,"status":152,"phases":4675,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":303,"conditions":4679,"interventions":4681},"NCT06351501","Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria",[92],"2029-06-24","2031-06-24","2024-06-25",[4680],"Gender Dysphoria",[4662,4682],"Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +\u002F- 6 months",{"trials":4684,"activeCount":102},[],{"trials":4686,"activeCount":102},[],{"intervention":4682,"totalTrials":180,"cells":4688},{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4693,"PHASE3":4695,"PHASE4":4701,"NA":4703},{"trials":4690,"activeCount":102},[],{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":180,"soonestReadout":4676},[4697],{"nctId":4673,"briefTitle":4674,"status":152,"phases":4698,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":303,"conditions":4699,"interventions":4700},[92],[4680],[4662,4682],{"trials":4702,"activeCount":102},[],{"trials":4704,"activeCount":102},[],{"intervention":1630,"totalTrials":180,"cells":4706},{"EARLY_PHASE1":4707,"PHASE1":4709,"PHASE2":4711,"PHASE3":4713,"PHASE4":4719,"NA":4721},{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[],{"trials":4712,"activeCount":102},[],{"trials":4714,"activeCount":180,"soonestReadout":1622},[4715],{"nctId":1619,"briefTitle":1620,"status":152,"phases":4716,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":1625,"conditions":4717,"interventions":4718},[92],[1627,1628],[1630,1631],{"trials":4720,"activeCount":102},[],{"trials":4722,"activeCount":102},[],{"intervention":4724,"totalTrials":180,"cells":4725},"Colchicine 0.5 MG",{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4730,"PHASE3":4732,"PHASE4":4749,"NA":4751},{"trials":4727,"activeCount":102},[],{"trials":4729,"activeCount":102},[],{"trials":4731,"activeCount":102},[],{"trials":4733,"activeCount":180,"soonestReadout":128},[4734],{"nctId":4735,"briefTitle":4736,"status":152,"phases":4737,"primaryCompletion":128,"completion":128,"start":4738,"enrollment":4739,"conditions":4740,"interventions":4746},"NCT05476991","Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis",[92],"2023-05-17",2800,[464,3548,4741,4742,4743,4744,4745,466],"Atherosclerosis","Myocardial Infarction","Coronary Syndrome","TIA","Cardiac Disease",[4724,4747,4748],"Ticagrelor 90mg","Aspirin 75-300mg",{"trials":4750,"activeCount":102},[],{"trials":4752,"activeCount":102},[],{"intervention":4747,"totalTrials":180,"cells":4754},{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4759,"PHASE3":4761,"PHASE4":4767,"NA":4769},{"trials":4756,"activeCount":102},[],{"trials":4758,"activeCount":102},[],{"trials":4760,"activeCount":102},[],{"trials":4762,"activeCount":180,"soonestReadout":128},[4763],{"nctId":4735,"briefTitle":4736,"status":152,"phases":4764,"primaryCompletion":128,"completion":128,"start":4738,"enrollment":4739,"conditions":4765,"interventions":4766},[92],[464,3548,4741,4742,4743,4744,4745,466],[4724,4747,4748],{"trials":4768,"activeCount":102},[],{"trials":4770,"activeCount":102},[],{"intervention":4748,"totalTrials":180,"cells":4772},{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4777,"PHASE3":4779,"PHASE4":4785,"NA":4787},{"trials":4774,"activeCount":102},[],{"trials":4776,"activeCount":102},[],{"trials":4778,"activeCount":102},[],{"trials":4780,"activeCount":180,"soonestReadout":128},[4781],{"nctId":4735,"briefTitle":4736,"status":152,"phases":4782,"primaryCompletion":128,"completion":128,"start":4738,"enrollment":4739,"conditions":4783,"interventions":4784},[92],[464,3548,4741,4742,4743,4744,4745,466],[4724,4747,4748],{"trials":4786,"activeCount":102},[],{"trials":4788,"activeCount":102},[],{"intervention":4790,"totalTrials":180,"cells":4791},"Postoperative reintroduction of FOLFIRI based chemotherapy",{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4811,"NA":4813},{"trials":4793,"activeCount":102},[],{"trials":4795,"activeCount":102},[],{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":180,"soonestReadout":4804},[4800],{"nctId":4801,"briefTitle":4802,"status":152,"phases":4803,"primaryCompletion":4804,"completion":4805,"start":3649,"enrollment":4806,"conditions":4807,"interventions":4810},"NCT06501482","Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI",[92],"2028-06-27","2031-06-27",254,[4808,4809],"Colorectal Cancer","Colorectal Liver Metastases",[4790],{"trials":4812,"activeCount":102},[],{"trials":4814,"activeCount":102},[],{"intervention":4816,"totalTrials":180,"cells":4817},"Colchicine Pill",{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4835,"NA":4837},{"trials":4819,"activeCount":102},[],{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[],{"trials":4825,"activeCount":180,"soonestReadout":4830},[4826],{"nctId":4827,"briefTitle":4828,"status":152,"phases":4829,"primaryCompletion":4830,"completion":4831,"start":4832,"enrollment":489,"conditions":4833,"interventions":4834},"NCT05855746","Colchicine Versus Placebo in Acute Myocarditis Patients",[92],"2028-01-16","2028-07-16","2024-07-16",[2511],[4816],{"trials":4836,"activeCount":102},[],{"trials":4838,"activeCount":102},[],{"intervention":4840,"totalTrials":180,"cells":4841},"Fampridine 10 mg prolonged-release",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4848,"PHASE4":4859,"NA":4861},{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"trials":4849,"activeCount":180,"soonestReadout":4854},[4850],{"nctId":4851,"briefTitle":4852,"status":152,"phases":4853,"primaryCompletion":4854,"completion":4854,"start":4855,"enrollment":400,"conditions":4856,"interventions":4858},"NCT07185347","A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene",[92],"2027-05-21","2025-10-21",[4857],"Spinocerebellar Ataxia 27B (SCA27B)",[4840],{"trials":4860,"activeCount":102},[],{"trials":4862,"activeCount":102},[],{"intervention":4864,"totalTrials":180,"cells":4865},"Sufentanil",{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4872,"PHASE4":4885,"NA":4887},{"trials":4867,"activeCount":102},[],{"trials":4869,"activeCount":102},[],{"trials":4871,"activeCount":102},[],{"trials":4873,"activeCount":180,"soonestReadout":4878},[4874],{"nctId":4875,"briefTitle":4876,"status":126,"phases":4877,"primaryCompletion":4878,"completion":4879,"start":4880,"enrollment":4881,"conditions":4882,"interventions":4884},"NCT06181695","Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric",[92],"2026-05-30","2027-05-29","2024-05-02",182,[4883],"Vaso-occlusive Crisis",[4864],{"trials":4886,"activeCount":102},[],{"trials":4888,"activeCount":102},[],{"intervention":2026,"totalTrials":180,"cells":4890},{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4895,"PHASE3":4897,"PHASE4":4903,"NA":4905},{"trials":4892,"activeCount":102},[],{"trials":4894,"activeCount":102},[],{"trials":4896,"activeCount":102},[],{"trials":4898,"activeCount":180,"soonestReadout":2017},[4899],{"nctId":2014,"briefTitle":2015,"status":152,"phases":4900,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":2020,"conditions":4901,"interventions":4902},[92],[2022,2023,2024],[1994,2026],{"trials":4904,"activeCount":102},[],{"trials":4906,"activeCount":102},[],{"intervention":4908,"totalTrials":180,"cells":4909},"Alteplase",{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4914,"PHASE3":4916,"PHASE4":4928,"NA":4930},{"trials":4911,"activeCount":102},[],{"trials":4913,"activeCount":102},[],{"trials":4915,"activeCount":102},[],{"trials":4917,"activeCount":180,"soonestReadout":4589},[4918],{"nctId":4919,"briefTitle":4920,"status":152,"phases":4921,"primaryCompletion":4589,"completion":4922,"start":4923,"enrollment":4924,"conditions":4925,"interventions":4927},"NCT04430569","Pulmonary Embolism International THrOmbolysis Study-3",[92],"2028-08","2021-08-04",800,[4926],"Pulmonary Embolism",[4908],{"trials":4929,"activeCount":102},[],{"trials":4931,"activeCount":102},[],{"intervention":4933,"totalTrials":180,"cells":4934},"Cyclophosphamide 35mg\u002Fkg\u002Fday",{"EARLY_PHASE1":4935,"PHASE1":4937,"PHASE2":4939,"PHASE3":4941,"PHASE4":4955,"NA":4957},{"trials":4936,"activeCount":102},[],{"trials":4938,"activeCount":102},[],{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":180,"soonestReadout":4947},[4943],{"nctId":4944,"briefTitle":4945,"status":126,"phases":4946,"primaryCompletion":4947,"completion":4947,"start":194,"enrollment":4948,"conditions":4949,"interventions":4953},"NCT07193420","Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies",[92],"2030-06",180,[4950,4951,4952],"GVHD - Graft-Versus-Host Disease","HSCT","Haploidentical Stem Cell Transplantation",[4933,4954],"Cyclophosphamide 50mg\u002Fkg\u002Fday",{"trials":4956,"activeCount":102},[],{"trials":4958,"activeCount":102},[],{"intervention":4954,"totalTrials":180,"cells":4960},{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4973,"NA":4975},{"trials":4962,"activeCount":102},[],{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[],{"trials":4968,"activeCount":180,"soonestReadout":4947},[4969],{"nctId":4944,"briefTitle":4945,"status":126,"phases":4970,"primaryCompletion":4947,"completion":4947,"start":194,"enrollment":4948,"conditions":4971,"interventions":4972},[92],[4950,4951,4952],[4933,4954],{"trials":4974,"activeCount":102},[],{"trials":4976,"activeCount":102},[],{"intervention":4978,"totalTrials":180,"cells":4979},"Administration of fecal microbiota transplantation",{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4986,"PHASE4":4998,"NA":5000},{"trials":4981,"activeCount":102},[],{"trials":4983,"activeCount":102},[],{"trials":4985,"activeCount":102},[],{"trials":4987,"activeCount":180,"soonestReadout":4992},[4988],{"nctId":4989,"briefTitle":4990,"status":126,"phases":4991,"primaryCompletion":4992,"completion":4993,"start":129,"enrollment":1330,"conditions":4994,"interventions":4996},"NCT06433180","Study of Fecal Microbiota Transplantation (FMT) in Severe IBS Patients",[92],"2028-07-15","2029-07-15",[4995],"Irritable Bowel Syndrome",[4978,4997],"Administration of the sham",{"trials":4999,"activeCount":102},[],{"trials":5001,"activeCount":102},[],{"intervention":4997,"totalTrials":180,"cells":5003},{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5010,"PHASE4":5016,"NA":5018},{"trials":5005,"activeCount":102},[],{"trials":5007,"activeCount":102},[],{"trials":5009,"activeCount":102},[],{"trials":5011,"activeCount":180,"soonestReadout":4992},[5012],{"nctId":4989,"briefTitle":4990,"status":126,"phases":5013,"primaryCompletion":4992,"completion":4993,"start":129,"enrollment":1330,"conditions":5014,"interventions":5015},[92],[4995],[4978,4997],{"trials":5017,"activeCount":102},[],{"trials":5019,"activeCount":102},[],{"intervention":2266,"totalTrials":180,"cells":5021},{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5028,"PHASE4":5034,"NA":5036},{"trials":5023,"activeCount":102},[],{"trials":5025,"activeCount":102},[],{"trials":5027,"activeCount":102},[],{"trials":5029,"activeCount":180,"soonestReadout":871},[5030],{"nctId":2259,"briefTitle":2260,"status":126,"phases":5031,"primaryCompletion":871,"completion":1410,"start":2262,"enrollment":206,"conditions":5032,"interventions":5033},[92],[2264],[2266,2267,2268,2269],{"trials":5035,"activeCount":102},[],{"trials":5037,"activeCount":102},[],{"intervention":2268,"totalTrials":180,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5044,"PHASE3":5046,"PHASE4":5052,"NA":5054},{"trials":5041,"activeCount":102},[],{"trials":5043,"activeCount":102},[],{"trials":5045,"activeCount":102},[],{"trials":5047,"activeCount":180,"soonestReadout":871},[5048],{"nctId":2259,"briefTitle":2260,"status":126,"phases":5049,"primaryCompletion":871,"completion":1410,"start":2262,"enrollment":206,"conditions":5050,"interventions":5051},[92],[2264],[2266,2267,2268,2269],{"trials":5053,"activeCount":102},[],{"trials":5055,"activeCount":102},[],{"intervention":2269,"totalTrials":180,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5064,"PHASE4":5070,"NA":5072},{"trials":5059,"activeCount":102},[],{"trials":5061,"activeCount":102},[],{"trials":5063,"activeCount":102},[],{"trials":5065,"activeCount":180,"soonestReadout":871},[5066],{"nctId":2259,"briefTitle":2260,"status":126,"phases":5067,"primaryCompletion":871,"completion":1410,"start":2262,"enrollment":206,"conditions":5068,"interventions":5069},[92],[2264],[2266,2267,2268,2269],{"trials":5071,"activeCount":102},[],{"trials":5073,"activeCount":102},[],{"intervention":5075,"totalTrials":180,"cells":5076},"Aspirin + Acid folic",{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5081,"PHASE3":5083,"PHASE4":5092,"NA":5094},{"trials":5078,"activeCount":102},[],{"trials":5080,"activeCount":102},[],{"trials":5082,"activeCount":102},[],{"trials":5084,"activeCount":180,"soonestReadout":4202},[5085],{"nctId":5086,"briefTitle":5087,"status":126,"phases":5088,"primaryCompletion":4202,"completion":1274,"start":1276,"enrollment":2253,"conditions":5089,"interventions":5091},"NCT07113158","Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss",[92],[5090],"Sudden Sensorineural Hearing Loss",[5075],{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"intervention":5097,"totalTrials":180,"cells":5098},"Botulinum Toxin Type A Injection [Xeomin]",{"EARLY_PHASE1":5099,"PHASE1":5101,"PHASE2":5103,"PHASE3":5105,"PHASE4":5117,"NA":5119},{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[],{"trials":5106,"activeCount":180,"soonestReadout":5111},[5107],{"nctId":5108,"briefTitle":5109,"status":152,"phases":5110,"primaryCompletion":5111,"completion":3190,"start":5112,"enrollment":5113,"conditions":5114,"interventions":5116},"NCT04075981","Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)",[92],"2025-10-30","2019-09-30",220,[5115],"Cardiac Surgery",[5097],{"trials":5118,"activeCount":102},[],{"trials":5120,"activeCount":102},[],{"intervention":5122,"totalTrials":280,"cells":5123},"Ketamine",{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5128,"PHASE3":5130,"PHASE4":5177,"NA":5190},{"trials":5125,"activeCount":102},[],{"trials":5127,"activeCount":102},[],{"trials":5129,"activeCount":102},[],{"trials":5131,"activeCount":180,"soonestReadout":5136},[5132,5140,5148,5158,5167],{"nctId":5133,"briefTitle":5134,"status":152,"phases":5135,"primaryCompletion":5136,"completion":1107,"start":2196,"enrollment":303,"conditions":5137,"interventions":5139},"NCT06508710","Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients",[92],"2026-03",[5138],"Major Depressive Episode",[5122],{"nctId":5141,"briefTitle":5142,"status":139,"phases":5143,"primaryCompletion":1909,"completion":1909,"start":5144,"enrollment":3149,"conditions":5145,"interventions":5147},"NCT00484484","Ketamine Associated With Opioids in Refractory Cancer Pain Treatment",[92],"2007-05",[5146],"Pain",[5122],{"nctId":5149,"briefTitle":5150,"status":139,"phases":5151,"primaryCompletion":5152,"completion":5152,"start":5153,"enrollment":5154,"conditions":5155,"interventions":5157},"NCT02892916","Ketamine and Postoperative Cognitive Dysfunction",[92],"2019-08-31","2017-03-20",307,[5156],"Post Operative Cognitive Dysfunction",[5122],{"nctId":5159,"briefTitle":5160,"status":139,"phases":5161,"primaryCompletion":5162,"completion":386,"start":5163,"enrollment":27,"conditions":5164,"interventions":5165},"NCT01326325","Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment",[92],"2013-02","2011-07",[5146],[5122,5166],"NaCl",{"nctId":5168,"briefTitle":5169,"status":139,"phases":5170,"completion":5171,"start":2151,"enrollment":1108,"conditions":5172,"interventions":5176},"NCT00224588","KETOR: Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain",[92],"2005-05",[5122,5173,5174,5146,5175],"Chronic Post Thoracotomy Pain","Thoracotomy","Neuralgia",[5122],{"trials":5178,"activeCount":102},[5179],{"nctId":5180,"briefTitle":5181,"status":139,"phases":5182,"primaryCompletion":5183,"completion":5183,"start":5184,"enrollment":5185,"conditions":5186,"interventions":5188},"NCT00440102","Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity",[93],"2008-03","2007-04",655,[5187],"Intubation; Difficult",[5122,5189],"Etomidate",{"trials":5191,"activeCount":102},[5192,5202],{"nctId":5193,"briefTitle":5194,"status":110,"phases":5195,"completion":957,"start":5196,"enrollment":3149,"conditions":5197,"interventions":5200},"NCT00122759","Ketamine Sedation in Mechanically Ventilated Patients",[94],"2005-12",[5198,5146,5199],"Respiratory Insufficiency","Psychomotor Agitation",[5201],"ketamine",{"nctId":5203,"briefTitle":5204,"status":139,"phases":5205,"primaryCompletion":523,"completion":523,"start":1000,"enrollment":1001,"conditions":5206,"interventions":5208},"NCT01146145","Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine",[94],[5207],"Postoperative Pain",[5122],{"intervention":1737,"totalTrials":473,"cells":5210},{"EARLY_PHASE1":5211,"PHASE1":5213,"PHASE2":5224,"PHASE3":5226,"PHASE4":5248,"NA":5260},{"trials":5212,"activeCount":102},[],{"trials":5214,"activeCount":102},[5215],{"nctId":5216,"briefTitle":5217,"status":110,"phases":5218,"primaryCompletion":2160,"completion":5219,"start":4116,"enrollment":1225,"conditions":5220,"interventions":5222},"NCT05135858","Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma",[90],"2025-07-31",[5221],"Primary Central Nervous System Lymphoma",[5223,1737],"Glucarpidase",{"trials":5225,"activeCount":102},[],{"trials":5227,"activeCount":180,"soonestReadout":917},[5228,5232,5244],{"nctId":1727,"briefTitle":1728,"status":110,"phases":5229,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":5230,"interventions":5231},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"nctId":5233,"briefTitle":5234,"status":110,"phases":5235,"primaryCompletion":5236,"completion":5236,"start":342,"enrollment":5237,"conditions":5238,"interventions":5243},"NCT03371667","To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids",[92],"2024-12",102,[5239,5240,5241,5242],"Allogeneic Disease","GVH - Graft Versus Host Reaction","GVHD, Acute","Stem Cell Transplant Complications",[1737],{"nctId":4199,"briefTitle":4200,"status":126,"phases":5245,"primaryCompletion":917,"completion":4202,"start":4203,"enrollment":4204,"conditions":5246,"interventions":5247},[92],[4206],[4188,1737],{"trials":5249,"activeCount":102},[5250],{"nctId":5251,"briefTitle":5252,"status":241,"phases":5253,"primaryCompletion":5254,"completion":5254,"start":1909,"enrollment":1361,"conditions":5255,"interventions":5259},"NCT00918554","Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis",[93],"2010-08",[5256,5257,5258],"Sarcoid-associated Uveitis","Ocular Sarcoidosis","Macular Edema",[1737],{"trials":5261,"activeCount":102},[5262],{"nctId":5263,"briefTitle":5264,"status":139,"phases":5265,"primaryCompletion":5266,"completion":5267,"start":5268,"enrollment":5269,"conditions":5270,"interventions":5272},"NCT04360785","Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis",[94],"2022-09-13","2023-02-27","2020-11-11",124,[5271],"Spondyloarthritis",[1737],{"intervention":5274,"totalTrials":429,"cells":5275},"pioglitazone",{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5282,"PHASE4":5305,"NA":5307},{"trials":5277,"activeCount":102},[],{"trials":5279,"activeCount":102},[],{"trials":5281,"activeCount":102},[],{"trials":5283,"activeCount":180,"soonestReadout":5288},[5284,5297],{"nctId":5285,"briefTitle":5286,"status":152,"phases":5287,"primaryCompletion":5288,"completion":5289,"start":5290,"enrollment":1531,"conditions":5291,"interventions":5295},"NCT05946564","A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial",[92],"2027-04-24","2027-10-24","2023-10-24",[5292,5293,5294],"ANCA Associated Vasculitis","Rapidly Progressive Glomerulonephritis","Crescentic Glomerulonephritis",[5296],"Pioglitazone",{"nctId":5298,"briefTitle":5299,"status":139,"phases":5300,"primaryCompletion":385,"completion":385,"start":5301,"enrollment":1931,"conditions":5302,"interventions":5304},"NCT00811681","Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept",[92],"2008-12",[5303],"Friedreich's Ataxia",[5274],{"trials":5306,"activeCount":102},[],{"trials":5308,"activeCount":102},[5309],{"nctId":5310,"briefTitle":5311,"status":241,"phases":5312,"completion":5144,"start":5171,"enrollment":24,"conditions":5313,"interventions":5314},"NCT00159211","Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin",[94],[3503],[5315,5274],"UMULINE NPH",{"intervention":5317,"totalTrials":429,"cells":5318},"Ruxolitinib",{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5323,"PHASE3":5353,"PHASE4":5355,"NA":5357},{"trials":5320,"activeCount":102},[],{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":163,"soonestReadout":2087},[5325,5334,5343],{"nctId":5326,"briefTitle":5327,"status":110,"phases":5328,"primaryCompletion":5329,"completion":5330,"start":1674,"enrollment":291,"conditions":5331,"interventions":5333},"NCT06244862","JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit",[91],"2025-08-08","2026-02-01",[5332],"Hemophagocytic Syndromes",[5317],{"nctId":5335,"briefTitle":5336,"status":152,"phases":5337,"primaryCompletion":2087,"completion":5338,"start":5339,"enrollment":36,"conditions":5340,"interventions":5342},"NCT05762640","Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)",[91],"2028-03","2024-11-10",[5341],"Haemophagocytic Lymphohistiocytosis",[5317],{"nctId":5344,"briefTitle":5345,"status":152,"phases":5346,"primaryCompletion":5347,"completion":5348,"start":5349,"enrollment":1108,"conditions":5350,"interventions":5352},"NCT06536166","Ruxolitinib Treatment in Inclusion Body Myositis",[91],"2028-06-10","2028-09-10","2025-05-27",[5351],"Inclusion Body Myositis, Sporadic",[5317],{"trials":5354,"activeCount":102},[],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"intervention":5360,"totalTrials":163,"cells":5361},"Obinutuzumab",{"EARLY_PHASE1":5362,"PHASE1":5364,"PHASE2":5366,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5363,"activeCount":102},[],{"trials":5365,"activeCount":102},[],{"trials":5367,"activeCount":163,"soonestReadout":5372},[5368,5376],{"nctId":5369,"briefTitle":5370,"status":152,"phases":5371,"primaryCompletion":5372,"completion":4177,"start":5373,"enrollment":16,"conditions":5374,"interventions":5375},"NCT06940661","Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis",[91],"2027-12","2025-12-19",[293],[5360],{"nctId":5377,"briefTitle":5378,"status":126,"phases":5379,"primaryCompletion":5380,"completion":5381,"start":5382,"enrollment":21,"conditions":5383,"interventions":5385},"NCT07268521","A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab",[91],"2028-04-01","2028-09-01","2025-12-01",[5384],"Cryoglobulinemic Vasculitis (CV)",[5360],{"trials":5387,"activeCount":102},[],{"trials":5389,"activeCount":102},[],{"trials":5391,"activeCount":102},[],{"intervention":5166,"totalTrials":1299,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5411,"PHASE4":5441,"NA":5443},{"trials":5395,"activeCount":102},[],{"trials":5397,"activeCount":102},[],{"trials":5399,"activeCount":180,"soonestReadout":5404},[5400],{"nctId":5401,"briefTitle":5402,"status":126,"phases":5403,"primaryCompletion":5404,"completion":5405,"start":5406,"enrollment":323,"conditions":5407,"interventions":5409},"NCT07589842","Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders",[91],"2028-11-30","2029-08-01","2026-10-01",[5408],"Autism Spectrum Disorder",[5410,5166],"ILT-101 ld-",{"trials":5412,"activeCount":102},[5413,5426,5430],{"nctId":5414,"briefTitle":5415,"status":139,"phases":5416,"primaryCompletion":5417,"completion":5162,"start":5418,"enrollment":5419,"conditions":5420,"interventions":5422},"NCT01077752","Local Anesthetic Continuous Preperitoneal Infiltration and Wound Hyperalgesia",[92],"2012-06","2010-02",95,[5421],"Pain, Postoperative",[5423,5424,5425,5166],"continuous ropivacaine preperitoneal","intravenous lidocaine","parenteral analgesia combining acetaminophen and morphine",{"nctId":5159,"briefTitle":5160,"status":139,"phases":5427,"primaryCompletion":5162,"completion":386,"start":5163,"enrollment":27,"conditions":5428,"interventions":5429},[92],[5146],[5122,5166],{"nctId":5431,"briefTitle":5432,"status":139,"phases":5433,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":2673,"conditions":5437,"interventions":5439},"NCT03788837","ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)",[92],"2024-01-05","2024-01-18","2019-07-03",[5438],"Septic Shock Hyperdynamic",[5440,5166],"ILOPROST",{"trials":5442,"activeCount":102},[],{"trials":5444,"activeCount":102},[],{"intervention":5446,"totalTrials":1299,"cells":5447},"Levosimendan",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5463,"PHASE4":5496,"NA":5498},{"trials":5449,"activeCount":102},[],{"trials":5451,"activeCount":102},[],{"trials":5453,"activeCount":180,"soonestReadout":5458},[5454],{"nctId":5455,"briefTitle":5456,"status":152,"phases":5457,"primaryCompletion":5458,"completion":5458,"start":5459,"enrollment":21,"conditions":5460,"interventions":5462},"NCT05664191","Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage",[91],"2026-04-13","2023-10-13",[5461],"Sub-arachnoid Haemorrhage",[5446],{"trials":5464,"activeCount":102},[5465,5476,5485],{"nctId":5466,"briefTitle":5467,"status":139,"phases":5468,"primaryCompletion":989,"completion":5469,"start":386,"enrollment":5470,"conditions":5471,"interventions":5474},"NCT02184819","Preoperative Levosimendan in CABG Patients With Poor LV Function",[92],"2015-11",335,[5472,5473],"Coronary Artery Bypass Grafting","Left Ventricular Dysfonction",[5475],"levosimendan",{"nctId":5477,"briefTitle":5478,"status":110,"phases":5479,"primaryCompletion":5480,"completion":5480,"start":5481,"enrollment":1520,"conditions":5482,"interventions":5484},"NCT05233202","Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction",[92],"2025-01-23","2023-01-23",[5483],"Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid",[5446],{"nctId":5486,"briefTitle":5487,"status":139,"phases":5488,"primaryCompletion":5489,"completion":5489,"start":5490,"enrollment":5491,"conditions":5492,"interventions":5495},"NCT04728932","LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients",[92],"2024-11-09","2021-08-27",206,[5493,5494],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation Complication",[5446],{"trials":5497,"activeCount":102},[],{"trials":5499,"activeCount":102},[],{"intervention":1164,"totalTrials":429,"cells":5501},{"EARLY_PHASE1":5502,"PHASE1":5504,"PHASE2":5506,"PHASE3":5512,"PHASE4":5529,"NA":5531},{"trials":5503,"activeCount":102},[],{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":180,"soonestReadout":1157},[5508],{"nctId":1154,"briefTitle":1155,"status":126,"phases":5509,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":5510,"interventions":5511},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":5513,"activeCount":102},[5514,5525],{"nctId":5515,"briefTitle":5516,"status":139,"phases":5517,"primaryCompletion":5518,"completion":5518,"start":5519,"enrollment":5520,"conditions":5521,"interventions":5523},"NCT00623740","PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates",[92],"2016-01","2008-04",523,[5522],"Bronchopulmonary Dysplasia",[5524],"hydrocortisone",{"nctId":2122,"briefTitle":2123,"status":139,"phases":5526,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":2127,"conditions":5527,"interventions":5528},[92],[2129],[2131,2132,2099,1164],{"trials":5530,"activeCount":102},[],{"trials":5532,"activeCount":102},[],{"intervention":5534,"totalTrials":429,"cells":5535},"Glibenclamide",{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5566,"PHASE4":5579,"NA":5581},{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":102},[],{"trials":5541,"activeCount":180,"soonestReadout":5111},[5542,5551],{"nctId":5543,"briefTitle":5544,"status":139,"phases":5545,"primaryCompletion":5254,"completion":216,"start":2046,"enrollment":5546,"conditions":5547,"interventions":5549},"NCT00610038","Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus",[91],19,[5548],"Diabetes Mellitus",[5550],"glibenclamide",{"nctId":5552,"briefTitle":5553,"status":169,"phases":5554,"primaryCompletion":5111,"completion":5555,"start":5556,"enrollment":5557,"conditions":5558,"interventions":5562},"NCT05687500","Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)",[91],"2026-04-30","2023-05-20",35,[5559,5560,5561],"Transient; Hypoglycemia, Neonatal","Preterm","Glibenclamide Adverse Reaction",[5534,5563,5564,5565],"Pharmacokinetics study","C-peptide proinsulin ratio","Routine biological monitoring",{"trials":5567,"activeCount":102},[5568],{"nctId":5569,"briefTitle":5570,"status":139,"phases":5571,"primaryCompletion":5572,"completion":5573,"start":5574,"enrollment":5575,"conditions":5576,"interventions":5578},"NCT02375828","Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels",[92],"2016-03-04","2019-07-22","2015-03-20",10,[5577],"Neonatal Diabetes Secondary to Mutation in the Potassium Channel",[5534],{"trials":5580,"activeCount":102},[],{"trials":5582,"activeCount":102},[],{"intervention":5584,"totalTrials":163,"cells":5585},"Nintedanib",{"EARLY_PHASE1":5586,"PHASE1":5588,"PHASE2":5590,"PHASE3":5603,"PHASE4":5614,"NA":5616},{"trials":5587,"activeCount":102},[],{"trials":5589,"activeCount":102},[],{"trials":5591,"activeCount":180,"soonestReadout":5596},[5592],{"nctId":5593,"briefTitle":5594,"status":126,"phases":5595,"primaryCompletion":5596,"completion":5597,"start":5598,"enrollment":5599,"conditions":5600,"interventions":5602},"NCT06643091","Nintedanib Treatment in Unicentric Castleman Disease",[91],"2030-05-01","2030-09-01","2024-11-01",13,[5601],"Castleman Disease",[5584],{"trials":5604,"activeCount":102},[5605],{"nctId":5606,"briefTitle":5607,"status":139,"phases":5608,"primaryCompletion":5609,"completion":5609,"start":5610,"enrollment":958,"conditions":5611,"interventions":5613},"NCT03283007","Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2",[92],"2025-03-30","2019-10-30",[5612],"Lung-transplant Recipients",[5584],{"trials":5615,"activeCount":102},[],{"trials":5617,"activeCount":102},[],{"intervention":5619,"totalTrials":1299,"cells":5620},"Bevacizumab",{"EARLY_PHASE1":5621,"PHASE1":5623,"PHASE2":5625,"PHASE3":5665,"PHASE4":5667,"NA":5669},{"trials":5622,"activeCount":102},[],{"trials":5624,"activeCount":102},[],{"trials":5626,"activeCount":180,"soonestReadout":4270},[5627,5637,5647,5655],{"nctId":5628,"briefTitle":5629,"status":110,"phases":5630,"primaryCompletion":5631,"completion":5632,"start":5633,"enrollment":3299,"conditions":5634,"interventions":5636},"NCT04344782","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®\u002FZeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",[91],"2020-09-30","2020-11-30","2020-04-15",[5635],"COVID19 Pneumonia",[5619],{"nctId":5638,"briefTitle":5639,"status":139,"phases":5640,"primaryCompletion":5641,"completion":386,"start":1833,"enrollment":400,"conditions":5642,"interventions":5645},"NCT02898012","Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status",[91],"2013-05",[5643,5644],"Glioblastoma Multiforme","Primary Brain Tumor",[5646,5619],"Temozolomide",{"nctId":5648,"briefTitle":5649,"status":126,"phases":5650,"primaryCompletion":4270,"completion":5651,"start":4203,"enrollment":33,"conditions":5652,"interventions":5654},"NCT07089719","Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)",[91],"2028-05-01",[5653],"Dyspnea Caused by 2019-nCoV",[5619],{"nctId":5656,"briefTitle":5657,"status":110,"phases":5658,"primaryCompletion":5659,"completion":1129,"start":5660,"enrollment":21,"conditions":5661,"interventions":5663},"NCT01966913","Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors",[90,91],"2019-03","2012-04",[5662],"Germ Cell Tumor",[5619,5664],"ICE chemotherapy regimen",{"trials":5666,"activeCount":102},[],{"trials":5668,"activeCount":102},[],{"trials":5670,"activeCount":102},[],{"intervention":5672,"totalTrials":429,"cells":5673},"Bosentan",{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5687,"PHASE3":5706,"PHASE4":5708,"NA":5710},{"trials":5675,"activeCount":102},[],{"trials":5677,"activeCount":102},[5678],{"nctId":5679,"briefTitle":5680,"status":139,"phases":5681,"primaryCompletion":5519,"completion":5519,"start":5682,"enrollment":36,"conditions":5683,"interventions":5685},"NCT00260819","Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia",[90],"2006-01",[5684],"Hypoxia-Induced Pulmonary Artery Hypertension",[5672,5686],"Bosentam TRACLEER",{"trials":5688,"activeCount":180,"soonestReadout":1809},[5689,5697],{"nctId":5690,"briefTitle":5691,"status":126,"phases":5692,"primaryCompletion":1809,"completion":4947,"start":194,"enrollment":1931,"conditions":5693,"interventions":5695},"NCT06957002","Bosentan in the Treatment of Giant Cell Arteritis",[91],[5694],"Giant Cell Arteritis (GCA)",[5672,5696],"Glucocorticoids",{"nctId":5698,"briefTitle":5699,"status":139,"phases":5700,"primaryCompletion":1050,"completion":5701,"start":5702,"enrollment":1258,"conditions":5703,"interventions":5705},"NCT01241383","Effect of Bosentan in Scleroderma Renal Crisis",[91],"2016-06","2010-12-06",[5704],"Scleroderma Renal Crisis",[5672],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"intervention":5713,"totalTrials":429,"cells":5714},"ILT101",{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5729,"PHASE3":5752,"PHASE4":5754,"NA":5756},{"trials":5716,"activeCount":102},[],{"trials":5718,"activeCount":102},[5719],{"nctId":5720,"briefTitle":5721,"status":139,"phases":5722,"primaryCompletion":5723,"completion":5724,"start":5725,"enrollment":1931,"conditions":5726,"interventions":5728},"NCT03837093","Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers",[90],"2021-03-03","2021-11-06","2019-06-06",[5727],"Healthy Volunteers",[5713],{"trials":5730,"activeCount":180,"soonestReadout":5735},[5731,5741],{"nctId":5732,"briefTitle":5733,"status":152,"phases":5734,"primaryCompletion":5735,"completion":5736,"start":5737,"enrollment":27,"conditions":5738,"interventions":5739},"NCT05153070","Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes",[91],"2026-04-21","2028-04-21","2022-09-21",[1522],[5740,5713],"Cyclosporin",{"nctId":5742,"briefTitle":5743,"status":139,"phases":5744,"primaryCompletion":5745,"completion":5746,"start":5747,"enrollment":245,"conditions":5748,"interventions":5750},"NCT04133233","Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder",[91],"2022-05-20","2022-05-21","2020-06-15",[5749],"Bipolar Depression",[5713,5751],"Placebos",{"trials":5753,"activeCount":102},[],{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":102},[],{"intervention":5759,"totalTrials":163,"cells":5760},"Itacitinib",{"EARLY_PHASE1":5761,"PHASE1":5763,"PHASE2":5765,"PHASE3":5784,"PHASE4":5786,"NA":5788},{"trials":5762,"activeCount":102},[],{"trials":5764,"activeCount":102},[],{"trials":5766,"activeCount":180,"soonestReadout":399},[5767,5775],{"nctId":5768,"briefTitle":5769,"status":152,"phases":5770,"primaryCompletion":399,"completion":399,"start":5771,"enrollment":5772,"conditions":5773,"interventions":5774},"NCT04789850","Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis",[91],"2023-02-02",74,[325],[5759],{"nctId":5776,"briefTitle":5777,"status":139,"phases":5778,"primaryCompletion":5779,"completion":4203,"start":5780,"enrollment":5557,"conditions":5781,"interventions":5783},"NCT05063110","Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB",[91],"2025-04-03","2022-05-03",[5782],"Adults Patients Having Non Severe HLH",[5759],{"trials":5785,"activeCount":102},[],{"trials":5787,"activeCount":102},[],{"trials":5789,"activeCount":102},[],{"intervention":5791,"totalTrials":163,"cells":5792},"Isatuximab",{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5797,"PHASE3":5819,"PHASE4":5821,"NA":5823},{"trials":5794,"activeCount":102},[],{"trials":5796,"activeCount":102},[],{"trials":5798,"activeCount":180,"soonestReadout":1105},[5799,5808],{"nctId":5800,"briefTitle":5801,"status":126,"phases":5802,"primaryCompletion":1105,"completion":1105,"start":5803,"enrollment":5804,"conditions":5805,"interventions":5807},"NCT05559827","Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation",[91],"2022-09",90,[5806],"Immunological Pure Red Cell Aplasia",[5791],{"nctId":5809,"briefTitle":5810,"status":110,"phases":5811,"primaryCompletion":5812,"completion":5813,"start":5814,"enrollment":33,"conditions":5815,"interventions":5818},"NCT05114109","Isatuximab in Type I Cryoglobulinemia",[91],"2022-12-31","2023-12-31","2021-11-01",[1768,5816,5817],"Monoclonal Gammopathy of Undetermined Significance","Cryoglobulinemic Vasculitis",[5791],{"trials":5820,"activeCount":102},[],{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[],{"intervention":5826,"totalTrials":163,"cells":5827},"Human T Lymphoid Progenitor (HTLP)",{"EARLY_PHASE1":5828,"PHASE1":5830,"PHASE2":5832,"PHASE3":5854,"PHASE4":5856,"NA":5858},{"trials":5829,"activeCount":102},[],{"trials":5831,"activeCount":102},[],{"trials":5833,"activeCount":180,"soonestReadout":1095},[5834,5842],{"nctId":5835,"briefTitle":5836,"status":152,"phases":5837,"primaryCompletion":1095,"completion":4922,"start":5838,"enrollment":5575,"conditions":5839,"interventions":5841},"NCT04707300","Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)",[90,91],"2022-02-16",[5840],"Hematologic Malignancy",[5826],{"nctId":5843,"briefTitle":5844,"status":139,"phases":5845,"primaryCompletion":5846,"completion":5847,"start":5848,"enrollment":1299,"conditions":5849,"interventions":5853},"NCT03879876","Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients",[90,91],"2023-09-03","2024-04-24","2020-05-13",[5850,5851,5852],"Pediatric Patients","Any Type of Severe Combined Immunodeficiency (SCID)","Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[5826],{"trials":5855,"activeCount":102},[],{"trials":5857,"activeCount":102},[],{"trials":5859,"activeCount":102},[],{"intervention":5410,"totalTrials":163,"cells":5861},{"EARLY_PHASE1":5862,"PHASE1":5864,"PHASE2":5866,"PHASE3":5881,"PHASE4":5883,"NA":5885},{"trials":5863,"activeCount":102},[],{"trials":5865,"activeCount":102},[],{"trials":5867,"activeCount":180,"soonestReadout":5404},[5868,5872],{"nctId":5401,"briefTitle":5402,"status":126,"phases":5869,"primaryCompletion":5404,"completion":5405,"start":5406,"enrollment":323,"conditions":5870,"interventions":5871},[91],[5408],[5410,5166],{"nctId":5873,"briefTitle":5874,"status":139,"phases":5875,"primaryCompletion":5876,"completion":5876,"start":1223,"enrollment":27,"conditions":5877,"interventions":5880},"NCT03776643","Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy",[91],"2022-08-16",[5878,5879],"Allergic Rhinoconjunctivitis to Birch Pollen","With a Positive Skin Prick Test to Birch Pollen",[5410],{"trials":5882,"activeCount":102},[],{"trials":5884,"activeCount":102},[],{"trials":5886,"activeCount":102},[],{"intervention":5888,"totalTrials":163,"cells":5889},"Belimumab",{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5894,"PHASE3":5915,"PHASE4":5917,"NA":5919},{"trials":5891,"activeCount":102},[],{"trials":5893,"activeCount":102},[],{"trials":5895,"activeCount":180,"soonestReadout":5908},[5896,5904],{"nctId":5897,"briefTitle":5898,"status":139,"phases":5899,"primaryCompletion":216,"completion":5417,"start":5900,"enrollment":36,"conditions":5901,"interventions":5903},"NCT01160666","Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome",[91],"2010-03",[5902],"Sjögren's Syndrome",[5888],{"nctId":5905,"briefTitle":5906,"status":152,"phases":5907,"primaryCompletion":5908,"completion":5909,"start":5910,"enrollment":5911,"conditions":5912,"interventions":5914},"NCT04629144","Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)",[91],"2025-04-20","2025-10-20","2021-10-20",48,[5913,247],"Vasculitis",[5888],{"trials":5916,"activeCount":102},[],{"trials":5918,"activeCount":102},[],{"trials":5920,"activeCount":102},[],{"intervention":62,"totalTrials":163,"cells":5922},{"EARLY_PHASE1":5923,"PHASE1":5925,"PHASE2":5927,"PHASE3":5944,"PHASE4":5946,"NA":5948},{"trials":5924,"activeCount":102},[],{"trials":5926,"activeCount":102},[],{"trials":5928,"activeCount":180,"soonestReadout":61},[5929,5937],{"nctId":5930,"briefTitle":5931,"status":5932,"phases":5933,"primaryCompletion":66,"completion":66,"start":5934,"enrollment":102,"conditions":5935,"interventions":5936},"NCT04024384","Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial","WITHDRAWN",[91],"2019-07",[1768],[62],{"nctId":59,"briefTitle":60,"status":126,"phases":5938,"primaryCompletion":61,"completion":1775,"start":5939,"enrollment":5940,"conditions":5941,"interventions":5943},[91],"2021-10",29,[5942],"Plasma Cell Leukemia",[62],{"trials":5945,"activeCount":102},[],{"trials":5947,"activeCount":102},[],{"trials":5949,"activeCount":102},[],{"intervention":1262,"totalTrials":163,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5966,"PHASE4":5968,"NA":5970},{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[],{"trials":5957,"activeCount":180,"soonestReadout":5111},[5958,5962],{"nctId":1252,"briefTitle":1253,"status":139,"phases":5959,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":5960,"interventions":5961},[91],[1260],[1163,1262,1263,1264,1265],{"nctId":5552,"briefTitle":5553,"status":169,"phases":5963,"primaryCompletion":5111,"completion":5555,"start":5556,"enrollment":5557,"conditions":5964,"interventions":5965},[91],[5559,5560,5561],[5534,5563,5564,5565],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[],{"trials":5971,"activeCount":102},[],{"intervention":5973,"totalTrials":180,"cells":5974},"Lenvatinib",{"EARLY_PHASE1":5975,"PHASE1":5977,"PHASE2":5979,"PHASE3":5989,"PHASE4":5991,"NA":5993},{"trials":5976,"activeCount":102},[],{"trials":5978,"activeCount":102},[],{"trials":5980,"activeCount":180,"soonestReadout":154},[5981],{"nctId":5982,"briefTitle":5983,"status":169,"phases":5984,"primaryCompletion":154,"completion":154,"start":5985,"enrollment":1247,"conditions":5986,"interventions":5988},"NCT05901194","Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma",[90,91],"2024-07-10",[5987],"Hepatocellular Carcinoma Non-resectable",[5973],{"trials":5990,"activeCount":102},[],{"trials":5992,"activeCount":102},[],{"trials":5994,"activeCount":102},[],{"intervention":5996,"totalTrials":180,"cells":5997},"Blinatumomab",{"EARLY_PHASE1":5998,"PHASE1":6000,"PHASE2":6002,"PHASE3":6013,"PHASE4":6015,"NA":6017},{"trials":5999,"activeCount":102},[],{"trials":6001,"activeCount":102},[],{"trials":6003,"activeCount":180,"soonestReadout":6008},[6004],{"nctId":6005,"briefTitle":6006,"status":169,"phases":6007,"primaryCompletion":6008,"completion":758,"start":6009,"enrollment":5419,"conditions":6010,"interventions":6012},"NCT03709719","Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia",[91],"2026-10-30","2018-10-20",[6011],"Acute Lymphoblastic Leukemia, Adult B-Cell",[5996],{"trials":6014,"activeCount":102},[],{"trials":6016,"activeCount":102},[],{"trials":6018,"activeCount":102},[],{"intervention":6020,"totalTrials":180,"cells":6021},"Immunoglobulins IV",{"EARLY_PHASE1":6022,"PHASE1":6024,"PHASE2":6026,"PHASE3":6038,"PHASE4":6040,"NA":6042},{"trials":6023,"activeCount":102},[],{"trials":6025,"activeCount":102},[],{"trials":6027,"activeCount":180,"soonestReadout":4176},[6028],{"nctId":6029,"briefTitle":6030,"status":152,"phases":6031,"primaryCompletion":4176,"completion":4176,"start":6032,"enrollment":33,"conditions":6033,"interventions":6035},"NCT06373211","Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy",[91],"2025-01-10",[6034],"Paraneoplastic Sensory Neuronopathy",[6020,6036,6037],"Cyclophosphamide IV","Methylprednisolone IV",{"trials":6039,"activeCount":102},[],{"trials":6041,"activeCount":102},[],{"trials":6043,"activeCount":102},[],{"intervention":6036,"totalTrials":180,"cells":6045},{"EARLY_PHASE1":6046,"PHASE1":6048,"PHASE2":6050,"PHASE3":6056,"PHASE4":6058,"NA":6060},{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[],{"trials":6051,"activeCount":180,"soonestReadout":4176},[6052],{"nctId":6029,"briefTitle":6030,"status":152,"phases":6053,"primaryCompletion":4176,"completion":4176,"start":6032,"enrollment":33,"conditions":6054,"interventions":6055},[91],[6034],[6020,6036,6037],{"trials":6057,"activeCount":102},[],{"trials":6059,"activeCount":102},[],{"trials":6061,"activeCount":102},[],{"intervention":6037,"totalTrials":180,"cells":6063},{"EARLY_PHASE1":6064,"PHASE1":6066,"PHASE2":6068,"PHASE3":6074,"PHASE4":6076,"NA":6078},{"trials":6065,"activeCount":102},[],{"trials":6067,"activeCount":102},[],{"trials":6069,"activeCount":180,"soonestReadout":4176},[6070],{"nctId":6029,"briefTitle":6030,"status":152,"phases":6071,"primaryCompletion":4176,"completion":4176,"start":6032,"enrollment":33,"conditions":6072,"interventions":6073},[91],[6034],[6020,6036,6037],{"trials":6075,"activeCount":102},[],{"trials":6077,"activeCount":102},[],{"trials":6079,"activeCount":102},[],{"intervention":6081,"totalTrials":180,"cells":6082},"Lenvatinib Pill",{"EARLY_PHASE1":6083,"PHASE1":6085,"PHASE2":6087,"PHASE3":6098,"PHASE4":6100,"NA":6102},{"trials":6084,"activeCount":102},[],{"trials":6086,"activeCount":102},[],{"trials":6088,"activeCount":180,"soonestReadout":6093},[6089],{"nctId":6090,"briefTitle":6091,"status":169,"phases":6092,"primaryCompletion":6093,"completion":6094,"start":6095,"enrollment":228,"conditions":6096,"interventions":6097},"NCT05113186","Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative",[91],"2025-06-19","2026-10-02","2022-02-02",[35],[6081],{"trials":6099,"activeCount":102},[],{"trials":6101,"activeCount":102},[],{"trials":6103,"activeCount":102},[],{"intervention":6105,"totalTrials":180,"cells":6106},"Active arm 1000 mg",{"EARLY_PHASE1":6107,"PHASE1":6109,"PHASE2":6111,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6108,"activeCount":102},[],{"trials":6110,"activeCount":102},[],{"trials":6112,"activeCount":180,"soonestReadout":1866},[6113],{"nctId":6114,"briefTitle":6115,"status":152,"phases":6116,"primaryCompletion":1866,"completion":1776,"start":6117,"enrollment":6118,"conditions":6119,"interventions":6121},"NCT05211401","Rituximab in Patients With ST-elevation Myocardial Infarction",[91],"2022-06-01",372,[6120],"ST Elevated Myocardial Infarction",[6105],{"trials":6123,"activeCount":102},[],{"trials":6125,"activeCount":102},[],{"trials":6127,"activeCount":102},[],{"intervention":6129,"totalTrials":180,"cells":6130},"immunization",{"EARLY_PHASE1":6131,"PHASE1":6133,"PHASE2":6135,"PHASE3":6146,"PHASE4":6148,"NA":6150},{"trials":6132,"activeCount":102},[],{"trials":6134,"activeCount":102},[],{"trials":6136,"activeCount":180,"soonestReadout":6141},[6137],{"nctId":6138,"briefTitle":6139,"status":152,"phases":6140,"primaryCompletion":6141,"completion":6141,"start":6142,"enrollment":5557,"conditions":6143,"interventions":6145},"NCT06622434","New Adjuvant Vaccine in Glioblastoma, a Phase 1\u002F2a Study",[90,91],"2028-03-08","2024-11-08",[6144],"Newly Diagnosed Glioblastoma",[6129],{"trials":6147,"activeCount":102},[],{"trials":6149,"activeCount":102},[],{"trials":6151,"activeCount":102},[],{"intervention":87,"totalTrials":180,"cells":6153},{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6168,"PHASE4":6170,"NA":6172},{"trials":6155,"activeCount":102},[],{"trials":6157,"activeCount":102},[],{"trials":6159,"activeCount":180,"soonestReadout":86},[6160],{"nctId":84,"briefTitle":85,"status":152,"phases":6161,"primaryCompletion":86,"completion":4203,"start":6162,"enrollment":489,"conditions":6163,"interventions":6165},[91],"2022-01-20",[6164],"Primary Sjögren's Syndrome (pSS)",[87,6166,6167],"Leflunomide 20mg\u002Fd","Mycophenolate mofetil 2000mg\u002Fd",{"trials":6169,"activeCount":102},[],{"trials":6171,"activeCount":102},[],{"trials":6173,"activeCount":102},[],{"intervention":6166,"totalTrials":180,"cells":6175},{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6186,"PHASE4":6188,"NA":6190},{"trials":6177,"activeCount":102},[],{"trials":6179,"activeCount":102},[],{"trials":6181,"activeCount":180,"soonestReadout":86},[6182],{"nctId":84,"briefTitle":85,"status":152,"phases":6183,"primaryCompletion":86,"completion":4203,"start":6162,"enrollment":489,"conditions":6184,"interventions":6185},[91],[6164],[87,6166,6167],{"trials":6187,"activeCount":102},[],{"trials":6189,"activeCount":102},[],{"trials":6191,"activeCount":102},[],{"intervention":6167,"totalTrials":180,"cells":6193},{"EARLY_PHASE1":6194,"PHASE1":6196,"PHASE2":6198,"PHASE3":6204,"PHASE4":6206,"NA":6208},{"trials":6195,"activeCount":102},[],{"trials":6197,"activeCount":102},[],{"trials":6199,"activeCount":180,"soonestReadout":86},[6200],{"nctId":84,"briefTitle":85,"status":152,"phases":6201,"primaryCompletion":86,"completion":4203,"start":6162,"enrollment":489,"conditions":6202,"interventions":6203},[91],[6164],[87,6166,6167],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[],{"intervention":6211,"totalTrials":180,"cells":6212},"Vancomycin \u002FAmphotericin B (Fungizone®) \u002FGentamicine 80 mg",{"EARLY_PHASE1":6213,"PHASE1":6215,"PHASE2":6217,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6214,"activeCount":102},[],{"trials":6216,"activeCount":102},[],{"trials":6218,"activeCount":180,"soonestReadout":1095},[6219],{"nctId":6220,"briefTitle":6221,"status":152,"phases":6222,"primaryCompletion":1095,"completion":6223,"start":1256,"enrollment":6224,"conditions":6225,"interventions":6228},"NCT07300553","Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease",[91],"2027-08",45,[6226,1332,6227],"IBD","Ulcerative Colitis (UC)",[6211],{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[],{"trials":6234,"activeCount":102},[],{"intervention":67,"totalTrials":180,"cells":6236},{"EARLY_PHASE1":6237,"PHASE1":6239,"PHASE2":6241,"PHASE3":6247,"PHASE4":6249,"NA":6251},{"trials":6238,"activeCount":102},[],{"trials":6240,"activeCount":102},[],{"trials":6242,"activeCount":180,"soonestReadout":66},[6243],{"nctId":64,"briefTitle":65,"status":152,"phases":6244,"primaryCompletion":66,"completion":194,"start":195,"enrollment":36,"conditions":6245,"interventions":6246},[91],[197],[67,184],{"trials":6248,"activeCount":102},[],{"trials":6250,"activeCount":102},[],{"trials":6252,"activeCount":102},[],{"intervention":6254,"totalTrials":180,"cells":6255},"T-reg depleted DLI",{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6260,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6257,"activeCount":102},[],{"trials":6259,"activeCount":102},[],{"trials":6261,"activeCount":180,"soonestReadout":1551},[6262],{"nctId":6263,"briefTitle":6264,"status":126,"phases":6265,"primaryCompletion":1551,"completion":6266,"start":6267,"enrollment":6268,"conditions":6269,"interventions":6273},"NCT06180499","Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion",[90,91],"2029-09","2024-03",27,[6270,6271,6272],"Hematological Malignancies","Regulatory T Cell Depletion","Relapse",[6254],{"trials":6275,"activeCount":102},[],{"trials":6277,"activeCount":102},[],{"trials":6279,"activeCount":102},[],{"intervention":52,"totalTrials":180,"cells":6281},{"EARLY_PHASE1":6282,"PHASE1":6284,"PHASE2":6286,"PHASE3":6294,"PHASE4":6296,"NA":6298},{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[],{"trials":6287,"activeCount":180,"soonestReadout":51},[6288],{"nctId":49,"briefTitle":50,"status":169,"phases":6289,"primaryCompletion":51,"completion":2849,"start":6290,"enrollment":33,"conditions":6291,"interventions":6293},[91],"2022-10-04",[6292],"Myocarditis",[52],{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[],{"intervention":6301,"totalTrials":180,"cells":6302},"Durvalumab\u002FTremelimumab in neoadjuvant and Durvalumab in adjuvant setting",{"EARLY_PHASE1":6303,"PHASE1":6305,"PHASE2":6307,"PHASE3":6317,"PHASE4":6319,"NA":6321},{"trials":6304,"activeCount":102},[],{"trials":6306,"activeCount":102},[],{"trials":6308,"activeCount":180,"soonestReadout":3322},[6309],{"nctId":6310,"briefTitle":6311,"status":169,"phases":6312,"primaryCompletion":3322,"completion":6313,"start":3944,"enrollment":21,"conditions":6314,"interventions":6316},"NCT06045975","Durvalumab\u002FTremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure",[91],"2028-09-27",[6315],"HCC - Hepatocellular Carcinoma",[6301],{"trials":6318,"activeCount":102},[],{"trials":6320,"activeCount":102},[],{"trials":6322,"activeCount":102},[],{"intervention":6324,"totalTrials":180,"cells":6325},"[68Ga]Ga-PentixaFor PET imaging",{"EARLY_PHASE1":6326,"PHASE1":6328,"PHASE2":6330,"PHASE3":6340,"PHASE4":6342,"NA":6344},{"trials":6327,"activeCount":102},[],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":180,"soonestReadout":194},[6332],{"nctId":6333,"briefTitle":6334,"status":126,"phases":6335,"primaryCompletion":194,"completion":6336,"start":61,"enrollment":36,"conditions":6337,"interventions":6339},"NCT06478875","Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism",[91],"2027-06",[6338],"Primary Aldosteronism",[6324],{"trials":6341,"activeCount":102},[],{"trials":6343,"activeCount":102},[],{"trials":6345,"activeCount":102},[],{"intervention":6347,"totalTrials":180,"cells":6348},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":6349,"PHASE1":6351,"PHASE2":6353,"PHASE3":6365,"PHASE4":6367,"NA":6369},{"trials":6350,"activeCount":102},[],{"trials":6352,"activeCount":102},[],{"trials":6354,"activeCount":180,"soonestReadout":6359},[6355],{"nctId":6356,"briefTitle":6357,"status":152,"phases":6358,"primaryCompletion":6359,"completion":6360,"start":4678,"enrollment":6361,"conditions":6362,"interventions":6364},"NCT06146062","Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury.",[91],"2027-08-31","2028-03-31",68,[6363],"Traumatic Brain Injury",[6347],{"trials":6366,"activeCount":102},[],{"trials":6368,"activeCount":102},[],{"trials":6370,"activeCount":102},[],{"intervention":6372,"totalTrials":180,"cells":6373},"Azithromycin 250 mg x3\u002Fweek",{"EARLY_PHASE1":6374,"PHASE1":6376,"PHASE2":6378,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6375,"activeCount":102},[],{"trials":6377,"activeCount":102},[],{"trials":6379,"activeCount":180,"soonestReadout":6384},[6380],{"nctId":6381,"briefTitle":6382,"status":126,"phases":6383,"primaryCompletion":6384,"completion":6384,"start":5406,"enrollment":21,"conditions":6385,"interventions":6387},"NCT07443436","Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants",[91],"2027-10-01",[6386],"Interstitial Lung Disease",[6372,6388,6389,6390],"Prednisone 10 mg\u002Fday","Hydroxychloroquine 400 mg\u002Fday","Active Comparator: Standard of care",{"trials":6392,"activeCount":102},[],{"trials":6394,"activeCount":102},[],{"trials":6396,"activeCount":102},[],{"intervention":6388,"totalTrials":180,"cells":6398},{"EARLY_PHASE1":6399,"PHASE1":6401,"PHASE2":6403,"PHASE3":6409,"PHASE4":6411,"NA":6413},{"trials":6400,"activeCount":102},[],{"trials":6402,"activeCount":102},[],{"trials":6404,"activeCount":180,"soonestReadout":6384},[6405],{"nctId":6381,"briefTitle":6382,"status":126,"phases":6406,"primaryCompletion":6384,"completion":6384,"start":5406,"enrollment":21,"conditions":6407,"interventions":6408},[91],[6386],[6372,6388,6389,6390],{"trials":6410,"activeCount":102},[],{"trials":6412,"activeCount":102},[],{"trials":6414,"activeCount":102},[],{"intervention":6389,"totalTrials":180,"cells":6416},{"EARLY_PHASE1":6417,"PHASE1":6419,"PHASE2":6421,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6418,"activeCount":102},[],{"trials":6420,"activeCount":102},[],{"trials":6422,"activeCount":180,"soonestReadout":6384},[6423],{"nctId":6381,"briefTitle":6382,"status":126,"phases":6424,"primaryCompletion":6384,"completion":6384,"start":5406,"enrollment":21,"conditions":6425,"interventions":6426},[91],[6386],[6372,6388,6389,6390],{"trials":6428,"activeCount":102},[],{"trials":6430,"activeCount":102},[],{"trials":6432,"activeCount":102},[],{"intervention":6390,"totalTrials":180,"cells":6434},{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6445,"PHASE4":6447,"NA":6449},{"trials":6436,"activeCount":102},[],{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":180,"soonestReadout":6384},[6441],{"nctId":6381,"briefTitle":6382,"status":126,"phases":6442,"primaryCompletion":6384,"completion":6384,"start":5406,"enrollment":21,"conditions":6443,"interventions":6444},[91],[6386],[6372,6388,6389,6390],{"trials":6446,"activeCount":102},[],{"trials":6448,"activeCount":102},[],{"trials":6450,"activeCount":102},[],{"intervention":6452,"totalTrials":180,"cells":6453},"Secukinumab",{"EARLY_PHASE1":6454,"PHASE1":6456,"PHASE2":6458,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[],{"trials":6459,"activeCount":180,"soonestReadout":6464},[6460],{"nctId":6461,"briefTitle":6462,"status":126,"phases":6463,"primaryCompletion":6464,"completion":1275,"start":1276,"enrollment":1750,"conditions":6465,"interventions":6467},"NCT07477795","Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients",[91],"2029-10-01",[1132,6466],"Large Vessel Vasculitis",[6452],{"trials":6469,"activeCount":102},[],{"trials":6471,"activeCount":102},[],{"trials":6473,"activeCount":102},[],{"intervention":6475,"totalTrials":180,"cells":6476},"Ifenprodil",{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6481,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6478,"activeCount":102},[],{"trials":6480,"activeCount":102},[],{"trials":6482,"activeCount":180,"soonestReadout":1472},[6483],{"nctId":6484,"briefTitle":6485,"status":126,"phases":6486,"primaryCompletion":1472,"completion":6336,"start":6267,"enrollment":303,"conditions":6487,"interventions":6490},"NCT06330077","Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis",[91],[6488,6489],"Multiple Sclerosis","Remitting Relapsing Multiple Sclerosis",[6475],{"trials":6492,"activeCount":102},[],{"trials":6494,"activeCount":102},[],{"trials":6496,"activeCount":102},[],{"intervention":5696,"totalTrials":180,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":102},[],{"trials":6502,"activeCount":102},[],{"trials":6504,"activeCount":180,"soonestReadout":1809},[6505],{"nctId":5690,"briefTitle":5691,"status":126,"phases":6506,"primaryCompletion":1809,"completion":4947,"start":194,"enrollment":1931,"conditions":6507,"interventions":6508},[91],[5694],[5672,5696],{"trials":6510,"activeCount":102},[],{"trials":6512,"activeCount":102},[],{"trials":6514,"activeCount":102},[],{"intervention":6516,"totalTrials":180,"cells":6517},"Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6519,"activeCount":102},[],{"trials":6521,"activeCount":102},[],{"trials":6523,"activeCount":180,"soonestReadout":6528},[6524],{"nctId":6525,"briefTitle":6526,"status":152,"phases":6527,"primaryCompletion":6528,"completion":6528,"start":6529,"enrollment":1750,"conditions":6530,"interventions":6532},"NCT06646497","Indication of HSCT in Patients With Refractory\u002FRelapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years",[91],"2030-01-24","2025-01-24",[6531],"Aplastic Anemia",[6516],{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"trials":6538,"activeCount":102},[],{"intervention":6540,"totalTrials":180,"cells":6541},"Systemic therapy",{"EARLY_PHASE1":6542,"PHASE1":6544,"PHASE2":6546,"PHASE3":6559,"PHASE4":6561,"NA":6563},{"trials":6543,"activeCount":102},[],{"trials":6545,"activeCount":102},[],{"trials":6547,"activeCount":180,"soonestReadout":6552},[6548],{"nctId":6549,"briefTitle":6550,"status":152,"phases":6551,"primaryCompletion":6552,"completion":6552,"start":6553,"enrollment":1130,"conditions":6554,"interventions":6558},"NCT06254248","Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma",[91],"2030-01-01","2026-01-22",[6555,6556,6557],"Liver Transplant","Hepatocellular Carcinoma Recurrent","Systemic Treatment",[6540],{"trials":6560,"activeCount":102},[],{"trials":6562,"activeCount":102},[],{"trials":6564,"activeCount":102},[],{"intervention":6566,"totalTrials":180,"cells":6567},"Fecal Microbiota Transplantation by Stool",{"EARLY_PHASE1":6568,"PHASE1":6570,"PHASE2":6572,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6569,"activeCount":102},[],{"trials":6571,"activeCount":102},[],{"trials":6573,"activeCount":180,"soonestReadout":6578},[6574],{"nctId":6575,"briefTitle":6576,"status":126,"phases":6577,"primaryCompletion":6578,"completion":4271,"start":6579,"enrollment":115,"conditions":6580,"interventions":6582},"NCT05202990","Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis",[91],"2028-07-01","2026-07-01",[6581],"Pediatric Ulcerative Colitis in Remission",[6566,6583],"Fecal Microbiota Transplantation by Intra-rectal enemas",{"trials":6585,"activeCount":102},[],{"trials":6587,"activeCount":102},[],{"trials":6589,"activeCount":102},[],{"intervention":6583,"totalTrials":180,"cells":6591},{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6593,"activeCount":102},[],{"trials":6595,"activeCount":102},[],{"trials":6597,"activeCount":180,"soonestReadout":6578},[6598],{"nctId":6575,"briefTitle":6576,"status":126,"phases":6599,"primaryCompletion":6578,"completion":4271,"start":6579,"enrollment":115,"conditions":6600,"interventions":6601},[91],[6581],[6566,6583],{"trials":6603,"activeCount":102},[],{"trials":6605,"activeCount":102},[],{"trials":6607,"activeCount":102},[],{"intervention":6609,"totalTrials":180,"cells":6610},"Discontibuation of oral ULT",{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6615,"PHASE3":6627,"PHASE4":6629,"NA":6631},{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[],{"trials":6616,"activeCount":180,"soonestReadout":6621},[6617],{"nctId":6618,"briefTitle":6619,"status":126,"phases":6620,"primaryCompletion":6621,"completion":5596,"start":6622,"enrollment":3895,"conditions":6623,"interventions":6625},"NCT06956885","Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout",[91],"2029-05-01","2025-05-01",[6624],"Gout Chronic",[6609,6626],"Maintenance of ULT",{"trials":6628,"activeCount":102},[],{"trials":6630,"activeCount":102},[],{"trials":6632,"activeCount":102},[],{"intervention":6626,"totalTrials":180,"cells":6634},{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6639,"PHASE3":6645,"PHASE4":6647,"NA":6649},{"trials":6636,"activeCount":102},[],{"trials":6638,"activeCount":102},[],{"trials":6640,"activeCount":180,"soonestReadout":6621},[6641],{"nctId":6618,"briefTitle":6619,"status":126,"phases":6642,"primaryCompletion":6621,"completion":5596,"start":6622,"enrollment":3895,"conditions":6643,"interventions":6644},[91],[6624],[6609,6626],{"trials":6646,"activeCount":102},[],{"trials":6648,"activeCount":102},[],{"trials":6650,"activeCount":102},[],{"intervention":6652,"totalTrials":180,"cells":6653},"Half dose CBD",{"EARLY_PHASE1":6654,"PHASE1":6656,"PHASE2":6658,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6655,"activeCount":102},[],{"trials":6657,"activeCount":102},[],{"trials":6659,"activeCount":180,"soonestReadout":6664},[6660],{"nctId":6661,"briefTitle":6662,"status":152,"phases":6663,"primaryCompletion":6664,"completion":6664,"start":6665,"enrollment":6666,"conditions":6667,"interventions":6669},"NCT05860699","Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH",[91],"2026-05-23","2024-04-08",210,[6668],"Severe Alcohol Use Disorder (DSM 5)",[6652,6670],"Full dose CBD",{"trials":6672,"activeCount":102},[],{"trials":6674,"activeCount":102},[],{"trials":6676,"activeCount":102},[],{"intervention":6670,"totalTrials":180,"cells":6678},{"EARLY_PHASE1":6679,"PHASE1":6681,"PHASE2":6683,"PHASE3":6689,"PHASE4":6691,"NA":6693},{"trials":6680,"activeCount":102},[],{"trials":6682,"activeCount":102},[],{"trials":6684,"activeCount":180,"soonestReadout":6664},[6685],{"nctId":6661,"briefTitle":6662,"status":152,"phases":6686,"primaryCompletion":6664,"completion":6664,"start":6665,"enrollment":6666,"conditions":6687,"interventions":6688},[91],[6668],[6652,6670],{"trials":6690,"activeCount":102},[],{"trials":6692,"activeCount":102},[],{"trials":6694,"activeCount":102},[],{"intervention":6696,"totalTrials":180,"cells":6697},"oral prednisone or placebo at a dose of 60 mg per day for 7 days",{"EARLY_PHASE1":6698,"PHASE1":6700,"PHASE2":6702,"PHASE3":6712,"PHASE4":6714,"NA":6716},{"trials":6699,"activeCount":102},[],{"trials":6701,"activeCount":102},[],{"trials":6703,"activeCount":180,"soonestReadout":4589},[6704],{"nctId":6705,"briefTitle":6706,"status":126,"phases":6707,"primaryCompletion":4589,"completion":4589,"start":6708,"enrollment":1015,"conditions":6709,"interventions":6711},"NCT07440238","Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults",[91],"2026-03-30",[6710],"Septic Arthritis",[6696],{"trials":6713,"activeCount":102},[],{"trials":6715,"activeCount":102},[],{"trials":6717,"activeCount":102},[],{"intervention":6719,"totalTrials":180,"cells":6720},"Combination of activated charcoal with polyethylene glycol for digestive decontamination",{"EARLY_PHASE1":6721,"PHASE1":6723,"PHASE2":6725,"PHASE3":6736,"PHASE4":6738,"NA":6740},{"trials":6722,"activeCount":102},[],{"trials":6724,"activeCount":102},[],{"trials":6726,"activeCount":180,"soonestReadout":5338},[6727],{"nctId":6728,"briefTitle":6729,"status":126,"phases":6730,"primaryCompletion":5338,"completion":1338,"start":5136,"enrollment":1015,"conditions":6731,"interventions":6734},"NCT07201311","Combined Gastrointestinal Decontamination in Acute Severe Poisoning",[91],[6732,6733],"Severe Poisoning With Cardiotropic or Psychotropic Drug","Admission to Intensive Care",[6719,6735],"Standard Treatment",{"trials":6737,"activeCount":102},[],{"trials":6739,"activeCount":102},[],{"trials":6741,"activeCount":102},[],{"intervention":6735,"totalTrials":180,"cells":6743},{"EARLY_PHASE1":6744,"PHASE1":6746,"PHASE2":6748,"PHASE3":6754,"PHASE4":6756,"NA":6758},{"trials":6745,"activeCount":102},[],{"trials":6747,"activeCount":102},[],{"trials":6749,"activeCount":180,"soonestReadout":5338},[6750],{"nctId":6728,"briefTitle":6729,"status":126,"phases":6751,"primaryCompletion":5338,"completion":1338,"start":5136,"enrollment":1015,"conditions":6752,"interventions":6753},[91],[6732,6733],[6719,6735],{"trials":6755,"activeCount":102},[],{"trials":6757,"activeCount":102},[],{"trials":6759,"activeCount":102},[],{"intervention":6761,"totalTrials":180,"cells":6762},"Sulfasalazine",{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6767,"PHASE3":6776,"PHASE4":6778,"NA":6780},{"trials":6764,"activeCount":102},[],{"trials":6766,"activeCount":102},[],{"trials":6768,"activeCount":180,"soonestReadout":3147},[6769],{"nctId":6770,"briefTitle":6771,"status":152,"phases":6772,"primaryCompletion":3147,"completion":3474,"start":4738,"enrollment":6773,"conditions":6774,"interventions":6775},"NCT05580861","Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment",[90,91],64,[1590],[6761],{"trials":6777,"activeCount":102},[],{"trials":6779,"activeCount":102},[],{"trials":6781,"activeCount":102},[],{"intervention":6783,"totalTrials":180,"cells":6784},"FMT Protocol",{"EARLY_PHASE1":6785,"PHASE1":6787,"PHASE2":6789,"PHASE3":6798,"PHASE4":6800,"NA":6802},{"trials":6786,"activeCount":102},[],{"trials":6788,"activeCount":102},[],{"trials":6790,"activeCount":180,"soonestReadout":6795},[6791],{"nctId":6792,"briefTitle":6793,"status":126,"phases":6794,"primaryCompletion":6795,"completion":6795,"start":459,"enrollment":98,"conditions":6796,"interventions":6797},"NCT07105267","Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms",[91],"2027-04-01",[5408,1344],[6783],{"trials":6799,"activeCount":102},[],{"trials":6801,"activeCount":102},[],{"trials":6803,"activeCount":102},[],{"intervention":6805,"totalTrials":180,"cells":6806},"Glycerol Phenylbutyrate 1100 MG\u002FML [Ravicti]",{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6811,"PHASE3":6820,"PHASE4":6822,"NA":6824},{"trials":6808,"activeCount":102},[],{"trials":6810,"activeCount":102},[],{"trials":6812,"activeCount":180,"soonestReadout":1276},[6813],{"nctId":6814,"briefTitle":6815,"status":152,"phases":6816,"primaryCompletion":1276,"completion":6795,"start":4203,"enrollment":413,"conditions":6817,"interventions":6819},"NCT06887777","Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)",[91],[6818],"Pyruvate Dehydrogenase Complex Deficiency Disease",[6805],{"trials":6821,"activeCount":102},[],{"trials":6823,"activeCount":102},[],{"trials":6825,"activeCount":102},[],{"intervention":6827,"totalTrials":180,"cells":6828},"Dimethyl Fumarate",{"EARLY_PHASE1":6829,"PHASE1":6831,"PHASE2":6833,"PHASE3":6845,"PHASE4":6847,"NA":6849},{"trials":6830,"activeCount":102},[],{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":180,"soonestReadout":6839},[6835],{"nctId":6836,"briefTitle":6837,"status":152,"phases":6838,"primaryCompletion":6839,"completion":6840,"start":6841,"enrollment":5804,"conditions":6842,"interventions":6844},"NCT04292080","Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy",[91],"2027-04-07","2029-04-07","2022-02-07",[6843],"Age-related Macular Degeneration (AMD)",[6827],{"trials":6846,"activeCount":102},[],{"trials":6848,"activeCount":102},[],{"trials":6850,"activeCount":102},[],{"intervention":6852,"totalTrials":180,"cells":6853},"Administration of a combination of treatments",{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6867,"PHASE4":6869,"NA":6871},{"trials":6855,"activeCount":102},[],{"trials":6857,"activeCount":102},[],{"trials":6859,"activeCount":180,"soonestReadout":3499},[6860],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6863,"primaryCompletion":3499,"completion":3499,"start":399,"enrollment":400,"conditions":6864,"interventions":6866},"NCT07348393","A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)",[91],[6865],"Relapsed or Refractory Multiple Myeloma (RRMM)",[6852],{"trials":6868,"activeCount":102},[],{"trials":6870,"activeCount":102},[],{"trials":6872,"activeCount":102},[],{"intervention":6874,"totalTrials":180,"cells":6875},"Decreasing starting times for beginning nivolumab",{"EARLY_PHASE1":6876,"PHASE1":6878,"PHASE2":6880,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6877,"activeCount":102},[],{"trials":6879,"activeCount":102},[],{"trials":6881,"activeCount":180,"soonestReadout":1472},[6882],{"nctId":6883,"briefTitle":6884,"status":152,"phases":6885,"primaryCompletion":1472,"completion":1472,"start":6886,"enrollment":115,"conditions":6887,"interventions":6890},"NCT05310591","Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence",[90,91],"2023-03-15",[6888,6889],"B Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia, in Relapse",[6874,6891],"Nivolumab starting at day -1",{"trials":6893,"activeCount":102},[],{"trials":6895,"activeCount":102},[],{"trials":6897,"activeCount":102},[],{"intervention":6891,"totalTrials":180,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6901,"activeCount":102},[],{"trials":6903,"activeCount":102},[],{"trials":6905,"activeCount":180,"soonestReadout":1472},[6906],{"nctId":6883,"briefTitle":6884,"status":152,"phases":6907,"primaryCompletion":1472,"completion":1472,"start":6886,"enrollment":115,"conditions":6908,"interventions":6909},[90,91],[6888,6889],[6874,6891],{"trials":6911,"activeCount":102},[],{"trials":6913,"activeCount":102},[],{"trials":6915,"activeCount":102},[],{"intervention":6917,"totalTrials":180,"cells":6918},"Sildenafil Citrate",{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6923,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6920,"activeCount":102},[],{"trials":6922,"activeCount":102},[],{"trials":6924,"activeCount":180,"soonestReadout":6336},[6925],{"nctId":6926,"briefTitle":6927,"status":126,"phases":6928,"primaryCompletion":6336,"completion":6929,"start":1105,"enrollment":27,"conditions":6930,"interventions":6932},"NCT06810284","Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy",[91],"2029-05",[6931],"Hypoxic-Ischemic Encephalopathy",[6917],{"trials":6934,"activeCount":102},[],{"trials":6936,"activeCount":102},[],{"trials":6938,"activeCount":102},[],{"intervention":6940,"totalTrials":180,"cells":6941},"Pulse bolus corticosteroids",{"EARLY_PHASE1":6942,"PHASE1":6944,"PHASE2":6946,"PHASE3":6956,"PHASE4":6958,"NA":6960},{"trials":6943,"activeCount":102},[],{"trials":6945,"activeCount":102},[],{"trials":6947,"activeCount":180,"soonestReadout":6929},[6948],{"nctId":6949,"briefTitle":6950,"status":126,"phases":6951,"primaryCompletion":6929,"completion":1106,"start":156,"enrollment":1277,"conditions":6952,"interventions":6954},"NCT06896253","Pulse Corticosteroids Or\u002Fand Immunoglobulins to Treat Fulminant Myocarditis",[91],[6953],"Myocarditis Acute",[6940,6955,6940],"Pulse bolus corticosteroids and IVIG",{"trials":6957,"activeCount":102},[],{"trials":6959,"activeCount":102},[],{"trials":6961,"activeCount":102},[],{"intervention":6955,"totalTrials":180,"cells":6963},{"EARLY_PHASE1":6964,"PHASE1":6966,"PHASE2":6968,"PHASE3":6974,"PHASE4":6976,"NA":6978},{"trials":6965,"activeCount":102},[],{"trials":6967,"activeCount":102},[],{"trials":6969,"activeCount":180,"soonestReadout":6929},[6970],{"nctId":6949,"briefTitle":6950,"status":126,"phases":6971,"primaryCompletion":6929,"completion":1106,"start":156,"enrollment":1277,"conditions":6972,"interventions":6973},[91],[6953],[6940,6955,6940],{"trials":6975,"activeCount":102},[],{"trials":6977,"activeCount":102},[],{"trials":6979,"activeCount":102},[],{"intervention":6981,"totalTrials":180,"cells":6982},"Tedizolid arm",{"EARLY_PHASE1":6983,"PHASE1":6985,"PHASE2":6987,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6984,"activeCount":102},[],{"trials":6986,"activeCount":102},[],{"trials":6988,"activeCount":180,"soonestReadout":1107},[6989],{"nctId":6990,"briefTitle":6991,"status":152,"phases":6992,"primaryCompletion":1107,"completion":1313,"start":6993,"enrollment":303,"conditions":6994,"interventions":6997},"NCT05534750","Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)",[91],"2023-04-20",[6995,6996],"Tuberculosis","Multidrug Resistant Tuberculosis",[6981,6998,6999],"Linezolid arm","Standard quadruple therapy arm",{"trials":7001,"activeCount":102},[],{"trials":7003,"activeCount":102},[],{"trials":7005,"activeCount":102},[],{"intervention":6998,"totalTrials":180,"cells":7007},{"EARLY_PHASE1":7008,"PHASE1":7010,"PHASE2":7012,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":180,"soonestReadout":1107},[7014],{"nctId":6990,"briefTitle":6991,"status":152,"phases":7015,"primaryCompletion":1107,"completion":1313,"start":6993,"enrollment":303,"conditions":7016,"interventions":7017},[91],[6995,6996],[6981,6998,6999],{"trials":7019,"activeCount":102},[],{"trials":7021,"activeCount":102},[],{"trials":7023,"activeCount":102},[],{"intervention":6999,"totalTrials":180,"cells":7025},{"EARLY_PHASE1":7026,"PHASE1":7028,"PHASE2":7030,"PHASE3":7036,"PHASE4":7038,"NA":7040},{"trials":7027,"activeCount":102},[],{"trials":7029,"activeCount":102},[],{"trials":7031,"activeCount":180,"soonestReadout":1107},[7032],{"nctId":6990,"briefTitle":6991,"status":152,"phases":7033,"primaryCompletion":1107,"completion":1313,"start":6993,"enrollment":303,"conditions":7034,"interventions":7035},[91],[6995,6996],[6981,6998,6999],{"trials":7037,"activeCount":102},[],{"trials":7039,"activeCount":102},[],{"trials":7041,"activeCount":102},[],{"intervention":5740,"totalTrials":180,"cells":7043},{"EARLY_PHASE1":7044,"PHASE1":7046,"PHASE2":7048,"PHASE3":7054,"PHASE4":7056,"NA":7058},{"trials":7045,"activeCount":102},[],{"trials":7047,"activeCount":102},[],{"trials":7049,"activeCount":180,"soonestReadout":5735},[7050],{"nctId":5732,"briefTitle":5733,"status":152,"phases":7051,"primaryCompletion":5735,"completion":5736,"start":5737,"enrollment":27,"conditions":7052,"interventions":7053},[91],[1522],[5740,5713],{"trials":7055,"activeCount":102},[],{"trials":7057,"activeCount":102},[],{"trials":7059,"activeCount":102},[],{"intervention":7061,"totalTrials":180,"cells":7062},"Hematopoietic stem-cell transplantation",{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7077,"PHASE4":7079,"NA":7081},{"trials":7064,"activeCount":102},[],{"trials":7066,"activeCount":102},[],{"trials":7068,"activeCount":180,"soonestReadout":7073},[7069],{"nctId":7070,"briefTitle":7071,"status":126,"phases":7072,"primaryCompletion":7073,"completion":7073,"start":1674,"enrollment":1710,"conditions":7074,"interventions":7076},"NCT06235398","Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial",[91],"2028-02-01",[7075],"Myelodysplastic Syndromes",[7061],{"trials":7078,"activeCount":102},[],{"trials":7080,"activeCount":102},[],{"trials":7082,"activeCount":102},[],{"intervention":5564,"totalTrials":180,"cells":7084},{"EARLY_PHASE1":7085,"PHASE1":7087,"PHASE2":7089,"PHASE3":7095,"PHASE4":7097,"NA":7099},{"trials":7086,"activeCount":102},[],{"trials":7088,"activeCount":102},[],{"trials":7090,"activeCount":180,"soonestReadout":5111},[7091],{"nctId":5552,"briefTitle":5553,"status":169,"phases":7092,"primaryCompletion":5111,"completion":5555,"start":5556,"enrollment":5557,"conditions":7093,"interventions":7094},[91],[5559,5560,5561],[5534,5563,5564,5565],{"trials":7096,"activeCount":102},[],{"trials":7098,"activeCount":102},[],{"trials":7100,"activeCount":102},[],{"intervention":5565,"totalTrials":180,"cells":7102},{"EARLY_PHASE1":7103,"PHASE1":7105,"PHASE2":7107,"PHASE3":7113,"PHASE4":7115,"NA":7117},{"trials":7104,"activeCount":102},[],{"trials":7106,"activeCount":102},[],{"trials":7108,"activeCount":180,"soonestReadout":5111},[7109],{"nctId":5552,"briefTitle":5553,"status":169,"phases":7110,"primaryCompletion":5111,"completion":5555,"start":5556,"enrollment":5557,"conditions":7111,"interventions":7112},[91],[5559,5560,5561],[5534,5563,5564,5565],{"trials":7114,"activeCount":102},[],{"trials":7116,"activeCount":102},[],{"trials":7118,"activeCount":102},[],{"intervention":57,"totalTrials":180,"cells":7120},{"EARLY_PHASE1":7121,"PHASE1":7123,"PHASE2":7125,"PHASE3":7133,"PHASE4":7135,"NA":7137},{"trials":7122,"activeCount":102},[],{"trials":7124,"activeCount":102},[],{"trials":7126,"activeCount":180,"soonestReadout":56},[7127],{"nctId":54,"briefTitle":55,"status":126,"phases":7128,"primaryCompletion":56,"completion":2087,"start":7129,"enrollment":5575,"conditions":7130,"interventions":7132},[91],"2022-07",[3721,7131],"Cutaneous Sarcoidosis",[57],{"trials":7134,"activeCount":102},[],{"trials":7136,"activeCount":102},[],{"trials":7138,"activeCount":102},[],{"intervention":7140,"totalTrials":180,"cells":7141},"DREAM01 drug product",{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7157,"PHASE4":7159,"NA":7161},{"trials":7143,"activeCount":102},[],{"trials":7145,"activeCount":102},[],{"trials":7147,"activeCount":180,"soonestReadout":3368},[7148],{"nctId":7149,"briefTitle":7150,"status":152,"phases":7151,"primaryCompletion":3368,"completion":7152,"start":7153,"enrollment":413,"conditions":7154,"interventions":7155},"NCT07432867","Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.",[90,91],"2033-02","2026-02-25",[20],[7140,7156],"anti-inflammatory therapy",{"trials":7158,"activeCount":102},[],{"trials":7160,"activeCount":102},[],{"trials":7162,"activeCount":102},[],{"intervention":7156,"totalTrials":180,"cells":7164},{"EARLY_PHASE1":7165,"PHASE1":7167,"PHASE2":7169,"PHASE3":7175,"PHASE4":7177,"NA":7179},{"trials":7166,"activeCount":102},[],{"trials":7168,"activeCount":102},[],{"trials":7170,"activeCount":180,"soonestReadout":3368},[7171],{"nctId":7149,"briefTitle":7150,"status":152,"phases":7172,"primaryCompletion":3368,"completion":7152,"start":7153,"enrollment":413,"conditions":7173,"interventions":7174},[90,91],[20],[7140,7156],{"trials":7176,"activeCount":102},[],{"trials":7178,"activeCount":102},[],{"trials":7180,"activeCount":102},[],{"intervention":7182,"totalTrials":180,"cells":7183},"ARTEGENE drug product",{"EARLY_PHASE1":7184,"PHASE1":7186,"PHASE2":7188,"PHASE3":7199,"PHASE4":7201,"NA":7203},{"trials":7185,"activeCount":102},[],{"trials":7187,"activeCount":102},[],{"trials":7189,"activeCount":180,"soonestReadout":7194},[7190],{"nctId":7191,"briefTitle":7192,"status":152,"phases":7193,"primaryCompletion":7194,"completion":7194,"start":7195,"enrollment":1361,"conditions":7196,"interventions":7198},"NCT05071222","Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)",[90,91],"2041-11-19","2023-07-19",[7197],"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency",[7182],{"trials":7200,"activeCount":102},[],{"trials":7202,"activeCount":102},[],{"trials":7204,"activeCount":102},[],{"intervention":7206,"totalTrials":180,"cells":7207},"Adipose derived stromal cells intravenously injected",{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7226,"PHASE4":7228,"NA":7230},{"trials":7209,"activeCount":102},[],{"trials":7211,"activeCount":102},[],{"trials":7213,"activeCount":180,"soonestReadout":154},[7214],{"nctId":7215,"briefTitle":7216,"status":152,"phases":7217,"primaryCompletion":154,"completion":154,"start":7218,"enrollment":413,"conditions":7219,"interventions":7225},"NCT04711200","LYell SYndrome MEsenchymal Stromal Cells Treatment",[90,91],"2024-04-15",[7220,7221,7222,7223,6347,7224],"Epidermal Necrolysis","Lyell Syndrome","Toxic Epidermal Necrolysis","Overlap Syndrome","Adipose Derived Stromal Cells",[7206],{"trials":7227,"activeCount":102},[],{"trials":7229,"activeCount":102},[],{"trials":7231,"activeCount":102},[],{"intervention":7233,"totalTrials":180,"cells":7234},"IV Methylprednisolone pulses",{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7239,"PHASE3":7250,"PHASE4":7252,"NA":7254},{"trials":7236,"activeCount":102},[],{"trials":7238,"activeCount":102},[],{"trials":7240,"activeCount":180,"soonestReadout":7245},[7241],{"nctId":7242,"briefTitle":7243,"status":152,"phases":7244,"primaryCompletion":7245,"completion":7245,"start":7246,"enrollment":1225,"conditions":7247,"interventions":7249},"NCT06471556","Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study",[91],"2029-02-28","2025-06-30",[7248],"Neuroendocrine Cell Hyperplasia of Infancy",[7233],{"trials":7251,"activeCount":102},[],{"trials":7253,"activeCount":102},[],{"trials":7255,"activeCount":102},[],{"intervention":7257,"totalTrials":180,"cells":7258},"2 infusions of MSC",{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7263,"PHASE3":7275,"PHASE4":7277,"NA":7279},{"trials":7260,"activeCount":102},[],{"trials":7262,"activeCount":102},[],{"trials":7264,"activeCount":180,"soonestReadout":1276},[7265],{"nctId":7266,"briefTitle":7267,"status":126,"phases":7268,"primaryCompletion":1276,"completion":7269,"start":7270,"enrollment":1225,"conditions":7271,"interventions":7273},"NCT06722105","Phase I\u002FII Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis",[90,91],"2027-05-01","2024-12-01",[7272],"Severe Systemic Sclerosis",[7257,7274],"1 infusion of MSC",{"trials":7276,"activeCount":102},[],{"trials":7278,"activeCount":102},[],{"trials":7280,"activeCount":102},[],{"intervention":7274,"totalTrials":180,"cells":7282},{"EARLY_PHASE1":7283,"PHASE1":7285,"PHASE2":7287,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7284,"activeCount":102},[],{"trials":7286,"activeCount":102},[],{"trials":7288,"activeCount":180,"soonestReadout":1276},[7289],{"nctId":7266,"briefTitle":7267,"status":126,"phases":7290,"primaryCompletion":1276,"completion":7269,"start":7270,"enrollment":1225,"conditions":7291,"interventions":7292},[90,91],[7272],[7257,7274],{"trials":7294,"activeCount":102},[],{"trials":7296,"activeCount":102},[],{"trials":7298,"activeCount":102},[],{"intervention":1165,"totalTrials":180,"cells":7300},{"EARLY_PHASE1":7301,"PHASE1":7303,"PHASE2":7305,"PHASE3":7311,"PHASE4":7313,"NA":7315},{"trials":7302,"activeCount":102},[],{"trials":7304,"activeCount":102},[],{"trials":7306,"activeCount":180,"soonestReadout":1157},[7307],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7308,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7309,"interventions":7310},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7312,"activeCount":102},[],{"trials":7314,"activeCount":102},[],{"trials":7316,"activeCount":102},[],{"intervention":1166,"totalTrials":180,"cells":7318},{"EARLY_PHASE1":7319,"PHASE1":7321,"PHASE2":7323,"PHASE3":7329,"PHASE4":7331,"NA":7333},{"trials":7320,"activeCount":102},[],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":180,"soonestReadout":1157},[7325],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7326,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7327,"interventions":7328},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7330,"activeCount":102},[],{"trials":7332,"activeCount":102},[],{"trials":7334,"activeCount":102},[],{"intervention":1167,"totalTrials":180,"cells":7336},{"EARLY_PHASE1":7337,"PHASE1":7339,"PHASE2":7341,"PHASE3":7347,"PHASE4":7349,"NA":7351},{"trials":7338,"activeCount":102},[],{"trials":7340,"activeCount":102},[],{"trials":7342,"activeCount":180,"soonestReadout":1157},[7343],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7344,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7345,"interventions":7346},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7348,"activeCount":102},[],{"trials":7350,"activeCount":102},[],{"trials":7352,"activeCount":102},[],{"intervention":1168,"totalTrials":180,"cells":7354},{"EARLY_PHASE1":7355,"PHASE1":7357,"PHASE2":7359,"PHASE3":7365,"PHASE4":7367,"NA":7369},{"trials":7356,"activeCount":102},[],{"trials":7358,"activeCount":102},[],{"trials":7360,"activeCount":180,"soonestReadout":1157},[7361],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7362,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7363,"interventions":7364},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7366,"activeCount":102},[],{"trials":7368,"activeCount":102},[],{"trials":7370,"activeCount":102},[],{"intervention":1169,"totalTrials":180,"cells":7372},{"EARLY_PHASE1":7373,"PHASE1":7375,"PHASE2":7377,"PHASE3":7383,"PHASE4":7385,"NA":7387},{"trials":7374,"activeCount":102},[],{"trials":7376,"activeCount":102},[],{"trials":7378,"activeCount":180,"soonestReadout":1157},[7379],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7380,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7381,"interventions":7382},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7384,"activeCount":102},[],{"trials":7386,"activeCount":102},[],{"trials":7388,"activeCount":102},[],{"intervention":1170,"totalTrials":180,"cells":7390},{"EARLY_PHASE1":7391,"PHASE1":7393,"PHASE2":7395,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7392,"activeCount":102},[],{"trials":7394,"activeCount":102},[],{"trials":7396,"activeCount":180,"soonestReadout":1157},[7397],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7398,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7399,"interventions":7400},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7402,"activeCount":102},[],{"trials":7404,"activeCount":102},[],{"trials":7406,"activeCount":102},[],{"intervention":1171,"totalTrials":180,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7413,"PHASE3":7419,"PHASE4":7421,"NA":7423},{"trials":7410,"activeCount":102},[],{"trials":7412,"activeCount":102},[],{"trials":7414,"activeCount":180,"soonestReadout":1157},[7415],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7416,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7417,"interventions":7418},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7420,"activeCount":102},[],{"trials":7422,"activeCount":102},[],{"trials":7424,"activeCount":102},[],{"intervention":1172,"totalTrials":180,"cells":7426},{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7431,"PHASE3":7437,"PHASE4":7439,"NA":7441},{"trials":7428,"activeCount":102},[],{"trials":7430,"activeCount":102},[],{"trials":7432,"activeCount":180,"soonestReadout":1157},[7433],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7434,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7435,"interventions":7436},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7438,"activeCount":102},[],{"trials":7440,"activeCount":102},[],{"trials":7442,"activeCount":102},[],{"intervention":1173,"totalTrials":180,"cells":7444},{"EARLY_PHASE1":7445,"PHASE1":7447,"PHASE2":7449,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7446,"activeCount":102},[],{"trials":7448,"activeCount":102},[],{"trials":7450,"activeCount":180,"soonestReadout":1157},[7451],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7452,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7453,"interventions":7454},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7456,"activeCount":102},[],{"trials":7458,"activeCount":102},[],{"trials":7460,"activeCount":102},[],{"intervention":1174,"totalTrials":180,"cells":7462},{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7467,"PHASE3":7473,"PHASE4":7475,"NA":7477},{"trials":7464,"activeCount":102},[],{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":180,"soonestReadout":1157},[7469],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7470,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7471,"interventions":7472},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7474,"activeCount":102},[],{"trials":7476,"activeCount":102},[],{"trials":7478,"activeCount":102},[],{"intervention":1175,"totalTrials":180,"cells":7480},{"EARLY_PHASE1":7481,"PHASE1":7483,"PHASE2":7485,"PHASE3":7491,"PHASE4":7493,"NA":7495},{"trials":7482,"activeCount":102},[],{"trials":7484,"activeCount":102},[],{"trials":7486,"activeCount":180,"soonestReadout":1157},[7487],{"nctId":1154,"briefTitle":1155,"status":126,"phases":7488,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":1160,"conditions":7489,"interventions":7490},[91],[679],[77,1163,1089,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175],{"trials":7492,"activeCount":102},[],{"trials":7494,"activeCount":102},[],{"trials":7496,"activeCount":102},[],{"intervention":7498,"totalTrials":180,"cells":7499},"MUNC-CD34",{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7504,"PHASE3":7516,"PHASE4":7518,"NA":7520},{"trials":7501,"activeCount":102},[],{"trials":7503,"activeCount":102},[],{"trials":7505,"activeCount":180,"soonestReadout":7510},[7506],{"nctId":7507,"briefTitle":7508,"status":126,"phases":7509,"primaryCompletion":7510,"completion":7511,"start":1313,"enrollment":98,"conditions":7512,"interventions":7514},"NCT06736080","Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNA",[90,91],"2029-01","2030-01",[7513],"Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)",[7498,7515],"MUNC-T3",{"trials":7517,"activeCount":102},[],{"trials":7519,"activeCount":102},[],{"trials":7521,"activeCount":102},[],{"intervention":7515,"totalTrials":180,"cells":7523},{"EARLY_PHASE1":7524,"PHASE1":7526,"PHASE2":7528,"PHASE3":7534,"PHASE4":7536,"NA":7538},{"trials":7525,"activeCount":102},[],{"trials":7527,"activeCount":102},[],{"trials":7529,"activeCount":180,"soonestReadout":7510},[7530],{"nctId":7507,"briefTitle":7508,"status":126,"phases":7531,"primaryCompletion":7510,"completion":7511,"start":1313,"enrollment":98,"conditions":7532,"interventions":7533},[90,91],[7513],[7498,7515],{"trials":7535,"activeCount":102},[],{"trials":7537,"activeCount":102},[],{"trials":7539,"activeCount":102},[],{"intervention":1281,"totalTrials":180,"cells":7541},{"EARLY_PHASE1":7542,"PHASE1":7544,"PHASE2":7546,"PHASE3":7552,"PHASE4":7554,"NA":7556},{"trials":7543,"activeCount":102},[],{"trials":7545,"activeCount":102},[],{"trials":7547,"activeCount":180,"soonestReadout":1274},[7548],{"nctId":1271,"briefTitle":1272,"status":126,"phases":7549,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":1277,"conditions":7550,"interventions":7551},[91],[1279],[1090,1281,1163],{"trials":7553,"activeCount":102},[],{"trials":7555,"activeCount":102},[],{"trials":7557,"activeCount":102},[],{"intervention":7559,"totalTrials":180,"cells":7560},"The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).",{"EARLY_PHASE1":7561,"PHASE1":7563,"PHASE2":7565,"PHASE3":7576,"PHASE4":7578,"NA":7580},{"trials":7562,"activeCount":102},[],{"trials":7564,"activeCount":102},[],{"trials":7566,"activeCount":180,"soonestReadout":7571},[7567],{"nctId":7568,"briefTitle":7569,"status":152,"phases":7570,"primaryCompletion":7571,"completion":7571,"start":7572,"enrollment":303,"conditions":7573,"interventions":7575},"NCT05327972","DEgenerative ROtator Cuff Disease and Botulinum TOXin",[91],"2027-02","2023-01-20",[7574],"Degenerative Rotator Cuff Disease",[7559],{"trials":7577,"activeCount":102},[],{"trials":7579,"activeCount":102},[],{"trials":7581,"activeCount":102},[],{"intervention":72,"totalTrials":180,"cells":7583},{"EARLY_PHASE1":7584,"PHASE1":7586,"PHASE2":7588,"PHASE3":7596,"PHASE4":7598,"NA":7600},{"trials":7585,"activeCount":102},[],{"trials":7587,"activeCount":102},[],{"trials":7589,"activeCount":180,"soonestReadout":71},[7590],{"nctId":69,"briefTitle":70,"status":126,"phases":7591,"primaryCompletion":71,"completion":1312,"start":7592,"enrollment":268,"conditions":7593,"interventions":7595},[91],"2022-05",[7594],"Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers",[72],{"trials":7597,"activeCount":102},[],{"trials":7599,"activeCount":102},[],{"trials":7601,"activeCount":102},[],{"intervention":7603,"totalTrials":180,"cells":7604},"82-Rb",{"EARLY_PHASE1":7605,"PHASE1":7607,"PHASE2":7609,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7606,"activeCount":102},[],{"trials":7608,"activeCount":102},[],{"trials":7610,"activeCount":180,"soonestReadout":4270},[7611],{"nctId":7612,"briefTitle":7613,"status":126,"phases":7614,"primaryCompletion":4270,"completion":4270,"start":918,"enrollment":1130,"conditions":7615,"interventions":7617},"NCT07346404","Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma",[91],[7616],"Renal Cell Carcinoma",[7603],{"trials":7619,"activeCount":102},[],{"trials":7621,"activeCount":102},[],{"trials":7623,"activeCount":102},[],{"intervention":7625,"totalTrials":180,"cells":7626},"GHB",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7641,"PHASE4":7643,"NA":7645},{"trials":7628,"activeCount":102},[],{"trials":7630,"activeCount":102},[],{"trials":7632,"activeCount":180,"soonestReadout":4245},[7633],{"nctId":7634,"briefTitle":7635,"status":126,"phases":7636,"primaryCompletion":4245,"completion":4245,"start":194,"enrollment":27,"conditions":7637,"interventions":7640},"NCT07596342","Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients",[91],[7638,7639],"Sleep Disorder (Disorder)","Critical Care",[7625],{"trials":7642,"activeCount":102},[],{"trials":7644,"activeCount":102},[],{"trials":7646,"activeCount":102},[],{"intervention":7648,"totalTrials":429,"cells":7649},"Cannabidiol",{"EARLY_PHASE1":7650,"PHASE1":7652,"PHASE2":7654,"PHASE3":7672,"PHASE4":7674,"NA":7676},{"trials":7651,"activeCount":102},[],{"trials":7653,"activeCount":102},[],{"trials":7655,"activeCount":180,"soonestReadout":6929},[7656,7663],{"nctId":7657,"briefTitle":7658,"status":126,"phases":7659,"primaryCompletion":6929,"completion":398,"start":1313,"enrollment":33,"conditions":7660,"interventions":7662},"NCT07564245","Efficacy of Cannabidiol in the Management of Self-injuries in Children and Adolescents With Severe Neurodevelopmental Disorders.",[91],[7661],"Neurodevelopmental Disorders With Severe Self-injuries",[7648],{"nctId":7664,"briefTitle":7665,"status":139,"phases":7666,"primaryCompletion":7667,"completion":7667,"start":7668,"enrollment":5575,"conditions":7669,"interventions":7671},"NCT05651607","Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa",[91],"2023-11-17","2023-09-07",[7670],"Hereditary Epidermolysis Bullosa",[7648],{"trials":7673,"activeCount":102},[],{"trials":7675,"activeCount":102},[],{"trials":7677,"activeCount":102},[7678],{"nctId":7679,"briefTitle":7680,"status":139,"phases":7681,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":7685,"interventions":7687},"NCT03196466","Population Pharmacokinetics of Antiepileptic in Pediatrics",[],"2023-06-15","2017-06-19",753,[7686],"Epilepsy",[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],"Valproic acid","carbamazepine","phenobarbital","phenytoin","levetiracetam","lamotrigine","topiramate","oxcarbazepine","stiripentol","clobazam","brivaracétam","felbamate","lacosamide","rufinamide","gabapentine","pregabaline","sultiame","tiagabine","vigabatrine","mesuximide","primidone","perampanel","ethosuximide","zonisamide","cannabidiol",{"intervention":7714,"totalTrials":180,"cells":7715},"Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells",{"EARLY_PHASE1":7716,"PHASE1":7718,"PHASE2":7730,"PHASE3":7732,"PHASE4":7734,"NA":7736},{"trials":7717,"activeCount":102},[],{"trials":7719,"activeCount":180,"soonestReadout":7724},[7720],{"nctId":7721,"briefTitle":7722,"status":152,"phases":7723,"primaryCompletion":7724,"completion":7725,"start":7726,"enrollment":268,"conditions":7727,"interventions":7729},"NCT05774509","Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells",[90],"2025-08-15","2026-07-15","2023-05-31",[7728],"Heart Failure With Reduced Ejection Fraction",[7714],{"trials":7731,"activeCount":102},[],{"trials":7733,"activeCount":102},[],{"trials":7735,"activeCount":102},[],{"trials":7737,"activeCount":102},[],{"intervention":1556,"totalTrials":180,"cells":7739},{"EARLY_PHASE1":7740,"PHASE1":7742,"PHASE2":7748,"PHASE3":7750,"PHASE4":7752,"NA":7754},{"trials":7741,"activeCount":102},[],{"trials":7743,"activeCount":180,"soonestReadout":1551},[7744],{"nctId":1548,"briefTitle":1549,"status":126,"phases":7745,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":268,"conditions":7746,"interventions":7747},[90],[1554],[1541,1556],{"trials":7749,"activeCount":102},[],{"trials":7751,"activeCount":102},[],{"trials":7753,"activeCount":102},[],{"trials":7755,"activeCount":102},[],{"intervention":7757,"totalTrials":180,"cells":7758},"Single in situ intra-arterial injection of bevacizumab",{"EARLY_PHASE1":7759,"PHASE1":7761,"PHASE2":7771,"PHASE3":7773,"PHASE4":7775,"NA":7777},{"trials":7760,"activeCount":102},[],{"trials":7762,"activeCount":180,"soonestReadout":7767},[7763],{"nctId":7764,"briefTitle":7765,"status":126,"phases":7766,"primaryCompletion":7767,"completion":7767,"start":4203,"enrollment":36,"conditions":7768,"interventions":7770},"NCT07075757","In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment",[90],"2028-11-01",[7769],"Brain Arteriovenous Malformations",[7757],{"trials":7772,"activeCount":102},[],{"trials":7774,"activeCount":102},[],{"trials":7776,"activeCount":102},[],{"trials":7778,"activeCount":102},[],{"intervention":7780,"totalTrials":180,"cells":7781},"DT-7012",{"EARLY_PHASE1":7782,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7783,"activeCount":180,"soonestReadout":7788},[7784],{"nctId":7785,"briefTitle":7786,"status":126,"phases":7787,"primaryCompletion":7788,"completion":7788,"start":918,"enrollment":21,"conditions":7789,"interventions":7792},"NCT07213882","A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)",[89],"2028-08-01",[4460,7790,7791],"Mycosis Fungoides","Sezary Syndrome",[7780],{"trials":7794,"activeCount":102},[],{"trials":7796,"activeCount":102},[],{"trials":7798,"activeCount":102},[],{"trials":7800,"activeCount":102},[],{"trials":7802,"activeCount":102},[],{"intervention":7804,"totalTrials":1384,"cells":7805},"Blood sampling",{"EARLY_PHASE1":7806,"PHASE1":7808,"PHASE2":7810,"PHASE3":7812,"PHASE4":7814,"NA":7816},{"trials":7807,"activeCount":102},[],{"trials":7809,"activeCount":102},[],{"trials":7811,"activeCount":102},[],{"trials":7813,"activeCount":102},[],{"trials":7815,"activeCount":102},[],{"trials":7817,"activeCount":473,"soonestReadout":1107},[7818,7829,7838,7846,7852,7861,7871,7883,7892,7901,7909],{"nctId":7819,"briefTitle":7820,"status":152,"phases":7821,"primaryCompletion":7822,"completion":7823,"start":7824,"enrollment":4321,"conditions":7825,"interventions":7827},"NCT06979765","Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients",[94],"2028-03-26","2028-06-26","2025-03-26",[7826],"Thrombopenia",[7828],"blood sampling",{"nctId":7830,"briefTitle":7831,"status":152,"phases":7832,"primaryCompletion":1095,"completion":1095,"start":7833,"enrollment":7834,"conditions":7835,"interventions":7836},"NCT04292067","Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis",[],"2020-11-23",400,[5271,32],[7837,7804],"Faecal sampling",{"nctId":7839,"briefTitle":7840,"status":139,"phases":7841,"primaryCompletion":2672,"completion":2672,"start":7842,"enrollment":303,"conditions":7843,"interventions":7845},"NCT03895736","Transcriptome Assessment After Cardiac Arrest",[94],"2020-02-24",[7844],"Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation",[7828],{"nctId":7847,"briefTitle":7848,"status":126,"phases":7849,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":3895,"conditions":7850,"interventions":7851},"NCT07347613","Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study",[],[1533],[7828],{"nctId":7853,"briefTitle":7854,"status":152,"phases":7855,"primaryCompletion":3084,"completion":7856,"start":7857,"enrollment":7858,"conditions":7859,"interventions":7860},"NCT03518099","Searching Biomarkers of Acute Intestinal Ischemic Injuries",[94],"2028-07-30","2018-11-16",556,[2163],[7828],{"nctId":7862,"briefTitle":7863,"status":139,"phases":7864,"primaryCompletion":7865,"completion":7865,"start":7866,"enrollment":7867,"conditions":7868,"interventions":7870},"NCT02961868","Cohort Follow-up of Patients With Renal or Craniocervical Fibromuscular Dysplasia",[94],"2018-01","2009-11",340,[7869],"Fibromuscular Dysplasia",[7804],{"nctId":7872,"briefTitle":7873,"status":152,"phases":7874,"primaryCompletion":1107,"completion":1107,"start":7875,"enrollment":303,"conditions":7876,"interventions":7878},"NCT06387030","EDN and Eosinophilic Esophagitis",[94],"2024-04-19",[7877],"Eosinophilic Esophagitis",[7804,7879,7880,7881,7882],"Esophageal biopsies","Unstimulated saliva sampling","Urine sampling","Stool sampling",{"nctId":7884,"briefTitle":7885,"status":139,"phases":7886,"primaryCompletion":7887,"completion":7887,"start":7888,"enrollment":1108,"conditions":7889,"interventions":7891},"NCT04318691","Netosis in Determination of Respiratory Infection Severity",[],"2023-01-03","2022-06-07",[7890],"Respiratory Infection",[7804],{"nctId":7893,"briefTitle":7894,"status":139,"phases":7895,"primaryCompletion":5469,"completion":5701,"start":7896,"enrollment":7897,"conditions":7898,"interventions":7900},"NCT02274402","Pharmacokinetics of Prednisone in Adults",[],"2014-11",114,[7899],"Patients Receiving Prednisone",[7828],{"nctId":7902,"briefTitle":7903,"status":139,"phases":7904,"primaryCompletion":7905,"completion":7905,"start":1749,"enrollment":21,"conditions":7906,"interventions":7907},"NCT03482895","MINI Bypass Versus Roux-en-Y Bypass: Differences in HOrmonal Secretions at 2 Years of Surgery",[],"2019-05-14",[1534],[7804,7908],"Feces sampling",{"nctId":7910,"briefTitle":7911,"status":152,"phases":7912,"primaryCompletion":7913,"completion":7913,"start":7914,"enrollment":7915,"conditions":7916,"interventions":7918},"NCT04363983","Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms",[94],"2031-01","2021-01-13",6300,[7917],"Gastrointestinal Neoplasms",[7804,7919],"Stool collect",{"intervention":7921,"totalTrials":413,"cells":7922},"Blood sample",{"EARLY_PHASE1":7923,"PHASE1":7925,"PHASE2":7927,"PHASE3":7940,"PHASE4":7942,"NA":7944},{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"trials":7928,"activeCount":102},[7929],{"nctId":7930,"briefTitle":7931,"status":110,"phases":7932,"primaryCompletion":7933,"completion":61,"start":7934,"enrollment":7935,"conditions":7936,"interventions":7938},"NCT03873727","Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.",[91],"2023-06","2019-08-27",39,[7937],"Splenectomised Patients",[7939,7921],"Prevenar13",{"trials":7941,"activeCount":102},[],{"trials":7943,"activeCount":102},[],{"trials":7945,"activeCount":429,"soonestReadout":1313},[7946,7956,7968,7979,7989,8001,8010,8021,8041,8049,8057,8068,8078,8087],{"nctId":7947,"briefTitle":7948,"status":110,"phases":7949,"primaryCompletion":7950,"completion":7950,"start":7951,"enrollment":7952,"conditions":7953,"interventions":7955},"NCT05338359","Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis",[],"2023-02","2022-01-25",209,[7954],"Sepsis Syndrome",[7921],{"nctId":7957,"briefTitle":7958,"status":139,"phases":7959,"primaryCompletion":7960,"completion":7960,"start":7961,"enrollment":7962,"conditions":7963,"interventions":7966},"NCT01488461","Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias",[],"2014-10","2012-01",165,[7964,7965],"Congenital Cerebellar Ataxias","Early-onset Cerebellar Ataxias",[7967],"blood sample",{"nctId":7969,"briefTitle":7970,"status":139,"phases":7971,"primaryCompletion":7972,"completion":7972,"start":7973,"enrollment":7974,"conditions":7975,"interventions":7977},"NCT04253080","Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and\u002For in Predictive Response to Immune Checkpoint Inhibitors",[94],"2024-11-04","2022-04-12",127,[7976],"Cutaneous Melanoma",[7921,7978],"Cutaneous melanoma biopsy",{"nctId":7980,"briefTitle":7981,"status":110,"phases":7982,"primaryCompletion":4116,"completion":4116,"start":7983,"enrollment":245,"conditions":7984,"interventions":7988},"NCT03810859","Non-syndromic Inherited Anomalies of Mineralized Tooth Tissues: a Whole Exome Study to Identify New Pathogenic Variants",[94],"2019-10-09",[7985,7986,7987],"Amelogenesis Imperfecta","Dentinogenesis Imperfecta","Dentin Anomalies",[7921],{"nctId":7990,"briefTitle":7991,"status":110,"phases":7992,"primaryCompletion":7993,"completion":7994,"start":7995,"enrollment":1029,"conditions":7996,"interventions":8000},"NCT05026021","Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia",[],"2023-09-02","2025-09-02","2021-09-02",[7997,7998,7999],"BK Virus Infection","Nephropathy","Kidney Transplantation",[7921],{"nctId":8002,"briefTitle":8003,"status":139,"phases":8004,"primaryCompletion":7960,"completion":8005,"start":535,"enrollment":2779,"conditions":8006,"interventions":8009},"NCT01911871","Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations",[],"2015-03",[8007,20,8008],"Thalassemia","Myelodysplasia",[7921],{"nctId":8011,"briefTitle":8012,"status":241,"phases":8013,"primaryCompletion":8014,"completion":8015,"start":8016,"enrollment":8017,"conditions":8018,"interventions":8020},"NCT04870411","Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and\u002For Biologics",[],"2021-08-31","2022-03-13","2021-05-12",78,[231,8019],"Inflammatory Disorder",[7921],{"nctId":8022,"briefTitle":8023,"status":152,"phases":8024,"primaryCompletion":2087,"completion":2087,"start":8025,"enrollment":848,"conditions":8026,"interventions":8040},"NCT06147414","Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders",[],"2024-10-23",[8027,20,23,8028,8029,8030,8031,8032,8033,8034,8035,8036,8037,8038,8039],"Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including","Fragile X Syndrome","Proximal Spinal Muscular Atrophy","Myotonic Dystrophy","Muscular Dystrophy, Duchenne","Muscular Dystrophy, Becker","Neurofibromatosis-Noonan Syndrome","Huntington Disease","Hemophilia A","Hemophilia B","MODY2 Diabetes","X-Linked Hydrocephalus","Autosomal Recessive Polycystic Kidney Disease",[7921],{"nctId":8042,"briefTitle":8043,"status":126,"phases":8044,"primaryCompletion":1313,"completion":1866,"start":1313,"enrollment":473,"conditions":8045,"interventions":8048},"NCT07445490","Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis",[],[8046,8047],"Tay-Sachs Disease Ganglioside","Sandhoff Disease Ganglioside",[7967],{"nctId":8050,"briefTitle":8051,"status":139,"phases":8052,"primaryCompletion":1050,"completion":1050,"start":8053,"enrollment":206,"conditions":8054,"interventions":8056},"NCT02634229","Predisposition Genes in Monogenic Diabetes (DIAMONO)",[],"2012-09",[8055],"Non Autoimmune Monogenic Diabetes",[7967],{"nctId":8058,"briefTitle":8059,"status":139,"phases":8060,"primaryCompletion":8061,"completion":8062,"start":8063,"enrollment":8064,"conditions":8065,"interventions":8067},"NCT02175264","Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia",[],"2016-02","2016-05","2014-06",73,[8066],"Isolated Non Syndromic Left CDH With Postero Lateral Diaphragmatic Defect With Good Perinatal Outcome",[7921],{"nctId":8069,"briefTitle":8070,"status":152,"phases":8071,"primaryCompletion":8072,"completion":8072,"start":8073,"enrollment":489,"conditions":8074,"interventions":8076},"NCT05534347","Angiogenic Biomarkers in Juvenile Idiopathic Arthritis",[],"2030-03","2023-03-13",[8075],"Juvenile Idiopathic Arthritis (JIA)",[7921,8077],"Joint puncture",{"nctId":8079,"briefTitle":8080,"status":139,"phases":8081,"primaryCompletion":5660,"completion":5660,"start":8082,"enrollment":8083,"conditions":8084,"interventions":8086},"NCT01150305","Epidemiology of Non-syndromic Dominant Deafness",[],"2009-04",183,[8085],"Hearing Impairment",[7967],{"nctId":8088,"briefTitle":8089,"status":139,"phases":8090,"primaryCompletion":8091,"completion":8092,"start":8091,"enrollment":1931,"conditions":8093,"interventions":8095},"NCT05165030","Identification of Genetic Mutations Involved in Chiari Type I Malformations",[94],"2022-06-15","2025-07-25",[8094],"Chiari Malformation, Type 1",[8096],"Blood Sample",{"intervention":8098,"totalTrials":473,"cells":8099},"Blood samples",{"EARLY_PHASE1":8100,"PHASE1":8102,"PHASE2":8104,"PHASE3":8106,"PHASE4":8108,"NA":8110},{"trials":8101,"activeCount":102},[],{"trials":8103,"activeCount":102},[],{"trials":8105,"activeCount":102},[],{"trials":8107,"activeCount":102},[],{"trials":8109,"activeCount":102},[],{"trials":8111,"activeCount":429,"soonestReadout":5372},[8112,8121,8133,8144,8155,8163],{"nctId":8113,"briefTitle":8114,"status":5932,"phases":8115,"primaryCompletion":3474,"completion":4245,"start":7933,"enrollment":102,"conditions":8116,"interventions":8118},"NCT04316650","Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia",[94],[8117],"Paraphilia",[8119,8120],"blood samples","Blood and saliva samples",{"nctId":8122,"briefTitle":8123,"status":152,"phases":8124,"primaryCompletion":8125,"completion":8126,"start":8127,"enrollment":245,"conditions":8128,"interventions":8130},"NCT06694363","New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome",[],"2029-06-27","2029-12-27","2025-06-26",[8129],"Activated PI3K Delta Syndrome",[8098,8131,8132],"Urine samples","Stool samples",{"nctId":8134,"briefTitle":8135,"status":139,"phases":8136,"primaryCompletion":8137,"completion":8138,"start":8139,"enrollment":8140,"conditions":8141,"interventions":8143},"NCT02484274","Iron Deficiency (ID) in Infants",[94],"2018-01-15","2018-05","2016-01-06",830,[8142],"Iron Deficiency in Young Children Living in France",[8098],{"nctId":8145,"briefTitle":8146,"status":5932,"phases":8147,"primaryCompletion":8148,"completion":66,"start":8149,"enrollment":102,"conditions":8150,"interventions":8154},"NCT04953312","Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)",[94],"2023-12","2023-01",[8151,8152,7075,8153],"Severe\u002FModerate Coronavirus","Chronic Myelomonocytic Leukemia","Old Age",[8098],{"nctId":8156,"briefTitle":8157,"status":126,"phases":8158,"primaryCompletion":5372,"completion":5372,"start":1731,"enrollment":21,"conditions":8159,"interventions":8160},"NCT07280091","Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome",[],[1386],[8161,8161,8132,8162,8098,8098],"Superficial skin swabs","Saliva samples",{"nctId":8164,"briefTitle":8165,"status":152,"phases":8166,"primaryCompletion":4177,"completion":8167,"start":8168,"enrollment":8169,"conditions":8170,"interventions":8172},"NCT06923618","Cancer of the Lung And SeneScencE - Prospective Cohort 1",[94],"2032-07","2025-07-09",385,[8171],"Non-Small Cell Lung Cancer",[8098],{"intervention":8132,"totalTrials":163,"cells":8174},{"EARLY_PHASE1":8175,"PHASE1":8177,"PHASE2":8179,"PHASE3":8181,"PHASE4":8183,"NA":8185},{"trials":8176,"activeCount":102},[],{"trials":8178,"activeCount":102},[],{"trials":8180,"activeCount":102},[],{"trials":8182,"activeCount":102},[],{"trials":8184,"activeCount":102},[],{"trials":8186,"activeCount":163,"soonestReadout":5372},[8187,8191],{"nctId":8122,"briefTitle":8123,"status":152,"phases":8188,"primaryCompletion":8125,"completion":8126,"start":8127,"enrollment":245,"conditions":8189,"interventions":8190},[],[8129],[8098,8131,8132],{"nctId":8156,"briefTitle":8157,"status":126,"phases":8192,"primaryCompletion":5372,"completion":5372,"start":1731,"enrollment":21,"conditions":8193,"interventions":8194},[],[1386],[8161,8161,8132,8162,8098,8098],{"intervention":8196,"totalTrials":1361,"cells":8197},"Blood collection",{"EARLY_PHASE1":8198,"PHASE1":8200,"PHASE2":8202,"PHASE3":8204,"PHASE4":8206,"NA":8208},{"trials":8199,"activeCount":102},[],{"trials":8201,"activeCount":102},[],{"trials":8203,"activeCount":102},[],{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":180,"soonestReadout":8276},[8210,8221,8231,8242,8251,8262,8272],{"nctId":8211,"briefTitle":8212,"status":5932,"phases":8213,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":102,"conditions":8216,"interventions":8218},"NCT03784781","Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma",[],"2020-04","2016-06-09",[8217],"Severe Asthma",[8219,8196,8220],"Biopsy","Bronchoalveolar lavage",{"nctId":8222,"briefTitle":8223,"status":139,"phases":8224,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":8228,"interventions":8230},"NCT03776474","Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children",[],"2023-09-19","2020-11-17",135,[8229],"Food Allergy in Children",[8196],{"nctId":8232,"briefTitle":8233,"status":139,"phases":8234,"primaryCompletion":5417,"completion":5417,"start":8235,"enrollment":8236,"conditions":8237,"interventions":8239},"NCT00842465","Prolactin Receptor and Breast Diseases",[],"2008-09",735,[8238,29],"Benign Breast Disease",[8240,8241],"blood collection for hormonal status analysis","blood collection",{"nctId":8243,"briefTitle":8244,"status":110,"phases":8245,"primaryCompletion":1552,"completion":1552,"start":8246,"enrollment":3149,"conditions":8247,"interventions":8250},"NCT05285579","Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer",[],"2022-05-05",[7616,8248,8249],"Renal Cancer","Renal Cancer Metastatic",[8196],{"nctId":8252,"briefTitle":8253,"status":139,"phases":8254,"primaryCompletion":5724,"completion":5724,"start":8255,"enrollment":36,"conditions":8256,"interventions":8260},"NCT04811274","Macrophages, GM-CSF and MARS Proteinosis",[],"2021-06-07",[8257,8258,8259],"Pulmonary Alveolar Proteinosis (PAP)","MARS","Genetic Mutation",[8196,8261],"Bronchoalveolar lavage fluid collection",{"nctId":8263,"briefTitle":8264,"status":139,"phases":8265,"primaryCompletion":8266,"completion":8266,"start":8267,"enrollment":8268,"conditions":8269,"interventions":8271},"NCT02955966","PET\u002FCT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis",[94],"2022-05-02","2017-06-02",51,[8270],"Aspergillosis and Haematological Malignancy",[8196],{"nctId":8273,"briefTitle":8274,"status":152,"phases":8275,"primaryCompletion":8276,"completion":8276,"start":8277,"enrollment":6224,"conditions":8278,"interventions":8280},"NCT07134491","Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity",[],"2029-03-13","2026-03-13",[8279],"Antibody Mediated Rejection After Kidney Transplantation",[8281,8282,8196],"Piece of kidney removal","Stool collection",{"intervention":8284,"totalTrials":473,"cells":8285},"Biological collection",{"EARLY_PHASE1":8286,"PHASE1":8288,"PHASE2":8290,"PHASE3":8292,"PHASE4":8294,"NA":8296},{"trials":8287,"activeCount":102},[],{"trials":8289,"activeCount":102},[],{"trials":8291,"activeCount":102},[],{"trials":8293,"activeCount":102},[],{"trials":8295,"activeCount":102},[],{"trials":8297,"activeCount":180,"soonestReadout":1775},[8298,8308,8317,8325,8334,8345],{"nctId":8299,"briefTitle":8300,"status":139,"phases":8301,"primaryCompletion":8302,"completion":1223,"start":8303,"enrollment":8304,"conditions":8305,"interventions":8307},"NCT02498691","Perinatal Consequences of Endometriosis",[94],"2018-12-30","2016-02-04",1444,[8306],"Endometriosis",[8284],{"nctId":8309,"briefTitle":8310,"status":110,"phases":8311,"primaryCompletion":7933,"completion":1128,"start":8312,"enrollment":1130,"conditions":8313,"interventions":8315},"NCT04117425","Pharmacokinetic and Placental Transfer of Levetiracetam",[94],"2022-04-20",[8314],"Epilepsy in Pregnancy",[8316],"biological collection",{"nctId":8318,"briefTitle":8319,"status":152,"phases":8320,"primaryCompletion":1775,"completion":1551,"start":8321,"enrollment":3149,"conditions":8322,"interventions":8324},"NCT06464159","New Therapeutic Strategy Against Preeclampsia",[],"2026-02-10",[8323],"Preeclampsia",[8284],{"nctId":8326,"briefTitle":8327,"status":110,"phases":8328,"primaryCompletion":8329,"completion":8329,"start":1747,"enrollment":1108,"conditions":8330,"interventions":8332},"NCT03659006","Identification of Predictive Neuroinflammatory Biomarkers of Neuro-radiological Evolution in Severe Traumatic Brain Injury",[94],"2020-07-30",[8331],"Severe Traumatic Brain Injury",[8333],"Biological Collection",{"nctId":8335,"briefTitle":8336,"status":139,"phases":8337,"primaryCompletion":8338,"completion":8338,"start":8339,"enrollment":8340,"conditions":8341,"interventions":8344},"NCT03343834","Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation",[94],"2021-08-05","2017-12-21",138,[8342,8343,5239],"Epstein-Barr Viraemia","Hematologic Diseases",[8316],{"nctId":8346,"briefTitle":8347,"status":110,"phases":8348,"primaryCompletion":8349,"completion":8349,"start":8214,"enrollment":8350,"conditions":8351,"interventions":8353},"NCT04361604","Clinical Characterisation Protocol for COVID-19 in People Living With HIV",[],"2020-10",270,[8352],"Adult Patients Living With HIV (PLWHIV) With Confirmed Infection With SARS-CoV-2 Since 1st January 2020",[8284],{"intervention":8355,"totalTrials":429,"cells":8356},"Genetic analysis",{"EARLY_PHASE1":8357,"PHASE1":8359,"PHASE2":8361,"PHASE3":8363,"PHASE4":8365,"NA":8367},{"trials":8358,"activeCount":102},[],{"trials":8360,"activeCount":102},[],{"trials":8362,"activeCount":102},[],{"trials":8364,"activeCount":102},[],{"trials":8366,"activeCount":102},[],{"trials":8368,"activeCount":180,"soonestReadout":1673},[8369,8379,8389],{"nctId":8370,"briefTitle":8371,"status":126,"phases":8372,"primaryCompletion":1673,"completion":1673,"start":399,"enrollment":8373,"conditions":8374,"interventions":8378},"NCT07412028","Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With \"Classic\" Polycystic Ovary Syndrome (PCOS)",[94],81,[8375,8376,8377],"Polycystic Ovary Syndrome","Familial Partial Lipodystrophy","LMNA (LaMin Nuclear A) Related Disorders",[8355],{"nctId":8380,"briefTitle":8381,"status":139,"phases":8382,"primaryCompletion":8383,"completion":8384,"start":8385,"enrollment":1330,"conditions":8386,"interventions":8388},"NCT04202185","Evaluation of a Cohort of Congenital Deep Deafness Patients and\u002For With Auditory Neuropathy, Looking for DFNB9",[],"2023-10-22","2024-12-06","2020-04-02",[8387],"Congenital Profound Hearing Loss",[8355],{"nctId":8390,"briefTitle":8391,"status":139,"phases":8392,"primaryCompletion":8393,"completion":8393,"start":8394,"enrollment":8227,"conditions":8395,"interventions":8397},"NCT01252992","Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis",[],"2018-02-21","2011-03-14",[8396],"Extrapulmonary Tuberculosis",[8355],{"intervention":8399,"totalTrials":163,"cells":8400},"Botulinum toxin",{"EARLY_PHASE1":8401,"PHASE1":8403,"PHASE2":8405,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8402,"activeCount":102},[],{"trials":8404,"activeCount":102},[],{"trials":8406,"activeCount":102},[8407],{"nctId":8408,"briefTitle":8409,"status":110,"phases":8410,"primaryCompletion":8411,"completion":8412,"start":8413,"enrollment":1213,"conditions":8414,"interventions":8416},"NCT03119948","Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis",[91],"2017-11","2018-12","2014-12",[8415,6363],"Hemiparesis After Stroke",[8399],{"trials":8418,"activeCount":102},[],{"trials":8420,"activeCount":102},[],{"trials":8422,"activeCount":180,"soonestReadout":444},[8423],{"nctId":8424,"briefTitle":8425,"status":152,"phases":8426,"primaryCompletion":444,"completion":2289,"start":8427,"enrollment":9,"conditions":8428,"interventions":8431},"NCT04220931","Intrapapillary Botulinum Toxin Injection for PREvention of Post-surgical PAncREactic Fistula",[94],"2023-03-27",[8429,8430],"Distal Pancreatectomy","Postoperative Pancreatic Fistula",[8432],"botulinum toxin",{"intervention":8434,"totalTrials":180,"cells":8435},"Best chemotherapy treatment",{"EARLY_PHASE1":8436,"PHASE1":8438,"PHASE2":8440,"PHASE3":8442,"PHASE4":8444,"NA":8446},{"trials":8437,"activeCount":102},[],{"trials":8439,"activeCount":102},[],{"trials":8441,"activeCount":102},[],{"trials":8443,"activeCount":102},[],{"trials":8445,"activeCount":102},[],{"trials":8447,"activeCount":180,"soonestReadout":6336},[8448],{"nctId":8449,"briefTitle":8450,"status":169,"phases":8451,"primaryCompletion":6336,"completion":6336,"start":1789,"enrollment":27,"conditions":8452,"interventions":8453},"NCT04822766","A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia",[94],[1590],[8434],{"intervention":8455,"totalTrials":180,"cells":8456},"Patients treated with FOLFOX or FOLFIRINOX in first line",{"EARLY_PHASE1":8457,"PHASE1":8459,"PHASE2":8461,"PHASE3":8463,"PHASE4":8465,"NA":8467},{"trials":8458,"activeCount":102},[],{"trials":8460,"activeCount":102},[],{"trials":8462,"activeCount":102},[],{"trials":8464,"activeCount":102},[],{"trials":8466,"activeCount":102},[],{"trials":8468,"activeCount":180,"soonestReadout":1731},[8469],{"nctId":8470,"briefTitle":8471,"status":169,"phases":8472,"primaryCompletion":1731,"completion":3474,"start":8473,"enrollment":7834,"conditions":8474,"interventions":8477},"NCT07243288","Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy",[],"2024-01-09",[8475,8476],"Pancreatic Cancer","MeSH Term-Pancreatic Cancer, Adult)",[8455,8478],"Patients treated with GEMCITABINE in first line",{"intervention":8478,"totalTrials":180,"cells":8480},{"EARLY_PHASE1":8481,"PHASE1":8483,"PHASE2":8485,"PHASE3":8487,"PHASE4":8489,"NA":8491},{"trials":8482,"activeCount":102},[],{"trials":8484,"activeCount":102},[],{"trials":8486,"activeCount":102},[],{"trials":8488,"activeCount":102},[],{"trials":8490,"activeCount":102},[],{"trials":8492,"activeCount":180,"soonestReadout":1731},[8493],{"nctId":8470,"briefTitle":8471,"status":169,"phases":8494,"primaryCompletion":1731,"completion":3474,"start":8473,"enrollment":7834,"conditions":8495,"interventions":8496},[],[8475,8476],[8455,8478],{"intervention":8498,"totalTrials":180,"cells":8499},"Methylation analysis",{"EARLY_PHASE1":8500,"PHASE1":8502,"PHASE2":8504,"PHASE3":8506,"PHASE4":8508,"NA":8510},{"trials":8501,"activeCount":102},[],{"trials":8503,"activeCount":102},[],{"trials":8505,"activeCount":102},[],{"trials":8507,"activeCount":102},[],{"trials":8509,"activeCount":102},[],{"trials":8511,"activeCount":180,"soonestReadout":8516},[8512],{"nctId":8513,"briefTitle":8514,"status":152,"phases":8515,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":8518,"conditions":8519,"interventions":8522},"NCT06475651","Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset",[],"2026-08-26","2026-02-26",63,[8520,8521],"Rare Fetal Genetic Diseases","Congenital Malformation",[8498],{"intervention":8131,"totalTrials":180,"cells":8524},{"EARLY_PHASE1":8525,"PHASE1":8527,"PHASE2":8529,"PHASE3":8531,"PHASE4":8533,"NA":8535},{"trials":8526,"activeCount":102},[],{"trials":8528,"activeCount":102},[],{"trials":8530,"activeCount":102},[],{"trials":8532,"activeCount":102},[],{"trials":8534,"activeCount":102},[],{"trials":8536,"activeCount":180,"soonestReadout":8125},[8537],{"nctId":8122,"briefTitle":8123,"status":152,"phases":8538,"primaryCompletion":8125,"completion":8126,"start":8127,"enrollment":245,"conditions":8539,"interventions":8540},[],[8129],[8098,8131,8132],{"intervention":8542,"totalTrials":180,"cells":8543},"Biological\u002FVaccine",{"EARLY_PHASE1":8544,"PHASE1":8546,"PHASE2":8548,"PHASE3":8550,"PHASE4":8552,"NA":8554},{"trials":8545,"activeCount":102},[],{"trials":8547,"activeCount":102},[],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[],{"trials":8553,"activeCount":102},[],{"trials":8555,"activeCount":180,"soonestReadout":8560},[8556],{"nctId":8557,"briefTitle":8558,"status":152,"phases":8559,"primaryCompletion":8560,"completion":8561,"start":375,"enrollment":8562,"conditions":8563,"interventions":8565},"NCT04481321","Clinical and Molecular Study of Endometriosis and Adenomyosis",[],"2040-06","2040-12",5300,[8306,8564],"Adenomyosis",[8542],{"intervention":8567,"totalTrials":180,"cells":8568},"Research of genetic anomalies",{"EARLY_PHASE1":8569,"PHASE1":8571,"PHASE2":8573,"PHASE3":8575,"PHASE4":8577,"NA":8579},{"trials":8570,"activeCount":102},[],{"trials":8572,"activeCount":102},[],{"trials":8574,"activeCount":102},[],{"trials":8576,"activeCount":102},[],{"trials":8578,"activeCount":102},[],{"trials":8580,"activeCount":180,"soonestReadout":1311},[8581],{"nctId":8582,"briefTitle":8583,"status":152,"phases":8584,"primaryCompletion":1311,"completion":8585,"start":8586,"enrollment":1001,"conditions":8587,"interventions":8588},"NCT06334588","Understanding the Mechanisms of Autism : an MRI and Social Cognition Study",[94],"2031-04","2024-04-17",[5408],[8567],{"intervention":8590,"totalTrials":180,"cells":8591},"Samples Without DNA",{"EARLY_PHASE1":8592,"PHASE1":8594,"PHASE2":8596,"PHASE3":8598,"PHASE4":8600,"NA":8602},{"trials":8593,"activeCount":102},[],{"trials":8595,"activeCount":102},[],{"trials":8597,"activeCount":102},[],{"trials":8599,"activeCount":102},[],{"trials":8601,"activeCount":102},[],{"trials":8603,"activeCount":180,"soonestReadout":1410},[8604],{"nctId":8605,"briefTitle":8606,"status":126,"phases":8607,"primaryCompletion":1410,"completion":5651,"start":3276,"enrollment":303,"conditions":8608,"interventions":8610},"NCT07554183","4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis",[94],[1500,8609],"Portal Hypertension",[8590],{"intervention":8612,"totalTrials":180,"cells":8613},"Antimicrobial Stewardship",{"EARLY_PHASE1":8614,"PHASE1":8616,"PHASE2":8618,"PHASE3":8620,"PHASE4":8622,"NA":8624},{"trials":8615,"activeCount":102},[],{"trials":8617,"activeCount":102},[],{"trials":8619,"activeCount":102},[],{"trials":8621,"activeCount":102},[],{"trials":8623,"activeCount":102},[],{"trials":8625,"activeCount":180,"soonestReadout":2185},[8626],{"nctId":8627,"briefTitle":8628,"status":152,"phases":8629,"primaryCompletion":2185,"completion":5136,"start":8630,"enrollment":8631,"conditions":8632,"interventions":8633},"NCT05124977","Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care",[94],"2022-09-20",590,[1615],[8612,8634],"Standard management",{"intervention":8634,"totalTrials":180,"cells":8636},{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8643,"PHASE4":8645,"NA":8647},{"trials":8638,"activeCount":102},[],{"trials":8640,"activeCount":102},[],{"trials":8642,"activeCount":102},[],{"trials":8644,"activeCount":102},[],{"trials":8646,"activeCount":102},[],{"trials":8648,"activeCount":180,"soonestReadout":2185},[8649],{"nctId":8627,"briefTitle":8628,"status":152,"phases":8650,"primaryCompletion":2185,"completion":5136,"start":8630,"enrollment":8631,"conditions":8651,"interventions":8652},[94],[1615],[8612,8634],{"intervention":8654,"totalTrials":180,"cells":8655},"Prospective Biological Collection",{"EARLY_PHASE1":8656,"PHASE1":8658,"PHASE2":8660,"PHASE3":8662,"PHASE4":8664,"NA":8666},{"trials":8657,"activeCount":102},[],{"trials":8659,"activeCount":102},[],{"trials":8661,"activeCount":102},[],{"trials":8663,"activeCount":102},[],{"trials":8665,"activeCount":102},[],{"trials":8667,"activeCount":180,"soonestReadout":8672},[8668],{"nctId":8669,"briefTitle":8670,"status":152,"phases":8671,"primaryCompletion":8672,"completion":8672,"start":8673,"enrollment":8674,"conditions":8675,"interventions":8678},"NCT06314607","Genetic and Molecular Characterization of Nervous System Lesions",[],"2034-03","2024-03-26",10000,[8676,8677],"Brain Tumor","Brain Lesion (General)",[8654,8679],"Retrospective Biological Collection",{"intervention":8679,"totalTrials":180,"cells":8681},{"EARLY_PHASE1":8682,"PHASE1":8684,"PHASE2":8686,"PHASE3":8688,"PHASE4":8690,"NA":8692},{"trials":8683,"activeCount":102},[],{"trials":8685,"activeCount":102},[],{"trials":8687,"activeCount":102},[],{"trials":8689,"activeCount":102},[],{"trials":8691,"activeCount":102},[],{"trials":8693,"activeCount":180,"soonestReadout":8672},[8694],{"nctId":8669,"briefTitle":8670,"status":152,"phases":8695,"primaryCompletion":8672,"completion":8672,"start":8673,"enrollment":8674,"conditions":8696,"interventions":8697},[],[8676,8677],[8654,8679],{"intervention":8699,"totalTrials":180,"cells":8700},"Prospective",{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8705,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8702,"activeCount":102},[],{"trials":8704,"activeCount":102},[],{"trials":8706,"activeCount":102},[],{"trials":8708,"activeCount":102},[],{"trials":8710,"activeCount":102},[],{"trials":8712,"activeCount":180,"soonestReadout":8717},[8713],{"nctId":8714,"briefTitle":8715,"status":126,"phases":8716,"primaryCompletion":8717,"completion":8717,"start":8718,"enrollment":489,"conditions":8719,"interventions":8721},"NCT05569356","Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)",[],"2032-10-20","2022-10-20",[8720],"Arrhythmogenic Cardiomyopathy",[8699],{"intervention":8723,"totalTrials":180,"cells":8724},"Biological samples",{"EARLY_PHASE1":8725,"PHASE1":8727,"PHASE2":8729,"PHASE3":8731,"PHASE4":8733,"NA":8735},{"trials":8726,"activeCount":102},[],{"trials":8728,"activeCount":102},[],{"trials":8730,"activeCount":102},[],{"trials":8732,"activeCount":102},[],{"trials":8734,"activeCount":102},[],{"trials":8736,"activeCount":180,"soonestReadout":2671},[8737],{"nctId":8738,"briefTitle":8739,"status":169,"phases":8740,"primaryCompletion":2671,"completion":2671,"start":8741,"enrollment":8742,"conditions":8743,"interventions":8746},"NCT04840693","Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)",[94],"2023-08-01",31,[8744,8745],"Adult Glucocorticoid Excess","Adult Adrenal Insufficiency",[8723],{"intervention":7837,"totalTrials":180,"cells":8748},{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8753,"PHASE3":8755,"PHASE4":8757,"NA":8759},{"trials":8750,"activeCount":102},[],{"trials":8752,"activeCount":102},[],{"trials":8754,"activeCount":102},[],{"trials":8756,"activeCount":102},[],{"trials":8758,"activeCount":102},[],{"trials":8760,"activeCount":180,"soonestReadout":1095},[8761],{"nctId":7830,"briefTitle":7831,"status":152,"phases":8762,"primaryCompletion":1095,"completion":1095,"start":7833,"enrollment":7834,"conditions":8763,"interventions":8764},[],[5271,32],[7837,7804],{"intervention":8766,"totalTrials":180,"cells":8767},"blood sampling for DNA",{"EARLY_PHASE1":8768,"PHASE1":8770,"PHASE2":8772,"PHASE3":8774,"PHASE4":8776,"NA":8778},{"trials":8769,"activeCount":102},[],{"trials":8771,"activeCount":102},[],{"trials":8773,"activeCount":102},[],{"trials":8775,"activeCount":102},[],{"trials":8777,"activeCount":102},[],{"trials":8779,"activeCount":180,"soonestReadout":5372},[8780],{"nctId":8781,"briefTitle":8782,"status":152,"phases":8783,"primaryCompletion":5372,"completion":5372,"start":8784,"enrollment":1015,"conditions":8785,"interventions":8787},"NCT06949579","Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.",[94],"2026-02-02",[8786],"High Myopia",[8766],{"intervention":8789,"totalTrials":180,"cells":8790},"Stool and blood samples",{"EARLY_PHASE1":8791,"PHASE1":8793,"PHASE2":8795,"PHASE3":8797,"PHASE4":8799,"NA":8801},{"trials":8792,"activeCount":102},[],{"trials":8794,"activeCount":102},[],{"trials":8796,"activeCount":102},[],{"trials":8798,"activeCount":102},[],{"trials":8800,"activeCount":102},[],{"trials":8802,"activeCount":180,"soonestReadout":4589},[8803],{"nctId":8804,"briefTitle":8805,"status":152,"phases":8806,"primaryCompletion":4589,"completion":1105,"start":8807,"enrollment":1277,"conditions":8808,"interventions":8812},"NCT05632497","Alteration of Symbiosis Intestinal Microbiota on Patients With Anorexia Nervosa",[],"2024-05-23",[8809,8810,8811],"Anorexia Nervosa","Dysbiosis","Anxious Depression",[8789],{"intervention":8161,"totalTrials":180,"cells":8814},{"EARLY_PHASE1":8815,"PHASE1":8817,"PHASE2":8819,"PHASE3":8821,"PHASE4":8823,"NA":8825},{"trials":8816,"activeCount":102},[],{"trials":8818,"activeCount":102},[],{"trials":8820,"activeCount":102},[],{"trials":8822,"activeCount":102},[],{"trials":8824,"activeCount":102},[],{"trials":8826,"activeCount":180,"soonestReadout":5372},[8827],{"nctId":8156,"briefTitle":8157,"status":126,"phases":8828,"primaryCompletion":5372,"completion":5372,"start":1731,"enrollment":21,"conditions":8829,"interventions":8830},[],[1386],[8161,8161,8132,8162,8098,8098],{"intervention":8162,"totalTrials":180,"cells":8832},{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8837,"PHASE3":8839,"PHASE4":8841,"NA":8843},{"trials":8834,"activeCount":102},[],{"trials":8836,"activeCount":102},[],{"trials":8838,"activeCount":102},[],{"trials":8840,"activeCount":102},[],{"trials":8842,"activeCount":102},[],{"trials":8844,"activeCount":180,"soonestReadout":5372},[8845],{"nctId":8156,"briefTitle":8157,"status":126,"phases":8846,"primaryCompletion":5372,"completion":5372,"start":1731,"enrollment":21,"conditions":8847,"interventions":8848},[],[1386],[8161,8161,8132,8162,8098,8098],{"intervention":8850,"totalTrials":180,"cells":8851},"GBA gene",{"EARLY_PHASE1":8852,"PHASE1":8854,"PHASE2":8856,"PHASE3":8858,"PHASE4":8860,"NA":8862},{"trials":8853,"activeCount":102},[],{"trials":8855,"activeCount":102},[],{"trials":8857,"activeCount":102},[],{"trials":8859,"activeCount":102},[],{"trials":8861,"activeCount":102},[],{"trials":8863,"activeCount":180,"soonestReadout":194},[8864],{"nctId":8865,"briefTitle":8866,"status":152,"phases":8867,"primaryCompletion":194,"completion":194,"start":8868,"enrollment":8869,"conditions":8870,"interventions":8872},"NCT05304195","Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies",[],"2023-02-17",236,[8871],"Dementia With Lewy Bodies",[8850],{"intervention":8874,"totalTrials":180,"cells":8875},"Titration of paracetamol and its metabolites - scheme1",{"EARLY_PHASE1":8876,"PHASE1":8878,"PHASE2":8880,"PHASE3":8882,"PHASE4":8884,"NA":8886},{"trials":8877,"activeCount":102},[],{"trials":8879,"activeCount":102},[],{"trials":8881,"activeCount":102},[],{"trials":8883,"activeCount":102},[],{"trials":8885,"activeCount":102},[],{"trials":8887,"activeCount":180,"soonestReadout":5136},[8888],{"nctId":8889,"briefTitle":8890,"status":126,"phases":8891,"primaryCompletion":5136,"completion":5136,"start":8892,"enrollment":303,"conditions":8893,"interventions":8895},"NCT06135389","Population Pharmacokinetics of Paracetamol in Overweight and Obese Children",[],"2025-03",[8894,18],"Overweight",[8874,8896],"Titration of paracetamol and its metabolites - scheme 2",{"intervention":8896,"totalTrials":180,"cells":8898},{"EARLY_PHASE1":8899,"PHASE1":8901,"PHASE2":8903,"PHASE3":8905,"PHASE4":8907,"NA":8909},{"trials":8900,"activeCount":102},[],{"trials":8902,"activeCount":102},[],{"trials":8904,"activeCount":102},[],{"trials":8906,"activeCount":102},[],{"trials":8908,"activeCount":102},[],{"trials":8910,"activeCount":180,"soonestReadout":5136},[8911],{"nctId":8889,"briefTitle":8890,"status":126,"phases":8912,"primaryCompletion":5136,"completion":5136,"start":8892,"enrollment":303,"conditions":8913,"interventions":8914},[],[8894,18],[8874,8896],{"intervention":8916,"totalTrials":180,"cells":8917},"Hormone replacement therapy:effect on ventricular repolarization",{"EARLY_PHASE1":8918,"PHASE1":8920,"PHASE2":8922,"PHASE3":8924,"PHASE4":8926,"NA":8928},{"trials":8919,"activeCount":102},[],{"trials":8921,"activeCount":102},[],{"trials":8923,"activeCount":102},[],{"trials":8925,"activeCount":102},[],{"trials":8927,"activeCount":102},[],{"trials":8929,"activeCount":180,"soonestReadout":8934},[8930],{"nctId":8931,"briefTitle":8932,"status":152,"phases":8933,"primaryCompletion":8934,"completion":8935,"start":8936,"enrollment":1277,"conditions":8937,"interventions":8939},"NCT04167033","Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)",[94],"2027-04-13","2027-06-13","2021-04-14",[8938],"Premature Ovarian Insufficiency",[8916],{"intervention":8941,"totalTrials":180,"cells":8942},"Collection of blood samples for the study of HBV biomarkers",{"EARLY_PHASE1":8943,"PHASE1":8945,"PHASE2":8947,"PHASE3":8949,"PHASE4":8951,"NA":8953},{"trials":8944,"activeCount":102},[],{"trials":8946,"activeCount":102},[],{"trials":8948,"activeCount":102},[],{"trials":8950,"activeCount":102},[],{"trials":8952,"activeCount":102},[],{"trials":8954,"activeCount":180,"soonestReadout":8959},[8955],{"nctId":8956,"briefTitle":8957,"status":152,"phases":8958,"primaryCompletion":8959,"completion":8959,"start":4633,"enrollment":8960,"conditions":8961,"interventions":8963},"NCT06906016","New HBV Infection Biomarkers: Clinical Characterization and Impact on Management",[],"2038-11-27",900,[8962],"Chronic Hepatitis B Virus (HBV) Infection",[8941],{"intervention":8965,"totalTrials":180,"cells":8966},"Blood sample for genetic test",{"EARLY_PHASE1":8967,"PHASE1":8969,"PHASE2":8971,"PHASE3":8973,"PHASE4":8975,"NA":8977},{"trials":8968,"activeCount":102},[],{"trials":8970,"activeCount":102},[],{"trials":8972,"activeCount":102},[],{"trials":8974,"activeCount":102},[],{"trials":8976,"activeCount":102},[],{"trials":8978,"activeCount":180,"soonestReadout":1105},[8979],{"nctId":8980,"briefTitle":8981,"status":169,"phases":8982,"primaryCompletion":1105,"completion":8983,"start":8984,"enrollment":8064,"conditions":8985,"interventions":8986},"NCT03731845","Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer",[94],"2027-01","2019-04-01",[29],[8965,8987],"Blood sample for hormonal measurement",{"intervention":8987,"totalTrials":180,"cells":8989},{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8994,"PHASE3":8996,"PHASE4":8998,"NA":9000},{"trials":8991,"activeCount":102},[],{"trials":8993,"activeCount":102},[],{"trials":8995,"activeCount":102},[],{"trials":8997,"activeCount":102},[],{"trials":8999,"activeCount":102},[],{"trials":9001,"activeCount":180,"soonestReadout":1105},[9002],{"nctId":8980,"briefTitle":8981,"status":169,"phases":9003,"primaryCompletion":1105,"completion":8983,"start":8984,"enrollment":8064,"conditions":9004,"interventions":9005},[94],[29],[8965,8987],{"intervention":9007,"totalTrials":180,"cells":9008},"Determination of beta-hydroxybutyrate (BHB) in capillary blood",{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9013,"PHASE3":9015,"PHASE4":9017,"NA":9019},{"trials":9010,"activeCount":102},[],{"trials":9012,"activeCount":102},[],{"trials":9014,"activeCount":102},[],{"trials":9016,"activeCount":102},[],{"trials":9018,"activeCount":102},[],{"trials":9020,"activeCount":180,"soonestReadout":6359},[9021],{"nctId":9022,"briefTitle":9023,"status":126,"phases":9024,"primaryCompletion":6359,"completion":6359,"start":129,"enrollment":8340,"conditions":9025,"interventions":9028},"NCT07029295","Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation",[94],[9026,9027],"Infective Endocarditis","Cardiac Sarcoidosis",[9007],{"intervention":9030,"totalTrials":180,"cells":9031},"Hepatocellular carcinoma",{"EARLY_PHASE1":9032,"PHASE1":9034,"PHASE2":9036,"PHASE3":9038,"PHASE4":9040,"NA":9042},{"trials":9033,"activeCount":102},[],{"trials":9035,"activeCount":102},[],{"trials":9037,"activeCount":102},[],{"trials":9039,"activeCount":102},[],{"trials":9041,"activeCount":102},[],{"trials":9043,"activeCount":180,"soonestReadout":112},[9044],{"nctId":9045,"briefTitle":9046,"status":152,"phases":9047,"primaryCompletion":112,"completion":9048,"start":9049,"enrollment":489,"conditions":9050,"interventions":9053},"NCT05794048","METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors",[94],"2026-09-08","2022-06-08",[9051,9052],"Hepatocarcinoma","Pancreatic Tumor",[9030,9054,9055],"Pancreatic adenocarcinoma","Pancreatic neuroendocrine tumor",{"intervention":9054,"totalTrials":180,"cells":9057},{"EARLY_PHASE1":9058,"PHASE1":9060,"PHASE2":9062,"PHASE3":9064,"PHASE4":9066,"NA":9068},{"trials":9059,"activeCount":102},[],{"trials":9061,"activeCount":102},[],{"trials":9063,"activeCount":102},[],{"trials":9065,"activeCount":102},[],{"trials":9067,"activeCount":102},[],{"trials":9069,"activeCount":180,"soonestReadout":112},[9070],{"nctId":9045,"briefTitle":9046,"status":152,"phases":9071,"primaryCompletion":112,"completion":9048,"start":9049,"enrollment":489,"conditions":9072,"interventions":9073},[94],[9051,9052],[9030,9054,9055],{"intervention":9055,"totalTrials":180,"cells":9075},{"EARLY_PHASE1":9076,"PHASE1":9078,"PHASE2":9080,"PHASE3":9082,"PHASE4":9084,"NA":9086},{"trials":9077,"activeCount":102},[],{"trials":9079,"activeCount":102},[],{"trials":9081,"activeCount":102},[],{"trials":9083,"activeCount":102},[],{"trials":9085,"activeCount":102},[],{"trials":9087,"activeCount":180,"soonestReadout":112},[9088],{"nctId":9045,"briefTitle":9046,"status":152,"phases":9089,"primaryCompletion":112,"completion":9048,"start":9049,"enrollment":489,"conditions":9090,"interventions":9091},[94],[9051,9052],[9030,9054,9055],{"intervention":9093,"totalTrials":180,"cells":9094},"Sequential sampling (stool, saliva, serum) .",{"EARLY_PHASE1":9095,"PHASE1":9097,"PHASE2":9099,"PHASE3":9101,"PHASE4":9103,"NA":9105},{"trials":9096,"activeCount":102},[],{"trials":9098,"activeCount":102},[],{"trials":9100,"activeCount":102},[],{"trials":9102,"activeCount":102},[],{"trials":9104,"activeCount":102},[],{"trials":9106,"activeCount":180,"soonestReadout":9111},[9107],{"nctId":9108,"briefTitle":9109,"status":152,"phases":9110,"primaryCompletion":9111,"completion":9112,"start":9113,"enrollment":9114,"conditions":9115,"interventions":9117},"NCT05895890","French National MICMAF Cohort",[],"2043-02-01","2053-02-01","2022-10-01",1000,[9116],"Alcoholic Liver Disease",[9093],{"intervention":7879,"totalTrials":180,"cells":9119},{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[],{"trials":9125,"activeCount":102},[],{"trials":9127,"activeCount":102},[],{"trials":9129,"activeCount":102},[],{"trials":9131,"activeCount":180,"soonestReadout":1107},[9132],{"nctId":7872,"briefTitle":7873,"status":152,"phases":9133,"primaryCompletion":1107,"completion":1107,"start":7875,"enrollment":303,"conditions":9134,"interventions":9135},[94],[7877],[7804,7879,7880,7881,7882],{"intervention":7880,"totalTrials":180,"cells":9137},{"EARLY_PHASE1":9138,"PHASE1":9140,"PHASE2":9142,"PHASE3":9144,"PHASE4":9146,"NA":9148},{"trials":9139,"activeCount":102},[],{"trials":9141,"activeCount":102},[],{"trials":9143,"activeCount":102},[],{"trials":9145,"activeCount":102},[],{"trials":9147,"activeCount":102},[],{"trials":9149,"activeCount":180,"soonestReadout":1107},[9150],{"nctId":7872,"briefTitle":7873,"status":152,"phases":9151,"primaryCompletion":1107,"completion":1107,"start":7875,"enrollment":303,"conditions":9152,"interventions":9153},[94],[7877],[7804,7879,7880,7881,7882],{"intervention":7881,"totalTrials":180,"cells":9155},{"EARLY_PHASE1":9156,"PHASE1":9158,"PHASE2":9160,"PHASE3":9162,"PHASE4":9164,"NA":9166},{"trials":9157,"activeCount":102},[],{"trials":9159,"activeCount":102},[],{"trials":9161,"activeCount":102},[],{"trials":9163,"activeCount":102},[],{"trials":9165,"activeCount":102},[],{"trials":9167,"activeCount":180,"soonestReadout":1107},[9168],{"nctId":7872,"briefTitle":7873,"status":152,"phases":9169,"primaryCompletion":1107,"completion":1107,"start":7875,"enrollment":303,"conditions":9170,"interventions":9171},[94],[7877],[7804,7879,7880,7881,7882],{"intervention":7882,"totalTrials":180,"cells":9173},{"EARLY_PHASE1":9174,"PHASE1":9176,"PHASE2":9178,"PHASE3":9180,"PHASE4":9182,"NA":9184},{"trials":9175,"activeCount":102},[],{"trials":9177,"activeCount":102},[],{"trials":9179,"activeCount":102},[],{"trials":9181,"activeCount":102},[],{"trials":9183,"activeCount":102},[],{"trials":9185,"activeCount":180,"soonestReadout":1107},[9186],{"nctId":7872,"briefTitle":7873,"status":152,"phases":9187,"primaryCompletion":1107,"completion":1107,"start":7875,"enrollment":303,"conditions":9188,"interventions":9189},[94],[7877],[7804,7879,7880,7881,7882],{"intervention":9191,"totalTrials":180,"cells":9192},"Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization",{"EARLY_PHASE1":9193,"PHASE1":9195,"PHASE2":9197,"PHASE3":9199,"PHASE4":9201,"NA":9203},{"trials":9194,"activeCount":102},[],{"trials":9196,"activeCount":102},[],{"trials":9198,"activeCount":102},[],{"trials":9200,"activeCount":102},[],{"trials":9202,"activeCount":102},[],{"trials":9204,"activeCount":180,"soonestReadout":6579},[9205],{"nctId":9206,"briefTitle":9207,"status":126,"phases":9208,"primaryCompletion":6579,"completion":6579,"start":9209,"enrollment":303,"conditions":9210,"interventions":9212},"NCT06971237","SIRT and Peri-immunotherapy : a New Concept",[],"2025-06-01",[9211],"Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy",[9191,9213],"Atezolizumab ± Bevacizumab",{"intervention":9213,"totalTrials":180,"cells":9215},{"EARLY_PHASE1":9216,"PHASE1":9218,"PHASE2":9220,"PHASE3":9222,"PHASE4":9224,"NA":9226},{"trials":9217,"activeCount":102},[],{"trials":9219,"activeCount":102},[],{"trials":9221,"activeCount":102},[],{"trials":9223,"activeCount":102},[],{"trials":9225,"activeCount":102},[],{"trials":9227,"activeCount":180,"soonestReadout":6579},[9228],{"nctId":9206,"briefTitle":9207,"status":126,"phases":9229,"primaryCompletion":6579,"completion":6579,"start":9209,"enrollment":303,"conditions":9230,"interventions":9231},[],[9211],[9191,9213],{"intervention":9233,"totalTrials":180,"cells":9234},"OVIHD",{"EARLY_PHASE1":9235,"PHASE1":9237,"PHASE2":9239,"PHASE3":9241,"PHASE4":9243,"NA":9245},{"trials":9236,"activeCount":102},[],{"trials":9238,"activeCount":102},[],{"trials":9240,"activeCount":102},[],{"trials":9242,"activeCount":102},[],{"trials":9244,"activeCount":102},[],{"trials":9246,"activeCount":180,"soonestReadout":9251},[9247],{"nctId":9248,"briefTitle":9249,"status":169,"phases":9250,"primaryCompletion":9251,"completion":9251,"start":9252,"enrollment":9253,"conditions":9254,"interventions":9256},"NCT02203006","HIV Patients Cohort",[94],"2030-11-19","2011-10-19",1613,[9255],"Patients Affected by the HIV",[9233],{"intervention":9258,"totalTrials":180,"cells":9259},"dd-cfDNA-guided",{"EARLY_PHASE1":9260,"PHASE1":9262,"PHASE2":9264,"PHASE3":9266,"PHASE4":9268,"NA":9270},{"trials":9261,"activeCount":102},[],{"trials":9263,"activeCount":102},[],{"trials":9265,"activeCount":102},[],{"trials":9267,"activeCount":102},[],{"trials":9269,"activeCount":102},[],{"trials":9271,"activeCount":180,"soonestReadout":5404},[9272],{"nctId":9273,"briefTitle":9274,"status":152,"phases":9275,"primaryCompletion":5404,"completion":5404,"start":9276,"enrollment":632,"conditions":9277,"interventions":9278},"NCT06406179","Evaluation of the Efficacy of Dd-cfDNA in Routine Patient Care in Kidney Transplant Recipients\"",[94],"2025-05-31",[945],[9258],{"intervention":9280,"totalTrials":180,"cells":9281},"Tumor samples",{"EARLY_PHASE1":9282,"PHASE1":9284,"PHASE2":9286,"PHASE3":9288,"PHASE4":9290,"NA":9292},{"trials":9283,"activeCount":102},[],{"trials":9285,"activeCount":102},[],{"trials":9287,"activeCount":102},[],{"trials":9289,"activeCount":102},[],{"trials":9291,"activeCount":102},[],{"trials":9293,"activeCount":180,"soonestReadout":9298},[9294],{"nctId":9295,"briefTitle":9296,"status":126,"phases":9297,"primaryCompletion":9298,"completion":9298,"start":9299,"enrollment":1015,"conditions":9300,"interventions":9304},"NCT04707365","Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort",[94],"2035-03","2021-03",[4808,9301,9302,9303],"Pancreas Tumor","Biliary Tract Tumor","Immune System and Related Disorders",[9280],{"intervention":8281,"totalTrials":180,"cells":9306},{"EARLY_PHASE1":9307,"PHASE1":9309,"PHASE2":9311,"PHASE3":9313,"PHASE4":9315,"NA":9317},{"trials":9308,"activeCount":102},[],{"trials":9310,"activeCount":102},[],{"trials":9312,"activeCount":102},[],{"trials":9314,"activeCount":102},[],{"trials":9316,"activeCount":102},[],{"trials":9318,"activeCount":180,"soonestReadout":8276},[9319],{"nctId":8273,"briefTitle":8274,"status":152,"phases":9320,"primaryCompletion":8276,"completion":8276,"start":8277,"enrollment":6224,"conditions":9321,"interventions":9322},[],[8279],[8281,8282,8196],{"intervention":8282,"totalTrials":180,"cells":9324},{"EARLY_PHASE1":9325,"PHASE1":9327,"PHASE2":9329,"PHASE3":9331,"PHASE4":9333,"NA":9335},{"trials":9326,"activeCount":102},[],{"trials":9328,"activeCount":102},[],{"trials":9330,"activeCount":102},[],{"trials":9332,"activeCount":102},[],{"trials":9334,"activeCount":102},[],{"trials":9336,"activeCount":180,"soonestReadout":8276},[9337],{"nctId":8273,"briefTitle":8274,"status":152,"phases":9338,"primaryCompletion":8276,"completion":8276,"start":8277,"enrollment":6224,"conditions":9339,"interventions":9340},[],[8279],[8281,8282,8196],{"intervention":9342,"totalTrials":180,"cells":9343},"Collection of vaginal secretions",{"EARLY_PHASE1":9344,"PHASE1":9346,"PHASE2":9348,"PHASE3":9350,"PHASE4":9352,"NA":9354},{"trials":9345,"activeCount":102},[],{"trials":9347,"activeCount":102},[],{"trials":9349,"activeCount":102},[],{"trials":9351,"activeCount":102},[],{"trials":9353,"activeCount":102},[],{"trials":9355,"activeCount":180,"soonestReadout":6336},[9356],{"nctId":9357,"briefTitle":9358,"status":152,"phases":9359,"primaryCompletion":6336,"completion":5372,"start":9360,"enrollment":9361,"conditions":9362,"interventions":9364},"NCT05586334","Development and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP)",[94],"2023-06-08",3600,[9363],"Preterm Labor",[9342,9365],"Collection of the placenta and the membranes",{"intervention":9365,"totalTrials":180,"cells":9367},{"EARLY_PHASE1":9368,"PHASE1":9370,"PHASE2":9372,"PHASE3":9374,"PHASE4":9376,"NA":9378},{"trials":9369,"activeCount":102},[],{"trials":9371,"activeCount":102},[],{"trials":9373,"activeCount":102},[],{"trials":9375,"activeCount":102},[],{"trials":9377,"activeCount":102},[],{"trials":9379,"activeCount":180,"soonestReadout":6336},[9380],{"nctId":9357,"briefTitle":9358,"status":152,"phases":9381,"primaryCompletion":6336,"completion":5372,"start":9360,"enrollment":9361,"conditions":9382,"interventions":9383},[94],[9363],[9342,9365],{"intervention":9385,"totalTrials":180,"cells":9386},"Frequency of Treg and Teffs",{"EARLY_PHASE1":9387,"PHASE1":9389,"PHASE2":9391,"PHASE3":9393,"PHASE4":9395,"NA":9397},{"trials":9388,"activeCount":102},[],{"trials":9390,"activeCount":102},[],{"trials":9392,"activeCount":102},[],{"trials":9394,"activeCount":102},[],{"trials":9396,"activeCount":102},[],{"trials":9398,"activeCount":180,"soonestReadout":2087},[9399],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9402,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9403,"interventions":9404},"NCT06427421","Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals",[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],"Phenotype of Treg and Teffs","RNA seq analysis","HLA typing","beta-cell autoantibody dosage","Glycated haemoglobin (HbA1C) dosage","blood glucose dosage","C-peptide dosage",{"intervention":9405,"totalTrials":180,"cells":9413},{"EARLY_PHASE1":9414,"PHASE1":9416,"PHASE2":9418,"PHASE3":9420,"PHASE4":9422,"NA":9424},{"trials":9415,"activeCount":102},[],{"trials":9417,"activeCount":102},[],{"trials":9419,"activeCount":102},[],{"trials":9421,"activeCount":102},[],{"trials":9423,"activeCount":102},[],{"trials":9425,"activeCount":180,"soonestReadout":2087},[9426],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9427,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9428,"interventions":9429},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9406,"totalTrials":180,"cells":9431},{"EARLY_PHASE1":9432,"PHASE1":9434,"PHASE2":9436,"PHASE3":9438,"PHASE4":9440,"NA":9442},{"trials":9433,"activeCount":102},[],{"trials":9435,"activeCount":102},[],{"trials":9437,"activeCount":102},[],{"trials":9439,"activeCount":102},[],{"trials":9441,"activeCount":102},[],{"trials":9443,"activeCount":180,"soonestReadout":2087},[9444],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9445,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9446,"interventions":9447},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9407,"totalTrials":180,"cells":9449},{"EARLY_PHASE1":9450,"PHASE1":9452,"PHASE2":9454,"PHASE3":9456,"PHASE4":9458,"NA":9460},{"trials":9451,"activeCount":102},[],{"trials":9453,"activeCount":102},[],{"trials":9455,"activeCount":102},[],{"trials":9457,"activeCount":102},[],{"trials":9459,"activeCount":102},[],{"trials":9461,"activeCount":180,"soonestReadout":2087},[9462],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9463,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9464,"interventions":9465},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9408,"totalTrials":180,"cells":9467},{"EARLY_PHASE1":9468,"PHASE1":9470,"PHASE2":9472,"PHASE3":9474,"PHASE4":9476,"NA":9478},{"trials":9469,"activeCount":102},[],{"trials":9471,"activeCount":102},[],{"trials":9473,"activeCount":102},[],{"trials":9475,"activeCount":102},[],{"trials":9477,"activeCount":102},[],{"trials":9479,"activeCount":180,"soonestReadout":2087},[9480],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9481,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9482,"interventions":9483},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9409,"totalTrials":180,"cells":9485},{"EARLY_PHASE1":9486,"PHASE1":9488,"PHASE2":9490,"PHASE3":9492,"PHASE4":9494,"NA":9496},{"trials":9487,"activeCount":102},[],{"trials":9489,"activeCount":102},[],{"trials":9491,"activeCount":102},[],{"trials":9493,"activeCount":102},[],{"trials":9495,"activeCount":102},[],{"trials":9497,"activeCount":180,"soonestReadout":2087},[9498],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9499,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9500,"interventions":9501},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9410,"totalTrials":180,"cells":9503},{"EARLY_PHASE1":9504,"PHASE1":9506,"PHASE2":9508,"PHASE3":9510,"PHASE4":9512,"NA":9514},{"trials":9505,"activeCount":102},[],{"trials":9507,"activeCount":102},[],{"trials":9509,"activeCount":102},[],{"trials":9511,"activeCount":102},[],{"trials":9513,"activeCount":102},[],{"trials":9515,"activeCount":180,"soonestReadout":2087},[9516],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9517,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9518,"interventions":9519},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9411,"totalTrials":180,"cells":9521},{"EARLY_PHASE1":9522,"PHASE1":9524,"PHASE2":9526,"PHASE3":9528,"PHASE4":9530,"NA":9532},{"trials":9523,"activeCount":102},[],{"trials":9525,"activeCount":102},[],{"trials":9527,"activeCount":102},[],{"trials":9529,"activeCount":102},[],{"trials":9531,"activeCount":102},[],{"trials":9533,"activeCount":180,"soonestReadout":2087},[9534],{"nctId":9400,"briefTitle":9401,"status":152,"phases":9535,"primaryCompletion":2087,"completion":2087,"start":3588,"enrollment":1108,"conditions":9536,"interventions":9537},[94],[1522],[9385,9405,9406,9407,9408,9409,9410,9411],{"intervention":9539,"totalTrials":180,"cells":9540},"Propranolol",{"EARLY_PHASE1":9541,"PHASE1":9543,"PHASE2":9545,"PHASE3":9547,"PHASE4":9549,"NA":9551},{"trials":9542,"activeCount":102},[],{"trials":9544,"activeCount":102},[],{"trials":9546,"activeCount":102},[],{"trials":9548,"activeCount":102},[],{"trials":9550,"activeCount":102},[],{"trials":9552,"activeCount":180,"soonestReadout":9557},[9553],{"nctId":9554,"briefTitle":9555,"status":152,"phases":9556,"primaryCompletion":9557,"completion":9557,"start":9558,"enrollment":9559,"conditions":9560,"interventions":9563},"NCT05424016","Propranolol and Von Hippel-Lindau Disease",[94],"2026-11-01","2023-01-16",85,[9561,9562],"Hemangioblastoma of CNS","Von Hippel-Lindau Disease",[9539],{"intervention":9565,"totalTrials":180,"cells":9566},"Blood and urine minimal biology",{"EARLY_PHASE1":9567,"PHASE1":9569,"PHASE2":9571,"PHASE3":9573,"PHASE4":9575,"NA":9577},{"trials":9568,"activeCount":102},[],{"trials":9570,"activeCount":102},[],{"trials":9572,"activeCount":102},[],{"trials":9574,"activeCount":102},[],{"trials":9576,"activeCount":102},[],{"trials":9578,"activeCount":180,"soonestReadout":9583},[9579],{"nctId":9580,"briefTitle":9581,"status":126,"phases":9582,"primaryCompletion":9583,"completion":9583,"start":918,"enrollment":21,"conditions":9584,"interventions":9586},"NCT07285421","Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications",[94],"2029-10-30",[9585],"Enamel Renal Syndrome",[9565],{"intervention":9588,"totalTrials":180,"cells":9589},"determination of circulating biomarkers of renal origin circulating biomarkers of renal origin",{"EARLY_PHASE1":9590,"PHASE1":9592,"PHASE2":9594,"PHASE3":9596,"PHASE4":9598,"NA":9600},{"trials":9591,"activeCount":102},[],{"trials":9593,"activeCount":102},[],{"trials":9595,"activeCount":102},[],{"trials":9597,"activeCount":102},[],{"trials":9599,"activeCount":102},[],{"trials":9601,"activeCount":180,"soonestReadout":9606},[9602],{"nctId":9603,"briefTitle":9604,"status":152,"phases":9605,"primaryCompletion":9606,"completion":2977,"start":9607,"enrollment":21,"conditions":9608,"interventions":9609},"NCT06026592","Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients",[],"2026-07-02","2024-09-02",[3654,945],[9588],{"intervention":9611,"totalTrials":180,"cells":9612},"Collection of a sample",{"EARLY_PHASE1":9613,"PHASE1":9615,"PHASE2":9617,"PHASE3":9619,"PHASE4":9621,"NA":9623},{"trials":9614,"activeCount":102},[],{"trials":9616,"activeCount":102},[],{"trials":9618,"activeCount":102},[],{"trials":9620,"activeCount":102},[],{"trials":9622,"activeCount":102},[],{"trials":9624,"activeCount":180,"soonestReadout":9630},[9625],{"nctId":9626,"briefTitle":9627,"status":9628,"phases":9629,"primaryCompletion":9630,"completion":9631,"start":9632,"enrollment":489,"conditions":9633,"interventions":9636},"NCT07448025","ADN Fœtal Circulant, Grossesse et Pathologies Malignes","ENROLLING_BY_INVITATION",[],"2028-04-15","2028-11-15","2026-04-15",[9634,9635],"Femmes Enceintes","Cancer",[9611],{"intervention":9638,"totalTrials":180,"cells":9639},"saliva sampling",{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9644,"PHASE3":9646,"PHASE4":9648,"NA":9650},{"trials":9641,"activeCount":102},[],{"trials":9643,"activeCount":102},[],{"trials":9645,"activeCount":102},[],{"trials":9647,"activeCount":102},[],{"trials":9649,"activeCount":102},[],{"trials":9651,"activeCount":180,"soonestReadout":9656},[9652],{"nctId":9653,"briefTitle":9654,"status":126,"phases":9655,"primaryCompletion":9656,"completion":9656,"start":9657,"enrollment":1015,"conditions":9658,"interventions":9660},"NCT06786377","Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations",[],"2026-01-30","2025-01-30",[9659],"Narcolepsy",[9638],{"intervention":9662,"totalTrials":180,"cells":9663},"Blood and Urine Sampling",{"EARLY_PHASE1":9664,"PHASE1":9666,"PHASE2":9668,"PHASE3":9670,"PHASE4":9672,"NA":9674},{"trials":9665,"activeCount":102},[],{"trials":9667,"activeCount":102},[],{"trials":9669,"activeCount":102},[],{"trials":9671,"activeCount":102},[],{"trials":9673,"activeCount":102},[],{"trials":9675,"activeCount":180,"soonestReadout":9680},[9676],{"nctId":9677,"briefTitle":9678,"status":126,"phases":9679,"primaryCompletion":9680,"completion":9680,"start":4458,"enrollment":1931,"conditions":9681,"interventions":9683},"NCT06997146","Identifying Biomarkers & Dysregulated Biological Pathways in Blood and Urine of Congenital Central Hypoventilation Syndrome (CCHS) Patients",[94],"2028-12-02",[9682],"Congenital Central Hypoventilation Syndrome (CCHS)",[9662],{"intervention":9685,"totalTrials":180,"cells":9686},"DNA sample",{"EARLY_PHASE1":9687,"PHASE1":9689,"PHASE2":9691,"PHASE3":9693,"PHASE4":9695,"NA":9697},{"trials":9688,"activeCount":102},[],{"trials":9690,"activeCount":102},[],{"trials":9692,"activeCount":102},[],{"trials":9694,"activeCount":102},[],{"trials":9696,"activeCount":102},[],{"trials":9698,"activeCount":180,"soonestReadout":9703},[9699],{"nctId":9700,"briefTitle":9701,"status":152,"phases":9702,"primaryCompletion":9703,"completion":9703,"start":9704,"enrollment":9705,"conditions":9706,"interventions":9707},"NCT06669000","Time Required to Dissolve Urate Deposits",[],"2032-09-24","2024-09-24",250,[943],[9685,9708],"Serum collection",{"intervention":9708,"totalTrials":180,"cells":9710},{"EARLY_PHASE1":9711,"PHASE1":9713,"PHASE2":9715,"PHASE3":9717,"PHASE4":9719,"NA":9721},{"trials":9712,"activeCount":102},[],{"trials":9714,"activeCount":102},[],{"trials":9716,"activeCount":102},[],{"trials":9718,"activeCount":102},[],{"trials":9720,"activeCount":102},[],{"trials":9722,"activeCount":180,"soonestReadout":9703},[9723],{"nctId":9700,"briefTitle":9701,"status":152,"phases":9724,"primaryCompletion":9703,"completion":9703,"start":9704,"enrollment":9705,"conditions":9725,"interventions":9726},[],[943],[9685,9708],{"intervention":9728,"totalTrials":180,"cells":9729},"Intravenous acyclovir",{"EARLY_PHASE1":9730,"PHASE1":9732,"PHASE2":9734,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9731,"activeCount":102},[],{"trials":9733,"activeCount":102},[],{"trials":9735,"activeCount":102},[],{"trials":9737,"activeCount":102},[],{"trials":9739,"activeCount":102},[],{"trials":9741,"activeCount":180,"soonestReadout":2289},[9742],{"nctId":9743,"briefTitle":9744,"status":126,"phases":9745,"primaryCompletion":2289,"completion":2289,"start":1013,"enrollment":9746,"conditions":9747,"interventions":9750},"NCT06217406","Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2)",[94],246,[9748,9749],"Invasive Mechanical Ventilation","HSV Throat Reactivation",[9728,9751],"Saline bags",{"intervention":9751,"totalTrials":180,"cells":9753},{"EARLY_PHASE1":9754,"PHASE1":9756,"PHASE2":9758,"PHASE3":9760,"PHASE4":9762,"NA":9764},{"trials":9755,"activeCount":102},[],{"trials":9757,"activeCount":102},[],{"trials":9759,"activeCount":102},[],{"trials":9761,"activeCount":102},[],{"trials":9763,"activeCount":102},[],{"trials":9765,"activeCount":180,"soonestReadout":2289},[9766],{"nctId":9743,"briefTitle":9744,"status":126,"phases":9767,"primaryCompletion":2289,"completion":2289,"start":1013,"enrollment":9746,"conditions":9768,"interventions":9769},[94],[9748,9749],[9728,9751],{"intervention":9771,"totalTrials":180,"cells":9772},"Administration procedures",{"EARLY_PHASE1":9773,"PHASE1":9775,"PHASE2":9777,"PHASE3":9779,"PHASE4":9781,"NA":9783},{"trials":9774,"activeCount":102},[],{"trials":9776,"activeCount":102},[],{"trials":9778,"activeCount":102},[],{"trials":9780,"activeCount":102},[],{"trials":9782,"activeCount":102},[],{"trials":9784,"activeCount":180,"soonestReadout":1731},[9785],{"nctId":9786,"briefTitle":9787,"status":152,"phases":9788,"primaryCompletion":1731,"completion":1731,"start":1790,"enrollment":9789,"conditions":9790,"interventions":9791},"NCT04280497","Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis",[94],1800,[679],[9771],{"intervention":8077,"totalTrials":180,"cells":9793},{"EARLY_PHASE1":9794,"PHASE1":9796,"PHASE2":9798,"PHASE3":9800,"PHASE4":9802,"NA":9804},{"trials":9795,"activeCount":102},[],{"trials":9797,"activeCount":102},[],{"trials":9799,"activeCount":102},[],{"trials":9801,"activeCount":102},[],{"trials":9803,"activeCount":102},[],{"trials":9805,"activeCount":180,"soonestReadout":8072},[9806],{"nctId":8069,"briefTitle":8070,"status":152,"phases":9807,"primaryCompletion":8072,"completion":8072,"start":8073,"enrollment":489,"conditions":9808,"interventions":9809},[],[8075],[7921,8077],{"intervention":7919,"totalTrials":180,"cells":9811},{"EARLY_PHASE1":9812,"PHASE1":9814,"PHASE2":9816,"PHASE3":9818,"PHASE4":9820,"NA":9822},{"trials":9813,"activeCount":102},[],{"trials":9815,"activeCount":102},[],{"trials":9817,"activeCount":102},[],{"trials":9819,"activeCount":102},[],{"trials":9821,"activeCount":102},[],{"trials":9823,"activeCount":180,"soonestReadout":7913},[9824],{"nctId":7910,"briefTitle":7911,"status":152,"phases":9825,"primaryCompletion":7913,"completion":7913,"start":7914,"enrollment":7915,"conditions":9826,"interventions":9827},[94],[7917],[7804,7919],{"intervention":9829,"totalTrials":180,"cells":9830},"3 blood tests",{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9835,"PHASE3":9837,"PHASE4":9839,"NA":9841},{"trials":9832,"activeCount":102},[],{"trials":9834,"activeCount":102},[],{"trials":9836,"activeCount":102},[],{"trials":9838,"activeCount":102},[],{"trials":9840,"activeCount":102},[],{"trials":9842,"activeCount":180,"soonestReadout":9847},[9843],{"nctId":9844,"briefTitle":9845,"status":152,"phases":9846,"primaryCompletion":9847,"completion":9847,"start":9848,"enrollment":36,"conditions":9849,"interventions":9851},"NCT06050304","CRACK-TARGET 1: Descriptive Study of Observed Behavioral Sensitization and Expectations",[94],"2026-03-04","2025-03-04",[9850],"Cocaine Use Disorder",[9829],{"intervention":9853,"totalTrials":429,"cells":9854},"Nicotine patch",{"EARLY_PHASE1":9855,"PHASE1":9857,"PHASE2":9859,"PHASE3":9861,"PHASE4":9874,"NA":9895},{"trials":9856,"activeCount":102},[],{"trials":9858,"activeCount":102},[],{"trials":9860,"activeCount":102},[],{"trials":9862,"activeCount":102},[9863],{"nctId":9864,"briefTitle":9865,"status":110,"phases":9866,"primaryCompletion":9867,"completion":9868,"start":9869,"enrollment":9870,"conditions":9871,"interventions":9873},"NCT04583410","Efficacy of Nicotine in Preventing COVID-19 Infection",[92],"2021-12","2022-06","2020-10-22",1633,[26,9872],"SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",[9853],{"trials":9875,"activeCount":102},[9876,9885],{"nctId":9877,"briefTitle":9878,"status":139,"phases":9879,"primaryCompletion":9880,"completion":9880,"start":9881,"enrollment":489,"conditions":9882,"interventions":9883},"NCT00235313","Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)",[93],"2007-11","2005-10",[3745],[9884],"nicotine patch",{"nctId":9886,"briefTitle":9887,"status":139,"phases":9888,"primaryCompletion":9889,"completion":9890,"start":9891,"enrollment":4924,"conditions":9892,"interventions":9894},"NCT02905734","Nicotine Replacement Therapy in Nicotine-dependent Arrestees",[93],"2020-11-25","2021-05-30","2017-01-03",[9893],"Nicotine Dependence",[9853],{"trials":9896,"activeCount":102},[],{"intervention":9898,"totalTrials":429,"cells":9899},"Bortezomib",{"EARLY_PHASE1":9900,"PHASE1":9902,"PHASE2":9904,"PHASE3":9925,"PHASE4":9927,"NA":9938},{"trials":9901,"activeCount":102},[],{"trials":9903,"activeCount":102},[],{"trials":9905,"activeCount":102},[9906,9916],{"nctId":9907,"briefTitle":9908,"status":139,"phases":9909,"primaryCompletion":9910,"completion":9910,"start":387,"enrollment":9911,"conditions":9912,"interventions":9914},"NCT00777738","Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia",[91],"2012-08",34,[9913],"Waldenstrom Macroglobulinemia",[9915],"BORTEZOMIB",{"nctId":9917,"briefTitle":9918,"status":139,"phases":9919,"primaryCompletion":1140,"completion":1140,"start":9920,"enrollment":303,"conditions":9921,"interventions":9923},"NCT02201576","Bortezomib in Rejection of Kidney Transplants",[91],"2015-02-11",[9922],"Chronic Antibody-mediated Transplant Rejection",[9898,9924],"Plasma exchanges and intravenous immunoglobulins",{"trials":9926,"activeCount":102},[],{"trials":9928,"activeCount":102},[9929],{"nctId":9930,"briefTitle":9931,"status":110,"phases":9932,"primaryCompletion":9933,"completion":9934,"start":385,"enrollment":5575,"conditions":9935,"interventions":9937},"NCT01842074","Desensitization With Bortezomib Before a Living Kidney Donation",[93],"2017-03","2018-03",[9936],"Patients Awaiting a Living Kidney Donation",[9898],{"trials":9939,"activeCount":102},[],{"intervention":9941,"totalTrials":163,"cells":9942},"Amoxicillin",{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9947,"PHASE3":9949,"PHASE4":9951,"NA":9967},{"trials":9944,"activeCount":102},[],{"trials":9946,"activeCount":102},[],{"trials":9948,"activeCount":102},[],{"trials":9950,"activeCount":102},[],{"trials":9952,"activeCount":102},[9953,9961],{"nctId":9954,"briefTitle":9955,"status":241,"phases":9956,"primaryCompletion":1708,"completion":1708,"start":9957,"enrollment":8373,"conditions":9958,"interventions":9960},"NCT00764062","Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy",[93],"2005-09",[9959],"Odontogenic Infection",[9941],{"nctId":9962,"briefTitle":9963,"status":241,"phases":9964,"primaryCompletion":5163,"completion":5163,"start":1940,"enrollment":5575,"conditions":9965,"interventions":9966},"NCT01059123","Short Course of Amoxicillin for Erysipelas",[93],[921],[9941,9941],{"trials":9968,"activeCount":102},[],{"intervention":9970,"totalTrials":163,"cells":9971},"antibiotic",{"EARLY_PHASE1":9972,"PHASE1":9974,"PHASE2":9976,"PHASE3":9978,"PHASE4":9980,"NA":10002},{"trials":9973,"activeCount":102},[],{"trials":9975,"activeCount":102},[],{"trials":9977,"activeCount":102},[],{"trials":9979,"activeCount":102},[],{"trials":9981,"activeCount":102},[9982,9992],{"nctId":9983,"briefTitle":9984,"status":139,"phases":9985,"primaryCompletion":9986,"completion":2008,"start":9987,"enrollment":1810,"conditions":9988,"interventions":9990},"NCT00136656","Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old",[93],"2008-06","2005-07",[9989],"Pyelonephritis",[9970,9991],"antibiotics",{"nctId":9993,"briefTitle":9994,"status":139,"phases":9995,"primaryCompletion":9910,"completion":9996,"start":9997,"enrollment":9998,"conditions":9999,"interventions":10001},"NCT00764114","Comparison of Two Antimicrobial Therapy Duration for Spondylodiscitis",[93],"2013-04","2006-11",351,[10000],"Vertebral Osteomyelitis",[9970],{"trials":10003,"activeCount":102},[],{"intervention":10005,"totalTrials":163,"cells":10006},"Sunitinib",{"EARLY_PHASE1":10007,"PHASE1":10009,"PHASE2":10011,"PHASE3":10026,"PHASE4":10028,"NA":10037},{"trials":10008,"activeCount":102},[],{"trials":10010,"activeCount":102},[],{"trials":10012,"activeCount":102},[10013],{"nctId":10014,"briefTitle":10015,"status":139,"phases":10016,"primaryCompletion":10017,"completion":10017,"start":5183,"enrollment":1130,"conditions":10018,"interventions":10024},"NCT00748358","An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer",[91],"2011-04",[10019,10020,10021,10022,10023],"Prostatic Neoplasms","Neoplasms, Hormone-Dependent","Tumor Markers, Biological","Survival Rate","Disease-Free Survival",[10025],"sunitinib",{"trials":10027,"activeCount":102},[],{"trials":10029,"activeCount":102},[10030],{"nctId":10031,"briefTitle":10032,"status":241,"phases":10033,"primaryCompletion":1052,"completion":1052,"start":5301,"enrollment":16,"conditions":10034,"interventions":10036},"NCT00930345","Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",[93],[10035],"Metastatic Renal Cell Carcinoma",[10005],{"trials":10038,"activeCount":102},[],{"intervention":10040,"totalTrials":163,"cells":10041},"MEOPA",{"EARLY_PHASE1":10042,"PHASE1":10044,"PHASE2":10046,"PHASE3":10048,"PHASE4":10061,"NA":10072},{"trials":10043,"activeCount":102},[],{"trials":10045,"activeCount":102},[],{"trials":10047,"activeCount":102},[],{"trials":10049,"activeCount":102},[10050],{"nctId":10051,"briefTitle":10052,"status":139,"phases":10053,"primaryCompletion":1908,"completion":1908,"start":5183,"enrollment":6773,"conditions":10054,"interventions":10059},"NCT00632528","MEOPA to Improve Physical Therapy Results After Multilevel Surgery",[92],[10055,10056,10057,10058],"Cerebral Palsy","Spastic Diplegia","Quadriplegia","Hemiplegia",[10040,10060],"Medicinal air",{"trials":10062,"activeCount":102},[10063],{"nctId":10064,"briefTitle":10065,"status":241,"phases":10066,"primaryCompletion":10067,"completion":10067,"start":2008,"enrollment":5113,"conditions":10068,"interventions":10070},"NCT00930358","Safety Study of Colonoscopy Under Sedation",[93],"2011-01",[10069],"Colonoscopy Procedure",[10040,10071],"general anaesthesia",{"trials":10073,"activeCount":102},[],{"intervention":10075,"totalTrials":180,"cells":10076},"celiprolol",{"EARLY_PHASE1":10077,"PHASE1":10079,"PHASE2":10081,"PHASE3":10083,"PHASE4":10085,"NA":10097},{"trials":10078,"activeCount":102},[],{"trials":10080,"activeCount":102},[],{"trials":10082,"activeCount":102},[],{"trials":10084,"activeCount":102},[],{"trials":10086,"activeCount":102},[10087],{"nctId":10088,"briefTitle":10089,"status":139,"phases":10090,"primaryCompletion":10017,"completion":10017,"start":10091,"enrollment":3501,"conditions":10092,"interventions":10095},"NCT00190411","Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type",[93],"2003-10",[10093,10094],"EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT","CHROMOSOME 2q31.2 DELETION SYNDROME",[10075,10096],"Control",{"trials":10098,"activeCount":102},[],{"intervention":10096,"totalTrials":180,"cells":10100},{"EARLY_PHASE1":10101,"PHASE1":10103,"PHASE2":10105,"PHASE3":10107,"PHASE4":10109,"NA":10115},{"trials":10102,"activeCount":102},[],{"trials":10104,"activeCount":102},[],{"trials":10106,"activeCount":102},[],{"trials":10108,"activeCount":102},[],{"trials":10110,"activeCount":102},[10111],{"nctId":10088,"briefTitle":10089,"status":139,"phases":10112,"primaryCompletion":10017,"completion":10017,"start":10091,"enrollment":3501,"conditions":10113,"interventions":10114},[93],[10093,10094],[10075,10096],{"trials":10116,"activeCount":102},[],{"intervention":10118,"totalTrials":180,"cells":10119},"Amphotericin B",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10126,"PHASE4":10128,"NA":10139},{"trials":10121,"activeCount":102},[],{"trials":10123,"activeCount":102},[],{"trials":10125,"activeCount":102},[],{"trials":10127,"activeCount":102},[],{"trials":10129,"activeCount":102},[10130],{"nctId":10131,"briefTitle":10132,"status":241,"phases":10133,"completion":2046,"start":10134,"enrollment":489,"conditions":10135,"interventions":10138},"NCT00190463","Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia",[93],"2003-04",[10136,10137],"Malignant Hemopathy","Duration of Neutropenia Following Chemotherapy > 10 Days",[10118],{"trials":10140,"activeCount":102},[],{"intervention":10142,"totalTrials":180,"cells":10143},"prednisone, methylprednisolone,cyclophosphamides",{"EARLY_PHASE1":10144,"PHASE1":10146,"PHASE2":10148,"PHASE3":10150,"PHASE4":10152,"NA":10163},{"trials":10145,"activeCount":102},[],{"trials":10147,"activeCount":102},[],{"trials":10149,"activeCount":102},[],{"trials":10151,"activeCount":102},[],{"trials":10153,"activeCount":102},[10154],{"nctId":10155,"briefTitle":10156,"status":139,"phases":10157,"primaryCompletion":5163,"completion":5163,"start":9987,"enrollment":2804,"conditions":10158,"interventions":10160},"NCT00307671","Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years",[93],[5913,424,335,425,10159],"Polyarteritis Nodosa",[10142,10161,10162],"Cyclophosphamide, Azathioprine,prednisone,methylprednisolone","Mycophenolate mofetil,methotrexate",{"trials":10164,"activeCount":102},[],{"intervention":10161,"totalTrials":180,"cells":10166},{"EARLY_PHASE1":10167,"PHASE1":10169,"PHASE2":10171,"PHASE3":10173,"PHASE4":10175,"NA":10181},{"trials":10168,"activeCount":102},[],{"trials":10170,"activeCount":102},[],{"trials":10172,"activeCount":102},[],{"trials":10174,"activeCount":102},[],{"trials":10176,"activeCount":102},[10177],{"nctId":10155,"briefTitle":10156,"status":139,"phases":10178,"primaryCompletion":5163,"completion":5163,"start":9987,"enrollment":2804,"conditions":10179,"interventions":10180},[93],[5913,424,335,425,10159],[10142,10161,10162],{"trials":10182,"activeCount":102},[],{"intervention":10162,"totalTrials":180,"cells":10184},{"EARLY_PHASE1":10185,"PHASE1":10187,"PHASE2":10189,"PHASE3":10191,"PHASE4":10193,"NA":10199},{"trials":10186,"activeCount":102},[],{"trials":10188,"activeCount":102},[],{"trials":10190,"activeCount":102},[],{"trials":10192,"activeCount":102},[],{"trials":10194,"activeCount":102},[10195],{"nctId":10155,"briefTitle":10156,"status":139,"phases":10196,"primaryCompletion":5163,"completion":5163,"start":9987,"enrollment":2804,"conditions":10197,"interventions":10198},[93],[5913,424,335,425,10159],[10142,10161,10162],{"trials":10200,"activeCount":102},[],{"intervention":530,"totalTrials":180,"cells":10202},{"EARLY_PHASE1":10203,"PHASE1":10205,"PHASE2":10207,"PHASE3":10209,"PHASE4":10211,"NA":10217},{"trials":10204,"activeCount":102},[],{"trials":10206,"activeCount":102},[],{"trials":10208,"activeCount":102},[],{"trials":10210,"activeCount":102},[],{"trials":10212,"activeCount":102},[10213],{"nctId":519,"briefTitle":520,"status":139,"phases":10214,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":10215,"interventions":10216},[93],[526,527,528],[530,469],{"trials":10218,"activeCount":102},[],{"intervention":10220,"totalTrials":180,"cells":10221},"conventional therapy",{"EARLY_PHASE1":10222,"PHASE1":10224,"PHASE2":10226,"PHASE3":10228,"PHASE4":10230,"NA":10241},{"trials":10223,"activeCount":102},[],{"trials":10225,"activeCount":102},[],{"trials":10227,"activeCount":102},[],{"trials":10229,"activeCount":102},[],{"trials":10231,"activeCount":102},[10232],{"nctId":10233,"briefTitle":10234,"status":139,"phases":10235,"primaryCompletion":10236,"completion":10237,"start":10238,"enrollment":941,"conditions":10239,"interventions":10240},"NCT02231229","Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation",[93],"2018-07-04","2020-02-18","2014-07-23",[6995],[10220],{"trials":10242,"activeCount":102},[],{"intervention":10244,"totalTrials":180,"cells":10245},"Hydrea®",{"EARLY_PHASE1":10246,"PHASE1":10248,"PHASE2":10250,"PHASE3":10252,"PHASE4":10254,"NA":10264},{"trials":10247,"activeCount":102},[],{"trials":10249,"activeCount":102},[],{"trials":10251,"activeCount":102},[],{"trials":10253,"activeCount":102},[],{"trials":10255,"activeCount":102},[10256],{"nctId":10257,"briefTitle":10258,"status":139,"phases":10259,"primaryCompletion":5162,"completion":5162,"start":10260,"enrollment":1130,"conditions":10261,"interventions":10263},"NCT01609192","Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated",[93],"2010-04",[10262],"Drepanocytic Men Treated by Hydroxyurea for the First Time",[10244],{"trials":10265,"activeCount":102},[],{"intervention":10267,"totalTrials":180,"cells":10268},"Duraphat",{"EARLY_PHASE1":10269,"PHASE1":10271,"PHASE2":10273,"PHASE3":10275,"PHASE4":10277,"NA":10287},{"trials":10270,"activeCount":102},[],{"trials":10272,"activeCount":102},[],{"trials":10274,"activeCount":102},[],{"trials":10276,"activeCount":102},[],{"trials":10278,"activeCount":102},[10279],{"nctId":10280,"briefTitle":10281,"status":139,"phases":10282,"primaryCompletion":5641,"completion":8062,"start":990,"enrollment":10283,"conditions":10284,"interventions":10286},"NCT01038817","Impact of Fluoride Vanish Application in Dental Prevention for Elderly",[93],179,[10285],"Tooth Decay",[10267],{"trials":10288,"activeCount":102},[],{"intervention":10290,"totalTrials":180,"cells":10291},"Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin",{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10296,"PHASE3":10298,"PHASE4":10300,"NA":10310},{"trials":10293,"activeCount":102},[],{"trials":10295,"activeCount":102},[],{"trials":10297,"activeCount":102},[],{"trials":10299,"activeCount":102},[],{"trials":10301,"activeCount":102},[10302],{"nctId":10303,"briefTitle":10304,"status":139,"phases":10305,"primaryCompletion":5518,"completion":5518,"start":5660,"enrollment":1247,"conditions":10306,"interventions":10309},"NCT01588795","Renal Denervation in Diabetic Nephropathy",[93],[10307,10308],"Diabetic Nephropathy","Persistent Proteinuria With Type II Diabetes",[10290],{"trials":10311,"activeCount":102},[],{"intervention":10313,"totalTrials":180,"cells":10314},"beta-blocker treatment",{"EARLY_PHASE1":10315,"PHASE1":10317,"PHASE2":10319,"PHASE3":10321,"PHASE4":10323,"NA":10333},{"trials":10316,"activeCount":102},[],{"trials":10318,"activeCount":102},[],{"trials":10320,"activeCount":102},[],{"trials":10322,"activeCount":102},[],{"trials":10324,"activeCount":102},[10325],{"nctId":10326,"briefTitle":10327,"status":139,"phases":10328,"primaryCompletion":2008,"completion":2008,"start":10329,"enrollment":4948,"conditions":10330,"interventions":10332},"NCT00162565","Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening",[93],"2004-11",[10331],"Heart Failure, Congestive",[10313],{"trials":10334,"activeCount":102},[],{"intervention":10336,"totalTrials":180,"cells":10337},"Deescalation therapy",{"EARLY_PHASE1":10338,"PHASE1":10340,"PHASE2":10342,"PHASE3":10344,"PHASE4":10346,"NA":10359},{"trials":10339,"activeCount":102},[],{"trials":10341,"activeCount":102},[],{"trials":10343,"activeCount":102},[],{"trials":10345,"activeCount":102},[],{"trials":10347,"activeCount":102},[10348],{"nctId":10349,"briefTitle":10350,"status":241,"phases":10351,"primaryCompletion":5701,"completion":5701,"start":989,"enrollment":473,"conditions":10352,"interventions":10357},"NCT02265445","Deescalating Carbapenems in Hospital Setting",[93],[10353,10354,10355,10356],"Urinary Infection","Digestive Infection","Biliary Infection","Expanded-spectrum Beta-lactamase Producing ESBL",[10336,10358],"Maintaining carbapenem therapy",{"trials":10360,"activeCount":102},[],{"intervention":10358,"totalTrials":180,"cells":10362},{"EARLY_PHASE1":10363,"PHASE1":10365,"PHASE2":10367,"PHASE3":10369,"PHASE4":10371,"NA":10377},{"trials":10364,"activeCount":102},[],{"trials":10366,"activeCount":102},[],{"trials":10368,"activeCount":102},[],{"trials":10370,"activeCount":102},[],{"trials":10372,"activeCount":102},[10373],{"nctId":10349,"briefTitle":10350,"status":241,"phases":10374,"primaryCompletion":5701,"completion":5701,"start":989,"enrollment":473,"conditions":10375,"interventions":10376},[93],[10353,10354,10355,10356],[10336,10358],{"trials":10378,"activeCount":102},[],{"intervention":10380,"totalTrials":180,"cells":10381},"rhGH",{"EARLY_PHASE1":10382,"PHASE1":10384,"PHASE2":10386,"PHASE3":10388,"PHASE4":10390,"NA":10400},{"trials":10383,"activeCount":102},[],{"trials":10385,"activeCount":102},[],{"trials":10387,"activeCount":102},[],{"trials":10389,"activeCount":102},[],{"trials":10391,"activeCount":102},[10392],{"nctId":10393,"briefTitle":10394,"status":241,"phases":10395,"primaryCompletion":7961,"completion":7961,"start":217,"enrollment":5575,"conditions":10396,"interventions":10398},"NCT00597480","Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)",[93],[10397],"Small for Gestational Age",[10380,10399],"rhGH norditropine simple Xx",{"trials":10401,"activeCount":102},[],{"intervention":10399,"totalTrials":180,"cells":10403},{"EARLY_PHASE1":10404,"PHASE1":10406,"PHASE2":10408,"PHASE3":10410,"PHASE4":10412,"NA":10418},{"trials":10405,"activeCount":102},[],{"trials":10407,"activeCount":102},[],{"trials":10409,"activeCount":102},[],{"trials":10411,"activeCount":102},[],{"trials":10413,"activeCount":102},[10414],{"nctId":10393,"briefTitle":10394,"status":241,"phases":10415,"primaryCompletion":7961,"completion":7961,"start":217,"enrollment":5575,"conditions":10416,"interventions":10417},[93],[10397],[10380,10399],{"trials":10419,"activeCount":102},[],{"intervention":10421,"totalTrials":180,"cells":10422},"Tpo-RA discontinuation",{"EARLY_PHASE1":10423,"PHASE1":10425,"PHASE2":10427,"PHASE3":10429,"PHASE4":10431,"NA":10443},{"trials":10424,"activeCount":102},[],{"trials":10426,"activeCount":102},[],{"trials":10428,"activeCount":102},[],{"trials":10430,"activeCount":102},[],{"trials":10432,"activeCount":102},[10433],{"nctId":10434,"briefTitle":10435,"status":139,"phases":10436,"primaryCompletion":10437,"completion":10438,"start":10439,"enrollment":5911,"conditions":10440,"interventions":10442},"NCT03119974","Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP",[93],"2020-08-26","2021-02-16","2017-09-26",[10441],"Persistent or Chronic ITP",[10421],{"trials":10444,"activeCount":102},[],{"intervention":10446,"totalTrials":180,"cells":10447},"discontinuation of oxytocin administration",{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10452,"PHASE3":10454,"PHASE4":10456,"NA":10469},{"trials":10449,"activeCount":102},[],{"trials":10451,"activeCount":102},[],{"trials":10453,"activeCount":102},[],{"trials":10455,"activeCount":102},[],{"trials":10457,"activeCount":102},[10458],{"nctId":10459,"briefTitle":10460,"status":139,"phases":10461,"primaryCompletion":10462,"completion":10462,"start":10463,"enrollment":10464,"conditions":10465,"interventions":10467},"NCT03991091","Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor",[93],"2022-04-25","2020-01-17",2459,[10466],"Neonatal Morbidity",[10446,10468],"continuation of oxytocin administration",{"trials":10470,"activeCount":102},[],{"intervention":10468,"totalTrials":180,"cells":10472},{"EARLY_PHASE1":10473,"PHASE1":10475,"PHASE2":10477,"PHASE3":10479,"PHASE4":10481,"NA":10487},{"trials":10474,"activeCount":102},[],{"trials":10476,"activeCount":102},[],{"trials":10478,"activeCount":102},[],{"trials":10480,"activeCount":102},[],{"trials":10482,"activeCount":102},[10483],{"nctId":10459,"briefTitle":10460,"status":139,"phases":10484,"primaryCompletion":10462,"completion":10462,"start":10463,"enrollment":10464,"conditions":10485,"interventions":10486},[93],[10466],[10446,10468],{"trials":10488,"activeCount":102},[],{"intervention":10490,"totalTrials":180,"cells":10491},"levofloxacin, ciprofloxacin and ofloxacin",{"EARLY_PHASE1":10492,"PHASE1":10494,"PHASE2":10496,"PHASE3":10498,"PHASE4":10500,"NA":10513},{"trials":10493,"activeCount":102},[],{"trials":10495,"activeCount":102},[],{"trials":10497,"activeCount":102},[],{"trials":10499,"activeCount":102},[],{"trials":10501,"activeCount":102},[10502],{"nctId":10503,"briefTitle":10504,"status":139,"phases":10505,"primaryCompletion":10506,"completion":10506,"start":10507,"enrollment":10508,"conditions":10509,"interventions":10512},"NCT00873626","Treatment's Duration of Acute Uncomplicated Pyelonephritis",[93],"2011-08","2009-06",310,[10510,10511],"Urinary Tract Infection","Fever",[10490],{"trials":10514,"activeCount":102},[],{"intervention":10516,"totalTrials":180,"cells":10517},"Sertraline",{"EARLY_PHASE1":10518,"PHASE1":10520,"PHASE2":10522,"PHASE3":10524,"PHASE4":10526,"NA":10537},{"trials":10519,"activeCount":102},[],{"trials":10521,"activeCount":102},[],{"trials":10523,"activeCount":102},[],{"trials":10525,"activeCount":102},[],{"trials":10527,"activeCount":102},[10528],{"nctId":10529,"briefTitle":10530,"status":241,"phases":10531,"primaryCompletion":8061,"completion":8061,"start":10532,"enrollment":163,"conditions":10533,"interventions":10535},"NCT02463110","Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin",[93],"2015-07",[10534,526],"Depression",[10516,10536],"No treatment",{"trials":10538,"activeCount":102},[],{"intervention":10536,"totalTrials":180,"cells":10540},{"EARLY_PHASE1":10541,"PHASE1":10543,"PHASE2":10545,"PHASE3":10547,"PHASE4":10549,"NA":10555},{"trials":10542,"activeCount":102},[],{"trials":10544,"activeCount":102},[],{"trials":10546,"activeCount":102},[],{"trials":10548,"activeCount":102},[],{"trials":10550,"activeCount":102},[10551],{"nctId":10529,"briefTitle":10530,"status":241,"phases":10552,"primaryCompletion":8061,"completion":8061,"start":10532,"enrollment":163,"conditions":10553,"interventions":10554},[93],[10534,526],[10516,10536],{"trials":10556,"activeCount":102},[],{"intervention":10558,"totalTrials":180,"cells":10559},"Gonal-F®",{"EARLY_PHASE1":10560,"PHASE1":10562,"PHASE2":10564,"PHASE3":10566,"PHASE4":10568,"NA":10580},{"trials":10561,"activeCount":102},[],{"trials":10563,"activeCount":102},[],{"trials":10565,"activeCount":102},[],{"trials":10567,"activeCount":102},[],{"trials":10569,"activeCount":102},[10570],{"nctId":10571,"briefTitle":10572,"status":139,"phases":10573,"primaryCompletion":10574,"completion":10574,"start":10575,"enrollment":10576,"conditions":10577,"interventions":10578},"NCT02892942","NATural Ovarian Stimulation",[93],"2019-02-08","2017-01-13",129,[4408],[10558,10579,10579],"Cetrotide®",{"trials":10581,"activeCount":102},[],{"intervention":10579,"totalTrials":180,"cells":10583},{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10588,"PHASE3":10590,"PHASE4":10592,"NA":10598},{"trials":10585,"activeCount":102},[],{"trials":10587,"activeCount":102},[],{"trials":10589,"activeCount":102},[],{"trials":10591,"activeCount":102},[],{"trials":10593,"activeCount":102},[10594],{"nctId":10571,"briefTitle":10572,"status":139,"phases":10595,"primaryCompletion":10574,"completion":10574,"start":10575,"enrollment":10576,"conditions":10596,"interventions":10597},[93],[4408],[10558,10579,10579],{"trials":10599,"activeCount":102},[],{"intervention":10601,"totalTrials":180,"cells":10602},"Modification of Prasugrel based on a biological assay",{"EARLY_PHASE1":10603,"PHASE1":10605,"PHASE2":10607,"PHASE3":10609,"PHASE4":10611,"NA":10621},{"trials":10604,"activeCount":102},[],{"trials":10606,"activeCount":102},[],{"trials":10608,"activeCount":102},[],{"trials":10610,"activeCount":102},[],{"trials":10612,"activeCount":102},[10613],{"nctId":10614,"briefTitle":10615,"status":139,"phases":10616,"primaryCompletion":8062,"completion":8062,"start":535,"enrollment":10617,"conditions":10618,"interventions":10619},"NCT01538446","Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel",[93],880,[539],[10601,10620],"prasugrel \u002F clopidogrel",{"trials":10622,"activeCount":102},[],{"intervention":10620,"totalTrials":180,"cells":10624},{"EARLY_PHASE1":10625,"PHASE1":10627,"PHASE2":10629,"PHASE3":10631,"PHASE4":10633,"NA":10639},{"trials":10626,"activeCount":102},[],{"trials":10628,"activeCount":102},[],{"trials":10630,"activeCount":102},[],{"trials":10632,"activeCount":102},[],{"trials":10634,"activeCount":102},[10635],{"nctId":10614,"briefTitle":10615,"status":139,"phases":10636,"primaryCompletion":8062,"completion":8062,"start":535,"enrollment":10617,"conditions":10637,"interventions":10638},[93],[539],[10601,10620],{"trials":10640,"activeCount":102},[],{"intervention":10642,"totalTrials":180,"cells":10643},"Disulfiram",{"EARLY_PHASE1":10644,"PHASE1":10646,"PHASE2":10648,"PHASE3":10650,"PHASE4":10652,"NA":10661},{"trials":10645,"activeCount":102},[],{"trials":10647,"activeCount":102},[],{"trials":10649,"activeCount":102},[],{"trials":10651,"activeCount":102},[],{"trials":10653,"activeCount":102},[10654],{"nctId":10655,"briefTitle":10656,"status":5932,"phases":10657,"primaryCompletion":1509,"completion":497,"start":8063,"enrollment":102,"conditions":10658,"interventions":10660},"NCT02134002","A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts",[93],[10659],"Cocaine Dependence",[10642],{"trials":10662,"activeCount":102},[],{"intervention":10664,"totalTrials":180,"cells":10665},"progressive spacing of TNF-blocker injections",{"EARLY_PHASE1":10666,"PHASE1":10668,"PHASE2":10670,"PHASE3":10672,"PHASE4":10674,"NA":10684},{"trials":10667,"activeCount":102},[],{"trials":10669,"activeCount":102},[],{"trials":10671,"activeCount":102},[],{"trials":10673,"activeCount":102},[],{"trials":10675,"activeCount":102},[10676],{"nctId":10677,"briefTitle":10678,"status":139,"phases":10679,"primaryCompletion":10680,"completion":10680,"start":8235,"enrollment":9705,"conditions":10681,"interventions":10682},"NCT00780793","Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study",[93],"2011-09",[32],[10664,10683],"DMARD maintenance",{"trials":10685,"activeCount":102},[],{"intervention":10683,"totalTrials":180,"cells":10687},{"EARLY_PHASE1":10688,"PHASE1":10690,"PHASE2":10692,"PHASE3":10694,"PHASE4":10696,"NA":10702},{"trials":10689,"activeCount":102},[],{"trials":10691,"activeCount":102},[],{"trials":10693,"activeCount":102},[],{"trials":10695,"activeCount":102},[],{"trials":10697,"activeCount":102},[10698],{"nctId":10677,"briefTitle":10678,"status":139,"phases":10699,"primaryCompletion":10680,"completion":10680,"start":8235,"enrollment":9705,"conditions":10700,"interventions":10701},[93],[32],[10664,10683],{"trials":10703,"activeCount":102},[],{"intervention":10705,"totalTrials":180,"cells":10706},"Bayesian based dose adjustment of enoxaparin",{"EARLY_PHASE1":10707,"PHASE1":10709,"PHASE2":10711,"PHASE3":10713,"PHASE4":10715,"NA":10726},{"trials":10708,"activeCount":102},[],{"trials":10710,"activeCount":102},[],{"trials":10712,"activeCount":102},[],{"trials":10714,"activeCount":102},[],{"trials":10716,"activeCount":102},[10717],{"nctId":10718,"briefTitle":10719,"status":139,"phases":10720,"primaryCompletion":459,"completion":1256,"start":10721,"enrollment":1130,"conditions":10722,"interventions":10724},"NCT05672550","Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)",[93],"2023-06-28",[10723],"Pediatric Kidney Transplant Recipients",[10705,10725],"Usual dose adjustment of enoxaparin",{"trials":10727,"activeCount":102},[],{"intervention":10725,"totalTrials":180,"cells":10729},{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10734,"PHASE3":10736,"PHASE4":10738,"NA":10744},{"trials":10731,"activeCount":102},[],{"trials":10733,"activeCount":102},[],{"trials":10735,"activeCount":102},[],{"trials":10737,"activeCount":102},[],{"trials":10739,"activeCount":102},[10740],{"nctId":10718,"briefTitle":10719,"status":139,"phases":10741,"primaryCompletion":459,"completion":1256,"start":10721,"enrollment":1130,"conditions":10742,"interventions":10743},[93],[10723],[10705,10725],{"trials":10745,"activeCount":102},[],{"intervention":10747,"totalTrials":180,"cells":10748},"Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo",{"EARLY_PHASE1":10749,"PHASE1":10751,"PHASE2":10753,"PHASE3":10755,"PHASE4":10757,"NA":10768},{"trials":10750,"activeCount":102},[],{"trials":10752,"activeCount":102},[],{"trials":10754,"activeCount":102},[],{"trials":10756,"activeCount":102},[],{"trials":10758,"activeCount":102},[10759],{"nctId":10760,"briefTitle":10761,"status":139,"phases":10762,"primaryCompletion":5900,"completion":5900,"start":5183,"enrollment":5599,"conditions":10763,"interventions":10766},"NCT00603317","Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid",[93],[10764,10765,467,4926],"Oral Anticoagulation","Deep Venous Thrombosis",[10747,10767],"Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid",{"trials":10769,"activeCount":102},[],{"intervention":10767,"totalTrials":180,"cells":10771},{"EARLY_PHASE1":10772,"PHASE1":10774,"PHASE2":10776,"PHASE3":10778,"PHASE4":10780,"NA":10786},{"trials":10773,"activeCount":102},[],{"trials":10775,"activeCount":102},[],{"trials":10777,"activeCount":102},[],{"trials":10779,"activeCount":102},[],{"trials":10781,"activeCount":102},[10782],{"nctId":10760,"briefTitle":10761,"status":139,"phases":10783,"primaryCompletion":5900,"completion":5900,"start":5183,"enrollment":5599,"conditions":10784,"interventions":10785},[93],[10764,10765,467,4926],[10747,10767],{"trials":10787,"activeCount":102},[],{"intervention":10789,"totalTrials":180,"cells":10790},"Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®",{"EARLY_PHASE1":10791,"PHASE1":10793,"PHASE2":10795,"PHASE3":10797,"PHASE4":10799,"NA":10813},{"trials":10792,"activeCount":102},[],{"trials":10794,"activeCount":102},[],{"trials":10796,"activeCount":102},[],{"trials":10798,"activeCount":102},[],{"trials":10800,"activeCount":102},[10801],{"nctId":10802,"briefTitle":10803,"status":139,"phases":10804,"primaryCompletion":10805,"completion":10806,"start":10807,"enrollment":245,"conditions":10808,"interventions":10812},"NCT02325310","Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR",[93],"2016-05-03","2017-11-01","2015-02-04",[10809,10810,10811],"Measles","Rubella","Mumps",[10789],{"trials":10814,"activeCount":102},[],{"intervention":10816,"totalTrials":180,"cells":10817},"Evaluation of vaccines against flu",{"EARLY_PHASE1":10818,"PHASE1":10820,"PHASE2":10822,"PHASE3":10824,"PHASE4":10826,"NA":10835},{"trials":10819,"activeCount":102},[],{"trials":10821,"activeCount":102},[],{"trials":10823,"activeCount":102},[],{"trials":10825,"activeCount":102},[],{"trials":10827,"activeCount":102},[10828],{"nctId":10829,"briefTitle":10830,"status":139,"phases":10831,"primaryCompletion":5163,"completion":10832,"start":990,"enrollment":567,"conditions":10833,"interventions":10834},"NCT01065285","Vaccination Against Influenza in Autoimmune Diseases",[93],"2012-02",[231],[10816],{"trials":10836,"activeCount":102},[],{"intervention":9991,"totalTrials":180,"cells":10838},{"EARLY_PHASE1":10839,"PHASE1":10841,"PHASE2":10843,"PHASE3":10845,"PHASE4":10847,"NA":10853},{"trials":10840,"activeCount":102},[],{"trials":10842,"activeCount":102},[],{"trials":10844,"activeCount":102},[],{"trials":10846,"activeCount":102},[],{"trials":10848,"activeCount":102},[10849],{"nctId":9983,"briefTitle":9984,"status":139,"phases":10850,"primaryCompletion":9986,"completion":2008,"start":9987,"enrollment":1810,"conditions":10851,"interventions":10852},[93],[9989],[9970,9991],{"trials":10854,"activeCount":102},[],{"intervention":10856,"totalTrials":180,"cells":10857},"Novel strategy Aspirin",{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10864,"PHASE4":10866,"NA":10878},{"trials":10859,"activeCount":102},[],{"trials":10861,"activeCount":102},[],{"trials":10863,"activeCount":102},[],{"trials":10865,"activeCount":102},[],{"trials":10867,"activeCount":102},[10868],{"nctId":10869,"briefTitle":10870,"status":139,"phases":10871,"primaryCompletion":10872,"completion":10872,"start":10873,"enrollment":10874,"conditions":10875,"interventions":10876},"NCT02520921","Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome",[93],"2024-07-18","2016-06-13",2484,[5548,539,526,18],[10856,10877],"Conventional strategy Aspirin",{"trials":10879,"activeCount":102},[],{"intervention":10877,"totalTrials":180,"cells":10881},{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10890,"NA":10896},{"trials":10883,"activeCount":102},[],{"trials":10885,"activeCount":102},[],{"trials":10887,"activeCount":102},[],{"trials":10889,"activeCount":102},[],{"trials":10891,"activeCount":102},[10892],{"nctId":10869,"briefTitle":10870,"status":139,"phases":10893,"primaryCompletion":10872,"completion":10872,"start":10873,"enrollment":10874,"conditions":10894,"interventions":10895},[93],[5548,539,526,18],[10856,10877],{"trials":10897,"activeCount":102},[],{"intervention":10899,"totalTrials":180,"cells":10900},"Amoxicillin-clavulanic",{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10907,"PHASE4":10909,"NA":10921},{"trials":10902,"activeCount":102},[],{"trials":10904,"activeCount":102},[],{"trials":10906,"activeCount":102},[],{"trials":10908,"activeCount":102},[],{"trials":10910,"activeCount":102},[10911],{"nctId":10912,"briefTitle":10913,"status":139,"phases":10914,"primaryCompletion":10915,"completion":10915,"start":10916,"enrollment":10917,"conditions":10918,"interventions":10920},"NCT00190437","ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD",[93],"2006-10","2003-08",520,[10919],"Chronic Obstructive Lung Disease (COLD)",[10899],{"trials":10922,"activeCount":102},[],{"intervention":10924,"totalTrials":180,"cells":10925},"L-arginine",{"EARLY_PHASE1":10926,"PHASE1":10928,"PHASE2":10930,"PHASE3":10932,"PHASE4":10934,"NA":10944},{"trials":10927,"activeCount":102},[],{"trials":10929,"activeCount":102},[],{"trials":10931,"activeCount":102},[],{"trials":10933,"activeCount":102},[],{"trials":10935,"activeCount":102},[10936],{"nctId":10937,"briefTitle":10938,"status":139,"phases":10939,"primaryCompletion":10940,"completion":10067,"start":7866,"enrollment":21,"conditions":10941,"interventions":10943},"NCT01038622","Directed Immuno Nutrition by L-arginine for Critically Ill Patients",[93],"2010-11",[10942],"Critically Ill",[10924],{"trials":10945,"activeCount":102},[],{"intervention":10947,"totalTrials":180,"cells":10948},"Valacyclovir arrow",{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10953,"PHASE3":10955,"PHASE4":10957,"NA":10968},{"trials":10950,"activeCount":102},[],{"trials":10952,"activeCount":102},[],{"trials":10954,"activeCount":102},[],{"trials":10956,"activeCount":102},[],{"trials":10958,"activeCount":102},[10959],{"nctId":10960,"briefTitle":10961,"status":139,"phases":10962,"primaryCompletion":10963,"completion":10532,"start":5163,"enrollment":1029,"conditions":10964,"interventions":10967},"NCT01651585","In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir",[93],"2015-05",[10965,10966],"Foetuses Infection","Cytomegalovirus (CMV)Infection",[10947],{"trials":10969,"activeCount":102},[],{"intervention":10971,"totalTrials":180,"cells":10972},"Lidocaïne Aguettant 20 mg\u002Fml",{"EARLY_PHASE1":10973,"PHASE1":10975,"PHASE2":10977,"PHASE3":10979,"PHASE4":10981,"NA":10992},{"trials":10974,"activeCount":102},[],{"trials":10976,"activeCount":102},[],{"trials":10978,"activeCount":102},[],{"trials":10980,"activeCount":102},[],{"trials":10982,"activeCount":102},[10983],{"nctId":10984,"briefTitle":10985,"status":139,"phases":10986,"primaryCompletion":10987,"completion":10987,"start":7888,"enrollment":303,"conditions":10988,"interventions":10990},"NCT05032508","Efficacy of the Application of Xylocaine Impregnated Compress in Reducing Per-procedural Pain During Ultrasound-guided Infiltration of Trigger Finger",[93],"2023-06-07",[10989],"Trigger Finger",[10971,10991],"NaCl 0,9%",{"trials":10993,"activeCount":102},[],{"intervention":10991,"totalTrials":180,"cells":10995},{"EARLY_PHASE1":10996,"PHASE1":10998,"PHASE2":11000,"PHASE3":11002,"PHASE4":11004,"NA":11010},{"trials":10997,"activeCount":102},[],{"trials":10999,"activeCount":102},[],{"trials":11001,"activeCount":102},[],{"trials":11003,"activeCount":102},[],{"trials":11005,"activeCount":102},[11006],{"nctId":10984,"briefTitle":10985,"status":139,"phases":11007,"primaryCompletion":10987,"completion":10987,"start":7888,"enrollment":303,"conditions":11008,"interventions":11009},[93],[10989],[10971,10991],{"trials":11011,"activeCount":102},[],{"intervention":541,"totalTrials":180,"cells":11013},{"EARLY_PHASE1":11014,"PHASE1":11016,"PHASE2":11018,"PHASE3":11020,"PHASE4":11022,"NA":11028},{"trials":11015,"activeCount":102},[],{"trials":11017,"activeCount":102},[],{"trials":11019,"activeCount":102},[],{"trials":11021,"activeCount":102},[],{"trials":11023,"activeCount":102},[11024],{"nctId":532,"briefTitle":533,"status":139,"phases":11025,"primaryCompletion":535,"completion":536,"start":523,"enrollment":537,"conditions":11026,"interventions":11027},[93],[526,539],[541,541,541,469],{"trials":11029,"activeCount":102},[],{"intervention":11031,"totalTrials":180,"cells":11032},"aspirin 75 mg\u002Fday",{"EARLY_PHASE1":11033,"PHASE1":11035,"PHASE2":11037,"PHASE3":11039,"PHASE4":11041,"NA":11052},{"trials":11034,"activeCount":102},[],{"trials":11036,"activeCount":102},[],{"trials":11038,"activeCount":102},[],{"trials":11040,"activeCount":102},[],{"trials":11042,"activeCount":102},[11043],{"nctId":11044,"briefTitle":11045,"status":139,"phases":11046,"primaryCompletion":11047,"completion":11047,"start":2150,"enrollment":11048,"conditions":11049,"interventions":11051},"NCT00190307","STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery",[93],"2009-12",293,[11050],"Thrombosis",[11031],{"trials":11053,"activeCount":102},[],{"intervention":11055,"totalTrials":180,"cells":11056},"Visipaque - Hydrocortancyl",{"EARLY_PHASE1":11057,"PHASE1":11059,"PHASE2":11061,"PHASE3":11063,"PHASE4":11065,"NA":11075},{"trials":11058,"activeCount":102},[],{"trials":11060,"activeCount":102},[],{"trials":11062,"activeCount":102},[],{"trials":11064,"activeCount":102},[],{"trials":11066,"activeCount":102},[11067],{"nctId":11068,"briefTitle":11069,"status":139,"phases":11070,"primaryCompletion":10963,"completion":5469,"start":8082,"enrollment":11071,"conditions":11072,"interventions":11074},"NCT00804531","Intra-discal Steroid Injection for MODIC I Discopathy",[93],137,[11073],"Back Pain Lower Back Chronic",[11055],{"trials":11076,"activeCount":102},[],{"intervention":11078,"totalTrials":180,"cells":11079},"Salicylate ointment",{"EARLY_PHASE1":11080,"PHASE1":11082,"PHASE2":11084,"PHASE3":11086,"PHASE4":11088,"NA":11102},{"trials":11081,"activeCount":102},[],{"trials":11083,"activeCount":102},[],{"trials":11085,"activeCount":102},[],{"trials":11087,"activeCount":102},[],{"trials":11089,"activeCount":102},[11090],{"nctId":11091,"briefTitle":11092,"status":241,"phases":11093,"primaryCompletion":11094,"completion":497,"start":5418,"enrollment":11095,"conditions":11096,"interventions":11098},"NCT01059110","Comparison of Five Treatments in Patients With Plantar Warts",[93],"2015-01",358,[11097],"Plantar Warts",[11078,11099,11100,11101],"Imiquimod","5-Fluoro-Uracil","Cryotherapy",{"trials":11103,"activeCount":102},[],{"intervention":11099,"totalTrials":180,"cells":11105},{"EARLY_PHASE1":11106,"PHASE1":11108,"PHASE2":11110,"PHASE3":11112,"PHASE4":11114,"NA":11120},{"trials":11107,"activeCount":102},[],{"trials":11109,"activeCount":102},[],{"trials":11111,"activeCount":102},[],{"trials":11113,"activeCount":102},[],{"trials":11115,"activeCount":102},[11116],{"nctId":11091,"briefTitle":11092,"status":241,"phases":11117,"primaryCompletion":11094,"completion":497,"start":5418,"enrollment":11095,"conditions":11118,"interventions":11119},[93],[11097],[11078,11099,11100,11101],{"trials":11121,"activeCount":102},[],{"intervention":11100,"totalTrials":180,"cells":11123},{"EARLY_PHASE1":11124,"PHASE1":11126,"PHASE2":11128,"PHASE3":11130,"PHASE4":11132,"NA":11138},{"trials":11125,"activeCount":102},[],{"trials":11127,"activeCount":102},[],{"trials":11129,"activeCount":102},[],{"trials":11131,"activeCount":102},[],{"trials":11133,"activeCount":102},[11134],{"nctId":11091,"briefTitle":11092,"status":241,"phases":11135,"primaryCompletion":11094,"completion":497,"start":5418,"enrollment":11095,"conditions":11136,"interventions":11137},[93],[11097],[11078,11099,11100,11101],{"trials":11139,"activeCount":102},[],{"intervention":11101,"totalTrials":180,"cells":11141},{"EARLY_PHASE1":11142,"PHASE1":11144,"PHASE2":11146,"PHASE3":11148,"PHASE4":11150,"NA":11156},{"trials":11143,"activeCount":102},[],{"trials":11145,"activeCount":102},[],{"trials":11147,"activeCount":102},[],{"trials":11149,"activeCount":102},[],{"trials":11151,"activeCount":102},[11152],{"nctId":11091,"briefTitle":11092,"status":241,"phases":11153,"primaryCompletion":11094,"completion":497,"start":5418,"enrollment":11095,"conditions":11154,"interventions":11155},[93],[11097],[11078,11099,11100,11101],{"trials":11157,"activeCount":102},[],{"intervention":11159,"totalTrials":180,"cells":11160},"recombinant alpha-galactosidase A",{"EARLY_PHASE1":11161,"PHASE1":11163,"PHASE2":11165,"PHASE3":11167,"PHASE4":11169,"NA":11178},{"trials":11162,"activeCount":102},[],{"trials":11164,"activeCount":102},[],{"trials":11166,"activeCount":102},[],{"trials":11168,"activeCount":102},[],{"trials":11170,"activeCount":102},[11171],{"nctId":11172,"briefTitle":11173,"status":110,"phases":11174,"completion":10507,"start":2150,"enrollment":9911,"conditions":11175,"interventions":11177},"NCT00487630","Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease",[93],[11176],"Fabry Disease",[11159],{"trials":11179,"activeCount":102},[],{"intervention":11181,"totalTrials":180,"cells":11182},"MIFEPRISTONE 200 mg and misoprostol 400 µg",{"EARLY_PHASE1":11183,"PHASE1":11185,"PHASE2":11187,"PHASE3":11189,"PHASE4":11191,"NA":11201},{"trials":11184,"activeCount":102},[],{"trials":11186,"activeCount":102},[],{"trials":11188,"activeCount":102},[],{"trials":11190,"activeCount":102},[],{"trials":11192,"activeCount":102},[11193],{"nctId":11194,"briefTitle":11195,"status":139,"phases":11196,"primaryCompletion":11197,"completion":11197,"start":10134,"enrollment":1015,"conditions":11198,"interventions":11200},"NCT00190294","Expectant Versus Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW",[93],"2006-09",[11199],"Pregnancy Complications",[11181],{"trials":11202,"activeCount":102},[],{"intervention":11204,"totalTrials":180,"cells":11205},"influenza vaccination",{"EARLY_PHASE1":11206,"PHASE1":11208,"PHASE2":11210,"PHASE3":11212,"PHASE4":11214,"NA":11225},{"trials":11207,"activeCount":102},[],{"trials":11209,"activeCount":102},[],{"trials":11211,"activeCount":102},[],{"trials":11213,"activeCount":102},[],{"trials":11215,"activeCount":102},[11216],{"nctId":11217,"briefTitle":11218,"status":139,"phases":11219,"primaryCompletion":10067,"completion":11220,"start":7866,"enrollment":11221,"conditions":11222,"interventions":11224},"NCT01499914","Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination",[93],"2012-12",439,[11223],"Cystic Fibrosis With Gastrointestinal Manifestation",[11204],{"trials":11226,"activeCount":102},[],{"intervention":10071,"totalTrials":180,"cells":11228},{"EARLY_PHASE1":11229,"PHASE1":11231,"PHASE2":11233,"PHASE3":11235,"PHASE4":11237,"NA":11243},{"trials":11230,"activeCount":102},[],{"trials":11232,"activeCount":102},[],{"trials":11234,"activeCount":102},[],{"trials":11236,"activeCount":102},[],{"trials":11238,"activeCount":102},[11239],{"nctId":10064,"briefTitle":10065,"status":241,"phases":11240,"primaryCompletion":10067,"completion":10067,"start":2008,"enrollment":5113,"conditions":11241,"interventions":11242},[93],[10069],[10040,10071],{"trials":11244,"activeCount":102},[],{"intervention":11246,"totalTrials":180,"cells":11247},"Baricitinib Oral Tablet [Olumiant]",{"EARLY_PHASE1":11248,"PHASE1":11250,"PHASE2":11252,"PHASE3":11254,"PHASE4":11256,"NA":11267},{"trials":11249,"activeCount":102},[],{"trials":11251,"activeCount":102},[],{"trials":11253,"activeCount":102},[],{"trials":11255,"activeCount":102},[],{"trials":11257,"activeCount":102},[11258],{"nctId":11259,"briefTitle":11260,"status":241,"phases":11261,"primaryCompletion":11262,"completion":11263,"start":11264,"enrollment":98,"conditions":11265,"interventions":11266},"NCT05238896","BARIcitinib Cognitive Emotional and Neural signaTuRE",[93],"2023-02-23","2023-03-31","2022-06-27",[32],[11246],{"trials":11268,"activeCount":102},[],{"intervention":11270,"totalTrials":180,"cells":11271},"Oxytocin 4 mIU\u002FmL",{"EARLY_PHASE1":11272,"PHASE1":11274,"PHASE2":11276,"PHASE3":11278,"PHASE4":11280,"NA":11295},{"trials":11273,"activeCount":102},[],{"trials":11275,"activeCount":102},[],{"trials":11277,"activeCount":102},[],{"trials":11279,"activeCount":102},[],{"trials":11281,"activeCount":102},[11282],{"nctId":11283,"briefTitle":11284,"status":139,"phases":11285,"primaryCompletion":11286,"completion":9657,"start":11287,"enrollment":11288,"conditions":11289,"interventions":11293},"NCT04760496","Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour",[93],"2024-12-30","2021-10-02",443,[11290,11291,11292],"Obese","Primiparous Women","Oxytocin",[11270,11294],"Oxytocin 2 mIU\u002FmL",{"trials":11296,"activeCount":102},[],{"intervention":11294,"totalTrials":180,"cells":11298},{"EARLY_PHASE1":11299,"PHASE1":11301,"PHASE2":11303,"PHASE3":11305,"PHASE4":11307,"NA":11313},{"trials":11300,"activeCount":102},[],{"trials":11302,"activeCount":102},[],{"trials":11304,"activeCount":102},[],{"trials":11306,"activeCount":102},[],{"trials":11308,"activeCount":102},[11309],{"nctId":11283,"briefTitle":11284,"status":139,"phases":11310,"primaryCompletion":11286,"completion":9657,"start":11287,"enrollment":11288,"conditions":11311,"interventions":11312},[93],[11290,11291,11292],[11270,11294],{"trials":11314,"activeCount":102},[],{"intervention":11316,"totalTrials":180,"cells":11317},"Metformin and FSHr",{"EARLY_PHASE1":11318,"PHASE1":11320,"PHASE2":11322,"PHASE3":11324,"PHASE4":11326,"NA":11335},{"trials":11319,"activeCount":102},[],{"trials":11321,"activeCount":102},[],{"trials":11323,"activeCount":102},[],{"trials":11325,"activeCount":102},[],{"trials":11327,"activeCount":102},[11328],{"nctId":11329,"briefTitle":11330,"status":110,"phases":11331,"primaryCompletion":956,"completion":956,"start":10915,"enrollment":11332,"conditions":11333,"interventions":11334},"NCT00378729","Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)",[93],252,[8375],[11316],{"trials":11336,"activeCount":102},[],{"intervention":11338,"totalTrials":180,"cells":11339},"Colchicine,",{"EARLY_PHASE1":11340,"PHASE1":11342,"PHASE2":11344,"PHASE3":11346,"PHASE4":11348,"NA":11361},{"trials":11341,"activeCount":102},[],{"trials":11343,"activeCount":102},[],{"trials":11345,"activeCount":102},[],{"trials":11347,"activeCount":102},[],{"trials":11349,"activeCount":102},[11350],{"nctId":11351,"briefTitle":11352,"status":241,"phases":11353,"primaryCompletion":11354,"completion":46,"start":11355,"enrollment":115,"conditions":11356,"interventions":11358},"NCT03933007","Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare",[93],"2019-10-10","2019-09-10",[11357],"Gout Flare",[11338,11359,11360],"midazolam,","fexofenadine",{"trials":11362,"activeCount":102},[],{"intervention":11359,"totalTrials":180,"cells":11364},{"EARLY_PHASE1":11365,"PHASE1":11367,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11379},{"trials":11366,"activeCount":102},[],{"trials":11368,"activeCount":102},[],{"trials":11370,"activeCount":102},[],{"trials":11372,"activeCount":102},[],{"trials":11374,"activeCount":102},[11375],{"nctId":11351,"briefTitle":11352,"status":241,"phases":11376,"primaryCompletion":11354,"completion":46,"start":11355,"enrollment":115,"conditions":11377,"interventions":11378},[93],[11357],[11338,11359,11360],{"trials":11380,"activeCount":102},[],{"intervention":11360,"totalTrials":180,"cells":11382},{"EARLY_PHASE1":11383,"PHASE1":11385,"PHASE2":11387,"PHASE3":11389,"PHASE4":11391,"NA":11397},{"trials":11384,"activeCount":102},[],{"trials":11386,"activeCount":102},[],{"trials":11388,"activeCount":102},[],{"trials":11390,"activeCount":102},[],{"trials":11392,"activeCount":102},[11393],{"nctId":11351,"briefTitle":11352,"status":241,"phases":11394,"primaryCompletion":11354,"completion":46,"start":11355,"enrollment":115,"conditions":11395,"interventions":11396},[93],[11357],[11338,11359,11360],{"trials":11398,"activeCount":102},[],{"intervention":11400,"totalTrials":180,"cells":11401},"Tranexamic acid",{"EARLY_PHASE1":11402,"PHASE1":11404,"PHASE2":11406,"PHASE3":11408,"PHASE4":11410,"NA":11421},{"trials":11403,"activeCount":102},[],{"trials":11405,"activeCount":102},[],{"trials":11407,"activeCount":102},[],{"trials":11409,"activeCount":102},[],{"trials":11411,"activeCount":102},[11412],{"nctId":11413,"briefTitle":11414,"status":110,"phases":11415,"primaryCompletion":11416,"completion":8214,"start":11417,"enrollment":632,"conditions":11418,"interventions":11420},"NCT03023189","Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding",[93],"2019-04","2017-04-03",[11419,1500],"Upper Digestive Bleeding",[11400],{"trials":11422,"activeCount":102},[],{"intervention":11424,"totalTrials":180,"cells":11425},"Beta-blockers withdrawal",{"EARLY_PHASE1":11426,"PHASE1":11428,"PHASE2":11430,"PHASE3":11432,"PHASE4":11434,"NA":11446},{"trials":11427,"activeCount":102},[],{"trials":11429,"activeCount":102},[],{"trials":11431,"activeCount":102},[],{"trials":11433,"activeCount":102},[],{"trials":11435,"activeCount":102},[11436],{"nctId":11437,"briefTitle":11438,"status":139,"phases":11439,"primaryCompletion":11440,"completion":11440,"start":11441,"enrollment":11442,"conditions":11443,"interventions":11444},"NCT03498066","Beta Blocker Interruption After Uncomplicated Myocardial Infarction",[93],"2023-10-31","2018-08-29",3700,[4742],[11424,11445],"Continuation of the Betablockers (βB) treatment",{"trials":11447,"activeCount":102},[],{"intervention":11445,"totalTrials":180,"cells":11449},{"EARLY_PHASE1":11450,"PHASE1":11452,"PHASE2":11454,"PHASE3":11456,"PHASE4":11458,"NA":11464},{"trials":11451,"activeCount":102},[],{"trials":11453,"activeCount":102},[],{"trials":11455,"activeCount":102},[],{"trials":11457,"activeCount":102},[],{"trials":11459,"activeCount":102},[11460],{"nctId":11437,"briefTitle":11438,"status":139,"phases":11461,"primaryCompletion":11440,"completion":11440,"start":11441,"enrollment":11442,"conditions":11462,"interventions":11463},[93],[4742],[11424,11445],{"trials":11465,"activeCount":102},[],{"intervention":11467,"totalTrials":180,"cells":11468},"1: Remifentanil",{"EARLY_PHASE1":11469,"PHASE1":11471,"PHASE2":11473,"PHASE3":11475,"PHASE4":11477,"NA":11489},{"trials":11470,"activeCount":102},[],{"trials":11472,"activeCount":102},[],{"trials":11474,"activeCount":102},[],{"trials":11476,"activeCount":102},[],{"trials":11478,"activeCount":102},[11479],{"nctId":11480,"briefTitle":11481,"status":139,"phases":11482,"primaryCompletion":11417,"completion":11417,"start":11483,"enrollment":11484,"conditions":11485,"interventions":11487},"NCT01872754","Study Comparing the Use of Remifentanil Versus Propofol for Performing Bronchial Fibroscopy",[93],"2013-07-31",71,[11486],"Realisation of Bronchial Fibroscopy",[11467,11488],"2: Propofol",{"trials":11490,"activeCount":102},[],{"intervention":11488,"totalTrials":180,"cells":11492},{"EARLY_PHASE1":11493,"PHASE1":11495,"PHASE2":11497,"PHASE3":11499,"PHASE4":11501,"NA":11507},{"trials":11494,"activeCount":102},[],{"trials":11496,"activeCount":102},[],{"trials":11498,"activeCount":102},[],{"trials":11500,"activeCount":102},[],{"trials":11502,"activeCount":102},[11503],{"nctId":11480,"briefTitle":11481,"status":139,"phases":11504,"primaryCompletion":11417,"completion":11417,"start":11483,"enrollment":11484,"conditions":11505,"interventions":11506},[93],[11486],[11467,11488],{"trials":11508,"activeCount":102},[],{"intervention":11510,"totalTrials":180,"cells":11511},"entacapone",{"EARLY_PHASE1":11512,"PHASE1":11514,"PHASE2":11516,"PHASE3":11518,"PHASE4":11520,"NA":11530},{"trials":11513,"activeCount":102},[],{"trials":11515,"activeCount":102},[],{"trials":11517,"activeCount":102},[],{"trials":11519,"activeCount":102},[],{"trials":11521,"activeCount":102},[11522],{"nctId":11523,"briefTitle":11524,"status":139,"phases":11525,"primaryCompletion":7866,"completion":7866,"start":10915,"enrollment":303,"conditions":11526,"interventions":11528},"NCT00373087","COMT Polymorphism and Entacapone Efficacy",[93],[11527],"Parkinson's Disease",[11510,11529],"l dopa versus placebo",{"trials":11531,"activeCount":102},[],{"intervention":11529,"totalTrials":180,"cells":11533},{"EARLY_PHASE1":11534,"PHASE1":11536,"PHASE2":11538,"PHASE3":11540,"PHASE4":11542,"NA":11548},{"trials":11535,"activeCount":102},[],{"trials":11537,"activeCount":102},[],{"trials":11539,"activeCount":102},[],{"trials":11541,"activeCount":102},[],{"trials":11543,"activeCount":102},[11544],{"nctId":11523,"briefTitle":11524,"status":139,"phases":11545,"primaryCompletion":7866,"completion":7866,"start":10915,"enrollment":303,"conditions":11546,"interventions":11547},[93],[11527],[11510,11529],{"trials":11549,"activeCount":102},[],{"intervention":11551,"totalTrials":180,"cells":11552},"Teduglutide",{"EARLY_PHASE1":11553,"PHASE1":11555,"PHASE2":11557,"PHASE3":11559,"PHASE4":11561,"NA":11573},{"trials":11554,"activeCount":102},[],{"trials":11556,"activeCount":102},[],{"trials":11558,"activeCount":102},[],{"trials":11560,"activeCount":102},[],{"trials":11562,"activeCount":102},[11563],{"nctId":11564,"briefTitle":11565,"status":139,"phases":11566,"primaryCompletion":11567,"completion":11568,"start":11569,"enrollment":1247,"conditions":11570,"interventions":11572},"NCT03562130","Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients",[93],"2019-12-11","2020-07-13","2018-07-02",[11571],"Short Bowel Syndrome",[11551],{"trials":11574,"activeCount":102},[],{"intervention":11576,"totalTrials":180,"cells":11577},"Anti hypertensive, statin and antiplatelet medication.",{"EARLY_PHASE1":11578,"PHASE1":11580,"PHASE2":11582,"PHASE3":11584,"PHASE4":11586,"NA":11599},{"trials":11579,"activeCount":102},[],{"trials":11581,"activeCount":102},[],{"trials":11583,"activeCount":102},[],{"trials":11585,"activeCount":102},[],{"trials":11587,"activeCount":102},[11588],{"nctId":11589,"briefTitle":11590,"status":241,"phases":11591,"primaryCompletion":497,"completion":11592,"start":11593,"enrollment":1299,"conditions":11594,"interventions":11598},"NCT02539810","Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)",[93],"2017-07","2015-09",[11595,11596,11597],"Hypertension","Hypertension Resistant to Conventional Therapy","Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent",[11576],{"trials":11600,"activeCount":102},[],{"intervention":11602,"totalTrials":180,"cells":11603},"Prednisone - Azathioprine",{"EARLY_PHASE1":11604,"PHASE1":11606,"PHASE2":11608,"PHASE3":11610,"PHASE4":11612,"NA":11622},{"trials":11605,"activeCount":102},[],{"trials":11607,"activeCount":102},[],{"trials":11609,"activeCount":102},[],{"trials":11611,"activeCount":102},[],{"trials":11613,"activeCount":102},[11614],{"nctId":11615,"briefTitle":11616,"status":139,"phases":11617,"primaryCompletion":11592,"completion":11618,"start":10507,"enrollment":11619,"conditions":11620,"interventions":11621},"NCT00987116","Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis",[93],"2017-09",118,[220],[11602],{"trials":11623,"activeCount":102},[],{"intervention":11625,"totalTrials":180,"cells":11626},"Malarone",{"EARLY_PHASE1":11627,"PHASE1":11629,"PHASE2":11631,"PHASE3":11633,"PHASE4":11635,"NA":11647},{"trials":11628,"activeCount":102},[],{"trials":11630,"activeCount":102},[],{"trials":11632,"activeCount":102},[],{"trials":11634,"activeCount":102},[],{"trials":11636,"activeCount":102},[11637],{"nctId":11638,"briefTitle":11639,"status":139,"phases":11640,"primaryCompletion":374,"completion":5469,"start":11641,"enrollment":11642,"conditions":11643,"interventions":11645},"NCT01150344","Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria",[93],"2010-07",317,[11644],"Malaria",[11625,11646],"RIAMET",{"trials":11648,"activeCount":102},[],{"intervention":11646,"totalTrials":180,"cells":11650},{"EARLY_PHASE1":11651,"PHASE1":11653,"PHASE2":11655,"PHASE3":11657,"PHASE4":11659,"NA":11665},{"trials":11652,"activeCount":102},[],{"trials":11654,"activeCount":102},[],{"trials":11656,"activeCount":102},[],{"trials":11658,"activeCount":102},[],{"trials":11660,"activeCount":102},[11661],{"nctId":11638,"briefTitle":11639,"status":139,"phases":11662,"primaryCompletion":374,"completion":5469,"start":11641,"enrollment":11642,"conditions":11663,"interventions":11664},[93],[11644],[11625,11646],{"trials":11666,"activeCount":102},[],{"intervention":11668,"totalTrials":180,"cells":11669},"Conversion at day 7 ± 3 Prograf® to Advagraf®",{"EARLY_PHASE1":11670,"PHASE1":11672,"PHASE2":11674,"PHASE3":11676,"PHASE4":11678,"NA":11689},{"trials":11671,"activeCount":102},[],{"trials":11673,"activeCount":102},[],{"trials":11675,"activeCount":102},[],{"trials":11677,"activeCount":102},[],{"trials":11679,"activeCount":102},[11680],{"nctId":11681,"briefTitle":11682,"status":139,"phases":11683,"primaryCompletion":1051,"completion":11684,"start":7896,"enrollment":5804,"conditions":11685,"interventions":11687},"NCT02105155","Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation",[93],"2016-10-17",[11686],"Immunosuppression After Liver Transplantation",[11668,11688],"Conversion at day 90±5 Prograf® to Advagraf®",{"trials":11690,"activeCount":102},[],{"intervention":11688,"totalTrials":180,"cells":11692},{"EARLY_PHASE1":11693,"PHASE1":11695,"PHASE2":11697,"PHASE3":11699,"PHASE4":11701,"NA":11707},{"trials":11694,"activeCount":102},[],{"trials":11696,"activeCount":102},[],{"trials":11698,"activeCount":102},[],{"trials":11700,"activeCount":102},[],{"trials":11702,"activeCount":102},[11703],{"nctId":11681,"briefTitle":11682,"status":139,"phases":11704,"primaryCompletion":1051,"completion":11684,"start":7896,"enrollment":5804,"conditions":11705,"interventions":11706},[93],[11686],[11668,11688],{"trials":11708,"activeCount":102},[],{"intervention":11710,"totalTrials":180,"cells":11711},"Tocilizumab, Abatacept",{"EARLY_PHASE1":11712,"PHASE1":11714,"PHASE2":11716,"PHASE3":11718,"PHASE4":11720,"NA":11731},{"trials":11713,"activeCount":102},[],{"trials":11715,"activeCount":102},[],{"trials":11717,"activeCount":102},[],{"trials":11719,"activeCount":102},[],{"trials":11721,"activeCount":102},[11722],{"nctId":11723,"briefTitle":11724,"status":139,"phases":11725,"primaryCompletion":11726,"completion":11726,"start":5660,"enrollment":11727,"conditions":11728,"interventions":11729},"NCT01557374","TOward the Lowest Effective DOse of Abatacept or Tocilizumab",[93],"2019-11-08",232,[32],[11710,11730],"Decrease Tocilizumab, Abatacept",{"trials":11732,"activeCount":102},[],{"intervention":11730,"totalTrials":180,"cells":11734},{"EARLY_PHASE1":11735,"PHASE1":11737,"PHASE2":11739,"PHASE3":11741,"PHASE4":11743,"NA":11749},{"trials":11736,"activeCount":102},[],{"trials":11738,"activeCount":102},[],{"trials":11740,"activeCount":102},[],{"trials":11742,"activeCount":102},[],{"trials":11744,"activeCount":102},[11745],{"nctId":11723,"briefTitle":11724,"status":139,"phases":11746,"primaryCompletion":11726,"completion":11726,"start":5660,"enrollment":11727,"conditions":11747,"interventions":11748},[93],[32],[11710,11730],{"trials":11750,"activeCount":102},[],{"intervention":11752,"totalTrials":180,"cells":11753},"Ertapenem",{"EARLY_PHASE1":11754,"PHASE1":11756,"PHASE2":11758,"PHASE3":11760,"PHASE4":11762,"NA":11772},{"trials":11755,"activeCount":102},[],{"trials":11757,"activeCount":102},[],{"trials":11759,"activeCount":102},[],{"trials":11761,"activeCount":102},[],{"trials":11763,"activeCount":102},[11764],{"nctId":11765,"briefTitle":11766,"status":139,"phases":11767,"primaryCompletion":11094,"completion":989,"start":11768,"enrollment":36,"conditions":11769,"interventions":11771},"NCT02041767","Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration",[93],"2013-12",[11770],"Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection",[11752],{"trials":11773,"activeCount":102},[],{"intervention":11775,"totalTrials":180,"cells":11776},"Acetazolamide",{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11781,"PHASE3":11783,"PHASE4":11785,"NA":11794},{"trials":11778,"activeCount":102},[],{"trials":11780,"activeCount":102},[],{"trials":11782,"activeCount":102},[],{"trials":11784,"activeCount":102},[],{"trials":11786,"activeCount":102},[11787],{"nctId":11788,"briefTitle":11789,"status":139,"phases":11790,"primaryCompletion":988,"completion":988,"start":956,"enrollment":2020,"conditions":11791,"interventions":11793},"NCT01627639","Effectiveness of Acetazolamide for Reversal of Metabolic Alkalosis in Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients",[93],[11792],"Decompensated Chronic Obstructive Pulmonary Disease",[11775],{"trials":11795,"activeCount":102},[],{"intervention":11797,"totalTrials":180,"cells":11798},"17 alpha-hydroxyprogesterones caproate",{"EARLY_PHASE1":11799,"PHASE1":11801,"PHASE2":11803,"PHASE3":11805,"PHASE4":11807,"NA":11818},{"trials":11800,"activeCount":102},[],{"trials":11802,"activeCount":102},[],{"trials":11804,"activeCount":102},[],{"trials":11806,"activeCount":102},[],{"trials":11808,"activeCount":102},[11809],{"nctId":11810,"briefTitle":11811,"status":139,"phases":11812,"primaryCompletion":267,"completion":267,"start":11813,"enrollment":11814,"conditions":11815,"interventions":11817},"NCT00331695","Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery",[93],"2006-06",560,[11816],"Preterm Delivery",[11797],{"trials":11819,"activeCount":102},[],{"intervention":11821,"totalTrials":180,"cells":11822},"irbesartan, amlodipine and hydrochlorothiazide",{"EARLY_PHASE1":11823,"PHASE1":11825,"PHASE2":11827,"PHASE3":11829,"PHASE4":11831,"NA":11840},{"trials":11824,"activeCount":102},[],{"trials":11826,"activeCount":102},[],{"trials":11828,"activeCount":102},[],{"trials":11830,"activeCount":102},[],{"trials":11832,"activeCount":102},[11833],{"nctId":11834,"briefTitle":11835,"status":139,"phases":11836,"primaryCompletion":999,"completion":999,"start":11837,"enrollment":4948,"conditions":11838,"interventions":11839},"NCT00224549","PHARES Study: Management of Resistant Hypertension",[93],"2005-04",[11595],[11821],{"trials":11841,"activeCount":102},[],{"intervention":11843,"totalTrials":180,"cells":11844},"versus hydroxychloroquine",{"EARLY_PHASE1":11845,"PHASE1":11847,"PHASE2":11849,"PHASE3":11851,"PHASE4":11853,"NA":11863},{"trials":11846,"activeCount":102},[],{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":102},[],{"trials":11852,"activeCount":102},[],{"trials":11854,"activeCount":102},[11855],{"nctId":11856,"briefTitle":11857,"status":139,"phases":11858,"primaryCompletion":10067,"completion":10067,"start":421,"enrollment":11859,"conditions":11860,"interventions":11862},"NCT00413361","The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS",[93],543,[11861],"Systemic Lupus Erythematosus",[11843],{"trials":11864,"activeCount":102},[],{"intervention":11866,"totalTrials":180,"cells":11867},"during one week for the active treatments",{"EARLY_PHASE1":11868,"PHASE1":11870,"PHASE2":11872,"PHASE3":11874,"PHASE4":11876,"NA":11889},{"trials":11869,"activeCount":102},[],{"trials":11871,"activeCount":102},[],{"trials":11873,"activeCount":102},[],{"trials":11875,"activeCount":102},[],{"trials":11877,"activeCount":102},[11878],{"nctId":11879,"briefTitle":11880,"status":5932,"phases":11881,"primaryCompletion":11882,"completion":5900,"start":5519,"enrollment":102,"conditions":11883,"interventions":11887},"NCT00713947","Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control",[93],"2009-03",[11884,11885,11886],"Positive Helicobacter Pylori Serology","Coronary Thrombosis","Supra-aortic Artery Thrombosis",[11866,11888],"Pantoprazole",{"trials":11890,"activeCount":102},[],{"intervention":11888,"totalTrials":180,"cells":11892},{"EARLY_PHASE1":11893,"PHASE1":11895,"PHASE2":11897,"PHASE3":11899,"PHASE4":11901,"NA":11907},{"trials":11894,"activeCount":102},[],{"trials":11896,"activeCount":102},[],{"trials":11898,"activeCount":102},[],{"trials":11900,"activeCount":102},[],{"trials":11902,"activeCount":102},[11903],{"nctId":11879,"briefTitle":11880,"status":5932,"phases":11904,"primaryCompletion":11882,"completion":5900,"start":5519,"enrollment":102,"conditions":11905,"interventions":11906},[93],[11884,11885,11886],[11866,11888],{"trials":11908,"activeCount":102},[],{"intervention":11910,"totalTrials":180,"cells":11911},"Misoprostol",{"EARLY_PHASE1":11912,"PHASE1":11914,"PHASE2":11916,"PHASE3":11918,"PHASE4":11920,"NA":11930},{"trials":11913,"activeCount":102},[],{"trials":11915,"activeCount":102},[],{"trials":11917,"activeCount":102},[],{"trials":11919,"activeCount":102},[],{"trials":11921,"activeCount":102},[11922],{"nctId":11923,"briefTitle":11924,"status":241,"phases":11925,"primaryCompletion":988,"completion":8413,"start":5900,"enrollment":11926,"conditions":11927,"interventions":11929},"NCT01113229","Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage",[93],1721,[11928],"Hemorrhage; Complicating Delivery",[11910],{"trials":11931,"activeCount":102},[],{"intervention":11933,"totalTrials":180,"cells":11934},"Cholecalciferol 100 000 UI",{"EARLY_PHASE1":11935,"PHASE1":11937,"PHASE2":11939,"PHASE3":11941,"PHASE4":11943,"NA":11956},{"trials":11936,"activeCount":102},[],{"trials":11938,"activeCount":102},[],{"trials":11940,"activeCount":102},[],{"trials":11942,"activeCount":102},[],{"trials":11944,"activeCount":102},[11945],{"nctId":11946,"briefTitle":11947,"status":139,"phases":11948,"primaryCompletion":11949,"completion":11949,"start":11950,"enrollment":11951,"conditions":11952,"interventions":11954},"NCT01431430","VITamine D Supplementation in RenAL Transplant Recipients - VITALE",[93],"2016-02-02","2012-01-06",538,[11953],"Renal Transplant Candidate for Right Kidney",[11933,11955],"Cholecalciferol 12 000 UI",{"trials":11957,"activeCount":102},[],{"intervention":11955,"totalTrials":180,"cells":11959},{"EARLY_PHASE1":11960,"PHASE1":11962,"PHASE2":11964,"PHASE3":11966,"PHASE4":11968,"NA":11974},{"trials":11961,"activeCount":102},[],{"trials":11963,"activeCount":102},[],{"trials":11965,"activeCount":102},[],{"trials":11967,"activeCount":102},[],{"trials":11969,"activeCount":102},[11970],{"nctId":11946,"briefTitle":11947,"status":139,"phases":11971,"primaryCompletion":11949,"completion":11949,"start":11950,"enrollment":11951,"conditions":11972,"interventions":11973},[93],[11953],[11933,11955],{"trials":11975,"activeCount":102},[],{"intervention":5189,"totalTrials":180,"cells":11977},{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":11984,"PHASE4":11986,"NA":11992},{"trials":11979,"activeCount":102},[],{"trials":11981,"activeCount":102},[],{"trials":11983,"activeCount":102},[],{"trials":11985,"activeCount":102},[],{"trials":11987,"activeCount":102},[11988],{"nctId":5180,"briefTitle":5181,"status":139,"phases":11989,"primaryCompletion":5183,"completion":5183,"start":5184,"enrollment":5185,"conditions":11990,"interventions":11991},[93],[5187],[5122,5189],{"trials":11993,"activeCount":102},[],{"intervention":11995,"totalTrials":180,"cells":11996},"Ferinject",{"EARLY_PHASE1":11997,"PHASE1":11999,"PHASE2":12001,"PHASE3":12003,"PHASE4":12005,"NA":12016},{"trials":11998,"activeCount":102},[],{"trials":12000,"activeCount":102},[],{"trials":12002,"activeCount":102},[],{"trials":12004,"activeCount":102},[],{"trials":12006,"activeCount":102},[12007],{"nctId":12008,"briefTitle":12009,"status":110,"phases":12010,"primaryCompletion":9632,"completion":9632,"start":12011,"enrollment":941,"conditions":12012,"interventions":12014},"NCT05114278","Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)",[93],"2022-02-15",[12013],"Celiac Disease",[11995,12015],"oral iron",{"trials":12017,"activeCount":102},[],{"intervention":12015,"totalTrials":180,"cells":12019},{"EARLY_PHASE1":12020,"PHASE1":12022,"PHASE2":12024,"PHASE3":12026,"PHASE4":12028,"NA":12034},{"trials":12021,"activeCount":102},[],{"trials":12023,"activeCount":102},[],{"trials":12025,"activeCount":102},[],{"trials":12027,"activeCount":102},[],{"trials":12029,"activeCount":102},[12030],{"nctId":12008,"briefTitle":12009,"status":110,"phases":12031,"primaryCompletion":9632,"completion":9632,"start":12011,"enrollment":941,"conditions":12032,"interventions":12033},[93],[12013],[11995,12015],{"trials":12035,"activeCount":102},[],{"intervention":12037,"totalTrials":180,"cells":12038},"Liraglutide",{"EARLY_PHASE1":12039,"PHASE1":12041,"PHASE2":12043,"PHASE3":12045,"PHASE4":12047,"NA":12059},{"trials":12040,"activeCount":102},[],{"trials":12042,"activeCount":102},[],{"trials":12044,"activeCount":102},[],{"trials":12046,"activeCount":102},[],{"trials":12048,"activeCount":102},[12049],{"nctId":12050,"briefTitle":12051,"status":139,"phases":12052,"primaryCompletion":12053,"completion":12054,"start":12055,"enrollment":1130,"conditions":12056,"interventions":12057},"NCT02686177","Effect of GLP-1 on Angiogenesis",[93],"2017-08-08","2021-05-28","2016-05-18",[3503],[12037,12058],"Metformin or sulfonylurea",{"trials":12060,"activeCount":102},[],{"intervention":12058,"totalTrials":180,"cells":12062},{"EARLY_PHASE1":12063,"PHASE1":12065,"PHASE2":12067,"PHASE3":12069,"PHASE4":12071,"NA":12077},{"trials":12064,"activeCount":102},[],{"trials":12066,"activeCount":102},[],{"trials":12068,"activeCount":102},[],{"trials":12070,"activeCount":102},[],{"trials":12072,"activeCount":102},[12073],{"nctId":12050,"briefTitle":12051,"status":139,"phases":12074,"primaryCompletion":12053,"completion":12054,"start":12055,"enrollment":1130,"conditions":12075,"interventions":12076},[93],[3503],[12037,12058],{"trials":12078,"activeCount":102},[],{"intervention":2131,"totalTrials":1299,"cells":12080},{"EARLY_PHASE1":12081,"PHASE1":12083,"PHASE2":12085,"PHASE3":12087,"PHASE4":12123,"NA":12125},{"trials":12082,"activeCount":102},[],{"trials":12084,"activeCount":102},[],{"trials":12086,"activeCount":102},[],{"trials":12088,"activeCount":102},[12089,12100,12108,12119],{"nctId":12090,"briefTitle":12091,"status":139,"phases":12092,"primaryCompletion":12093,"completion":12094,"start":12093,"enrollment":323,"conditions":12095,"interventions":12097},"NCT02659033","Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.",[92],"2016-03","2017-12",[12096],"Emergence of Bacterial Resistance to Antibiotics",[12098,12099],"ceftriaxone","Cefotaxime",{"nctId":12101,"briefTitle":12102,"status":110,"phases":12103,"primaryCompletion":1731,"completion":1731,"start":1128,"enrollment":4806,"conditions":12104,"interventions":12107},"NCT05971550","Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study",[92],[12105,12106],"Neisseria Gonorrhoeae Infection","Asymptomatic Pharyngeal Carriage",[2131],{"nctId":12109,"briefTitle":12110,"status":139,"phases":12111,"primaryCompletion":12112,"completion":3675,"start":12113,"enrollment":12114,"conditions":12115,"interventions":12117},"NCT02424461","Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection",[92],"2019-02-25","2015-01-25",274,[12116],"Acute Male Urinary Tract Infection",[2131,12118,12118],"Ofloxacine",{"nctId":2122,"briefTitle":2123,"status":139,"phases":12120,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":2127,"conditions":12121,"interventions":12122},[92],[2129],[2131,2132,2099,1164],{"trials":12124,"activeCount":102},[],{"trials":12126,"activeCount":102},[],{"intervention":12128,"totalTrials":1299,"cells":12129},"Clopidogrel",{"EARLY_PHASE1":12130,"PHASE1":12132,"PHASE2":12142,"PHASE3":12144,"PHASE4":12178,"NA":12180},{"trials":12131,"activeCount":102},[],{"trials":12133,"activeCount":102},[12134],{"nctId":12135,"briefTitle":12136,"status":139,"phases":12137,"primaryCompletion":523,"completion":523,"start":2009,"enrollment":12138,"conditions":12139,"interventions":12141},"NCT00413608","Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects",[90],140,[12140],"Healthy",[12128],{"trials":12143,"activeCount":102},[],{"trials":12145,"activeCount":102},[12146,12154,12166],{"nctId":12147,"briefTitle":12148,"status":139,"phases":12149,"primaryCompletion":11047,"completion":11047,"start":387,"enrollment":12150,"conditions":12151,"interventions":12152},"NCT00822666","Clopidogrel and Response Variability Investigation Study 2",[92],109,[526],[12153],"clopidogrel",{"nctId":12155,"briefTitle":12156,"status":241,"phases":12157,"primaryCompletion":12158,"completion":12159,"start":12160,"enrollment":7935,"conditions":12161,"interventions":12165},"NCT02404363","Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy",[92],"2017-12-04","2018-03-27","2016-01-11",[12162,12163,12164],"Locally Advanced Pancreatic Cancer","Adenocarcinoma, Pancreas","Metastatic Pancreatic Cancer",[12128],{"nctId":12167,"briefTitle":12168,"status":139,"phases":12169,"primaryCompletion":12170,"completion":12171,"start":12172,"enrollment":12173,"conditions":12174,"interventions":12176},"NCT02617290","Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting",[92],"2020-05-29","2020-09-15","2017-01-09",1900,[526,528,4742,527,12175],"Cardiovascular Diseases",[12177,12128],"Ticagrelor",{"trials":12179,"activeCount":102},[],{"trials":12181,"activeCount":102},[],{"intervention":12183,"totalTrials":429,"cells":12184},"Oxygen",{"EARLY_PHASE1":12185,"PHASE1":12187,"PHASE2":12189,"PHASE3":12201,"PHASE4":12222,"NA":12224},{"trials":12186,"activeCount":102},[],{"trials":12188,"activeCount":102},[],{"trials":12190,"activeCount":102},[12191],{"nctId":12192,"briefTitle":12193,"status":139,"phases":12194,"primaryCompletion":12195,"completion":12196,"start":12197,"enrollment":27,"conditions":12198,"interventions":12200},"NCT06248645","Oxygen as an Acute Treatment in Alternating Hemiplegia of Childhood",[91],"2026-03-03","2026-03-31","2024-09-16",[12199],"Alternating Hemiplegia of Childhood",[12183],{"trials":12202,"activeCount":102},[12203,12211],{"nctId":12204,"briefTitle":12205,"status":139,"phases":12206,"primaryCompletion":216,"completion":216,"start":8235,"enrollment":16,"conditions":12207,"interventions":12209},"NCT00948103","The Interest of the Nitrous Oxide During Intravesical Injection of Botulinum Toxin A",[92],[12208],"Injection Site Vesicles",[12210,12183],"Nitrous Oxide",{"nctId":12212,"briefTitle":12213,"status":139,"phases":12214,"primaryCompletion":7896,"completion":12215,"start":12216,"enrollment":3149,"conditions":12217,"interventions":12221},"NCT02424773","Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients",[92],"2015-04","2012-11",[12218,12219,12220],"Acute Respiratory Failure","Immunocompromised Host","High Flow Oxygen Cannula",[12183],{"trials":12223,"activeCount":102},[],{"trials":12225,"activeCount":102},[],{"intervention":12227,"totalTrials":429,"cells":12228},"Methylprednisolone",{"EARLY_PHASE1":12229,"PHASE1":12231,"PHASE2":12233,"PHASE3":12247,"PHASE4":12274,"NA":12276},{"trials":12230,"activeCount":102},[],{"trials":12232,"activeCount":102},[],{"trials":12234,"activeCount":102},[12235],{"nctId":12236,"briefTitle":12237,"status":110,"phases":12238,"primaryCompletion":12239,"completion":12240,"start":12241,"enrollment":21,"conditions":12242,"interventions":12246},"NCT03760354","Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management",[91],"2020-02-15","2023-02-15","2019-02-15",[12243,12244,12245],"Caustic Esophageal Injury","Esophageal Stenosis","Pharyngeal Stenosis",[12227],{"trials":12248,"activeCount":102},[12249,12264],{"nctId":12250,"briefTitle":12251,"status":110,"phases":12252,"primaryCompletion":5939,"completion":12253,"start":12254,"enrollment":12255,"conditions":12256,"interventions":12263},"NCT02944045","Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients",[92],"2022-10","2017-02-15",222,[12257,12258,12259,12260,12261,12262],"Pneumocystis","Steroids","Immunocompromised Patient","Hematologic Neoplasms","Immunosuppressive Agents","Neoplasms",[12227],{"nctId":12265,"briefTitle":12266,"status":139,"phases":12267,"primaryCompletion":5900,"completion":10067,"start":12268,"enrollment":12269,"conditions":12270,"interventions":12272},"NCT00438087","Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery",[92],"2007-03",313,[12271],"Facial Palsy",[12273],"methylprednisolone",{"trials":12275,"activeCount":102},[],{"trials":12277,"activeCount":102},[],{"intervention":12279,"totalTrials":429,"cells":12280},"Hydroxychloroquine",{"EARLY_PHASE1":12281,"PHASE1":12283,"PHASE2":12285,"PHASE3":12287,"PHASE4":12321,"NA":12323},{"trials":12282,"activeCount":102},[],{"trials":12284,"activeCount":102},[],{"trials":12286,"activeCount":102},[],{"trials":12288,"activeCount":102},[12289,12301,12309],{"nctId":12290,"briefTitle":12291,"status":139,"phases":12292,"primaryCompletion":12293,"completion":12293,"start":12294,"enrollment":4204,"conditions":12295,"interventions":12297},"NCT04344379","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus",[92],"2020-06-18","2020-04-17",[12296],"SARS-CoV-2 Infection",[12298,12299,12300],"hydroxychloroquine","azithromycin","hydroxychloroquine placebo",{"nctId":12302,"briefTitle":12303,"status":139,"phases":12304,"primaryCompletion":1402,"completion":12305,"start":5183,"enrollment":1277,"conditions":12306,"interventions":12308},"NCT00632866","Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome",[92],"2012-05",[12307],"Primary Sjögren's Syndrome",[12279],{"nctId":12310,"briefTitle":12311,"status":936,"phases":12312,"primaryCompletion":12313,"completion":12314,"start":12315,"enrollment":6268,"conditions":12316,"interventions":12318},"NCT04341870","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",[91,92],"2020-05-08","2020-08","2020-04-11",[12317,12296],"COVID19",[12319,12320,12279],"Sarilumab","Azithromycin",{"trials":12322,"activeCount":102},[],{"trials":12324,"activeCount":102},[],{"intervention":369,"totalTrials":429,"cells":12326},{"EARLY_PHASE1":12327,"PHASE1":12329,"PHASE2":12331,"PHASE3":12333,"PHASE4":12347,"NA":12349},{"trials":12328,"activeCount":102},[],{"trials":12330,"activeCount":102},[],{"trials":12332,"activeCount":102},[],{"trials":12334,"activeCount":102},[12335,12339,12343],{"nctId":360,"briefTitle":361,"status":139,"phases":12336,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":12337,"interventions":12338},[92],[367],[184,369],{"nctId":996,"briefTitle":997,"status":241,"phases":12340,"completion":999,"start":1000,"enrollment":1001,"conditions":12341,"interventions":12342},[92],[1003,1004,1005],[358,1007,369,251],{"nctId":382,"briefTitle":383,"status":139,"phases":12344,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":12345,"interventions":12346},[92],[390,335],[184,369],{"trials":12348,"activeCount":102},[],{"trials":12350,"activeCount":102},[],{"intervention":12352,"totalTrials":429,"cells":12353},"Vaccine",{"EARLY_PHASE1":12354,"PHASE1":12356,"PHASE2":12358,"PHASE3":12366,"PHASE4":12384,"NA":12386},{"trials":12355,"activeCount":102},[],{"trials":12357,"activeCount":102},[],{"trials":12359,"activeCount":102},[12360],{"nctId":12361,"briefTitle":12362,"status":139,"phases":12363,"primaryCompletion":301,"completion":5418,"start":1909,"enrollment":24,"conditions":12364,"interventions":12365},"NCT01072734","Auto-immunity in Lupus Patients After Influenza Vaccine",[91],[3006],[12352],{"trials":12367,"activeCount":102},[12368,12376],{"nctId":12369,"briefTitle":12370,"status":241,"phases":12371,"primaryCompletion":375,"completion":5183,"start":9881,"enrollment":12138,"conditions":12372,"interventions":12374},"NCT00647465","Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer",[92],[12373],"Influenza Infection",[12375],"vaccine",{"nctId":12377,"briefTitle":12378,"status":139,"phases":12379,"primaryCompletion":5163,"completion":12380,"start":1909,"enrollment":1119,"conditions":12381,"interventions":12382},"NCT01022749","Efficacy Safety Study of Flu Vaccine in Immunodepression Patients",[92],"2013-07",[1317],[12352,12383],"Vaccine anti-H1N1",{"trials":12385,"activeCount":102},[],{"trials":12387,"activeCount":102},[],{"intervention":1736,"totalTrials":163,"cells":12389},{"EARLY_PHASE1":12390,"PHASE1":12392,"PHASE2":12394,"PHASE3":12406,"PHASE4":12412,"NA":12414},{"trials":12391,"activeCount":102},[],{"trials":12393,"activeCount":102},[],{"trials":12395,"activeCount":102},[12396],{"nctId":12397,"briefTitle":12398,"status":110,"phases":12399,"primaryCompletion":11768,"completion":11768,"start":11641,"enrollment":1247,"conditions":12400,"interventions":12405},"NCT01168050","Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.",[91],[12401,12402,12403,12404],"Malignant Skin Melanoma T0","Stage III Melanoma","Stage IV Melanoma","Amplification",[1736],{"trials":12407,"activeCount":102},[12408],{"nctId":1727,"briefTitle":1728,"status":110,"phases":12409,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":12410,"interventions":12411},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":12413,"activeCount":102},[],{"trials":12415,"activeCount":102},[],{"intervention":1719,"totalTrials":163,"cells":12417},{"EARLY_PHASE1":12418,"PHASE1":12420,"PHASE2":12422,"PHASE3":12428,"PHASE4":12434,"NA":12436},{"trials":12419,"activeCount":102},[],{"trials":12421,"activeCount":102},[],{"trials":12423,"activeCount":102},[12424],{"nctId":1705,"briefTitle":1706,"status":139,"phases":12425,"primaryCompletion":1708,"completion":301,"start":1709,"enrollment":1710,"conditions":12426,"interventions":12427},[91],[1712,1713,1714,1715],[1717,1718,1719,1152],{"trials":12429,"activeCount":102},[12430],{"nctId":1727,"briefTitle":1728,"status":110,"phases":12431,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":12432,"interventions":12433},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":12435,"activeCount":102},[],{"trials":12437,"activeCount":102},[],{"intervention":12439,"totalTrials":163,"cells":12440},"Sennosides colonic preparation",{"EARLY_PHASE1":12441,"PHASE1":12443,"PHASE2":12445,"PHASE3":12447,"PHASE4":12476,"NA":12478},{"trials":12442,"activeCount":102},[],{"trials":12444,"activeCount":102},[],{"trials":12446,"activeCount":102},[],{"trials":12448,"activeCount":102},[12449,12464],{"nctId":12450,"briefTitle":12451,"status":139,"phases":12452,"primaryCompletion":12453,"completion":12454,"start":12455,"enrollment":12456,"conditions":12457,"interventions":12459},"NCT03491540","Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery",[92],"2023-10-23","2023-12-12","2018-09-03",414,[12458],"Rectal Cancer Surgery",[12439,12460,12461,12462,12463],"Oral Gentamycin","Oral Ornidazole","Oral Placebo Gentamycin","Oral Placebo Ornidazole",{"nctId":12465,"briefTitle":12466,"status":241,"phases":12467,"primaryCompletion":12468,"completion":2711,"start":12469,"enrollment":12470,"conditions":12471,"interventions":12473},"NCT03475680","Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery",[92],"2021-08-26","2018-08-08",193,[12472],"Colon Cancer",[12439,12460,12461,12474,12475],"Oral placebo Gentamycin","Oral placebo Ornidazole",{"trials":12477,"activeCount":102},[],{"trials":12479,"activeCount":102},[],{"intervention":12460,"totalTrials":163,"cells":12481},{"EARLY_PHASE1":12482,"PHASE1":12484,"PHASE2":12486,"PHASE3":12488,"PHASE4":12498,"NA":12500},{"trials":12483,"activeCount":102},[],{"trials":12485,"activeCount":102},[],{"trials":12487,"activeCount":102},[],{"trials":12489,"activeCount":102},[12490,12494],{"nctId":12450,"briefTitle":12451,"status":139,"phases":12491,"primaryCompletion":12453,"completion":12454,"start":12455,"enrollment":12456,"conditions":12492,"interventions":12493},[92],[12458],[12439,12460,12461,12462,12463],{"nctId":12465,"briefTitle":12466,"status":241,"phases":12495,"primaryCompletion":12468,"completion":2711,"start":12469,"enrollment":12470,"conditions":12496,"interventions":12497},[92],[12472],[12439,12460,12461,12474,12475],{"trials":12499,"activeCount":102},[],{"trials":12501,"activeCount":102},[],{"intervention":12461,"totalTrials":163,"cells":12503},{"EARLY_PHASE1":12504,"PHASE1":12506,"PHASE2":12508,"PHASE3":12510,"PHASE4":12520,"NA":12522},{"trials":12505,"activeCount":102},[],{"trials":12507,"activeCount":102},[],{"trials":12509,"activeCount":102},[],{"trials":12511,"activeCount":102},[12512,12516],{"nctId":12450,"briefTitle":12451,"status":139,"phases":12513,"primaryCompletion":12453,"completion":12454,"start":12455,"enrollment":12456,"conditions":12514,"interventions":12515},[92],[12458],[12439,12460,12461,12462,12463],{"nctId":12465,"briefTitle":12466,"status":241,"phases":12517,"primaryCompletion":12468,"completion":2711,"start":12469,"enrollment":12470,"conditions":12518,"interventions":12519},[92],[12472],[12439,12460,12461,12474,12475],{"trials":12521,"activeCount":102},[],{"trials":12523,"activeCount":102},[],{"intervention":12462,"totalTrials":163,"cells":12525},{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12530,"PHASE3":12532,"PHASE4":12542,"NA":12544},{"trials":12527,"activeCount":102},[],{"trials":12529,"activeCount":102},[],{"trials":12531,"activeCount":102},[],{"trials":12533,"activeCount":102},[12534,12538],{"nctId":12450,"briefTitle":12451,"status":139,"phases":12535,"primaryCompletion":12453,"completion":12454,"start":12455,"enrollment":12456,"conditions":12536,"interventions":12537},[92],[12458],[12439,12460,12461,12462,12463],{"nctId":12465,"briefTitle":12466,"status":241,"phases":12539,"primaryCompletion":12468,"completion":2711,"start":12469,"enrollment":12470,"conditions":12540,"interventions":12541},[92],[12472],[12439,12460,12461,12474,12475],{"trials":12543,"activeCount":102},[],{"trials":12545,"activeCount":102},[],{"intervention":12463,"totalTrials":163,"cells":12547},{"EARLY_PHASE1":12548,"PHASE1":12550,"PHASE2":12552,"PHASE3":12554,"PHASE4":12564,"NA":12566},{"trials":12549,"activeCount":102},[],{"trials":12551,"activeCount":102},[],{"trials":12553,"activeCount":102},[],{"trials":12555,"activeCount":102},[12556,12560],{"nctId":12450,"briefTitle":12451,"status":139,"phases":12557,"primaryCompletion":12453,"completion":12454,"start":12455,"enrollment":12456,"conditions":12558,"interventions":12559},[92],[12458],[12439,12460,12461,12462,12463],{"nctId":12465,"briefTitle":12466,"status":241,"phases":12561,"primaryCompletion":12468,"completion":2711,"start":12469,"enrollment":12470,"conditions":12562,"interventions":12563},[92],[12472],[12439,12460,12461,12474,12475],{"trials":12565,"activeCount":102},[],{"trials":12567,"activeCount":102},[],{"intervention":12569,"totalTrials":163,"cells":12570},"Baclofen",{"EARLY_PHASE1":12571,"PHASE1":12573,"PHASE2":12583,"PHASE3":12585,"PHASE4":12596,"NA":12598},{"trials":12572,"activeCount":102},[],{"trials":12574,"activeCount":102},[12575],{"nctId":12576,"briefTitle":12577,"status":139,"phases":12578,"primaryCompletion":10680,"completion":10680,"start":5900,"enrollment":12579,"conditions":12580,"interventions":12582},"NCT01095679","Baclofen and Hypoxia-induced Periodic Ventilation",[90],53,[12581],"CHEYNE Stokes Respiration",[12569],{"trials":12584,"activeCount":102},[],{"trials":12586,"activeCount":102},[12587],{"nctId":12588,"briefTitle":12589,"status":139,"phases":12590,"primaryCompletion":522,"completion":1050,"start":12591,"enrollment":12592,"conditions":12593,"interventions":12595},"NCT01604330","Baclofen for the Treatment of Alcohol Drinkers",[91,92],"2012-05-29",323,[12594],"Alcoholism",[12569],{"trials":12597,"activeCount":102},[],{"trials":12599,"activeCount":102},[],{"intervention":12601,"totalTrials":163,"cells":12602},"Terlipressin",{"EARLY_PHASE1":12603,"PHASE1":12605,"PHASE2":12607,"PHASE3":12609,"PHASE4":12630,"NA":12632},{"trials":12604,"activeCount":102},[],{"trials":12606,"activeCount":102},[],{"trials":12608,"activeCount":102},[],{"trials":12610,"activeCount":102},[12611,12623],{"nctId":12612,"briefTitle":12613,"status":139,"phases":12614,"primaryCompletion":12615,"completion":12616,"start":12617,"enrollment":12618,"conditions":12619,"interventions":12621},"NCT04961528","ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.",[92],"2025-12-28","2026-03-25","2022-03-27",315,[12620],"Hemoptysis",[12622,12601],"Tranexamic Acid 500 MG",{"nctId":12624,"briefTitle":12625,"status":139,"phases":12626,"primaryCompletion":8005,"completion":12215,"start":7866,"enrollment":12627,"conditions":12628,"interventions":12629},"NCT00986817","Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin",[92],82,[1500],[12601],{"trials":12631,"activeCount":102},[],{"trials":12633,"activeCount":102},[],{"intervention":12635,"totalTrials":163,"cells":12636},"saline",{"EARLY_PHASE1":12637,"PHASE1":12639,"PHASE2":12641,"PHASE3":12643,"PHASE4":12665,"NA":12667},{"trials":12638,"activeCount":102},[],{"trials":12640,"activeCount":102},[],{"trials":12642,"activeCount":102},[],{"trials":12644,"activeCount":102},[12645,12656],{"nctId":12646,"briefTitle":12647,"status":139,"phases":12648,"primaryCompletion":12649,"completion":12649,"start":12650,"enrollment":12651,"conditions":12652,"interventions":12654},"NCT02127437","Lanreotide In Polycystic Kidney Disease Study",[92],"2019-07-31","2014-09-19",159,[12653],"Autosomal Dominant Polycystic Kidney Disease (ADPKD",[12655,12635],"Lanreotide",{"nctId":12657,"briefTitle":12658,"status":139,"phases":12659,"primaryCompletion":10438,"completion":12660,"start":12661,"enrollment":303,"conditions":12662,"interventions":12663},"NCT03187626","Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis",[91,92],"2021-04-23","2018-11-29",[2090],[12664,12635],"botulinum toxin A",{"trials":12666,"activeCount":102},[],{"trials":12668,"activeCount":102},[],{"intervention":12670,"totalTrials":163,"cells":12671},"Nebulized placebo",{"EARLY_PHASE1":12672,"PHASE1":12674,"PHASE2":12676,"PHASE3":12678,"PHASE4":12704,"NA":12706},{"trials":12673,"activeCount":102},[],{"trials":12675,"activeCount":102},[],{"trials":12677,"activeCount":102},[],{"trials":12679,"activeCount":102},[12680,12692],{"nctId":12681,"briefTitle":12682,"status":241,"phases":12683,"primaryCompletion":12159,"completion":12684,"start":12685,"enrollment":1361,"conditions":12686,"interventions":12688},"NCT02906722","Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia",[92],"2018-06-19","2017-07-31",[12687],"Ventilator-associated Pneumonia",[12689,12690,12691,12670],"Intravenous colimycin","Intravenous placebo","Nebulized colimycin",{"nctId":12693,"briefTitle":12694,"status":5932,"phases":12695,"primaryCompletion":12696,"completion":1187,"start":12697,"enrollment":102,"conditions":12698,"interventions":12700},"NCT02782052","Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension",[92],"2018-10","2016-07",[12699],"Pulmonary Arterial Hypertension",[12701,12702,12703],"Nebulized ipratropium bromide","Nebulized combination ipratropium bromide with salbutamol","Nebulized Placebo",{"trials":12705,"activeCount":102},[],{"trials":12707,"activeCount":102},[],{"intervention":12709,"totalTrials":163,"cells":12710},"Riluzole",{"EARLY_PHASE1":12711,"PHASE1":12713,"PHASE2":12715,"PHASE3":12717,"PHASE4":12736,"NA":12738},{"trials":12712,"activeCount":102},[],{"trials":12714,"activeCount":102},[],{"trials":12716,"activeCount":102},[],{"trials":12718,"activeCount":102},[12719,12727],{"nctId":12720,"briefTitle":12721,"status":139,"phases":12722,"primaryCompletion":10680,"completion":216,"start":5682,"enrollment":12723,"conditions":12724,"interventions":12726},"NCT00774423","Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)",[91,92],141,[12725],"SMA",[12709],{"nctId":12728,"briefTitle":12729,"status":139,"phases":12730,"primaryCompletion":12731,"completion":12731,"start":12732,"enrollment":291,"conditions":12733,"interventions":12735},"NCT03347344","Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)",[92],"2020-12-14","2018-01-17",[12734],"Spinocerebellar Ataxia Type 2",[12709],{"trials":12737,"activeCount":102},[],{"trials":12739,"activeCount":102},[],{"intervention":12741,"totalTrials":163,"cells":12742},"Losartan",{"EARLY_PHASE1":12743,"PHASE1":12745,"PHASE2":12747,"PHASE3":12749,"PHASE4":12770,"NA":12772},{"trials":12744,"activeCount":102},[],{"trials":12746,"activeCount":102},[],{"trials":12748,"activeCount":102},[],{"trials":12750,"activeCount":102},[12751,12761],{"nctId":12752,"briefTitle":12753,"status":139,"phases":12754,"primaryCompletion":12755,"completion":12756,"start":12757,"enrollment":1108,"conditions":12758,"interventions":12760},"NCT01805453","Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma",[92],"2015-01-15","2017-05-15","2013-03-29",[12759],"Newly-diagnosed Glioblastoma",[12741],{"nctId":12762,"briefTitle":12763,"status":241,"phases":12764,"primaryCompletion":12765,"completion":8413,"start":8235,"enrollment":12766,"conditions":12767,"interventions":12769},"NCT00763893","Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome",[92],"2014-01",303,[12768],"Marfan Syndrome",[12741],{"trials":12771,"activeCount":102},[],{"trials":12773,"activeCount":102},[],{"intervention":12775,"totalTrials":163,"cells":12776},"pentoxifylline",{"EARLY_PHASE1":12777,"PHASE1":12779,"PHASE2":12781,"PHASE3":12783,"PHASE4":12810,"NA":12812},{"trials":12778,"activeCount":102},[],{"trials":12780,"activeCount":102},[],{"trials":12782,"activeCount":102},[],{"trials":12784,"activeCount":102},[12785,12794],{"nctId":12786,"briefTitle":12787,"status":139,"phases":12788,"primaryCompletion":498,"completion":498,"start":12789,"enrollment":12790,"conditions":12791,"interventions":12793},"NCT00162552","Clinical Trial of Pentoxifylline in Patient With Cirrhosis",[92],"2004-08",342,[1500,12792],"Liver Failure",[12775],{"nctId":12795,"briefTitle":12796,"status":139,"phases":12797,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":12801,"interventions":12803},"NCT01291433","Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy",[92],"2017-05","2017-10",59,[12802],"Radiation Induced Brachial Plexopathy",[12804,12805,12806,12807,12808,12809],"Pentoxifylline placebo","Pentoxifylline","Tocopherol acetate","Clodronic Acid","Tocopherol placebo","Clodronate placebo",{"trials":12811,"activeCount":102},[],{"trials":12813,"activeCount":102},[],{"intervention":12815,"totalTrials":163,"cells":12816},"Bezafibrate",{"EARLY_PHASE1":12817,"PHASE1":12819,"PHASE2":12821,"PHASE3":12823,"PHASE4":12842,"NA":12844},{"trials":12818,"activeCount":102},[],{"trials":12820,"activeCount":102},[],{"trials":12822,"activeCount":102},[],{"trials":12824,"activeCount":102},[12825,12834],{"nctId":12826,"briefTitle":12827,"status":139,"phases":12828,"primaryCompletion":12829,"completion":12829,"start":12830,"enrollment":3149,"conditions":12831,"interventions":12833},"NCT01654731","Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis",[92],"2016-12-31","2012-10-15",[12832],"PBC",[12815],{"nctId":12835,"briefTitle":12836,"status":110,"phases":12837,"completion":1588,"start":11813,"enrollment":268,"conditions":12838,"interventions":12840},"NCT00336167","Bezafibrate Trial in CPT2 Deficiency",[92],[12839],"Carnitine Palmitoyl Transferase 2 Deficiency",[12841],"bezafibrate",{"trials":12843,"activeCount":102},[],{"trials":12845,"activeCount":102},[],{"intervention":12319,"totalTrials":163,"cells":12847},{"EARLY_PHASE1":12848,"PHASE1":12850,"PHASE2":12852,"PHASE3":12854,"PHASE4":12870,"NA":12872},{"trials":12849,"activeCount":102},[],{"trials":12851,"activeCount":102},[],{"trials":12853,"activeCount":102},[],{"trials":12855,"activeCount":102},[12856,12866],{"nctId":12857,"briefTitle":12858,"status":139,"phases":12859,"primaryCompletion":12860,"completion":12861,"start":12862,"enrollment":12863,"conditions":12864,"interventions":12865},"NCT04324073","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI",[91,92],"2020-04-21","2020-09-24","2020-03-27",239,[1121],[12319],{"nctId":12310,"briefTitle":12311,"status":936,"phases":12867,"primaryCompletion":12313,"completion":12314,"start":12315,"enrollment":6268,"conditions":12868,"interventions":12869},[91,92],[12317,12296],[12319,12320,12279],{"trials":12871,"activeCount":102},[],{"trials":12873,"activeCount":102},[],{"intervention":1717,"totalTrials":163,"cells":12875},{"EARLY_PHASE1":12876,"PHASE1":12878,"PHASE2":12880,"PHASE3":12886,"PHASE4":12892,"NA":12894},{"trials":12877,"activeCount":102},[],{"trials":12879,"activeCount":102},[],{"trials":12881,"activeCount":102},[12882],{"nctId":1705,"briefTitle":1706,"status":139,"phases":12883,"primaryCompletion":1708,"completion":301,"start":1709,"enrollment":1710,"conditions":12884,"interventions":12885},[91],[1712,1713,1714,1715],[1717,1718,1719,1152],{"trials":12887,"activeCount":102},[12888],{"nctId":371,"briefTitle":372,"status":139,"phases":12889,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":12890,"interventions":12891},[92],[378],[184,380],{"trials":12893,"activeCount":102},[],{"trials":12895,"activeCount":102},[],{"intervention":12897,"totalTrials":163,"cells":12898},"CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi\u002FGSK",{"EARLY_PHASE1":12899,"PHASE1":12901,"PHASE2":12903,"PHASE3":12905,"PHASE4":12928,"NA":12930},{"trials":12900,"activeCount":102},[],{"trials":12902,"activeCount":102},[],{"trials":12904,"activeCount":102},[],{"trials":12906,"activeCount":102},[12907,12919],{"nctId":12908,"briefTitle":12909,"status":110,"phases":12910,"primaryCompletion":12911,"completion":12911,"start":12912,"enrollment":12913,"conditions":12914,"interventions":12916},"NCT05124171","Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP\u002FGSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination",[92],"2022-12","2021-12-08",247,[15,12915],"Vaccine Reaction",[12917,12918,12897],"BNT162b2","CoV2 preS dTM adjuvanted vaccine (D614), Sanofi\u002FGSK",{"nctId":12920,"briefTitle":12921,"status":110,"phases":12922,"primaryCompletion":12923,"completion":1097,"start":9049,"enrollment":1039,"conditions":12924,"interventions":12926},"NCT05405283","Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi \u002FGSK B.1.351 Adjuvanted Vaccine in Adults",[92],"2022-07-15",[12925],"COVID-19 Vaccines",[12927,12897],"2nd booster with Comirnaty®",{"trials":12929,"activeCount":102},[],{"trials":12931,"activeCount":102},[],{"intervention":12933,"totalTrials":163,"cells":12934},"Botulinum Toxin A",{"EARLY_PHASE1":12935,"PHASE1":12937,"PHASE2":12939,"PHASE3":12949,"PHASE4":12955,"NA":12957},{"trials":12936,"activeCount":102},[],{"trials":12938,"activeCount":102},[],{"trials":12940,"activeCount":102},[12941],{"nctId":12942,"briefTitle":12943,"status":139,"phases":12944,"primaryCompletion":10260,"completion":10260,"start":12945,"enrollment":1001,"conditions":12946,"interventions":12948},"NCT00231491","Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.",[91],"2005-11",[12947],"Overactive Bladder",[12933],{"trials":12950,"activeCount":102},[12951],{"nctId":12657,"briefTitle":12658,"status":139,"phases":12952,"primaryCompletion":10438,"completion":12660,"start":12661,"enrollment":303,"conditions":12953,"interventions":12954},[91,92],[2090],[12664,12635],{"trials":12956,"activeCount":102},[],{"trials":12958,"activeCount":102},[],{"intervention":12960,"totalTrials":180,"cells":12961},"erythomycin",{"EARLY_PHASE1":12962,"PHASE1":12964,"PHASE2":12966,"PHASE3":12968,"PHASE4":12978,"NA":12980},{"trials":12963,"activeCount":102},[],{"trials":12965,"activeCount":102},[],{"trials":12967,"activeCount":102},[],{"trials":12969,"activeCount":102},[12970],{"nctId":12971,"briefTitle":12972,"status":139,"phases":12973,"primaryCompletion":12974,"completion":12974,"start":5196,"enrollment":8350,"conditions":12975,"interventions":12977},"NCT00259220","HDUPE 2004: Gastro-Oesophageal Haemorrhage in Emergency : Gastric Préparation to Endoscopy",[92],"2008-08",[12976],"Upper Gastrointestinal Bleeding",[12960],{"trials":12979,"activeCount":102},[],{"trials":12981,"activeCount":102},[],{"intervention":12983,"totalTrials":180,"cells":12984},"1: Naproxen",{"EARLY_PHASE1":12985,"PHASE1":12987,"PHASE2":12989,"PHASE3":12991,"PHASE4":13002,"NA":13004},{"trials":12986,"activeCount":102},[],{"trials":12988,"activeCount":102},[],{"trials":12990,"activeCount":102},[],{"trials":12992,"activeCount":102},[12993],{"nctId":12994,"briefTitle":12995,"status":241,"phases":12996,"primaryCompletion":12997,"completion":12997,"start":12998,"enrollment":21,"conditions":12999,"interventions":13000},"NCT04325633","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection",[92],"2020-12-15","2020-04-24",[15],[12983,13001],"2: Standard of care",{"trials":13003,"activeCount":102},[],{"trials":13005,"activeCount":102},[],{"intervention":13001,"totalTrials":180,"cells":13007},{"EARLY_PHASE1":13008,"PHASE1":13010,"PHASE2":13012,"PHASE3":13014,"PHASE4":13020,"NA":13022},{"trials":13009,"activeCount":102},[],{"trials":13011,"activeCount":102},[],{"trials":13013,"activeCount":102},[],{"trials":13015,"activeCount":102},[13016],{"nctId":12994,"briefTitle":12995,"status":241,"phases":13017,"primaryCompletion":12997,"completion":12997,"start":12998,"enrollment":21,"conditions":13018,"interventions":13019},[92],[15],[12983,13001],{"trials":13021,"activeCount":102},[],{"trials":13023,"activeCount":102},[],{"intervention":13025,"totalTrials":180,"cells":13026},"Prevenar® and Pneumo23®",{"EARLY_PHASE1":13027,"PHASE1":13029,"PHASE2":13031,"PHASE3":13033,"PHASE4":13044,"NA":13046},{"trials":13028,"activeCount":102},[],{"trials":13030,"activeCount":102},[],{"trials":13032,"activeCount":102},[],{"trials":13034,"activeCount":102},[13035],{"nctId":13036,"briefTitle":13037,"status":139,"phases":13038,"primaryCompletion":8413,"completion":1509,"start":13039,"enrollment":13040,"conditions":13041,"interventions":13043},"NCT00611663","Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus",[91,92],"2008-05",47,[13042],"Lupus Erythematosus, Systemic",[13025],{"trials":13045,"activeCount":102},[],{"trials":13047,"activeCount":102},[],{"intervention":13049,"totalTrials":180,"cells":13050},"Supemtek®",{"EARLY_PHASE1":13051,"PHASE1":13053,"PHASE2":13055,"PHASE3":13057,"PHASE4":13070,"NA":13072},{"trials":13052,"activeCount":102},[],{"trials":13054,"activeCount":102},[],{"trials":13056,"activeCount":102},[],{"trials":13058,"activeCount":102},[13059],{"nctId":13060,"briefTitle":13061,"status":139,"phases":13062,"primaryCompletion":6993,"completion":13063,"start":13064,"enrollment":5491,"conditions":13065,"interventions":13068},"NCT05409612","Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients",[92],"2023-10-03","2022-11-07",[13066,13067],"Morbid Obesity","Severe Obesity",[13049,13069],"Vaxigriptetra®",{"trials":13071,"activeCount":102},[],{"trials":13073,"activeCount":102},[],{"intervention":13069,"totalTrials":180,"cells":13075},{"EARLY_PHASE1":13076,"PHASE1":13078,"PHASE2":13080,"PHASE3":13082,"PHASE4":13088,"NA":13090},{"trials":13077,"activeCount":102},[],{"trials":13079,"activeCount":102},[],{"trials":13081,"activeCount":102},[],{"trials":13083,"activeCount":102},[13084],{"nctId":13060,"briefTitle":13061,"status":139,"phases":13085,"primaryCompletion":6993,"completion":13063,"start":13064,"enrollment":5491,"conditions":13086,"interventions":13087},[92],[13066,13067],[13049,13069],{"trials":13089,"activeCount":102},[],{"trials":13091,"activeCount":102},[],{"intervention":1738,"totalTrials":180,"cells":13093},{"EARLY_PHASE1":13094,"PHASE1":13096,"PHASE2":13098,"PHASE3":13100,"PHASE4":13106,"NA":13108},{"trials":13095,"activeCount":102},[],{"trials":13097,"activeCount":102},[],{"trials":13099,"activeCount":102},[],{"trials":13101,"activeCount":102},[13102],{"nctId":1727,"briefTitle":1728,"status":110,"phases":13103,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":13104,"interventions":13105},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":13107,"activeCount":102},[],{"trials":13109,"activeCount":102},[],{"intervention":1739,"totalTrials":180,"cells":13111},{"EARLY_PHASE1":13112,"PHASE1":13114,"PHASE2":13116,"PHASE3":13118,"PHASE4":13124,"NA":13126},{"trials":13113,"activeCount":102},[],{"trials":13115,"activeCount":102},[],{"trials":13117,"activeCount":102},[],{"trials":13119,"activeCount":102},[13120],{"nctId":1727,"briefTitle":1728,"status":110,"phases":13121,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":13122,"interventions":13123},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":13125,"activeCount":102},[],{"trials":13127,"activeCount":102},[],{"intervention":1740,"totalTrials":180,"cells":13129},{"EARLY_PHASE1":13130,"PHASE1":13132,"PHASE2":13134,"PHASE3":13136,"PHASE4":13142,"NA":13144},{"trials":13131,"activeCount":102},[],{"trials":13133,"activeCount":102},[],{"trials":13135,"activeCount":102},[],{"trials":13137,"activeCount":102},[13138],{"nctId":1727,"briefTitle":1728,"status":110,"phases":13139,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":13140,"interventions":13141},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":13143,"activeCount":102},[],{"trials":13145,"activeCount":102},[],{"intervention":1741,"totalTrials":180,"cells":13147},{"EARLY_PHASE1":13148,"PHASE1":13150,"PHASE2":13152,"PHASE3":13154,"PHASE4":13160,"NA":13162},{"trials":13149,"activeCount":102},[],{"trials":13151,"activeCount":102},[],{"trials":13153,"activeCount":102},[],{"trials":13155,"activeCount":102},[13156],{"nctId":1727,"briefTitle":1728,"status":110,"phases":13157,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":13158,"interventions":13159},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":13161,"activeCount":102},[],{"trials":13163,"activeCount":102},[],{"intervention":1742,"totalTrials":180,"cells":13165},{"EARLY_PHASE1":13166,"PHASE1":13168,"PHASE2":13170,"PHASE3":13172,"PHASE4":13178,"NA":13180},{"trials":13167,"activeCount":102},[],{"trials":13169,"activeCount":102},[],{"trials":13171,"activeCount":102},[],{"trials":13173,"activeCount":102},[13174],{"nctId":1727,"briefTitle":1728,"status":110,"phases":13175,"primaryCompletion":1730,"completion":1731,"start":1509,"enrollment":1732,"conditions":13176,"interventions":13177},[92],[1734],[1736,1737,1738,1739,1740,1152,1719,1741,1742],{"trials":13179,"activeCount":102},[],{"trials":13181,"activeCount":102},[],{"intervention":13183,"totalTrials":180,"cells":13184},"Radiotherapy",{"EARLY_PHASE1":13185,"PHASE1":13187,"PHASE2":13189,"PHASE3":13191,"PHASE4":13201,"NA":13203},{"trials":13186,"activeCount":102},[],{"trials":13188,"activeCount":102},[],{"trials":13190,"activeCount":102},[],{"trials":13192,"activeCount":102},[13193],{"nctId":13194,"briefTitle":13195,"status":139,"phases":13196,"start":13197,"conditions":13198,"interventions":13200},"NCT00430911","Radiotherapy for Malignant Astrocytomas in the Elderly",[92],"2001-02",[5644,13199,5643],"Anaplastic Astrocytoma",[13183],{"trials":13202,"activeCount":102},[],{"trials":13204,"activeCount":102},[],{"intervention":12099,"totalTrials":180,"cells":13206},{"EARLY_PHASE1":13207,"PHASE1":13209,"PHASE2":13211,"PHASE3":13213,"PHASE4":13219,"NA":13221},{"trials":13208,"activeCount":102},[],{"trials":13210,"activeCount":102},[],{"trials":13212,"activeCount":102},[],{"trials":13214,"activeCount":102},[13215],{"nctId":12090,"briefTitle":12091,"status":139,"phases":13216,"primaryCompletion":12093,"completion":12094,"start":12093,"enrollment":323,"conditions":13217,"interventions":13218},[92],[12096],[12098,12099],{"trials":13220,"activeCount":102},[],{"trials":13222,"activeCount":102},[],{"intervention":13224,"totalTrials":180,"cells":13225},"flowable composite",{"EARLY_PHASE1":13226,"PHASE1":13228,"PHASE2":13230,"PHASE3":13232,"PHASE4":13242,"NA":13244},{"trials":13227,"activeCount":102},[],{"trials":13229,"activeCount":102},[],{"trials":13231,"activeCount":102},[],{"trials":13233,"activeCount":102},[13234],{"nctId":13235,"briefTitle":13236,"status":110,"phases":13237,"primaryCompletion":13238,"completion":4458,"start":1138,"enrollment":303,"conditions":13239,"interventions":13241},"NCT04872907","Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT",[92],"2025-01-01",[13240],"X-linked Hypophosphatemia (XLH)",[13224],{"trials":13243,"activeCount":102},[],{"trials":13245,"activeCount":102},[],{"intervention":13247,"totalTrials":180,"cells":13248},"Warfarin",{"EARLY_PHASE1":13249,"PHASE1":13251,"PHASE2":13253,"PHASE3":13255,"PHASE4":13270,"NA":13272},{"trials":13250,"activeCount":102},[],{"trials":13252,"activeCount":102},[],{"trials":13254,"activeCount":102},[],{"trials":13256,"activeCount":102},[13257],{"nctId":13258,"briefTitle":13259,"status":139,"phases":13260,"primaryCompletion":13261,"completion":13262,"start":13263,"enrollment":4590,"conditions":13264,"interventions":13268},"NCT00235248","Aortic Arch Related Cerebral Hazard Trial (ARCH)",[92],"2010-12","2012-07","2002-02",[13265,13266,13267],"Brain Infarction","Transient Ischemic Attack","Embolism",[13247,13269],"Clopidogrel-aspirin",{"trials":13271,"activeCount":102},[],{"trials":13273,"activeCount":102},[],{"intervention":13269,"totalTrials":180,"cells":13275},{"EARLY_PHASE1":13276,"PHASE1":13278,"PHASE2":13280,"PHASE3":13282,"PHASE4":13288,"NA":13290},{"trials":13277,"activeCount":102},[],{"trials":13279,"activeCount":102},[],{"trials":13281,"activeCount":102},[],{"trials":13283,"activeCount":102},[13284],{"nctId":13258,"briefTitle":13259,"status":139,"phases":13285,"primaryCompletion":13261,"completion":13262,"start":13263,"enrollment":4590,"conditions":13286,"interventions":13287},[92],[13265,13266,13267],[13247,13269],{"trials":13289,"activeCount":102},[],{"trials":13291,"activeCount":102},[],{"intervention":13293,"totalTrials":180,"cells":13294},"Acide Zoledronique",{"EARLY_PHASE1":13295,"PHASE1":13297,"PHASE2":13299,"PHASE3":13301,"PHASE4":13313,"NA":13315},{"trials":13296,"activeCount":102},[],{"trials":13298,"activeCount":102},[],{"trials":13300,"activeCount":102},[],{"trials":13302,"activeCount":102},[13303],{"nctId":13304,"briefTitle":13305,"status":241,"phases":13306,"primaryCompletion":13307,"completion":13308,"start":13309,"enrollment":413,"conditions":13310,"interventions":13312},"NCT02739555","Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma",[92],"2018-04-20","2019-06-28","2016-06-23",[13311],"Osteoid Osteoma",[13293],{"trials":13314,"activeCount":102},[],{"trials":13316,"activeCount":102},[],{"intervention":5423,"totalTrials":180,"cells":13318},{"EARLY_PHASE1":13319,"PHASE1":13321,"PHASE2":13323,"PHASE3":13325,"PHASE4":13331,"NA":13333},{"trials":13320,"activeCount":102},[],{"trials":13322,"activeCount":102},[],{"trials":13324,"activeCount":102},[],{"trials":13326,"activeCount":102},[13327],{"nctId":5414,"briefTitle":5415,"status":139,"phases":13328,"primaryCompletion":5417,"completion":5162,"start":5418,"enrollment":5419,"conditions":13329,"interventions":13330},[92],[5421],[5423,5424,5425,5166],{"trials":13332,"activeCount":102},[],{"trials":13334,"activeCount":102},[],{"intervention":5424,"totalTrials":180,"cells":13336},{"EARLY_PHASE1":13337,"PHASE1":13339,"PHASE2":13341,"PHASE3":13343,"PHASE4":13349,"NA":13351},{"trials":13338,"activeCount":102},[],{"trials":13340,"activeCount":102},[],{"trials":13342,"activeCount":102},[],{"trials":13344,"activeCount":102},[13345],{"nctId":5414,"briefTitle":5415,"status":139,"phases":13346,"primaryCompletion":5417,"completion":5162,"start":5418,"enrollment":5419,"conditions":13347,"interventions":13348},[92],[5421],[5423,5424,5425,5166],{"trials":13350,"activeCount":102},[],{"trials":13352,"activeCount":102},[],{"intervention":5425,"totalTrials":180,"cells":13354},{"EARLY_PHASE1":13355,"PHASE1":13357,"PHASE2":13359,"PHASE3":13361,"PHASE4":13367,"NA":13369},{"trials":13356,"activeCount":102},[],{"trials":13358,"activeCount":102},[],{"trials":13360,"activeCount":102},[],{"trials":13362,"activeCount":102},[13363],{"nctId":5414,"briefTitle":5415,"status":139,"phases":13364,"primaryCompletion":5417,"completion":5162,"start":5418,"enrollment":5419,"conditions":13365,"interventions":13366},[92],[5421],[5423,5424,5425,5166],{"trials":13368,"activeCount":102},[],{"trials":13370,"activeCount":102},[],{"intervention":13372,"totalTrials":180,"cells":13373},"group1",{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13378,"PHASE3":13380,"PHASE4":13392,"NA":13394},{"trials":13375,"activeCount":102},[],{"trials":13377,"activeCount":102},[],{"trials":13379,"activeCount":102},[],{"trials":13381,"activeCount":102},[13382],{"nctId":13383,"briefTitle":13384,"status":139,"phases":13385,"primaryCompletion":10915,"completion":990,"start":13386,"enrollment":13387,"conditions":13388,"interventions":13390},"NCT00190242","Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients",[92],"2003-06",99,[13389],"HIV Infection",[13372,13391],"group2",{"trials":13393,"activeCount":102},[],{"trials":13395,"activeCount":102},[],{"intervention":13391,"totalTrials":180,"cells":13397},{"EARLY_PHASE1":13398,"PHASE1":13400,"PHASE2":13402,"PHASE3":13404,"PHASE4":13410,"NA":13412},{"trials":13399,"activeCount":102},[],{"trials":13401,"activeCount":102},[],{"trials":13403,"activeCount":102},[],{"trials":13405,"activeCount":102},[13406],{"nctId":13383,"briefTitle":13384,"status":139,"phases":13407,"primaryCompletion":10915,"completion":990,"start":13386,"enrollment":13387,"conditions":13408,"interventions":13409},[92],[13389],[13372,13391],{"trials":13411,"activeCount":102},[],{"trials":13413,"activeCount":102},[],{"intervention":13415,"totalTrials":180,"cells":13416},"Citrate",{"EARLY_PHASE1":13417,"PHASE1":13419,"PHASE2":13421,"PHASE3":13423,"PHASE4":13434,"NA":13436},{"trials":13418,"activeCount":102},[],{"trials":13420,"activeCount":102},[],{"trials":13422,"activeCount":102},[],{"trials":13424,"activeCount":102},[13425],{"nctId":13426,"briefTitle":13427,"status":139,"phases":13428,"primaryCompletion":13429,"completion":13429,"start":13430,"enrollment":2804,"conditions":13431,"interventions":13433},"NCT05814341","Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy",[92],"2024-12-15","2023-07-01",[13432],"Renal Replacement Therapy",[13415],{"trials":13435,"activeCount":102},[],{"trials":13437,"activeCount":102},[],{"intervention":13439,"totalTrials":180,"cells":13440},"proleukin",{"EARLY_PHASE1":13441,"PHASE1":13443,"PHASE2":13445,"PHASE3":13447,"PHASE4":13458,"NA":13460},{"trials":13442,"activeCount":102},[],{"trials":13444,"activeCount":102},[],{"trials":13446,"activeCount":102},[],{"trials":13448,"activeCount":102},[13449],{"nctId":13450,"briefTitle":13451,"status":110,"phases":13452,"primaryCompletion":13261,"completion":535,"start":13453,"enrollment":13454,"conditions":13455,"interventions":13457},"NCT00149162","Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2",[92],"2005-03",580,[13456],"Leukemia",[13439],{"trials":13459,"activeCount":102},[],{"trials":13461,"activeCount":102},[],{"intervention":13463,"totalTrials":180,"cells":13464},"botulinum toxin type A",{"EARLY_PHASE1":13465,"PHASE1":13467,"PHASE2":13469,"PHASE3":13471,"PHASE4":13484,"NA":13486},{"trials":13466,"activeCount":102},[],{"trials":13468,"activeCount":102},[],{"trials":13470,"activeCount":102},[],{"trials":13472,"activeCount":102},[13473],{"nctId":13474,"briefTitle":13475,"status":139,"phases":13476,"primaryCompletion":13477,"completion":13478,"start":12380,"enrollment":13479,"conditions":13480,"interventions":13482},"NCT01821573","Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients",[92],"2017-09-05","2019-05-23",36,[13481],"COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO",[13463,13483],"injection of NaCl 0.9%",{"trials":13485,"activeCount":102},[],{"trials":13487,"activeCount":102},[],{"intervention":13483,"totalTrials":180,"cells":13489},{"EARLY_PHASE1":13490,"PHASE1":13492,"PHASE2":13494,"PHASE3":13496,"PHASE4":13502,"NA":13504},{"trials":13491,"activeCount":102},[],{"trials":13493,"activeCount":102},[],{"trials":13495,"activeCount":102},[],{"trials":13497,"activeCount":102},[13498],{"nctId":13474,"briefTitle":13475,"status":139,"phases":13499,"primaryCompletion":13477,"completion":13478,"start":12380,"enrollment":13479,"conditions":13500,"interventions":13501},[92],[13481],[13463,13483],{"trials":13503,"activeCount":102},[],{"trials":13505,"activeCount":102},[],{"intervention":13507,"totalTrials":180,"cells":13508},"vancomycin monotherapy",{"EARLY_PHASE1":13509,"PHASE1":13511,"PHASE2":13513,"PHASE3":13515,"PHASE4":13526,"NA":13528},{"trials":13510,"activeCount":102},[],{"trials":13512,"activeCount":102},[],{"trials":13514,"activeCount":102},[],{"trials":13516,"activeCount":102},[13517],{"nctId":13518,"briefTitle":13519,"status":241,"phases":13520,"primaryCompletion":386,"completion":988,"start":12305,"enrollment":5575,"conditions":13521,"interventions":13524},"NCT01515020","Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia",[92],[13522,13523],"Nosocomial Infection","Healthcare-associated Infection",[13507,13525],"daptomycin monotherapy",{"trials":13527,"activeCount":102},[],{"trials":13529,"activeCount":102},[],{"intervention":13525,"totalTrials":180,"cells":13531},{"EARLY_PHASE1":13532,"PHASE1":13534,"PHASE2":13536,"PHASE3":13538,"PHASE4":13544,"NA":13546},{"trials":13533,"activeCount":102},[],{"trials":13535,"activeCount":102},[],{"trials":13537,"activeCount":102},[],{"trials":13539,"activeCount":102},[13540],{"nctId":13518,"briefTitle":13519,"status":241,"phases":13541,"primaryCompletion":386,"completion":988,"start":12305,"enrollment":5575,"conditions":13542,"interventions":13543},[92],[13522,13523],[13507,13525],{"trials":13545,"activeCount":102},[],{"trials":13547,"activeCount":102},[],{"intervention":13549,"totalTrials":180,"cells":13550},"EPOETINE ALPHA",{"EARLY_PHASE1":13551,"PHASE1":13553,"PHASE2":13555,"PHASE3":13557,"PHASE4":13567,"NA":13569},{"trials":13552,"activeCount":102},[],{"trials":13554,"activeCount":102},[],{"trials":13556,"activeCount":102},[],{"trials":13558,"activeCount":102},[13559],{"nctId":13560,"briefTitle":13561,"status":139,"phases":13562,"primaryCompletion":12380,"completion":13563,"start":990,"enrollment":632,"conditions":13564,"interventions":13566},"NCT00999583","High Dose of Erythropoietin Analogue After Cardiac Arrest",[92],"2014-05",[13565],"Comatose Survivors of Cardiac Arrest",[13549],{"trials":13568,"activeCount":102},[],{"trials":13570,"activeCount":102},[],{"intervention":13572,"totalTrials":180,"cells":13573},"3,4-Di-amino-Pyridine",{"EARLY_PHASE1":13574,"PHASE1":13576,"PHASE2":13578,"PHASE3":13580,"PHASE4":13590,"NA":13592},{"trials":13575,"activeCount":102},[],{"trials":13577,"activeCount":102},[],{"trials":13579,"activeCount":102},[],{"trials":13581,"activeCount":102},[13582],{"nctId":13583,"briefTitle":13584,"status":241,"phases":13585,"primaryCompletion":5900,"completion":10260,"start":13586,"enrollment":98,"conditions":13587,"interventions":13589},"NCT00701077","DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome",[92],"2008-09-12",[13588],"Brugada Syndrome",[13572],{"trials":13591,"activeCount":102},[],{"trials":13593,"activeCount":102},[],{"intervention":13595,"totalTrials":180,"cells":13596},"Rituximab, Methotrexate, Temozolomide",{"EARLY_PHASE1":13597,"PHASE1":13599,"PHASE2":13601,"PHASE3":13603,"PHASE4":13613,"NA":13615},{"trials":13598,"activeCount":102},[],{"trials":13600,"activeCount":102},[],{"trials":13602,"activeCount":102},[],{"trials":13604,"activeCount":102},[13605],{"nctId":13606,"briefTitle":13607,"status":110,"phases":13608,"primaryCompletion":13609,"completion":13609,"start":11593,"enrollment":13610,"conditions":13611,"interventions":13612},"NCT02313389","Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma",[92],"2023-04",428,[5221],[13595],{"trials":13614,"activeCount":102},[],{"trials":13616,"activeCount":102},[],{"intervention":13618,"totalTrials":180,"cells":13619},"Olanzapine",{"EARLY_PHASE1":13620,"PHASE1":13622,"PHASE2":13624,"PHASE3":13626,"PHASE4":13637,"NA":13639},{"trials":13621,"activeCount":102},[],{"trials":13623,"activeCount":102},[],{"trials":13625,"activeCount":102},[],{"trials":13627,"activeCount":102},[13628],{"nctId":13629,"briefTitle":13630,"status":139,"phases":13631,"primaryCompletion":13632,"completion":13632,"start":8082,"enrollment":4948,"conditions":13633,"interventions":13634},"NCT00632645","Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride",[92],"2017-04-28",[8034],[13618,13635,13636],"Xenazine","Tiapridal",{"trials":13638,"activeCount":102},[],{"trials":13640,"activeCount":102},[],{"intervention":13635,"totalTrials":180,"cells":13642},{"EARLY_PHASE1":13643,"PHASE1":13645,"PHASE2":13647,"PHASE3":13649,"PHASE4":13655,"NA":13657},{"trials":13644,"activeCount":102},[],{"trials":13646,"activeCount":102},[],{"trials":13648,"activeCount":102},[],{"trials":13650,"activeCount":102},[13651],{"nctId":13629,"briefTitle":13630,"status":139,"phases":13652,"primaryCompletion":13632,"completion":13632,"start":8082,"enrollment":4948,"conditions":13653,"interventions":13654},[92],[8034],[13618,13635,13636],{"trials":13656,"activeCount":102},[],{"trials":13658,"activeCount":102},[],{"intervention":13636,"totalTrials":180,"cells":13660},{"EARLY_PHASE1":13661,"PHASE1":13663,"PHASE2":13665,"PHASE3":13667,"PHASE4":13673,"NA":13675},{"trials":13662,"activeCount":102},[],{"trials":13664,"activeCount":102},[],{"trials":13666,"activeCount":102},[],{"trials":13668,"activeCount":102},[13669],{"nctId":13629,"briefTitle":13630,"status":139,"phases":13670,"primaryCompletion":13632,"completion":13632,"start":8082,"enrollment":4948,"conditions":13671,"interventions":13672},[92],[8034],[13618,13635,13636],{"trials":13674,"activeCount":102},[],{"trials":13676,"activeCount":102},[],{"intervention":13678,"totalTrials":180,"cells":13679},"Famotidine 400 mg\u002F50 mL",{"EARLY_PHASE1":13680,"PHASE1":13682,"PHASE2":13684,"PHASE3":13686,"PHASE4":13696,"NA":13698},{"trials":13681,"activeCount":102},[],{"trials":13683,"activeCount":102},[],{"trials":13685,"activeCount":102},[],{"trials":13687,"activeCount":102},[13688],{"nctId":13689,"briefTitle":13690,"status":139,"phases":13691,"primaryCompletion":13692,"completion":13692,"start":13693,"enrollment":21,"conditions":13694,"interventions":13695},"NCT05084521","Interest of Famotidine in Children With Sickle Cell Disease",[91,92],"2022-12-12","2022-01-12",[20],[13678],{"trials":13697,"activeCount":102},[],{"trials":13699,"activeCount":102},[],{"intervention":13701,"totalTrials":180,"cells":13702},"Additional angioplasty with paclitaxel-coated balloon",{"EARLY_PHASE1":13703,"PHASE1":13705,"PHASE2":13707,"PHASE3":13709,"PHASE4":13723,"NA":13725},{"trials":13704,"activeCount":102},[],{"trials":13706,"activeCount":102},[],{"trials":13708,"activeCount":102},[],{"trials":13710,"activeCount":102},[13711],{"nctId":13712,"briefTitle":13713,"status":139,"phases":13714,"primaryCompletion":13715,"completion":13716,"start":497,"enrollment":13717,"conditions":13718,"interventions":13721},"NCT02753998","Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula",[92],"2022-02","2022-03",145,[13719,13720],"Angioplasty","Stenosis of Arteriovenous Fistula",[13701,13722],"Additional angioplasty with placebo balloon",{"trials":13724,"activeCount":102},[],{"trials":13726,"activeCount":102},[],{"intervention":13722,"totalTrials":180,"cells":13728},{"EARLY_PHASE1":13729,"PHASE1":13731,"PHASE2":13733,"PHASE3":13735,"PHASE4":13741,"NA":13743},{"trials":13730,"activeCount":102},[],{"trials":13732,"activeCount":102},[],{"trials":13734,"activeCount":102},[],{"trials":13736,"activeCount":102},[13737],{"nctId":13712,"briefTitle":13713,"status":139,"phases":13738,"primaryCompletion":13715,"completion":13716,"start":497,"enrollment":13717,"conditions":13739,"interventions":13740},[92],[13719,13720],[13701,13722],{"trials":13742,"activeCount":102},[],{"trials":13744,"activeCount":102},[],{"intervention":13746,"totalTrials":180,"cells":13747},"3% Saline",{"EARLY_PHASE1":13748,"PHASE1":13750,"PHASE2":13752,"PHASE3":13754,"PHASE4":13766,"NA":13768},{"trials":13749,"activeCount":102},[],{"trials":13751,"activeCount":102},[],{"trials":13753,"activeCount":102},[],{"trials":13755,"activeCount":102},[13756],{"nctId":13757,"briefTitle":13758,"status":139,"phases":13759,"primaryCompletion":374,"completion":374,"start":13760,"enrollment":13761,"conditions":13762,"interventions":13764},"NCT01777347","Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis",[92],"2012-10",778,[13763],"Acute Viral Bronchiolitis",[13746,13765],"0.9% Normal Saline",{"trials":13767,"activeCount":102},[],{"trials":13769,"activeCount":102},[],{"intervention":13765,"totalTrials":180,"cells":13771},{"EARLY_PHASE1":13772,"PHASE1":13774,"PHASE2":13776,"PHASE3":13778,"PHASE4":13784,"NA":13786},{"trials":13773,"activeCount":102},[],{"trials":13775,"activeCount":102},[],{"trials":13777,"activeCount":102},[],{"trials":13779,"activeCount":102},[13780],{"nctId":13757,"briefTitle":13758,"status":139,"phases":13781,"primaryCompletion":374,"completion":374,"start":13760,"enrollment":13761,"conditions":13782,"interventions":13783},[92],[13763],[13746,13765],{"trials":13785,"activeCount":102},[],{"trials":13787,"activeCount":102},[],{"intervention":13789,"totalTrials":180,"cells":13790},"Aminoglycosides intervention",{"EARLY_PHASE1":13791,"PHASE1":13793,"PHASE2":13795,"PHASE3":13797,"PHASE4":13807,"NA":13809},{"trials":13792,"activeCount":102},[],{"trials":13794,"activeCount":102},[],{"trials":13796,"activeCount":102},[],{"trials":13798,"activeCount":102},[13799],{"nctId":13800,"briefTitle":13801,"status":110,"phases":13802,"primaryCompletion":61,"completion":61,"start":5803,"enrollment":7867,"conditions":13803,"interventions":13806},"NCT05443854","Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)",[92],[679,2462,5840,13804,13805],"Tumor","Allogeneic Stem Cell Transplantation",[13789],{"trials":13808,"activeCount":102},[],{"trials":13810,"activeCount":102},[],{"intervention":13812,"totalTrials":180,"cells":13813},"Privigen",{"EARLY_PHASE1":13814,"PHASE1":13816,"PHASE2":13818,"PHASE3":13820,"PHASE4":13830,"NA":13832},{"trials":13815,"activeCount":102},[],{"trials":13817,"activeCount":102},[],{"trials":13819,"activeCount":102},[],{"trials":13821,"activeCount":102},[13822],{"nctId":13823,"briefTitle":13824,"status":139,"phases":13825,"primaryCompletion":13826,"completion":13827,"start":1447,"enrollment":1225,"conditions":13828,"interventions":13829},"NCT02374736","Effect of Privigen Against Graft Loss",[92],"2018-03-09","2019-05-09",[7999],[13812],{"trials":13831,"activeCount":102},[],{"trials":13833,"activeCount":102},[],{"intervention":13835,"totalTrials":180,"cells":13836},"Folic acid",{"EARLY_PHASE1":13837,"PHASE1":13839,"PHASE2":13841,"PHASE3":13843,"PHASE4":13853,"NA":13855},{"trials":13838,"activeCount":102},[],{"trials":13840,"activeCount":102},[],{"trials":13842,"activeCount":102},[],{"trials":13844,"activeCount":102},[13845],{"nctId":13846,"briefTitle":13847,"status":139,"phases":13848,"primaryCompletion":1509,"completion":1509,"start":13849,"enrollment":13850,"conditions":13851,"interventions":13852},"NCT01407432","Impact of Folates in the Care of the Male Infertility",[92],"2011-11",162,[1065],[13835],{"trials":13854,"activeCount":102},[],{"trials":13856,"activeCount":102},[],{"intervention":13858,"totalTrials":180,"cells":13859},"Prophylactic anticoagulation",{"EARLY_PHASE1":13860,"PHASE1":13862,"PHASE2":13864,"PHASE3":13866,"PHASE4":13882,"NA":13884},{"trials":13861,"activeCount":102},[],{"trials":13863,"activeCount":102},[],{"trials":13865,"activeCount":102},[],{"trials":13867,"activeCount":102},[13868],{"nctId":13869,"briefTitle":13870,"status":139,"phases":13871,"primaryCompletion":13872,"completion":13873,"start":13874,"enrollment":13875,"conditions":13876,"interventions":13880},"NCT02580773","Therapeutic Anticoagulation Strategy for Acute Chest Syndrome",[92],"2021-02-04","2021-09-15","2016-12-16",198,[13877,13878,3301,13879],"Anemia","Sickle Cell","Low-Molecular-Weight Heparin",[13858,13881],"Curative anticoagulation",{"trials":13883,"activeCount":102},[],{"trials":13885,"activeCount":102},[],{"intervention":13881,"totalTrials":180,"cells":13887},{"EARLY_PHASE1":13888,"PHASE1":13890,"PHASE2":13892,"PHASE3":13894,"PHASE4":13900,"NA":13902},{"trials":13889,"activeCount":102},[],{"trials":13891,"activeCount":102},[],{"trials":13893,"activeCount":102},[],{"trials":13895,"activeCount":102},[13896],{"nctId":13869,"briefTitle":13870,"status":139,"phases":13897,"primaryCompletion":13872,"completion":13873,"start":13874,"enrollment":13875,"conditions":13898,"interventions":13899},[92],[13877,13878,3301,13879],[13858,13881],{"trials":13901,"activeCount":102},[],{"trials":13903,"activeCount":102},[],{"intervention":13905,"totalTrials":180,"cells":13906},"2: Usual practice + SYMBICORT RAPIHALER",{"EARLY_PHASE1":13907,"PHASE1":13909,"PHASE2":13911,"PHASE3":13913,"PHASE4":13924,"NA":13926},{"trials":13908,"activeCount":102},[],{"trials":13910,"activeCount":102},[],{"trials":13912,"activeCount":102},[],{"trials":13914,"activeCount":102},[13915],{"nctId":13916,"briefTitle":13917,"status":241,"phases":13918,"primaryCompletion":12054,"completion":12054,"start":13919,"enrollment":3993,"conditions":13920,"interventions":13923},"NCT04331054","Protective Role of Inhaled Steroids for Covid-19 Infection",[92],"2020-04-13",[13921,13922],"Covid-19 Infection","Hospitalization in Respiratory Disease Department",[13905],{"trials":13925,"activeCount":102},[],{"trials":13927,"activeCount":102},[],{"intervention":13929,"totalTrials":180,"cells":13930},"Diuretics : Furosemide",{"EARLY_PHASE1":13931,"PHASE1":13933,"PHASE2":13935,"PHASE3":13937,"PHASE4":13948,"NA":13950},{"trials":13932,"activeCount":102},[],{"trials":13934,"activeCount":102},[],{"trials":13936,"activeCount":102},[],{"trials":13938,"activeCount":102},[13939],{"nctId":13940,"briefTitle":13941,"status":110,"phases":13942,"primaryCompletion":13943,"completion":8138,"start":13944,"enrollment":8350,"conditions":13945,"interventions":13947},"NCT02268903","Diuretic Versus Placebo in Pulmonary Embolism",[92],"2018-04","2015-04-13",[13946],"Pulmonary Embolism With Right Ventricle Enlargement",[13929],{"trials":13949,"activeCount":102},[],{"trials":13951,"activeCount":102},[],{"intervention":13953,"totalTrials":180,"cells":13954},"Patch, Nicotine",{"EARLY_PHASE1":13955,"PHASE1":13957,"PHASE2":13959,"PHASE3":13961,"PHASE4":13973,"NA":13975},{"trials":13956,"activeCount":102},[],{"trials":13958,"activeCount":102},[],{"trials":13960,"activeCount":102},[],{"trials":13962,"activeCount":102},[13963],{"nctId":13964,"briefTitle":13965,"status":139,"phases":13966,"primaryCompletion":13967,"completion":13968,"start":13969,"enrollment":5113,"conditions":13970,"interventions":13971},"NCT04598594","Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients",[92],"2021-04-29","2021-06-20","2020-11-06",[26,9872],[13953,13972],"Patch, Placebo",{"trials":13974,"activeCount":102},[],{"trials":13976,"activeCount":102},[],{"intervention":13972,"totalTrials":180,"cells":13978},{"EARLY_PHASE1":13979,"PHASE1":13981,"PHASE2":13983,"PHASE3":13985,"PHASE4":13991,"NA":13993},{"trials":13980,"activeCount":102},[],{"trials":13982,"activeCount":102},[],{"trials":13984,"activeCount":102},[],{"trials":13986,"activeCount":102},[13987],{"nctId":13964,"briefTitle":13965,"status":139,"phases":13988,"primaryCompletion":13967,"completion":13968,"start":13969,"enrollment":5113,"conditions":13989,"interventions":13990},[92],[26,9872],[13953,13972],{"trials":13992,"activeCount":102},[],{"trials":13994,"activeCount":102},[],{"intervention":13996,"totalTrials":180,"cells":13997},"Corticosteroid",{"EARLY_PHASE1":13998,"PHASE1":14000,"PHASE2":14002,"PHASE3":14004,"PHASE4":14014,"NA":14016},{"trials":13999,"activeCount":102},[],{"trials":14001,"activeCount":102},[],{"trials":14003,"activeCount":102},[],{"trials":14005,"activeCount":102},[14006],{"nctId":14007,"briefTitle":14008,"status":139,"phases":14009,"primaryCompletion":14010,"completion":5934,"start":977,"enrollment":1277,"conditions":14011,"interventions":14013},"NCT02460588","Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis",[92],"2019-01",[14012],"Idiopathic Pulmonary Fibrosis",[358,13996],{"trials":14015,"activeCount":102},[],{"trials":14017,"activeCount":102},[],{"intervention":14019,"totalTrials":180,"cells":14020},"0.9% saline solution",{"EARLY_PHASE1":14021,"PHASE1":14023,"PHASE2":14025,"PHASE3":14027,"PHASE4":14040,"NA":14042},{"trials":14022,"activeCount":102},[],{"trials":14024,"activeCount":102},[],{"trials":14026,"activeCount":102},[],{"trials":14028,"activeCount":102},[14029],{"nctId":14030,"briefTitle":14031,"status":241,"phases":14032,"primaryCompletion":11618,"completion":12799,"start":1050,"enrollment":14033,"conditions":14034,"interventions":14036},"NCT02586961","Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.",[91,92],195,[1450,14035],"Bronchiolitis",[14019,14037,14038,14039],"oral betamethasone placebo","adrenaline","oral betamethasone",{"trials":14041,"activeCount":102},[],{"trials":14043,"activeCount":102},[],{"intervention":14037,"totalTrials":180,"cells":14045},{"EARLY_PHASE1":14046,"PHASE1":14048,"PHASE2":14050,"PHASE3":14052,"PHASE4":14058,"NA":14060},{"trials":14047,"activeCount":102},[],{"trials":14049,"activeCount":102},[],{"trials":14051,"activeCount":102},[],{"trials":14053,"activeCount":102},[14054],{"nctId":14030,"briefTitle":14031,"status":241,"phases":14055,"primaryCompletion":11618,"completion":12799,"start":1050,"enrollment":14033,"conditions":14056,"interventions":14057},[91,92],[1450,14035],[14019,14037,14038,14039],{"trials":14059,"activeCount":102},[],{"trials":14061,"activeCount":102},[],{"intervention":14038,"totalTrials":180,"cells":14063},{"EARLY_PHASE1":14064,"PHASE1":14066,"PHASE2":14068,"PHASE3":14070,"PHASE4":14076,"NA":14078},{"trials":14065,"activeCount":102},[],{"trials":14067,"activeCount":102},[],{"trials":14069,"activeCount":102},[],{"trials":14071,"activeCount":102},[14072],{"nctId":14030,"briefTitle":14031,"status":241,"phases":14073,"primaryCompletion":11618,"completion":12799,"start":1050,"enrollment":14033,"conditions":14074,"interventions":14075},[91,92],[1450,14035],[14019,14037,14038,14039],{"trials":14077,"activeCount":102},[],{"trials":14079,"activeCount":102},[],{"intervention":14039,"totalTrials":180,"cells":14081},{"EARLY_PHASE1":14082,"PHASE1":14084,"PHASE2":14086,"PHASE3":14088,"PHASE4":14094,"NA":14096},{"trials":14083,"activeCount":102},[],{"trials":14085,"activeCount":102},[],{"trials":14087,"activeCount":102},[],{"trials":14089,"activeCount":102},[14090],{"nctId":14030,"briefTitle":14031,"status":241,"phases":14091,"primaryCompletion":11618,"completion":12799,"start":1050,"enrollment":14033,"conditions":14092,"interventions":14093},[91,92],[1450,14035],[14019,14037,14038,14039],{"trials":14095,"activeCount":102},[],{"trials":14097,"activeCount":102},[],{"intervention":14099,"totalTrials":180,"cells":14100},"Levetiracetam\u002FClonazepam",{"EARLY_PHASE1":14101,"PHASE1":14103,"PHASE2":14105,"PHASE3":14107,"PHASE4":14119,"NA":14121},{"trials":14102,"activeCount":102},[],{"trials":14104,"activeCount":102},[],{"trials":14106,"activeCount":102},[],{"trials":14108,"activeCount":102},[14109],{"nctId":14110,"briefTitle":14111,"status":139,"phases":14112,"primaryCompletion":5641,"completion":1052,"start":14113,"enrollment":14114,"conditions":14115,"interventions":14117},"NCT01150331","Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus",[92],"2009-07",203,[14116],"Status; Epilepticus, Tonic-clonic",[14099,14118],"Clonazepam\u002FPlacebo levetiracetam IV",{"trials":14120,"activeCount":102},[],{"trials":14122,"activeCount":102},[],{"intervention":14118,"totalTrials":180,"cells":14124},{"EARLY_PHASE1":14125,"PHASE1":14127,"PHASE2":14129,"PHASE3":14131,"PHASE4":14137,"NA":14139},{"trials":14126,"activeCount":102},[],{"trials":14128,"activeCount":102},[],{"trials":14130,"activeCount":102},[],{"trials":14132,"activeCount":102},[14133],{"nctId":14110,"briefTitle":14111,"status":139,"phases":14134,"primaryCompletion":5641,"completion":1052,"start":14113,"enrollment":14114,"conditions":14135,"interventions":14136},[92],[14116],[14099,14118],{"trials":14138,"activeCount":102},[],{"trials":14140,"activeCount":102},[],{"intervention":14142,"totalTrials":180,"cells":14143},"ALTIM, cortivazol injections",{"EARLY_PHASE1":14144,"PHASE1":14146,"PHASE2":14148,"PHASE3":14150,"PHASE4":14162,"NA":14164},{"trials":14145,"activeCount":102},[],{"trials":14147,"activeCount":102},[],{"trials":14149,"activeCount":102},[],{"trials":14151,"activeCount":102},[14152],{"nctId":14153,"briefTitle":14154,"status":139,"phases":14155,"primaryCompletion":990,"completion":990,"start":5301,"enrollment":14156,"conditions":14157,"interventions":14159},"NCT00804895","Cluster Headache Cortivazol Injection (CHCI)",[91,92],43,[14158],"Cluster Headache",[14142,14160,14161],"PROAMP, subcutaneous serum physiological saline","Verapamil",{"trials":14163,"activeCount":102},[],{"trials":14165,"activeCount":102},[],{"intervention":14160,"totalTrials":180,"cells":14167},{"EARLY_PHASE1":14168,"PHASE1":14170,"PHASE2":14172,"PHASE3":14174,"PHASE4":14180,"NA":14182},{"trials":14169,"activeCount":102},[],{"trials":14171,"activeCount":102},[],{"trials":14173,"activeCount":102},[],{"trials":14175,"activeCount":102},[14176],{"nctId":14153,"briefTitle":14154,"status":139,"phases":14177,"primaryCompletion":990,"completion":990,"start":5301,"enrollment":14156,"conditions":14178,"interventions":14179},[91,92],[14158],[14142,14160,14161],{"trials":14181,"activeCount":102},[],{"trials":14183,"activeCount":102},[],{"intervention":14161,"totalTrials":180,"cells":14185},{"EARLY_PHASE1":14186,"PHASE1":14188,"PHASE2":14190,"PHASE3":14192,"PHASE4":14198,"NA":14200},{"trials":14187,"activeCount":102},[],{"trials":14189,"activeCount":102},[],{"trials":14191,"activeCount":102},[],{"trials":14193,"activeCount":102},[14194],{"nctId":14153,"briefTitle":14154,"status":139,"phases":14195,"primaryCompletion":990,"completion":990,"start":5301,"enrollment":14156,"conditions":14196,"interventions":14197},[91,92],[14158],[14142,14160,14161],{"trials":14199,"activeCount":102},[],{"trials":14201,"activeCount":102},[],{"intervention":14203,"totalTrials":180,"cells":14204},"Rivastigmine transdermal patch",{"EARLY_PHASE1":14205,"PHASE1":14207,"PHASE2":14209,"PHASE3":14211,"PHASE4":14221,"NA":14223},{"trials":14206,"activeCount":102},[],{"trials":14208,"activeCount":102},[],{"trials":14210,"activeCount":102},[],{"trials":14212,"activeCount":102},[14213],{"nctId":14214,"briefTitle":14215,"status":139,"phases":14216,"primaryCompletion":14217,"completion":8061,"start":1587,"enrollment":30,"conditions":14218,"interventions":14220},"NCT01487317","Rivastigmine in the Management of Delirium",[92],"2015-08",[14219],"Delirium",[14203],{"trials":14222,"activeCount":102},[],{"trials":14224,"activeCount":102},[],{"intervention":14226,"totalTrials":180,"cells":14227},"Methylphenidate",{"EARLY_PHASE1":14228,"PHASE1":14230,"PHASE2":14232,"PHASE3":14234,"PHASE4":14245,"NA":14247},{"trials":14229,"activeCount":102},[],{"trials":14231,"activeCount":102},[],{"trials":14233,"activeCount":102},[],{"trials":14235,"activeCount":102},[14236],{"nctId":14237,"briefTitle":14238,"status":241,"phases":14239,"primaryCompletion":14240,"completion":14240,"start":14241,"enrollment":429,"conditions":14242,"interventions":14244},"NCT03481959","Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity",[92],"2020-09-01","2019-05-07",[14243],"Attention Deficit Hyperactivity Disorder (ADHD)",[14226],{"trials":14246,"activeCount":102},[],{"trials":14248,"activeCount":102},[],{"intervention":1194,"totalTrials":180,"cells":14250},{"EARLY_PHASE1":14251,"PHASE1":14253,"PHASE2":14255,"PHASE3":14257,"PHASE4":14263,"NA":14265},{"trials":14252,"activeCount":102},[],{"trials":14254,"activeCount":102},[],{"trials":14256,"activeCount":102},[],{"trials":14258,"activeCount":102},[14259],{"nctId":1183,"briefTitle":1184,"status":139,"phases":14260,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":14261,"interventions":14262},[92],[1191],[1193,1194],{"trials":14264,"activeCount":102},[],{"trials":14266,"activeCount":102},[],{"intervention":14268,"totalTrials":180,"cells":14269},"Fluoro-L-thymidine-",{"EARLY_PHASE1":14270,"PHASE1":14272,"PHASE2":14274,"PHASE3":14276,"PHASE4":14284,"NA":14286},{"trials":14271,"activeCount":102},[],{"trials":14273,"activeCount":102},[],{"trials":14275,"activeCount":102},[],{"trials":14277,"activeCount":102},[14278],{"nctId":14279,"briefTitle":14280,"status":139,"phases":14281,"primaryCompletion":498,"completion":498,"start":422,"enrollment":303,"conditions":14282,"interventions":14283},"NCT00236275","PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer",[92],[29],[14268],{"trials":14285,"activeCount":102},[],{"trials":14287,"activeCount":102},[],{"intervention":14289,"totalTrials":180,"cells":14290},"oseltamivir + zanamivir",{"EARLY_PHASE1":14291,"PHASE1":14293,"PHASE2":14295,"PHASE3":14297,"PHASE4":14309,"NA":14311},{"trials":14292,"activeCount":102},[],{"trials":14294,"activeCount":102},[],{"trials":14296,"activeCount":102},[],{"trials":14298,"activeCount":102},[14299],{"nctId":14300,"briefTitle":14301,"status":241,"phases":14302,"primaryCompletion":7866,"completion":10940,"start":5301,"enrollment":14303,"conditions":14304,"interventions":14306},"NCT00799760","Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir",[92],541,[14305],"Gastric Influenza",[14289,14307,14308],"oseltamivir + zanamivir's placebo","oseltamivir's placebo + zanamivir",{"trials":14310,"activeCount":102},[],{"trials":14312,"activeCount":102},[],{"intervention":14307,"totalTrials":180,"cells":14314},{"EARLY_PHASE1":14315,"PHASE1":14317,"PHASE2":14319,"PHASE3":14321,"PHASE4":14327,"NA":14329},{"trials":14316,"activeCount":102},[],{"trials":14318,"activeCount":102},[],{"trials":14320,"activeCount":102},[],{"trials":14322,"activeCount":102},[14323],{"nctId":14300,"briefTitle":14301,"status":241,"phases":14324,"primaryCompletion":7866,"completion":10940,"start":5301,"enrollment":14303,"conditions":14325,"interventions":14326},[92],[14305],[14289,14307,14308],{"trials":14328,"activeCount":102},[],{"trials":14330,"activeCount":102},[],{"intervention":14308,"totalTrials":180,"cells":14332},{"EARLY_PHASE1":14333,"PHASE1":14335,"PHASE2":14337,"PHASE3":14339,"PHASE4":14345,"NA":14347},{"trials":14334,"activeCount":102},[],{"trials":14336,"activeCount":102},[],{"trials":14338,"activeCount":102},[],{"trials":14340,"activeCount":102},[14341],{"nctId":14300,"briefTitle":14301,"status":241,"phases":14342,"primaryCompletion":7866,"completion":10940,"start":5301,"enrollment":14303,"conditions":14343,"interventions":14344},[92],[14305],[14289,14307,14308],{"trials":14346,"activeCount":102},[],{"trials":14348,"activeCount":102},[],{"intervention":14350,"totalTrials":180,"cells":14351},"Ondansetron",{"EARLY_PHASE1":14352,"PHASE1":14354,"PHASE2":14356,"PHASE3":14358,"PHASE4":14368,"NA":14370},{"trials":14353,"activeCount":102},[],{"trials":14355,"activeCount":102},[],{"trials":14357,"activeCount":102},[],{"trials":14359,"activeCount":102},[14360],{"nctId":14361,"briefTitle":14362,"status":241,"phases":14363,"primaryCompletion":7960,"completion":7960,"start":12765,"enrollment":36,"conditions":14364,"interventions":14367},"NCT02028910","Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter",[92],[14365,14366],"Vomiting","Gastroenteritis",[14350],{"trials":14369,"activeCount":102},[],{"trials":14371,"activeCount":102},[],{"intervention":12622,"totalTrials":180,"cells":14373},{"EARLY_PHASE1":14374,"PHASE1":14376,"PHASE2":14378,"PHASE3":14380,"PHASE4":14386,"NA":14388},{"trials":14375,"activeCount":102},[],{"trials":14377,"activeCount":102},[],{"trials":14379,"activeCount":102},[],{"trials":14381,"activeCount":102},[14382],{"nctId":12612,"briefTitle":12613,"status":139,"phases":14383,"primaryCompletion":12615,"completion":12616,"start":12617,"enrollment":12618,"conditions":14384,"interventions":14385},[92],[12620],[12622,12601],{"trials":14387,"activeCount":102},[],{"trials":14389,"activeCount":102},[],{"intervention":1206,"totalTrials":180,"cells":14391},{"EARLY_PHASE1":14392,"PHASE1":14394,"PHASE2":14396,"PHASE3":14398,"PHASE4":14404,"NA":14406},{"trials":14393,"activeCount":102},[],{"trials":14395,"activeCount":102},[],{"trials":14397,"activeCount":102},[],{"trials":14399,"activeCount":102},[14400],{"nctId":1196,"briefTitle":1197,"status":139,"phases":14401,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":14402,"interventions":14403},[92],[1204],[1206,1207,1208,77],{"trials":14405,"activeCount":102},[],{"trials":14407,"activeCount":102},[],{"intervention":1208,"totalTrials":180,"cells":14409},{"EARLY_PHASE1":14410,"PHASE1":14412,"PHASE2":14414,"PHASE3":14416,"PHASE4":14422,"NA":14424},{"trials":14411,"activeCount":102},[],{"trials":14413,"activeCount":102},[],{"trials":14415,"activeCount":102},[],{"trials":14417,"activeCount":102},[14418],{"nctId":1196,"briefTitle":1197,"status":139,"phases":14419,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":14420,"interventions":14421},[92],[1204],[1206,1207,1208,77],{"trials":14423,"activeCount":102},[],{"trials":14425,"activeCount":102},[],{"intervention":14427,"totalTrials":180,"cells":14428},"Hydroxychloroquine and Azithromycin",{"EARLY_PHASE1":14429,"PHASE1":14431,"PHASE2":14433,"PHASE3":14435,"PHASE4":14444,"NA":14446},{"trials":14430,"activeCount":102},[],{"trials":14432,"activeCount":102},[],{"trials":14434,"activeCount":102},[],{"trials":14436,"activeCount":102},[14437],{"nctId":14438,"briefTitle":14439,"status":5932,"phases":14440,"primaryCompletion":12314,"completion":1129,"start":8214,"enrollment":102,"conditions":14441,"interventions":14443},"NCT04371406","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients",[92],[14442],"Covid-19",[14427],{"trials":14445,"activeCount":102},[],{"trials":14447,"activeCount":102},[],{"intervention":14449,"totalTrials":180,"cells":14450},"Melatonin 4 mg",{"EARLY_PHASE1":14451,"PHASE1":14453,"PHASE2":14455,"PHASE3":14457,"PHASE4":14469,"NA":14471},{"trials":14452,"activeCount":102},[],{"trials":14454,"activeCount":102},[],{"trials":14456,"activeCount":102},[],{"trials":14458,"activeCount":102},[14459],{"nctId":14460,"briefTitle":14461,"status":139,"phases":14462,"primaryCompletion":14463,"completion":14463,"start":14464,"enrollment":14465,"conditions":14466,"interventions":14468},"NCT04335968","Melatonin for Prevention of Postoperative Delirium After Lower Limb Fracture Surgery in Elderly Patients",[92],"2025-04-18","2021-01-23",357,[14467],"Orthopedic Surgery",[14449],{"trials":14470,"activeCount":102},[],{"trials":14472,"activeCount":102},[],{"intervention":14474,"totalTrials":180,"cells":14475},"CLIMASTON",{"EARLY_PHASE1":14476,"PHASE1":14478,"PHASE2":14480,"PHASE3":14482,"PHASE4":14493,"NA":14495},{"trials":14477,"activeCount":102},[],{"trials":14479,"activeCount":102},[],{"trials":14481,"activeCount":102},[],{"trials":14483,"activeCount":102},[14484],{"nctId":14485,"briefTitle":14486,"status":241,"phases":14487,"primaryCompletion":11813,"completion":2009,"start":14488,"enrollment":13387,"conditions":14489,"interventions":14491},"NCT00236301","Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers",[92],"2004-03",[14490],"Healthy Symptomatic Menopausal Women",[14474,14492],"17 Beta-estradiol",{"trials":14494,"activeCount":102},[],{"trials":14496,"activeCount":102},[],{"intervention":14492,"totalTrials":180,"cells":14498},{"EARLY_PHASE1":14499,"PHASE1":14501,"PHASE2":14503,"PHASE3":14505,"PHASE4":14511,"NA":14513},{"trials":14500,"activeCount":102},[],{"trials":14502,"activeCount":102},[],{"trials":14504,"activeCount":102},[],{"trials":14506,"activeCount":102},[14507],{"nctId":14485,"briefTitle":14486,"status":241,"phases":14508,"primaryCompletion":11813,"completion":2009,"start":14488,"enrollment":13387,"conditions":14509,"interventions":14510},[92],[14490],[14474,14492],{"trials":14512,"activeCount":102},[],{"trials":14514,"activeCount":102},[],{"intervention":14516,"totalTrials":180,"cells":14517},"Rosuvastatin",{"EARLY_PHASE1":14518,"PHASE1":14520,"PHASE2":14522,"PHASE3":14524,"PHASE4":14536,"NA":14538},{"trials":14519,"activeCount":102},[],{"trials":14521,"activeCount":102},[],{"trials":14523,"activeCount":102},[],{"trials":14525,"activeCount":102},[14526],{"nctId":14527,"briefTitle":14528,"status":139,"phases":14529,"primaryCompletion":14530,"completion":14530,"start":14531,"enrollment":14532,"conditions":14533,"interventions":14535},"NCT02117453","Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides",[92],"2019-11-07","2014-10-27",121,[14534],"ANCA-associated Primary Necrotizing Vasculitides",[14516],{"trials":14537,"activeCount":102},[],{"trials":14539,"activeCount":102},[],{"intervention":14541,"totalTrials":180,"cells":14542},"rivaroxaban",{"EARLY_PHASE1":14543,"PHASE1":14545,"PHASE2":14547,"PHASE3":14549,"PHASE4":14562,"NA":14564},{"trials":14544,"activeCount":102},[],{"trials":14546,"activeCount":102},[],{"trials":14548,"activeCount":102},[],{"trials":14550,"activeCount":102},[14551],{"nctId":14552,"briefTitle":14553,"status":139,"phases":14554,"primaryCompletion":14555,"completion":14555,"start":14556,"enrollment":12651,"conditions":14557,"interventions":14560},"NCT02746185","Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban",[92],"2018-04-25","2016-09",[14558,14559],"Neoplasm","Venous Thromboembolism",[14541,14561],"Low-molecular-weight heparin",{"trials":14563,"activeCount":102},[],{"trials":14565,"activeCount":102},[],{"intervention":14561,"totalTrials":180,"cells":14567},{"EARLY_PHASE1":14568,"PHASE1":14570,"PHASE2":14572,"PHASE3":14574,"PHASE4":14580,"NA":14582},{"trials":14569,"activeCount":102},[],{"trials":14571,"activeCount":102},[],{"trials":14573,"activeCount":102},[],{"trials":14575,"activeCount":102},[14576],{"nctId":14552,"briefTitle":14553,"status":139,"phases":14577,"primaryCompletion":14555,"completion":14555,"start":14556,"enrollment":12651,"conditions":14578,"interventions":14579},[92],[14558,14559],[14541,14561],{"trials":14581,"activeCount":102},[],{"trials":14583,"activeCount":102},[],{"intervention":14585,"totalTrials":180,"cells":14586},"Triptorelin (GnRHa) + Chemotherapy",{"EARLY_PHASE1":14587,"PHASE1":14589,"PHASE2":14591,"PHASE3":14593,"PHASE4":14607,"NA":14609},{"trials":14588,"activeCount":102},[],{"trials":14590,"activeCount":102},[],{"trials":14592,"activeCount":102},[],{"trials":14594,"activeCount":102},[14595],{"nctId":14596,"briefTitle":14597,"status":110,"phases":14598,"primaryCompletion":1127,"completion":1127,"start":14599,"enrollment":1384,"conditions":14600,"interventions":14606},"NCT02856048","Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer",[91,92],"2016-11-23",[9635,14601,14602,14603,14604,14605],"Toxicity Due to Chemotherapy","Sarcoma","Osteosarcoma","Lymphoma","Ewing Sarcoma",[14585],{"trials":14608,"activeCount":102},[],{"trials":14610,"activeCount":102},[],{"intervention":14612,"totalTrials":180,"cells":14613},"Pyrimethamine\u002FSulfadiazine",{"EARLY_PHASE1":14614,"PHASE1":14616,"PHASE2":14618,"PHASE3":14620,"PHASE4":14631,"NA":14633},{"trials":14615,"activeCount":102},[],{"trials":14617,"activeCount":102},[],{"trials":14619,"activeCount":102},[],{"trials":14621,"activeCount":102},[14622],{"nctId":14623,"briefTitle":14624,"status":139,"phases":14625,"primaryCompletion":988,"completion":1509,"start":10940,"enrollment":14626,"conditions":14627,"interventions":14629},"NCT01189448","Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy",[92],149,[14628],"Congenital Toxoplasmosis",[14612,14630],"Spiramycine",{"trials":14632,"activeCount":102},[],{"trials":14634,"activeCount":102},[],{"intervention":14630,"totalTrials":180,"cells":14636},{"EARLY_PHASE1":14637,"PHASE1":14639,"PHASE2":14641,"PHASE3":14643,"PHASE4":14649,"NA":14651},{"trials":14638,"activeCount":102},[],{"trials":14640,"activeCount":102},[],{"trials":14642,"activeCount":102},[],{"trials":14644,"activeCount":102},[14645],{"nctId":14623,"briefTitle":14624,"status":139,"phases":14646,"primaryCompletion":988,"completion":1509,"start":10940,"enrollment":14626,"conditions":14647,"interventions":14648},[92],[14628],[14612,14630],{"trials":14650,"activeCount":102},[],{"trials":14652,"activeCount":102},[],{"intervention":14654,"totalTrials":180,"cells":14655},"Ocrelizumab",{"EARLY_PHASE1":14656,"PHASE1":14658,"PHASE2":14660,"PHASE3":14662,"PHASE4":14672,"NA":14674},{"trials":14657,"activeCount":102},[],{"trials":14659,"activeCount":102},[],{"trials":14661,"activeCount":102},[],{"trials":14663,"activeCount":102},[14664],{"nctId":14665,"briefTitle":14666,"status":110,"phases":14667,"primaryCompletion":56,"completion":71,"start":14668,"enrollment":8268,"conditions":14669,"interventions":14671},"NCT03691077","Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714",[92],"2018-11-11",[6488,6272,14670],"Primary Progressive Multiple Sclerosis",[14654],{"trials":14673,"activeCount":102},[],{"trials":14675,"activeCount":102},[],{"intervention":14677,"totalTrials":180,"cells":14678},"immunoglobulin IV",{"EARLY_PHASE1":14679,"PHASE1":14681,"PHASE2":14683,"PHASE3":14685,"PHASE4":14695,"NA":14697},{"trials":14680,"activeCount":102},[],{"trials":14682,"activeCount":102},[],{"trials":14684,"activeCount":102},[],{"trials":14686,"activeCount":102},[14687],{"nctId":14688,"briefTitle":14689,"status":936,"phases":14690,"primaryCompletion":1530,"completion":14691,"start":14692,"enrollment":5804,"conditions":14693,"interventions":14694},"NCT03560011","Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome",[91,92],"2022-11-04","2019-04-03",[3088],[14677],{"trials":14696,"activeCount":102},[],{"trials":14698,"activeCount":102},[],{"intervention":14700,"totalTrials":180,"cells":14701},"Sulfate, Magnesium",{"EARLY_PHASE1":14702,"PHASE1":14704,"PHASE2":14706,"PHASE3":14708,"PHASE4":14718,"NA":14720},{"trials":14703,"activeCount":102},[],{"trials":14705,"activeCount":102},[],{"trials":14707,"activeCount":102},[],{"trials":14709,"activeCount":102},[14710],{"nctId":14711,"briefTitle":14712,"status":110,"phases":14713,"primaryCompletion":14714,"completion":14714,"start":14715,"enrollment":5772,"conditions":14716,"interventions":14717},"NCT03237819","Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care",[92],"2021-12-01","2018-05-27",[270],[14700],{"trials":14719,"activeCount":102},[],{"trials":14721,"activeCount":102},[],{"intervention":14723,"totalTrials":180,"cells":14724},"L-Carnitine",{"EARLY_PHASE1":14725,"PHASE1":14727,"PHASE2":14729,"PHASE3":14731,"PHASE4":14742,"NA":14744},{"trials":14726,"activeCount":102},[],{"trials":14728,"activeCount":102},[],{"trials":14730,"activeCount":102},[],{"trials":14732,"activeCount":102},[14733],{"nctId":14734,"briefTitle":14735,"status":139,"phases":14736,"primaryCompletion":14737,"completion":14737,"start":11813,"enrollment":2779,"conditions":14738,"interventions":14741},"NCT00322322","Early Administration of L-carnitine in Hemodialysis Patients",[92],"2010-06",[14739,14740],"Complication of Hemodialysis","Hyperthyroidism Treated or Under Control",[14723],{"trials":14743,"activeCount":102},[],{"trials":14745,"activeCount":102},[],{"intervention":12655,"totalTrials":180,"cells":14747},{"EARLY_PHASE1":14748,"PHASE1":14750,"PHASE2":14752,"PHASE3":14754,"PHASE4":14760,"NA":14762},{"trials":14749,"activeCount":102},[],{"trials":14751,"activeCount":102},[],{"trials":14753,"activeCount":102},[],{"trials":14755,"activeCount":102},[14756],{"nctId":12646,"briefTitle":12647,"status":139,"phases":14757,"primaryCompletion":12649,"completion":12649,"start":12650,"enrollment":12651,"conditions":14758,"interventions":14759},[92],[12653],[12655,12635],{"trials":14761,"activeCount":102},[],{"trials":14763,"activeCount":102},[],{"intervention":14765,"totalTrials":180,"cells":14766},"Tinzaparin sodium 100 UI\u002FKg\u002FOD for 12 weeks",{"EARLY_PHASE1":14767,"PHASE1":14769,"PHASE2":14771,"PHASE3":14773,"PHASE4":14785,"NA":14787},{"trials":14768,"activeCount":102},[],{"trials":14770,"activeCount":102},[],{"trials":14772,"activeCount":102},[],{"trials":14774,"activeCount":102},[14775],{"nctId":14776,"briefTitle":14777,"status":139,"phases":14778,"primaryCompletion":14779,"completion":14779,"start":421,"enrollment":14780,"conditions":14781,"interventions":14784},"NCT00475098","Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)",[92],"2016-08",553,[14782,14783],"Lung Cancer","Non Small Cell Lung Cancer",[14765],{"trials":14786,"activeCount":102},[],{"trials":14788,"activeCount":102},[],{"intervention":14790,"totalTrials":180,"cells":14791},"Xarelto",{"EARLY_PHASE1":14792,"PHASE1":14794,"PHASE2":14796,"PHASE3":14798,"PHASE4":14809,"NA":14811},{"trials":14793,"activeCount":102},[],{"trials":14795,"activeCount":102},[],{"trials":14797,"activeCount":102},[],{"trials":14799,"activeCount":102},[14800],{"nctId":14801,"briefTitle":14802,"status":139,"phases":14803,"primaryCompletion":14804,"completion":14804,"start":11593,"enrollment":1053,"conditions":14805,"interventions":14808},"NCT02555111","Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.",[92],"2020-02",[14806,14807],"Deep Vein Thrombosis","Chronic Portal Vein Thrombosis",[14790],{"trials":14810,"activeCount":102},[],{"trials":14812,"activeCount":102},[],{"intervention":14814,"totalTrials":180,"cells":14815},"VOLUVEN and others solute",{"EARLY_PHASE1":14816,"PHASE1":14818,"PHASE2":14820,"PHASE3":14822,"PHASE4":14832,"NA":14834},{"trials":14817,"activeCount":102},[],{"trials":14819,"activeCount":102},[],{"trials":14821,"activeCount":102},[],{"trials":14823,"activeCount":102},[14824],{"nctId":14825,"briefTitle":14826,"status":241,"phases":14827,"primaryCompletion":10940,"completion":1908,"start":5184,"enrollment":14828,"conditions":14829,"interventions":14831},"NCT00444262","Stroke Volume Optimisation in Patients With Hip Fracture",[92],215,[14830],"Hip Fractures",[14814],{"trials":14833,"activeCount":102},[],{"trials":14835,"activeCount":102},[],{"intervention":14837,"totalTrials":180,"cells":14838},"Mydriasert®",{"EARLY_PHASE1":14839,"PHASE1":14841,"PHASE2":14843,"PHASE3":14845,"PHASE4":14857,"NA":14859},{"trials":14840,"activeCount":102},[],{"trials":14842,"activeCount":102},[],{"trials":14844,"activeCount":102},[],{"trials":14846,"activeCount":102},[14847],{"nctId":14848,"briefTitle":14849,"status":241,"phases":14850,"primaryCompletion":14851,"completion":9986,"start":5682,"enrollment":1108,"conditions":14852,"interventions":14855},"NCT00642135","CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment",[92],"2008-02",[14853,14854],"Retinal Anomalies","Premature Birth",[14837,14856],"phenylephrine and tropicamide eyedrops",{"trials":14858,"activeCount":102},[],{"trials":14860,"activeCount":102},[],{"intervention":14856,"totalTrials":180,"cells":14862},{"EARLY_PHASE1":14863,"PHASE1":14865,"PHASE2":14867,"PHASE3":14869,"PHASE4":14875,"NA":14877},{"trials":14864,"activeCount":102},[],{"trials":14866,"activeCount":102},[],{"trials":14868,"activeCount":102},[],{"trials":14870,"activeCount":102},[14871],{"nctId":14848,"briefTitle":14849,"status":241,"phases":14872,"primaryCompletion":14851,"completion":9986,"start":5682,"enrollment":1108,"conditions":14873,"interventions":14874},[92],[14853,14854],[14837,14856],{"trials":14876,"activeCount":102},[],{"trials":14878,"activeCount":102},[],{"intervention":14880,"totalTrials":180,"cells":14881},"SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM",{"EARLY_PHASE1":14882,"PHASE1":14884,"PHASE2":14886,"PHASE3":14888,"PHASE4":14897,"NA":14899},{"trials":14883,"activeCount":102},[],{"trials":14885,"activeCount":102},[],{"trials":14887,"activeCount":102},[],{"trials":14889,"activeCount":102},[14890],{"nctId":14891,"briefTitle":14892,"status":139,"phases":14893,"primaryCompletion":7960,"completion":7960,"start":13760,"enrollment":1258,"conditions":14894,"interventions":14896},"NCT01160263","Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls",[92],[14895],"Amyotrophic Lateral Sclerosis",[14880],{"trials":14898,"activeCount":102},[],{"trials":14900,"activeCount":102},[],{"intervention":14902,"totalTrials":180,"cells":14903},"Enoxaparin",{"EARLY_PHASE1":14904,"PHASE1":14906,"PHASE2":14908,"PHASE3":14910,"PHASE4":14921,"NA":14923},{"trials":14905,"activeCount":102},[],{"trials":14907,"activeCount":102},[],{"trials":14909,"activeCount":102},[],{"trials":14911,"activeCount":102},[14912],{"nctId":14913,"briefTitle":14914,"status":139,"phases":14915,"primaryCompletion":5900,"completion":5254,"start":12974,"enrollment":14916,"conditions":14917,"interventions":14919},"NCT00718471","STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)",[92],910,[14918],"Primary PCI - STEMI",[14902,14920],"UFH",{"trials":14922,"activeCount":102},[],{"trials":14924,"activeCount":102},[],{"intervention":14920,"totalTrials":180,"cells":14926},{"EARLY_PHASE1":14927,"PHASE1":14929,"PHASE2":14931,"PHASE3":14933,"PHASE4":14939,"NA":14941},{"trials":14928,"activeCount":102},[],{"trials":14930,"activeCount":102},[],{"trials":14932,"activeCount":102},[],{"trials":14934,"activeCount":102},[14935],{"nctId":14913,"briefTitle":14914,"status":139,"phases":14936,"primaryCompletion":5900,"completion":5254,"start":12974,"enrollment":14916,"conditions":14937,"interventions":14938},[92],[14918],[14902,14920],{"trials":14940,"activeCount":102},[],{"trials":14942,"activeCount":102},[],{"intervention":14944,"totalTrials":180,"cells":14945},"Nebivolol",{"EARLY_PHASE1":14946,"PHASE1":14948,"PHASE2":14950,"PHASE3":14952,"PHASE4":14964,"NA":14966},{"trials":14947,"activeCount":102},[],{"trials":14949,"activeCount":102},[],{"trials":14951,"activeCount":102},[],{"trials":14953,"activeCount":102},[14954],{"nctId":14955,"briefTitle":14956,"status":139,"phases":14957,"primaryCompletion":14958,"completion":14958,"start":14959,"enrollment":8268,"conditions":14960,"interventions":14963},"NCT01648634","Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy",[92],"2021-07-20","2012-02-13",[14961,14962,4249],"Duchenne Muscular Dystrophy","Cardiomyopathy",[14944],{"trials":14965,"activeCount":102},[],{"trials":14967,"activeCount":102},[],{"intervention":14969,"totalTrials":180,"cells":14970},"Intravitreal triamcinolone injections",{"EARLY_PHASE1":14971,"PHASE1":14973,"PHASE2":14975,"PHASE3":14977,"PHASE4":14987,"NA":14989},{"trials":14972,"activeCount":102},[],{"trials":14974,"activeCount":102},[],{"trials":14976,"activeCount":102},[],{"trials":14978,"activeCount":102},[14979],{"nctId":14980,"briefTitle":14981,"status":139,"phases":14982,"primaryCompletion":11047,"completion":11047,"start":14983,"enrollment":1314,"conditions":14984,"interventions":14986},"NCT00764244","Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema",[92],"2005-01",[14985,1533],"Diabetic Macular Edema",[14969],{"trials":14988,"activeCount":102},[],{"trials":14990,"activeCount":102},[],{"intervention":12118,"totalTrials":180,"cells":14992},{"EARLY_PHASE1":14993,"PHASE1":14995,"PHASE2":14997,"PHASE3":14999,"PHASE4":15005,"NA":15007},{"trials":14994,"activeCount":102},[],{"trials":14996,"activeCount":102},[],{"trials":14998,"activeCount":102},[],{"trials":15000,"activeCount":102},[15001],{"nctId":12109,"briefTitle":12110,"status":139,"phases":15002,"primaryCompletion":12112,"completion":3675,"start":12113,"enrollment":12114,"conditions":15003,"interventions":15004},[92],[12116],[2131,12118,12118],{"trials":15006,"activeCount":102},[],{"trials":15008,"activeCount":102},[],{"intervention":12689,"totalTrials":180,"cells":15010},{"EARLY_PHASE1":15011,"PHASE1":15013,"PHASE2":15015,"PHASE3":15017,"PHASE4":15023,"NA":15025},{"trials":15012,"activeCount":102},[],{"trials":15014,"activeCount":102},[],{"trials":15016,"activeCount":102},[],{"trials":15018,"activeCount":102},[15019],{"nctId":12681,"briefTitle":12682,"status":241,"phases":15020,"primaryCompletion":12159,"completion":12684,"start":12685,"enrollment":1361,"conditions":15021,"interventions":15022},[92],[12687],[12689,12690,12691,12670],{"trials":15024,"activeCount":102},[],{"trials":15026,"activeCount":102},[],{"intervention":12690,"totalTrials":180,"cells":15028},{"EARLY_PHASE1":15029,"PHASE1":15031,"PHASE2":15033,"PHASE3":15035,"PHASE4":15041,"NA":15043},{"trials":15030,"activeCount":102},[],{"trials":15032,"activeCount":102},[],{"trials":15034,"activeCount":102},[],{"trials":15036,"activeCount":102},[15037],{"nctId":12681,"briefTitle":12682,"status":241,"phases":15038,"primaryCompletion":12159,"completion":12684,"start":12685,"enrollment":1361,"conditions":15039,"interventions":15040},[92],[12687],[12689,12690,12691,12670],{"trials":15042,"activeCount":102},[],{"trials":15044,"activeCount":102},[],{"intervention":12691,"totalTrials":180,"cells":15046},{"EARLY_PHASE1":15047,"PHASE1":15049,"PHASE2":15051,"PHASE3":15053,"PHASE4":15059,"NA":15061},{"trials":15048,"activeCount":102},[],{"trials":15050,"activeCount":102},[],{"trials":15052,"activeCount":102},[],{"trials":15054,"activeCount":102},[15055],{"nctId":12681,"briefTitle":12682,"status":241,"phases":15056,"primaryCompletion":12159,"completion":12684,"start":12685,"enrollment":1361,"conditions":15057,"interventions":15058},[92],[12687],[12689,12690,12691,12670],{"trials":15060,"activeCount":102},[],{"trials":15062,"activeCount":102},[],{"intervention":15064,"totalTrials":180,"cells":15065},"Almitrine",{"EARLY_PHASE1":15066,"PHASE1":15068,"PHASE2":15070,"PHASE3":15072,"PHASE4":15086,"NA":15088},{"trials":15067,"activeCount":102},[],{"trials":15069,"activeCount":102},[],{"trials":15071,"activeCount":102},[],{"trials":15073,"activeCount":102},[15074],{"nctId":15075,"briefTitle":15076,"status":139,"phases":15077,"primaryCompletion":15078,"completion":15079,"start":15080,"enrollment":15081,"conditions":15082,"interventions":15085},"NCT04357457","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia",[92],"2021-10-01","2021-12-17","2020-09-03",181,[15083,15084],"Covid 19","Hypoxemic Respiratory Failure",[15064],{"trials":15087,"activeCount":102},[],{"trials":15089,"activeCount":102},[],{"intervention":15091,"totalTrials":180,"cells":15092},"Rivaroxaban 2.5 MG [Xarelto]",{"EARLY_PHASE1":15093,"PHASE1":15095,"PHASE2":15097,"PHASE3":15099,"PHASE4":15113,"NA":15115},{"trials":15094,"activeCount":102},[],{"trials":15096,"activeCount":102},[],{"trials":15098,"activeCount":102},[],{"trials":15100,"activeCount":102},[15101],{"nctId":15102,"briefTitle":15103,"status":139,"phases":15104,"primaryCompletion":15105,"completion":15106,"start":15107,"enrollment":11814,"conditions":15108,"interventions":15111},"NCT05077683","Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF",[92],"2023-03-10","2024-02-09","2021-10-10",[15109,15110],"Myocardial Infarction, Acute","Left Ventricular Thrombus",[15091,15112],"DAPT strategy",{"trials":15114,"activeCount":102},[],{"trials":15116,"activeCount":102},[],{"intervention":15112,"totalTrials":180,"cells":15118},{"EARLY_PHASE1":15119,"PHASE1":15121,"PHASE2":15123,"PHASE3":15125,"PHASE4":15131,"NA":15133},{"trials":15120,"activeCount":102},[],{"trials":15122,"activeCount":102},[],{"trials":15124,"activeCount":102},[],{"trials":15126,"activeCount":102},[15127],{"nctId":15102,"briefTitle":15103,"status":139,"phases":15128,"primaryCompletion":15105,"completion":15106,"start":15107,"enrollment":11814,"conditions":15129,"interventions":15130},[92],[15109,15110],[15091,15112],{"trials":15132,"activeCount":102},[],{"trials":15134,"activeCount":102},[],{"intervention":15136,"totalTrials":180,"cells":15137},"desogestrel",{"EARLY_PHASE1":15138,"PHASE1":15140,"PHASE2":15142,"PHASE3":15144,"PHASE4":15154,"NA":15156},{"trials":15139,"activeCount":102},[],{"trials":15141,"activeCount":102},[],{"trials":15143,"activeCount":102},[],{"trials":15145,"activeCount":102},[15146],{"nctId":15147,"briefTitle":15148,"status":139,"phases":15149,"primaryCompletion":15150,"completion":15150,"start":10017,"enrollment":473,"conditions":15151,"interventions":15153},"NCT01243697","Assessment of Desogestrel in Ondine Syndrome",[91,92],"2013-09",[15152],"Ondine Syndrome",[15136],{"trials":15155,"activeCount":102},[],{"trials":15157,"activeCount":102},[],{"intervention":12300,"totalTrials":180,"cells":15159},{"EARLY_PHASE1":15160,"PHASE1":15162,"PHASE2":15164,"PHASE3":15166,"PHASE4":15172,"NA":15174},{"trials":15161,"activeCount":102},[],{"trials":15163,"activeCount":102},[],{"trials":15165,"activeCount":102},[],{"trials":15167,"activeCount":102},[15168],{"nctId":12290,"briefTitle":12291,"status":139,"phases":15169,"primaryCompletion":12293,"completion":12293,"start":12294,"enrollment":4204,"conditions":15170,"interventions":15171},[92],[12296],[12298,12299,12300],{"trials":15173,"activeCount":102},[],{"trials":15175,"activeCount":102},[],{"intervention":15177,"totalTrials":180,"cells":15178},"Prednisone arm",{"EARLY_PHASE1":15179,"PHASE1":15181,"PHASE2":15183,"PHASE3":15185,"PHASE4":15196,"NA":15198},{"trials":15180,"activeCount":102},[],{"trials":15182,"activeCount":102},[],{"trials":15184,"activeCount":102},[],{"trials":15186,"activeCount":102},[15187],{"nctId":15188,"briefTitle":15189,"status":139,"phases":15190,"primaryCompletion":5267,"completion":15191,"start":15192,"enrollment":429,"conditions":15193,"interventions":15195},"NCT05668676","Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF )",[91,92],"2023-03-20","2023-02-16",[15194],"Acute Heart Failure",[15177],{"trials":15197,"activeCount":102},[],{"trials":15199,"activeCount":102},[],{"intervention":15201,"totalTrials":180,"cells":15202},"Irbesartan",{"EARLY_PHASE1":15203,"PHASE1":15205,"PHASE2":15207,"PHASE3":15209,"PHASE4":15220,"NA":15222},{"trials":15204,"activeCount":102},[],{"trials":15206,"activeCount":102},[],{"trials":15208,"activeCount":102},[],{"trials":15210,"activeCount":102},[15211],{"nctId":15212,"briefTitle":15213,"status":139,"phases":15214,"primaryCompletion":15215,"completion":15215,"start":5518,"enrollment":15216,"conditions":15217,"interventions":15219},"NCT02597361","Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)",[92],"2020-02-19",61,[15218],"Ehlers-Danlos Syndrome, Vascular Type",[15201],{"trials":15221,"activeCount":102},[],{"trials":15223,"activeCount":102},[],{"intervention":15225,"totalTrials":180,"cells":15226},"Antitubercular treatment",{"EARLY_PHASE1":15227,"PHASE1":15229,"PHASE2":15231,"PHASE3":15233,"PHASE4":15247,"NA":15249},{"trials":15228,"activeCount":102},[],{"trials":15230,"activeCount":102},[],{"trials":15232,"activeCount":102},[],{"trials":15234,"activeCount":102},[15235],{"nctId":15236,"briefTitle":15237,"status":110,"phases":15238,"primaryCompletion":15239,"completion":15239,"start":15240,"enrollment":15241,"conditions":15242,"interventions":15244},"NCT04117698","Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)",[92],"2023-05-01","2019-11-01",116,[15243],"Uveitis, Anterior",[15225,15245,15246],"Ethambutol","RIFINAH ©",{"trials":15248,"activeCount":102},[],{"trials":15250,"activeCount":102},[],{"intervention":15245,"totalTrials":180,"cells":15252},{"EARLY_PHASE1":15253,"PHASE1":15255,"PHASE2":15257,"PHASE3":15259,"PHASE4":15265,"NA":15267},{"trials":15254,"activeCount":102},[],{"trials":15256,"activeCount":102},[],{"trials":15258,"activeCount":102},[],{"trials":15260,"activeCount":102},[15261],{"nctId":15236,"briefTitle":15237,"status":110,"phases":15262,"primaryCompletion":15239,"completion":15239,"start":15240,"enrollment":15241,"conditions":15263,"interventions":15264},[92],[15243],[15225,15245,15246],{"trials":15266,"activeCount":102},[],{"trials":15268,"activeCount":102},[],{"intervention":15246,"totalTrials":180,"cells":15270},{"EARLY_PHASE1":15271,"PHASE1":15273,"PHASE2":15275,"PHASE3":15277,"PHASE4":15283,"NA":15285},{"trials":15272,"activeCount":102},[],{"trials":15274,"activeCount":102},[],{"trials":15276,"activeCount":102},[],{"trials":15278,"activeCount":102},[15279],{"nctId":15236,"briefTitle":15237,"status":110,"phases":15280,"primaryCompletion":15239,"completion":15239,"start":15240,"enrollment":15241,"conditions":15281,"interventions":15282},[92],[15243],[15225,15245,15246],{"trials":15284,"activeCount":102},[],{"trials":15286,"activeCount":102},[],{"intervention":15288,"totalTrials":180,"cells":15289},"3,4-diaminopyridine",{"EARLY_PHASE1":15290,"PHASE1":15292,"PHASE2":15294,"PHASE3":15296,"PHASE4":15305,"NA":15307},{"trials":15291,"activeCount":102},[],{"trials":15293,"activeCount":102},[],{"trials":15295,"activeCount":102},[],{"trials":15297,"activeCount":102},[15298],{"nctId":15299,"briefTitle":15300,"status":139,"phases":15301,"primaryCompletion":9986,"completion":9986,"start":15302,"enrollment":1531,"conditions":15303,"interventions":15304},"NCT00190268","Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis",[92],"2005-02",[6488],[15288],{"trials":15306,"activeCount":102},[],{"trials":15308,"activeCount":102},[],{"intervention":15310,"totalTrials":180,"cells":15311},"Paracetamol",{"EARLY_PHASE1":15312,"PHASE1":15314,"PHASE2":15316,"PHASE3":15318,"PHASE4":15331,"NA":15333},{"trials":15313,"activeCount":102},[],{"trials":15315,"activeCount":102},[],{"trials":15317,"activeCount":102},[],{"trials":15319,"activeCount":102},[15320],{"nctId":15321,"briefTitle":15322,"status":139,"phases":15323,"primaryCompletion":15324,"completion":15324,"start":15325,"enrollment":2116,"conditions":15326,"interventions":15328},"NCT02477007","Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and\u002For Ibuprofen for Long-bones Fractures in Children",[92],"2018-11-21","2015-12-03",[5146,15327],"Long-bone Fractures",[15310,15329,15330],"Ibuprofen","paracetamol + ibuprofen",{"trials":15332,"activeCount":102},[],{"trials":15334,"activeCount":102},[],{"intervention":15329,"totalTrials":180,"cells":15336},{"EARLY_PHASE1":15337,"PHASE1":15339,"PHASE2":15341,"PHASE3":15343,"PHASE4":15349,"NA":15351},{"trials":15338,"activeCount":102},[],{"trials":15340,"activeCount":102},[],{"trials":15342,"activeCount":102},[],{"trials":15344,"activeCount":102},[15345],{"nctId":15321,"briefTitle":15322,"status":139,"phases":15346,"primaryCompletion":15324,"completion":15324,"start":15325,"enrollment":2116,"conditions":15347,"interventions":15348},[92],[5146,15327],[15310,15329,15330],{"trials":15350,"activeCount":102},[],{"trials":15352,"activeCount":102},[],{"intervention":15330,"totalTrials":180,"cells":15354},{"EARLY_PHASE1":15355,"PHASE1":15357,"PHASE2":15359,"PHASE3":15361,"PHASE4":15367,"NA":15369},{"trials":15356,"activeCount":102},[],{"trials":15358,"activeCount":102},[],{"trials":15360,"activeCount":102},[],{"trials":15362,"activeCount":102},[15363],{"nctId":15321,"briefTitle":15322,"status":139,"phases":15364,"primaryCompletion":15324,"completion":15324,"start":15325,"enrollment":2116,"conditions":15365,"interventions":15366},[92],[5146,15327],[15310,15329,15330],{"trials":15368,"activeCount":102},[],{"trials":15370,"activeCount":102},[],{"intervention":12177,"totalTrials":180,"cells":15372},{"EARLY_PHASE1":15373,"PHASE1":15375,"PHASE2":15377,"PHASE3":15379,"PHASE4":15385,"NA":15387},{"trials":15374,"activeCount":102},[],{"trials":15376,"activeCount":102},[],{"trials":15378,"activeCount":102},[],{"trials":15380,"activeCount":102},[15381],{"nctId":12167,"briefTitle":12168,"status":139,"phases":15382,"primaryCompletion":12170,"completion":12171,"start":12172,"enrollment":12173,"conditions":15383,"interventions":15384},[92],[526,528,4742,527,12175],[12177,12128],{"trials":15386,"activeCount":102},[],{"trials":15388,"activeCount":102},[],{"intervention":15390,"totalTrials":180,"cells":15391},"Norfloxacin",{"EARLY_PHASE1":15392,"PHASE1":15394,"PHASE2":15396,"PHASE3":15398,"PHASE4":15407,"NA":15409},{"trials":15393,"activeCount":102},[],{"trials":15395,"activeCount":102},[],{"trials":15397,"activeCount":102},[],{"trials":15399,"activeCount":102},[15400],{"nctId":15401,"briefTitle":15402,"status":241,"phases":15403,"primaryCompletion":7896,"completion":5469,"start":10260,"enrollment":15404,"conditions":15405,"interventions":15406},"NCT01037959","Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure",[92],291,[1500],[15390],{"trials":15408,"activeCount":102},[],{"trials":15410,"activeCount":102},[],{"intervention":15412,"totalTrials":180,"cells":15413},"TNF blocker",{"EARLY_PHASE1":15414,"PHASE1":15416,"PHASE2":15418,"PHASE3":15420,"PHASE4":15431,"NA":15433},{"trials":15415,"activeCount":102},[],{"trials":15417,"activeCount":102},[],{"trials":15419,"activeCount":102},[],{"trials":15421,"activeCount":102},[15422],{"nctId":15423,"briefTitle":15424,"status":139,"phases":15425,"primaryCompletion":13760,"completion":8413,"start":15426,"enrollment":15427,"conditions":15428,"interventions":15430},"NCT00385086","Lumbar Spinal Fibrosis and TNF Alpha Inhibition",[92],"2007-02",38,[15429],"Post Operative Sciatica by Lumbar Spinal Fibrosis",[15412],{"trials":15432,"activeCount":102},[],{"trials":15434,"activeCount":102},[],{"intervention":15436,"totalTrials":180,"cells":15437},"Liberal Red blood cell transfusion",{"EARLY_PHASE1":15438,"PHASE1":15440,"PHASE2":15442,"PHASE3":15444,"PHASE4":15456,"NA":15458},{"trials":15439,"activeCount":102},[],{"trials":15441,"activeCount":102},[],{"trials":15443,"activeCount":102},[],{"trials":15445,"activeCount":102},[15446],{"nctId":15447,"briefTitle":15448,"status":139,"phases":15449,"primaryCompletion":46,"completion":15450,"start":15451,"enrollment":15452,"conditions":15453,"interventions":15454},"NCT03837171","TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock",[92],"2024-03-04","2019-03-24",192,[2462,13877,9635],[15436,15455],"Restrictive Red blood cell transfusion",{"trials":15457,"activeCount":102},[],{"trials":15459,"activeCount":102},[],{"intervention":15455,"totalTrials":180,"cells":15461},{"EARLY_PHASE1":15462,"PHASE1":15464,"PHASE2":15466,"PHASE3":15468,"PHASE4":15474,"NA":15476},{"trials":15463,"activeCount":102},[],{"trials":15465,"activeCount":102},[],{"trials":15467,"activeCount":102},[],{"trials":15469,"activeCount":102},[15470],{"nctId":15447,"briefTitle":15448,"status":139,"phases":15471,"primaryCompletion":46,"completion":15450,"start":15451,"enrollment":15452,"conditions":15472,"interventions":15473},[92],[2462,13877,9635],[15436,15455],{"trials":15475,"activeCount":102},[],{"trials":15477,"activeCount":102},[],{"intervention":15479,"totalTrials":180,"cells":15480},"Clorazepate Dipotassium",{"EARLY_PHASE1":15481,"PHASE1":15483,"PHASE2":15485,"PHASE3":15487,"PHASE4":15502,"NA":15504},{"trials":15482,"activeCount":102},[],{"trials":15484,"activeCount":102},[],{"trials":15486,"activeCount":102},[],{"trials":15488,"activeCount":102},[15489],{"nctId":15490,"briefTitle":15491,"status":241,"phases":15492,"primaryCompletion":15493,"completion":15493,"start":15494,"enrollment":12592,"conditions":15495,"interventions":15499},"NCT04726592","Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room",[92],"2024-04-10","2021-07-08",[503,15496,15497,15498],"Migraine Without Aura","Migraine With Aura","Headache",[15479,15500,15501],"Ketoprofen","Metoclopramide",{"trials":15503,"activeCount":102},[],{"trials":15505,"activeCount":102},[],{"intervention":15500,"totalTrials":180,"cells":15507},{"EARLY_PHASE1":15508,"PHASE1":15510,"PHASE2":15512,"PHASE3":15514,"PHASE4":15520,"NA":15522},{"trials":15509,"activeCount":102},[],{"trials":15511,"activeCount":102},[],{"trials":15513,"activeCount":102},[],{"trials":15515,"activeCount":102},[15516],{"nctId":15490,"briefTitle":15491,"status":241,"phases":15517,"primaryCompletion":15493,"completion":15493,"start":15494,"enrollment":12592,"conditions":15518,"interventions":15519},[92],[503,15496,15497,15498],[15479,15500,15501],{"trials":15521,"activeCount":102},[],{"trials":15523,"activeCount":102},[],{"intervention":15501,"totalTrials":180,"cells":15525},{"EARLY_PHASE1":15526,"PHASE1":15528,"PHASE2":15530,"PHASE3":15532,"PHASE4":15538,"NA":15540},{"trials":15527,"activeCount":102},[],{"trials":15529,"activeCount":102},[],{"trials":15531,"activeCount":102},[],{"trials":15533,"activeCount":102},[15534],{"nctId":15490,"briefTitle":15491,"status":241,"phases":15535,"primaryCompletion":15493,"completion":15493,"start":15494,"enrollment":12592,"conditions":15536,"interventions":15537},[92],[503,15496,15497,15498],[15479,15500,15501],{"trials":15539,"activeCount":102},[],{"trials":15541,"activeCount":102},[],{"intervention":12925,"totalTrials":180,"cells":15543},{"EARLY_PHASE1":15544,"PHASE1":15546,"PHASE2":15548,"PHASE3":15550,"PHASE4":15560,"NA":15562},{"trials":15545,"activeCount":102},[],{"trials":15547,"activeCount":102},[],{"trials":15549,"activeCount":102},[],{"trials":15551,"activeCount":102},[15552],{"nctId":15553,"briefTitle":15554,"status":139,"phases":15555,"primaryCompletion":15556,"completion":15556,"start":13873,"enrollment":388,"conditions":15557,"interventions":15559},"NCT05028257","Allergy and COVID-19 Vaccines",[92],"2023-05-22",[15558,12915],"Anaphylactic Reaction",[12925],{"trials":15561,"activeCount":102},[],{"trials":15563,"activeCount":102},[],{"intervention":15565,"totalTrials":180,"cells":15566},"Cortancyl Oral",{"EARLY_PHASE1":15567,"PHASE1":15569,"PHASE2":15571,"PHASE3":15573,"PHASE4":15587,"NA":15589},{"trials":15568,"activeCount":102},[],{"trials":15570,"activeCount":102},[],{"trials":15572,"activeCount":102},[],{"trials":15574,"activeCount":102},[15575],{"nctId":15576,"briefTitle":15577,"status":139,"phases":15578,"primaryCompletion":15579,"completion":15580,"start":15581,"enrollment":11071,"conditions":15582,"interventions":15585},"NCT03545464","COrticosteroids in acUte uRticAria in emerGency dEpartment",[92],"2025-02-28","2025-09-17","2019-09-21",[15583,15584],"Urticaria","Angiœdema",[15565,15586],"Levocetirizine Oral",{"trials":15588,"activeCount":102},[],{"trials":15590,"activeCount":102},[],{"intervention":15586,"totalTrials":180,"cells":15592},{"EARLY_PHASE1":15593,"PHASE1":15595,"PHASE2":15597,"PHASE3":15599,"PHASE4":15605,"NA":15607},{"trials":15594,"activeCount":102},[],{"trials":15596,"activeCount":102},[],{"trials":15598,"activeCount":102},[],{"trials":15600,"activeCount":102},[15601],{"nctId":15576,"briefTitle":15577,"status":139,"phases":15602,"primaryCompletion":15579,"completion":15580,"start":15581,"enrollment":11071,"conditions":15603,"interventions":15604},[92],[15583,15584],[15565,15586],{"trials":15606,"activeCount":102},[],{"trials":15608,"activeCount":102},[],{"intervention":15610,"totalTrials":180,"cells":15611},"Cyclophosphamide + Bortezomib + Dexamethasone regimen",{"EARLY_PHASE1":15612,"PHASE1":15614,"PHASE2":15616,"PHASE3":15618,"PHASE4":15629,"NA":15631},{"trials":15613,"activeCount":102},[],{"trials":15615,"activeCount":102},[],{"trials":15617,"activeCount":102},[],{"trials":15619,"activeCount":102},[15620],{"nctId":15621,"briefTitle":15622,"status":139,"phases":15623,"primaryCompletion":11593,"completion":12094,"start":1587,"enrollment":15624,"conditions":15625,"interventions":15627},"NCT01208818","Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy",[92],284,[15626],"Chronic Renal Failure With Uremic Nephropathy",[15610,15628],"Bortezomib +Dexamethasone regimen",{"trials":15630,"activeCount":102},[],{"trials":15632,"activeCount":102},[],{"intervention":15628,"totalTrials":180,"cells":15634},{"EARLY_PHASE1":15635,"PHASE1":15637,"PHASE2":15639,"PHASE3":15641,"PHASE4":15647,"NA":15649},{"trials":15636,"activeCount":102},[],{"trials":15638,"activeCount":102},[],{"trials":15640,"activeCount":102},[],{"trials":15642,"activeCount":102},[15643],{"nctId":15621,"briefTitle":15622,"status":139,"phases":15644,"primaryCompletion":11593,"completion":12094,"start":1587,"enrollment":15624,"conditions":15645,"interventions":15646},[92],[15626],[15610,15628],{"trials":15648,"activeCount":102},[],{"trials":15650,"activeCount":102},[],{"intervention":15652,"totalTrials":180,"cells":15653},"MELATONIN",{"EARLY_PHASE1":15654,"PHASE1":15656,"PHASE2":15658,"PHASE3":15660,"PHASE4":15671,"NA":15673},{"trials":15655,"activeCount":102},[],{"trials":15657,"activeCount":102},[],{"trials":15659,"activeCount":102},[],{"trials":15661,"activeCount":102},[15662],{"nctId":15663,"briefTitle":15664,"status":139,"phases":15665,"primaryCompletion":15666,"completion":566,"start":1223,"enrollment":15667,"conditions":15668,"interventions":15670},"NCT03524937","Prevention of Delirium in Intensive Care by Melatonin",[91,92],"2021-05-01",355,[15669],"Mechanically Ventilated Patients",[15652,15652],{"trials":15672,"activeCount":102},[],{"trials":15674,"activeCount":102},[],{"intervention":15676,"totalTrials":180,"cells":15677},"Docetaxel + hormonal treatment",{"EARLY_PHASE1":15678,"PHASE1":15680,"PHASE2":15682,"PHASE3":15684,"PHASE4":15694,"NA":15696},{"trials":15679,"activeCount":102},[],{"trials":15681,"activeCount":102},[],{"trials":15683,"activeCount":102},[],{"trials":15685,"activeCount":102},[15686],{"nctId":15687,"briefTitle":15688,"status":110,"phases":15689,"primaryCompletion":7866,"completion":10940,"start":13386,"enrollment":4806,"conditions":15690,"interventions":15692},"NCT00764166","A Prospective Randomized Phase III Study Comparing Hormonal Therapy +\u002F-Docetaxel",[92],[15691],"Adenocarcinoma of the Prostate",[15676,15693],"Hormonal treatment",{"trials":15695,"activeCount":102},[],{"trials":15697,"activeCount":102},[],{"intervention":15693,"totalTrials":180,"cells":15699},{"EARLY_PHASE1":15700,"PHASE1":15702,"PHASE2":15704,"PHASE3":15706,"PHASE4":15712,"NA":15714},{"trials":15701,"activeCount":102},[],{"trials":15703,"activeCount":102},[],{"trials":15705,"activeCount":102},[],{"trials":15707,"activeCount":102},[15708],{"nctId":15687,"briefTitle":15688,"status":110,"phases":15709,"primaryCompletion":7866,"completion":10940,"start":13386,"enrollment":4806,"conditions":15710,"interventions":15711},[92],[15691],[15676,15693],{"trials":15713,"activeCount":102},[],{"trials":15715,"activeCount":102},[],{"intervention":15717,"totalTrials":180,"cells":15718},"Rivaroxaban 10 mg qd",{"EARLY_PHASE1":15719,"PHASE1":15721,"PHASE2":15723,"PHASE3":15725,"PHASE4":15740,"NA":15742},{"trials":15720,"activeCount":102},[],{"trials":15722,"activeCount":102},[],{"trials":15724,"activeCount":102},[],{"trials":15726,"activeCount":102},[15727],{"nctId":15728,"briefTitle":15729,"status":139,"phases":15730,"primaryCompletion":15731,"completion":5112,"start":15732,"enrollment":15733,"conditions":15734,"interventions":15737},"NCT03273322","Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure",[91,92],"2018-11-20","2017-09-13",105,[467,15735,15736],"Atrial Appendage","Hemorrhage",[15717,15738,15739],"Rivaroxaban 15 mg qd","DAPT",{"trials":15741,"activeCount":102},[],{"trials":15743,"activeCount":102},[],{"intervention":15738,"totalTrials":180,"cells":15745},{"EARLY_PHASE1":15746,"PHASE1":15748,"PHASE2":15750,"PHASE3":15752,"PHASE4":15758,"NA":15760},{"trials":15747,"activeCount":102},[],{"trials":15749,"activeCount":102},[],{"trials":15751,"activeCount":102},[],{"trials":15753,"activeCount":102},[15754],{"nctId":15728,"briefTitle":15729,"status":139,"phases":15755,"primaryCompletion":15731,"completion":5112,"start":15732,"enrollment":15733,"conditions":15756,"interventions":15757},[91,92],[467,15735,15736],[15717,15738,15739],{"trials":15759,"activeCount":102},[],{"trials":15761,"activeCount":102},[],{"intervention":15739,"totalTrials":180,"cells":15763},{"EARLY_PHASE1":15764,"PHASE1":15766,"PHASE2":15768,"PHASE3":15770,"PHASE4":15776,"NA":15778},{"trials":15765,"activeCount":102},[],{"trials":15767,"activeCount":102},[],{"trials":15769,"activeCount":102},[],{"trials":15771,"activeCount":102},[15772],{"nctId":15728,"briefTitle":15729,"status":139,"phases":15773,"primaryCompletion":15731,"completion":5112,"start":15732,"enrollment":15733,"conditions":15774,"interventions":15775},[91,92],[467,15735,15736],[15717,15738,15739],{"trials":15777,"activeCount":102},[],{"trials":15779,"activeCount":102},[],{"intervention":15781,"totalTrials":180,"cells":15782},"corticosteroid and azathioprine",{"EARLY_PHASE1":15783,"PHASE1":15785,"PHASE2":15787,"PHASE3":15789,"PHASE4":15801,"NA":15803},{"trials":15784,"activeCount":102},[],{"trials":15786,"activeCount":102},[],{"trials":15788,"activeCount":102},[],{"trials":15790,"activeCount":102},[15791],{"nctId":15792,"briefTitle":15793,"status":139,"phases":15794,"primaryCompletion":8005,"completion":12215,"start":13039,"enrollment":7897,"conditions":15795,"interventions":15799},"NCT00647166","Association Corticosteroid\u002FAzathioprine in Microscopic Polyangiitis\u002F Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)",[92],[15796,15797,15798],"MPA","PAN or EGPA With FFS=0","At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids",[15781,15800],"corticosteroid and placebo",{"trials":15802,"activeCount":102},[],{"trials":15804,"activeCount":102},[],{"intervention":15800,"totalTrials":180,"cells":15806},{"EARLY_PHASE1":15807,"PHASE1":15809,"PHASE2":15811,"PHASE3":15813,"PHASE4":15819,"NA":15821},{"trials":15808,"activeCount":102},[],{"trials":15810,"activeCount":102},[],{"trials":15812,"activeCount":102},[],{"trials":15814,"activeCount":102},[15815],{"nctId":15792,"briefTitle":15793,"status":139,"phases":15816,"primaryCompletion":8005,"completion":12215,"start":13039,"enrollment":7897,"conditions":15817,"interventions":15818},[92],[15796,15797,15798],[15781,15800],{"trials":15820,"activeCount":102},[],{"trials":15822,"activeCount":102},[],{"intervention":15824,"totalTrials":180,"cells":15825},"Magnesium",{"EARLY_PHASE1":15826,"PHASE1":15828,"PHASE2":15830,"PHASE3":15832,"PHASE4":15843,"NA":15845},{"trials":15827,"activeCount":102},[],{"trials":15829,"activeCount":102},[],{"trials":15831,"activeCount":102},[],{"trials":15833,"activeCount":102},[15834],{"nctId":15835,"briefTitle":15836,"status":139,"phases":15837,"primaryCompletion":15838,"completion":15838,"start":15839,"enrollment":15733,"conditions":15840,"interventions":15842},"NCT03033823","MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)",[92],"2020-10-23","2017-11-16",[15841],"Alcohol Withdrawal Syndrome",[15824],{"trials":15844,"activeCount":102},[],{"trials":15846,"activeCount":102},[],{"intervention":15848,"totalTrials":180,"cells":15849},"β-adrenergic blocker propranolol",{"EARLY_PHASE1":15850,"PHASE1":15852,"PHASE2":15854,"PHASE3":15856,"PHASE4":15868,"NA":15870},{"trials":15851,"activeCount":102},[],{"trials":15853,"activeCount":102},[],{"trials":15855,"activeCount":102},[],{"trials":15857,"activeCount":102},[15858],{"nctId":15859,"briefTitle":15860,"status":139,"phases":15861,"primaryCompletion":15862,"completion":15862,"start":15863,"enrollment":15864,"conditions":15865,"interventions":15867},"NCT02789982","Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study",[92],"2019-12-30","2016-05-27",364,[15866],"Post-traumatic Stress Disorder",[15848],{"trials":15869,"activeCount":102},[],{"trials":15871,"activeCount":102},[],{"intervention":15873,"totalTrials":180,"cells":15874},"THALIDOMIDE",{"EARLY_PHASE1":15875,"PHASE1":15877,"PHASE2":15879,"PHASE3":15881,"PHASE4":15889,"NA":15891},{"trials":15876,"activeCount":102},[],{"trials":15878,"activeCount":102},[],{"trials":15880,"activeCount":102},[],{"trials":15882,"activeCount":102},[15883],{"nctId":15884,"briefTitle":15885,"status":139,"phases":15886,"primaryCompletion":9880,"completion":9880,"start":15302,"enrollment":1931,"conditions":15887,"interventions":15888},"NCT00305552","SARCOTHAL. Thalidomide in Skin Sarcoidosis",[92],[3721],[15873],{"trials":15890,"activeCount":102},[],{"trials":15892,"activeCount":102},[],{"intervention":981,"totalTrials":180,"cells":15894},{"EARLY_PHASE1":15895,"PHASE1":15897,"PHASE2":15899,"PHASE3":15901,"PHASE4":15907,"NA":15909},{"trials":15896,"activeCount":102},[],{"trials":15898,"activeCount":102},[],{"trials":15900,"activeCount":102},[],{"trials":15902,"activeCount":102},[15903],{"nctId":973,"briefTitle":974,"status":110,"phases":15904,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":15905,"interventions":15906},[92],[980,981],[981,983,251],{"trials":15908,"activeCount":102},[],{"trials":15910,"activeCount":102},[],{"intervention":983,"totalTrials":180,"cells":15912},{"EARLY_PHASE1":15913,"PHASE1":15915,"PHASE2":15917,"PHASE3":15919,"PHASE4":15925,"NA":15927},{"trials":15914,"activeCount":102},[],{"trials":15916,"activeCount":102},[],{"trials":15918,"activeCount":102},[],{"trials":15920,"activeCount":102},[15921],{"nctId":973,"briefTitle":974,"status":110,"phases":15922,"primaryCompletion":976,"completion":976,"start":977,"enrollment":978,"conditions":15923,"interventions":15924},[92],[980,981],[981,983,251],{"trials":15926,"activeCount":102},[],{"trials":15928,"activeCount":102},[],{"intervention":15930,"totalTrials":180,"cells":15931},"BPG",{"EARLY_PHASE1":15932,"PHASE1":15934,"PHASE2":15936,"PHASE3":15938,"PHASE4":15950,"NA":15952},{"trials":15933,"activeCount":102},[],{"trials":15935,"activeCount":102},[],{"trials":15937,"activeCount":102},[],{"trials":15939,"activeCount":102},[15940],{"nctId":15941,"briefTitle":15942,"status":139,"phases":15943,"primaryCompletion":15944,"completion":15944,"start":15945,"enrollment":1015,"conditions":15946,"interventions":15948},"NCT04838717","Clinical Trial of Doxycycline VS BPG for Early Syphilis (SY-DOXY)",[92],"2025-07-23","2021-12-06",[15947],"Syphilis",[15930,15949],"Doxycycline",{"trials":15951,"activeCount":102},[],{"trials":15953,"activeCount":102},[],{"intervention":15949,"totalTrials":180,"cells":15955},{"EARLY_PHASE1":15956,"PHASE1":15958,"PHASE2":15960,"PHASE3":15962,"PHASE4":15968,"NA":15970},{"trials":15957,"activeCount":102},[],{"trials":15959,"activeCount":102},[],{"trials":15961,"activeCount":102},[],{"trials":15963,"activeCount":102},[15964],{"nctId":15941,"briefTitle":15942,"status":139,"phases":15965,"primaryCompletion":15944,"completion":15944,"start":15945,"enrollment":1015,"conditions":15966,"interventions":15967},[92],[15947],[15930,15949],{"trials":15969,"activeCount":102},[],{"trials":15971,"activeCount":102},[],{"intervention":15973,"totalTrials":180,"cells":15974},"IMN",{"EARLY_PHASE1":15975,"PHASE1":15977,"PHASE2":15979,"PHASE3":15981,"PHASE4":15992,"NA":15994},{"trials":15976,"activeCount":102},[],{"trials":15978,"activeCount":102},[],{"trials":15980,"activeCount":102},[],{"trials":15982,"activeCount":102},[15983],{"nctId":15984,"briefTitle":15985,"status":139,"phases":15986,"primaryCompletion":11768,"completion":374,"start":10507,"enrollment":15987,"conditions":15988,"interventions":15991},"NCT00930618","Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies",[92],1409,[15989,15990],"Prolonged Pregnancy","Nulliparity",[15973],{"trials":15993,"activeCount":102},[],{"trials":15995,"activeCount":102},[],{"intervention":15997,"totalTrials":180,"cells":15998},"Injection, botulinum toxin + corticoid",{"EARLY_PHASE1":15999,"PHASE1":16001,"PHASE2":16003,"PHASE3":16005,"PHASE4":16019,"NA":16021},{"trials":16000,"activeCount":102},[],{"trials":16002,"activeCount":102},[],{"trials":16004,"activeCount":102},[],{"trials":16006,"activeCount":102},[16007],{"nctId":16008,"briefTitle":16009,"status":139,"phases":16010,"primaryCompletion":16011,"completion":16012,"start":16013,"enrollment":16,"conditions":16014,"interventions":16016},"NCT03380559","A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis",[92],"2021-07-07","2021-08-19","2019-04-19",[16015],"Epicondylitis",[15997,16017,16018],"Injection, placebo of toxin + corticoid","Injection, botulinum toxin + placebo corticoid",{"trials":16020,"activeCount":102},[],{"trials":16022,"activeCount":102},[],{"intervention":16017,"totalTrials":180,"cells":16024},{"EARLY_PHASE1":16025,"PHASE1":16027,"PHASE2":16029,"PHASE3":16031,"PHASE4":16037,"NA":16039},{"trials":16026,"activeCount":102},[],{"trials":16028,"activeCount":102},[],{"trials":16030,"activeCount":102},[],{"trials":16032,"activeCount":102},[16033],{"nctId":16008,"briefTitle":16009,"status":139,"phases":16034,"primaryCompletion":16011,"completion":16012,"start":16013,"enrollment":16,"conditions":16035,"interventions":16036},[92],[16015],[15997,16017,16018],{"trials":16038,"activeCount":102},[],{"trials":16040,"activeCount":102},[],{"intervention":16018,"totalTrials":180,"cells":16042},{"EARLY_PHASE1":16043,"PHASE1":16045,"PHASE2":16047,"PHASE3":16049,"PHASE4":16055,"NA":16057},{"trials":16044,"activeCount":102},[],{"trials":16046,"activeCount":102},[],{"trials":16048,"activeCount":102},[],{"trials":16050,"activeCount":102},[16051],{"nctId":16008,"briefTitle":16009,"status":139,"phases":16052,"primaryCompletion":16011,"completion":16012,"start":16013,"enrollment":16,"conditions":16053,"interventions":16054},[92],[16015],[15997,16017,16018],{"trials":16056,"activeCount":102},[],{"trials":16058,"activeCount":102},[],{"intervention":16060,"totalTrials":180,"cells":16061},"BOTOX®, Allergan",{"EARLY_PHASE1":16062,"PHASE1":16064,"PHASE2":16066,"PHASE3":16068,"PHASE4":16080,"NA":16082},{"trials":16063,"activeCount":102},[],{"trials":16065,"activeCount":102},[],{"trials":16067,"activeCount":102},[],{"trials":16069,"activeCount":102},[16070],{"nctId":16071,"briefTitle":16072,"status":139,"phases":16073,"primaryCompletion":16074,"completion":16075,"start":16076,"enrollment":14156,"conditions":16077,"interventions":16079},"NCT03555916","Botulinum Toxin Injections for Oral Neuropathic Pain",[92],"2022-07-19","2022-11-08","2019-04-04",[16078],"Trigeminal Neuropathy, Traumatic",[16060],{"trials":16081,"activeCount":102},[],{"trials":16083,"activeCount":102},[],{"intervention":16085,"totalTrials":180,"cells":16086},"Intranasal midazolam",{"EARLY_PHASE1":16087,"PHASE1":16089,"PHASE2":16091,"PHASE3":16093,"PHASE4":16105,"NA":16107},{"trials":16088,"activeCount":102},[],{"trials":16090,"activeCount":102},[],{"trials":16092,"activeCount":102},[],{"trials":16094,"activeCount":102},[16095],{"nctId":16096,"briefTitle":16097,"status":241,"phases":16098,"primaryCompletion":16099,"completion":16100,"start":16099,"enrollment":180,"conditions":16101,"interventions":16103},"NCT05324852","AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine",[92],"2023-04-09","2024-04-23",[16102],"Emergence Delirium",[16085,16104],"Intramuscular loxapine",{"trials":16106,"activeCount":102},[],{"trials":16108,"activeCount":102},[],{"intervention":16104,"totalTrials":180,"cells":16110},{"EARLY_PHASE1":16111,"PHASE1":16113,"PHASE2":16115,"PHASE3":16117,"PHASE4":16123,"NA":16125},{"trials":16112,"activeCount":102},[],{"trials":16114,"activeCount":102},[],{"trials":16116,"activeCount":102},[],{"trials":16118,"activeCount":102},[16119],{"nctId":16096,"briefTitle":16097,"status":241,"phases":16120,"primaryCompletion":16099,"completion":16100,"start":16099,"enrollment":180,"conditions":16121,"interventions":16122},[92],[16102],[16085,16104],{"trials":16124,"activeCount":102},[],{"trials":16126,"activeCount":102},[],{"intervention":16128,"totalTrials":180,"cells":16129},"Somatostatin",{"EARLY_PHASE1":16130,"PHASE1":16132,"PHASE2":16134,"PHASE3":16136,"PHASE4":16147,"NA":16149},{"trials":16131,"activeCount":102},[],{"trials":16133,"activeCount":102},[],{"trials":16135,"activeCount":102},[],{"trials":16137,"activeCount":102},[16138],{"nctId":16139,"briefTitle":16140,"status":139,"phases":16141,"primaryCompletion":16142,"completion":16142,"start":12756,"enrollment":5185,"conditions":16143,"interventions":16145},"NCT03000946","Prevention of Postoperative Pancreatic Fistula by Somatostatin",[92],"2021-02-09",[16144],"Pancreatic Surgery",[16128,16146],"Octreotide",{"trials":16148,"activeCount":102},[],{"trials":16150,"activeCount":102},[],{"intervention":16146,"totalTrials":180,"cells":16152},{"EARLY_PHASE1":16153,"PHASE1":16155,"PHASE2":16157,"PHASE3":16159,"PHASE4":16165,"NA":16167},{"trials":16154,"activeCount":102},[],{"trials":16156,"activeCount":102},[],{"trials":16158,"activeCount":102},[],{"trials":16160,"activeCount":102},[16161],{"nctId":16139,"briefTitle":16140,"status":139,"phases":16162,"primaryCompletion":16142,"completion":16142,"start":12756,"enrollment":5185,"conditions":16163,"interventions":16164},[92],[16144],[16128,16146],{"trials":16166,"activeCount":102},[],{"trials":16168,"activeCount":102},[],{"intervention":16170,"totalTrials":180,"cells":16171},"symptomatic treatment",{"EARLY_PHASE1":16172,"PHASE1":16174,"PHASE2":16176,"PHASE3":16178,"PHASE4":16190,"NA":16192},{"trials":16173,"activeCount":102},[],{"trials":16175,"activeCount":102},[],{"trials":16177,"activeCount":102},[],{"trials":16179,"activeCount":102},[16180],{"nctId":16181,"briefTitle":16182,"status":139,"phases":16183,"primaryCompletion":16184,"completion":16184,"start":16185,"enrollment":1108,"conditions":16186,"interventions":16188},"NCT01508468","Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy",[92],"2016-08-31","2012-01-17",[16187],"Idiopathic Membranous Nephropathy",[16170,16189],"experimental",{"trials":16191,"activeCount":102},[],{"trials":16193,"activeCount":102},[],{"intervention":16189,"totalTrials":180,"cells":16195},{"EARLY_PHASE1":16196,"PHASE1":16198,"PHASE2":16200,"PHASE3":16202,"PHASE4":16208,"NA":16210},{"trials":16197,"activeCount":102},[],{"trials":16199,"activeCount":102},[],{"trials":16201,"activeCount":102},[],{"trials":16203,"activeCount":102},[16204],{"nctId":16181,"briefTitle":16182,"status":139,"phases":16205,"primaryCompletion":16184,"completion":16184,"start":16185,"enrollment":1108,"conditions":16206,"interventions":16207},[92],[16187],[16170,16189],{"trials":16209,"activeCount":102},[],{"trials":16211,"activeCount":102},[],{"intervention":16213,"totalTrials":180,"cells":16214},"Dexamfetamine sulphate",{"EARLY_PHASE1":16215,"PHASE1":16217,"PHASE2":16219,"PHASE3":16221,"PHASE4":16230,"NA":16232},{"trials":16216,"activeCount":102},[],{"trials":16218,"activeCount":102},[],{"trials":16220,"activeCount":102},[],{"trials":16222,"activeCount":102},[16223],{"nctId":16224,"briefTitle":16225,"status":110,"phases":16226,"primaryCompletion":11592,"completion":7865,"start":9996,"enrollment":958,"conditions":16227,"interventions":16229},"NCT02363075","Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia",[92],[16228],"Glioma",[16213],{"trials":16231,"activeCount":102},[],{"trials":16233,"activeCount":102},[],{"intervention":16235,"totalTrials":180,"cells":16236},"Josamycin",{"EARLY_PHASE1":16237,"PHASE1":16239,"PHASE2":16241,"PHASE3":16243,"PHASE4":16254,"NA":16256},{"trials":16238,"activeCount":102},[],{"trials":16240,"activeCount":102},[],{"trials":16242,"activeCount":102},[],{"trials":16244,"activeCount":102},[16245],{"nctId":16246,"briefTitle":16247,"status":139,"phases":16248,"primaryCompletion":10680,"completion":10680,"start":16249,"enrollment":16250,"conditions":16251,"interventions":16253},"NCT00718705","Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin)",[92],"2008-07",3200,[16252],"Prematurity",[16235],{"trials":16255,"activeCount":102},[],{"trials":16257,"activeCount":102},[],{"intervention":16259,"totalTrials":180,"cells":16260},"D->R->C+R",{"EARLY_PHASE1":16261,"PHASE1":16263,"PHASE2":16265,"PHASE3":16267,"PHASE4":16278,"NA":16280},{"trials":16262,"activeCount":102},[],{"trials":16264,"activeCount":102},[],{"trials":16266,"activeCount":102},[],{"trials":16268,"activeCount":102},[16269],{"nctId":16270,"briefTitle":16271,"status":139,"phases":16272,"primaryCompletion":8063,"completion":8063,"start":956,"enrollment":6773,"conditions":16273,"interventions":16274},"NCT01627665","Pharmacogenomic Study on PKD\u002FPKC of Dabigatran Etexilate and Rivaroxaban",[91,92],[5727],[16259,16275,16276,16277],"D->R->C+D","R->D->C+D","R->D->C+R",{"trials":16279,"activeCount":102},[],{"trials":16281,"activeCount":102},[],{"intervention":16275,"totalTrials":180,"cells":16283},{"EARLY_PHASE1":16284,"PHASE1":16286,"PHASE2":16288,"PHASE3":16290,"PHASE4":16296,"NA":16298},{"trials":16285,"activeCount":102},[],{"trials":16287,"activeCount":102},[],{"trials":16289,"activeCount":102},[],{"trials":16291,"activeCount":102},[16292],{"nctId":16270,"briefTitle":16271,"status":139,"phases":16293,"primaryCompletion":8063,"completion":8063,"start":956,"enrollment":6773,"conditions":16294,"interventions":16295},[91,92],[5727],[16259,16275,16276,16277],{"trials":16297,"activeCount":102},[],{"trials":16299,"activeCount":102},[],{"intervention":16276,"totalTrials":180,"cells":16301},{"EARLY_PHASE1":16302,"PHASE1":16304,"PHASE2":16306,"PHASE3":16308,"PHASE4":16314,"NA":16316},{"trials":16303,"activeCount":102},[],{"trials":16305,"activeCount":102},[],{"trials":16307,"activeCount":102},[],{"trials":16309,"activeCount":102},[16310],{"nctId":16270,"briefTitle":16271,"status":139,"phases":16311,"primaryCompletion":8063,"completion":8063,"start":956,"enrollment":6773,"conditions":16312,"interventions":16313},[91,92],[5727],[16259,16275,16276,16277],{"trials":16315,"activeCount":102},[],{"trials":16317,"activeCount":102},[],{"intervention":16277,"totalTrials":180,"cells":16319},{"EARLY_PHASE1":16320,"PHASE1":16322,"PHASE2":16324,"PHASE3":16326,"PHASE4":16332,"NA":16334},{"trials":16321,"activeCount":102},[],{"trials":16323,"activeCount":102},[],{"trials":16325,"activeCount":102},[],{"trials":16327,"activeCount":102},[16328],{"nctId":16270,"briefTitle":16271,"status":139,"phases":16329,"primaryCompletion":8063,"completion":8063,"start":956,"enrollment":6773,"conditions":16330,"interventions":16331},[91,92],[5727],[16259,16275,16276,16277],{"trials":16333,"activeCount":102},[],{"trials":16335,"activeCount":102},[],{"intervention":994,"totalTrials":180,"cells":16337},{"EARLY_PHASE1":16338,"PHASE1":16340,"PHASE2":16342,"PHASE3":16344,"PHASE4":16350,"NA":16352},{"trials":16339,"activeCount":102},[],{"trials":16341,"activeCount":102},[],{"trials":16343,"activeCount":102},[],{"trials":16345,"activeCount":102},[16346],{"nctId":985,"briefTitle":986,"status":139,"phases":16347,"primaryCompletion":988,"completion":989,"start":990,"enrollment":388,"conditions":16348,"interventions":16349},[92],[992],[251,994],{"trials":16351,"activeCount":102},[],{"trials":16353,"activeCount":102},[],{"intervention":16355,"totalTrials":180,"cells":16356},"Plasmalyte",{"EARLY_PHASE1":16357,"PHASE1":16359,"PHASE2":16361,"PHASE3":16363,"PHASE4":16377,"NA":16379},{"trials":16358,"activeCount":102},[],{"trials":16360,"activeCount":102},[],{"trials":16362,"activeCount":102},[],{"trials":16364,"activeCount":102},[16365],{"nctId":16366,"briefTitle":16367,"status":139,"phases":16368,"primaryCompletion":16369,"completion":16370,"start":16371,"enrollment":24,"conditions":16372,"interventions":16375},"NCT03118362","Fluid Resuscitation in Burn Patients",[92],"2018-09-12","2019-12-02","2017-08-09",[16373,16374],"Severe Burns","Fluid Resuscitation",[16355,16376],"Ringer lactate",{"trials":16378,"activeCount":102},[],{"trials":16380,"activeCount":102},[],{"intervention":16376,"totalTrials":180,"cells":16382},{"EARLY_PHASE1":16383,"PHASE1":16385,"PHASE2":16387,"PHASE3":16389,"PHASE4":16395,"NA":16397},{"trials":16384,"activeCount":102},[],{"trials":16386,"activeCount":102},[],{"trials":16388,"activeCount":102},[],{"trials":16390,"activeCount":102},[16391],{"nctId":16366,"briefTitle":16367,"status":139,"phases":16392,"primaryCompletion":16369,"completion":16370,"start":16371,"enrollment":24,"conditions":16393,"interventions":16394},[92],[16373,16374],[16355,16376],{"trials":16396,"activeCount":102},[],{"trials":16398,"activeCount":102},[],{"intervention":16400,"totalTrials":180,"cells":16401},"optimal medical therapy",{"EARLY_PHASE1":16402,"PHASE1":16404,"PHASE2":16406,"PHASE3":16408,"PHASE4":16417,"NA":16419},{"trials":16403,"activeCount":102},[],{"trials":16405,"activeCount":102},[],{"trials":16407,"activeCount":102},[],{"trials":16409,"activeCount":102},[16410],{"nctId":16411,"briefTitle":16412,"status":241,"phases":16413,"primaryCompletion":1939,"completion":1939,"start":5162,"enrollment":473,"conditions":16414,"interventions":16416},"NCT01795729","Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction",[92],[16415],"Heart-lung Transplant Rejection",[16400],{"trials":16418,"activeCount":102},[],{"trials":16420,"activeCount":102},[],{"intervention":16422,"totalTrials":180,"cells":16423},"Darbepoetin alfa",{"EARLY_PHASE1":16424,"PHASE1":16426,"PHASE2":16428,"PHASE3":16430,"PHASE4":16438,"NA":16440},{"trials":16425,"activeCount":102},[],{"trials":16427,"activeCount":102},[],{"trials":16429,"activeCount":102},[],{"trials":16431,"activeCount":102},[16432],{"nctId":16433,"briefTitle":16434,"status":5932,"phases":16435,"primaryCompletion":990,"completion":990,"start":1834,"enrollment":102,"conditions":16436,"interventions":16437},"NCT00579046","Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease",[92],[13877,1677],[16422],{"trials":16439,"activeCount":102},[],{"trials":16441,"activeCount":102},[],{"intervention":16443,"totalTrials":180,"cells":16444},"Denosumab",{"EARLY_PHASE1":16445,"PHASE1":16447,"PHASE2":16449,"PHASE3":16451,"PHASE4":16463,"NA":16465},{"trials":16446,"activeCount":102},[],{"trials":16448,"activeCount":102},[],{"trials":16450,"activeCount":102},[],{"trials":16452,"activeCount":102},[16453],{"nctId":16454,"briefTitle":16455,"status":139,"phases":16456,"primaryCompletion":16457,"completion":16457,"start":16458,"enrollment":27,"conditions":16459,"interventions":16462},"NCT03401060","Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis",[92],"2024-03-11","2018-03-05",[16460,16461],"Osteoporosis","Systemic Mastocytosis",[16443],{"trials":16464,"activeCount":102},[],{"trials":16466,"activeCount":102},[],{"intervention":16468,"totalTrials":180,"cells":16469},"Experimental for steroid",{"EARLY_PHASE1":16470,"PHASE1":16472,"PHASE2":16474,"PHASE3":16476,"PHASE4":16490,"NA":16492},{"trials":16471,"activeCount":102},[],{"trials":16473,"activeCount":102},[],{"trials":16475,"activeCount":102},[],{"trials":16477,"activeCount":102},[16478],{"nctId":16479,"briefTitle":16480,"status":110,"phases":16481,"primaryCompletion":16482,"completion":16483,"start":16484,"enrollment":2509,"conditions":16485,"interventions":16487},"NCT04680884","Empirical Steroids and\u002For Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial",[92],"2023-09-21","2023-12-21","2020-12-21",[12218,16486],"Immunocompromised Patients",[16468,16488,16489],"Experimental for antifungals","Experimental for steroids and antifungals",{"trials":16491,"activeCount":102},[],{"trials":16493,"activeCount":102},[],{"intervention":16488,"totalTrials":180,"cells":16495},{"EARLY_PHASE1":16496,"PHASE1":16498,"PHASE2":16500,"PHASE3":16502,"PHASE4":16508,"NA":16510},{"trials":16497,"activeCount":102},[],{"trials":16499,"activeCount":102},[],{"trials":16501,"activeCount":102},[],{"trials":16503,"activeCount":102},[16504],{"nctId":16479,"briefTitle":16480,"status":110,"phases":16505,"primaryCompletion":16482,"completion":16483,"start":16484,"enrollment":2509,"conditions":16506,"interventions":16507},[92],[12218,16486],[16468,16488,16489],{"trials":16509,"activeCount":102},[],{"trials":16511,"activeCount":102},[],{"intervention":16489,"totalTrials":180,"cells":16513},{"EARLY_PHASE1":16514,"PHASE1":16516,"PHASE2":16518,"PHASE3":16520,"PHASE4":16526,"NA":16528},{"trials":16515,"activeCount":102},[],{"trials":16517,"activeCount":102},[],{"trials":16519,"activeCount":102},[],{"trials":16521,"activeCount":102},[16522],{"nctId":16479,"briefTitle":16480,"status":110,"phases":16523,"primaryCompletion":16482,"completion":16483,"start":16484,"enrollment":2509,"conditions":16524,"interventions":16525},[92],[12218,16486],[16468,16488,16489],{"trials":16527,"activeCount":102},[],{"trials":16529,"activeCount":102},[],{"intervention":16531,"totalTrials":180,"cells":16532},"tenecteplase",{"EARLY_PHASE1":16533,"PHASE1":16535,"PHASE2":16537,"PHASE3":16539,"PHASE4":16550,"NA":16552},{"trials":16534,"activeCount":102},[],{"trials":16536,"activeCount":102},[],{"trials":16538,"activeCount":102},[],{"trials":16540,"activeCount":102},[16541],{"nctId":16542,"briefTitle":16543,"status":139,"phases":16544,"primaryCompletion":16545,"completion":7896,"start":16546,"enrollment":16547,"conditions":16548,"interventions":16549},"NCT00639743","PEITHO Pulmonary Embolism Thrombolysis Study",[92],"2012-07-26","2007-11-16",1005,[4926],[16531],{"trials":16551,"activeCount":102},[],{"trials":16553,"activeCount":102},[],{"intervention":16555,"totalTrials":180,"cells":16556},"PCV chemotherapy alone",{"EARLY_PHASE1":16557,"PHASE1":16559,"PHASE2":16561,"PHASE3":16563,"PHASE4":16576,"NA":16578},{"trials":16558,"activeCount":102},[],{"trials":16560,"activeCount":102},[],{"trials":16562,"activeCount":102},[],{"trials":16564,"activeCount":102},[16565],{"nctId":16566,"briefTitle":16567,"status":139,"phases":16568,"primaryCompletion":16569,"completion":16570,"start":16571,"enrollment":4321,"conditions":16572,"interventions":16574},"NCT02444000","gliomasPCV Only in 1p\u002F19q Codeleted Anaplastic Gliomas",[92],"2022-10-11","2024-09-21","2015-09-22",[16573],"Anaplastic Gliomas With 1p\u002F19q Codeletion",[16555,16575],"Radiotherapy+PCV chemotherapy",{"trials":16577,"activeCount":102},[],{"trials":16579,"activeCount":102},[],{"intervention":16575,"totalTrials":180,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16588,"PHASE4":16594,"NA":16596},{"trials":16583,"activeCount":102},[],{"trials":16585,"activeCount":102},[],{"trials":16587,"activeCount":102},[],{"trials":16589,"activeCount":102},[16590],{"nctId":16566,"briefTitle":16567,"status":139,"phases":16591,"primaryCompletion":16569,"completion":16570,"start":16571,"enrollment":4321,"conditions":16592,"interventions":16593},[92],[16573],[16555,16575],{"trials":16595,"activeCount":102},[],{"trials":16597,"activeCount":102},[],{"intervention":16599,"totalTrials":180,"cells":16600},"Buspirone",{"EARLY_PHASE1":16601,"PHASE1":16603,"PHASE2":16605,"PHASE3":16607,"PHASE4":16617,"NA":16619},{"trials":16602,"activeCount":102},[],{"trials":16604,"activeCount":102},[],{"trials":16606,"activeCount":102},[],{"trials":16608,"activeCount":102},[16609],{"nctId":16610,"briefTitle":16611,"status":139,"phases":16612,"primaryCompletion":3719,"completion":3719,"start":16613,"enrollment":13387,"conditions":16614,"interventions":16616},"NCT02617017","Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease",[92],"2016-06-17",[16615],"Parkinson",[16599],{"trials":16618,"activeCount":102},[],{"trials":16620,"activeCount":102},[],{"intervention":16622,"totalTrials":180,"cells":16623},"Melatonin 10 µg",{"EARLY_PHASE1":16624,"PHASE1":16626,"PHASE2":16628,"PHASE3":16630,"PHASE4":16640,"NA":16642},{"trials":16625,"activeCount":102},[],{"trials":16627,"activeCount":102},[],{"trials":16629,"activeCount":102},[],{"trials":16631,"activeCount":102},[16632],{"nctId":16633,"briefTitle":16634,"status":241,"phases":16635,"primaryCompletion":16636,"completion":16636,"start":8005,"enrollment":245,"conditions":16637,"interventions":16638},"NCT02395783","Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease",[91,92],"2018-02",[14854],[16622,16639],"Melatonin 20 µg",{"trials":16641,"activeCount":102},[],{"trials":16643,"activeCount":102},[],{"intervention":16639,"totalTrials":180,"cells":16645},{"EARLY_PHASE1":16646,"PHASE1":16648,"PHASE2":16650,"PHASE3":16652,"PHASE4":16658,"NA":16660},{"trials":16647,"activeCount":102},[],{"trials":16649,"activeCount":102},[],{"trials":16651,"activeCount":102},[],{"trials":16653,"activeCount":102},[16654],{"nctId":16633,"briefTitle":16634,"status":241,"phases":16655,"primaryCompletion":16636,"completion":16636,"start":8005,"enrollment":245,"conditions":16656,"interventions":16657},[91,92],[14854],[16622,16639],{"trials":16659,"activeCount":102},[],{"trials":16661,"activeCount":102},[],{"intervention":16663,"totalTrials":180,"cells":16664},"Clonazepam",{"EARLY_PHASE1":16665,"PHASE1":16667,"PHASE2":16669,"PHASE3":16671,"PHASE4":16685,"NA":16687},{"trials":16666,"activeCount":102},[],{"trials":16668,"activeCount":102},[],{"trials":16670,"activeCount":102},[],{"trials":16672,"activeCount":102},[16673],{"nctId":16674,"briefTitle":16675,"status":139,"phases":16676,"primaryCompletion":16677,"completion":16677,"start":16678,"enrollment":16679,"conditions":16680,"interventions":16682},"NCT01870024","Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus",[92],"2018-02-23","2013-06-26",434,[16681,7686],"Status Epilepticus",[16663,16683,16684],"Fosphenytoin","Lorazepam",{"trials":16686,"activeCount":102},[],{"trials":16688,"activeCount":102},[],{"intervention":16683,"totalTrials":180,"cells":16690},{"EARLY_PHASE1":16691,"PHASE1":16693,"PHASE2":16695,"PHASE3":16697,"PHASE4":16703,"NA":16705},{"trials":16692,"activeCount":102},[],{"trials":16694,"activeCount":102},[],{"trials":16696,"activeCount":102},[],{"trials":16698,"activeCount":102},[16699],{"nctId":16674,"briefTitle":16675,"status":139,"phases":16700,"primaryCompletion":16677,"completion":16677,"start":16678,"enrollment":16679,"conditions":16701,"interventions":16702},[92],[16681,7686],[16663,16683,16684],{"trials":16704,"activeCount":102},[],{"trials":16706,"activeCount":102},[],{"intervention":16684,"totalTrials":180,"cells":16708},{"EARLY_PHASE1":16709,"PHASE1":16711,"PHASE2":16713,"PHASE3":16715,"PHASE4":16721,"NA":16723},{"trials":16710,"activeCount":102},[],{"trials":16712,"activeCount":102},[],{"trials":16714,"activeCount":102},[],{"trials":16716,"activeCount":102},[16717],{"nctId":16674,"briefTitle":16675,"status":139,"phases":16718,"primaryCompletion":16677,"completion":16677,"start":16678,"enrollment":16679,"conditions":16719,"interventions":16720},[92],[16681,7686],[16663,16683,16684],{"trials":16722,"activeCount":102},[],{"trials":16724,"activeCount":102},[],{"intervention":10060,"totalTrials":180,"cells":16726},{"EARLY_PHASE1":16727,"PHASE1":16729,"PHASE2":16731,"PHASE3":16733,"PHASE4":16739,"NA":16741},{"trials":16728,"activeCount":102},[],{"trials":16730,"activeCount":102},[],{"trials":16732,"activeCount":102},[],{"trials":16734,"activeCount":102},[16735],{"nctId":10051,"briefTitle":10052,"status":139,"phases":16736,"primaryCompletion":1908,"completion":1908,"start":5183,"enrollment":6773,"conditions":16737,"interventions":16738},[92],[10055,10056,10057,10058],[10040,10060],{"trials":16740,"activeCount":102},[],{"trials":16742,"activeCount":102},[],{"intervention":16744,"totalTrials":180,"cells":16745},"Glyburide",{"EARLY_PHASE1":16746,"PHASE1":16748,"PHASE2":16750,"PHASE3":16752,"PHASE4":16764,"NA":16766},{"trials":16747,"activeCount":102},[],{"trials":16749,"activeCount":102},[],{"trials":16751,"activeCount":102},[],{"trials":16753,"activeCount":102},[16754],{"nctId":16755,"briefTitle":16756,"status":139,"phases":16757,"primaryCompletion":16758,"completion":8267,"start":16759,"enrollment":16760,"conditions":16761,"interventions":16763},"NCT01731431","Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes",[92],"2017-03-15","2012-05-18",914,[1533,16762],"Gestational",[16744],{"trials":16765,"activeCount":102},[],{"trials":16767,"activeCount":102},[],{"intervention":506,"totalTrials":180,"cells":16769},{"EARLY_PHASE1":16770,"PHASE1":16772,"PHASE2":16774,"PHASE3":16776,"PHASE4":16782,"NA":16784},{"trials":16771,"activeCount":102},[],{"trials":16773,"activeCount":102},[],{"trials":16775,"activeCount":102},[],{"trials":16777,"activeCount":102},[16778],{"nctId":494,"briefTitle":495,"status":139,"phases":16779,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":16780,"interventions":16781},[92],[465,501,502,503],[505,506],{"trials":16783,"activeCount":102},[],{"trials":16785,"activeCount":102},[],{"intervention":16787,"totalTrials":180,"cells":16788},"Seasonal influenza vaccine available for the 2012-2013 vaccine campaign",{"EARLY_PHASE1":16789,"PHASE1":16791,"PHASE2":16793,"PHASE3":16795,"PHASE4":16805,"NA":16807},{"trials":16790,"activeCount":102},[],{"trials":16792,"activeCount":102},[],{"trials":16794,"activeCount":102},[],{"trials":16796,"activeCount":102},[16797],{"nctId":16798,"briefTitle":16799,"status":139,"phases":16800,"primaryCompletion":386,"completion":7960,"start":13760,"enrollment":16801,"conditions":16802,"interventions":16804},"NCT01687517","Efficacy and Safety of Influenza Vaccine During Sarcoidosis",[92],190,[3721,16803],"Influenza Vaccine",[16787],{"trials":16806,"activeCount":102},[],{"trials":16808,"activeCount":102},[],{"intervention":2257,"totalTrials":180,"cells":16810},{"EARLY_PHASE1":16811,"PHASE1":16813,"PHASE2":16815,"PHASE3":16817,"PHASE4":16823,"NA":16825},{"trials":16812,"activeCount":102},[],{"trials":16814,"activeCount":102},[],{"trials":16816,"activeCount":102},[],{"trials":16818,"activeCount":102},[16819],{"nctId":2247,"briefTitle":2248,"status":139,"phases":16820,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":2253,"conditions":16821,"interventions":16822},[92],[2255],[2257,2236],{"trials":16824,"activeCount":102},[],{"trials":16826,"activeCount":102},[],{"intervention":16828,"totalTrials":180,"cells":16829},"Temocillin",{"EARLY_PHASE1":16830,"PHASE1":16832,"PHASE2":16834,"PHASE3":16836,"PHASE4":16848,"NA":16850},{"trials":16831,"activeCount":102},[],{"trials":16833,"activeCount":102},[],{"trials":16835,"activeCount":102},[],{"trials":16837,"activeCount":102},[16838],{"nctId":16839,"briefTitle":16840,"status":139,"phases":16841,"primaryCompletion":16842,"completion":12731,"start":16843,"enrollment":5940,"conditions":16844,"interventions":16846},"NCT03543436","Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections",[92],"2020-10-29","2019-01-04",[16845],"Urinary Tract Infections",[16828,16847],"meropenem or imipenem",{"trials":16849,"activeCount":102},[],{"trials":16851,"activeCount":102},[],{"intervention":16847,"totalTrials":180,"cells":16853},{"EARLY_PHASE1":16854,"PHASE1":16856,"PHASE2":16858,"PHASE3":16860,"PHASE4":16866,"NA":16868},{"trials":16855,"activeCount":102},[],{"trials":16857,"activeCount":102},[],{"trials":16859,"activeCount":102},[],{"trials":16861,"activeCount":102},[16862],{"nctId":16839,"briefTitle":16840,"status":139,"phases":16863,"primaryCompletion":16842,"completion":12731,"start":16843,"enrollment":5940,"conditions":16864,"interventions":16865},[92],[16845],[16828,16847],{"trials":16867,"activeCount":102},[],{"trials":16869,"activeCount":102},[],{"intervention":16871,"totalTrials":180,"cells":16872},"ANAKINRA 100 mg\u002Fdaily subcutaneously",{"EARLY_PHASE1":16873,"PHASE1":16875,"PHASE2":16877,"PHASE3":16879,"PHASE4":16889,"NA":16891},{"trials":16874,"activeCount":102},[],{"trials":16876,"activeCount":102},[],{"trials":16878,"activeCount":102},[],{"trials":16880,"activeCount":102},[16881],{"nctId":16882,"briefTitle":16883,"status":139,"phases":16884,"primaryCompletion":16885,"completion":3148,"start":16886,"enrollment":1277,"conditions":16887,"interventions":16888},"NCT03018834","Anakinra Versus Placebo for the Treatment of Acute MyocarditIS",[91,92],"2021-06-28","2017-05-30",[2511],[16871],{"trials":16890,"activeCount":102},[],{"trials":16892,"activeCount":102},[],{"intervention":16894,"totalTrials":180,"cells":16895},"Spironolactone",{"EARLY_PHASE1":16896,"PHASE1":16898,"PHASE2":16900,"PHASE3":16902,"PHASE4":16912,"NA":16914},{"trials":16897,"activeCount":102},[],{"trials":16899,"activeCount":102},[],{"trials":16901,"activeCount":102},[],{"trials":16903,"activeCount":102},[16904],{"nctId":16905,"briefTitle":16906,"status":139,"phases":16907,"primaryCompletion":16908,"completion":16908,"start":5418,"enrollment":16909,"conditions":16910,"interventions":16911},"NCT01059136","Aldosterone Blockade Early After Acute Myocardial Infarction",[92],"2014-08",1603,[4742],[16894],{"trials":16913,"activeCount":102},[],{"trials":16915,"activeCount":102},[],{"intervention":16917,"totalTrials":180,"cells":16918},"Enoxaparine",{"EARLY_PHASE1":16919,"PHASE1":16921,"PHASE2":16923,"PHASE3":16925,"PHASE4":16935,"NA":16937},{"trials":16920,"activeCount":102},[],{"trials":16922,"activeCount":102},[],{"trials":16924,"activeCount":102},[],{"trials":16926,"activeCount":102},[16927],{"nctId":16928,"briefTitle":16929,"status":936,"phases":16930,"primaryCompletion":16931,"completion":16931,"start":16932,"enrollment":1258,"conditions":16933,"interventions":16934},"NCT02271295","Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients",[92],"2019-07-02","2015-07-27",[1500],[16917],{"trials":16936,"activeCount":102},[],{"trials":16938,"activeCount":102},[],{"intervention":16940,"totalTrials":180,"cells":16941},"Comirnaty® BNT162b2 \u002FOmicron BA.4-5 vaccine",{"EARLY_PHASE1":16942,"PHASE1":16944,"PHASE2":16946,"PHASE3":16948,"PHASE4":16961,"NA":16963},{"trials":16943,"activeCount":102},[],{"trials":16945,"activeCount":102},[],{"trials":16947,"activeCount":102},[],{"trials":16949,"activeCount":102},[16950],{"nctId":16951,"briefTitle":16952,"status":110,"phases":16953,"primaryCompletion":16954,"completion":16955,"start":16956,"enrollment":16957,"conditions":16958,"interventions":16959},"NCT05749926","Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original\u002FOmicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine",[92],"2023-07-12","2024-07-12","2023-05-16",248,[12915,15],[16940,16960],"VidPrevtyn® Beta vaccine",{"trials":16962,"activeCount":102},[],{"trials":16964,"activeCount":102},[],{"intervention":16960,"totalTrials":180,"cells":16966},{"EARLY_PHASE1":16967,"PHASE1":16969,"PHASE2":16971,"PHASE3":16973,"PHASE4":16979,"NA":16981},{"trials":16968,"activeCount":102},[],{"trials":16970,"activeCount":102},[],{"trials":16972,"activeCount":102},[],{"trials":16974,"activeCount":102},[16975],{"nctId":16951,"briefTitle":16952,"status":110,"phases":16976,"primaryCompletion":16954,"completion":16955,"start":16956,"enrollment":16957,"conditions":16977,"interventions":16978},[92],[12915,15],[16940,16960],{"trials":16980,"activeCount":102},[],{"trials":16982,"activeCount":102},[],{"intervention":16984,"totalTrials":180,"cells":16985},"Lithium Carbonate",{"EARLY_PHASE1":16986,"PHASE1":16988,"PHASE2":16990,"PHASE3":16992,"PHASE4":17002,"NA":17004},{"trials":16987,"activeCount":102},[],{"trials":16989,"activeCount":102},[],{"trials":16991,"activeCount":102},[],{"trials":16993,"activeCount":102},[16994],{"nctId":16995,"briefTitle":16996,"status":139,"phases":16997,"primaryCompletion":16998,"completion":16998,"start":16999,"enrollment":323,"conditions":17000,"interventions":17001},"NCT04623398","Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)",[92],"2024-08-26","2022-02-21",[5408],[16984],{"trials":17003,"activeCount":102},[],{"trials":17005,"activeCount":102},[],{"intervention":12701,"totalTrials":180,"cells":17007},{"EARLY_PHASE1":17008,"PHASE1":17010,"PHASE2":17012,"PHASE3":17014,"PHASE4":17020,"NA":17022},{"trials":17009,"activeCount":102},[],{"trials":17011,"activeCount":102},[],{"trials":17013,"activeCount":102},[],{"trials":17015,"activeCount":102},[17016],{"nctId":12693,"briefTitle":12694,"status":5932,"phases":17017,"primaryCompletion":12696,"completion":1187,"start":12697,"enrollment":102,"conditions":17018,"interventions":17019},[92],[12699],[12701,12702,12703],{"trials":17021,"activeCount":102},[],{"trials":17023,"activeCount":102},[],{"intervention":12702,"totalTrials":180,"cells":17025},{"EARLY_PHASE1":17026,"PHASE1":17028,"PHASE2":17030,"PHASE3":17032,"PHASE4":17038,"NA":17040},{"trials":17027,"activeCount":102},[],{"trials":17029,"activeCount":102},[],{"trials":17031,"activeCount":102},[],{"trials":17033,"activeCount":102},[17034],{"nctId":12693,"briefTitle":12694,"status":5932,"phases":17035,"primaryCompletion":12696,"completion":1187,"start":12697,"enrollment":102,"conditions":17036,"interventions":17037},[92],[12699],[12701,12702,12703],{"trials":17039,"activeCount":102},[],{"trials":17041,"activeCount":102},[],{"intervention":17043,"totalTrials":180,"cells":17044},"Tamsulosin",{"EARLY_PHASE1":17045,"PHASE1":17047,"PHASE2":17049,"PHASE3":17051,"PHASE4":17060,"NA":17062},{"trials":17046,"activeCount":102},[],{"trials":17048,"activeCount":102},[],{"trials":17050,"activeCount":102},[],{"trials":17052,"activeCount":102},[17053],{"nctId":17054,"briefTitle":17055,"status":241,"phases":17056,"primaryCompletion":8063,"completion":8063,"start":536,"enrollment":9911,"conditions":17057,"interventions":17059},"NCT01747993","Tamsulosin for Urinary Retention in Hospitalized Older Women",[92],[17058],"Urinary Retention",[17043],{"trials":17061,"activeCount":102},[],{"trials":17063,"activeCount":102},[],{"intervention":17065,"totalTrials":180,"cells":17066},"Ursodeoxycholic acid",{"EARLY_PHASE1":17067,"PHASE1":17069,"PHASE2":17071,"PHASE3":17073,"PHASE4":17083,"NA":17085},{"trials":17068,"activeCount":102},[],{"trials":17070,"activeCount":102},[],{"trials":17072,"activeCount":102},[],{"trials":17074,"activeCount":102},[17075],{"nctId":17076,"briefTitle":17077,"status":110,"phases":17078,"primaryCompletion":10507,"completion":990,"start":17079,"enrollment":5804,"conditions":17080,"interventions":17082},"NCT00134758","Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients",[91,92],"2004-10",[17081],"Adenomatous Polyposis Coli, Familial",[17065],{"trials":17084,"activeCount":102},[],{"trials":17086,"activeCount":102},[],{"intervention":17088,"totalTrials":180,"cells":17089},"zonegran",{"EARLY_PHASE1":17090,"PHASE1":17092,"PHASE2":17094,"PHASE3":17096,"PHASE4":17105,"NA":17107},{"trials":17091,"activeCount":102},[],{"trials":17093,"activeCount":102},[],{"trials":17095,"activeCount":102},[],{"trials":17097,"activeCount":102},[17098],{"nctId":17099,"briefTitle":17100,"status":139,"phases":17101,"primaryCompletion":988,"completion":988,"start":10832,"enrollment":27,"conditions":17102,"interventions":17104},"NCT01806805","Efficacy Trial of Zonisamide for Myoclonus Dystonia",[92],[17103],"Myoclonus Dystonia",[17088],{"trials":17106,"activeCount":102},[],{"trials":17108,"activeCount":102},[],{"intervention":17110,"totalTrials":180,"cells":17111},"nicotine versus placebo",{"EARLY_PHASE1":17112,"PHASE1":17114,"PHASE2":17116,"PHASE3":17118,"PHASE4":17128,"NA":17130},{"trials":17113,"activeCount":102},[],{"trials":17115,"activeCount":102},[],{"trials":17117,"activeCount":102},[],{"trials":17119,"activeCount":102},[17120],{"nctId":17121,"briefTitle":17122,"status":139,"phases":17123,"primaryCompletion":12216,"completion":12216,"start":9880,"enrollment":17124,"conditions":17125,"interventions":17127},"NCT00507975","Study of Nicotine Patch in Pregnancy (SNIPP)",[92],404,[17126],"Smoking",[17110],{"trials":17129,"activeCount":102},[],{"trials":17131,"activeCount":102},[],{"intervention":17133,"totalTrials":180,"cells":17134},"tiludronic acid",{"EARLY_PHASE1":17135,"PHASE1":17137,"PHASE2":17139,"PHASE3":17141,"PHASE4":17150,"NA":17152},{"trials":17136,"activeCount":102},[],{"trials":17138,"activeCount":102},[],{"trials":17140,"activeCount":102},[],{"trials":17142,"activeCount":102},[17143],{"nctId":17144,"briefTitle":17145,"status":241,"phases":17146,"primaryCompletion":12093,"completion":11592,"start":12305,"enrollment":8742,"conditions":17147,"interventions":17149},"NCT01617057","Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis",[92],[17148],"Otosclerosis",[17133],{"trials":17151,"activeCount":102},[],{"trials":17153,"activeCount":102},[],{"intervention":17155,"totalTrials":180,"cells":17156},"becaplermin gel",{"EARLY_PHASE1":17157,"PHASE1":17159,"PHASE2":17161,"PHASE3":17163,"PHASE4":17177,"NA":17179},{"trials":17158,"activeCount":102},[],{"trials":17160,"activeCount":102},[],{"trials":17162,"activeCount":102},[],{"trials":17164,"activeCount":102},[17165],{"nctId":17166,"briefTitle":17167,"status":139,"phases":17168,"primaryCompletion":17169,"completion":10507,"start":17170,"enrollment":6773,"conditions":17171,"interventions":17175},"NCT00970697","Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers",[92],"2009-05","2004-01",[17172,17173,17174],"MARTORELL'S ULCER","Hypertensive Leg Ulcer","Necrotic Angiodermatitis",[17155,17176],"Duoderm Hydrogel™",{"trials":17178,"activeCount":102},[],{"trials":17180,"activeCount":102},[],{"intervention":17176,"totalTrials":180,"cells":17182},{"EARLY_PHASE1":17183,"PHASE1":17185,"PHASE2":17187,"PHASE3":17189,"PHASE4":17195,"NA":17197},{"trials":17184,"activeCount":102},[],{"trials":17186,"activeCount":102},[],{"trials":17188,"activeCount":102},[],{"trials":17190,"activeCount":102},[17191],{"nctId":17166,"briefTitle":17167,"status":139,"phases":17192,"primaryCompletion":17169,"completion":10507,"start":17170,"enrollment":6773,"conditions":17193,"interventions":17194},[92],[17172,17173,17174],[17155,17176],{"trials":17196,"activeCount":102},[],{"trials":17198,"activeCount":102},[],{"intervention":17200,"totalTrials":180,"cells":17201},"Hydrochlorothiazide",{"EARLY_PHASE1":17202,"PHASE1":17204,"PHASE2":17206,"PHASE3":17208,"PHASE4":17219,"NA":17221},{"trials":17203,"activeCount":102},[],{"trials":17205,"activeCount":102},[],{"trials":17207,"activeCount":102},[],{"trials":17209,"activeCount":102},[17210],{"nctId":17211,"briefTitle":17212,"status":241,"phases":17213,"primaryCompletion":5196,"completion":5196,"start":17214,"enrollment":5575,"conditions":17215,"interventions":17218},"NCT00638482","Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria",[91,92],"2003-07",[17216,17217],"Dent's Disease","Nephrolithiasis",[17200],{"trials":17220,"activeCount":102},[],{"trials":17222,"activeCount":102},[],{"intervention":17224,"totalTrials":180,"cells":17225},"erythropoietin Beta",{"EARLY_PHASE1":17226,"PHASE1":17228,"PHASE2":17230,"PHASE3":17232,"PHASE4":17243,"NA":17245},{"trials":17227,"activeCount":102},[],{"trials":17229,"activeCount":102},[],{"trials":17231,"activeCount":102},[],{"trials":17233,"activeCount":102},[17234],{"nctId":17235,"briefTitle":17236,"status":139,"phases":17237,"primaryCompletion":17238,"completion":17238,"start":17239,"enrollment":1277,"conditions":17240,"interventions":17242},"NCT01732146","Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy",[92],"2017-02-14","2013-03-28",[17241],"Hypoxic Ischemic Encephalopathy",[17224],{"trials":17244,"activeCount":102},[],{"trials":17246,"activeCount":102},[],{"intervention":12917,"totalTrials":180,"cells":17248},{"EARLY_PHASE1":17249,"PHASE1":17251,"PHASE2":17253,"PHASE3":17255,"PHASE4":17261,"NA":17263},{"trials":17250,"activeCount":102},[],{"trials":17252,"activeCount":102},[],{"trials":17254,"activeCount":102},[],{"trials":17256,"activeCount":102},[17257],{"nctId":12908,"briefTitle":12909,"status":110,"phases":17258,"primaryCompletion":12911,"completion":12911,"start":12912,"enrollment":12913,"conditions":17259,"interventions":17260},[92],[15,12915],[12917,12918,12897],{"trials":17262,"activeCount":102},[],{"trials":17264,"activeCount":102},[],{"intervention":12918,"totalTrials":180,"cells":17266},{"EARLY_PHASE1":17267,"PHASE1":17269,"PHASE2":17271,"PHASE3":17273,"PHASE4":17279,"NA":17281},{"trials":17268,"activeCount":102},[],{"trials":17270,"activeCount":102},[],{"trials":17272,"activeCount":102},[],{"trials":17274,"activeCount":102},[17275],{"nctId":12908,"briefTitle":12909,"status":110,"phases":17276,"primaryCompletion":12911,"completion":12911,"start":12912,"enrollment":12913,"conditions":17277,"interventions":17278},[92],[15,12915],[12917,12918,12897],{"trials":17280,"activeCount":102},[],{"trials":17282,"activeCount":102},[],{"intervention":17284,"totalTrials":180,"cells":17285},"Modafinil and PET",{"EARLY_PHASE1":17286,"PHASE1":17288,"PHASE2":17290,"PHASE3":17292,"PHASE4":17301,"NA":17303},{"trials":17287,"activeCount":102},[],{"trials":17289,"activeCount":102},[],{"trials":17291,"activeCount":102},[],{"trials":17293,"activeCount":102},[17294],{"nctId":17295,"briefTitle":17296,"status":139,"phases":17297,"primaryCompletion":13760,"completion":536,"start":8082,"enrollment":5940,"conditions":17298,"interventions":17300},"NCT00701532","Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction",[92],[17299,10659],"Cocaine Addiction",[17284],{"trials":17302,"activeCount":102},[],{"trials":17304,"activeCount":102},[],{"intervention":17306,"totalTrials":180,"cells":17307},"BEVA+SOC",{"EARLY_PHASE1":17308,"PHASE1":17310,"PHASE2":17312,"PHASE3":17314,"PHASE4":17327,"NA":17329},{"trials":17309,"activeCount":102},[],{"trials":17311,"activeCount":102},[],{"trials":17313,"activeCount":102},[],{"trials":17315,"activeCount":102},[17316],{"nctId":17317,"briefTitle":17318,"status":139,"phases":17319,"primaryCompletion":17320,"completion":17321,"start":17322,"enrollment":206,"conditions":17323,"interventions":17325},"NCT04822818","EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19",[92],"2022-04-10","2022-07-11","2021-04-17",[1121,1144,1145,1146,1147,1148,1149,17324],"Respiratory Tract Diseases",[17306,17326],"SOC",{"trials":17328,"activeCount":102},[],{"trials":17330,"activeCount":102},[],{"intervention":17326,"totalTrials":180,"cells":17332},{"EARLY_PHASE1":17333,"PHASE1":17335,"PHASE2":17337,"PHASE3":17339,"PHASE4":17345,"NA":17347},{"trials":17334,"activeCount":102},[],{"trials":17336,"activeCount":102},[],{"trials":17338,"activeCount":102},[],{"trials":17340,"activeCount":102},[17341],{"nctId":17317,"briefTitle":17318,"status":139,"phases":17342,"primaryCompletion":17320,"completion":17321,"start":17322,"enrollment":206,"conditions":17343,"interventions":17344},[92],[1121,1144,1145,1146,1147,1148,1149,17324],[17306,17326],{"trials":17346,"activeCount":102},[],{"trials":17348,"activeCount":102},[],{"intervention":17350,"totalTrials":180,"cells":17351},"Cobimetinib",{"EARLY_PHASE1":17352,"PHASE1":17354,"PHASE2":17356,"PHASE3":17358,"PHASE4":17369,"NA":17371},{"trials":17353,"activeCount":102},[],{"trials":17355,"activeCount":102},[],{"trials":17357,"activeCount":102},[],{"trials":17359,"activeCount":102},[17360],{"nctId":17361,"briefTitle":17362,"status":139,"phases":17363,"primaryCompletion":17364,"completion":17365,"start":3675,"enrollment":3501,"conditions":17366,"interventions":17368},"NCT04007848","Cobimetinib for BRAF-wild-type or Mutated Histiocytoses",[92],"2021-10-05","2022-03-14",[17367],"Disease or R Group Histiocytoses",[17350],{"trials":17370,"activeCount":102},[],{"trials":17372,"activeCount":102},[],{"intervention":17374,"totalTrials":180,"cells":17375},"Caspofungin",{"EARLY_PHASE1":17376,"PHASE1":17378,"PHASE2":17380,"PHASE3":17382,"PHASE4":17391,"NA":17393},{"trials":17377,"activeCount":102},[],{"trials":17379,"activeCount":102},[],{"trials":17381,"activeCount":102},[],{"trials":17383,"activeCount":102},[17384],{"nctId":17385,"briefTitle":17386,"status":139,"phases":17387,"primaryCompletion":5418,"completion":13261,"start":2008,"enrollment":163,"conditions":17388,"interventions":17390},"NCT00748345","Pharmacokinetics of Caspofungin in Burn Patients",[91,92],[17389],"Thermal Injury",[17374],{"trials":17392,"activeCount":102},[],{"trials":17394,"activeCount":102},[],{"intervention":17396,"totalTrials":180,"cells":17397},"injection of 68Ga-DOTATATE",{"EARLY_PHASE1":17398,"PHASE1":17400,"PHASE2":17402,"PHASE3":17404,"PHASE4":17415,"NA":17417},{"trials":17399,"activeCount":102},[],{"trials":17401,"activeCount":102},[],{"trials":17403,"activeCount":102},[],{"trials":17405,"activeCount":102},[17406],{"nctId":17407,"briefTitle":17408,"status":241,"phases":17409,"primaryCompletion":17410,"completion":17410,"start":17411,"enrollment":268,"conditions":17412,"interventions":17414},"NCT04043377","68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis",[92],"2021-09-13","2019-11-21",[17413],"Coronary Arteriosclerosis",[17396],{"trials":17416,"activeCount":102},[],{"trials":17418,"activeCount":102},[],{"intervention":17420,"totalTrials":180,"cells":17421},"Administration of vitamin C",{"EARLY_PHASE1":17422,"PHASE1":17424,"PHASE2":17426,"PHASE3":17428,"PHASE4":17440,"NA":17442},{"trials":17423,"activeCount":102},[],{"trials":17425,"activeCount":102},[],{"trials":17427,"activeCount":102},[],{"trials":17429,"activeCount":102},[17430],{"nctId":17431,"briefTitle":17432,"status":110,"phases":17433,"primaryCompletion":66,"completion":66,"start":17434,"enrollment":4924,"conditions":17435,"interventions":17438},"NCT04404387","Lessening Organ Dysfunction With VITamin C in Septic ARDS",[92],"2022-07-22",[17436,17437],"Septic","Acute Respiratory Distress Syndrome",[17420,17439],"Administration of placebo",{"trials":17441,"activeCount":102},[],{"trials":17443,"activeCount":102},[],{"intervention":17439,"totalTrials":180,"cells":17445},{"EARLY_PHASE1":17446,"PHASE1":17448,"PHASE2":17450,"PHASE3":17452,"PHASE4":17458,"NA":17460},{"trials":17447,"activeCount":102},[],{"trials":17449,"activeCount":102},[],{"trials":17451,"activeCount":102},[],{"trials":17453,"activeCount":102},[17454],{"nctId":17431,"briefTitle":17432,"status":110,"phases":17455,"primaryCompletion":66,"completion":66,"start":17434,"enrollment":4924,"conditions":17456,"interventions":17457},[92],[17436,17437],[17420,17439],{"trials":17459,"activeCount":102},[],{"trials":17461,"activeCount":102},[],{"intervention":17463,"totalTrials":180,"cells":17464},"Everolimus",{"EARLY_PHASE1":17465,"PHASE1":17467,"PHASE2":17469,"PHASE3":17471,"PHASE4":17483,"NA":17485},{"trials":17466,"activeCount":102},[],{"trials":17468,"activeCount":102},[],{"trials":17470,"activeCount":102},[],{"trials":17472,"activeCount":102},[17473],{"nctId":17474,"briefTitle":17475,"status":139,"phases":17476,"primaryCompletion":17477,"completion":17477,"start":17478,"enrollment":429,"conditions":17479,"interventions":17481},"NCT02134899","The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients",[92],"2017-11-11","2014-10-14",[17480],"Autosomal Dominant Polycystic Kidney Disease",[17463,17482],"Calcineurin inhibitors maintenance",{"trials":17484,"activeCount":102},[],{"trials":17486,"activeCount":102},[],{"intervention":17482,"totalTrials":180,"cells":17488},{"EARLY_PHASE1":17489,"PHASE1":17491,"PHASE2":17493,"PHASE3":17495,"PHASE4":17501,"NA":17503},{"trials":17490,"activeCount":102},[],{"trials":17492,"activeCount":102},[],{"trials":17494,"activeCount":102},[],{"trials":17496,"activeCount":102},[17497],{"nctId":17474,"briefTitle":17475,"status":139,"phases":17498,"primaryCompletion":17477,"completion":17477,"start":17478,"enrollment":429,"conditions":17499,"interventions":17500},[92],[17480],[17463,17482],{"trials":17502,"activeCount":102},[],{"trials":17504,"activeCount":102},[],{"intervention":17506,"totalTrials":180,"cells":17507},"Gemcitabine",{"EARLY_PHASE1":17508,"PHASE1":17510,"PHASE2":17512,"PHASE3":17514,"PHASE4":17526,"NA":17528},{"trials":17509,"activeCount":102},[],{"trials":17511,"activeCount":102},[],{"trials":17513,"activeCount":102},[],{"trials":17515,"activeCount":102},[17516],{"nctId":17517,"briefTitle":17518,"status":110,"phases":17519,"primaryCompletion":17520,"completion":17520,"start":17521,"enrollment":7834,"conditions":17522,"interventions":17524},"NCT04167007","FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX",[92],"2025-07","2020-07-20",[17523],"Pancreatic Adenocarcinoma",[17506,17525],"FOLFOX",{"trials":17527,"activeCount":102},[],{"trials":17529,"activeCount":102},[],{"intervention":17525,"totalTrials":180,"cells":17531},{"EARLY_PHASE1":17532,"PHASE1":17534,"PHASE2":17536,"PHASE3":17538,"PHASE4":17544,"NA":17546},{"trials":17533,"activeCount":102},[],{"trials":17535,"activeCount":102},[],{"trials":17537,"activeCount":102},[],{"trials":17539,"activeCount":102},[17540],{"nctId":17517,"briefTitle":17518,"status":110,"phases":17541,"primaryCompletion":17520,"completion":17520,"start":17521,"enrollment":7834,"conditions":17542,"interventions":17543},[92],[17523],[17506,17525],{"trials":17545,"activeCount":102},[],{"trials":17547,"activeCount":102},[],{"intervention":17549,"totalTrials":180,"cells":17550},"Cyclophosphamide and azathioprine",{"EARLY_PHASE1":17551,"PHASE1":17553,"PHASE2":17555,"PHASE3":17557,"PHASE4":17569,"NA":17571},{"trials":17552,"activeCount":102},[],{"trials":17554,"activeCount":102},[],{"trials":17556,"activeCount":102},[],{"trials":17558,"activeCount":102},[17559],{"nctId":17560,"briefTitle":17561,"status":110,"phases":17562,"primaryCompletion":17563,"completion":17563,"start":17564,"enrollment":1498,"conditions":17565,"interventions":17567},"NCT03770663","Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease",[92],"2024-01-02","2021-02-05",[17566,6386],"Antisynthetase Syndrome (ASS)",[17549,17568],"Tacrolimus",{"trials":17570,"activeCount":102},[],{"trials":17572,"activeCount":102},[],{"intervention":17574,"totalTrials":180,"cells":17575},"Colchicine",{"EARLY_PHASE1":17576,"PHASE1":17578,"PHASE2":17580,"PHASE3":17582,"PHASE4":17595,"NA":17597},{"trials":17577,"activeCount":102},[],{"trials":17579,"activeCount":102},[],{"trials":17581,"activeCount":102},[],{"trials":17583,"activeCount":102},[17584],{"nctId":17585,"briefTitle":17586,"status":110,"phases":17587,"primaryCompletion":17588,"completion":17589,"start":17590,"enrollment":17591,"conditions":17592,"interventions":17594},"NCT04008316","Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis",[92],"2022-11-12","2023-05-12","2019-11-12",264,[17593],"IgA Vasculitis",[17574],{"trials":17596,"activeCount":102},[],{"trials":17598,"activeCount":102},[],{"intervention":17600,"totalTrials":180,"cells":17601},"Levamisole Hydrochloride",{"EARLY_PHASE1":17602,"PHASE1":17604,"PHASE2":17606,"PHASE3":17608,"PHASE4":17620,"NA":17622},{"trials":17603,"activeCount":102},[],{"trials":17605,"activeCount":102},[],{"trials":17607,"activeCount":102},[],{"trials":17609,"activeCount":102},[17610],{"nctId":17611,"briefTitle":17612,"status":139,"phases":17613,"primaryCompletion":17614,"completion":17615,"start":17616,"enrollment":157,"conditions":17617,"interventions":17619},"NCT02818738","Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children",[92],"2021-02-07","2021-02-11","2017-09-06",[17618],"First Manifestation of Steroid Sensitive Nephrotic Syndrome",[17600],{"trials":17621,"activeCount":102},[],{"trials":17623,"activeCount":102},[],{"intervention":17625,"totalTrials":180,"cells":17626},"Plasmalyte Viaflo",{"EARLY_PHASE1":17627,"PHASE1":17629,"PHASE2":17631,"PHASE3":17633,"PHASE4":17645,"NA":17647},{"trials":17628,"activeCount":102},[],{"trials":17630,"activeCount":102},[],{"trials":17632,"activeCount":102},[],{"trials":17634,"activeCount":102},[17635],{"nctId":17636,"briefTitle":17637,"status":241,"phases":17638,"primaryCompletion":17639,"completion":17639,"start":445,"enrollment":17640,"conditions":17641,"interventions":17643},"NCT03630224","Plasmalyte Versus Saline in Trauma Patients",[92],"2023-08-18",365,[17642,3654],"Severe Trauma Patients",[17625,17644],"NaCl 0.9%",{"trials":17646,"activeCount":102},[],{"trials":17648,"activeCount":102},[],{"intervention":17644,"totalTrials":180,"cells":17650},{"EARLY_PHASE1":17651,"PHASE1":17653,"PHASE2":17655,"PHASE3":17657,"PHASE4":17663,"NA":17665},{"trials":17652,"activeCount":102},[],{"trials":17654,"activeCount":102},[],{"trials":17656,"activeCount":102},[],{"trials":17658,"activeCount":102},[17659],{"nctId":17636,"briefTitle":17637,"status":241,"phases":17660,"primaryCompletion":17639,"completion":17639,"start":445,"enrollment":17640,"conditions":17661,"interventions":17662},[92],[17642,3654],[17625,17644],{"trials":17664,"activeCount":102},[],{"trials":17666,"activeCount":102},[],{"intervention":17668,"totalTrials":180,"cells":17669},"Vaccination with Gardasil",{"EARLY_PHASE1":17670,"PHASE1":17672,"PHASE2":17674,"PHASE3":17676,"PHASE4":17688,"NA":17690},{"trials":17671,"activeCount":102},[],{"trials":17673,"activeCount":102},[],{"trials":17675,"activeCount":102},[],{"trials":17677,"activeCount":102},[17678],{"nctId":17679,"briefTitle":17680,"status":110,"phases":17681,"primaryCompletion":17682,"completion":8214,"start":17683,"enrollment":489,"conditions":17684,"interventions":17686},"NCT03296397","Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response",[92],"2020-03","2017-11-15",[17685],"Genital Warts",[17668,17687],"Injection of Normal Saline",{"trials":17689,"activeCount":102},[],{"trials":17691,"activeCount":102},[],{"intervention":17687,"totalTrials":180,"cells":17693},{"EARLY_PHASE1":17694,"PHASE1":17696,"PHASE2":17698,"PHASE3":17700,"PHASE4":17706,"NA":17708},{"trials":17695,"activeCount":102},[],{"trials":17697,"activeCount":102},[],{"trials":17699,"activeCount":102},[],{"trials":17701,"activeCount":102},[17702],{"nctId":17679,"briefTitle":17680,"status":110,"phases":17703,"primaryCompletion":17682,"completion":8214,"start":17683,"enrollment":489,"conditions":17704,"interventions":17705},[92],[17685],[17668,17687],{"trials":17707,"activeCount":102},[],{"trials":17709,"activeCount":102},[],{"intervention":17711,"totalTrials":180,"cells":17712},"escitalopram",{"EARLY_PHASE1":17713,"PHASE1":17715,"PHASE2":17717,"PHASE3":17719,"PHASE4":17727,"NA":17729},{"trials":17714,"activeCount":102},[],{"trials":17716,"activeCount":102},[],{"trials":17718,"activeCount":102},[],{"trials":17720,"activeCount":102},[17721],{"nctId":17722,"briefTitle":17723,"status":139,"phases":17724,"primaryCompletion":5301,"completion":5301,"start":2150,"enrollment":21,"conditions":17725,"interventions":17726},"NCT00190333","Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension",[92],[1676],[17711],{"trials":17728,"activeCount":102},[],{"trials":17730,"activeCount":102},[],{"intervention":17732,"totalTrials":180,"cells":17733},"Nefopam",{"EARLY_PHASE1":17734,"PHASE1":17736,"PHASE2":17738,"PHASE3":17740,"PHASE4":17749,"NA":17751},{"trials":17735,"activeCount":102},[],{"trials":17737,"activeCount":102},[],{"trials":17739,"activeCount":102},[],{"trials":17741,"activeCount":102},[17742],{"nctId":17743,"briefTitle":17744,"status":139,"phases":17745,"primaryCompletion":12305,"completion":12305,"start":10680,"enrollment":413,"conditions":17746,"interventions":17748},"NCT01577407","Non Opioid Treatment for Experimental Dyspnea",[92],[17747,5146],"Dyspnea",[17732],{"trials":17750,"activeCount":102},[],{"trials":17752,"activeCount":102},[],{"intervention":17754,"totalTrials":180,"cells":17755},"Mexiletine",{"EARLY_PHASE1":17756,"PHASE1":17758,"PHASE2":17760,"PHASE3":17762,"PHASE4":17773,"NA":17775},{"trials":17757,"activeCount":102},[],{"trials":17759,"activeCount":102},[],{"trials":17761,"activeCount":102},[],{"trials":17763,"activeCount":102},[17764],{"nctId":17765,"briefTitle":17766,"status":139,"phases":17767,"primaryCompletion":12765,"completion":12765,"start":1587,"enrollment":27,"conditions":17768,"interventions":17772},"NCT02336477","Mexiletine and Non Dystrophic Myotonias",[92],[17769,17770,17771],"Non-dystrophic Myotonias","Paramyotonia Congenita","Myotonia Congenita",[17754],{"trials":17774,"activeCount":102},[],{"trials":17776,"activeCount":102},[],{"intervention":17778,"totalTrials":180,"cells":17779},"BOTOX® solution",{"EARLY_PHASE1":17780,"PHASE1":17782,"PHASE2":17784,"PHASE3":17786,"PHASE4":17797,"NA":17799},{"trials":17781,"activeCount":102},[],{"trials":17783,"activeCount":102},[],{"trials":17785,"activeCount":102},[],{"trials":17787,"activeCount":102},[17788],{"nctId":17789,"briefTitle":17790,"status":139,"phases":17791,"primaryCompletion":17792,"completion":17792,"start":1747,"enrollment":17793,"conditions":17794,"interventions":17796},"NCT03717961","Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis",[92],"2020-07-31",91,[17795],"Raynaud Phenomenon Secondary to Systemic Sclerosis",[17778],{"trials":17798,"activeCount":102},[],{"trials":17800,"activeCount":102},[],{"intervention":17802,"totalTrials":180,"cells":17803},"Miglustat ; placebo",{"EARLY_PHASE1":17804,"PHASE1":17806,"PHASE2":17808,"PHASE3":17810,"PHASE4":17819,"NA":17821},{"trials":17805,"activeCount":102},[],{"trials":17807,"activeCount":102},[],{"trials":17809,"activeCount":102},[],{"trials":17811,"activeCount":102},[17812],{"nctId":17813,"briefTitle":17814,"status":139,"phases":17815,"primaryCompletion":11417,"completion":11417,"start":17816,"enrollment":1258,"conditions":17817,"interventions":17818},"NCT02325362","Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation",[91,92],"2015-03-17",[23],[17802],{"trials":17820,"activeCount":102},[],{"trials":17822,"activeCount":102},[],{"intervention":17824,"totalTrials":180,"cells":17825},"Acarbose",{"EARLY_PHASE1":17826,"PHASE1":17828,"PHASE2":17830,"PHASE3":17832,"PHASE4":17844,"NA":17846},{"trials":17827,"activeCount":102},[],{"trials":17829,"activeCount":102},[],{"trials":17831,"activeCount":102},[],{"trials":17833,"activeCount":102},[17834],{"nctId":17835,"briefTitle":17836,"status":241,"phases":17837,"primaryCompletion":17838,"completion":4501,"start":10236,"enrollment":17839,"conditions":17840,"interventions":17842},"NCT03380546","Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.",[92],"2023-08-12",341,[17841],"Gestational Diabetes Mellitus in Pregnancy",[17824,17843],"Prandial insulin",{"trials":17845,"activeCount":102},[],{"trials":17847,"activeCount":102},[],{"intervention":17843,"totalTrials":180,"cells":17849},{"EARLY_PHASE1":17850,"PHASE1":17852,"PHASE2":17854,"PHASE3":17856,"PHASE4":17862,"NA":17864},{"trials":17851,"activeCount":102},[],{"trials":17853,"activeCount":102},[],{"trials":17855,"activeCount":102},[],{"trials":17857,"activeCount":102},[17858],{"nctId":17835,"briefTitle":17836,"status":241,"phases":17859,"primaryCompletion":17838,"completion":4501,"start":10236,"enrollment":17839,"conditions":17860,"interventions":17861},[92],[17841],[17824,17843],{"trials":17863,"activeCount":102},[],{"trials":17865,"activeCount":102},[],{"intervention":12804,"totalTrials":180,"cells":17867},{"EARLY_PHASE1":17868,"PHASE1":17870,"PHASE2":17872,"PHASE3":17874,"PHASE4":17880,"NA":17882},{"trials":17869,"activeCount":102},[],{"trials":17871,"activeCount":102},[],{"trials":17873,"activeCount":102},[],{"trials":17875,"activeCount":102},[17876],{"nctId":12795,"briefTitle":12796,"status":139,"phases":17877,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":17878,"interventions":17879},[92],[12802],[12804,12805,12806,12807,12808,12809],{"trials":17881,"activeCount":102},[],{"trials":17883,"activeCount":102},[],{"intervention":12806,"totalTrials":180,"cells":17885},{"EARLY_PHASE1":17886,"PHASE1":17888,"PHASE2":17890,"PHASE3":17892,"PHASE4":17898,"NA":17900},{"trials":17887,"activeCount":102},[],{"trials":17889,"activeCount":102},[],{"trials":17891,"activeCount":102},[],{"trials":17893,"activeCount":102},[17894],{"nctId":12795,"briefTitle":12796,"status":139,"phases":17895,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":17896,"interventions":17897},[92],[12802],[12804,12805,12806,12807,12808,12809],{"trials":17899,"activeCount":102},[],{"trials":17901,"activeCount":102},[],{"intervention":12807,"totalTrials":180,"cells":17903},{"EARLY_PHASE1":17904,"PHASE1":17906,"PHASE2":17908,"PHASE3":17910,"PHASE4":17916,"NA":17918},{"trials":17905,"activeCount":102},[],{"trials":17907,"activeCount":102},[],{"trials":17909,"activeCount":102},[],{"trials":17911,"activeCount":102},[17912],{"nctId":12795,"briefTitle":12796,"status":139,"phases":17913,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":17914,"interventions":17915},[92],[12802],[12804,12805,12806,12807,12808,12809],{"trials":17917,"activeCount":102},[],{"trials":17919,"activeCount":102},[],{"intervention":12808,"totalTrials":180,"cells":17921},{"EARLY_PHASE1":17922,"PHASE1":17924,"PHASE2":17926,"PHASE3":17928,"PHASE4":17934,"NA":17936},{"trials":17923,"activeCount":102},[],{"trials":17925,"activeCount":102},[],{"trials":17927,"activeCount":102},[],{"trials":17929,"activeCount":102},[17930],{"nctId":12795,"briefTitle":12796,"status":139,"phases":17931,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":17932,"interventions":17933},[92],[12802],[12804,12805,12806,12807,12808,12809],{"trials":17935,"activeCount":102},[],{"trials":17937,"activeCount":102},[],{"intervention":12809,"totalTrials":180,"cells":17939},{"EARLY_PHASE1":17940,"PHASE1":17942,"PHASE2":17944,"PHASE3":17946,"PHASE4":17952,"NA":17954},{"trials":17941,"activeCount":102},[],{"trials":17943,"activeCount":102},[],{"trials":17945,"activeCount":102},[],{"trials":17947,"activeCount":102},[17948],{"nctId":12795,"briefTitle":12796,"status":139,"phases":17949,"primaryCompletion":12798,"completion":12799,"start":1908,"enrollment":12800,"conditions":17950,"interventions":17951},[92],[12802],[12804,12805,12806,12807,12808,12809],{"trials":17953,"activeCount":102},[],{"trials":17955,"activeCount":102},[],{"intervention":17957,"totalTrials":180,"cells":17958},"Nicotinamide treatment",{"EARLY_PHASE1":17959,"PHASE1":17961,"PHASE2":17963,"PHASE3":17965,"PHASE4":17977,"NA":17979},{"trials":17960,"activeCount":102},[],{"trials":17962,"activeCount":102},[],{"trials":17964,"activeCount":102},[],{"trials":17966,"activeCount":102},[17967],{"nctId":17968,"briefTitle":17969,"status":139,"phases":17970,"primaryCompletion":17971,"completion":17972,"start":17973,"enrollment":941,"conditions":17974,"interventions":17976},"NCT05513807","Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant",[92],"2024-02-17","2024-06-18","2023-01-12",[17975],"Delayed Graft Function",[17957],{"trials":17978,"activeCount":102},[],{"trials":17980,"activeCount":102},[],{"intervention":17982,"totalTrials":180,"cells":17983},"Tinzaparin Sodium",{"EARLY_PHASE1":17984,"PHASE1":17986,"PHASE2":17988,"PHASE3":17990,"PHASE4":18001,"NA":18003},{"trials":17985,"activeCount":102},[],{"trials":17987,"activeCount":102},[],{"trials":17989,"activeCount":102},[],{"trials":17991,"activeCount":102},[17992],{"nctId":17993,"briefTitle":17994,"status":241,"phases":17995,"primaryCompletion":17996,"completion":17996,"start":17997,"enrollment":12800,"conditions":17998,"interventions":18000},"NCT03090880","Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)",[92],"2021-08-18","2018-09-14",[14559,17999],"Lung Neoplasm",[17982],{"trials":18002,"activeCount":102},[],{"trials":18004,"activeCount":102},[],{"intervention":18006,"totalTrials":180,"cells":18007},"Vancomycin",{"EARLY_PHASE1":18008,"PHASE1":18010,"PHASE2":18012,"PHASE3":18014,"PHASE4":18024,"NA":18026},{"trials":18009,"activeCount":102},[],{"trials":18011,"activeCount":102},[],{"trials":18013,"activeCount":102},[],{"trials":18015,"activeCount":102},[18016],{"nctId":18017,"briefTitle":18018,"status":110,"phases":18019,"primaryCompletion":61,"completion":17520,"start":13716,"enrollment":18020,"conditions":18021,"interventions":18023},"NCT05256693","Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant",[92],336,[18022,5242],"Clostridium Difficile Infections",[18006],{"trials":18025,"activeCount":102},[],{"trials":18027,"activeCount":102},[],{"intervention":2132,"totalTrials":180,"cells":18029},{"EARLY_PHASE1":18030,"PHASE1":18032,"PHASE2":18034,"PHASE3":18036,"PHASE4":18042,"NA":18044},{"trials":18031,"activeCount":102},[],{"trials":18033,"activeCount":102},[],{"trials":18035,"activeCount":102},[],{"trials":18037,"activeCount":102},[18038],{"nctId":2122,"briefTitle":2123,"status":139,"phases":18039,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":2127,"conditions":18040,"interventions":18041},[92],[2129],[2131,2132,2099,1164],{"trials":18043,"activeCount":102},[],{"trials":18045,"activeCount":102},[],{"intervention":18047,"totalTrials":180,"cells":18048},"PBA 7,5g\u002Fd",{"EARLY_PHASE1":18049,"PHASE1":18051,"PHASE2":18053,"PHASE3":18055,"PHASE4":18065,"NA":18067},{"trials":18050,"activeCount":102},[],{"trials":18052,"activeCount":102},[],{"trials":18054,"activeCount":102},[],{"trials":18056,"activeCount":102},[18057],{"nctId":18058,"briefTitle":18059,"status":139,"phases":18060,"primaryCompletion":977,"completion":12697,"start":1939,"enrollment":115,"conditions":18061,"interventions":18063},"NCT02343094","Phenylbutyrate in Proteinuric Nephropathies",[91,92],[18062],"Proteinuric Diseases",[18047,18064],"PBA 15g\u002Fd",{"trials":18066,"activeCount":102},[],{"trials":18068,"activeCount":102},[],{"intervention":18064,"totalTrials":180,"cells":18070},{"EARLY_PHASE1":18071,"PHASE1":18073,"PHASE2":18075,"PHASE3":18077,"PHASE4":18083,"NA":18085},{"trials":18072,"activeCount":102},[],{"trials":18074,"activeCount":102},[],{"trials":18076,"activeCount":102},[],{"trials":18078,"activeCount":102},[18079],{"nctId":18058,"briefTitle":18059,"status":139,"phases":18080,"primaryCompletion":977,"completion":12697,"start":1939,"enrollment":115,"conditions":18081,"interventions":18082},[91,92],[18062],[18047,18064],{"trials":18084,"activeCount":102},[],{"trials":18086,"activeCount":102},[],{"intervention":12383,"totalTrials":180,"cells":18088},{"EARLY_PHASE1":18089,"PHASE1":18091,"PHASE2":18093,"PHASE3":18095,"PHASE4":18101,"NA":18103},{"trials":18090,"activeCount":102},[],{"trials":18092,"activeCount":102},[],{"trials":18094,"activeCount":102},[],{"trials":18096,"activeCount":102},[18097],{"nctId":12377,"briefTitle":12378,"status":139,"phases":18098,"primaryCompletion":5163,"completion":12380,"start":1909,"enrollment":1119,"conditions":18099,"interventions":18100},[92],[1317],[12352,12383],{"trials":18102,"activeCount":102},[],{"trials":18104,"activeCount":102},[],{"intervention":18106,"totalTrials":180,"cells":18107},"Nicotine 7 mg\u002F 24h Transdermal Patch - 24 Hour",{"EARLY_PHASE1":18108,"PHASE1":18110,"PHASE2":18112,"PHASE3":18114,"PHASE4":18124,"NA":18126},{"trials":18109,"activeCount":102},[],{"trials":18111,"activeCount":102},[],{"trials":18113,"activeCount":102},[],{"trials":18115,"activeCount":102},[18116],{"nctId":18117,"briefTitle":18118,"status":139,"phases":18119,"primaryCompletion":1881,"completion":1881,"start":18120,"enrollment":228,"conditions":18121,"interventions":18123},"NCT04608201","Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients",[92],"2020-12-09",[18122],"SARS-COV2",[18106],{"trials":18125,"activeCount":102},[],{"trials":18127,"activeCount":102},[],{"intervention":18129,"totalTrials":180,"cells":18130},"SOMATROPINE* : Norditropine® simplexx®",{"EARLY_PHASE1":18131,"PHASE1":18133,"PHASE2":18135,"PHASE3":18137,"PHASE4":18148,"NA":18150},{"trials":18132,"activeCount":102},[],{"trials":18134,"activeCount":102},[],{"trials":18136,"activeCount":102},[],{"trials":18138,"activeCount":102},[18139],{"nctId":18140,"briefTitle":18141,"status":139,"phases":18142,"primaryCompletion":9299,"completion":9299,"start":385,"enrollment":413,"conditions":18143,"interventions":18147},"NCT01626833","Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone",[91,92],[8809,18144,18145,18146],"Interruption of Growth","Delayed Puberty","Osteopenia With Failure of Acquisition of Bone Mass",[18129],{"trials":18149,"activeCount":102},[],{"trials":18151,"activeCount":102},[],{"intervention":18153,"totalTrials":180,"cells":18154},"Low dose ketamine",{"EARLY_PHASE1":18155,"PHASE1":18157,"PHASE2":18159,"PHASE3":18161,"PHASE4":18172,"NA":18174},{"trials":18156,"activeCount":102},[],{"trials":18158,"activeCount":102},[],{"trials":18160,"activeCount":102},[],{"trials":18162,"activeCount":102},[18163],{"nctId":18164,"briefTitle":18165,"status":241,"phases":18166,"completion":18167,"start":18168,"enrollment":1130,"conditions":18169,"interventions":18171},"NCT00224692","Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine",[92],"2006-08","2003-02",[9635,18170],"Mucositis",[18153],{"trials":18173,"activeCount":102},[],{"trials":18175,"activeCount":102},[],{"intervention":18177,"totalTrials":180,"cells":18178},"Ivermectin 200 µg\u002Fkg",{"EARLY_PHASE1":18179,"PHASE1":18181,"PHASE2":18183,"PHASE3":18185,"PHASE4":18200,"NA":18202},{"trials":18180,"activeCount":102},[],{"trials":18182,"activeCount":102},[],{"trials":18184,"activeCount":102},[],{"trials":18186,"activeCount":102},[18187],{"nctId":18188,"briefTitle":18189,"status":139,"phases":18190,"primaryCompletion":13693,"completion":13693,"start":18191,"enrollment":18192,"conditions":18193,"interventions":18198},"NCT02841215","Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies",[92],"2017-10-11",133,[18194,18195,18196,18197],"Gale","Severe Forms of Scabies","Oral Parasitic Drug","Ivermectin",[18177,18199],"Ivermectin 400 µg\u002Fkg",{"trials":18201,"activeCount":102},[],{"trials":18203,"activeCount":102},[],{"intervention":18199,"totalTrials":180,"cells":18205},{"EARLY_PHASE1":18206,"PHASE1":18208,"PHASE2":18210,"PHASE3":18212,"PHASE4":18218,"NA":18220},{"trials":18207,"activeCount":102},[],{"trials":18209,"activeCount":102},[],{"trials":18211,"activeCount":102},[],{"trials":18213,"activeCount":102},[18214],{"nctId":18188,"briefTitle":18189,"status":139,"phases":18215,"primaryCompletion":13693,"completion":13693,"start":18191,"enrollment":18192,"conditions":18216,"interventions":18217},[92],[18194,18195,18196,18197],[18177,18199],{"trials":18219,"activeCount":102},[],{"trials":18221,"activeCount":102},[],{"intervention":18223,"totalTrials":180,"cells":18224},"Oxaliplatin, gemcitabine, cisplatin, lipiodol",{"EARLY_PHASE1":18225,"PHASE1":18227,"PHASE2":18229,"PHASE3":18231,"PHASE4":18245,"NA":18247},{"trials":18226,"activeCount":102},[],{"trials":18228,"activeCount":102},[],{"trials":18230,"activeCount":102},[],{"trials":18232,"activeCount":102},[18233],{"nctId":18234,"briefTitle":18235,"status":241,"phases":18236,"primaryCompletion":1834,"completion":1834,"start":421,"enrollment":18237,"conditions":18238,"interventions":18244},"NCT00470340","Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients",[92],263,[18239,18240,18241,18242,18243],"Liver Neoplasms","Liver Cirrhosis","Carcinoma, Hepatocellular","Recurrence","Neoplasm Recurrence, Local",[18223],{"trials":18246,"activeCount":102},[],{"trials":18248,"activeCount":102},[],{"intervention":18250,"totalTrials":180,"cells":18251},"DIAZOXIDE",{"EARLY_PHASE1":18252,"PHASE1":18254,"PHASE2":18256,"PHASE3":18258,"PHASE4":18268,"NA":18270},{"trials":18253,"activeCount":102},[],{"trials":18255,"activeCount":102},[],{"trials":18257,"activeCount":102},[],{"trials":18259,"activeCount":102},[18260],{"nctId":18261,"briefTitle":18262,"status":139,"phases":18263,"primaryCompletion":8082,"completion":8082,"start":302,"enrollment":1931,"conditions":18264,"interventions":18267},"NCT00306683","Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions",[92],[18265,18266],"Hypothalamic-pituitary Lesions","Craniopharyngiomas",[18250],{"trials":18269,"activeCount":102},[],{"trials":18271,"activeCount":102},[],{"intervention":18273,"totalTrials":180,"cells":18274},"Seretide",{"EARLY_PHASE1":18275,"PHASE1":18277,"PHASE2":18279,"PHASE3":18281,"PHASE4":18293,"NA":18295},{"trials":18276,"activeCount":102},[],{"trials":18278,"activeCount":102},[],{"trials":18280,"activeCount":102},[],{"trials":18282,"activeCount":102},[18283],{"nctId":18284,"briefTitle":18285,"status":241,"phases":18286,"primaryCompletion":18287,"completion":18287,"start":18288,"enrollment":5557,"conditions":18289,"interventions":18292},"NCT04655508","Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation",[92],"2023-09-27","2021-05-21",[5242,18290,18291],"Respiratory Disease","Bronchiolitis Obliterans",[18273],{"trials":18294,"activeCount":102},[],{"trials":18296,"activeCount":102},[],{"intervention":5440,"totalTrials":180,"cells":18298},{"EARLY_PHASE1":18299,"PHASE1":18301,"PHASE2":18303,"PHASE3":18305,"PHASE4":18311,"NA":18313},{"trials":18300,"activeCount":102},[],{"trials":18302,"activeCount":102},[],{"trials":18304,"activeCount":102},[],{"trials":18306,"activeCount":102},[18307],{"nctId":5431,"briefTitle":5432,"status":139,"phases":18308,"primaryCompletion":5434,"completion":5435,"start":5436,"enrollment":2673,"conditions":18309,"interventions":18310},[92],[5438],[5440,5166],{"trials":18312,"activeCount":102},[],{"trials":18314,"activeCount":102},[],{"intervention":18316,"totalTrials":180,"cells":18317},"Vascular filling",{"EARLY_PHASE1":18318,"PHASE1":18320,"PHASE2":18322,"PHASE3":18324,"PHASE4":18335,"NA":18337},{"trials":18319,"activeCount":102},[],{"trials":18321,"activeCount":102},[],{"trials":18323,"activeCount":102},[],{"trials":18325,"activeCount":102},[18326],{"nctId":18327,"briefTitle":18328,"status":110,"phases":18329,"primaryCompletion":18330,"completion":14010,"start":497,"enrollment":3086,"conditions":18331,"interventions":18333},"NCT02905760","Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction",[92],"2018-11",[18332],"Acute Myocardial Infarction With Right Ventricular Extension",[18334,18316],"Furosemide",{"trials":18336,"activeCount":102},[],{"trials":18338,"activeCount":102},[],{"intervention":18340,"totalTrials":180,"cells":18341},"AVLOCARDYL",{"EARLY_PHASE1":18342,"PHASE1":18344,"PHASE2":18346,"PHASE3":18348,"PHASE4":18357,"NA":18359},{"trials":18343,"activeCount":102},[],{"trials":18345,"activeCount":102},[],{"trials":18347,"activeCount":102},[],{"trials":18349,"activeCount":102},[18350],{"nctId":18351,"briefTitle":18352,"status":241,"phases":18353,"primaryCompletion":13849,"completion":10832,"start":1940,"enrollment":98,"conditions":18354,"interventions":18356},"NCT01239173","Emotional Memory Reactivation in Posttraumatic Stress Disorder",[92],[18355],"Posttraumatic Stress Disorder",[18340,18340],{"trials":18358,"activeCount":102},[],{"trials":18360,"activeCount":102},[],{"intervention":18362,"totalTrials":180,"cells":18363},"Bezafibrate (400mg) in addition to standard 15-20 mg\u002Fkg\u002Fjour UDCA therapy",{"EARLY_PHASE1":18364,"PHASE1":18366,"PHASE2":18368,"PHASE3":18370,"PHASE4":18382,"NA":18384},{"trials":18365,"activeCount":102},[],{"trials":18367,"activeCount":102},[],{"trials":18369,"activeCount":102},[],{"trials":18371,"activeCount":102},[18372],{"nctId":18373,"briefTitle":18374,"status":110,"phases":18375,"primaryCompletion":18376,"completion":8892,"start":18377,"enrollment":1189,"conditions":18378,"interventions":18381},"NCT04309773","Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy",[92],"2023-03","2021-04-06",[18379,18380],"Primary Sclerosing Cholangitis","Cholestasis",[18362],{"trials":18383,"activeCount":102},[],{"trials":18385,"activeCount":102},[],{"intervention":12927,"totalTrials":180,"cells":18387},{"EARLY_PHASE1":18388,"PHASE1":18390,"PHASE2":18392,"PHASE3":18394,"PHASE4":18400,"NA":18402},{"trials":18389,"activeCount":102},[],{"trials":18391,"activeCount":102},[],{"trials":18393,"activeCount":102},[],{"trials":18395,"activeCount":102},[18396],{"nctId":12920,"briefTitle":12921,"status":110,"phases":18397,"primaryCompletion":12923,"completion":1097,"start":9049,"enrollment":1039,"conditions":18398,"interventions":18399},[92],[12925],[12927,12897],{"trials":18401,"activeCount":102},[],{"trials":18403,"activeCount":102},[],{"intervention":18405,"totalTrials":180,"cells":18406},"Mineral Trioxide Aggregate",{"EARLY_PHASE1":18407,"PHASE1":18409,"PHASE2":18411,"PHASE3":18413,"PHASE4":18423,"NA":18425},{"trials":18408,"activeCount":102},[],{"trials":18410,"activeCount":102},[],{"trials":18412,"activeCount":102},[],{"trials":18414,"activeCount":102},[18415],{"nctId":18416,"briefTitle":18417,"status":139,"phases":18418,"primaryCompletion":10940,"completion":1402,"start":5144,"enrollment":9911,"conditions":18419,"interventions":18421},"NCT00472173","Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth",[92],[18420],"Dental Pulp Necrosis",[18405,18422],"Calcium hydroxide",{"trials":18424,"activeCount":102},[],{"trials":18426,"activeCount":102},[],{"intervention":18422,"totalTrials":180,"cells":18428},{"EARLY_PHASE1":18429,"PHASE1":18431,"PHASE2":18433,"PHASE3":18435,"PHASE4":18441,"NA":18443},{"trials":18430,"activeCount":102},[],{"trials":18432,"activeCount":102},[],{"trials":18434,"activeCount":102},[],{"trials":18436,"activeCount":102},[18437],{"nctId":18416,"briefTitle":18417,"status":139,"phases":18438,"primaryCompletion":10940,"completion":1402,"start":5144,"enrollment":9911,"conditions":18439,"interventions":18440},[92],[18420],[18405,18422],{"trials":18442,"activeCount":102},[],{"trials":18444,"activeCount":102},[],{"intervention":18446,"totalTrials":180,"cells":18447},"betamethasone 24 mg",{"EARLY_PHASE1":18448,"PHASE1":18450,"PHASE2":18452,"PHASE3":18454,"PHASE4":18467,"NA":18469},{"trials":18449,"activeCount":102},[],{"trials":18451,"activeCount":102},[],{"trials":18453,"activeCount":102},[],{"trials":18455,"activeCount":102},[18456],{"nctId":18457,"briefTitle":18458,"status":139,"phases":18459,"primaryCompletion":18460,"completion":18460,"start":18461,"enrollment":18462,"conditions":18463,"interventions":18465},"NCT02897076","Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth",[92],"2020-01-05","2017-01",3250,[18464],"Neonatal Complications",[18446,18466],"12mg betamethasone +placebo",{"trials":18468,"activeCount":102},[],{"trials":18470,"activeCount":102},[],{"intervention":18466,"totalTrials":180,"cells":18472},{"EARLY_PHASE1":18473,"PHASE1":18475,"PHASE2":18477,"PHASE3":18479,"PHASE4":18485,"NA":18487},{"trials":18474,"activeCount":102},[],{"trials":18476,"activeCount":102},[],{"trials":18478,"activeCount":102},[],{"trials":18480,"activeCount":102},[18481],{"nctId":18457,"briefTitle":18458,"status":139,"phases":18482,"primaryCompletion":18460,"completion":18460,"start":18461,"enrollment":18462,"conditions":18483,"interventions":18484},[92],[18464],[18446,18466],{"trials":18486,"activeCount":102},[],{"trials":18488,"activeCount":102},[],{"intervention":18490,"totalTrials":180,"cells":18491},"Macitentan 10mg",{"EARLY_PHASE1":18492,"PHASE1":18494,"PHASE2":18496,"PHASE3":18498,"PHASE4":18511,"NA":18513},{"trials":18493,"activeCount":102},[],{"trials":18495,"activeCount":102},[],{"trials":18497,"activeCount":102},[],{"trials":18499,"activeCount":102},[18500],{"nctId":18501,"briefTitle":18502,"status":139,"phases":18503,"primaryCompletion":18504,"completion":18504,"start":18505,"enrollment":206,"conditions":18506,"interventions":18510},"NCT04780932","Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension",[91,92],"2025-07-03","2021-06-14",[18507,18508,18509],"Thromboembolic Pulmonary Hypertension","Chronic Disease","Inoperable Disease",[18490],{"trials":18512,"activeCount":102},[],{"trials":18514,"activeCount":102},[],{"intervention":18516,"totalTrials":180,"cells":18517},"Nintedanib 150 MG [Ofev]",{"EARLY_PHASE1":18518,"PHASE1":18520,"PHASE2":18522,"PHASE3":18524,"PHASE4":18534,"NA":18536},{"trials":18519,"activeCount":102},[],{"trials":18521,"activeCount":102},[],{"trials":18523,"activeCount":102},[],{"trials":18525,"activeCount":102},[18526],{"nctId":18527,"briefTitle":18528,"status":110,"phases":18529,"primaryCompletion":18530,"completion":66,"start":16842,"enrollment":9705,"conditions":18531,"interventions":18533},"NCT04541680","Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis",[92],"2023-10-11",[18532],"SARS-Cov-2 Induced Pulmonary Fibrosis",[18516],{"trials":18535,"activeCount":102},[],{"trials":18537,"activeCount":102},[],{"intervention":18539,"totalTrials":180,"cells":18540},"Gel",{"EARLY_PHASE1":18541,"PHASE1":18543,"PHASE2":18545,"PHASE3":18547,"PHASE4":18557,"NA":18559},{"trials":18542,"activeCount":102},[],{"trials":18544,"activeCount":102},[],{"trials":18546,"activeCount":102},[],{"trials":18548,"activeCount":102},[18549],{"nctId":18550,"briefTitle":18551,"status":139,"phases":18552,"primaryCompletion":17997,"completion":17997,"start":18553,"enrollment":15864,"conditions":18554,"interventions":18556},"NCT02248376","Hyaluronic Acid and Uterine Synechiae",[92],"2014-11-14",[18555],"Uterine Synechiae After Scraping for Natural Miscarriage",[18539],{"trials":18558,"activeCount":102},[],{"trials":18560,"activeCount":102},[],{"intervention":18562,"totalTrials":180,"cells":18563},"Nitric Oxide",{"EARLY_PHASE1":18564,"PHASE1":18566,"PHASE2":18568,"PHASE3":18570,"PHASE4":18578,"NA":18580},{"trials":18565,"activeCount":102},[],{"trials":18567,"activeCount":102},[],{"trials":18569,"activeCount":102},[],{"trials":18571,"activeCount":102},[18572],{"nctId":18573,"briefTitle":18574,"status":139,"phases":18575,"primaryCompletion":11220,"completion":11220,"start":5301,"enrollment":3149,"conditions":18576,"interventions":18577},"NCT00748423","Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)",[91,92],[20,3301],[18562],{"trials":18579,"activeCount":102},[],{"trials":18581,"activeCount":102},[],{"intervention":18583,"totalTrials":180,"cells":18584},"Camostat Mesylate",{"EARLY_PHASE1":18585,"PHASE1":18587,"PHASE2":18589,"PHASE3":18591,"PHASE4":18602,"NA":18604},{"trials":18586,"activeCount":102},[],{"trials":18588,"activeCount":102},[],{"trials":18590,"activeCount":102},[],{"trials":18592,"activeCount":102},[18593],{"nctId":18594,"briefTitle":18595,"status":241,"phases":18596,"primaryCompletion":18597,"completion":18598,"start":18599,"enrollment":400,"conditions":18600,"interventions":18601},"NCT04608266","CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients",[92],"2021-09-27","2021-12-02","2020-12-03",[26],[18583],{"trials":18603,"activeCount":102},[],{"trials":18605,"activeCount":102},[],{"intervention":18607,"totalTrials":180,"cells":18608},"corticotherapy",{"EARLY_PHASE1":18609,"PHASE1":18611,"PHASE2":18613,"PHASE3":18615,"PHASE4":18627,"NA":18629},{"trials":18610,"activeCount":102},[],{"trials":18612,"activeCount":102},[],{"trials":18614,"activeCount":102},[],{"trials":18616,"activeCount":102},[18617],{"nctId":18618,"briefTitle":18619,"status":139,"phases":18620,"primaryCompletion":18621,"completion":18621,"start":18622,"enrollment":1202,"conditions":18623,"interventions":18625},"NCT03188887","Treatment of IgA Nephropathy According to Renal Lesions",[92],"2024-01-12","2018-02-20",[18624],"IgA Nephropathy",[18607,18626],"Renin Angiotensin system",{"trials":18628,"activeCount":102},[],{"trials":18630,"activeCount":102},[],{"intervention":18626,"totalTrials":180,"cells":18632},{"EARLY_PHASE1":18633,"PHASE1":18635,"PHASE2":18637,"PHASE3":18639,"PHASE4":18645,"NA":18647},{"trials":18634,"activeCount":102},[],{"trials":18636,"activeCount":102},[],{"trials":18638,"activeCount":102},[],{"trials":18640,"activeCount":102},[18641],{"nctId":18618,"briefTitle":18619,"status":139,"phases":18642,"primaryCompletion":18621,"completion":18621,"start":18622,"enrollment":1202,"conditions":18643,"interventions":18644},[92],[18624],[18607,18626],{"trials":18646,"activeCount":102},[],{"trials":18648,"activeCount":102},[],{"intervention":18650,"totalTrials":180,"cells":18651},"Lovenox®",{"EARLY_PHASE1":18652,"PHASE1":18654,"PHASE2":18656,"PHASE3":18658,"PHASE4":18668,"NA":18670},{"trials":18653,"activeCount":102},[],{"trials":18655,"activeCount":102},[],{"trials":18657,"activeCount":102},[],{"trials":18659,"activeCount":102},[18660],{"nctId":18661,"briefTitle":18662,"status":139,"phases":18663,"primaryCompletion":5469,"completion":5469,"start":10507,"enrollment":18664,"conditions":18665,"interventions":18666},"NCT00986765","Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia",[92],257,[8323],[18650,18667],"Aspegic ®",{"trials":18669,"activeCount":102},[],{"trials":18671,"activeCount":102},[],{"intervention":18667,"totalTrials":180,"cells":18673},{"EARLY_PHASE1":18674,"PHASE1":18676,"PHASE2":18678,"PHASE3":18680,"PHASE4":18686,"NA":18688},{"trials":18675,"activeCount":102},[],{"trials":18677,"activeCount":102},[],{"trials":18679,"activeCount":102},[],{"trials":18681,"activeCount":102},[18682],{"nctId":18661,"briefTitle":18662,"status":139,"phases":18683,"primaryCompletion":5469,"completion":5469,"start":10507,"enrollment":18664,"conditions":18684,"interventions":18685},[92],[8323],[18650,18667],{"trials":18687,"activeCount":102},[],{"trials":18689,"activeCount":102},[],{"intervention":18691,"totalTrials":180,"cells":18692},"N-Acetylcysteine followed by Placebo",{"EARLY_PHASE1":18693,"PHASE1":18695,"PHASE2":18697,"PHASE3":18699,"PHASE4":18710,"NA":18712},{"trials":18694,"activeCount":102},[],{"trials":18696,"activeCount":102},[],{"trials":18698,"activeCount":102},[],{"trials":18700,"activeCount":102},[18701],{"nctId":18702,"briefTitle":18703,"status":241,"phases":18704,"primaryCompletion":18705,"completion":18706,"start":11593,"enrollment":1361,"conditions":18707,"interventions":18709},"NCT02505087","Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM)",[91,92],"2018-04-24","2020-08-31",[18708],"Selenoprotein N-related Myopathy",[18691],{"trials":18711,"activeCount":102},[],{"trials":18713,"activeCount":102},[],{"intervention":18715,"totalTrials":180,"cells":18716},"Anti-tumor necrosis factor alpha monoclonal antibody",{"EARLY_PHASE1":18717,"PHASE1":18719,"PHASE2":18721,"PHASE3":18723,"PHASE4":18735,"NA":18737},{"trials":18718,"activeCount":102},[],{"trials":18720,"activeCount":102},[],{"trials":18722,"activeCount":102},[],{"trials":18724,"activeCount":102},[18725],{"nctId":18726,"briefTitle":18727,"status":139,"phases":18728,"primaryCompletion":18729,"completion":18730,"start":18731,"enrollment":9911,"conditions":18732,"interventions":18734},"NCT01385826","Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis",[91,92],"2014-11-04","2015-08-27","2011-06-29",[1086,18733],"Juvenile Arthritis",[18715],{"trials":18736,"activeCount":102},[],{"trials":18738,"activeCount":102},[],{"intervention":18740,"totalTrials":180,"cells":18741},"Lidocaine",{"EARLY_PHASE1":18742,"PHASE1":18744,"PHASE2":18746,"PHASE3":18748,"PHASE4":18757,"NA":18759},{"trials":18743,"activeCount":102},[],{"trials":18745,"activeCount":102},[],{"trials":18747,"activeCount":102},[],{"trials":18749,"activeCount":102},[18750],{"nctId":18751,"briefTitle":18752,"status":139,"phases":18753,"primaryCompletion":5144,"completion":5144,"start":5171,"enrollment":2779,"conditions":18754,"interventions":18756},"NCT00236249","Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB",[92],[18755],"Colorectal Neoplasms",[18740],{"trials":18758,"activeCount":102},[],{"trials":18760,"activeCount":102},[],{"intervention":18762,"totalTrials":180,"cells":18763},"1: discontinuation of RAS blocker therapy",{"EARLY_PHASE1":18764,"PHASE1":18766,"PHASE2":18768,"PHASE3":18770,"PHASE4":18782,"NA":18784},{"trials":18765,"activeCount":102},[],{"trials":18767,"activeCount":102},[],{"trials":18769,"activeCount":102},[],{"trials":18771,"activeCount":102},[18772],{"nctId":18773,"briefTitle":18774,"status":241,"phases":18775,"primaryCompletion":18120,"completion":18776,"start":18777,"enrollment":3922,"conditions":18778,"interventions":18780},"NCT04329195","ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic",[92],"2021-01-09","2020-04-09",[18779],"History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection",[18762,18781],"2: continuation of RAS blocker therapy",{"trials":18783,"activeCount":102},[],{"trials":18785,"activeCount":102},[],{"intervention":18781,"totalTrials":180,"cells":18787},{"EARLY_PHASE1":18788,"PHASE1":18790,"PHASE2":18792,"PHASE3":18794,"PHASE4":18800,"NA":18802},{"trials":18789,"activeCount":102},[],{"trials":18791,"activeCount":102},[],{"trials":18793,"activeCount":102},[],{"trials":18795,"activeCount":102},[18796],{"nctId":18773,"briefTitle":18774,"status":241,"phases":18797,"primaryCompletion":18120,"completion":18776,"start":18777,"enrollment":3922,"conditions":18798,"interventions":18799},[92],[18779],[18762,18781],{"trials":18801,"activeCount":102},[],{"trials":18803,"activeCount":102},[],{"intervention":18805,"totalTrials":180,"cells":18806},"sorafenib",{"EARLY_PHASE1":18807,"PHASE1":18809,"PHASE2":18811,"PHASE3":18813,"PHASE4":18824,"NA":18826},{"trials":18808,"activeCount":102},[],{"trials":18810,"activeCount":102},[],{"trials":18812,"activeCount":102},[],{"trials":18814,"activeCount":102},[18815],{"nctId":18816,"briefTitle":18817,"status":139,"phases":18818,"primaryCompletion":1509,"completion":1509,"start":216,"enrollment":18819,"conditions":18820,"interventions":18822},"NCT01482442","SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma",[92],496,[18821],"Liver Carcinoma",[18805,18823],"SIR-Sphere",{"trials":18825,"activeCount":102},[],{"trials":18827,"activeCount":102},[],{"intervention":18823,"totalTrials":180,"cells":18829},{"EARLY_PHASE1":18830,"PHASE1":18832,"PHASE2":18834,"PHASE3":18836,"PHASE4":18842,"NA":18844},{"trials":18831,"activeCount":102},[],{"trials":18833,"activeCount":102},[],{"trials":18835,"activeCount":102},[],{"trials":18837,"activeCount":102},[18838],{"nctId":18816,"briefTitle":18817,"status":139,"phases":18839,"primaryCompletion":1509,"completion":1509,"start":216,"enrollment":18819,"conditions":18840,"interventions":18841},[92],[18821],[18805,18823],{"trials":18843,"activeCount":102},[],{"trials":18845,"activeCount":102},[],{"intervention":1019,"totalTrials":180,"cells":18847},{"EARLY_PHASE1":18848,"PHASE1":18850,"PHASE2":18852,"PHASE3":18854,"PHASE4":18860,"NA":18862},{"trials":18849,"activeCount":102},[],{"trials":18851,"activeCount":102},[],{"trials":18853,"activeCount":102},[],{"trials":18855,"activeCount":102},[18856],{"nctId":1009,"briefTitle":1010,"status":110,"phases":18857,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":18858,"interventions":18859},[92],[1017],[1019,251],{"trials":18861,"activeCount":102},[],{"trials":18863,"activeCount":102},[],{"intervention":18865,"totalTrials":180,"cells":18866},"Comparison of two anesthetics protocol",{"EARLY_PHASE1":18867,"PHASE1":18869,"PHASE2":18871,"PHASE3":18873,"PHASE4":18882,"NA":18884},{"trials":18868,"activeCount":102},[],{"trials":18870,"activeCount":102},[],{"trials":18872,"activeCount":102},[],{"trials":18874,"activeCount":102},[18875],{"nctId":18876,"briefTitle":18877,"status":139,"phases":18878,"primaryCompletion":301,"completion":13849,"start":9997,"enrollment":1403,"conditions":18879,"interventions":18881},"NCT00389883","Anaesthesia for Supratentorial Tumor Resection",[92],[18880],"Supratentorial Neoplasms",[18865],{"trials":18883,"activeCount":102},[],{"trials":18885,"activeCount":102},[],{"intervention":18887,"totalTrials":180,"cells":18888},"Hydroxyurea treatment",{"EARLY_PHASE1":18889,"PHASE1":18891,"PHASE2":18893,"PHASE3":18895,"PHASE4":18909,"NA":18911},{"trials":18890,"activeCount":102},[],{"trials":18892,"activeCount":102},[],{"trials":18894,"activeCount":102},[],{"trials":18896,"activeCount":102},[18897],{"nctId":18898,"briefTitle":18899,"status":110,"phases":18900,"primaryCompletion":18901,"completion":18902,"start":18903,"enrollment":18904,"conditions":18905,"interventions":18908},"NCT02611973","Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia",[92],"2019-11","2022-11","2016-03-10",2250,[18906,18907],"MPN","Essential Thrombocythemia",[18887],{"trials":18910,"activeCount":102},[],{"trials":18912,"activeCount":102},[],{"intervention":18914,"totalTrials":180,"cells":18915},"Oral prednisolone",{"EARLY_PHASE1":18916,"PHASE1":18918,"PHASE2":18920,"PHASE3":18922,"PHASE4":18932,"NA":18934},{"trials":18917,"activeCount":102},[],{"trials":18919,"activeCount":102},[],{"trials":18921,"activeCount":102},[],{"trials":18923,"activeCount":102},[18924],{"nctId":18925,"briefTitle":18926,"status":110,"phases":18927,"primaryCompletion":18928,"completion":1276,"start":18929,"enrollment":1108,"conditions":18930,"interventions":18931},"NCT05284136","Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease",[91,92],"2025-08-01","2022-04-01",[1332],[18914],{"trials":18933,"activeCount":102},[],{"trials":18935,"activeCount":102},[],{"intervention":18937,"totalTrials":180,"cells":18938},"Drug therapy",{"EARLY_PHASE1":18939,"PHASE1":18941,"PHASE2":18943,"PHASE3":18945,"PHASE4":18955,"NA":18957},{"trials":18940,"activeCount":102},[],{"trials":18942,"activeCount":102},[],{"trials":18944,"activeCount":102},[],{"trials":18946,"activeCount":102},[18947],{"nctId":18948,"briefTitle":18949,"status":139,"phases":18950,"primaryCompletion":18599,"completion":18951,"start":14779,"enrollment":5804,"conditions":18952,"interventions":18954},"NCT02869971","Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia",[92],"2022-03-25",[18953],"Benign Prostatic Hyperplasia",[18937],{"trials":18956,"activeCount":102},[],{"trials":18958,"activeCount":102},[],{"intervention":18960,"totalTrials":180,"cells":18961},"BCG GROUP",{"EARLY_PHASE1":18962,"PHASE1":18964,"PHASE2":18966,"PHASE3":18968,"PHASE4":18981,"NA":18983},{"trials":18963,"activeCount":102},[],{"trials":18965,"activeCount":102},[],{"trials":18967,"activeCount":102},[],{"trials":18969,"activeCount":102},[18970],{"nctId":18971,"briefTitle":18972,"status":110,"phases":18973,"primaryCompletion":18974,"completion":18974,"start":18975,"enrollment":18976,"conditions":18977,"interventions":18980},"NCT04384549","Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers",[92],"2021-02-20","2020-05-20",1120,[18978,18979],"Infection","Viral, Agent as Cause of Disease Classified Elsewhere",[18960],{"trials":18982,"activeCount":102},[],{"trials":18984,"activeCount":102},[],{"intervention":18986,"totalTrials":1299,"cells":18987},"Nivolumab",{"EARLY_PHASE1":18988,"PHASE1":18990,"PHASE2":18992,"PHASE3":19035,"PHASE4":19037,"NA":19039},{"trials":18989,"activeCount":102},[],{"trials":18991,"activeCount":102},[],{"trials":18993,"activeCount":102},[18994,19007,19015,19025],{"nctId":18995,"briefTitle":18996,"status":139,"phases":18997,"primaryCompletion":18998,"completion":18999,"start":6162,"enrollment":400,"conditions":19000,"interventions":19002},"NCT04988841","Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma",[91],"2024-08-30","2025-04-22",[19001],"Melanoma",[19003,19004,18986,19005,19006],"MaaT013","Ipilimumab","MoviPrep","Normacol",{"nctId":19008,"briefTitle":19009,"status":110,"phases":19010,"primaryCompletion":17792,"completion":5631,"start":5633,"enrollment":19011,"conditions":19012,"interventions":19014},"NCT04343144","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.",[91],92,[19013],"COVID19- Infection With SARS-CoV-2 Virus",[18986],{"nctId":19016,"briefTitle":19017,"status":110,"phases":19018,"primaryCompletion":19019,"completion":19020,"start":19021,"enrollment":33,"conditions":19022,"interventions":19024},"NCT04021420","Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma",[90,91],"2022-01-01","2023-07-05","2019-10-24",[19001,19023],"Metastatic Melanoma",[18986],{"nctId":19026,"briefTitle":19027,"status":139,"phases":19028,"primaryCompletion":19029,"completion":17996,"start":19030,"enrollment":14156,"conditions":19031,"interventions":19034},"NCT03925246","Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas",[91],"2020-12-02","2019-07-30",[19032,19033],"High Grade Glioma","Brain Cancer",[18986],{"trials":19036,"activeCount":102},[],{"trials":19038,"activeCount":102},[],{"trials":19040,"activeCount":102},[],{"intervention":5646,"totalTrials":429,"cells":19042},{"EARLY_PHASE1":19043,"PHASE1":19045,"PHASE2":19047,"PHASE3":19070,"PHASE4":19072,"NA":19074},{"trials":19044,"activeCount":102},[],{"trials":19046,"activeCount":102},[],{"trials":19048,"activeCount":102},[19049,19053,19060],{"nctId":5638,"briefTitle":5639,"status":139,"phases":19050,"primaryCompletion":5641,"completion":386,"start":1833,"enrollment":400,"conditions":19051,"interventions":19052},[91],[5643,5644],[5646,5619],{"nctId":19054,"briefTitle":19055,"status":139,"phases":19056,"primaryCompletion":267,"completion":1940,"start":1588,"enrollment":400,"conditions":19057,"interventions":19059},"NCT01242566","Temozolomide in Elderly Patients With KPS \u003C 70",[91],[5644,19058],"Glioblastoma",[5646],{"nctId":19061,"briefTitle":19062,"status":110,"phases":19063,"primaryCompletion":19064,"completion":19065,"start":19066,"enrollment":303,"conditions":19067,"interventions":19069},"NCT03932981","First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and\u002For Radiological Infiltrative Pattern of Progression",[91],"2023-04-30","2023-09-30","2019-07-26",[19068],"Adult Brainstem Glioma",[5646],{"trials":19071,"activeCount":102},[],{"trials":19073,"activeCount":102},[],{"trials":19075,"activeCount":102},[],{"intervention":19077,"totalTrials":163,"cells":19078},"Pembrolizumab",{"EARLY_PHASE1":19079,"PHASE1":19081,"PHASE2":19083,"PHASE3":19107,"PHASE4":19109,"NA":19111},{"trials":19080,"activeCount":102},[],{"trials":19082,"activeCount":102},[],{"trials":19084,"activeCount":102},[19085,19097],{"nctId":19086,"briefTitle":19087,"status":110,"phases":19088,"primaryCompletion":19089,"completion":19090,"start":19091,"enrollment":19092,"conditions":19093,"interventions":19096},"NCT03469804","Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma",[91],"2020-03-20","2020-09-20","2018-07-01",17,[19094,19095],"Kaposi Sarcoma","Progression, Disease",[19077],{"nctId":19098,"briefTitle":19099,"status":139,"phases":19100,"primaryCompletion":19101,"completion":12997,"start":19102,"enrollment":19103,"conditions":19104,"interventions":19106},"NCT02883556","Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin",[91],"2019-03-23","2017-03-27",57,[19105],"Carcinoma, Squamous Cell",[19077],{"trials":19108,"activeCount":102},[],{"trials":19110,"activeCount":102},[],{"trials":19112,"activeCount":102},[],{"intervention":1976,"totalTrials":163,"cells":19114},{"EARLY_PHASE1":19115,"PHASE1":19117,"PHASE2":19119,"PHASE3":19132,"PHASE4":19134,"NA":19136},{"trials":19116,"activeCount":102},[],{"trials":19118,"activeCount":102},[],{"trials":19120,"activeCount":102},[19121,19125],{"nctId":1966,"briefTitle":1967,"status":139,"phases":19122,"primaryCompletion":301,"completion":301,"start":1969,"enrollment":1130,"conditions":19123,"interventions":19124},[91],[1971],[1973,1974,1957,1975,1976],{"nctId":19126,"briefTitle":19127,"status":139,"phases":19128,"primaryCompletion":1577,"completion":1577,"start":988,"enrollment":6268,"conditions":19129,"interventions":19130},"NCT02253212","Safety of BBB Opening With the SonoCloud",[90,91],[19058,16228,8676],[19131],"Carboplatin",{"trials":19133,"activeCount":102},[],{"trials":19135,"activeCount":102},[],{"trials":19137,"activeCount":102},[],{"intervention":19139,"totalTrials":163,"cells":19140},"Plerixafor",{"EARLY_PHASE1":19141,"PHASE1":19143,"PHASE2":19145,"PHASE3":19167,"PHASE4":19169,"NA":19171},{"trials":19142,"activeCount":102},[],{"trials":19144,"activeCount":102},[],{"trials":19146,"activeCount":102},[19147,19157],{"nctId":19148,"briefTitle":19149,"status":139,"phases":19150,"primaryCompletion":15731,"completion":19151,"start":19152,"enrollment":1299,"conditions":19153,"interventions":19155},"NCT02678533","Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor",[90,91],"2019-05-03","2017-02-10",[19154],"Fanconi Anemia",[19156,19139],"G-CSF",{"nctId":19158,"briefTitle":19159,"status":139,"phases":19160,"primaryCompletion":19161,"completion":19162,"start":19163,"enrollment":429,"conditions":19164,"interventions":19166},"NCT02212535","Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients",[90,91],"2017-04-04","2017-09-27","2016-01-15",[19165],"Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia",[19139],{"trials":19168,"activeCount":102},[],{"trials":19170,"activeCount":102},[],{"trials":19172,"activeCount":102},[],{"intervention":19174,"totalTrials":163,"cells":19175},"Azacitidine",{"EARLY_PHASE1":19176,"PHASE1":19178,"PHASE2":19180,"PHASE3":19203,"PHASE4":19205,"NA":19207},{"trials":19177,"activeCount":102},[],{"trials":19179,"activeCount":102},[],{"trials":19181,"activeCount":102},[19182,19194],{"nctId":19183,"briefTitle":19184,"status":110,"phases":19185,"primaryCompletion":1577,"completion":19186,"start":1587,"enrollment":19187,"conditions":19188,"interventions":19190},"NCT01342692","Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes",[91],"2019-06",320,[19189],"MDS",[19174,19191,19192,19193],"Azacitidine associated with Valproic acid","Azacitidine associated with Lenalidomide","Azacitidine associated with Idarubicine",{"nctId":19195,"briefTitle":19196,"status":110,"phases":19197,"primaryCompletion":11262,"completion":19198,"start":19199,"enrollment":280,"conditions":19200,"interventions":19202},"NCT03666559","Treatment With Azacitidine of Recurrent Gliomas With IDH1\u002F2 Mutation",[91],"2024-03-23","2020-09-22",[19201],"Recurrent IDH1\u002F2 Mutated Glioma",[19174],{"trials":19204,"activeCount":102},[],{"trials":19206,"activeCount":102},[],{"trials":19208,"activeCount":102},[],{"intervention":19210,"totalTrials":163,"cells":19211},"Digoxin",{"EARLY_PHASE1":19212,"PHASE1":19214,"PHASE2":19216,"PHASE3":19237,"PHASE4":19239,"NA":19241},{"trials":19213,"activeCount":102},[],{"trials":19215,"activeCount":102},[],{"trials":19217,"activeCount":102},[19218,19225],{"nctId":19219,"briefTitle":19220,"status":110,"phases":19221,"primaryCompletion":976,"completion":976,"start":18461,"enrollment":413,"conditions":19222,"interventions":19224},"NCT02906800","Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients",[90,91],[19223],"Head and Neck Cancer",[19210],{"nctId":19226,"briefTitle":19227,"status":110,"phases":19228,"primaryCompletion":14010,"completion":19229,"start":522,"enrollment":19092,"conditions":19230,"interventions":19235},"NCT02212639","Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma",[91],"2019-09",[19231,19232,19233,19234],"Kaposi' s Sarcoma","Classic Kaposi' s Sarcoma","Endemic Kaposi' s Sarcoma","Lymph Angio Proliferations",[19236],"digoxin",{"trials":19238,"activeCount":102},[],{"trials":19240,"activeCount":102},[],{"trials":19242,"activeCount":102},[],{"intervention":19244,"totalTrials":163,"cells":19245},"Eculizumab",{"EARLY_PHASE1":19246,"PHASE1":19248,"PHASE2":19250,"PHASE3":19268,"PHASE4":19270,"NA":19272},{"trials":19247,"activeCount":102},[],{"trials":19249,"activeCount":102},[],{"trials":19251,"activeCount":102},[19252,19259],{"nctId":19253,"briefTitle":19254,"status":5932,"phases":19255,"primaryCompletion":11592,"completion":8411,"start":1939,"enrollment":102,"conditions":19256,"interventions":19258},"NCT02113891","Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation",[90,91],[19257],"Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation",[19244],{"nctId":19260,"briefTitle":19261,"status":110,"phases":19262,"primaryCompletion":5631,"completion":19263,"start":19264,"enrollment":1277,"conditions":19265,"interventions":19267},"NCT04346797","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",[91],"2020-12-31","2020-04-16",[19266,12317],"SARS-CoV-2",[19244],{"trials":19269,"activeCount":102},[],{"trials":19271,"activeCount":102},[],{"trials":19273,"activeCount":102},[],{"intervention":19275,"totalTrials":163,"cells":19276},"Sutent",{"EARLY_PHASE1":19277,"PHASE1":19279,"PHASE2":19281,"PHASE3":19299,"PHASE4":19301,"NA":19303},{"trials":19278,"activeCount":102},[],{"trials":19280,"activeCount":102},[],{"trials":19282,"activeCount":102},[19283,19290],{"nctId":19284,"briefTitle":19285,"status":241,"phases":19286,"primaryCompletion":1402,"completion":12305,"start":990,"enrollment":1299,"conditions":19287,"interventions":19289},"NCT01215565","Study of Sunitinib in Patients With Advanced\u002FInoperable Fibrolamellar Carcinoma",[91],[35,19288],"Fibrolamellar Hepatocellular Carcinoma",[19275],{"nctId":19291,"briefTitle":19292,"status":241,"phases":19293,"primaryCompletion":11768,"completion":8413,"start":387,"enrollment":16,"conditions":19294,"interventions":19298},"NCT01215578","Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors",[91],[19295,19296,19297,10005],"Neuroendocrine Tumors","Pancreatic Neoplasms","Advanced Disease",[19275],{"trials":19300,"activeCount":102},[],{"trials":19302,"activeCount":102},[],{"trials":19304,"activeCount":102},[],{"intervention":19306,"totalTrials":180,"cells":19307},"Omeprazole",{"EARLY_PHASE1":19308,"PHASE1":19310,"PHASE2":19312,"PHASE3":19321,"PHASE4":19323,"NA":19325},{"trials":19309,"activeCount":102},[],{"trials":19311,"activeCount":102},[],{"trials":19313,"activeCount":102},[19314],{"nctId":19315,"briefTitle":19316,"status":139,"phases":19317,"primaryCompletion":13261,"completion":10832,"start":421,"enrollment":1710,"conditions":19318,"interventions":19320},"NCT01657578","Optimal Dosing of Omeprazole in Neonates",[91],[19319],"Gastroesophageal Reflux Disease (GERD)",[19306],{"trials":19322,"activeCount":102},[],{"trials":19324,"activeCount":102},[],{"trials":19326,"activeCount":102},[],{"intervention":19328,"totalTrials":180,"cells":19329},"Oral Fludrocortisone",{"EARLY_PHASE1":19330,"PHASE1":19332,"PHASE2":19334,"PHASE3":19345,"PHASE4":19347,"NA":19349},{"trials":19331,"activeCount":102},[],{"trials":19333,"activeCount":102},[],{"trials":19335,"activeCount":102},[19336],{"nctId":19337,"briefTitle":19338,"status":139,"phases":19339,"primaryCompletion":19340,"completion":19340,"start":19341,"enrollment":1213,"conditions":19342,"interventions":19344},"NCT03001089","Impact of the Administration of Fludrocortisone in Very Premature Infants",[91],"2020-09-08","2017-06-01",[19343],"Partial Mineralocorticoid Deficiency",[19328],{"trials":19346,"activeCount":102},[],{"trials":19348,"activeCount":102},[],{"trials":19350,"activeCount":102},[],{"intervention":19352,"totalTrials":180,"cells":19353},"Degarelix",{"EARLY_PHASE1":19354,"PHASE1":19356,"PHASE2":19358,"PHASE3":19370,"PHASE4":19372,"NA":19374},{"trials":19355,"activeCount":102},[],{"trials":19357,"activeCount":102},[],{"trials":19359,"activeCount":102},[19360],{"nctId":19361,"briefTitle":19362,"status":139,"phases":19363,"primaryCompletion":19364,"completion":19365,"start":19366,"enrollment":280,"conditions":19367,"interventions":19369},"NCT03947151","Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer",[91],"2022-03-31","2022-08-30","2019-11-28",[19368],"Invasive Ductal Breast Carcinoma",[19352],{"trials":19371,"activeCount":102},[],{"trials":19373,"activeCount":102},[],{"trials":19375,"activeCount":102},[],{"intervention":19377,"totalTrials":180,"cells":19378},"mesenchymal stem cells",{"EARLY_PHASE1":19379,"PHASE1":19381,"PHASE2":19383,"PHASE3":19396,"PHASE4":19398,"NA":19400},{"trials":19380,"activeCount":102},[],{"trials":19382,"activeCount":102},[],{"trials":19384,"activeCount":102},[19385],{"nctId":19386,"briefTitle":19387,"status":110,"phases":19388,"primaryCompletion":19389,"completion":19390,"start":19391,"enrollment":5575,"conditions":19392,"interventions":19395},"NCT03562065","Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord",[90,91],"2023-06-01","2024-06-01","2019-09-11",[19393,19394],"Lupus Erythematosus","Stem Cell Transplant",[19377],{"trials":19397,"activeCount":102},[],{"trials":19399,"activeCount":102},[],{"trials":19401,"activeCount":102},[],{"intervention":19403,"totalTrials":180,"cells":19404},"Annexin",{"EARLY_PHASE1":19405,"PHASE1":19407,"PHASE2":19409,"PHASE3":19422,"PHASE4":19424,"NA":19426},{"trials":19406,"activeCount":102},[],{"trials":19408,"activeCount":102},[],{"trials":19410,"activeCount":102},[19411],{"nctId":19412,"briefTitle":19413,"status":110,"phases":19414,"primaryCompletion":19415,"completion":19416,"start":19417,"enrollment":19418,"conditions":19419,"interventions":19421},"NCT03832582","Annexin Imaging in Dissection of the Descending Aorta",[91],"2024-05-31","2024-12-31","2019-05-01",83,[19420],"Chronic Dissection of Thoracic Aorta (Disorder)",[19403],{"trials":19423,"activeCount":102},[],{"trials":19425,"activeCount":102},[],{"trials":19427,"activeCount":102},[],{"intervention":1973,"totalTrials":180,"cells":19429},{"EARLY_PHASE1":19430,"PHASE1":19432,"PHASE2":19434,"PHASE3":19440,"PHASE4":19442,"NA":19444},{"trials":19431,"activeCount":102},[],{"trials":19433,"activeCount":102},[],{"trials":19435,"activeCount":102},[19436],{"nctId":1966,"briefTitle":1967,"status":139,"phases":19437,"primaryCompletion":301,"completion":301,"start":1969,"enrollment":1130,"conditions":19438,"interventions":19439},[91],[1971],[1973,1974,1957,1975,1976],{"trials":19441,"activeCount":102},[],{"trials":19443,"activeCount":102},[],{"trials":19445,"activeCount":102},[],{"intervention":1974,"totalTrials":180,"cells":19447},{"EARLY_PHASE1":19448,"PHASE1":19450,"PHASE2":19452,"PHASE3":19458,"PHASE4":19460,"NA":19462},{"trials":19449,"activeCount":102},[],{"trials":19451,"activeCount":102},[],{"trials":19453,"activeCount":102},[19454],{"nctId":1966,"briefTitle":1967,"status":139,"phases":19455,"primaryCompletion":301,"completion":301,"start":1969,"enrollment":1130,"conditions":19456,"interventions":19457},[91],[1971],[1973,1974,1957,1975,1976],{"trials":19459,"activeCount":102},[],{"trials":19461,"activeCount":102},[],{"trials":19463,"activeCount":102},[],{"intervention":1975,"totalTrials":180,"cells":19465},{"EARLY_PHASE1":19466,"PHASE1":19468,"PHASE2":19470,"PHASE3":19476,"PHASE4":19478,"NA":19480},{"trials":19467,"activeCount":102},[],{"trials":19469,"activeCount":102},[],{"trials":19471,"activeCount":102},[19472],{"nctId":1966,"briefTitle":1967,"status":139,"phases":19473,"primaryCompletion":301,"completion":301,"start":1969,"enrollment":1130,"conditions":19474,"interventions":19475},[91],[1971],[1973,1974,1957,1975,1976],{"trials":19477,"activeCount":102},[],{"trials":19479,"activeCount":102},[],{"trials":19481,"activeCount":102},[],{"intervention":19156,"totalTrials":180,"cells":19483},{"EARLY_PHASE1":19484,"PHASE1":19486,"PHASE2":19488,"PHASE3":19494,"PHASE4":19496,"NA":19498},{"trials":19485,"activeCount":102},[],{"trials":19487,"activeCount":102},[],{"trials":19489,"activeCount":102},[19490],{"nctId":19148,"briefTitle":19149,"status":139,"phases":19491,"primaryCompletion":15731,"completion":19151,"start":19152,"enrollment":1299,"conditions":19492,"interventions":19493},[90,91],[19154],[19156,19139],{"trials":19495,"activeCount":102},[],{"trials":19497,"activeCount":102},[],{"trials":19499,"activeCount":102},[],{"intervention":19501,"totalTrials":180,"cells":19502},"Investigational product administration Xeomin®",{"EARLY_PHASE1":19503,"PHASE1":19505,"PHASE2":19507,"PHASE3":19519,"PHASE4":19521,"NA":19523},{"trials":19504,"activeCount":102},[],{"trials":19506,"activeCount":102},[],{"trials":19508,"activeCount":102},[19509],{"nctId":19510,"briefTitle":19511,"status":139,"phases":19512,"primaryCompletion":19513,"completion":114,"start":19514,"enrollment":19515,"conditions":19516,"interventions":19518},"NCT05196308","Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors",[91],"2024-07-23","2022-03-18",226,[19517],"Erectile Dysfunction",[19501],{"trials":19520,"activeCount":102},[],{"trials":19522,"activeCount":102},[],{"trials":19524,"activeCount":102},[],{"intervention":19526,"totalTrials":180,"cells":19527},"Iron chelating intervention",{"EARLY_PHASE1":19528,"PHASE1":19530,"PHASE2":19532,"PHASE3":19541,"PHASE4":19543,"NA":19545},{"trials":19529,"activeCount":102},[],{"trials":19531,"activeCount":102},[],{"trials":19533,"activeCount":102},[19534],{"nctId":19535,"briefTitle":19536,"status":139,"phases":19537,"primaryCompletion":5183,"completion":5183,"start":13453,"enrollment":413,"conditions":19538,"interventions":19540},"NCT00224640","Iron-Chelating Therapy and Friedreich Ataxia",[90,91],[19539],"Friedreich Ataxia",[19526],{"trials":19542,"activeCount":102},[],{"trials":19544,"activeCount":102},[],{"trials":19546,"activeCount":102},[],{"intervention":19548,"totalTrials":180,"cells":19549},"Pressurized intraperitoneal aerosol chemotherapy",{"EARLY_PHASE1":19550,"PHASE1":19552,"PHASE2":19554,"PHASE3":19568,"PHASE4":19570,"NA":19572},{"trials":19551,"activeCount":102},[],{"trials":19553,"activeCount":102},[],{"trials":19555,"activeCount":102},[19556],{"nctId":19557,"briefTitle":19558,"status":139,"phases":19559,"primaryCompletion":19560,"completion":19560,"start":19561,"enrollment":1213,"conditions":19562,"interventions":19566},"NCT04065139","Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study",[91],"2024-03-02","2020-06-11",[19563,19564,19565],"Gastric Adenocarcinoma","Cancer Metastatic","Chemotherapy Effect",[19548,19567],"Standard chemotherapy",{"trials":19569,"activeCount":102},[],{"trials":19571,"activeCount":102},[],{"trials":19573,"activeCount":102},[],{"intervention":19567,"totalTrials":180,"cells":19575},{"EARLY_PHASE1":19576,"PHASE1":19578,"PHASE2":19580,"PHASE3":19586,"PHASE4":19588,"NA":19590},{"trials":19577,"activeCount":102},[],{"trials":19579,"activeCount":102},[],{"trials":19581,"activeCount":102},[19582],{"nctId":19557,"briefTitle":19558,"status":139,"phases":19583,"primaryCompletion":19560,"completion":19560,"start":19561,"enrollment":1213,"conditions":19584,"interventions":19585},[91],[19563,19564,19565],[19548,19567],{"trials":19587,"activeCount":102},[],{"trials":19589,"activeCount":102},[],{"trials":19591,"activeCount":102},[],{"intervention":19593,"totalTrials":180,"cells":19594},"Alisporivir",{"EARLY_PHASE1":19595,"PHASE1":19597,"PHASE2":19599,"PHASE3":19610,"PHASE4":19612,"NA":19614},{"trials":19596,"activeCount":102},[],{"trials":19598,"activeCount":102},[],{"trials":19600,"activeCount":102},[19601],{"nctId":19602,"briefTitle":19603,"status":139,"phases":19604,"primaryCompletion":19605,"completion":19606,"start":19607,"enrollment":115,"conditions":19608,"interventions":19609},"NCT04608214","Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)",[91],"2022-01-19","2022-04-13","2021-01-08",[19266],[19593],{"trials":19611,"activeCount":102},[],{"trials":19613,"activeCount":102},[],{"trials":19615,"activeCount":102},[],{"intervention":19617,"totalTrials":180,"cells":19618},"Salbutamol - dose2",{"EARLY_PHASE1":19619,"PHASE1":19621,"PHASE2":19623,"PHASE3":19634,"PHASE4":19636,"NA":19638},{"trials":19620,"activeCount":102},[],{"trials":19622,"activeCount":102},[],{"trials":19624,"activeCount":102},[19625],{"nctId":19626,"briefTitle":19627,"status":139,"phases":19628,"primaryCompletion":12765,"completion":12765,"start":7961,"enrollment":5804,"conditions":19629,"interventions":19630},"NCT01470755","Study of Dose-response to Bronchodilator and Dose-finding in Child 2.5 to 6 Years - Study Golden",[91],[569],[19631,19617,19632,19633],"salbutamol","Salbutamol -dose3","salbutamol -dose4",{"trials":19635,"activeCount":102},[],{"trials":19637,"activeCount":102},[],{"trials":19639,"activeCount":102},[],{"intervention":19632,"totalTrials":180,"cells":19641},{"EARLY_PHASE1":19642,"PHASE1":19644,"PHASE2":19646,"PHASE3":19652,"PHASE4":19654,"NA":19656},{"trials":19643,"activeCount":102},[],{"trials":19645,"activeCount":102},[],{"trials":19647,"activeCount":102},[19648],{"nctId":19626,"briefTitle":19627,"status":139,"phases":19649,"primaryCompletion":12765,"completion":12765,"start":7961,"enrollment":5804,"conditions":19650,"interventions":19651},[91],[569],[19631,19617,19632,19633],{"trials":19653,"activeCount":102},[],{"trials":19655,"activeCount":102},[],{"trials":19657,"activeCount":102},[],{"intervention":19633,"totalTrials":180,"cells":19659},{"EARLY_PHASE1":19660,"PHASE1":19662,"PHASE2":19664,"PHASE3":19670,"PHASE4":19672,"NA":19674},{"trials":19661,"activeCount":102},[],{"trials":19663,"activeCount":102},[],{"trials":19665,"activeCount":102},[19666],{"nctId":19626,"briefTitle":19627,"status":139,"phases":19667,"primaryCompletion":12765,"completion":12765,"start":7961,"enrollment":5804,"conditions":19668,"interventions":19669},[91],[569],[19631,19617,19632,19633],{"trials":19671,"activeCount":102},[],{"trials":19673,"activeCount":102},[],{"trials":19675,"activeCount":102},[],{"intervention":19677,"totalTrials":180,"cells":19678},"Salivary samples",{"EARLY_PHASE1":19679,"PHASE1":19681,"PHASE2":19683,"PHASE3":19693,"PHASE4":19695,"NA":19697},{"trials":19680,"activeCount":102},[],{"trials":19682,"activeCount":102},[],{"trials":19684,"activeCount":102},[19685],{"nctId":19686,"briefTitle":19687,"status":139,"phases":19688,"primaryCompletion":6553,"completion":19689,"start":6095,"enrollment":36,"conditions":19690,"interventions":19692},"NCT04442061","Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus",[91],"2026-01-23",[19691],"Autism Spectrum Disorders",[19677],{"trials":19694,"activeCount":102},[],{"trials":19696,"activeCount":102},[],{"trials":19698,"activeCount":102},[],{"intervention":19700,"totalTrials":180,"cells":19701},"Interleukin 2",{"EARLY_PHASE1":19702,"PHASE1":19704,"PHASE2":19706,"PHASE3":19726,"PHASE4":19728,"NA":19730},{"trials":19703,"activeCount":102},[],{"trials":19705,"activeCount":102},[],{"trials":19707,"activeCount":102},[19708],{"nctId":19709,"briefTitle":19710,"status":139,"phases":19711,"primaryCompletion":19712,"completion":19713,"start":19714,"enrollment":8373,"conditions":19715,"interventions":19725},"NCT01988506","Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases",[91],"2019-10-16","2021-04-01","2014-01-06",[32,19716,11861,19717,19718,424,19719,19720,1353,19721,19722,19723,19724,325],"Ankylosing Spondylitis","Psoriasis","Behcet's Disease","Takayasu's Disease","Crohn's Disease","Autoimmune Hepatitis","Sclerosing Cholangitis","Gougerot-sjögren","Idiopathic Thrombocytopenic Purpura",[19700],{"trials":19727,"activeCount":102},[],{"trials":19729,"activeCount":102},[],{"trials":19731,"activeCount":102},[],{"intervention":19733,"totalTrials":180,"cells":19734},"Transdermal nicotine",{"EARLY_PHASE1":19735,"PHASE1":19737,"PHASE2":19739,"PHASE3":19748,"PHASE4":19750,"NA":19752},{"trials":19736,"activeCount":102},[],{"trials":19738,"activeCount":102},[],{"trials":19740,"activeCount":102},[19741],{"nctId":19742,"briefTitle":19743,"status":139,"phases":19744,"primaryCompletion":11220,"completion":5641,"start":2008,"enrollment":1931,"conditions":19745,"interventions":19747},"NCT00873392","Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease",[91],[19746],"Idiopathic Parkinson's Disease",[19733],{"trials":19749,"activeCount":102},[],{"trials":19751,"activeCount":102},[],{"trials":19753,"activeCount":102},[],{"intervention":19003,"totalTrials":180,"cells":19755},{"EARLY_PHASE1":19756,"PHASE1":19758,"PHASE2":19760,"PHASE3":19766,"PHASE4":19768,"NA":19770},{"trials":19757,"activeCount":102},[],{"trials":19759,"activeCount":102},[],{"trials":19761,"activeCount":102},[19762],{"nctId":18995,"briefTitle":18996,"status":139,"phases":19763,"primaryCompletion":18998,"completion":18999,"start":6162,"enrollment":400,"conditions":19764,"interventions":19765},[91],[19001],[19003,19004,18986,19005,19006],{"trials":19767,"activeCount":102},[],{"trials":19769,"activeCount":102},[],{"trials":19771,"activeCount":102},[],{"intervention":19004,"totalTrials":180,"cells":19773},{"EARLY_PHASE1":19774,"PHASE1":19776,"PHASE2":19778,"PHASE3":19784,"PHASE4":19786,"NA":19788},{"trials":19775,"activeCount":102},[],{"trials":19777,"activeCount":102},[],{"trials":19779,"activeCount":102},[19780],{"nctId":18995,"briefTitle":18996,"status":139,"phases":19781,"primaryCompletion":18998,"completion":18999,"start":6162,"enrollment":400,"conditions":19782,"interventions":19783},[91],[19001],[19003,19004,18986,19005,19006],{"trials":19785,"activeCount":102},[],{"trials":19787,"activeCount":102},[],{"trials":19789,"activeCount":102},[],{"intervention":19005,"totalTrials":180,"cells":19791},{"EARLY_PHASE1":19792,"PHASE1":19794,"PHASE2":19796,"PHASE3":19802,"PHASE4":19804,"NA":19806},{"trials":19793,"activeCount":102},[],{"trials":19795,"activeCount":102},[],{"trials":19797,"activeCount":102},[19798],{"nctId":18995,"briefTitle":18996,"status":139,"phases":19799,"primaryCompletion":18998,"completion":18999,"start":6162,"enrollment":400,"conditions":19800,"interventions":19801},[91],[19001],[19003,19004,18986,19005,19006],{"trials":19803,"activeCount":102},[],{"trials":19805,"activeCount":102},[],{"trials":19807,"activeCount":102},[],{"intervention":19006,"totalTrials":180,"cells":19809},{"EARLY_PHASE1":19810,"PHASE1":19812,"PHASE2":19814,"PHASE3":19820,"PHASE4":19822,"NA":19824},{"trials":19811,"activeCount":102},[],{"trials":19813,"activeCount":102},[],{"trials":19815,"activeCount":102},[19816],{"nctId":18995,"briefTitle":18996,"status":139,"phases":19817,"primaryCompletion":18998,"completion":18999,"start":6162,"enrollment":400,"conditions":19818,"interventions":19819},[91],[19001],[19003,19004,18986,19005,19006],{"trials":19821,"activeCount":102},[],{"trials":19823,"activeCount":102},[],{"trials":19825,"activeCount":102},[],{"intervention":19827,"totalTrials":180,"cells":19828},"Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir",{"EARLY_PHASE1":19829,"PHASE1":19831,"PHASE2":19833,"PHASE3":19844,"PHASE4":19846,"NA":19848},{"trials":19830,"activeCount":102},[],{"trials":19832,"activeCount":102},[],{"trials":19834,"activeCount":102},[19835],{"nctId":19836,"briefTitle":19837,"status":139,"phases":19838,"primaryCompletion":7865,"completion":19839,"start":19840,"enrollment":1384,"conditions":19841,"interventions":19843},"NCT02363452","Reverse Transcriptase Inhibitors in AGS",[91],"2018-06","2015-09-10",[19842],"Aicardi-Goutières Syndrome (AGS)",[19827],{"trials":19845,"activeCount":102},[],{"trials":19847,"activeCount":102},[],{"trials":19849,"activeCount":102},[],{"intervention":19851,"totalTrials":180,"cells":19852},"Methotrexate and temozolomide",{"EARLY_PHASE1":19853,"PHASE1":19855,"PHASE2":19857,"PHASE3":19866,"PHASE4":19868,"NA":19870},{"trials":19854,"activeCount":102},[],{"trials":19856,"activeCount":102},[],{"trials":19858,"activeCount":102},[19859],{"nctId":19860,"briefTitle":19861,"status":110,"phases":19862,"primaryCompletion":11641,"completion":13262,"start":1588,"enrollment":19011,"conditions":19863,"interventions":19864},"NCT00503594","Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine",[91],[14604],[19851,19865],"Methotrexate , procarbazine ,vincristine ,cytarabine",{"trials":19867,"activeCount":102},[],{"trials":19869,"activeCount":102},[],{"trials":19871,"activeCount":102},[],{"intervention":19865,"totalTrials":180,"cells":19873},{"EARLY_PHASE1":19874,"PHASE1":19876,"PHASE2":19878,"PHASE3":19884,"PHASE4":19886,"NA":19888},{"trials":19875,"activeCount":102},[],{"trials":19877,"activeCount":102},[],{"trials":19879,"activeCount":102},[19880],{"nctId":19860,"briefTitle":19861,"status":110,"phases":19881,"primaryCompletion":11641,"completion":13262,"start":1588,"enrollment":19011,"conditions":19882,"interventions":19883},[91],[14604],[19851,19865],{"trials":19885,"activeCount":102},[],{"trials":19887,"activeCount":102},[],{"trials":19889,"activeCount":102},[],{"intervention":19891,"totalTrials":180,"cells":19892},"low-dose IL-2",{"EARLY_PHASE1":19893,"PHASE1":19895,"PHASE2":19897,"PHASE3":19909,"PHASE4":19911,"NA":19913},{"trials":19894,"activeCount":102},[],{"trials":19896,"activeCount":102},[],{"trials":19898,"activeCount":102},[19899],{"nctId":19900,"briefTitle":19901,"status":139,"phases":19902,"primaryCompletion":19903,"completion":19904,"start":19905,"enrollment":1225,"conditions":19906,"interventions":19908},"NCT03970954","Low-dose Interleukin-2 in Women With Unexplained Miscarriages",[90,91],"2023-07-28","2024-03-20","2021-01-05",[19907],"Recurrent Miscarriage",[19891],{"trials":19910,"activeCount":102},[],{"trials":19912,"activeCount":102},[],{"trials":19914,"activeCount":102},[],{"intervention":19916,"totalTrials":180,"cells":19917},"rhIL-2",{"EARLY_PHASE1":19918,"PHASE1":19920,"PHASE2":19922,"PHASE3":19931,"PHASE4":19933,"NA":19935},{"trials":19919,"activeCount":102},[],{"trials":19921,"activeCount":102},[],{"trials":19923,"activeCount":102},[19924],{"nctId":19925,"briefTitle":19926,"status":139,"phases":19927,"primaryCompletion":19928,"completion":18902,"start":989,"enrollment":12723,"conditions":19929,"interventions":19930},"NCT02411253","Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes",[91],"2020-11",[1522],[19916],{"trials":19932,"activeCount":102},[],{"trials":19934,"activeCount":102},[],{"trials":19936,"activeCount":102},[],{"intervention":210,"totalTrials":180,"cells":19938},{"EARLY_PHASE1":19939,"PHASE1":19941,"PHASE2":19943,"PHASE3":19949,"PHASE4":19951,"NA":19953},{"trials":19940,"activeCount":102},[],{"trials":19942,"activeCount":102},[],{"trials":19944,"activeCount":102},[19945],{"nctId":200,"briefTitle":201,"status":139,"phases":19946,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":19947,"interventions":19948},[91],[208],[210,211,184],{"trials":19950,"activeCount":102},[],{"trials":19952,"activeCount":102},[],{"trials":19954,"activeCount":102},[],{"intervention":211,"totalTrials":180,"cells":19956},{"EARLY_PHASE1":19957,"PHASE1":19959,"PHASE2":19961,"PHASE3":19967,"PHASE4":19969,"NA":19971},{"trials":19958,"activeCount":102},[],{"trials":19960,"activeCount":102},[],{"trials":19962,"activeCount":102},[19963],{"nctId":200,"briefTitle":201,"status":139,"phases":19964,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":19965,"interventions":19966},[91],[208],[210,211,184],{"trials":19968,"activeCount":102},[],{"trials":19970,"activeCount":102},[],{"trials":19972,"activeCount":102},[],{"intervention":19974,"totalTrials":180,"cells":19975},"IL2",{"EARLY_PHASE1":19976,"PHASE1":19978,"PHASE2":19980,"PHASE3":19990,"PHASE4":19992,"NA":19994},{"trials":19977,"activeCount":102},[],{"trials":19979,"activeCount":102},[],{"trials":19981,"activeCount":102},[19982],{"nctId":19983,"briefTitle":19984,"status":139,"phases":19985,"primaryCompletion":19986,"completion":5747,"start":10873,"enrollment":21,"conditions":19987,"interventions":19989},"NCT02424396","Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis",[91],"2019-10-11",[19988],"Relapsing Remitting Multiple Sclerosis",[19974],{"trials":19991,"activeCount":102},[],{"trials":19993,"activeCount":102},[],{"trials":19995,"activeCount":102},[],{"intervention":19997,"totalTrials":180,"cells":19998},"Prime-boost pneumococcal immunization",{"EARLY_PHASE1":19999,"PHASE1":20001,"PHASE2":20003,"PHASE3":20015,"PHASE4":20017,"NA":20019},{"trials":20000,"activeCount":102},[],{"trials":20002,"activeCount":102},[],{"trials":20004,"activeCount":102},[20005],{"nctId":20006,"briefTitle":20007,"status":139,"phases":20008,"primaryCompletion":20009,"completion":20010,"start":20011,"enrollment":400,"conditions":20012,"interventions":20014},"NCT02052154","Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults",[91],"2016-07-19","2019-04-02","2014-03-10",[20013],"Splenectomized Patients",[19997],{"trials":20016,"activeCount":102},[],{"trials":20018,"activeCount":102},[],{"trials":20020,"activeCount":102},[],{"intervention":20022,"totalTrials":180,"cells":20023},"Adaptive autologous cell immunotherapy",{"EARLY_PHASE1":20024,"PHASE1":20026,"PHASE2":20028,"PHASE3":20036,"PHASE4":20038,"NA":20040},{"trials":20025,"activeCount":102},[],{"trials":20027,"activeCount":102},[],{"trials":20029,"activeCount":102},[20030],{"nctId":20031,"briefTitle":20032,"status":139,"phases":20033,"primaryCompletion":5162,"completion":5162,"start":13760,"enrollment":98,"conditions":20034,"interventions":20035},"NCT00986518","T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study",[90,91],[4808],[20022],{"trials":20037,"activeCount":102},[],{"trials":20039,"activeCount":102},[],{"trials":20041,"activeCount":102},[],{"intervention":20043,"totalTrials":180,"cells":20044},"TREATMENT",{"EARLY_PHASE1":20045,"PHASE1":20047,"PHASE2":20049,"PHASE3":20058,"PHASE4":20060,"NA":20062},{"trials":20046,"activeCount":102},[],{"trials":20048,"activeCount":102},[],{"trials":20050,"activeCount":102},[20051],{"nctId":20052,"briefTitle":20053,"status":139,"phases":20054,"primaryCompletion":11220,"completion":536,"start":5418,"enrollment":16,"conditions":20055,"interventions":20057},"NCT01146197","Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics",[90,91],[20056],"Gitelman Syndrome",[20043],{"trials":20059,"activeCount":102},[],{"trials":20061,"activeCount":102},[],{"trials":20063,"activeCount":102},[],{"intervention":20065,"totalTrials":180,"cells":20066},"Allopurinol",{"EARLY_PHASE1":20067,"PHASE1":20069,"PHASE2":20071,"PHASE3":20082,"PHASE4":20084,"NA":20086},{"trials":20068,"activeCount":102},[],{"trials":20070,"activeCount":102},[],{"trials":20072,"activeCount":102},[20073],{"nctId":20074,"briefTitle":20075,"status":139,"phases":20076,"primaryCompletion":20077,"completion":20077,"start":20078,"enrollment":280,"conditions":20079,"interventions":20081},"NCT03776656","Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency",[91],"2022-06-17","2019-10-14",[20080],"Adenylosuccinate Lyase Deficiency",[20065],{"trials":20083,"activeCount":102},[],{"trials":20085,"activeCount":102},[],{"trials":20087,"activeCount":102},[],{"intervention":20089,"totalTrials":180,"cells":20090},"Allogenic NK cells",{"EARLY_PHASE1":20091,"PHASE1":20093,"PHASE2":20095,"PHASE3":20103,"PHASE4":20105,"NA":20107},{"trials":20092,"activeCount":102},[],{"trials":20094,"activeCount":102},[],{"trials":20096,"activeCount":102},[20097],{"nctId":20098,"briefTitle":20099,"status":139,"phases":20100,"primaryCompletion":5518,"completion":5518,"start":1402,"enrollment":5575,"conditions":20101,"interventions":20102},"NCT01947322","Haploidentical NK-cell Infusion in Acute Myeloid Leukemia",[90,91],[1590],[20089],{"trials":20104,"activeCount":102},[],{"trials":20106,"activeCount":102},[],{"trials":20108,"activeCount":102},[],{"intervention":20110,"totalTrials":180,"cells":20111},"Aldesleukin",{"EARLY_PHASE1":20112,"PHASE1":20114,"PHASE2":20116,"PHASE3":20124,"PHASE4":20126,"NA":20128},{"trials":20113,"activeCount":102},[],{"trials":20115,"activeCount":102},[],{"trials":20117,"activeCount":102},[20118],{"nctId":20119,"briefTitle":20120,"status":139,"phases":20121,"primaryCompletion":956,"completion":5660,"start":1402,"enrollment":1247,"conditions":20122,"interventions":20123},"NCT01353833","Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes",[90,91],[1522],[20110],{"trials":20125,"activeCount":102},[],{"trials":20127,"activeCount":102},[],{"trials":20129,"activeCount":102},[],{"intervention":233,"totalTrials":180,"cells":20131},{"EARLY_PHASE1":20132,"PHASE1":20134,"PHASE2":20136,"PHASE3":20142,"PHASE4":20144,"NA":20146},{"trials":20133,"activeCount":102},[],{"trials":20135,"activeCount":102},[],{"trials":20137,"activeCount":102},[20138],{"nctId":223,"briefTitle":224,"status":139,"phases":20139,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":20140,"interventions":20141},[91],[230,231],[233,234,235,236,237,184],{"trials":20143,"activeCount":102},[],{"trials":20145,"activeCount":102},[],{"trials":20147,"activeCount":102},[],{"intervention":234,"totalTrials":180,"cells":20149},{"EARLY_PHASE1":20150,"PHASE1":20152,"PHASE2":20154,"PHASE3":20160,"PHASE4":20162,"NA":20164},{"trials":20151,"activeCount":102},[],{"trials":20153,"activeCount":102},[],{"trials":20155,"activeCount":102},[20156],{"nctId":223,"briefTitle":224,"status":139,"phases":20157,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":20158,"interventions":20159},[91],[230,231],[233,234,235,236,237,184],{"trials":20161,"activeCount":102},[],{"trials":20163,"activeCount":102},[],{"trials":20165,"activeCount":102},[],{"intervention":235,"totalTrials":180,"cells":20167},{"EARLY_PHASE1":20168,"PHASE1":20170,"PHASE2":20172,"PHASE3":20178,"PHASE4":20180,"NA":20182},{"trials":20169,"activeCount":102},[],{"trials":20171,"activeCount":102},[],{"trials":20173,"activeCount":102},[20174],{"nctId":223,"briefTitle":224,"status":139,"phases":20175,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":20176,"interventions":20177},[91],[230,231],[233,234,235,236,237,184],{"trials":20179,"activeCount":102},[],{"trials":20181,"activeCount":102},[],{"trials":20183,"activeCount":102},[],{"intervention":236,"totalTrials":180,"cells":20185},{"EARLY_PHASE1":20186,"PHASE1":20188,"PHASE2":20190,"PHASE3":20196,"PHASE4":20198,"NA":20200},{"trials":20187,"activeCount":102},[],{"trials":20189,"activeCount":102},[],{"trials":20191,"activeCount":102},[20192],{"nctId":223,"briefTitle":224,"status":139,"phases":20193,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":20194,"interventions":20195},[91],[230,231],[233,234,235,236,237,184],{"trials":20197,"activeCount":102},[],{"trials":20199,"activeCount":102},[],{"trials":20201,"activeCount":102},[],{"intervention":237,"totalTrials":180,"cells":20203},{"EARLY_PHASE1":20204,"PHASE1":20206,"PHASE2":20208,"PHASE3":20214,"PHASE4":20216,"NA":20218},{"trials":20205,"activeCount":102},[],{"trials":20207,"activeCount":102},[],{"trials":20209,"activeCount":102},[20210],{"nctId":223,"briefTitle":224,"status":139,"phases":20211,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":20212,"interventions":20213},[91],[230,231],[233,234,235,236,237,184],{"trials":20215,"activeCount":102},[],{"trials":20217,"activeCount":102},[],{"trials":20219,"activeCount":102},[],{"intervention":20221,"totalTrials":180,"cells":20222},"Tinzaparin or unfractionated heparin",{"EARLY_PHASE1":20223,"PHASE1":20225,"PHASE2":20227,"PHASE3":20237,"PHASE4":20239,"NA":20241},{"trials":20224,"activeCount":102},[],{"trials":20226,"activeCount":102},[],{"trials":20228,"activeCount":102},[20229],{"nctId":20230,"briefTitle":20231,"status":110,"phases":20232,"primaryCompletion":17792,"completion":5631,"start":20233,"enrollment":20234,"conditions":20235,"interventions":20236},"NCT04344756","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",[91],"2020-04-20",808,[5635],[20221],{"trials":20238,"activeCount":102},[],{"trials":20240,"activeCount":102},[],{"trials":20242,"activeCount":102},[],{"intervention":20244,"totalTrials":180,"cells":20245},"didanosine",{"EARLY_PHASE1":20246,"PHASE1":20248,"PHASE2":20250,"PHASE3":20259,"PHASE4":20261,"NA":20263},{"trials":20247,"activeCount":102},[],{"trials":20249,"activeCount":102},[],{"trials":20251,"activeCount":102},[20252],{"nctId":20253,"briefTitle":20254,"status":936,"phases":20255,"primaryCompletion":1940,"completion":13261,"start":1909,"enrollment":115,"conditions":20256,"interventions":20258},"NCT00668356","Bioequivalence Study of Didanosine in Children Treated for HIV",[91],[20257],"HIV Infections",[20244,20244],{"trials":20260,"activeCount":102},[],{"trials":20262,"activeCount":102},[],{"trials":20264,"activeCount":102},[],{"intervention":20266,"totalTrials":180,"cells":20267},"Tinzaparin, Low dose prophylactic anticoagulation",{"EARLY_PHASE1":20268,"PHASE1":20270,"PHASE2":20272,"PHASE3":20285,"PHASE4":20287,"NA":20289},{"trials":20269,"activeCount":102},[],{"trials":20271,"activeCount":102},[],{"trials":20273,"activeCount":102},[20274],{"nctId":20275,"briefTitle":20276,"status":139,"phases":20277,"primaryCompletion":20278,"completion":8015,"start":8936,"enrollment":20279,"conditions":20280,"interventions":20282},"NCT04808882","ANTIcoagulation in Severe COVID-19 Patients",[91],"2022-01-10",353,[20281],"Severe COVID-19 Pneumonia",[20266,20283,20284],"Tinzaparin, High dose prophylactic anticoagulation","Tinzaparin,Therapeutic anticoagulation",{"trials":20286,"activeCount":102},[],{"trials":20288,"activeCount":102},[],{"trials":20290,"activeCount":102},[],{"intervention":20283,"totalTrials":180,"cells":20292},{"EARLY_PHASE1":20293,"PHASE1":20295,"PHASE2":20297,"PHASE3":20303,"PHASE4":20305,"NA":20307},{"trials":20294,"activeCount":102},[],{"trials":20296,"activeCount":102},[],{"trials":20298,"activeCount":102},[20299],{"nctId":20275,"briefTitle":20276,"status":139,"phases":20300,"primaryCompletion":20278,"completion":8015,"start":8936,"enrollment":20279,"conditions":20301,"interventions":20302},[91],[20281],[20266,20283,20284],{"trials":20304,"activeCount":102},[],{"trials":20306,"activeCount":102},[],{"trials":20308,"activeCount":102},[],{"intervention":20284,"totalTrials":180,"cells":20310},{"EARLY_PHASE1":20311,"PHASE1":20313,"PHASE2":20315,"PHASE3":20321,"PHASE4":20323,"NA":20325},{"trials":20312,"activeCount":102},[],{"trials":20314,"activeCount":102},[],{"trials":20316,"activeCount":102},[20317],{"nctId":20275,"briefTitle":20276,"status":139,"phases":20318,"primaryCompletion":20278,"completion":8015,"start":8936,"enrollment":20279,"conditions":20319,"interventions":20320},[91],[20281],[20266,20283,20284],{"trials":20322,"activeCount":102},[],{"trials":20324,"activeCount":102},[],{"trials":20326,"activeCount":102},[],{"intervention":20328,"totalTrials":180,"cells":20329},"Sandostatine LP",{"EARLY_PHASE1":20330,"PHASE1":20332,"PHASE2":20334,"PHASE3":20343,"PHASE4":20345,"NA":20347},{"trials":20331,"activeCount":102},[],{"trials":20333,"activeCount":102},[],{"trials":20335,"activeCount":102},[20336],{"nctId":20337,"briefTitle":20338,"status":139,"phases":20339,"primaryCompletion":10017,"completion":1587,"start":17169,"enrollment":5575,"conditions":20340,"interventions":20342},"NCT00987168","Sandostatine® LP and Hyperinsulinism",[91],[20341],"Congenital Hyperinsulinism",[20328],{"trials":20344,"activeCount":102},[],{"trials":20346,"activeCount":102},[],{"trials":20348,"activeCount":102},[],{"intervention":20350,"totalTrials":180,"cells":20351},"Betaine",{"EARLY_PHASE1":20352,"PHASE1":20354,"PHASE2":20356,"PHASE3":20365,"PHASE4":20367,"NA":20369},{"trials":20353,"activeCount":102},[],{"trials":20355,"activeCount":102},[],{"trials":20357,"activeCount":102},[20358],{"nctId":20359,"briefTitle":20360,"status":139,"phases":20361,"primaryCompletion":12094,"completion":16636,"start":10532,"enrollment":268,"conditions":20362,"interventions":20364},"NCT02404337","Betaine METABOLISM OF PATIENTS With Homocystinuria",[91],[20363],"Homocystinuria",[20350],{"trials":20366,"activeCount":102},[],{"trials":20368,"activeCount":102},[],{"trials":20370,"activeCount":102},[],{"intervention":20372,"totalTrials":180,"cells":20373},"radiochemotherapy,combination Cetuximab-FOLFOX",{"EARLY_PHASE1":20374,"PHASE1":20376,"PHASE2":20378,"PHASE3":20388,"PHASE4":20390,"NA":20392},{"trials":20375,"activeCount":102},[],{"trials":20377,"activeCount":102},[],{"trials":20379,"activeCount":102},[20380],{"nctId":20381,"briefTitle":20382,"status":139,"phases":20383,"primaryCompletion":20384,"completion":20384,"start":9880,"enrollment":1108,"conditions":20385,"interventions":20387},"NCT00578201","FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer",[91],"2011-02",[20386],"Esophageal Cancer Stage III",[20372],{"trials":20389,"activeCount":102},[],{"trials":20391,"activeCount":102},[],{"trials":20393,"activeCount":102},[],{"intervention":20395,"totalTrials":180,"cells":20396},"Talimogene laherparepvec",{"EARLY_PHASE1":20397,"PHASE1":20399,"PHASE2":20401,"PHASE3":20411,"PHASE4":20413,"NA":20415},{"trials":20398,"activeCount":102},[],{"trials":20400,"activeCount":102},[],{"trials":20402,"activeCount":102},[20403],{"nctId":20404,"briefTitle":20405,"status":110,"phases":20406,"primaryCompletion":20407,"completion":1674,"start":20408,"enrollment":36,"conditions":20409,"interventions":20410},"NCT04065152","Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma",[91],"2023-02-01","2021-01-01",[19094],[20395],{"trials":20412,"activeCount":102},[],{"trials":20414,"activeCount":102},[],{"trials":20416,"activeCount":102},[],{"intervention":20418,"totalTrials":180,"cells":20419},"Formoterol\u002FBudesonide",{"EARLY_PHASE1":20420,"PHASE1":20422,"PHASE2":20424,"PHASE3":20434,"PHASE4":20436,"NA":20438},{"trials":20421,"activeCount":102},[],{"trials":20423,"activeCount":102},[],{"trials":20425,"activeCount":102},[20426],{"nctId":20427,"briefTitle":20428,"status":139,"phases":20429,"primaryCompletion":13262,"completion":13262,"start":5183,"enrollment":228,"conditions":20430,"interventions":20432},"NCT00624754","Prospective Evaluation of the Efficacy of Budesonide\u002FFormoterol in Bronchiolitis Obliterans in AHSCT",[91],[20431],"Obstructive Airway Disease",[20418,20433],"lactose",{"trials":20435,"activeCount":102},[],{"trials":20437,"activeCount":102},[],{"trials":20439,"activeCount":102},[],{"intervention":20433,"totalTrials":180,"cells":20441},{"EARLY_PHASE1":20442,"PHASE1":20444,"PHASE2":20446,"PHASE3":20452,"PHASE4":20454,"NA":20456},{"trials":20443,"activeCount":102},[],{"trials":20445,"activeCount":102},[],{"trials":20447,"activeCount":102},[20448],{"nctId":20427,"briefTitle":20428,"status":139,"phases":20449,"primaryCompletion":13262,"completion":13262,"start":5183,"enrollment":228,"conditions":20450,"interventions":20451},[91],[20431],[20418,20433],{"trials":20453,"activeCount":102},[],{"trials":20455,"activeCount":102},[],{"trials":20457,"activeCount":102},[],{"intervention":20459,"totalTrials":180,"cells":20460},"Alemtuzumab",{"EARLY_PHASE1":20461,"PHASE1":20463,"PHASE2":20465,"PHASE3":20478,"PHASE4":20480,"NA":20482},{"trials":20462,"activeCount":102},[],{"trials":20464,"activeCount":102},[],{"trials":20466,"activeCount":102},[20467],{"nctId":20468,"briefTitle":20469,"status":139,"phases":20470,"primaryCompletion":20471,"completion":18975,"start":20472,"enrollment":5940,"conditions":20473,"interventions":20475},"NCT02472054","Treatment of Familiar Lymphohistiocytosis",[90,91],"2019-09-12","2015-06-29",[20474],"Hemophagocytic Lymphohistiocytosis (HLH)",[20459,20476,20477],"Methyl Prednisolone","Cyclosporin A",{"trials":20479,"activeCount":102},[],{"trials":20481,"activeCount":102},[],{"trials":20483,"activeCount":102},[],{"intervention":20476,"totalTrials":180,"cells":20485},{"EARLY_PHASE1":20486,"PHASE1":20488,"PHASE2":20490,"PHASE3":20496,"PHASE4":20498,"NA":20500},{"trials":20487,"activeCount":102},[],{"trials":20489,"activeCount":102},[],{"trials":20491,"activeCount":102},[20492],{"nctId":20468,"briefTitle":20469,"status":139,"phases":20493,"primaryCompletion":20471,"completion":18975,"start":20472,"enrollment":5940,"conditions":20494,"interventions":20495},[90,91],[20474],[20459,20476,20477],{"trials":20497,"activeCount":102},[],{"trials":20499,"activeCount":102},[],{"trials":20501,"activeCount":102},[],{"intervention":20477,"totalTrials":180,"cells":20503},{"EARLY_PHASE1":20504,"PHASE1":20506,"PHASE2":20508,"PHASE3":20514,"PHASE4":20516,"NA":20518},{"trials":20505,"activeCount":102},[],{"trials":20507,"activeCount":102},[],{"trials":20509,"activeCount":102},[20510],{"nctId":20468,"briefTitle":20469,"status":139,"phases":20511,"primaryCompletion":20471,"completion":18975,"start":20472,"enrollment":5940,"conditions":20512,"interventions":20513},[90,91],[20474],[20459,20476,20477],{"trials":20515,"activeCount":102},[],{"trials":20517,"activeCount":102},[],{"trials":20519,"activeCount":102},[],{"intervention":20521,"totalTrials":180,"cells":20522},"Fulvestrant + palbociclib",{"EARLY_PHASE1":20523,"PHASE1":20525,"PHASE2":20527,"PHASE3":20538,"PHASE4":20540,"NA":20542},{"trials":20524,"activeCount":102},[],{"trials":20526,"activeCount":102},[],{"trials":20528,"activeCount":102},[20529],{"nctId":20530,"briefTitle":20531,"status":110,"phases":20532,"primaryCompletion":6117,"completion":6117,"start":20533,"enrollment":3501,"conditions":20534,"interventions":20537},"NCT03560856","A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+\u002Fher2- Advanced Breast Cancer",[91],"2018-06-27",[29,20535,20536],"HR+\u002FHER2-negative Breast Cancer","Metastasis",[20521],{"trials":20539,"activeCount":102},[],{"trials":20541,"activeCount":102},[],{"trials":20543,"activeCount":102},[],{"intervention":20545,"totalTrials":180,"cells":20546},"Dose D1 of interleukin-2",{"EARLY_PHASE1":20547,"PHASE1":20549,"PHASE2":20551,"PHASE3":20564,"PHASE4":20566,"NA":20568},{"trials":20548,"activeCount":102},[],{"trials":20550,"activeCount":102},[],{"trials":20552,"activeCount":102},[20553],{"nctId":20554,"briefTitle":20555,"status":139,"phases":20556,"primaryCompletion":20557,"completion":20558,"start":20559,"enrollment":27,"conditions":20560,"interventions":20561},"NCT01862120","Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes",[91],"2016-07-08","2017-03-16","2013-06-27",[1522],[20545,20562,20563],"Dose D2 of Interleukin-2","Dose D3 of interleukin-2",{"trials":20565,"activeCount":102},[],{"trials":20567,"activeCount":102},[],{"trials":20569,"activeCount":102},[],{"intervention":20562,"totalTrials":180,"cells":20571},{"EARLY_PHASE1":20572,"PHASE1":20574,"PHASE2":20576,"PHASE3":20582,"PHASE4":20584,"NA":20586},{"trials":20573,"activeCount":102},[],{"trials":20575,"activeCount":102},[],{"trials":20577,"activeCount":102},[20578],{"nctId":20554,"briefTitle":20555,"status":139,"phases":20579,"primaryCompletion":20557,"completion":20558,"start":20559,"enrollment":27,"conditions":20580,"interventions":20581},[91],[1522],[20545,20562,20563],{"trials":20583,"activeCount":102},[],{"trials":20585,"activeCount":102},[],{"trials":20587,"activeCount":102},[],{"intervention":20563,"totalTrials":180,"cells":20589},{"EARLY_PHASE1":20590,"PHASE1":20592,"PHASE2":20594,"PHASE3":20600,"PHASE4":20602,"NA":20604},{"trials":20591,"activeCount":102},[],{"trials":20593,"activeCount":102},[],{"trials":20595,"activeCount":102},[20596],{"nctId":20554,"briefTitle":20555,"status":139,"phases":20597,"primaryCompletion":20557,"completion":20558,"start":20559,"enrollment":27,"conditions":20598,"interventions":20599},[91],[1522],[20545,20562,20563],{"trials":20601,"activeCount":102},[],{"trials":20603,"activeCount":102},[],{"trials":20605,"activeCount":102},[],{"intervention":20607,"totalTrials":180,"cells":20608},"Romiplostim",{"EARLY_PHASE1":20609,"PHASE1":20611,"PHASE2":20613,"PHASE3":20623,"PHASE4":20625,"NA":20627},{"trials":20610,"activeCount":102},[],{"trials":20612,"activeCount":102},[],{"trials":20614,"activeCount":102},[20615],{"nctId":20616,"briefTitle":20617,"status":139,"phases":20618,"primaryCompletion":977,"completion":18330,"start":20619,"enrollment":27,"conditions":20620,"interventions":20622},"NCT01980030","Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell",[90,91],"2013-11",[20621],"Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[20607],{"trials":20624,"activeCount":102},[],{"trials":20626,"activeCount":102},[],{"trials":20628,"activeCount":102},[],{"intervention":20630,"totalTrials":180,"cells":20631},"WR 279,396",{"EARLY_PHASE1":20632,"PHASE1":20634,"PHASE2":20636,"PHASE3":20645,"PHASE4":20647,"NA":20649},{"trials":20633,"activeCount":102},[],{"trials":20635,"activeCount":102},[],{"trials":20637,"activeCount":102},[20638],{"nctId":20639,"briefTitle":20640,"status":139,"phases":20641,"primaryCompletion":977,"completion":977,"start":15150,"enrollment":1225,"conditions":20642,"interventions":20644},"NCT01988909","WR 279,396 for the Treatment of Cutaneous Leishmaniasis",[91],[20643],"Cutaneous Leishmaniasis",[20630],{"trials":20646,"activeCount":102},[],{"trials":20648,"activeCount":102},[],{"trials":20650,"activeCount":102},[],{"intervention":20652,"totalTrials":180,"cells":20653},"MYDICAR-single intracoronary",{"EARLY_PHASE1":20654,"PHASE1":20656,"PHASE2":20658,"PHASE3":20669,"PHASE4":20671,"NA":20673},{"trials":20655,"activeCount":102},[],{"trials":20657,"activeCount":102},[],{"trials":20659,"activeCount":102},[20660],{"nctId":20661,"briefTitle":20662,"status":241,"phases":20663,"primaryCompletion":11593,"completion":8061,"start":11768,"enrollment":5575,"conditions":20664,"interventions":20668},"NCT01966887","AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure",[91],[20665,20666,20667],"Heart Failure Congestive","Ischemic Cardiomyopathy","Non-ischemic Cardiomyopathy",[20652],{"trials":20670,"activeCount":102},[],{"trials":20672,"activeCount":102},[],{"trials":20674,"activeCount":102},[],{"intervention":20676,"totalTrials":180,"cells":20677},"radiopharmaceutical",{"EARLY_PHASE1":20678,"PHASE1":20680,"PHASE2":20682,"PHASE3":20693,"PHASE4":20695,"NA":20697},{"trials":20679,"activeCount":102},[],{"trials":20681,"activeCount":102},[],{"trials":20683,"activeCount":102},[20684],{"nctId":20685,"briefTitle":20686,"status":241,"phases":20687,"primaryCompletion":20688,"completion":20688,"start":5574,"enrollment":180,"conditions":20689,"interventions":20692},"NCT02325349","PET\u002FCT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents",[91],"2018-09-20",[20690,20691],"Advanced Head and Neck Carcinoma","Advanced Non-small Cell Lung Carcinoma",[20676],{"trials":20694,"activeCount":102},[],{"trials":20696,"activeCount":102},[],{"trials":20698,"activeCount":102},[],{"intervention":20700,"totalTrials":180,"cells":20701},"1: Sevoflurane",{"EARLY_PHASE1":20702,"PHASE1":20704,"PHASE2":20706,"PHASE3":20715,"PHASE4":20717,"NA":20719},{"trials":20703,"activeCount":102},[],{"trials":20705,"activeCount":102},[],{"trials":20707,"activeCount":102},[20708],{"nctId":20709,"briefTitle":20710,"status":241,"phases":20711,"primaryCompletion":385,"completion":385,"start":216,"enrollment":5575,"conditions":20712,"interventions":20714},"NCT01374633","Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients",[91],[20713],"Brain Injury",[20700],{"trials":20716,"activeCount":102},[],{"trials":20718,"activeCount":102},[],{"trials":20720,"activeCount":102},[],{"intervention":20722,"totalTrials":180,"cells":20723},"PD- 0332991",{"EARLY_PHASE1":20724,"PHASE1":20726,"PHASE2":20728,"PHASE3":20740,"PHASE4":20742,"NA":20744},{"trials":20725,"activeCount":102},[],{"trials":20727,"activeCount":102},[],{"trials":20729,"activeCount":102},[20730],{"nctId":20731,"briefTitle":20732,"status":110,"phases":20733,"primaryCompletion":20734,"completion":20735,"start":13563,"enrollment":1931,"conditions":20736,"interventions":20739},"NCT02202200","Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma",[90,91],"2016-11","2018-08",[20737,20738],"Melanoma BRAF V600E\u002FK Mutated","CDNKN2A Loss Defined",[20722],{"trials":20741,"activeCount":102},[],{"trials":20743,"activeCount":102},[],{"trials":20745,"activeCount":102},[],{"intervention":20747,"totalTrials":180,"cells":20748},"mRNA-1273",{"EARLY_PHASE1":20749,"PHASE1":20751,"PHASE2":20753,"PHASE3":20765,"PHASE4":20767,"NA":20769},{"trials":20750,"activeCount":102},[],{"trials":20752,"activeCount":102},[],{"trials":20754,"activeCount":102},[20755],{"nctId":20756,"briefTitle":20757,"status":110,"phases":20758,"primaryCompletion":20759,"completion":20760,"start":20761,"enrollment":4948,"conditions":20762,"interventions":20764},"NCT04748471","Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)",[91],"2021-07-01","2023-01-25","2021-02-10",[20763],"Prevention of COVID19",[20747],{"trials":20766,"activeCount":102},[],{"trials":20768,"activeCount":102},[],{"trials":20770,"activeCount":102},[],{"intervention":20772,"totalTrials":180,"cells":20773},"fluoxetine",{"EARLY_PHASE1":20774,"PHASE1":20776,"PHASE2":20778,"PHASE3":20787,"PHASE4":20789,"NA":20791},{"trials":20775,"activeCount":102},[],{"trials":20777,"activeCount":102},[],{"trials":20779,"activeCount":102},[20780],{"nctId":20781,"briefTitle":20782,"status":5932,"phases":20783,"primaryCompletion":10940,"completion":13849,"start":1909,"enrollment":102,"conditions":20784,"interventions":20786},"NCT00873834","Fluoxetine Essay in Children With Autism",[91],[20785],"Autism",[20772],{"trials":20788,"activeCount":102},[],{"trials":20790,"activeCount":102},[],{"trials":20792,"activeCount":102},[],{"intervention":20794,"totalTrials":180,"cells":20795},"Mabthéra",{"EARLY_PHASE1":20796,"PHASE1":20798,"PHASE2":20800,"PHASE3":20811,"PHASE4":20813,"NA":20815},{"trials":20797,"activeCount":102},[],{"trials":20799,"activeCount":102},[],{"trials":20801,"activeCount":102},[20802],{"nctId":20803,"briefTitle":20804,"status":241,"phases":20805,"completion":1588,"start":20806,"enrollment":20807,"conditions":20808,"interventions":20810},"NCT00225875","Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy",[91],"2003-09",65,[20809],"Autoimmune Thrombocytopenic Purpura",[20794],{"trials":20812,"activeCount":102},[],{"trials":20814,"activeCount":102},[],{"trials":20816,"activeCount":102},[],{"intervention":20818,"totalTrials":180,"cells":20819},"Mesenchymal Stromal Cell (MSC) injections",{"EARLY_PHASE1":20820,"PHASE1":20822,"PHASE2":20824,"PHASE3":20834,"PHASE4":20836,"NA":20838},{"trials":20821,"activeCount":102},[],{"trials":20823,"activeCount":102},[],{"trials":20825,"activeCount":102},[20826],{"nctId":20827,"briefTitle":20828,"status":110,"phases":20829,"primaryCompletion":41,"completion":41,"start":8936,"enrollment":268,"conditions":20830,"interventions":20833},"NCT02814864","Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",[91],[20831,20832],"Pelvic Radiation Therapy","Radiation-induced Hemorrhagic Cystitis",[20818],{"trials":20835,"activeCount":102},[],{"trials":20837,"activeCount":102},[],{"trials":20839,"activeCount":102},[],{"intervention":19191,"totalTrials":180,"cells":20841},{"EARLY_PHASE1":20842,"PHASE1":20844,"PHASE2":20846,"PHASE3":20852,"PHASE4":20854,"NA":20856},{"trials":20843,"activeCount":102},[],{"trials":20845,"activeCount":102},[],{"trials":20847,"activeCount":102},[20848],{"nctId":19183,"briefTitle":19184,"status":110,"phases":20849,"primaryCompletion":1577,"completion":19186,"start":1587,"enrollment":19187,"conditions":20850,"interventions":20851},[91],[19189],[19174,19191,19192,19193],{"trials":20853,"activeCount":102},[],{"trials":20855,"activeCount":102},[],{"trials":20857,"activeCount":102},[],{"intervention":19192,"totalTrials":180,"cells":20859},{"EARLY_PHASE1":20860,"PHASE1":20862,"PHASE2":20864,"PHASE3":20870,"PHASE4":20872,"NA":20874},{"trials":20861,"activeCount":102},[],{"trials":20863,"activeCount":102},[],{"trials":20865,"activeCount":102},[20866],{"nctId":19183,"briefTitle":19184,"status":110,"phases":20867,"primaryCompletion":1577,"completion":19186,"start":1587,"enrollment":19187,"conditions":20868,"interventions":20869},[91],[19189],[19174,19191,19192,19193],{"trials":20871,"activeCount":102},[],{"trials":20873,"activeCount":102},[],{"trials":20875,"activeCount":102},[],{"intervention":19193,"totalTrials":180,"cells":20877},{"EARLY_PHASE1":20878,"PHASE1":20880,"PHASE2":20882,"PHASE3":20888,"PHASE4":20890,"NA":20892},{"trials":20879,"activeCount":102},[],{"trials":20881,"activeCount":102},[],{"trials":20883,"activeCount":102},[20884],{"nctId":19183,"briefTitle":19184,"status":110,"phases":20885,"primaryCompletion":1577,"completion":19186,"start":1587,"enrollment":19187,"conditions":20886,"interventions":20887},[91],[19189],[19174,19191,19192,19193],{"trials":20889,"activeCount":102},[],{"trials":20891,"activeCount":102},[],{"trials":20893,"activeCount":102},[],{"intervention":20895,"totalTrials":180,"cells":20896},"Subcutaneous Ustekinumab",{"EARLY_PHASE1":20897,"PHASE1":20899,"PHASE2":20901,"PHASE3":20912,"PHASE4":20914,"NA":20916},{"trials":20898,"activeCount":102},[],{"trials":20900,"activeCount":102},[],{"trials":20902,"activeCount":102},[20903],{"nctId":20904,"briefTitle":20905,"status":139,"phases":20906,"primaryCompletion":14241,"completion":20907,"start":20908,"enrollment":1258,"conditions":20909,"interventions":20911},"NCT02648581","Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12\u002FIL-23 Antibody, in Patients With Behçet Disease",[91],"2019-11-19","2017-06-14",[20910],"Behçet Disease",[20895],{"trials":20913,"activeCount":102},[],{"trials":20915,"activeCount":102},[],{"trials":20917,"activeCount":102},[],{"intervention":20919,"totalTrials":180,"cells":20920},"Dapagliflozin",{"EARLY_PHASE1":20921,"PHASE1":20923,"PHASE2":20925,"PHASE3":20935,"PHASE4":20937,"NA":20939},{"trials":20922,"activeCount":102},[],{"trials":20924,"activeCount":102},[],{"trials":20926,"activeCount":102},[20927],{"nctId":20928,"briefTitle":20929,"status":110,"phases":20930,"primaryCompletion":1128,"completion":56,"start":20931,"enrollment":1931,"conditions":20932,"interventions":20934},"NCT05420285","Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction",[91],"2022-06-26",[4249,20933],"Reduced Ejection Fraction",[20919],{"trials":20936,"activeCount":102},[],{"trials":20938,"activeCount":102},[],{"trials":20940,"activeCount":102},[],{"intervention":20942,"totalTrials":180,"cells":20943},"Monalizumab\u002FMEDI5257",{"EARLY_PHASE1":20944,"PHASE1":20946,"PHASE2":20948,"PHASE3":20958,"PHASE4":20960,"NA":20962},{"trials":20945,"activeCount":102},[],{"trials":20947,"activeCount":102},[],{"trials":20949,"activeCount":102},[20950],{"nctId":20951,"briefTitle":20952,"status":5932,"phases":20953,"primaryCompletion":1764,"completion":1764,"start":8148,"enrollment":102,"conditions":20954,"interventions":20957},"NCT06152523","Monalizumab and MEDI5752 in Patients With MSI and\u002For dMMR Metastatic Cancer",[91],[20955,20956],"MSI","dMMR Colorectal Cancer",[20942],{"trials":20959,"activeCount":102},[],{"trials":20961,"activeCount":102},[],{"trials":20963,"activeCount":102},[],{"intervention":20965,"totalTrials":180,"cells":20966},"Mangafodipir",{"EARLY_PHASE1":20967,"PHASE1":20969,"PHASE2":20971,"PHASE3":20980,"PHASE4":20982,"NA":20984},{"trials":20968,"activeCount":102},[],{"trials":20970,"activeCount":102},[],{"trials":20972,"activeCount":102},[20973],{"nctId":20974,"briefTitle":20975,"status":139,"phases":20976,"primaryCompletion":301,"completion":10017,"start":9986,"enrollment":30,"conditions":20977,"interventions":20979},"NCT00727922","Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity",[91],[20978,9635],"Neurotoxic Disorders",[20965],{"trials":20981,"activeCount":102},[],{"trials":20983,"activeCount":102},[],{"trials":20985,"activeCount":102},[],{"intervention":20987,"totalTrials":180,"cells":20988},"Capmatinib",{"EARLY_PHASE1":20989,"PHASE1":20991,"PHASE2":20993,"PHASE3":21005,"PHASE4":21007,"NA":21009},{"trials":20990,"activeCount":102},[],{"trials":20992,"activeCount":102},[],{"trials":20994,"activeCount":102},[20995],{"nctId":20996,"briefTitle":20997,"status":936,"phases":20998,"primaryCompletion":13609,"completion":20999,"start":21000,"enrollment":5804,"conditions":21001,"interventions":21003},"NCT05135845","Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma",[91],"2025-10","2022-03-22",[21002,19563],"Oesophageal Adenocarcinoma",[20987,21004],"Spartalizumab",{"trials":21006,"activeCount":102},[],{"trials":21008,"activeCount":102},[],{"trials":21010,"activeCount":102},[],{"intervention":21004,"totalTrials":180,"cells":21012},{"EARLY_PHASE1":21013,"PHASE1":21015,"PHASE2":21017,"PHASE3":21023,"PHASE4":21025,"NA":21027},{"trials":21014,"activeCount":102},[],{"trials":21016,"activeCount":102},[],{"trials":21018,"activeCount":102},[21019],{"nctId":20996,"briefTitle":20997,"status":936,"phases":21020,"primaryCompletion":13609,"completion":20999,"start":21000,"enrollment":5804,"conditions":21021,"interventions":21022},[91],[21002,19563],[20987,21004],{"trials":21024,"activeCount":102},[],{"trials":21026,"activeCount":102},[],{"trials":21028,"activeCount":102},[],{"intervention":947,"totalTrials":180,"cells":21030},{"EARLY_PHASE1":21031,"PHASE1":21033,"PHASE2":21035,"PHASE3":21041,"PHASE4":21043,"NA":21045},{"trials":21032,"activeCount":102},[],{"trials":21034,"activeCount":102},[],{"trials":21036,"activeCount":102},[21037],{"nctId":934,"briefTitle":935,"status":936,"phases":21038,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":21039,"interventions":21040},[91],[943,944,945],[947,251],{"trials":21042,"activeCount":102},[],{"trials":21044,"activeCount":102},[],{"trials":21046,"activeCount":102},[],{"intervention":21048,"totalTrials":180,"cells":21049},"Potassium chloride",{"EARLY_PHASE1":21050,"PHASE1":21052,"PHASE2":21054,"PHASE3":21063,"PHASE4":21065,"NA":21067},{"trials":21051,"activeCount":102},[],{"trials":21053,"activeCount":102},[],{"trials":21055,"activeCount":102},[21056],{"nctId":21057,"briefTitle":21058,"status":5932,"phases":21059,"primaryCompletion":5236,"completion":5236,"start":8148,"enrollment":102,"conditions":21060,"interventions":21062},"NCT04316611","Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation",[91],[21061],"Out-of-hospital Cardiac Arrest (OHCA)",[21048],{"trials":21064,"activeCount":102},[],{"trials":21066,"activeCount":102},[],{"trials":21068,"activeCount":102},[],{"intervention":21070,"totalTrials":180,"cells":21071},"rhARSA",{"EARLY_PHASE1":21072,"PHASE1":21074,"PHASE2":21076,"PHASE3":21085,"PHASE4":21087,"NA":21089},{"trials":21073,"activeCount":102},[],{"trials":21075,"activeCount":102},[],{"trials":21077,"activeCount":102},[21078],{"nctId":21079,"briefTitle":21080,"status":139,"phases":21081,"primaryCompletion":5900,"completion":10260,"start":387,"enrollment":180,"conditions":21082,"interventions":21084},"NCT01303146","Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation",[91],[21083],"Metachromatic Leukodystrophy",[21070],{"trials":21086,"activeCount":102},[],{"trials":21088,"activeCount":102},[],{"trials":21090,"activeCount":102},[],{"intervention":21092,"totalTrials":180,"cells":21093},"INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS",{"EARLY_PHASE1":21094,"PHASE1":21096,"PHASE2":21098,"PHASE3":21112,"PHASE4":21114,"NA":21116},{"trials":21095,"activeCount":102},[],{"trials":21097,"activeCount":102},[],{"trials":21099,"activeCount":102},[21100],{"nctId":21101,"briefTitle":21102,"status":139,"phases":21103,"primaryCompletion":21104,"completion":21105,"start":21106,"enrollment":36,"conditions":21107,"interventions":21111},"NCT02213705","Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells",[90,91],"2020-02-09","2022-06-16","2014-05-06",[21108,21109,21110],"SYSTEMIC SCLERODERMA","ALLOGENEIC MESENCHYMAL STEM CELLS","ADULT",[21092],{"trials":21113,"activeCount":102},[],{"trials":21115,"activeCount":102},[],{"trials":21117,"activeCount":102},[],{"intervention":7939,"totalTrials":180,"cells":21119},{"EARLY_PHASE1":21120,"PHASE1":21122,"PHASE2":21124,"PHASE3":21130,"PHASE4":21132,"NA":21134},{"trials":21121,"activeCount":102},[],{"trials":21123,"activeCount":102},[],{"trials":21125,"activeCount":102},[21126],{"nctId":7930,"briefTitle":7931,"status":110,"phases":21127,"primaryCompletion":7933,"completion":61,"start":7934,"enrollment":7935,"conditions":21128,"interventions":21129},[91],[7937],[7939,7921],{"trials":21131,"activeCount":102},[],{"trials":21133,"activeCount":102},[],{"trials":21135,"activeCount":102},[],{"intervention":21137,"totalTrials":180,"cells":21138},"5 azacytidine - VALPROIC acid- Retinoic acid",{"EARLY_PHASE1":21139,"PHASE1":21141,"PHASE2":21143,"PHASE3":21153,"PHASE4":21155,"NA":21157},{"trials":21140,"activeCount":102},[],{"trials":21142,"activeCount":102},[],{"trials":21144,"activeCount":102},[21145],{"nctId":21146,"briefTitle":21147,"status":139,"phases":21148,"primaryCompletion":16249,"completion":16249,"start":2046,"enrollment":1247,"conditions":21149,"interventions":21152},"NCT00339196","5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS",[91],[21150,21151],"Acute Myelogenous Leukaemia (AML)","Myelodysplastic Syndrome (MDS)",[21137],{"trials":21154,"activeCount":102},[],{"trials":21156,"activeCount":102},[],{"trials":21158,"activeCount":102},[],{"intervention":21160,"totalTrials":180,"cells":21161},"Methionine",{"EARLY_PHASE1":21162,"PHASE1":21164,"PHASE2":21166,"PHASE3":21180,"PHASE4":21182,"NA":21184},{"trials":21163,"activeCount":102},[],{"trials":21165,"activeCount":102},[],{"trials":21167,"activeCount":102},[21168],{"nctId":21169,"briefTitle":21170,"status":139,"phases":21171,"primaryCompletion":21172,"completion":21172,"start":21173,"enrollment":429,"conditions":21174,"interventions":21178},"NCT03887169","Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.",[90,91],"2020-06-01","2019-09-16",[21175,21176,21177],"Pulmonary Alveolar Proteinosis","Mutation Ala393Thr of the MARS Gene","mutationSer567Leu of the MARS Gene",[21160,21179],"Vitamin B12, B9, B6, C supplementation",{"trials":21181,"activeCount":102},[],{"trials":21183,"activeCount":102},[],{"trials":21185,"activeCount":102},[],{"intervention":21179,"totalTrials":180,"cells":21187},{"EARLY_PHASE1":21188,"PHASE1":21190,"PHASE2":21192,"PHASE3":21198,"PHASE4":21200,"NA":21202},{"trials":21189,"activeCount":102},[],{"trials":21191,"activeCount":102},[],{"trials":21193,"activeCount":102},[21194],{"nctId":21169,"briefTitle":21170,"status":139,"phases":21195,"primaryCompletion":21172,"completion":21172,"start":21173,"enrollment":429,"conditions":21196,"interventions":21197},[90,91],[21175,21176,21177],[21160,21179],{"trials":21199,"activeCount":102},[],{"trials":21201,"activeCount":102},[],{"trials":21203,"activeCount":102},[],{"intervention":21205,"totalTrials":180,"cells":21206},"Lithium Gluconate",{"EARLY_PHASE1":21207,"PHASE1":21209,"PHASE2":21211,"PHASE3":21224,"PHASE4":21226,"NA":21228},{"trials":21208,"activeCount":102},[],{"trials":21210,"activeCount":102},[],{"trials":21212,"activeCount":102},[21213],{"nctId":21214,"briefTitle":21215,"status":5932,"phases":21216,"primaryCompletion":1940,"completion":10067,"start":1909,"enrollment":102,"conditions":21217,"interventions":21223},"NCT00657748","Lithium and Acetate for Canavan Disease",[91],[21218,21219,21220,21221,21222],"Canavan Disease","Infantile","Deficiency Disease","Aspartoacylase","Leukodystrophy, Spongiform",[21205],{"trials":21225,"activeCount":102},[],{"trials":21227,"activeCount":102},[],{"trials":21229,"activeCount":102},[],{"intervention":964,"totalTrials":180,"cells":21231},{"EARLY_PHASE1":21232,"PHASE1":21234,"PHASE2":21236,"PHASE3":21242,"PHASE4":21244,"NA":21246},{"trials":21233,"activeCount":102},[],{"trials":21235,"activeCount":102},[],{"trials":21237,"activeCount":102},[21238],{"nctId":953,"briefTitle":954,"status":139,"phases":21239,"primaryCompletion":956,"completion":536,"start":957,"enrollment":958,"conditions":21240,"interventions":21241},[91],[960,961,962],[964,965],{"trials":21243,"activeCount":102},[],{"trials":21245,"activeCount":102},[],{"trials":21247,"activeCount":102},[],{"intervention":21249,"totalTrials":180,"cells":21250},"Vaccination with the combined vaccine",{"EARLY_PHASE1":21251,"PHASE1":21253,"PHASE2":21255,"PHASE3":21269,"PHASE4":21271,"NA":21273},{"trials":21252,"activeCount":102},[],{"trials":21254,"activeCount":102},[],{"trials":21256,"activeCount":102},[21257],{"nctId":21258,"briefTitle":21259,"status":139,"phases":21260,"primaryCompletion":21261,"completion":21262,"start":21263,"enrollment":15241,"conditions":21264,"interventions":21267},"NCT02274415","Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease",[91],"2017-09-18","2019-04-10","2013-09-16",[21265,21266],"Invasive Pneumococcal Infections","Sickle Cells Disease",[21249,21268],"Vaccination with the polysaccharide vaccine",{"trials":21270,"activeCount":102},[],{"trials":21272,"activeCount":102},[],{"trials":21274,"activeCount":102},[],{"intervention":21268,"totalTrials":180,"cells":21276},{"EARLY_PHASE1":21277,"PHASE1":21279,"PHASE2":21281,"PHASE3":21287,"PHASE4":21289,"NA":21291},{"trials":21278,"activeCount":102},[],{"trials":21280,"activeCount":102},[],{"trials":21282,"activeCount":102},[21283],{"nctId":21258,"briefTitle":21259,"status":139,"phases":21284,"primaryCompletion":21261,"completion":21262,"start":21263,"enrollment":15241,"conditions":21285,"interventions":21286},[91],[21265,21266],[21249,21268],{"trials":21288,"activeCount":102},[],{"trials":21290,"activeCount":102},[],{"trials":21292,"activeCount":102},[],{"intervention":21294,"totalTrials":180,"cells":21295},"gemcitabine -oxaliplatine combination",{"EARLY_PHASE1":21296,"PHASE1":21298,"PHASE2":21300,"PHASE3":21311,"PHASE4":21313,"NA":21315},{"trials":21297,"activeCount":102},[],{"trials":21299,"activeCount":102},[],{"trials":21301,"activeCount":102},[21302],{"nctId":21303,"briefTitle":21304,"status":241,"phases":21305,"primaryCompletion":21306,"completion":512,"start":21307,"enrollment":33,"conditions":21308,"interventions":21310},"NCT02472080","Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study",[91],"2018-04-01","2016-04-07",[21309],"Thyroid Cancer",[21294],{"trials":21312,"activeCount":102},[],{"trials":21314,"activeCount":102},[],{"trials":21316,"activeCount":102},[],{"intervention":21318,"totalTrials":180,"cells":21319},"wound infusion ropivacaine",{"EARLY_PHASE1":21320,"PHASE1":21322,"PHASE2":21324,"PHASE3":21335,"PHASE4":21337,"NA":21339},{"trials":21321,"activeCount":102},[],{"trials":21323,"activeCount":102},[],{"trials":21325,"activeCount":102},[21326],{"nctId":21327,"briefTitle":21328,"status":241,"phases":21329,"primaryCompletion":21330,"completion":21330,"start":20619,"enrollment":98,"conditions":21331,"interventions":21334},"NCT01890408","Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity.",[91],"2014-02",[21332,21333],"Laparotomy","Hepatic Resection",[21318],{"trials":21336,"activeCount":102},[],{"trials":21338,"activeCount":102},[],{"trials":21340,"activeCount":102},[],{"intervention":21342,"totalTrials":180,"cells":21343},"Ninlaro",{"EARLY_PHASE1":21344,"PHASE1":21346,"PHASE2":21348,"PHASE3":21358,"PHASE4":21360,"NA":21362},{"trials":21345,"activeCount":102},[],{"trials":21347,"activeCount":102},[],{"trials":21349,"activeCount":102},[21350],{"nctId":21351,"briefTitle":21352,"status":5932,"phases":21353,"primaryCompletion":1012,"completion":21354,"start":21355,"enrollment":102,"conditions":21356,"interventions":21357},"NCT03965624","Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia",[91],"2023-09-01","2019-09-01",[415,315],[21342],{"trials":21359,"activeCount":102},[],{"trials":21361,"activeCount":102},[],{"trials":21363,"activeCount":102},[],{"intervention":21365,"totalTrials":180,"cells":21366},"Teriparatide",{"EARLY_PHASE1":21367,"PHASE1":21369,"PHASE2":21371,"PHASE3":21385,"PHASE4":21387,"NA":21389},{"trials":21368,"activeCount":102},[],{"trials":21370,"activeCount":102},[],{"trials":21372,"activeCount":102},[21373],{"nctId":21374,"briefTitle":21375,"status":139,"phases":21376,"primaryCompletion":21377,"completion":21377,"start":21378,"enrollment":1258,"conditions":21379,"interventions":21381},"NCT02824718","Recombinant Human rhPTH(1-34) VS Association Alfacalcidol\u002FHydrochlorothiazide in Severe Primary Hypoparathyroidism",[91],"2020-05-28","2017-06-06",[21380],"Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment",[21365,21382,21383,21384],"Thiazide","Potassium sparing diuretic","Alfacalcidol",{"trials":21386,"activeCount":102},[],{"trials":21388,"activeCount":102},[],{"trials":21390,"activeCount":102},[],{"intervention":21382,"totalTrials":180,"cells":21392},{"EARLY_PHASE1":21393,"PHASE1":21395,"PHASE2":21397,"PHASE3":21403,"PHASE4":21405,"NA":21407},{"trials":21394,"activeCount":102},[],{"trials":21396,"activeCount":102},[],{"trials":21398,"activeCount":102},[21399],{"nctId":21374,"briefTitle":21375,"status":139,"phases":21400,"primaryCompletion":21377,"completion":21377,"start":21378,"enrollment":1258,"conditions":21401,"interventions":21402},[91],[21380],[21365,21382,21383,21384],{"trials":21404,"activeCount":102},[],{"trials":21406,"activeCount":102},[],{"trials":21408,"activeCount":102},[],{"intervention":21383,"totalTrials":180,"cells":21410},{"EARLY_PHASE1":21411,"PHASE1":21413,"PHASE2":21415,"PHASE3":21421,"PHASE4":21423,"NA":21425},{"trials":21412,"activeCount":102},[],{"trials":21414,"activeCount":102},[],{"trials":21416,"activeCount":102},[21417],{"nctId":21374,"briefTitle":21375,"status":139,"phases":21418,"primaryCompletion":21377,"completion":21377,"start":21378,"enrollment":1258,"conditions":21419,"interventions":21420},[91],[21380],[21365,21382,21383,21384],{"trials":21422,"activeCount":102},[],{"trials":21424,"activeCount":102},[],{"trials":21426,"activeCount":102},[],{"intervention":21384,"totalTrials":180,"cells":21428},{"EARLY_PHASE1":21429,"PHASE1":21431,"PHASE2":21433,"PHASE3":21439,"PHASE4":21441,"NA":21443},{"trials":21430,"activeCount":102},[],{"trials":21432,"activeCount":102},[],{"trials":21434,"activeCount":102},[21435],{"nctId":21374,"briefTitle":21375,"status":139,"phases":21436,"primaryCompletion":21377,"completion":21377,"start":21378,"enrollment":1258,"conditions":21437,"interventions":21438},[91],[21380],[21365,21382,21383,21384],{"trials":21440,"activeCount":102},[],{"trials":21442,"activeCount":102},[],{"trials":21444,"activeCount":102},[],{"intervention":21446,"totalTrials":180,"cells":21447},"Tolvaptan 15 MG",{"EARLY_PHASE1":21448,"PHASE1":21450,"PHASE2":21452,"PHASE3":21462,"PHASE4":21464,"NA":21466},{"trials":21449,"activeCount":102},[],{"trials":21451,"activeCount":102},[],{"trials":21453,"activeCount":102},[21454],{"nctId":21455,"briefTitle":21456,"status":110,"phases":21457,"primaryCompletion":21458,"completion":21458,"start":21459,"enrollment":303,"conditions":21460,"interventions":21461},"NCT03931369","Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)",[91],"2020-12-30","2019-09-06",[5727],[21446],{"trials":21463,"activeCount":102},[],{"trials":21465,"activeCount":102},[],{"trials":21467,"activeCount":102},[],{"intervention":21469,"totalTrials":180,"cells":21470},"Nulojix",{"EARLY_PHASE1":21471,"PHASE1":21473,"PHASE2":21475,"PHASE3":21487,"PHASE4":21489,"NA":21491},{"trials":21472,"activeCount":102},[],{"trials":21474,"activeCount":102},[],{"trials":21476,"activeCount":102},[21477],{"nctId":21478,"briefTitle":21479,"status":139,"phases":21480,"primaryCompletion":21261,"completion":21261,"start":21481,"enrollment":8268,"conditions":21482,"interventions":21486},"NCT02738918","Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.",[91],"2014-12-01",[21483,21484,21485],"Renal Transplant","Acute Antibody Mediated Rejection","Mild Immunologic Risk Factor",[21469],{"trials":21488,"activeCount":102},[],{"trials":21490,"activeCount":102},[],{"trials":21492,"activeCount":102},[],{"intervention":21494,"totalTrials":180,"cells":21495},"Anti-Thymocyte Globulin",{"EARLY_PHASE1":21496,"PHASE1":21498,"PHASE2":21500,"PHASE3":21513,"PHASE4":21515,"NA":21517},{"trials":21497,"activeCount":102},[],{"trials":21499,"activeCount":102},[],{"trials":21501,"activeCount":102},[21502],{"nctId":21503,"briefTitle":21504,"status":139,"phases":21505,"primaryCompletion":21506,"completion":21506,"start":21507,"enrollment":21508,"conditions":21509,"interventions":21511},"NCT02876679","Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT",[91],"2020-10-12","2017-04-06",94,[21510],"Graft vs Host Disease",[358,21494,21512],"Conditioning regimen",{"trials":21514,"activeCount":102},[],{"trials":21516,"activeCount":102},[],{"trials":21518,"activeCount":102},[],{"intervention":21512,"totalTrials":180,"cells":21520},{"EARLY_PHASE1":21521,"PHASE1":21523,"PHASE2":21525,"PHASE3":21531,"PHASE4":21533,"NA":21535},{"trials":21522,"activeCount":102},[],{"trials":21524,"activeCount":102},[],{"trials":21526,"activeCount":102},[21527],{"nctId":21503,"briefTitle":21504,"status":139,"phases":21528,"primaryCompletion":21506,"completion":21506,"start":21507,"enrollment":21508,"conditions":21529,"interventions":21530},[91],[21510],[358,21494,21512],{"trials":21532,"activeCount":102},[],{"trials":21534,"activeCount":102},[],{"trials":21536,"activeCount":102},[],{"intervention":21538,"totalTrials":180,"cells":21539},"graft intracerebral of foetal neurons",{"EARLY_PHASE1":21540,"PHASE1":21542,"PHASE2":21544,"PHASE3":21553,"PHASE4":21555,"NA":21557},{"trials":21541,"activeCount":102},[],{"trials":21543,"activeCount":102},[],{"trials":21545,"activeCount":102},[21546],{"nctId":21547,"briefTitle":21548,"status":139,"phases":21549,"primaryCompletion":11768,"completion":11768,"start":21550,"enrollment":3501,"conditions":21551,"interventions":21552},"NCT00190450","MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease",[91],"2002-01",[8034],[21538],{"trials":21554,"activeCount":102},[],{"trials":21556,"activeCount":102},[],{"trials":21558,"activeCount":102},[],{"intervention":21560,"totalTrials":180,"cells":21561},"IV Thiotepa",{"EARLY_PHASE1":21562,"PHASE1":21564,"PHASE2":21566,"PHASE3":21578,"PHASE4":21580,"NA":21582},{"trials":21563,"activeCount":102},[],{"trials":21565,"activeCount":102},[],{"trials":21567,"activeCount":102},[21568],{"nctId":21569,"briefTitle":21570,"status":110,"phases":21571,"primaryCompletion":8138,"completion":976,"start":10963,"enrollment":8742,"conditions":21572,"interventions":21574},"NCT02333838","Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies",[91],[21573],"Leukemia, Myeloid",[21560,21575,21576,21577],"IV Fludarabine","IV Busulfan","IV Anti-thymocyte globuline",{"trials":21579,"activeCount":102},[],{"trials":21581,"activeCount":102},[],{"trials":21583,"activeCount":102},[],{"intervention":21575,"totalTrials":180,"cells":21585},{"EARLY_PHASE1":21586,"PHASE1":21588,"PHASE2":21590,"PHASE3":21596,"PHASE4":21598,"NA":21600},{"trials":21587,"activeCount":102},[],{"trials":21589,"activeCount":102},[],{"trials":21591,"activeCount":102},[21592],{"nctId":21569,"briefTitle":21570,"status":110,"phases":21593,"primaryCompletion":8138,"completion":976,"start":10963,"enrollment":8742,"conditions":21594,"interventions":21595},[91],[21573],[21560,21575,21576,21577],{"trials":21597,"activeCount":102},[],{"trials":21599,"activeCount":102},[],{"trials":21601,"activeCount":102},[],{"intervention":21576,"totalTrials":180,"cells":21603},{"EARLY_PHASE1":21604,"PHASE1":21606,"PHASE2":21608,"PHASE3":21614,"PHASE4":21616,"NA":21618},{"trials":21605,"activeCount":102},[],{"trials":21607,"activeCount":102},[],{"trials":21609,"activeCount":102},[21610],{"nctId":21569,"briefTitle":21570,"status":110,"phases":21611,"primaryCompletion":8138,"completion":976,"start":10963,"enrollment":8742,"conditions":21612,"interventions":21613},[91],[21573],[21560,21575,21576,21577],{"trials":21615,"activeCount":102},[],{"trials":21617,"activeCount":102},[],{"trials":21619,"activeCount":102},[],{"intervention":21577,"totalTrials":180,"cells":21621},{"EARLY_PHASE1":21622,"PHASE1":21624,"PHASE2":21626,"PHASE3":21632,"PHASE4":21634,"NA":21636},{"trials":21623,"activeCount":102},[],{"trials":21625,"activeCount":102},[],{"trials":21627,"activeCount":102},[21628],{"nctId":21569,"briefTitle":21570,"status":110,"phases":21629,"primaryCompletion":8138,"completion":976,"start":10963,"enrollment":8742,"conditions":21630,"interventions":21631},[91],[21573],[21560,21575,21576,21577],{"trials":21633,"activeCount":102},[],{"trials":21635,"activeCount":102},[],{"trials":21637,"activeCount":102},[],{"intervention":21639,"totalTrials":180,"cells":21640},"Plaquenil 200Mg",{"EARLY_PHASE1":21641,"PHASE1":21643,"PHASE2":21645,"PHASE3":21657,"PHASE4":21659,"NA":21661},{"trials":21642,"activeCount":102},[],{"trials":21644,"activeCount":102},[],{"trials":21646,"activeCount":102},[21647],{"nctId":21648,"briefTitle":21649,"status":5932,"phases":21650,"primaryCompletion":1246,"completion":21651,"start":21652,"enrollment":102,"conditions":21653,"interventions":21656},"NCT04275778","HYDROxychloroquine in Syndrome Primary AntiPhospholipid",[91],"2025-10-02","2021-07-09",[21654,21655],"Antiphospholipid Syndrome in Pregnancy","Anticoagulants",[21639],{"trials":21658,"activeCount":102},[],{"trials":21660,"activeCount":102},[],{"trials":21662,"activeCount":102},[],{"intervention":21664,"totalTrials":180,"cells":21665},"Intralipid®",{"EARLY_PHASE1":21666,"PHASE1":21668,"PHASE2":21670,"PHASE3":21680,"PHASE4":21682,"NA":21684},{"trials":21667,"activeCount":102},[],{"trials":21669,"activeCount":102},[],{"trials":21671,"activeCount":102},[21672],{"nctId":21673,"briefTitle":21674,"status":139,"phases":21675,"primaryCompletion":266,"completion":266,"start":10067,"enrollment":1258,"conditions":21676,"interventions":21679},"NCT01602250","Local Anaesthetics Toxicity and Intralipid®",[91],[21677,21678],"Toxicity","Adverse Effects",[21664],{"trials":21681,"activeCount":102},[],{"trials":21683,"activeCount":102},[],{"trials":21685,"activeCount":102},[],{"intervention":21687,"totalTrials":180,"cells":21688},"Transfusion of COVID-19 convalescent plasma",{"EARLY_PHASE1":21689,"PHASE1":21691,"PHASE2":21693,"PHASE3":21701,"PHASE4":21703,"NA":21705},{"trials":21690,"activeCount":102},[],{"trials":21692,"activeCount":102},[],{"trials":21694,"activeCount":102},[21695],{"nctId":21696,"briefTitle":21697,"status":139,"phases":21698,"primaryCompletion":12054,"completion":12054,"start":5633,"enrollment":1277,"conditions":21699,"interventions":21700},"NCT04345991","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",[91],[26],[21687],{"trials":21702,"activeCount":102},[],{"trials":21704,"activeCount":102},[],{"trials":21706,"activeCount":102},[],{"intervention":21708,"totalTrials":180,"cells":21709},"Cladribine",{"EARLY_PHASE1":21710,"PHASE1":21712,"PHASE2":21714,"PHASE3":21723,"PHASE4":21725,"NA":21727},{"trials":21711,"activeCount":102},[],{"trials":21713,"activeCount":102},[],{"trials":21715,"activeCount":102},[21716],{"nctId":21717,"briefTitle":21718,"status":110,"phases":21719,"primaryCompletion":13943,"completion":41,"start":13849,"enrollment":5575,"conditions":21720,"interventions":21722},"NCT01473797","Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis",[91],[21721],"Langerhans Cell Histiocytosis of Lung",[21708],{"trials":21724,"activeCount":102},[],{"trials":21726,"activeCount":102},[],{"trials":21728,"activeCount":102},[],{"intervention":21730,"totalTrials":180,"cells":21731},"Pirfenidone",{"EARLY_PHASE1":21732,"PHASE1":21734,"PHASE2":21736,"PHASE3":21747,"PHASE4":21749,"NA":21751},{"trials":21733,"activeCount":102},[],{"trials":21735,"activeCount":102},[],{"trials":21737,"activeCount":102},[21738],{"nctId":21739,"briefTitle":21740,"status":139,"phases":21741,"primaryCompletion":21742,"completion":21742,"start":21743,"enrollment":1361,"conditions":21744,"interventions":21746},"NCT03385668","Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies",[91],"2020-07-24","2018-01-31",[21745],"Pulmonary Fibrosis",[21730],{"trials":21748,"activeCount":102},[],{"trials":21750,"activeCount":102},[],{"trials":21752,"activeCount":102},[],{"intervention":21754,"totalTrials":180,"cells":21755},"AXITINIB",{"EARLY_PHASE1":21756,"PHASE1":21758,"PHASE2":21760,"PHASE3":21770,"PHASE4":21772,"NA":21774},{"trials":21757,"activeCount":102},[],{"trials":21759,"activeCount":102},[],{"trials":21761,"activeCount":102},[21762],{"nctId":21763,"briefTitle":21764,"status":139,"phases":21765,"primaryCompletion":5469,"completion":21766,"start":10832,"enrollment":33,"conditions":21767,"interventions":21769},"NCT02597322","Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)",[91],"2017-06",[21768],"cT2a N0NxM0 Renal Tumor",[21754],{"trials":21771,"activeCount":102},[],{"trials":21773,"activeCount":102},[],{"trials":21775,"activeCount":102},[],{"intervention":21777,"totalTrials":180,"cells":21778},"Cyclosporine A",{"EARLY_PHASE1":21779,"PHASE1":21781,"PHASE2":21783,"PHASE3":21795,"PHASE4":21797,"NA":21799},{"trials":21780,"activeCount":102},[],{"trials":21782,"activeCount":102},[],{"trials":21784,"activeCount":102},[21785],{"nctId":21786,"briefTitle":21787,"status":110,"phases":21788,"primaryCompletion":11618,"completion":21789,"start":11768,"enrollment":21790,"conditions":21791,"interventions":21794},"NCT02225756","Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms",[91],"2018-09",360,[21792,21793],"Abdominal Aortic Aneurysm,","Small Abdominal Aortic Aneurysm",[21777,21777],{"trials":21796,"activeCount":102},[],{"trials":21798,"activeCount":102},[],{"trials":21800,"activeCount":102},[],{"intervention":1718,"totalTrials":180,"cells":21802},{"EARLY_PHASE1":21803,"PHASE1":21805,"PHASE2":21807,"PHASE3":21813,"PHASE4":21815,"NA":21817},{"trials":21804,"activeCount":102},[],{"trials":21806,"activeCount":102},[],{"trials":21808,"activeCount":102},[21809],{"nctId":1705,"briefTitle":1706,"status":139,"phases":21810,"primaryCompletion":1708,"completion":301,"start":1709,"enrollment":1710,"conditions":21811,"interventions":21812},[91],[1712,1713,1714,1715],[1717,1718,1719,1152],{"trials":21814,"activeCount":102},[],{"trials":21816,"activeCount":102},[],{"trials":21818,"activeCount":102},[],{"intervention":21820,"totalTrials":180,"cells":21821},"Abiraterone acetate standard dose",{"EARLY_PHASE1":21822,"PHASE1":21824,"PHASE2":21826,"PHASE3":21838,"PHASE4":21840,"NA":21842},{"trials":21823,"activeCount":102},[],{"trials":21825,"activeCount":102},[],{"trials":21827,"activeCount":102},[21828],{"nctId":21829,"briefTitle":21830,"status":139,"phases":21831,"primaryCompletion":13967,"completion":21832,"start":21833,"enrollment":21508,"conditions":21834,"interventions":21836},"NCT03458247","Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer",[91],"2021-12-27","2018-06-22",[21835],"Prostate Cancer",[21820,21837],"Abiraterone acetate escalated dose",{"trials":21839,"activeCount":102},[],{"trials":21841,"activeCount":102},[],{"trials":21843,"activeCount":102},[],{"intervention":21837,"totalTrials":180,"cells":21845},{"EARLY_PHASE1":21846,"PHASE1":21848,"PHASE2":21850,"PHASE3":21856,"PHASE4":21858,"NA":21860},{"trials":21847,"activeCount":102},[],{"trials":21849,"activeCount":102},[],{"trials":21851,"activeCount":102},[21852],{"nctId":21829,"briefTitle":21830,"status":139,"phases":21853,"primaryCompletion":13967,"completion":21832,"start":21833,"enrollment":21508,"conditions":21854,"interventions":21855},[91],[21835],[21820,21837],{"trials":21857,"activeCount":102},[],{"trials":21859,"activeCount":102},[],{"trials":21861,"activeCount":102},[],{"intervention":21863,"totalTrials":180,"cells":21864},"Liposomal Amphotericin B",{"EARLY_PHASE1":21865,"PHASE1":21867,"PHASE2":21869,"PHASE3":21878,"PHASE4":21880,"NA":21882},{"trials":21866,"activeCount":102},[],{"trials":21868,"activeCount":102},[],{"trials":21870,"activeCount":102},[21871],{"nctId":21872,"briefTitle":21873,"status":139,"phases":21874,"primaryCompletion":1587,"completion":385,"start":421,"enrollment":1931,"conditions":21875,"interventions":21877},"NCT00467883","Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment",[91],[21876],"Zygomycosis",[21863],{"trials":21879,"activeCount":102},[],{"trials":21881,"activeCount":102},[],{"trials":21883,"activeCount":102},[],{"intervention":21885,"totalTrials":180,"cells":21886},"Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease",{"EARLY_PHASE1":21887,"PHASE1":21889,"PHASE2":21891,"PHASE3":21901,"PHASE4":21903,"NA":21905},{"trials":21888,"activeCount":102},[],{"trials":21890,"activeCount":102},[],{"trials":21892,"activeCount":102},[21893],{"nctId":21894,"briefTitle":21895,"status":110,"phases":21896,"primaryCompletion":21897,"completion":21898,"start":803,"enrollment":21,"conditions":21899,"interventions":21900},"NCT05199766","Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor",[91],"2024-03-22","2025-03-22",[20],[21885],{"trials":21902,"activeCount":102},[],{"trials":21904,"activeCount":102},[],{"trials":21906,"activeCount":102},[],{"intervention":21908,"totalTrials":180,"cells":21909},"FX06",{"EARLY_PHASE1":21910,"PHASE1":21912,"PHASE2":21914,"PHASE3":21927,"PHASE4":21929,"NA":21931},{"trials":21911,"activeCount":102},[],{"trials":21913,"activeCount":102},[],{"trials":21915,"activeCount":102},[21916],{"nctId":21917,"briefTitle":21918,"status":139,"phases":21919,"primaryCompletion":21920,"completion":21921,"start":21922,"enrollment":1130,"conditions":21923,"interventions":21926},"NCT04618042","FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia",[91],"2021-05-14","2021-06-13","2020-11-13",[21924,26,21925],"Ards","Pneumonia",[21908],{"trials":21928,"activeCount":102},[],{"trials":21930,"activeCount":102},[],{"trials":21932,"activeCount":102},[],{"intervention":21934,"totalTrials":180,"cells":21935},"Cyclosporine",{"EARLY_PHASE1":21936,"PHASE1":21938,"PHASE2":21940,"PHASE3":21950,"PHASE4":21952,"NA":21954},{"trials":21937,"activeCount":102},[],{"trials":21939,"activeCount":102},[],{"trials":21941,"activeCount":102},[21942],{"nctId":21943,"briefTitle":21944,"status":139,"phases":21945,"primaryCompletion":11197,"completion":9986,"start":17170,"enrollment":7935,"conditions":21946,"interventions":21949},"NCT00948727","Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation",[91],[21947,21948],"Hematopoietic Stem Cell Transplantation","Graft Versus Host Disease",[21934],{"trials":21951,"activeCount":102},[],{"trials":21953,"activeCount":102},[],{"trials":21955,"activeCount":102},[],{"intervention":21957,"totalTrials":180,"cells":21958},"Immunoglobulin",{"EARLY_PHASE1":21959,"PHASE1":21961,"PHASE2":21963,"PHASE3":21972,"PHASE4":21974,"NA":21976},{"trials":21960,"activeCount":102},[],{"trials":21962,"activeCount":102},[],{"trials":21964,"activeCount":102},[21965],{"nctId":21966,"briefTitle":21967,"status":139,"phases":21968,"primaryCompletion":5701,"completion":497,"start":20619,"enrollment":19092,"conditions":21969,"interventions":21971},"NCT02343211","Immunotherapy and Paraneoplastic Neurological Syndromes",[91],[21970],"Paraneoplastic Neurological Syndromes",[21957],{"trials":21973,"activeCount":102},[],{"trials":21975,"activeCount":102},[],{"trials":21977,"activeCount":102},[],{"intervention":5751,"totalTrials":180,"cells":21979},{"EARLY_PHASE1":21980,"PHASE1":21982,"PHASE2":21984,"PHASE3":21990,"PHASE4":21992,"NA":21994},{"trials":21981,"activeCount":102},[],{"trials":21983,"activeCount":102},[],{"trials":21985,"activeCount":102},[21986],{"nctId":5742,"briefTitle":5743,"status":139,"phases":21987,"primaryCompletion":5745,"completion":5746,"start":5747,"enrollment":245,"conditions":21988,"interventions":21989},[91],[5749],[5713,5751],{"trials":21991,"activeCount":102},[],{"trials":21993,"activeCount":102},[],{"trials":21995,"activeCount":102},[],{"intervention":1263,"totalTrials":180,"cells":21997},{"EARLY_PHASE1":21998,"PHASE1":22000,"PHASE2":22002,"PHASE3":22008,"PHASE4":22010,"NA":22012},{"trials":21999,"activeCount":102},[],{"trials":22001,"activeCount":102},[],{"trials":22003,"activeCount":102},[22004],{"nctId":1252,"briefTitle":1253,"status":139,"phases":22005,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":22006,"interventions":22007},[91],[1260],[1163,1262,1263,1264,1265],{"trials":22009,"activeCount":102},[],{"trials":22011,"activeCount":102},[],{"trials":22013,"activeCount":102},[],{"intervention":1264,"totalTrials":180,"cells":22015},{"EARLY_PHASE1":22016,"PHASE1":22018,"PHASE2":22020,"PHASE3":22026,"PHASE4":22028,"NA":22030},{"trials":22017,"activeCount":102},[],{"trials":22019,"activeCount":102},[],{"trials":22021,"activeCount":102},[22022],{"nctId":1252,"briefTitle":1253,"status":139,"phases":22023,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":22024,"interventions":22025},[91],[1260],[1163,1262,1263,1264,1265],{"trials":22027,"activeCount":102},[],{"trials":22029,"activeCount":102},[],{"trials":22031,"activeCount":102},[],{"intervention":22033,"totalTrials":180,"cells":22034},"Chlorhydrate de morphine",{"EARLY_PHASE1":22035,"PHASE1":22037,"PHASE2":22039,"PHASE3":22050,"PHASE4":22052,"NA":22054},{"trials":22036,"activeCount":102},[],{"trials":22038,"activeCount":102},[],{"trials":22040,"activeCount":102},[22041],{"nctId":22042,"briefTitle":22043,"status":139,"phases":22044,"primaryCompletion":22045,"completion":22045,"start":22046,"enrollment":30,"conditions":22047,"interventions":22048},"NCT04358133","Low Dose Morphine to Relieve Dyspnea in Acute Respiratory Failure (OPIDYS)",[91],"2022-10-07","2020-12-16",[12218],[22033,22049],"NaCl 0,9%,",{"trials":22051,"activeCount":102},[],{"trials":22053,"activeCount":102},[],{"trials":22055,"activeCount":102},[],{"intervention":22049,"totalTrials":180,"cells":22057},{"EARLY_PHASE1":22058,"PHASE1":22060,"PHASE2":22062,"PHASE3":22068,"PHASE4":22070,"NA":22072},{"trials":22059,"activeCount":102},[],{"trials":22061,"activeCount":102},[],{"trials":22063,"activeCount":102},[22064],{"nctId":22042,"briefTitle":22043,"status":139,"phases":22065,"primaryCompletion":22045,"completion":22045,"start":22046,"enrollment":30,"conditions":22066,"interventions":22067},[91],[12218],[22033,22049],{"trials":22069,"activeCount":102},[],{"trials":22071,"activeCount":102},[],{"trials":22073,"activeCount":102},[],{"intervention":22075,"totalTrials":180,"cells":22076},"Intraoperative anesthetic strategy by Propofol",{"EARLY_PHASE1":22077,"PHASE1":22079,"PHASE2":22081,"PHASE3":22092,"PHASE4":22094,"NA":22096},{"trials":22078,"activeCount":102},[],{"trials":22080,"activeCount":102},[],{"trials":22082,"activeCount":102},[22083],{"nctId":22084,"briefTitle":22085,"status":139,"phases":22086,"primaryCompletion":8413,"completion":8413,"start":9996,"enrollment":303,"conditions":22087,"interventions":22090},"NCT02036736","Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring - COGNIDES",[91],[14467,22088,22089],"Total Hip Prosthesis","Total Knee Replacement",[22075,22091],"Intraoperative anesthetic strategy by Desflurane",{"trials":22093,"activeCount":102},[],{"trials":22095,"activeCount":102},[],{"trials":22097,"activeCount":102},[],{"intervention":22091,"totalTrials":180,"cells":22099},{"EARLY_PHASE1":22100,"PHASE1":22102,"PHASE2":22104,"PHASE3":22110,"PHASE4":22112,"NA":22114},{"trials":22101,"activeCount":102},[],{"trials":22103,"activeCount":102},[],{"trials":22105,"activeCount":102},[22106],{"nctId":22084,"briefTitle":22085,"status":139,"phases":22107,"primaryCompletion":8413,"completion":8413,"start":9996,"enrollment":303,"conditions":22108,"interventions":22109},[91],[14467,22088,22089],[22075,22091],{"trials":22111,"activeCount":102},[],{"trials":22113,"activeCount":102},[],{"trials":22115,"activeCount":102},[],{"intervention":22117,"totalTrials":180,"cells":22118},"Depletion in CD45RA graft donor",{"EARLY_PHASE1":22119,"PHASE1":22121,"PHASE2":22123,"PHASE3":22134,"PHASE4":22136,"NA":22138},{"trials":22120,"activeCount":102},[],{"trials":22122,"activeCount":102},[],{"trials":22124,"activeCount":102},[22125],{"nctId":22126,"briefTitle":22127,"status":241,"phases":22128,"primaryCompletion":22129,"completion":22129,"start":22130,"enrollment":1299,"conditions":22131,"interventions":22133},"NCT02737384","Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)",[91],"2017-10-26","2016-06-14",[22132],"Combined Immunodeficiencies",[22117],{"trials":22135,"activeCount":102},[],{"trials":22137,"activeCount":102},[],{"trials":22139,"activeCount":102},[],{"intervention":22141,"totalTrials":180,"cells":22142},"Daratumumab dose escalation",{"EARLY_PHASE1":22143,"PHASE1":22145,"PHASE2":22147,"PHASE3":22159,"PHASE4":22161,"NA":22163},{"trials":22144,"activeCount":102},[],{"trials":22146,"activeCount":102},[],{"trials":22148,"activeCount":102},[22149],{"nctId":22150,"briefTitle":22151,"status":139,"phases":22152,"primaryCompletion":19389,"completion":19389,"start":10237,"enrollment":33,"conditions":22153,"interventions":22157},"NCT04204980","Desensitization in Kidney Allograft Using Daratumumab",[90,91],[22154,22155,22156],"Allosensitization","Kidney Transplant Rejection","Antibody-mediated Rejection",[22141,22158],"Daratumumab full dose",{"trials":22160,"activeCount":102},[],{"trials":22162,"activeCount":102},[],{"trials":22164,"activeCount":102},[],{"intervention":22158,"totalTrials":180,"cells":22166},{"EARLY_PHASE1":22167,"PHASE1":22169,"PHASE2":22171,"PHASE3":22177,"PHASE4":22179,"NA":22181},{"trials":22168,"activeCount":102},[],{"trials":22170,"activeCount":102},[],{"trials":22172,"activeCount":102},[22173],{"nctId":22150,"briefTitle":22151,"status":139,"phases":22174,"primaryCompletion":19389,"completion":19389,"start":10237,"enrollment":33,"conditions":22175,"interventions":22176},[90,91],[22154,22155,22156],[22141,22158],{"trials":22178,"activeCount":102},[],{"trials":22180,"activeCount":102},[],{"trials":22182,"activeCount":102},[],{"intervention":22184,"totalTrials":180,"cells":22185},"Umbilical cord Wharton's jelly-derived human",{"EARLY_PHASE1":22186,"PHASE1":22188,"PHASE2":22190,"PHASE3":22202,"PHASE4":22204,"NA":22206},{"trials":22187,"activeCount":102},[],{"trials":22189,"activeCount":102},[],{"trials":22191,"activeCount":102},[22192],{"nctId":22193,"briefTitle":22194,"status":139,"phases":22195,"primaryCompletion":22196,"completion":22196,"start":22197,"enrollment":13040,"conditions":22198,"interventions":22201},"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS",[90,91],"2021-10-26","2020-04-06",[22199,22200],"Severe Acute Respiratory Syndrome Coronavirus 2","Severe Acute Respiratory Distress Syndrome",[22184],{"trials":22203,"activeCount":102},[],{"trials":22205,"activeCount":102},[],{"trials":22207,"activeCount":102},[],{"intervention":22209,"totalTrials":180,"cells":22210},"1: ILT101",{"EARLY_PHASE1":22211,"PHASE1":22213,"PHASE2":22215,"PHASE3":22226,"PHASE4":22228,"NA":22230},{"trials":22212,"activeCount":102},[],{"trials":22214,"activeCount":102},[],{"trials":22216,"activeCount":102},[22217],{"nctId":22218,"briefTitle":22219,"status":139,"phases":22220,"primaryCompletion":22221,"completion":22222,"start":15838,"enrollment":21,"conditions":22223,"interventions":22225},"NCT04357444","Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19",[91],"2020-11-02","2021-04-05",[22224],"COVID 19",[22209],{"trials":22227,"activeCount":102},[],{"trials":22229,"activeCount":102},[],{"trials":22231,"activeCount":102},[],{"intervention":22233,"totalTrials":180,"cells":22234},"Clobetasol + Spironolactone",{"EARLY_PHASE1":22235,"PHASE1":22237,"PHASE2":22239,"PHASE3":22249,"PHASE4":22251,"NA":22253},{"trials":22236,"activeCount":102},[],{"trials":22238,"activeCount":102},[],{"trials":22240,"activeCount":102},[22241],{"nctId":22242,"briefTitle":22243,"status":139,"phases":22244,"primaryCompletion":12305,"completion":12305,"start":10680,"enrollment":115,"conditions":22245,"interventions":22247},"NCT01407471","Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy",[91],[22246],"Cutaneous Atrophy Due to Corticosteroids",[22233,22248],"Clobetasol + Placebo",{"trials":22250,"activeCount":102},[],{"trials":22252,"activeCount":102},[],{"trials":22254,"activeCount":102},[],{"intervention":22248,"totalTrials":180,"cells":22256},{"EARLY_PHASE1":22257,"PHASE1":22259,"PHASE2":22261,"PHASE3":22267,"PHASE4":22269,"NA":22271},{"trials":22258,"activeCount":102},[],{"trials":22260,"activeCount":102},[],{"trials":22262,"activeCount":102},[22263],{"nctId":22242,"briefTitle":22243,"status":139,"phases":22264,"primaryCompletion":12305,"completion":12305,"start":10680,"enrollment":115,"conditions":22265,"interventions":22266},[91],[22246],[22233,22248],{"trials":22268,"activeCount":102},[],{"trials":22270,"activeCount":102},[],{"trials":22272,"activeCount":102},[],{"intervention":22274,"totalTrials":180,"cells":22275},"Nitric oxide by inhalation INOMAX",{"EARLY_PHASE1":22276,"PHASE1":22278,"PHASE2":22280,"PHASE3":22288,"PHASE4":22290,"NA":22292},{"trials":22277,"activeCount":102},[],{"trials":22279,"activeCount":102},[],{"trials":22281,"activeCount":102},[22282],{"nctId":22283,"briefTitle":22284,"status":139,"phases":22285,"primaryCompletion":20619,"completion":20619,"start":14737,"enrollment":33,"conditions":22286,"interventions":22287},"NCT01089439","Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children",[91],[3301,20],[22274],{"trials":22289,"activeCount":102},[],{"trials":22291,"activeCount":102},[],{"trials":22293,"activeCount":102},[],{"intervention":22295,"totalTrials":180,"cells":22296},"L-Glutamine",{"EARLY_PHASE1":22297,"PHASE1":22299,"PHASE2":22301,"PHASE3":22310,"PHASE4":22312,"NA":22314},{"trials":22298,"activeCount":102},[],{"trials":22300,"activeCount":102},[],{"trials":22302,"activeCount":102},[22303],{"nctId":22304,"briefTitle":22305,"status":139,"phases":22306,"primaryCompletion":14851,"completion":9880,"start":22307,"enrollment":21,"conditions":22308,"interventions":22309},"NCT00296621","Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy",[91],"2006-02",[8031],[22295],{"trials":22311,"activeCount":102},[],{"trials":22313,"activeCount":102},[],{"trials":22315,"activeCount":102},[],{"intervention":22317,"totalTrials":180,"cells":22318},"nelarabine",{"EARLY_PHASE1":22319,"PHASE1":22321,"PHASE2":22323,"PHASE3":22333,"PHASE4":22335,"NA":22337},{"trials":22320,"activeCount":102},[],{"trials":22322,"activeCount":102},[],{"trials":22324,"activeCount":102},[22325],{"nctId":22326,"briefTitle":22327,"status":110,"phases":22328,"primaryCompletion":1730,"completion":1731,"start":977,"enrollment":22329,"conditions":22330,"interventions":22332},"NCT02619630","Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)",[91],275,[22331],"T-cell Adult Acute Lymphoblastic Leukemia",[22317],{"trials":22334,"activeCount":102},[],{"trials":22336,"activeCount":102},[],{"trials":22338,"activeCount":102},[],{"intervention":22340,"totalTrials":180,"cells":22341},"Rifaximin",{"EARLY_PHASE1":22342,"PHASE1":22344,"PHASE2":22346,"PHASE3":22359,"PHASE4":22361,"NA":22363},{"trials":22343,"activeCount":102},[],{"trials":22345,"activeCount":102},[],{"trials":22347,"activeCount":102},[22348],{"nctId":22349,"briefTitle":22350,"status":241,"phases":22351,"primaryCompletion":22352,"completion":9868,"start":977,"enrollment":27,"conditions":22353,"interventions":22355},"NCT02620007","Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease",[91],"2021-08",[1332,22354],"Adherent-invasive E. Coli",[22356,22340,22357,22358],"Ciprofloxacin","Ciprofloxacin Placebo","Rifaximin Placebo",{"trials":22360,"activeCount":102},[],{"trials":22362,"activeCount":102},[],{"trials":22364,"activeCount":102},[],{"intervention":22357,"totalTrials":180,"cells":22366},{"EARLY_PHASE1":22367,"PHASE1":22369,"PHASE2":22371,"PHASE3":22377,"PHASE4":22379,"NA":22381},{"trials":22368,"activeCount":102},[],{"trials":22370,"activeCount":102},[],{"trials":22372,"activeCount":102},[22373],{"nctId":22349,"briefTitle":22350,"status":241,"phases":22374,"primaryCompletion":22352,"completion":9868,"start":977,"enrollment":27,"conditions":22375,"interventions":22376},[91],[1332,22354],[22356,22340,22357,22358],{"trials":22378,"activeCount":102},[],{"trials":22380,"activeCount":102},[],{"trials":22382,"activeCount":102},[],{"intervention":22358,"totalTrials":180,"cells":22384},{"EARLY_PHASE1":22385,"PHASE1":22387,"PHASE2":22389,"PHASE3":22395,"PHASE4":22397,"NA":22399},{"trials":22386,"activeCount":102},[],{"trials":22388,"activeCount":102},[],{"trials":22390,"activeCount":102},[22391],{"nctId":22349,"briefTitle":22350,"status":241,"phases":22392,"primaryCompletion":22352,"completion":9868,"start":977,"enrollment":27,"conditions":22393,"interventions":22394},[91],[1332,22354],[22356,22340,22357,22358],{"trials":22396,"activeCount":102},[],{"trials":22398,"activeCount":102},[],{"trials":22400,"activeCount":102},[],{"intervention":22402,"totalTrials":180,"cells":22403},"bee venom",{"EARLY_PHASE1":22404,"PHASE1":22406,"PHASE2":22408,"PHASE3":22417,"PHASE4":22419,"NA":22421},{"trials":22405,"activeCount":102},[],{"trials":22407,"activeCount":102},[],{"trials":22409,"activeCount":102},[22410],{"nctId":22411,"briefTitle":22412,"status":139,"phases":22413,"primaryCompletion":11768,"completion":11768,"start":1908,"enrollment":1130,"conditions":22414,"interventions":22416},"NCT01341431","Bee Venom for the Treatment of Parkinson Disease",[91],[22415],"Parkinson Disease",[22402],{"trials":22418,"activeCount":102},[],{"trials":22420,"activeCount":102},[],{"trials":22422,"activeCount":102},[],{"intervention":22424,"totalTrials":180,"cells":22425},"captopril 25mg",{"EARLY_PHASE1":22426,"PHASE1":22428,"PHASE2":22430,"PHASE3":22440,"PHASE4":22442,"NA":22444},{"trials":22427,"activeCount":102},[],{"trials":22429,"activeCount":102},[],{"trials":22431,"activeCount":102},[22432],{"nctId":22433,"briefTitle":22434,"status":110,"phases":22435,"primaryCompletion":22436,"completion":12314,"start":22437,"enrollment":1520,"conditions":22438,"interventions":22439},"NCT04355429","Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)",[91],"2020-07","2020-05-05",[21925,1143,15],[22424],{"trials":22441,"activeCount":102},[],{"trials":22443,"activeCount":102},[],{"trials":22445,"activeCount":102},[],{"intervention":22447,"totalTrials":180,"cells":22448},"DREPAGLOBE drug product",{"EARLY_PHASE1":22449,"PHASE1":22451,"PHASE2":22453,"PHASE3":22463,"PHASE4":22465,"NA":22467},{"trials":22450,"activeCount":102},[],{"trials":22452,"activeCount":102},[],{"trials":22454,"activeCount":102},[22455],{"nctId":22456,"briefTitle":22457,"status":139,"phases":22458,"primaryCompletion":22459,"completion":22460,"start":17590,"enrollment":473,"conditions":22461,"interventions":22462},"NCT03964792","Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)",[90,91],"2022-07-28","2024-01-23",[20],[22447],{"trials":22464,"activeCount":102},[],{"trials":22466,"activeCount":102},[],{"trials":22468,"activeCount":102},[],{"intervention":22470,"totalTrials":180,"cells":22471},"RAD001: Everolimus",{"EARLY_PHASE1":22472,"PHASE1":22474,"PHASE2":22476,"PHASE3":22487,"PHASE4":22489,"NA":22491},{"trials":22473,"activeCount":102},[],{"trials":22475,"activeCount":102},[],{"trials":22477,"activeCount":102},[22478],{"nctId":22479,"briefTitle":22480,"status":139,"phases":22481,"primaryCompletion":1052,"completion":7960,"start":10017,"enrollment":21,"conditions":22482,"interventions":22486},"NCT01412892","Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas",[91],[22483,22484,22485],"Neurofibromatosis Type 1","Plexiform Neurofibroma","Neurofibromatoses",[22470],{"trials":22488,"activeCount":102},[],{"trials":22490,"activeCount":102},[],{"trials":22492,"activeCount":102},[],{"intervention":22494,"totalTrials":180,"cells":22495},"Combination of TG6002 and 5-flucytosine",{"EARLY_PHASE1":22496,"PHASE1":22498,"PHASE2":22500,"PHASE3":22510,"PHASE4":22512,"NA":22514},{"trials":22497,"activeCount":102},[],{"trials":22499,"activeCount":102},[],{"trials":22501,"activeCount":102},[22502],{"nctId":22503,"briefTitle":22504,"status":110,"phases":22505,"primaryCompletion":976,"completion":22506,"start":22507,"enrollment":8017,"conditions":22508,"interventions":22509},"NCT03294486","Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002\u002F5-FC, in Recurrent Glioblastoma Patients",[90,91],"2021-09","2017-10-12",[19058,19033],[22494],{"trials":22511,"activeCount":102},[],{"trials":22513,"activeCount":102},[],{"trials":22515,"activeCount":102},[],{"intervention":9924,"totalTrials":180,"cells":22517},{"EARLY_PHASE1":22518,"PHASE1":22520,"PHASE2":22522,"PHASE3":22528,"PHASE4":22530,"NA":22532},{"trials":22519,"activeCount":102},[],{"trials":22521,"activeCount":102},[],{"trials":22523,"activeCount":102},[22524],{"nctId":9917,"briefTitle":9918,"status":139,"phases":22525,"primaryCompletion":1140,"completion":1140,"start":9920,"enrollment":303,"conditions":22526,"interventions":22527},[91],[9922],[9898,9924],{"trials":22529,"activeCount":102},[],{"trials":22531,"activeCount":102},[],{"trials":22533,"activeCount":102},[],{"intervention":22535,"totalTrials":180,"cells":22536},"Epicutaneous Immunotherapy",{"EARLY_PHASE1":22537,"PHASE1":22539,"PHASE2":22541,"PHASE3":22550,"PHASE4":22552,"NA":22554},{"trials":22538,"activeCount":102},[],{"trials":22540,"activeCount":102},[],{"trials":22542,"activeCount":102},[22543],{"nctId":22544,"briefTitle":22545,"status":139,"phases":22546,"primaryCompletion":1939,"completion":12215,"start":5254,"enrollment":303,"conditions":22547,"interventions":22549},"NCT01197053","Epicutaneous Immunotherapy in Peanut Allergy in Children",[91],[22548],"Peanut Allergy",[22535],{"trials":22551,"activeCount":102},[],{"trials":22553,"activeCount":102},[],{"trials":22555,"activeCount":102},[],{"intervention":22557,"totalTrials":180,"cells":22558},"donor lymphocyte",{"EARLY_PHASE1":22559,"PHASE1":22561,"PHASE2":22563,"PHASE3":22572,"PHASE4":22574,"NA":22576},{"trials":22560,"activeCount":102},[],{"trials":22562,"activeCount":102},[],{"trials":22564,"activeCount":102},[22565],{"nctId":22566,"briefTitle":22567,"status":139,"phases":22568,"primaryCompletion":12216,"completion":12216,"start":5418,"enrollment":1384,"conditions":22569,"interventions":22571},"NCT01086735","Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation",[90,91],[22570],"Hematological Malignancy",[22557],{"trials":22573,"activeCount":102},[],{"trials":22575,"activeCount":102},[],{"trials":22577,"activeCount":102},[],{"intervention":22579,"totalTrials":180,"cells":22580},"AZD4547",{"EARLY_PHASE1":22581,"PHASE1":22583,"PHASE2":22585,"PHASE3":22595,"PHASE4":22597,"NA":22599},{"trials":22582,"activeCount":102},[],{"trials":22584,"activeCount":102},[],{"trials":22586,"activeCount":102},[22587],{"nctId":22588,"briefTitle":22589,"status":139,"phases":22590,"primaryCompletion":11618,"completion":12696,"start":11593,"enrollment":245,"conditions":22591,"interventions":22594},"NCT02824133","Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"",[90,91],[22592,22593],"Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion","Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion",[22579],{"trials":22596,"activeCount":102},[],{"trials":22598,"activeCount":102},[],{"trials":22600,"activeCount":102},[],{"intervention":22602,"totalTrials":180,"cells":22603},"Elotuzumab",{"EARLY_PHASE1":22604,"PHASE1":22606,"PHASE2":22608,"PHASE3":22616,"PHASE4":22618,"NA":22620},{"trials":22605,"activeCount":102},[],{"trials":22607,"activeCount":102},[],{"trials":22609,"activeCount":102},[22610],{"nctId":22611,"briefTitle":22612,"status":5932,"phases":22613,"primaryCompletion":512,"completion":512,"start":18622,"enrollment":102,"conditions":22614,"interventions":22615},"NCT03393273","Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft",[91],[1768],[22602],{"trials":22617,"activeCount":102},[],{"trials":22619,"activeCount":102},[],{"trials":22621,"activeCount":102},[],{"intervention":22623,"totalTrials":180,"cells":22624},"INTANZA® 15",{"EARLY_PHASE1":22625,"PHASE1":22627,"PHASE2":22629,"PHASE3":22640,"PHASE4":22642,"NA":22644},{"trials":22626,"activeCount":102},[],{"trials":22628,"activeCount":102},[],{"trials":22630,"activeCount":102},[22631],{"nctId":22632,"briefTitle":22633,"status":139,"phases":22634,"primaryCompletion":11220,"completion":9996,"start":13760,"enrollment":303,"conditions":22635,"interventions":22637},"NCT01707602","Routes of Immunization and Flu Immune Responses",[90,91],[22636],"Influenza",[22623,22638,22639],"Vaxigrip®","INTANZA® 15 T",{"trials":22641,"activeCount":102},[],{"trials":22643,"activeCount":102},[],{"trials":22645,"activeCount":102},[],{"intervention":22638,"totalTrials":180,"cells":22647},{"EARLY_PHASE1":22648,"PHASE1":22650,"PHASE2":22652,"PHASE3":22658,"PHASE4":22660,"NA":22662},{"trials":22649,"activeCount":102},[],{"trials":22651,"activeCount":102},[],{"trials":22653,"activeCount":102},[22654],{"nctId":22632,"briefTitle":22633,"status":139,"phases":22655,"primaryCompletion":11220,"completion":9996,"start":13760,"enrollment":303,"conditions":22656,"interventions":22657},[90,91],[22636],[22623,22638,22639],{"trials":22659,"activeCount":102},[],{"trials":22661,"activeCount":102},[],{"trials":22663,"activeCount":102},[],{"intervention":22639,"totalTrials":180,"cells":22665},{"EARLY_PHASE1":22666,"PHASE1":22668,"PHASE2":22670,"PHASE3":22676,"PHASE4":22678,"NA":22680},{"trials":22667,"activeCount":102},[],{"trials":22669,"activeCount":102},[],{"trials":22671,"activeCount":102},[22672],{"nctId":22632,"briefTitle":22633,"status":139,"phases":22673,"primaryCompletion":11220,"completion":9996,"start":13760,"enrollment":303,"conditions":22674,"interventions":22675},[90,91],[22636],[22623,22638,22639],{"trials":22677,"activeCount":102},[],{"trials":22679,"activeCount":102},[],{"trials":22681,"activeCount":102},[],{"intervention":22683,"totalTrials":180,"cells":22684},"Danazol 200 MG",{"EARLY_PHASE1":22685,"PHASE1":22687,"PHASE2":22689,"PHASE3":22699,"PHASE4":22701,"NA":22703},{"trials":22686,"activeCount":102},[],{"trials":22688,"activeCount":102},[],{"trials":22690,"activeCount":102},[22691],{"nctId":22692,"briefTitle":22693,"status":110,"phases":22694,"primaryCompletion":5910,"completion":8718,"start":6009,"enrollment":1931,"conditions":22695,"interventions":22698},"NCT03710356","Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy",[90,91],[22696,22697],"Telomere Shortening","Telomere Length, Mean Leukocyte",[22683],{"trials":22700,"activeCount":102},[],{"trials":22702,"activeCount":102},[],{"trials":22704,"activeCount":102},[],{"intervention":22706,"totalTrials":180,"cells":22707},"Nivolumab Injection [Opdivo]",{"EARLY_PHASE1":22708,"PHASE1":22710,"PHASE2":22712,"PHASE3":22722,"PHASE4":22724,"NA":22726},{"trials":22709,"activeCount":102},[],{"trials":22711,"activeCount":102},[],{"trials":22713,"activeCount":102},[22714],{"nctId":22715,"briefTitle":22716,"status":139,"phases":22717,"primaryCompletion":22718,"completion":22719,"start":2197,"enrollment":14156,"conditions":22720,"interventions":22721},"NCT03630640","Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation",[91],"2022-09-30","2023-08-19",[35],[22706],{"trials":22723,"activeCount":102},[],{"trials":22725,"activeCount":102},[],{"trials":22727,"activeCount":102},[],{"intervention":22729,"totalTrials":180,"cells":22730},"Calcium EDTA",{"EARLY_PHASE1":22731,"PHASE1":22733,"PHASE2":22735,"PHASE3":22747,"PHASE4":22749,"NA":22751},{"trials":22732,"activeCount":102},[],{"trials":22734,"activeCount":102},[],{"trials":22736,"activeCount":102},[22737],{"nctId":22738,"briefTitle":22739,"status":241,"phases":22740,"primaryCompletion":22741,"completion":22741,"start":7960,"enrollment":333,"conditions":22742,"interventions":22745},"NCT02286258","Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)",[90,91],"2017-02",[22743,22744],"Renal Insufficiency, Chronic","Kidney Diseases",[22729,22746],"Gd-DOTA",{"trials":22748,"activeCount":102},[],{"trials":22750,"activeCount":102},[],{"trials":22752,"activeCount":102},[],{"intervention":22746,"totalTrials":180,"cells":22754},{"EARLY_PHASE1":22755,"PHASE1":22757,"PHASE2":22759,"PHASE3":22765,"PHASE4":22767,"NA":22769},{"trials":22756,"activeCount":102},[],{"trials":22758,"activeCount":102},[],{"trials":22760,"activeCount":102},[22761],{"nctId":22738,"briefTitle":22739,"status":241,"phases":22762,"primaryCompletion":22741,"completion":22741,"start":7960,"enrollment":333,"conditions":22763,"interventions":22764},[90,91],[22743,22744],[22729,22746],{"trials":22766,"activeCount":102},[],{"trials":22768,"activeCount":102},[],{"trials":22770,"activeCount":102},[],{"intervention":22772,"totalTrials":180,"cells":22773},"vaccine COMIRNATY®",{"EARLY_PHASE1":22774,"PHASE1":22776,"PHASE2":22778,"PHASE3":22788,"PHASE4":22790,"NA":22792},{"trials":22775,"activeCount":102},[],{"trials":22777,"activeCount":102},[],{"trials":22779,"activeCount":102},[22780],{"nctId":22781,"briefTitle":22782,"status":139,"phases":22783,"primaryCompletion":22784,"completion":1013,"start":173,"enrollment":1498,"conditions":22785,"interventions":22787},"NCT04969601","Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings",[90,91],"2022-02-28",[22786,3235,1590],"Acute Leukemia",[22772],{"trials":22789,"activeCount":102},[],{"trials":22791,"activeCount":102},[],{"trials":22793,"activeCount":102},[],{"intervention":22795,"totalTrials":180,"cells":22796},"CpG-ODN",{"EARLY_PHASE1":22797,"PHASE1":22799,"PHASE2":22801,"PHASE3":22809,"PHASE4":22811,"NA":22813},{"trials":22798,"activeCount":102},[],{"trials":22800,"activeCount":102},[],{"trials":22802,"activeCount":102},[22803],{"nctId":22804,"briefTitle":22805,"status":139,"phases":22806,"primaryCompletion":387,"completion":1833,"start":9957,"enrollment":1108,"conditions":22807,"interventions":22808},"NCT00190424","Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma",[91],[19058],[22795],{"trials":22810,"activeCount":102},[],{"trials":22812,"activeCount":102},[],{"trials":22814,"activeCount":102},[],{"intervention":22816,"totalTrials":180,"cells":22817},"RAD001",{"EARLY_PHASE1":22818,"PHASE1":22820,"PHASE2":22822,"PHASE3":22831,"PHASE4":22833,"NA":22835},{"trials":22819,"activeCount":102},[],{"trials":22821,"activeCount":102},[],{"trials":22823,"activeCount":102},[22824],{"nctId":22825,"briefTitle":22826,"status":139,"phases":22827,"primaryCompletion":1509,"completion":18461,"start":7961,"enrollment":5575,"conditions":22828,"interventions":22830},"NCT01490476","Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients",[91],[22829],"Neurofibromatosis 2",[22816],{"trials":22832,"activeCount":102},[],{"trials":22834,"activeCount":102},[],{"trials":22836,"activeCount":102},[],{"intervention":22838,"totalTrials":180,"cells":22839},"lithium",{"EARLY_PHASE1":22840,"PHASE1":22842,"PHASE2":22844,"PHASE3":22852,"PHASE4":22854,"NA":22856},{"trials":22841,"activeCount":102},[],{"trials":22843,"activeCount":102},[],{"trials":22845,"activeCount":102},[22846],{"nctId":22847,"briefTitle":22848,"status":139,"phases":22849,"primaryCompletion":10017,"completion":10017,"start":10507,"enrollment":30,"conditions":22850,"interventions":22851},"NCT00925847","Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis",[91],[14895],[22838],{"trials":22853,"activeCount":102},[],{"trials":22855,"activeCount":102},[],{"trials":22857,"activeCount":102},[],{"intervention":22859,"totalTrials":180,"cells":22860},"Pneumo 23® 0,5",{"EARLY_PHASE1":22861,"PHASE1":22863,"PHASE2":22865,"PHASE3":22878,"PHASE4":22880,"NA":22882},{"trials":22862,"activeCount":102},[],{"trials":22864,"activeCount":102},[],{"trials":22866,"activeCount":102},[22867],{"nctId":22868,"briefTitle":22869,"status":139,"phases":22870,"primaryCompletion":5701,"completion":22871,"start":22872,"enrollment":303,"conditions":22873,"interventions":22875},"NCT02279589","Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers",[91],"2018-09-06","2014-12-04",[22874],"Pneumococcal Infection",[22859,22876,22877],"Pneumo 23® 0,1","Prevenar13® 0,5",{"trials":22879,"activeCount":102},[],{"trials":22881,"activeCount":102},[],{"trials":22883,"activeCount":102},[],{"intervention":22876,"totalTrials":180,"cells":22885},{"EARLY_PHASE1":22886,"PHASE1":22888,"PHASE2":22890,"PHASE3":22896,"PHASE4":22898,"NA":22900},{"trials":22887,"activeCount":102},[],{"trials":22889,"activeCount":102},[],{"trials":22891,"activeCount":102},[22892],{"nctId":22868,"briefTitle":22869,"status":139,"phases":22893,"primaryCompletion":5701,"completion":22871,"start":22872,"enrollment":303,"conditions":22894,"interventions":22895},[91],[22874],[22859,22876,22877],{"trials":22897,"activeCount":102},[],{"trials":22899,"activeCount":102},[],{"trials":22901,"activeCount":102},[],{"intervention":22877,"totalTrials":180,"cells":22903},{"EARLY_PHASE1":22904,"PHASE1":22906,"PHASE2":22908,"PHASE3":22914,"PHASE4":22916,"NA":22918},{"trials":22905,"activeCount":102},[],{"trials":22907,"activeCount":102},[],{"trials":22909,"activeCount":102},[22910],{"nctId":22868,"briefTitle":22869,"status":139,"phases":22911,"primaryCompletion":5701,"completion":22871,"start":22872,"enrollment":303,"conditions":22912,"interventions":22913},[91],[22874],[22859,22876,22877],{"trials":22915,"activeCount":102},[],{"trials":22917,"activeCount":102},[],{"trials":22919,"activeCount":102},[],{"intervention":22921,"totalTrials":180,"cells":22922},"Alemtuzumab (CAMPATH 1H) associated to G-CSF",{"EARLY_PHASE1":22923,"PHASE1":22925,"PHASE2":22927,"PHASE3":22936,"PHASE4":22938,"NA":22940},{"trials":22924,"activeCount":102},[],{"trials":22926,"activeCount":102},[],{"trials":22928,"activeCount":102},[22929],{"nctId":22930,"briefTitle":22931,"status":139,"phases":22932,"primaryCompletion":10067,"completion":5163,"start":10915,"enrollment":268,"conditions":22933,"interventions":22935},"NCT00773149","Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia",[90,91],[22934],"Acute Lymphocytic Leukemia",[22921],{"trials":22937,"activeCount":102},[],{"trials":22939,"activeCount":102},[],{"trials":22941,"activeCount":102},[],{"intervention":22943,"totalTrials":180,"cells":22944},"Pazopanib",{"EARLY_PHASE1":22945,"PHASE1":22947,"PHASE2":22949,"PHASE3":22958,"PHASE4":22960,"NA":22962},{"trials":22946,"activeCount":102},[],{"trials":22948,"activeCount":102},[],{"trials":22950,"activeCount":102},[22951],{"nctId":22952,"briefTitle":22953,"status":241,"phases":22954,"primaryCompletion":374,"completion":374,"start":11641,"enrollment":30,"conditions":22955,"interventions":22957},"NCT01059656","Phase II Pazopanib Study in Advanced Dermatofibrosarcomas",[91],[22956],"Dermatofibrosarcomas of DARIER FERRAND(DFSP)",[22943],{"trials":22959,"activeCount":102},[],{"trials":22961,"activeCount":102},[],{"trials":22963,"activeCount":102},[],{"intervention":22965,"totalTrials":180,"cells":22966},"saxagliptin",{"EARLY_PHASE1":22967,"PHASE1":22969,"PHASE2":22971,"PHASE3":22980,"PHASE4":22982,"NA":22984},{"trials":22968,"activeCount":102},[],{"trials":22970,"activeCount":102},[],{"trials":22972,"activeCount":102},[22973],{"nctId":22974,"briefTitle":22975,"status":139,"phases":22976,"primaryCompletion":522,"completion":522,"start":8053,"enrollment":27,"conditions":22977,"interventions":22979},"NCT01521312","ACute and Chronic Effects of Saxagliptin",[91],[22978],"Impaired Glucose Tolerance",[22965],{"trials":22981,"activeCount":102},[],{"trials":22983,"activeCount":102},[],{"trials":22985,"activeCount":102},[],{"intervention":22987,"totalTrials":180,"cells":22988},"Budesonide\u002Fformoterol",{"EARLY_PHASE1":22989,"PHASE1":22991,"PHASE2":22993,"PHASE3":23001,"PHASE4":23003,"NA":23005},{"trials":22990,"activeCount":102},[],{"trials":22992,"activeCount":102},[],{"trials":22994,"activeCount":102},[22995],{"nctId":22996,"briefTitle":22997,"status":139,"phases":22998,"primaryCompletion":13262,"completion":13262,"start":9986,"enrollment":228,"conditions":22999,"interventions":23000},"NCT01560689","Inhaled BUDESONIDE\u002FFORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation",[91],[18291,13805],[22987],{"trials":23002,"activeCount":102},[],{"trials":23004,"activeCount":102},[],{"trials":23006,"activeCount":102},[],{"intervention":5664,"totalTrials":180,"cells":23008},{"EARLY_PHASE1":23009,"PHASE1":23011,"PHASE2":23013,"PHASE3":23019,"PHASE4":23021,"NA":23023},{"trials":23010,"activeCount":102},[],{"trials":23012,"activeCount":102},[],{"trials":23014,"activeCount":102},[23015],{"nctId":5656,"briefTitle":5657,"status":110,"phases":23016,"primaryCompletion":5659,"completion":1129,"start":5660,"enrollment":21,"conditions":23017,"interventions":23018},[90,91],[5662],[5619,5664],{"trials":23020,"activeCount":102},[],{"trials":23022,"activeCount":102},[],{"trials":23024,"activeCount":102},[],{"intervention":23026,"totalTrials":180,"cells":23027},"Esmolol administration",{"EARLY_PHASE1":23028,"PHASE1":23030,"PHASE2":23032,"PHASE3":23041,"PHASE4":23043,"NA":23045},{"trials":23029,"activeCount":102},[],{"trials":23031,"activeCount":102},[],{"trials":23033,"activeCount":102},[23034],{"nctId":23035,"briefTitle":23036,"status":110,"phases":23037,"primaryCompletion":23038,"completion":23038,"start":12215,"enrollment":6224,"conditions":23039,"interventions":23040},"NCT02120404","Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock",[91],"2023-10",[2462],[23026],{"trials":23042,"activeCount":102},[],{"trials":23044,"activeCount":102},[],{"trials":23046,"activeCount":102},[],{"intervention":23048,"totalTrials":180,"cells":23049},"N-acetylcystein",{"EARLY_PHASE1":23050,"PHASE1":23052,"PHASE2":23054,"PHASE3":23064,"PHASE4":23066,"NA":23068},{"trials":23051,"activeCount":102},[],{"trials":23053,"activeCount":102},[],{"trials":23055,"activeCount":102},[23056],{"nctId":23057,"briefTitle":23058,"status":241,"phases":23059,"primaryCompletion":10832,"completion":1939,"start":10832,"enrollment":473,"conditions":23060,"interventions":23063},"NCT01439828","Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal",[91],[23061,23062],"Cannabis Dependence","Cannabis Abuse",[23048],{"trials":23065,"activeCount":102},[],{"trials":23067,"activeCount":102},[],{"trials":23069,"activeCount":102},[],{"intervention":23071,"totalTrials":180,"cells":23072},"Ulipristal acetate",{"EARLY_PHASE1":23073,"PHASE1":23075,"PHASE2":23077,"PHASE3":23088,"PHASE4":23090,"NA":23092},{"trials":23074,"activeCount":102},[],{"trials":23076,"activeCount":102},[],{"trials":23078,"activeCount":102},[23079],{"nctId":23080,"briefTitle":23081,"status":139,"phases":23082,"primaryCompletion":23083,"completion":23084,"start":23085,"enrollment":115,"conditions":23086,"interventions":23087},"NCT02587000","Adenomyosis and Ulipristal Acetate",[91],"2018-02-02","2020-03-17","2015-06-16",[8564],[23071],{"trials":23089,"activeCount":102},[],{"trials":23091,"activeCount":102},[],{"trials":23093,"activeCount":102},[],{"intervention":23095,"totalTrials":180,"cells":23096},"Carbocaine Injectable Product",{"EARLY_PHASE1":23097,"PHASE1":23099,"PHASE2":23101,"PHASE3":23111,"PHASE4":23113,"NA":23115},{"trials":23098,"activeCount":102},[],{"trials":23100,"activeCount":102},[],{"trials":23102,"activeCount":102},[23103],{"nctId":23104,"briefTitle":23105,"status":110,"phases":23106,"primaryCompletion":23107,"completion":23107,"start":23108,"enrollment":15427,"conditions":23109,"interventions":23110},"NCT05222828","Effects of Mepivacaine on the Neurological Sequelae of Cerebral Infarction",[91],"2024-06-22","2022-06-22",[465],[23095],{"trials":23112,"activeCount":102},[],{"trials":23114,"activeCount":102},[],{"trials":23116,"activeCount":102},[],{"intervention":23118,"totalTrials":180,"cells":23119},"Temozolomide according Stupp protocol",{"EARLY_PHASE1":23120,"PHASE1":23122,"PHASE2":23124,"PHASE3":23136,"PHASE4":23138,"NA":23140},{"trials":23121,"activeCount":102},[],{"trials":23123,"activeCount":102},[],{"trials":23125,"activeCount":102},[23126],{"nctId":23127,"briefTitle":23128,"status":110,"phases":23129,"primaryCompletion":6267,"completion":6267,"start":23130,"enrollment":1213,"conditions":23131,"interventions":23135},"NCT04614493","Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.",[91],"2021-09-11",[23132,23133,23134],"Initial Radiological Diagnosis Eligible for Tumor Resection","Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)","Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide",[23118],{"trials":23137,"activeCount":102},[],{"trials":23139,"activeCount":102},[],{"trials":23141,"activeCount":102},[],{"intervention":120,"totalTrials":180,"cells":23143},{"EARLY_PHASE1":23144,"PHASE1":23146,"PHASE2":23148,"PHASE3":23154,"PHASE4":23156,"NA":23158},{"trials":23145,"activeCount":102},[],{"trials":23147,"activeCount":102},[],{"trials":23149,"activeCount":102},[23150],{"nctId":108,"briefTitle":109,"status":110,"phases":23151,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":23152,"interventions":23153},[91],[117,118],[120,97],{"trials":23155,"activeCount":102},[],{"trials":23157,"activeCount":102},[],{"trials":23159,"activeCount":102},[],{"intervention":23161,"totalTrials":180,"cells":23162},"Cal-1 (LVsh5\u002FC46) drug product",{"EARLY_PHASE1":23163,"PHASE1":23165,"PHASE2":23167,"PHASE3":23177,"PHASE4":23179,"NA":23181},{"trials":23164,"activeCount":102},[],{"trials":23166,"activeCount":102},[],{"trials":23168,"activeCount":102},[23169],{"nctId":23170,"briefTitle":23171,"status":139,"phases":23172,"primaryCompletion":23173,"completion":23173,"start":512,"enrollment":163,"conditions":23174,"interventions":23176},"NCT03593187","A Study Evaluating the Safety of Cal-1 (LVsh5\u002FC46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma",[90,91],"2020-07-28",[23175],"HIV-1 Infection",[23161],{"trials":23178,"activeCount":102},[],{"trials":23180,"activeCount":102},[],{"trials":23182,"activeCount":102},[],{"intervention":23184,"totalTrials":180,"cells":23185},"Exjade",{"EARLY_PHASE1":23186,"PHASE1":23188,"PHASE2":23190,"PHASE3":23199,"PHASE4":23201,"NA":23203},{"trials":23187,"activeCount":102},[],{"trials":23189,"activeCount":102},[],{"trials":23191,"activeCount":102},[23192],{"nctId":23193,"briefTitle":23194,"status":110,"phases":23195,"primaryCompletion":11220,"completion":11220,"start":10067,"enrollment":6224,"conditions":23196,"interventions":23198},"NCT01284946","Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda",[91],[23197],"Porphyria Cutanea Tarda",[23184],{"trials":23200,"activeCount":102},[],{"trials":23202,"activeCount":102},[],{"trials":23204,"activeCount":102},[],{"intervention":23206,"totalTrials":180,"cells":23207},"AcSDKP-NH2 inuline",{"EARLY_PHASE1":23208,"PHASE1":23210,"PHASE2":23212,"PHASE3":23221,"PHASE4":23223,"NA":23225},{"trials":23209,"activeCount":102},[],{"trials":23211,"activeCount":102},[],{"trials":23213,"activeCount":102},[23214],{"nctId":23215,"briefTitle":23216,"status":139,"phases":23217,"primaryCompletion":10963,"completion":10963,"start":1833,"enrollment":3149,"conditions":23218,"interventions":23219},"NCT01588756","Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)",[90,91],[12140,944],[23206,23220],"AcSDKP-NH2 Cr-EDTA",{"trials":23222,"activeCount":102},[],{"trials":23224,"activeCount":102},[],{"trials":23226,"activeCount":102},[],{"intervention":23220,"totalTrials":180,"cells":23228},{"EARLY_PHASE1":23229,"PHASE1":23231,"PHASE2":23233,"PHASE3":23239,"PHASE4":23241,"NA":23243},{"trials":23230,"activeCount":102},[],{"trials":23232,"activeCount":102},[],{"trials":23234,"activeCount":102},[23235],{"nctId":23215,"briefTitle":23216,"status":139,"phases":23236,"primaryCompletion":10963,"completion":10963,"start":1833,"enrollment":3149,"conditions":23237,"interventions":23238},[90,91],[12140,944],[23206,23220],{"trials":23240,"activeCount":102},[],{"trials":23242,"activeCount":102},[],{"trials":23244,"activeCount":102},[],{"intervention":23246,"totalTrials":180,"cells":23247},"Mesenchymal cell therapy",{"EARLY_PHASE1":23248,"PHASE1":23250,"PHASE2":23252,"PHASE3":23262,"PHASE4":23264,"NA":23266},{"trials":23249,"activeCount":102},[],{"trials":23251,"activeCount":102},[],{"trials":23253,"activeCount":102},[23254],{"nctId":23255,"briefTitle":23256,"status":936,"phases":23257,"primaryCompletion":7865,"completion":7865,"start":12765,"enrollment":245,"conditions":23258,"interventions":23261},"NCT02472002","Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients",[90,91],[23259,23260],"Coronary Disease","Heart Transplant",[23246],{"trials":23263,"activeCount":102},[],{"trials":23265,"activeCount":102},[],{"trials":23267,"activeCount":102},[],{"intervention":23269,"totalTrials":180,"cells":23270},"Topotecan",{"EARLY_PHASE1":23271,"PHASE1":23273,"PHASE2":23283,"PHASE3":23285,"PHASE4":23287,"NA":23289},{"trials":23272,"activeCount":102},[],{"trials":23274,"activeCount":102},[23275],{"nctId":23276,"briefTitle":23277,"status":241,"phases":23278,"primaryCompletion":535,"completion":535,"start":8082,"enrollment":429,"conditions":23279,"interventions":23282},"NCT01177501","Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma",[90],[23280,23281],"Ovarian Cancer","Relapses",[23269],{"trials":23284,"activeCount":102},[],{"trials":23286,"activeCount":102},[],{"trials":23288,"activeCount":102},[],{"trials":23290,"activeCount":102},[],{"intervention":5686,"totalTrials":180,"cells":23292},{"EARLY_PHASE1":23293,"PHASE1":23295,"PHASE2":23301,"PHASE3":23303,"PHASE4":23305,"NA":23307},{"trials":23294,"activeCount":102},[],{"trials":23296,"activeCount":102},[23297],{"nctId":5679,"briefTitle":5680,"status":139,"phases":23298,"primaryCompletion":5519,"completion":5519,"start":5682,"enrollment":36,"conditions":23299,"interventions":23300},[90],[5684],[5672,5686],{"trials":23302,"activeCount":102},[],{"trials":23304,"activeCount":102},[],{"trials":23306,"activeCount":102},[],{"trials":23308,"activeCount":102},[],{"intervention":23310,"totalTrials":180,"cells":23311},"repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor",{"EARLY_PHASE1":23312,"PHASE1":23314,"PHASE2":23322,"PHASE3":23324,"PHASE4":23326,"NA":23328},{"trials":23313,"activeCount":102},[],{"trials":23315,"activeCount":102},[23316],{"nctId":23317,"briefTitle":23318,"status":241,"phases":23319,"completion":12945,"start":9881,"enrollment":268,"conditions":23320,"interventions":23321},"NCT00399737","Effects of Peptides Derived From Fermented Milk on Blood Pressure Regulation System in Healthy Volunteers.",[90],[12140],[23310],{"trials":23323,"activeCount":102},[],{"trials":23325,"activeCount":102},[],{"trials":23327,"activeCount":102},[],{"trials":23329,"activeCount":102},[],{"intervention":23331,"totalTrials":180,"cells":23332},"Human embryonic stem cell-derived CD15+ Isl-1+ progenitors",{"EARLY_PHASE1":23333,"PHASE1":23335,"PHASE2":23346,"PHASE3":23348,"PHASE4":23350,"NA":23352},{"trials":23334,"activeCount":102},[],{"trials":23336,"activeCount":102},[23337],{"nctId":23338,"briefTitle":23339,"status":139,"phases":23340,"primaryCompletion":23341,"completion":23341,"start":23342,"enrollment":5575,"conditions":23343,"interventions":23345},"NCT02057900","Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure",[90],"2018-03-22","2013-05-27",[23344],"Ischemic Heart Disease",[23331],{"trials":23347,"activeCount":102},[],{"trials":23349,"activeCount":102},[],{"trials":23351,"activeCount":102},[],{"trials":23353,"activeCount":102},[],{"intervention":23355,"totalTrials":180,"cells":23356},"PET-MRI",{"EARLY_PHASE1":23357,"PHASE1":23359,"PHASE2":23369,"PHASE3":23371,"PHASE4":23373,"NA":23375},{"trials":23358,"activeCount":102},[],{"trials":23360,"activeCount":102},[23361],{"nctId":23362,"briefTitle":23363,"status":139,"phases":23364,"primaryCompletion":23365,"completion":23365,"start":23366,"enrollment":5575,"conditions":23367,"interventions":23368},"NCT05390814","[18F]-Fludarabine PET\u002FMRI in Primary Central Nervous System Lymphoma",[90],"2024-12-05","2023-12-18",[5221],[23355],{"trials":23370,"activeCount":102},[],{"trials":23372,"activeCount":102},[],{"trials":23374,"activeCount":102},[],{"trials":23376,"activeCount":102},[],{"intervention":23378,"totalTrials":180,"cells":23379},"99mTc-Fucoidan SPECT",{"EARLY_PHASE1":23380,"PHASE1":23382,"PHASE2":23392,"PHASE3":23394,"PHASE4":23396,"NA":23398},{"trials":23381,"activeCount":102},[],{"trials":23383,"activeCount":102},[23384],{"nctId":23385,"briefTitle":23386,"status":110,"phases":23387,"primaryCompletion":8138,"completion":23388,"start":16636,"enrollment":5575,"conditions":23389,"interventions":23391},"NCT03422055","Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m",[90],"2018-07-31",[23390],"Healthy Volunteer",[23378],{"trials":23393,"activeCount":102},[],{"trials":23395,"activeCount":102},[],{"trials":23397,"activeCount":102},[],{"trials":23399,"activeCount":102},[],{"intervention":23401,"totalTrials":180,"cells":23402},"cyclosporine+colchicine",{"EARLY_PHASE1":23403,"PHASE1":23405,"PHASE2":23415,"PHASE3":23417,"PHASE4":23419,"NA":23421},{"trials":23404,"activeCount":102},[],{"trials":23406,"activeCount":102},[23407],{"nctId":23408,"briefTitle":23409,"status":139,"phases":23410,"primaryCompletion":7961,"completion":7961,"start":267,"enrollment":19092,"conditions":23411,"interventions":23413},"NCT01160276","Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients",[90],[23412],"Renal Replacement Therapies",[23401,23414],"tacrolimus",{"trials":23416,"activeCount":102},[],{"trials":23418,"activeCount":102},[],{"trials":23420,"activeCount":102},[],{"trials":23422,"activeCount":102},[],{"intervention":23424,"totalTrials":180,"cells":23425},"high sodium diet",{"EARLY_PHASE1":23426,"PHASE1":23428,"PHASE2":23442,"PHASE3":23444,"PHASE4":23446,"NA":23448},{"trials":23427,"activeCount":102},[],{"trials":23429,"activeCount":102},[23430],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23433,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23435,"interventions":23436},"NCT00310778","Effects of Sodium Intake on (PK\u002FPD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker",[90],"2006-03",[12140],[23424,23437,23438,23439,23440,23441],"low sodium diet","ramipril 10 mg","valsartan 160 mg","candesartan 8 mg","atenolol 50 mg",{"trials":23443,"activeCount":102},[],{"trials":23445,"activeCount":102},[],{"trials":23447,"activeCount":102},[],{"trials":23449,"activeCount":102},[],{"intervention":23437,"totalTrials":180,"cells":23451},{"EARLY_PHASE1":23452,"PHASE1":23454,"PHASE2":23460,"PHASE3":23462,"PHASE4":23464,"NA":23466},{"trials":23453,"activeCount":102},[],{"trials":23455,"activeCount":102},[23456],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23457,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23458,"interventions":23459},[90],[12140],[23424,23437,23438,23439,23440,23441],{"trials":23461,"activeCount":102},[],{"trials":23463,"activeCount":102},[],{"trials":23465,"activeCount":102},[],{"trials":23467,"activeCount":102},[],{"intervention":23438,"totalTrials":180,"cells":23469},{"EARLY_PHASE1":23470,"PHASE1":23472,"PHASE2":23478,"PHASE3":23480,"PHASE4":23482,"NA":23484},{"trials":23471,"activeCount":102},[],{"trials":23473,"activeCount":102},[23474],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23475,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23476,"interventions":23477},[90],[12140],[23424,23437,23438,23439,23440,23441],{"trials":23479,"activeCount":102},[],{"trials":23481,"activeCount":102},[],{"trials":23483,"activeCount":102},[],{"trials":23485,"activeCount":102},[],{"intervention":23439,"totalTrials":180,"cells":23487},{"EARLY_PHASE1":23488,"PHASE1":23490,"PHASE2":23496,"PHASE3":23498,"PHASE4":23500,"NA":23502},{"trials":23489,"activeCount":102},[],{"trials":23491,"activeCount":102},[23492],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23493,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23494,"interventions":23495},[90],[12140],[23424,23437,23438,23439,23440,23441],{"trials":23497,"activeCount":102},[],{"trials":23499,"activeCount":102},[],{"trials":23501,"activeCount":102},[],{"trials":23503,"activeCount":102},[],{"intervention":23440,"totalTrials":180,"cells":23505},{"EARLY_PHASE1":23506,"PHASE1":23508,"PHASE2":23514,"PHASE3":23516,"PHASE4":23518,"NA":23520},{"trials":23507,"activeCount":102},[],{"trials":23509,"activeCount":102},[23510],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23511,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23512,"interventions":23513},[90],[12140],[23424,23437,23438,23439,23440,23441],{"trials":23515,"activeCount":102},[],{"trials":23517,"activeCount":102},[],{"trials":23519,"activeCount":102},[],{"trials":23521,"activeCount":102},[],{"intervention":23441,"totalTrials":180,"cells":23523},{"EARLY_PHASE1":23524,"PHASE1":23526,"PHASE2":23532,"PHASE3":23534,"PHASE4":23536,"NA":23538},{"trials":23525,"activeCount":102},[],{"trials":23527,"activeCount":102},[23528],{"nctId":23431,"briefTitle":23432,"status":139,"phases":23529,"primaryCompletion":12268,"completion":12268,"start":23434,"enrollment":6773,"conditions":23530,"interventions":23531},[90],[12140],[23424,23437,23438,23439,23440,23441],{"trials":23533,"activeCount":102},[],{"trials":23535,"activeCount":102},[],{"trials":23537,"activeCount":102},[],{"trials":23539,"activeCount":102},[],{"intervention":5223,"totalTrials":180,"cells":23541},{"EARLY_PHASE1":23542,"PHASE1":23544,"PHASE2":23550,"PHASE3":23552,"PHASE4":23554,"NA":23556},{"trials":23543,"activeCount":102},[],{"trials":23545,"activeCount":102},[23546],{"nctId":5216,"briefTitle":5217,"status":110,"phases":23547,"primaryCompletion":2160,"completion":5219,"start":4116,"enrollment":1225,"conditions":23548,"interventions":23549},[90],[5221],[5223,1737],{"trials":23551,"activeCount":102},[],{"trials":23553,"activeCount":102},[],{"trials":23555,"activeCount":102},[],{"trials":23557,"activeCount":102},[],{"intervention":23559,"totalTrials":180,"cells":23560},"phenotypical approach",{"EARLY_PHASE1":23561,"PHASE1":23563,"PHASE2":23571,"PHASE3":23573,"PHASE4":23575,"NA":23577},{"trials":23562,"activeCount":102},[],{"trials":23564,"activeCount":102},[23565],{"nctId":23566,"briefTitle":23567,"status":139,"phases":23568,"primaryCompletion":21330,"completion":21330,"start":10680,"enrollment":1384,"conditions":23569,"interventions":23570},"NCT01443039","Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass",[90],[18],[23559],{"trials":23572,"activeCount":102},[],{"trials":23574,"activeCount":102},[],{"trials":23576,"activeCount":102},[],{"trials":23578,"activeCount":102},[],{"intervention":23580,"totalTrials":180,"cells":23581},"Lipiodol",{"EARLY_PHASE1":23582,"PHASE1":23584,"PHASE2":23593,"PHASE3":23595,"PHASE4":23597,"NA":23599},{"trials":23583,"activeCount":102},[],{"trials":23585,"activeCount":102},[23586],{"nctId":23587,"briefTitle":23588,"status":139,"phases":23589,"primaryCompletion":23590,"completion":8630,"start":5723,"enrollment":323,"conditions":23591,"interventions":23592},"NCT04733092","Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)",[90],"2022-06-20",[2255],[23580],{"trials":23594,"activeCount":102},[],{"trials":23596,"activeCount":102},[],{"trials":23598,"activeCount":102},[],{"trials":23600,"activeCount":102},[],{"intervention":23602,"totalTrials":180,"cells":23603},"Sotalol 80 mg",{"EARLY_PHASE1":23604,"PHASE1":23606,"PHASE2":23615,"PHASE3":23617,"PHASE4":23619,"NA":23621},{"trials":23605,"activeCount":102},[],{"trials":23607,"activeCount":102},[23608],{"nctId":23609,"briefTitle":23610,"status":139,"phases":23611,"primaryCompletion":535,"completion":535,"start":14851,"enrollment":23612,"conditions":23613,"interventions":23614},"NCT00773201","Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation",[90],997,[5727],[23602],{"trials":23616,"activeCount":102},[],{"trials":23618,"activeCount":102},[],{"trials":23620,"activeCount":102},[],{"trials":23622,"activeCount":102},[],{"intervention":23624,"totalTrials":180,"cells":23625},"ADSVF",{"EARLY_PHASE1":23626,"PHASE1":23628,"PHASE2":23637,"PHASE3":23639,"PHASE4":23641,"NA":23643},{"trials":23627,"activeCount":102},[],{"trials":23629,"activeCount":102},[23630],{"nctId":23631,"briefTitle":23632,"status":110,"phases":23633,"primaryCompletion":23038,"completion":3967,"start":20407,"enrollment":228,"conditions":23634,"interventions":23636},"NCT05032131","Cell Therapy for IBM by Muscle Injection of ADSVF",[90],[23635],"Inclusion Body Myositis",[23624],{"trials":23638,"activeCount":102},[],{"trials":23640,"activeCount":102},[],{"trials":23642,"activeCount":102},[],{"trials":23644,"activeCount":102},[],{"intervention":358,"totalTrials":280,"cells":23646},{"EARLY_PHASE1":23647,"PHASE1":23649,"PHASE2":23651,"PHASE3":23657,"PHASE4":23694,"NA":23696},{"trials":23648,"activeCount":102},[],{"trials":23650,"activeCount":102},[],{"trials":23652,"activeCount":102},[23653],{"nctId":21503,"briefTitle":21504,"status":139,"phases":23654,"primaryCompletion":21506,"completion":21506,"start":21507,"enrollment":21508,"conditions":23655,"interventions":23656},[91],[21510],[358,21494,21512],{"trials":23658,"activeCount":102},[23659,23668,23672,23676,23680,23684],{"nctId":23660,"briefTitle":23661,"status":139,"phases":23662,"primaryCompletion":23663,"completion":23664,"start":23665,"enrollment":12579,"conditions":23666,"interventions":23667},"NCT03371095","Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease",[92],"2021-12-24","2022-04-11","2018-05-25",[19718,5913],[427,358],{"nctId":14007,"briefTitle":14008,"status":139,"phases":23669,"primaryCompletion":14010,"completion":5934,"start":977,"enrollment":1277,"conditions":23670,"interventions":23671},[92],[14012],[358,13996],{"nctId":1936,"briefTitle":1937,"status":139,"phases":23673,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":400,"conditions":23674,"interventions":23675},[92],[1942],[358,1007],{"nctId":349,"briefTitle":350,"status":139,"phases":23677,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":23678,"interventions":23679},[92],[356],[184,358],{"nctId":996,"briefTitle":997,"status":241,"phases":23681,"completion":999,"start":1000,"enrollment":1001,"conditions":23682,"interventions":23683},[92],[1003,1004,1005],[358,1007,369,251],{"nctId":23685,"briefTitle":23686,"status":139,"phases":23687,"primaryCompletion":23688,"completion":23688,"start":23689,"enrollment":1931,"conditions":23690,"interventions":23693},"NCT01570764","Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease",[92],"2018-02-22","2013-01-14",[325,23691,6386,23692],"Scleroderma","Lung Fibrosis",[358],{"trials":23695,"activeCount":102},[],{"trials":23697,"activeCount":102},[23698],{"nctId":23699,"briefTitle":23700,"status":139,"phases":23701,"primaryCompletion":217,"completion":217,"start":23702,"enrollment":1015,"conditions":23703,"interventions":23705},"NCT00190229","Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura",[94],"2002-09",[23704],"Henoch-Schoenlein Purpura",[358],{"intervention":427,"totalTrials":1299,"cells":23707},{"EARLY_PHASE1":23708,"PHASE1":23710,"PHASE2":23712,"PHASE3":23718,"PHASE4":23734,"NA":23736},{"trials":23709,"activeCount":102},[],{"trials":23711,"activeCount":102},[],{"trials":23713,"activeCount":102},[23714],{"nctId":1124,"briefTitle":1125,"status":110,"phases":23715,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":23716,"interventions":23717},[91],[1132],[427,77],{"trials":23719,"activeCount":102},[23720,23724],{"nctId":23660,"briefTitle":23661,"status":139,"phases":23721,"primaryCompletion":23663,"completion":23664,"start":23665,"enrollment":12579,"conditions":23722,"interventions":23723},[92],[19718,5913],[427,358],{"nctId":23725,"briefTitle":23726,"status":139,"phases":23727,"primaryCompletion":23728,"completion":23729,"start":23730,"enrollment":8742,"conditions":23731,"interventions":23733},"NCT03704610","Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)",[92],"2021-06-21","2021-09-28","2019-03-28",[23732],"Extrathoracic Sarcoidosis",[427],{"trials":23735,"activeCount":102},[],{"trials":23737,"activeCount":102},[23738],{"nctId":418,"briefTitle":419,"status":139,"phases":23739,"completion":421,"start":422,"enrollment":36,"conditions":23740,"interventions":23741},[94],[424,425,335],[427,184],{"intervention":12320,"totalTrials":1299,"cells":23743},{"EARLY_PHASE1":23744,"PHASE1":23746,"PHASE2":23748,"PHASE3":23750,"PHASE4":23769,"NA":23771},{"trials":23745,"activeCount":102},[],{"trials":23747,"activeCount":102},[],{"trials":23749,"activeCount":102},[],{"trials":23751,"activeCount":102},[23752,23756,23765],{"nctId":12290,"briefTitle":12291,"status":139,"phases":23753,"primaryCompletion":12293,"completion":12293,"start":12294,"enrollment":4204,"conditions":23754,"interventions":23755},[92],[12296],[12298,12299,12300],{"nctId":23757,"briefTitle":23758,"status":110,"phases":23759,"primaryCompletion":23760,"completion":23761,"start":21330,"enrollment":804,"conditions":23762,"interventions":23764},"NCT01959100","Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation",[92],"2017-04","2022-08",[23763],"Malignant Hematological Diseases",[12320],{"nctId":12310,"briefTitle":12311,"status":936,"phases":23766,"primaryCompletion":12313,"completion":12314,"start":12315,"enrollment":6268,"conditions":23767,"interventions":23768},[91,92],[12317,12296],[12319,12320,12279],{"trials":23770,"activeCount":102},[],{"trials":23772,"activeCount":102},[23773],{"nctId":23774,"briefTitle":23775,"status":139,"phases":23776,"primaryCompletion":23777,"completion":23777,"start":10532,"enrollment":258,"conditions":23778,"interventions":23780},"NCT02336516","Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome",[94],"2021-04",[23779],"Haemolytic and Uremic Syndrome",[12320],{"intervention":23782,"totalTrials":1299,"cells":23783},"Blood test",{"EARLY_PHASE1":23784,"PHASE1":23786,"PHASE2":23788,"PHASE3":23790,"PHASE4":23792,"NA":23794},{"trials":23785,"activeCount":102},[],{"trials":23787,"activeCount":102},[],{"trials":23789,"activeCount":102},[],{"trials":23791,"activeCount":102},[],{"trials":23793,"activeCount":102},[],{"trials":23795,"activeCount":102},[23796,23805,23814,23823],{"nctId":23797,"briefTitle":23798,"status":139,"phases":23799,"primaryCompletion":19366,"completion":19366,"start":23800,"enrollment":5575,"conditions":23801,"interventions":23803},"NCT03730584","Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa",[94],"2017-02-27",[23802],"Epidermolysis Bullosa",[23804,23782],"Ropivacaine",{"nctId":23806,"briefTitle":23807,"status":139,"phases":23808,"primaryCompletion":23809,"completion":23810,"start":23811,"enrollment":1531,"conditions":23812,"interventions":23813},"NCT02030613","Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis",[94],"2017-02-28","2017-03-30","2013-10-01",[1204],[23782],{"nctId":23815,"briefTitle":23816,"status":139,"phases":23817,"primaryCompletion":23818,"completion":23818,"start":23819,"enrollment":5940,"conditions":23820,"interventions":23822},"NCT04024150","Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn",[],"2021-01-14","2019-12-04",[23821],"Anti-integrases",[23782],{"nctId":23824,"briefTitle":23825,"status":139,"phases":23826,"primaryCompletion":10236,"completion":10236,"start":14555,"enrollment":1247,"conditions":23827,"interventions":23828},"NCT03492567","Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.",[94],[23],[23782],{"intervention":23830,"totalTrials":429,"cells":23831},"Topiramate",{"EARLY_PHASE1":23832,"PHASE1":23834,"PHASE2":23836,"PHASE3":23838,"PHASE4":23856,"NA":23858},{"trials":23833,"activeCount":102},[],{"trials":23835,"activeCount":102},[],{"trials":23837,"activeCount":102},[],{"trials":23839,"activeCount":102},[23840,23847],{"nctId":23841,"briefTitle":23842,"status":241,"phases":23843,"primaryCompletion":5469,"completion":5701,"start":11220,"enrollment":1403,"conditions":23844,"interventions":23846},"NCT02810483","Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks",[92],[23845],"Prader-Willi Syndrome",[23830],{"nctId":23848,"briefTitle":23849,"status":139,"phases":23850,"primaryCompletion":8339,"completion":23851,"start":23852,"enrollment":1225,"conditions":23853,"interventions":23855},"NCT02273804","Topiramate and Severe Obesity",[92],"2018-01-23","2016-06-01",[23854],"Obese Children and Adolescents",[23830],{"trials":23857,"activeCount":102},[],{"trials":23859,"activeCount":102},[23860],{"nctId":7679,"briefTitle":7680,"status":139,"phases":23861,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":23862,"interventions":23863},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":23865,"totalTrials":429,"cells":23866},"Salbutamol",{"EARLY_PHASE1":23867,"PHASE1":23869,"PHASE2":23871,"PHASE3":23884,"PHASE4":23886,"NA":23888},{"trials":23868,"activeCount":102},[],{"trials":23870,"activeCount":102},[],{"trials":23872,"activeCount":102},[23873,23877],{"nctId":19626,"briefTitle":19627,"status":139,"phases":23874,"primaryCompletion":12765,"completion":12765,"start":7961,"enrollment":5804,"conditions":23875,"interventions":23876},[91],[569],[19631,19617,19632,19633],{"nctId":23878,"briefTitle":23879,"status":110,"phases":23880,"primaryCompletion":17520,"completion":17520,"start":71,"enrollment":13479,"conditions":23881,"interventions":23883},"NCT05860244","Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients",[91],[23882,14895],"Walking Capacity",[23865],{"trials":23885,"activeCount":102},[],{"trials":23887,"activeCount":102},[],{"trials":23889,"activeCount":102},[23890],{"nctId":23891,"briefTitle":23892,"status":241,"phases":23893,"primaryCompletion":23894,"completion":23894,"start":23895,"enrollment":13387,"conditions":23896,"interventions":23897},"NCT03592212","Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma",[],"2019-11-14","2018-11-23",[569],[23865],{"intervention":17568,"totalTrials":429,"cells":23899},{"EARLY_PHASE1":23900,"PHASE1":23902,"PHASE2":23908,"PHASE3":23910,"PHASE4":23916,"NA":23918},{"trials":23901,"activeCount":102},[],{"trials":23903,"activeCount":102},[23904],{"nctId":23408,"briefTitle":23409,"status":139,"phases":23905,"primaryCompletion":7961,"completion":7961,"start":267,"enrollment":19092,"conditions":23906,"interventions":23907},[90],[23412],[23401,23414],{"trials":23909,"activeCount":102},[],{"trials":23911,"activeCount":102},[23912],{"nctId":17560,"briefTitle":17561,"status":110,"phases":23913,"primaryCompletion":17563,"completion":17563,"start":17564,"enrollment":1498,"conditions":23914,"interventions":23915},[92],[17566,6386],[17549,17568],{"trials":23917,"activeCount":102},[],{"trials":23919,"activeCount":102},[23920],{"nctId":23921,"briefTitle":23922,"status":110,"phases":23923,"primaryCompletion":1730,"completion":1730,"start":11768,"enrollment":1108,"conditions":23924,"interventions":23926},"NCT02337036","Pharmacokinetic of Tacrolimus in Paediatric Liver Transplant Patients",[94],[23925],"Liver Transplantation, Child",[17568],{"intervention":18334,"totalTrials":429,"cells":23928},{"EARLY_PHASE1":23929,"PHASE1":23931,"PHASE2":23933,"PHASE3":23935,"PHASE4":23941,"NA":23951},{"trials":23930,"activeCount":102},[],{"trials":23932,"activeCount":102},[],{"trials":23934,"activeCount":102},[],{"trials":23936,"activeCount":102},[23937],{"nctId":18327,"briefTitle":18328,"status":110,"phases":23938,"primaryCompletion":18330,"completion":14010,"start":497,"enrollment":3086,"conditions":23939,"interventions":23940},[92],[18332],[18334,18316],{"trials":23942,"activeCount":102},[23943],{"nctId":23944,"briefTitle":23945,"status":241,"phases":23946,"primaryCompletion":23947,"completion":23947,"start":23948,"enrollment":1384,"conditions":23949,"interventions":23950},"NCT03731117","FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU",[93],"2020-12-07","2019-07-15",[3654],[18334],{"trials":23952,"activeCount":102},[23953],{"nctId":23954,"briefTitle":23955,"status":139,"phases":23956,"primaryCompletion":11047,"completion":11047,"start":957,"enrollment":268,"conditions":23957,"interventions":23959},"NCT00531908","Physiopathology of Sodium Retention in Acromegaly",[94],[23958],"Acromegaly",[23960],"furosemide",{"intervention":23962,"totalTrials":163,"cells":23963},"whole exome sequencing",{"EARLY_PHASE1":23964,"PHASE1":23966,"PHASE2":23968,"PHASE3":23970,"PHASE4":23972,"NA":23974},{"trials":23965,"activeCount":102},[],{"trials":23967,"activeCount":102},[],{"trials":23969,"activeCount":102},[],{"trials":23971,"activeCount":102},[],{"trials":23973,"activeCount":102},[],{"trials":23975,"activeCount":102},[23976,23985],{"nctId":23977,"briefTitle":23978,"status":139,"phases":23979,"primaryCompletion":23980,"completion":23980,"start":23981,"enrollment":8742,"conditions":23982,"interventions":23984},"NCT03600792","Whole Exome Sequencing in Prenatal Diagnosis of Agenesis of the Corpus Callosum",[],"2019-10-19","2018-08-28",[23983],"Fetal Agenesis of the Corpus Callosum (ACC)",[23962],{"nctId":23986,"briefTitle":23987,"status":139,"phases":23988,"primaryCompletion":23989,"completion":23989,"start":23990,"enrollment":6224,"conditions":23991,"interventions":23993},"NCT03887182","Contribution of Functional MRI in Assessment of Auditory Processing Disorders",[94],"2023-10-10","2020-09-02",[23992],"Auditory Processing Disorders",[23962],{"intervention":23995,"totalTrials":163,"cells":23996},"Perampanel",{"EARLY_PHASE1":23997,"PHASE1":23999,"PHASE2":24001,"PHASE3":24003,"PHASE4":24013,"NA":24015},{"trials":23998,"activeCount":102},[],{"trials":24000,"activeCount":102},[],{"trials":24002,"activeCount":102},[],{"trials":24004,"activeCount":102},[24005],{"nctId":24006,"briefTitle":24007,"status":241,"phases":24008,"primaryCompletion":24009,"completion":676,"start":24009,"enrollment":180,"conditions":24010,"interventions":24012},"NCT04309721","Perampanel in Focal Status Epilepticus",[92],"2022-11-02",[24011],"Epilepticus; Status, Focal Motor",[23995],{"trials":24014,"activeCount":102},[],{"trials":24016,"activeCount":102},[24017],{"nctId":7679,"briefTitle":7680,"status":139,"phases":24018,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":24019,"interventions":24020},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":24022,"totalTrials":163,"cells":24023},"Genetic study",{"EARLY_PHASE1":24024,"PHASE1":24026,"PHASE2":24028,"PHASE3":24030,"PHASE4":24032,"NA":24034},{"trials":24025,"activeCount":102},[],{"trials":24027,"activeCount":102},[],{"trials":24029,"activeCount":102},[],{"trials":24031,"activeCount":102},[],{"trials":24033,"activeCount":102},[],{"trials":24035,"activeCount":102},[24036,24048],{"nctId":24037,"briefTitle":24038,"status":139,"phases":24039,"primaryCompletion":24040,"completion":24040,"start":24041,"enrollment":24042,"conditions":24043,"interventions":24046},"NCT02425397","Cancer and Hearing Loss Related in Children",[],"2016-01-05","2011-03-27",119,[24044,24045],"Cancer in Children","Hearing Loss",[24022,24047],"Genetic study MT-RN1",{"nctId":24049,"briefTitle":24050,"status":139,"phases":24051,"primaryCompletion":17616,"completion":17616,"start":24052,"enrollment":13040,"conditions":24053,"interventions":24054},"NCT02113930","Idiopathic CD4 Lymphocytopenia",[],"2013-09-10",[24050],[24055,24022],"Constitution of a biobank of frozen cells, plasma and serum samples",{"intervention":24057,"totalTrials":163,"cells":24058},"Insulin",{"EARLY_PHASE1":24059,"PHASE1":24061,"PHASE2":24063,"PHASE3":24065,"PHASE4":24075,"NA":24077},{"trials":24060,"activeCount":102},[],{"trials":24062,"activeCount":102},[],{"trials":24064,"activeCount":102},[],{"trials":24066,"activeCount":102},[24067],{"nctId":24068,"briefTitle":24069,"status":139,"phases":24070,"primaryCompletion":5417,"completion":5417,"start":5144,"enrollment":4948,"conditions":24071,"interventions":24074},"NCT00472381","Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke",[91,92],[24072,24073],"Acute Stroke","Acute Cerebral Ischemia",[24057],{"trials":24076,"activeCount":102},[],{"trials":24078,"activeCount":102},[24079],{"nctId":24080,"briefTitle":24081,"status":139,"phases":24082,"primaryCompletion":5163,"completion":5163,"start":301,"enrollment":291,"conditions":24083,"interventions":24084},"NCT01022658","INSUlin Regimens and VASCular Functions",[94],[3503],[24057],{"intervention":24086,"totalTrials":163,"cells":24087},"loxapine",{"EARLY_PHASE1":24088,"PHASE1":24090,"PHASE2":24092,"PHASE3":24094,"PHASE4":24096,"NA":24105},{"trials":24089,"activeCount":102},[],{"trials":24091,"activeCount":102},[],{"trials":24093,"activeCount":102},[],{"trials":24095,"activeCount":102},[],{"trials":24097,"activeCount":102},[24098],{"nctId":24099,"briefTitle":24100,"status":139,"phases":24101,"primaryCompletion":13563,"completion":988,"start":1402,"enrollment":3149,"conditions":24102,"interventions":24104},"NCT01193816","Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning",[93],[24103],"Restlessness",[24086],{"trials":24106,"activeCount":102},[24107],{"nctId":24108,"briefTitle":24109,"status":139,"phases":24110,"completion":24111,"start":5196,"enrollment":24112,"conditions":24113,"interventions":24114},"NCT00122733","Loxapine and Weaning From Ventilator",[94],"2006-12",9,[5198,5199],[24086],{"intervention":12210,"totalTrials":163,"cells":24116},{"EARLY_PHASE1":24117,"PHASE1":24119,"PHASE2":24121,"PHASE3":24123,"PHASE4":24129,"NA":24131},{"trials":24118,"activeCount":102},[],{"trials":24120,"activeCount":102},[],{"trials":24122,"activeCount":102},[],{"trials":24124,"activeCount":102},[24125],{"nctId":12204,"briefTitle":12205,"status":139,"phases":24126,"primaryCompletion":216,"completion":216,"start":8235,"enrollment":16,"conditions":24127,"interventions":24128},[92],[12208],[12210,12183],{"trials":24130,"activeCount":102},[],{"trials":24132,"activeCount":102},[24133],{"nctId":24134,"briefTitle":24135,"status":110,"phases":24136,"primaryCompletion":8148,"completion":8148,"start":24137,"enrollment":1001,"conditions":24138,"interventions":24140},"NCT04008628","Nitrous Oxide for Analgesia During Nasogastric Tube Placement in Young Children",[94],"2021-12-10",[24139],"Mild to Moderate Dehydration",[12210],{"intervention":24142,"totalTrials":163,"cells":24143},"Collect of blood samples for DNA extraction and genetic characterization",{"EARLY_PHASE1":24144,"PHASE1":24146,"PHASE2":24148,"PHASE3":24150,"PHASE4":24152,"NA":24154},{"trials":24145,"activeCount":102},[],{"trials":24147,"activeCount":102},[],{"trials":24149,"activeCount":102},[],{"trials":24151,"activeCount":102},[],{"trials":24153,"activeCount":102},[],{"trials":24155,"activeCount":102},[24156,24164],{"nctId":24157,"briefTitle":24158,"status":110,"phases":24159,"primaryCompletion":12094,"completion":19839,"start":10329,"enrollment":24160,"conditions":24161,"interventions":24163},"NCT02212522","Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications",[],20000,[5548,24162],"Insulin-Dependent",[24142,24142],{"nctId":24165,"briefTitle":24166,"status":110,"phases":24167,"primaryCompletion":12094,"completion":19839,"start":5900,"enrollment":1160,"conditions":24168,"interventions":24169},"NCT02425410","Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset",[],[5548,24162],[24142],{"intervention":1265,"totalTrials":163,"cells":24171},{"EARLY_PHASE1":24172,"PHASE1":24174,"PHASE2":24176,"PHASE3":24182,"PHASE4":24184,"NA":24186},{"trials":24173,"activeCount":102},[],{"trials":24175,"activeCount":102},[],{"trials":24177,"activeCount":102},[24178],{"nctId":1252,"briefTitle":1253,"status":139,"phases":24179,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":24180,"interventions":24181},[91],[1260],[1163,1262,1263,1264,1265],{"trials":24183,"activeCount":102},[],{"trials":24185,"activeCount":102},[],{"trials":24187,"activeCount":102},[24188],{"nctId":24189,"briefTitle":24190,"status":110,"phases":24191,"primaryCompletion":8411,"completion":8411,"start":14556,"enrollment":1108,"conditions":24192,"interventions":24194},"NCT02897401","Determination of Carcinogens Nicotine in Electronic Cigarettes Users",[94],[17126,24193],"Carcinogenesis of the Nicotine",[24195,24196,24197],"pregnancy test","urinary cotinine assesment","Urinary NNN assesement",{"intervention":22356,"totalTrials":163,"cells":24199},{"EARLY_PHASE1":24200,"PHASE1":24202,"PHASE2":24204,"PHASE3":24210,"PHASE4":24212,"NA":24214},{"trials":24201,"activeCount":102},[],{"trials":24203,"activeCount":102},[],{"trials":24205,"activeCount":102},[24206],{"nctId":22349,"briefTitle":22350,"status":241,"phases":24207,"primaryCompletion":22352,"completion":9868,"start":977,"enrollment":27,"conditions":24208,"interventions":24209},[91],[1332,22354],[22356,22340,22357,22358],{"trials":24211,"activeCount":102},[],{"trials":24213,"activeCount":102},[],{"trials":24215,"activeCount":102},[24216],{"nctId":24217,"briefTitle":24218,"status":241,"phases":24219,"primaryCompletion":9987,"completion":9987,"start":1969,"enrollment":5911,"conditions":24220,"interventions":24221},"NCT00190151","Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora",[94],[5727],[24222],"ciprofloxacin",{"intervention":24224,"totalTrials":180,"cells":24225},"Insulin 0.05 IU\u002Fkg\u002Fh",{"EARLY_PHASE1":24226,"PHASE1":24228,"PHASE2":24230,"PHASE3":24232,"PHASE4":24234,"NA":24236},{"trials":24227,"activeCount":102},[],{"trials":24229,"activeCount":102},[],{"trials":24231,"activeCount":102},[],{"trials":24233,"activeCount":102},[],{"trials":24235,"activeCount":102},[],{"trials":24237,"activeCount":102},[24238],{"nctId":24239,"briefTitle":24240,"status":139,"phases":24241,"primaryCompletion":24242,"completion":24242,"start":5876,"enrollment":1330,"conditions":24243,"interventions":24245},"NCT05443802","Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications",[94],"2025-03-31",[24244],"Diabetic Ketoacidosis",[24224,24246],"Insulin 0.10 IU\u002Fkg\u002Fh",{"intervention":24246,"totalTrials":180,"cells":24248},{"EARLY_PHASE1":24249,"PHASE1":24251,"PHASE2":24253,"PHASE3":24255,"PHASE4":24257,"NA":24259},{"trials":24250,"activeCount":102},[],{"trials":24252,"activeCount":102},[],{"trials":24254,"activeCount":102},[],{"trials":24256,"activeCount":102},[],{"trials":24258,"activeCount":102},[],{"trials":24260,"activeCount":102},[24261],{"nctId":24239,"briefTitle":24240,"status":139,"phases":24262,"primaryCompletion":24242,"completion":24242,"start":5876,"enrollment":1330,"conditions":24263,"interventions":24264},[94],[24244],[24224,24246],{"intervention":8120,"totalTrials":180,"cells":24266},{"EARLY_PHASE1":24267,"PHASE1":24269,"PHASE2":24271,"PHASE3":24273,"PHASE4":24275,"NA":24277},{"trials":24268,"activeCount":102},[],{"trials":24270,"activeCount":102},[],{"trials":24272,"activeCount":102},[],{"trials":24274,"activeCount":102},[],{"trials":24276,"activeCount":102},[],{"trials":24278,"activeCount":102},[24279],{"nctId":8113,"briefTitle":8114,"status":5932,"phases":24280,"primaryCompletion":3474,"completion":4245,"start":7933,"enrollment":102,"conditions":24281,"interventions":24282},[94],[8117],[8119,8120],{"intervention":24284,"totalTrials":180,"cells":24285},"QFTB-G and T-SPOT.TB tests",{"EARLY_PHASE1":24286,"PHASE1":24288,"PHASE2":24290,"PHASE3":24292,"PHASE4":24294,"NA":24296},{"trials":24287,"activeCount":102},[],{"trials":24289,"activeCount":102},[],{"trials":24291,"activeCount":102},[],{"trials":24293,"activeCount":102},[],{"trials":24295,"activeCount":102},[],{"trials":24297,"activeCount":102},[24298],{"nctId":24299,"briefTitle":24300,"status":139,"phases":24301,"primaryCompletion":13261,"completion":5417,"start":5301,"enrollment":24302,"conditions":24303,"interventions":24304},"NCT00811343","Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy",[94],430,[6995],[24284],{"intervention":8219,"totalTrials":180,"cells":24306},{"EARLY_PHASE1":24307,"PHASE1":24309,"PHASE2":24311,"PHASE3":24313,"PHASE4":24315,"NA":24317},{"trials":24308,"activeCount":102},[],{"trials":24310,"activeCount":102},[],{"trials":24312,"activeCount":102},[],{"trials":24314,"activeCount":102},[],{"trials":24316,"activeCount":102},[],{"trials":24318,"activeCount":102},[24319],{"nctId":8211,"briefTitle":8212,"status":5932,"phases":24320,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":102,"conditions":24321,"interventions":24322},[],[8217],[8219,8196,8220],{"intervention":8220,"totalTrials":180,"cells":24324},{"EARLY_PHASE1":24325,"PHASE1":24327,"PHASE2":24329,"PHASE3":24331,"PHASE4":24333,"NA":24335},{"trials":24326,"activeCount":102},[],{"trials":24328,"activeCount":102},[],{"trials":24330,"activeCount":102},[],{"trials":24332,"activeCount":102},[],{"trials":24334,"activeCount":102},[],{"trials":24336,"activeCount":102},[24337],{"nctId":8211,"briefTitle":8212,"status":5932,"phases":24338,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":102,"conditions":24339,"interventions":24340},[],[8217],[8219,8196,8220],{"intervention":24342,"totalTrials":180,"cells":24343},"Metatranscriptomic",{"EARLY_PHASE1":24344,"PHASE1":24346,"PHASE2":24348,"PHASE3":24350,"PHASE4":24352,"NA":24354},{"trials":24345,"activeCount":102},[],{"trials":24347,"activeCount":102},[],{"trials":24349,"activeCount":102},[],{"trials":24351,"activeCount":102},[],{"trials":24353,"activeCount":102},[],{"trials":24355,"activeCount":102},[24356],{"nctId":24357,"briefTitle":24358,"status":110,"phases":24359,"primaryCompletion":24360,"completion":399,"start":13064,"enrollment":2779,"conditions":24361,"interventions":24363},"NCT05388968","Metatranscriptomic Next Generation Sequencing in First Trimester Trophoblast With Increased Fetal Nuchal Translucency (METAHCN)",[],"2025-05",[24362],"Increased Nuchal Translucency in the First Trimester of Pregnancy",[24342],{"intervention":24365,"totalTrials":180,"cells":24366},"RAS Inhibitors",{"EARLY_PHASE1":24367,"PHASE1":24369,"PHASE2":24371,"PHASE3":24373,"PHASE4":24375,"NA":24377},{"trials":24368,"activeCount":102},[],{"trials":24370,"activeCount":102},[],{"trials":24372,"activeCount":102},[],{"trials":24374,"activeCount":102},[],{"trials":24376,"activeCount":102},[],{"trials":24378,"activeCount":102},[24379],{"nctId":24380,"briefTitle":24381,"status":139,"phases":24382,"primaryCompletion":522,"completion":522,"start":1940,"enrollment":12579,"conditions":24383,"interventions":24384},"NCT01195818","Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients",[94],[20],[24365],{"intervention":1057,"totalTrials":180,"cells":24386},{"EARLY_PHASE1":24387,"PHASE1":24389,"PHASE2":24391,"PHASE3":24393,"PHASE4":24395,"NA":24397},{"trials":24388,"activeCount":102},[],{"trials":24390,"activeCount":102},[],{"trials":24392,"activeCount":102},[],{"trials":24394,"activeCount":102},[],{"trials":24396,"activeCount":102},[],{"trials":24398,"activeCount":102},[24399],{"nctId":1047,"briefTitle":1048,"status":110,"phases":24400,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":24401,"interventions":24402},[94],[1055],[251,1057],{"intervention":24404,"totalTrials":180,"cells":24405},"ABCB1 genotyping",{"EARLY_PHASE1":24406,"PHASE1":24408,"PHASE2":24410,"PHASE3":24412,"PHASE4":24414,"NA":24416},{"trials":24407,"activeCount":102},[],{"trials":24409,"activeCount":102},[],{"trials":24411,"activeCount":102},[],{"trials":24413,"activeCount":102},[],{"trials":24415,"activeCount":102},[],{"trials":24417,"activeCount":102},[24418],{"nctId":24419,"briefTitle":24420,"status":139,"phases":24421,"primaryCompletion":24422,"completion":24422,"start":24423,"enrollment":24424,"conditions":24425,"interventions":24427},"NCT07393113","CLarifying ABCB1's Role in Alzheimer's Disease",[],"2025-12-31","2023-10-25",510,[24426],"Alzheimer Disease",[24404],{"intervention":24429,"totalTrials":180,"cells":24430},"Non-exposed group",{"EARLY_PHASE1":24431,"PHASE1":24433,"PHASE2":24435,"PHASE3":24437,"PHASE4":24439,"NA":24441},{"trials":24432,"activeCount":102},[],{"trials":24434,"activeCount":102},[],{"trials":24436,"activeCount":102},[],{"trials":24438,"activeCount":102},[],{"trials":24440,"activeCount":102},[],{"trials":24442,"activeCount":102},[24443],{"nctId":24444,"briefTitle":24445,"status":110,"phases":24446,"primaryCompletion":497,"completion":497,"start":1051,"enrollment":24447,"conditions":24448,"interventions":24450},"NCT02906527","Benefit\u002FRisk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)",[],150000,[24449],"Non Valvular Atrial Fibrillation (nv AF)",[24429,24451],"Exposed group",{"intervention":24451,"totalTrials":180,"cells":24453},{"EARLY_PHASE1":24454,"PHASE1":24456,"PHASE2":24458,"PHASE3":24460,"PHASE4":24462,"NA":24464},{"trials":24455,"activeCount":102},[],{"trials":24457,"activeCount":102},[],{"trials":24459,"activeCount":102},[],{"trials":24461,"activeCount":102},[],{"trials":24463,"activeCount":102},[],{"trials":24465,"activeCount":102},[24466],{"nctId":24444,"briefTitle":24445,"status":110,"phases":24467,"primaryCompletion":497,"completion":497,"start":1051,"enrollment":24447,"conditions":24468,"interventions":24469},[],[24449],[24429,24451],{"intervention":24471,"totalTrials":180,"cells":24472},"critical care patients venofer",{"EARLY_PHASE1":24473,"PHASE1":24475,"PHASE2":24477,"PHASE3":24479,"PHASE4":24481,"NA":24483},{"trials":24474,"activeCount":102},[],{"trials":24476,"activeCount":102},[],{"trials":24478,"activeCount":102},[],{"trials":24480,"activeCount":102},[],{"trials":24482,"activeCount":102},[],{"trials":24484,"activeCount":102},[24485],{"nctId":24486,"briefTitle":24487,"status":139,"phases":24488,"primaryCompletion":536,"completion":266,"start":956,"enrollment":1108,"conditions":24489,"interventions":24490},"NCT01443624","Evaluation of Oxidative Stress Induced by Iron Injection in Healthy Volunteers and Critical Care Patients",[94],[4436],[24471],{"intervention":24492,"totalTrials":180,"cells":24493},"IVIg",{"EARLY_PHASE1":24494,"PHASE1":24496,"PHASE2":24498,"PHASE3":24500,"PHASE4":24502,"NA":24504},{"trials":24495,"activeCount":102},[],{"trials":24497,"activeCount":102},[],{"trials":24499,"activeCount":102},[],{"trials":24501,"activeCount":102},[],{"trials":24503,"activeCount":102},[],{"trials":24505,"activeCount":102},[24506],{"nctId":24507,"briefTitle":24508,"status":110,"phases":24509,"primaryCompletion":7865,"completion":21789,"start":1939,"enrollment":1130,"conditions":24510,"interventions":24514},"NCT02404298","Transcriptome Analysis of the Peripheral Blood in CIDP",[94],[24511,231,24512,24513],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Clarkson Syndrome","Muscular Autoimmune Disorders",[24492],{"intervention":24516,"totalTrials":180,"cells":24517},"Patient",{"EARLY_PHASE1":24518,"PHASE1":24520,"PHASE2":24522,"PHASE3":24524,"PHASE4":24526,"NA":24528},{"trials":24519,"activeCount":102},[],{"trials":24521,"activeCount":102},[],{"trials":24523,"activeCount":102},[],{"trials":24525,"activeCount":102},[],{"trials":24527,"activeCount":102},[],{"trials":24529,"activeCount":102},[24530],{"nctId":24531,"briefTitle":24532,"status":139,"phases":24533,"primaryCompletion":24534,"completion":24534,"start":24535,"enrollment":6224,"conditions":24536,"interventions":24538},"NCT01732185","Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations",[94],"2015-10-11","2012-10-11",[24537],"Congenital Cystic Adenomatoid Malformation (CCAM)",[24516],{"intervention":24540,"totalTrials":180,"cells":24541},"Cloxacillin",{"EARLY_PHASE1":24542,"PHASE1":24544,"PHASE2":24546,"PHASE3":24548,"PHASE4":24550,"NA":24552},{"trials":24543,"activeCount":102},[],{"trials":24545,"activeCount":102},[],{"trials":24547,"activeCount":102},[],{"trials":24549,"activeCount":102},[],{"trials":24551,"activeCount":102},[],{"trials":24553,"activeCount":102},[24554],{"nctId":24555,"briefTitle":24556,"status":139,"phases":24557,"primaryCompletion":4501,"completion":1497,"start":24558,"enrollment":12618,"conditions":24559,"interventions":24561},"NCT03248063","Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia",[94],"2018-09-05",[24560],"Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus",[24540,24562],"Cefazolin",{"intervention":24562,"totalTrials":180,"cells":24564},{"EARLY_PHASE1":24565,"PHASE1":24567,"PHASE2":24569,"PHASE3":24571,"PHASE4":24573,"NA":24575},{"trials":24566,"activeCount":102},[],{"trials":24568,"activeCount":102},[],{"trials":24570,"activeCount":102},[],{"trials":24572,"activeCount":102},[],{"trials":24574,"activeCount":102},[],{"trials":24576,"activeCount":102},[24577],{"nctId":24555,"briefTitle":24556,"status":139,"phases":24578,"primaryCompletion":4501,"completion":1497,"start":24558,"enrollment":12618,"conditions":24579,"interventions":24580},[94],[24560],[24540,24562],{"intervention":24582,"totalTrials":180,"cells":24583},"Identification of COMT HH, COMT HL or COMT LL genes",{"EARLY_PHASE1":24584,"PHASE1":24586,"PHASE2":24588,"PHASE3":24590,"PHASE4":24592,"NA":24594},{"trials":24585,"activeCount":102},[],{"trials":24587,"activeCount":102},[],{"trials":24589,"activeCount":102},[],{"trials":24591,"activeCount":102},[],{"trials":24593,"activeCount":102},[],{"trials":24595,"activeCount":102},[24596],{"nctId":24597,"briefTitle":24598,"status":139,"phases":24599,"primaryCompletion":20759,"completion":20759,"start":14556,"enrollment":1130,"conditions":24600,"interventions":24601},"NCT02869945","Compensation Mechanisms in Parkinson's Disease",[94],[22415],[24582],{"intervention":24603,"totalTrials":180,"cells":24604},"ocytocine dosage and genetic analyse",{"EARLY_PHASE1":24605,"PHASE1":24607,"PHASE2":24609,"PHASE3":24611,"PHASE4":24613,"NA":24615},{"trials":24606,"activeCount":102},[],{"trials":24608,"activeCount":102},[],{"trials":24610,"activeCount":102},[],{"trials":24612,"activeCount":102},[],{"trials":24614,"activeCount":102},[],{"trials":24616,"activeCount":102},[24617],{"nctId":24618,"briefTitle":24619,"status":110,"phases":24620,"primaryCompletion":24621,"completion":8148,"start":24622,"enrollment":677,"conditions":24623,"interventions":24625},"NCT04928053","COG-PSYCHO : Social Cognition and Psychotic Characteristics: Genetic and Phenomic Approach",[94],"2023-02-04","2019-02-04",[24624],"Social Cognition of Schizophrenia, Bipolas or Depressed Patients",[24603],{"intervention":24627,"totalTrials":180,"cells":24628},"Vaccination with MVA vaccine",{"EARLY_PHASE1":24629,"PHASE1":24631,"PHASE2":24633,"PHASE3":24635,"PHASE4":24637,"NA":24639},{"trials":24630,"activeCount":102},[],{"trials":24632,"activeCount":102},[],{"trials":24634,"activeCount":102},[],{"trials":24636,"activeCount":102},[],{"trials":24638,"activeCount":102},[],{"trials":24640,"activeCount":102},[24641],{"nctId":24642,"briefTitle":24643,"status":110,"phases":24644,"primaryCompletion":24645,"completion":24645,"start":24646,"enrollment":24647,"conditions":24648,"interventions":24651},"NCT05438953","Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study",[94],"2024-10","2022-07-12",164,[24649,24650],"Monkey Pox","Monkey Diseases",[24627],{"intervention":24653,"totalTrials":180,"cells":24654},"TNF-alpha antagonists",{"EARLY_PHASE1":24655,"PHASE1":24657,"PHASE2":24659,"PHASE3":24661,"PHASE4":24663,"NA":24665},{"trials":24656,"activeCount":102},[],{"trials":24658,"activeCount":102},[],{"trials":24660,"activeCount":102},[],{"trials":24662,"activeCount":102},[],{"trials":24664,"activeCount":102},[],{"trials":24666,"activeCount":102},[24667],{"nctId":24668,"briefTitle":24669,"status":110,"phases":24670,"start":24671,"conditions":24672,"interventions":24673},"NCT00224562","The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists",[],"2004-02",[32,19720,19716,19717],[24653],{"intervention":24675,"totalTrials":180,"cells":24676},"Blood Sampling and DNA collection",{"EARLY_PHASE1":24677,"PHASE1":24679,"PHASE2":24681,"PHASE3":24683,"PHASE4":24685,"NA":24687},{"trials":24678,"activeCount":102},[],{"trials":24680,"activeCount":102},[],{"trials":24682,"activeCount":102},[],{"trials":24684,"activeCount":102},[],{"trials":24686,"activeCount":102},[],{"trials":24688,"activeCount":102},[24689],{"nctId":24690,"briefTitle":24691,"status":139,"phases":24692,"primaryCompletion":5469,"completion":12093,"start":13849,"enrollment":24693,"conditions":24694,"interventions":24696},"NCT02319395","Behavioural Addiction and Genetics in Parkinson's Disease",[],332,[22415,24695],"Impulse Control Disorders",[24675],{"intervention":24698,"totalTrials":180,"cells":24699},"red blood transfusion",{"EARLY_PHASE1":24700,"PHASE1":24702,"PHASE2":24704,"PHASE3":24706,"PHASE4":24708,"NA":24710},{"trials":24701,"activeCount":102},[],{"trials":24703,"activeCount":102},[],{"trials":24705,"activeCount":102},[],{"trials":24707,"activeCount":102},[],{"trials":24709,"activeCount":102},[],{"trials":24711,"activeCount":102},[24712],{"nctId":24713,"briefTitle":24714,"status":139,"phases":24715,"primaryCompletion":11354,"completion":24716,"start":24717,"enrollment":24718,"conditions":24719,"interventions":24721},"NCT02648113","Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia.",[94],"2020-09-10","2016-03-23",668,[4742,13877,24720],"Blood Transfusion",[24698],{"intervention":24723,"totalTrials":180,"cells":24724},"Haemostasis tests",{"EARLY_PHASE1":24725,"PHASE1":24727,"PHASE2":24729,"PHASE3":24731,"PHASE4":24733,"NA":24735},{"trials":24726,"activeCount":102},[],{"trials":24728,"activeCount":102},[],{"trials":24730,"activeCount":102},[],{"trials":24732,"activeCount":102},[],{"trials":24734,"activeCount":102},[],{"trials":24736,"activeCount":102},[24737],{"nctId":24738,"briefTitle":24739,"status":139,"phases":24740,"primaryCompletion":6886,"completion":6886,"start":24741,"enrollment":3299,"conditions":24742,"interventions":24743},"NCT03424460","Venous Thromboembolism in Myotonic Dystrophy Type 1",[94],"2018-06-11",[3478],[24723,24744,24745],"Monocytes and megacaryocytes culture and RNA extraction","RNA extraction",{"intervention":24744,"totalTrials":180,"cells":24747},{"EARLY_PHASE1":24748,"PHASE1":24750,"PHASE2":24752,"PHASE3":24754,"PHASE4":24756,"NA":24758},{"trials":24749,"activeCount":102},[],{"trials":24751,"activeCount":102},[],{"trials":24753,"activeCount":102},[],{"trials":24755,"activeCount":102},[],{"trials":24757,"activeCount":102},[],{"trials":24759,"activeCount":102},[24760],{"nctId":24738,"briefTitle":24739,"status":139,"phases":24761,"primaryCompletion":6886,"completion":6886,"start":24741,"enrollment":3299,"conditions":24762,"interventions":24763},[94],[3478],[24723,24744,24745],{"intervention":24745,"totalTrials":180,"cells":24765},{"EARLY_PHASE1":24766,"PHASE1":24768,"PHASE2":24770,"PHASE3":24772,"PHASE4":24774,"NA":24776},{"trials":24767,"activeCount":102},[],{"trials":24769,"activeCount":102},[],{"trials":24771,"activeCount":102},[],{"trials":24773,"activeCount":102},[],{"trials":24775,"activeCount":102},[],{"trials":24777,"activeCount":102},[24778],{"nctId":24738,"briefTitle":24739,"status":139,"phases":24779,"primaryCompletion":6886,"completion":6886,"start":24741,"enrollment":3299,"conditions":24780,"interventions":24781},[94],[3478],[24723,24744,24745],{"intervention":24783,"totalTrials":180,"cells":24784},"blood and urine samples",{"EARLY_PHASE1":24785,"PHASE1":24787,"PHASE2":24789,"PHASE3":24791,"PHASE4":24793,"NA":24795},{"trials":24786,"activeCount":102},[],{"trials":24788,"activeCount":102},[],{"trials":24790,"activeCount":102},[],{"trials":24792,"activeCount":102},[],{"trials":24794,"activeCount":102},[],{"trials":24796,"activeCount":102},[24797],{"nctId":24798,"briefTitle":24799,"status":139,"phases":24800,"primaryCompletion":24801,"completion":24802,"start":24803,"enrollment":1277,"conditions":24804,"interventions":24807},"NCT01845402","Chronic Kidney Disease in Teenagers With Congenital Cardiac Disease",[],"2015-06-19","2015-06-20","2013-04-02",[24805,24806],"Chronic Kidney Failure","Congenital Heart Defects",[24783],{"intervention":24809,"totalTrials":180,"cells":24810},"the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis",{"EARLY_PHASE1":24811,"PHASE1":24813,"PHASE2":24815,"PHASE3":24817,"PHASE4":24819,"NA":24821},{"trials":24812,"activeCount":102},[],{"trials":24814,"activeCount":102},[],{"trials":24816,"activeCount":102},[],{"trials":24818,"activeCount":102},[],{"trials":24820,"activeCount":102},[],{"trials":24822,"activeCount":102},[24823],{"nctId":24824,"briefTitle":24825,"status":110,"phases":24826,"primaryCompletion":24827,"completion":9868,"start":24828,"enrollment":19187,"conditions":24829,"interventions":24830},"NCT04155086","\"Circulating Fetal DNA, Pregnancy And Immune Diseases\"",[94],"2020-01","2019-12",[231,4410],[24809],{"intervention":24832,"totalTrials":180,"cells":24833},"Blood test at time of inclusion for sFlt-1\u002FPlGF ratio",{"EARLY_PHASE1":24834,"PHASE1":24836,"PHASE2":24838,"PHASE3":24840,"PHASE4":24842,"NA":24844},{"trials":24835,"activeCount":102},[],{"trials":24837,"activeCount":102},[],{"trials":24839,"activeCount":102},[],{"trials":24841,"activeCount":102},[],{"trials":24843,"activeCount":102},[],{"trials":24845,"activeCount":102},[24846],{"nctId":24847,"briefTitle":24848,"status":110,"phases":24849,"primaryCompletion":1083,"completion":1083,"start":24850,"enrollment":24851,"conditions":24852,"interventions":24855},"NCT05151289","Diagnostic Value of sFlt-1\u002FPlGF Ratio for the Etiology of Intra Uterine Growth Restriction - ANGIOPAG",[94],"2020-01-08",152,[24853,24854],"Intrauterine Growth Restriction","Fetal Growth Restriction (FGR)",[24832,24856],"Follow-up blood test 2 to 4 weeks after inclusion",{"intervention":24856,"totalTrials":180,"cells":24858},{"EARLY_PHASE1":24859,"PHASE1":24861,"PHASE2":24863,"PHASE3":24865,"PHASE4":24867,"NA":24869},{"trials":24860,"activeCount":102},[],{"trials":24862,"activeCount":102},[],{"trials":24864,"activeCount":102},[],{"trials":24866,"activeCount":102},[],{"trials":24868,"activeCount":102},[],{"trials":24870,"activeCount":102},[24871],{"nctId":24847,"briefTitle":24848,"status":110,"phases":24872,"primaryCompletion":1083,"completion":1083,"start":24850,"enrollment":24851,"conditions":24873,"interventions":24874},[94],[24853,24854],[24832,24856],{"intervention":24876,"totalTrials":180,"cells":24877},"Biological sampling",{"EARLY_PHASE1":24878,"PHASE1":24880,"PHASE2":24882,"PHASE3":24884,"PHASE4":24886,"NA":24888},{"trials":24879,"activeCount":102},[],{"trials":24881,"activeCount":102},[],{"trials":24883,"activeCount":102},[],{"trials":24885,"activeCount":102},[],{"trials":24887,"activeCount":102},[],{"trials":24889,"activeCount":102},[24890],{"nctId":24891,"briefTitle":24892,"status":110,"phases":24893,"primaryCompletion":24894,"completion":8149,"start":24827,"enrollment":1130,"conditions":24895,"interventions":24899},"NCT04198402","Microbiotic Analysis in Digestive Endocrine Tumors",[],"2022-01",[24896,24897,24898],"Digestive Neuroendocrine Tumor","Fecal Microbiota","Bacterial Signature",[24876],{"intervention":24901,"totalTrials":180,"cells":24902},"IFT80 screening",{"EARLY_PHASE1":24903,"PHASE1":24905,"PHASE2":24907,"PHASE3":24909,"PHASE4":24911,"NA":24913},{"trials":24904,"activeCount":102},[],{"trials":24906,"activeCount":102},[],{"trials":24908,"activeCount":102},[],{"trials":24910,"activeCount":102},[],{"trials":24912,"activeCount":102},[],{"trials":24914,"activeCount":102},[24915],{"nctId":24916,"briefTitle":24917,"status":139,"phases":24918,"primaryCompletion":5163,"completion":5163,"start":9880,"enrollment":1130,"conditions":24919,"interventions":24921},"NCT00948376","Natural History of Asphyxiating Thoracic Dystrophy (DTJ)",[],[24920],"Asphyxiating Thoracic Dystrophy",[24901],{"intervention":24923,"totalTrials":180,"cells":24924},"analyzes in singles cells",{"EARLY_PHASE1":24925,"PHASE1":24927,"PHASE2":24929,"PHASE3":24931,"PHASE4":24933,"NA":24935},{"trials":24926,"activeCount":102},[],{"trials":24928,"activeCount":102},[],{"trials":24930,"activeCount":102},[],{"trials":24932,"activeCount":102},[],{"trials":24934,"activeCount":102},[],{"trials":24936,"activeCount":102},[24937],{"nctId":24938,"briefTitle":24939,"status":139,"phases":24940,"primaryCompletion":24941,"completion":24941,"start":19364,"enrollment":413,"conditions":24942,"interventions":24944},"NCT04987476","Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)",[],"2025-02-21",[24943],"ATRT",[24923],{"intervention":24946,"totalTrials":180,"cells":24947},"remifentanyl",{"EARLY_PHASE1":24948,"PHASE1":24950,"PHASE2":24952,"PHASE3":24954,"PHASE4":24956,"NA":24958},{"trials":24949,"activeCount":102},[],{"trials":24951,"activeCount":102},[],{"trials":24953,"activeCount":102},[],{"trials":24955,"activeCount":102},[],{"trials":24957,"activeCount":102},[],{"trials":24959,"activeCount":102},[24960],{"nctId":24961,"briefTitle":24962,"status":110,"phases":24963,"start":17079,"enrollment":1931,"conditions":24964,"interventions":24965},"NCT00162591","Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl",[94],[5146],[24946],{"intervention":24967,"totalTrials":180,"cells":24968},"Fluoroestradiol",{"EARLY_PHASE1":24969,"PHASE1":24971,"PHASE2":24973,"PHASE3":24975,"PHASE4":24977,"NA":24979},{"trials":24970,"activeCount":102},[],{"trials":24972,"activeCount":102},[],{"trials":24974,"activeCount":102},[],{"trials":24976,"activeCount":102},[],{"trials":24978,"activeCount":102},[],{"trials":24980,"activeCount":102},[24981],{"nctId":24982,"briefTitle":24983,"status":139,"phases":24984,"primaryCompletion":11094,"completion":11094,"start":5417,"enrollment":1314,"conditions":24985,"interventions":24987},"NCT01627704","Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer",[94],[24986],"Metastatic Breast Cancer",[24967],{"intervention":24989,"totalTrials":180,"cells":24990},"Physiopathology Endpoint Classification",{"EARLY_PHASE1":24991,"PHASE1":24993,"PHASE2":24995,"PHASE3":24997,"PHASE4":24999,"NA":25001},{"trials":24992,"activeCount":102},[],{"trials":24994,"activeCount":102},[],{"trials":24996,"activeCount":102},[],{"trials":24998,"activeCount":102},[],{"trials":25000,"activeCount":102},[],{"trials":25002,"activeCount":102},[25003],{"nctId":25004,"briefTitle":25005,"status":139,"phases":25006,"primaryCompletion":20619,"completion":522,"start":267,"enrollment":8340,"conditions":25007,"interventions":25008},"NCT01167491","Study of One Protein Implicated in Wegener Disease",[94],[424],[24989],{"intervention":25010,"totalTrials":180,"cells":25011},"Imipenem\u002FAmikacin",{"EARLY_PHASE1":25012,"PHASE1":25014,"PHASE2":25016,"PHASE3":25018,"PHASE4":25020,"NA":25022},{"trials":25013,"activeCount":102},[],{"trials":25015,"activeCount":102},[],{"trials":25017,"activeCount":102},[],{"trials":25019,"activeCount":102},[],{"trials":25021,"activeCount":102},[],{"trials":25023,"activeCount":102},[25024],{"nctId":25025,"briefTitle":25026,"status":139,"phases":25027,"primaryCompletion":10680,"completion":7961,"start":10507,"enrollment":400,"conditions":25028,"interventions":25029},"NCT00950222","Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic",[94],[1615],[25010],{"intervention":25031,"totalTrials":180,"cells":25032},"serology test",{"EARLY_PHASE1":25033,"PHASE1":25035,"PHASE2":25037,"PHASE3":25039,"PHASE4":25041,"NA":25043},{"trials":25034,"activeCount":102},[],{"trials":25036,"activeCount":102},[],{"trials":25038,"activeCount":102},[],{"trials":25040,"activeCount":102},[],{"trials":25042,"activeCount":102},[],{"trials":25044,"activeCount":102},[25045],{"nctId":25046,"briefTitle":25047,"status":139,"phases":25048,"primaryCompletion":5745,"completion":25049,"start":257,"enrollment":25050,"conditions":25051,"interventions":25053},"NCT04355533","Immunity Against SARS-CoV2 in Children and Their Parents \u002F COVID-19",[94],"2022-05-24",1056,[25052],"COVID-19 Infection",[25031,25054,25055,25056],"nasopharyngeal swab","rectal swab","saliva sample",{"intervention":25054,"totalTrials":180,"cells":25058},{"EARLY_PHASE1":25059,"PHASE1":25061,"PHASE2":25063,"PHASE3":25065,"PHASE4":25067,"NA":25069},{"trials":25060,"activeCount":102},[],{"trials":25062,"activeCount":102},[],{"trials":25064,"activeCount":102},[],{"trials":25066,"activeCount":102},[],{"trials":25068,"activeCount":102},[],{"trials":25070,"activeCount":102},[25071],{"nctId":25046,"briefTitle":25047,"status":139,"phases":25072,"primaryCompletion":5745,"completion":25049,"start":257,"enrollment":25050,"conditions":25073,"interventions":25074},[94],[25052],[25031,25054,25055,25056],{"intervention":25055,"totalTrials":180,"cells":25076},{"EARLY_PHASE1":25077,"PHASE1":25079,"PHASE2":25081,"PHASE3":25083,"PHASE4":25085,"NA":25087},{"trials":25078,"activeCount":102},[],{"trials":25080,"activeCount":102},[],{"trials":25082,"activeCount":102},[],{"trials":25084,"activeCount":102},[],{"trials":25086,"activeCount":102},[],{"trials":25088,"activeCount":102},[25089],{"nctId":25046,"briefTitle":25047,"status":139,"phases":25090,"primaryCompletion":5745,"completion":25049,"start":257,"enrollment":25050,"conditions":25091,"interventions":25092},[94],[25052],[25031,25054,25055,25056],{"intervention":25056,"totalTrials":180,"cells":25094},{"EARLY_PHASE1":25095,"PHASE1":25097,"PHASE2":25099,"PHASE3":25101,"PHASE4":25103,"NA":25105},{"trials":25096,"activeCount":102},[],{"trials":25098,"activeCount":102},[],{"trials":25100,"activeCount":102},[],{"trials":25102,"activeCount":102},[],{"trials":25104,"activeCount":102},[],{"trials":25106,"activeCount":102},[25107],{"nctId":25046,"briefTitle":25047,"status":139,"phases":25108,"primaryCompletion":5745,"completion":25049,"start":257,"enrollment":25050,"conditions":25109,"interventions":25110},[94],[25052],[25031,25054,25055,25056],{"intervention":25112,"totalTrials":180,"cells":25113},"Immediate intervention",{"EARLY_PHASE1":25114,"PHASE1":25116,"PHASE2":25118,"PHASE3":25120,"PHASE4":25122,"NA":25124},{"trials":25115,"activeCount":102},[],{"trials":25117,"activeCount":102},[],{"trials":25119,"activeCount":102},[],{"trials":25121,"activeCount":102},[],{"trials":25123,"activeCount":102},[],{"trials":25125,"activeCount":102},[25126],{"nctId":25127,"briefTitle":25128,"status":139,"phases":25129,"primaryCompletion":8413,"completion":14217,"start":10832,"enrollment":15241,"conditions":25130,"interventions":25135},"NCT02715440","Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions",[94],[25131,25132,25133,25134],"Elderly","Drug Therapy Syndrome","Substance-Related Disorders","Substance Withdrawal Syndrome",[25112],{"intervention":25137,"totalTrials":180,"cells":25138},"REGulatory T cells in Autism induced by maternal Immune activation",{"EARLY_PHASE1":25139,"PHASE1":25141,"PHASE2":25143,"PHASE3":25145,"PHASE4":25147,"NA":25149},{"trials":25140,"activeCount":102},[],{"trials":25142,"activeCount":102},[],{"trials":25144,"activeCount":102},[],{"trials":25146,"activeCount":102},[],{"trials":25148,"activeCount":102},[],{"trials":25150,"activeCount":102},[25151],{"nctId":25152,"briefTitle":25153,"status":110,"phases":25154,"primaryCompletion":13238,"completion":918,"start":25155,"enrollment":400,"conditions":25156,"interventions":25157},"NCT06169111","REGulatory T Cells in Autism Induced by Maternal Immune Activation",[94],"2024-01-01",[5408],[25137],{"intervention":25159,"totalTrials":180,"cells":25160},"Hydroxychloroquine Sulfate",{"EARLY_PHASE1":25161,"PHASE1":25163,"PHASE2":25165,"PHASE3":25167,"PHASE4":25169,"NA":25171},{"trials":25162,"activeCount":102},[],{"trials":25164,"activeCount":102},[],{"trials":25166,"activeCount":102},[],{"trials":25168,"activeCount":102},[],{"trials":25170,"activeCount":102},[],{"trials":25172,"activeCount":102},[25173],{"nctId":25174,"briefTitle":25175,"status":5932,"phases":25176,"primaryCompletion":25177,"completion":25177,"start":25177,"enrollment":102,"conditions":25178,"interventions":25180},"NCT04007562","Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency",[],"2019-11-04",[25179],"LIPIN1 Deficiency",[25159],{"intervention":25182,"totalTrials":180,"cells":25183},"Methylation Index",{"EARLY_PHASE1":25184,"PHASE1":25186,"PHASE2":25188,"PHASE3":25190,"PHASE4":25192,"NA":25194},{"trials":25185,"activeCount":102},[],{"trials":25187,"activeCount":102},[],{"trials":25189,"activeCount":102},[],{"trials":25191,"activeCount":102},[],{"trials":25193,"activeCount":102},[],{"trials":25195,"activeCount":102},[25196],{"nctId":25197,"briefTitle":25198,"status":110,"phases":25199,"primaryCompletion":977,"completion":1051,"start":5641,"enrollment":25200,"conditions":25201,"interventions":25203},"NCT01842659","Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes",[94],67,[25202],"Pregnant Women Requiring Amniocentesis",[25182],{"intervention":25205,"totalTrials":180,"cells":25206},"Stool sample",{"EARLY_PHASE1":25207,"PHASE1":25209,"PHASE2":25211,"PHASE3":25213,"PHASE4":25215,"NA":25217},{"trials":25208,"activeCount":102},[],{"trials":25210,"activeCount":102},[],{"trials":25212,"activeCount":102},[],{"trials":25214,"activeCount":102},[],{"trials":25216,"activeCount":102},[],{"trials":25218,"activeCount":102},[25219],{"nctId":25220,"briefTitle":25221,"status":110,"phases":25222,"primaryCompletion":8148,"completion":8148,"start":7129,"enrollment":1931,"conditions":25223,"interventions":25226},"NCT05481554","Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency",[],[25224,25225],"Common Variable Immunodeficiency","Vascular Diseases",[25205],{"intervention":25228,"totalTrials":180,"cells":25229},"Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.",{"EARLY_PHASE1":25230,"PHASE1":25232,"PHASE2":25234,"PHASE3":25236,"PHASE4":25238,"NA":25240},{"trials":25231,"activeCount":102},[],{"trials":25233,"activeCount":102},[],{"trials":25235,"activeCount":102},[],{"trials":25237,"activeCount":102},[],{"trials":25239,"activeCount":102},[],{"trials":25241,"activeCount":102},[25242],{"nctId":25243,"briefTitle":25244,"status":139,"phases":25245,"primaryCompletion":25246,"completion":25247,"start":25248,"enrollment":21,"conditions":25249,"interventions":25252},"NCT05418686","Study of Colchicine Resistance in Familial Mediterranean Fever",[94],"2023-07-04","2023-10-27","2022-12-09",[25250,25251],"Mediterranean Fever","Colchicine Resistance",[25228],{"intervention":25254,"totalTrials":180,"cells":25255},"blood additional samples",{"EARLY_PHASE1":25256,"PHASE1":25258,"PHASE2":25260,"PHASE3":25262,"PHASE4":25264,"NA":25266},{"trials":25257,"activeCount":102},[],{"trials":25259,"activeCount":102},[],{"trials":25261,"activeCount":102},[],{"trials":25263,"activeCount":102},[],{"trials":25265,"activeCount":102},[],{"trials":25267,"activeCount":102},[25268],{"nctId":25269,"briefTitle":25270,"status":110,"phases":25271,"primaryCompletion":25272,"completion":1730,"start":25273,"enrollment":303,"conditions":25274,"interventions":25275},"NCT03385499","New Diagnostic Approach for Congenital Toxoplasmosis",[94],"2020-05","2018-06-21",[14628],[25254],{"intervention":25277,"totalTrials":180,"cells":25278},"Cefoxitin",{"EARLY_PHASE1":25279,"PHASE1":25281,"PHASE2":25283,"PHASE3":25285,"PHASE4":25287,"NA":25289},{"trials":25280,"activeCount":102},[],{"trials":25282,"activeCount":102},[],{"trials":25284,"activeCount":102},[],{"trials":25286,"activeCount":102},[],{"trials":25288,"activeCount":102},[],{"trials":25290,"activeCount":102},[25291],{"nctId":25292,"briefTitle":25293,"status":241,"phases":25294,"primaryCompletion":10532,"completion":5469,"start":5641,"enrollment":24112,"conditions":25295,"interventions":25297},"NCT01820793","Efficacy and Pharmacokinetic\u002FPharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli",[94],[25296],"Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli",[25277],{"intervention":25299,"totalTrials":180,"cells":25300},"Genetic",{"EARLY_PHASE1":25301,"PHASE1":25303,"PHASE2":25305,"PHASE3":25307,"PHASE4":25309,"NA":25311},{"trials":25302,"activeCount":102},[],{"trials":25304,"activeCount":102},[],{"trials":25306,"activeCount":102},[],{"trials":25308,"activeCount":102},[],{"trials":25310,"activeCount":102},[],{"trials":25312,"activeCount":102},[25313],{"nctId":25314,"briefTitle":25315,"status":139,"phases":25316,"primaryCompletion":8063,"completion":8063,"start":7961,"enrollment":21790,"conditions":25317,"interventions":25320},"NCT02167568","Corpus Callosum Agenesis and Intellectual Disability",[],[25318,25319],"Intellectual Deficiency","Cerebral Abnormality",[25299],{"intervention":25322,"totalTrials":180,"cells":25323},"Peripheral blood puncture",{"EARLY_PHASE1":25324,"PHASE1":25326,"PHASE2":25328,"PHASE3":25330,"PHASE4":25332,"NA":25334},{"trials":25325,"activeCount":102},[],{"trials":25327,"activeCount":102},[],{"trials":25329,"activeCount":102},[],{"trials":25331,"activeCount":102},[],{"trials":25333,"activeCount":102},[],{"trials":25335,"activeCount":102},[25336],{"nctId":25337,"briefTitle":25338,"status":139,"phases":25339,"primaryCompletion":25340,"completion":25340,"start":25341,"enrollment":473,"conditions":25342,"interventions":25344},"NCT03250728","Role of the Endothelium in Stroke-like Episode Among CDG Patients",[94],"2019-04-26","2017-11-23",[25343],"Congenital Disorders of Glycosylation",[25322],{"intervention":25346,"totalTrials":180,"cells":25347},"Trinitrin",{"EARLY_PHASE1":25348,"PHASE1":25350,"PHASE2":25352,"PHASE3":25354,"PHASE4":25356,"NA":25358},{"trials":25349,"activeCount":102},[],{"trials":25351,"activeCount":102},[],{"trials":25353,"activeCount":102},[],{"trials":25355,"activeCount":102},[],{"trials":25357,"activeCount":102},[],{"trials":25359,"activeCount":102},[25360],{"nctId":25361,"briefTitle":25362,"status":139,"phases":25363,"primaryCompletion":5163,"completion":5163,"start":10067,"enrollment":15427,"conditions":25364,"interventions":25366},"NCT01097551","Endothelial Dysfunction and Diabetes",[],[25365],"Type 1 Diabetes Mellitus",[25346,25367,25368],"Neosynephrine 10% collyrium","Iontophoresis with acetylcholine delivery",{"intervention":25367,"totalTrials":180,"cells":25370},{"EARLY_PHASE1":25371,"PHASE1":25373,"PHASE2":25375,"PHASE3":25377,"PHASE4":25379,"NA":25381},{"trials":25372,"activeCount":102},[],{"trials":25374,"activeCount":102},[],{"trials":25376,"activeCount":102},[],{"trials":25378,"activeCount":102},[],{"trials":25380,"activeCount":102},[],{"trials":25382,"activeCount":102},[25383],{"nctId":25361,"briefTitle":25362,"status":139,"phases":25384,"primaryCompletion":5163,"completion":5163,"start":10067,"enrollment":15427,"conditions":25385,"interventions":25386},[],[25365],[25346,25367,25368],{"intervention":25368,"totalTrials":180,"cells":25388},{"EARLY_PHASE1":25389,"PHASE1":25391,"PHASE2":25393,"PHASE3":25395,"PHASE4":25397,"NA":25399},{"trials":25390,"activeCount":102},[],{"trials":25392,"activeCount":102},[],{"trials":25394,"activeCount":102},[],{"trials":25396,"activeCount":102},[],{"trials":25398,"activeCount":102},[],{"trials":25400,"activeCount":102},[25401],{"nctId":25361,"briefTitle":25362,"status":139,"phases":25402,"primaryCompletion":5163,"completion":5163,"start":10067,"enrollment":15427,"conditions":25403,"interventions":25404},[],[25365],[25346,25367,25368],{"intervention":25406,"totalTrials":180,"cells":25407},"blood tests",{"EARLY_PHASE1":25408,"PHASE1":25410,"PHASE2":25412,"PHASE3":25414,"PHASE4":25416,"NA":25418},{"trials":25409,"activeCount":102},[],{"trials":25411,"activeCount":102},[],{"trials":25413,"activeCount":102},[],{"trials":25415,"activeCount":102},[],{"trials":25417,"activeCount":102},[],{"trials":25419,"activeCount":102},[25420],{"nctId":25421,"briefTitle":25422,"status":241,"phases":25423,"primaryCompletion":16999,"completion":16999,"start":19561,"enrollment":1330,"conditions":25424,"interventions":25425},"NCT04584541","SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism",[94],[5271,32,26],[25406,25426,25427],"Nasopharyngeal swabs","Stools",{"intervention":25426,"totalTrials":180,"cells":25429},{"EARLY_PHASE1":25430,"PHASE1":25432,"PHASE2":25434,"PHASE3":25436,"PHASE4":25438,"NA":25440},{"trials":25431,"activeCount":102},[],{"trials":25433,"activeCount":102},[],{"trials":25435,"activeCount":102},[],{"trials":25437,"activeCount":102},[],{"trials":25439,"activeCount":102},[],{"trials":25441,"activeCount":102},[25442],{"nctId":25421,"briefTitle":25422,"status":241,"phases":25443,"primaryCompletion":16999,"completion":16999,"start":19561,"enrollment":1330,"conditions":25444,"interventions":25445},[94],[5271,32,26],[25406,25426,25427],{"intervention":25427,"totalTrials":180,"cells":25447},{"EARLY_PHASE1":25448,"PHASE1":25450,"PHASE2":25452,"PHASE3":25454,"PHASE4":25456,"NA":25458},{"trials":25449,"activeCount":102},[],{"trials":25451,"activeCount":102},[],{"trials":25453,"activeCount":102},[],{"trials":25455,"activeCount":102},[],{"trials":25457,"activeCount":102},[],{"trials":25459,"activeCount":102},[25460],{"nctId":25421,"briefTitle":25422,"status":241,"phases":25461,"primaryCompletion":16999,"completion":16999,"start":19561,"enrollment":1330,"conditions":25462,"interventions":25463},[94],[5271,32,26],[25406,25426,25427],{"intervention":25465,"totalTrials":180,"cells":25466},"Intralipid 20%®",{"EARLY_PHASE1":25467,"PHASE1":25469,"PHASE2":25471,"PHASE3":25473,"PHASE4":25475,"NA":25477},{"trials":25468,"activeCount":102},[],{"trials":25470,"activeCount":102},[],{"trials":25472,"activeCount":102},[],{"trials":25474,"activeCount":102},[],{"trials":25476,"activeCount":102},[],{"trials":25478,"activeCount":102},[25479],{"nctId":25480,"briefTitle":25481,"status":139,"phases":25482,"primaryCompletion":12215,"completion":12093,"start":13849,"enrollment":8742,"conditions":25483,"interventions":25485},"NCT01284049","Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease",[94],[25484],"Liver Diseases",[25465,25486],"OMEGAVEN 10%®",{"intervention":25486,"totalTrials":180,"cells":25488},{"EARLY_PHASE1":25489,"PHASE1":25491,"PHASE2":25493,"PHASE3":25495,"PHASE4":25497,"NA":25499},{"trials":25490,"activeCount":102},[],{"trials":25492,"activeCount":102},[],{"trials":25494,"activeCount":102},[],{"trials":25496,"activeCount":102},[],{"trials":25498,"activeCount":102},[],{"trials":25500,"activeCount":102},[25501],{"nctId":25480,"briefTitle":25481,"status":139,"phases":25502,"primaryCompletion":12215,"completion":12093,"start":13849,"enrollment":8742,"conditions":25503,"interventions":25504},[94],[25484],[25465,25486],{"intervention":25506,"totalTrials":180,"cells":25507},"Ddimer testing",{"EARLY_PHASE1":25508,"PHASE1":25510,"PHASE2":25512,"PHASE3":25514,"PHASE4":25516,"NA":25518},{"trials":25509,"activeCount":102},[],{"trials":25511,"activeCount":102},[],{"trials":25513,"activeCount":102},[],{"trials":25515,"activeCount":102},[],{"trials":25517,"activeCount":102},[],{"trials":25519,"activeCount":102},[25520],{"nctId":25521,"briefTitle":25522,"status":139,"phases":25523,"primaryCompletion":25524,"completion":25524,"start":25525,"enrollment":25526,"conditions":25527,"interventions":25529},"NCT03487237","Prevalence of PE in ED Patients With Isolated Syncope",[94],"2018-12-18","2018-05-23",459,[25528],"Syncope",[25506],{"intervention":25531,"totalTrials":180,"cells":25532},"Blood and urine collection",{"EARLY_PHASE1":25533,"PHASE1":25535,"PHASE2":25537,"PHASE3":25539,"PHASE4":25541,"NA":25543},{"trials":25534,"activeCount":102},[],{"trials":25536,"activeCount":102},[],{"trials":25538,"activeCount":102},[],{"trials":25540,"activeCount":102},[],{"trials":25542,"activeCount":102},[],{"trials":25544,"activeCount":102},[25545],{"nctId":25546,"briefTitle":25547,"status":241,"phases":25548,"primaryCompletion":227,"completion":227,"start":25549,"enrollment":429,"conditions":25550,"interventions":25551},"NCT04111809","Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care",[],"2020-09-29",[1768],[25531],{"intervention":25553,"totalTrials":180,"cells":25554},"cocktail probe drugs",{"EARLY_PHASE1":25555,"PHASE1":25557,"PHASE2":25559,"PHASE3":25561,"PHASE4":25563,"NA":25565},{"trials":25556,"activeCount":102},[],{"trials":25558,"activeCount":102},[],{"trials":25560,"activeCount":102},[],{"trials":25562,"activeCount":102},[],{"trials":25564,"activeCount":102},[],{"trials":25566,"activeCount":102},[25567],{"nctId":25568,"briefTitle":25569,"status":110,"phases":25570,"primaryCompletion":24828,"completion":8214,"start":977,"enrollment":25571,"conditions":25572,"interventions":25574},"NCT02590185","MetAbolism vaRiability of VEnLafaxine",[94],205,[25573],"Major Depressive Disorders",[25553],{"intervention":25576,"totalTrials":180,"cells":25577},"Donor specific antibodies",{"EARLY_PHASE1":25578,"PHASE1":25580,"PHASE2":25582,"PHASE3":25584,"PHASE4":25586,"NA":25588},{"trials":25579,"activeCount":102},[],{"trials":25581,"activeCount":102},[],{"trials":25583,"activeCount":102},[],{"trials":25585,"activeCount":102},[],{"trials":25587,"activeCount":102},[],{"trials":25589,"activeCount":102},[25590],{"nctId":25591,"briefTitle":25592,"status":110,"phases":25593,"primaryCompletion":9867,"completion":9867,"start":25594,"enrollment":3149,"conditions":25595,"interventions":25598},"NCT02556879","Immunization Anti HLA in the Liver Transplant Recipients (DSATH)",[94],"2016-03-09",[25596,25597],"Liver Transplantation","Graft Failure",[25576,25599,25600],"Serum bank","DNA bank",{"intervention":25599,"totalTrials":180,"cells":25602},{"EARLY_PHASE1":25603,"PHASE1":25605,"PHASE2":25607,"PHASE3":25609,"PHASE4":25611,"NA":25613},{"trials":25604,"activeCount":102},[],{"trials":25606,"activeCount":102},[],{"trials":25608,"activeCount":102},[],{"trials":25610,"activeCount":102},[],{"trials":25612,"activeCount":102},[],{"trials":25614,"activeCount":102},[25615],{"nctId":25591,"briefTitle":25592,"status":110,"phases":25616,"primaryCompletion":9867,"completion":9867,"start":25594,"enrollment":3149,"conditions":25617,"interventions":25618},[94],[25596,25597],[25576,25599,25600],{"intervention":25600,"totalTrials":180,"cells":25620},{"EARLY_PHASE1":25621,"PHASE1":25623,"PHASE2":25625,"PHASE3":25627,"PHASE4":25629,"NA":25631},{"trials":25622,"activeCount":102},[],{"trials":25624,"activeCount":102},[],{"trials":25626,"activeCount":102},[],{"trials":25628,"activeCount":102},[],{"trials":25630,"activeCount":102},[],{"trials":25632,"activeCount":102},[25633],{"nctId":25591,"briefTitle":25592,"status":110,"phases":25634,"primaryCompletion":9867,"completion":9867,"start":25594,"enrollment":3149,"conditions":25635,"interventions":25636},[94],[25596,25597],[25576,25599,25600],{"intervention":25638,"totalTrials":180,"cells":25639},"Bacteriological analyses on clinical samples performed with swabs",{"EARLY_PHASE1":25640,"PHASE1":25642,"PHASE2":25644,"PHASE3":25646,"PHASE4":25648,"NA":25650},{"trials":25641,"activeCount":102},[],{"trials":25643,"activeCount":102},[],{"trials":25645,"activeCount":102},[],{"trials":25647,"activeCount":102},[],{"trials":25649,"activeCount":102},[],{"trials":25651,"activeCount":102},[25652],{"nctId":25653,"briefTitle":25654,"status":139,"phases":25655,"primaryCompletion":25656,"completion":25657,"start":23981,"enrollment":25658,"conditions":25659,"interventions":25661},"NCT03371056","Maternal- Fetal Infection",[94],"2023-08-30","2023-12-30",2569,[25660],"Neonatal Infection",[25638],{"intervention":25663,"totalTrials":180,"cells":25664},"Best medical treatment alone",{"EARLY_PHASE1":25665,"PHASE1":25667,"PHASE2":25669,"PHASE3":25671,"PHASE4":25673,"NA":25675},{"trials":25666,"activeCount":102},[],{"trials":25668,"activeCount":102},[],{"trials":25670,"activeCount":102},[],{"trials":25672,"activeCount":102},[],{"trials":25674,"activeCount":102},[],{"trials":25676,"activeCount":102},[25677],{"nctId":25678,"briefTitle":25679,"status":110,"phases":25680,"primaryCompletion":25681,"completion":25681,"start":25682,"enrollment":25683,"conditions":25684,"interventions":25686},"NCT05030142","Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion",[94],"2024-02-14","2021-11-14",488,[25685],"Acute Ischemic Stroke (AIS) Related to a Distal Occlusion",[25663],{"intervention":8240,"totalTrials":180,"cells":25688},{"EARLY_PHASE1":25689,"PHASE1":25691,"PHASE2":25693,"PHASE3":25695,"PHASE4":25697,"NA":25699},{"trials":25690,"activeCount":102},[],{"trials":25692,"activeCount":102},[],{"trials":25694,"activeCount":102},[],{"trials":25696,"activeCount":102},[],{"trials":25698,"activeCount":102},[],{"trials":25700,"activeCount":102},[25701],{"nctId":8232,"briefTitle":8233,"status":139,"phases":25702,"primaryCompletion":5417,"completion":5417,"start":8235,"enrollment":8236,"conditions":25703,"interventions":25704},[],[8238,29],[8240,8241],{"intervention":25706,"totalTrials":180,"cells":25707},"Tricyclic antidepressants",{"EARLY_PHASE1":25708,"PHASE1":25710,"PHASE2":25712,"PHASE3":25714,"PHASE4":25716,"NA":25718},{"trials":25709,"activeCount":102},[],{"trials":25711,"activeCount":102},[],{"trials":25713,"activeCount":102},[],{"trials":25715,"activeCount":102},[],{"trials":25717,"activeCount":102},[],{"trials":25719,"activeCount":102},[25720],{"nctId":25721,"briefTitle":25722,"status":139,"phases":25723,"primaryCompletion":9996,"completion":9996,"start":9880,"enrollment":25724,"conditions":25725,"interventions":25727},"NCT00526383","Do Antidepressants Induce Metabolic Syndromes METADAP Study",[94],624,[25726],"Major Depressive Disorder",[25706],{"intervention":25729,"totalTrials":180,"cells":25730},"DNA samples, GAS strains",{"EARLY_PHASE1":25731,"PHASE1":25733,"PHASE2":25735,"PHASE3":25737,"PHASE4":25739,"NA":25741},{"trials":25732,"activeCount":102},[],{"trials":25734,"activeCount":102},[],{"trials":25736,"activeCount":102},[],{"trials":25738,"activeCount":102},[],{"trials":25740,"activeCount":102},[],{"trials":25742,"activeCount":102},[25743],{"nctId":25744,"briefTitle":25745,"status":139,"phases":25746,"primaryCompletion":25747,"completion":25748,"start":25749,"enrollment":25750,"conditions":25751,"interventions":25753},"NCT02010294","Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and\u002For Genetic Factors of Predisposition to Infections",[],"2018-02-10","2018-07-20","2014-02-10",223,[25752],"Invasive GAS Infection",[25729],{"intervention":8261,"totalTrials":180,"cells":25755},{"EARLY_PHASE1":25756,"PHASE1":25758,"PHASE2":25760,"PHASE3":25762,"PHASE4":25764,"NA":25766},{"trials":25757,"activeCount":102},[],{"trials":25759,"activeCount":102},[],{"trials":25761,"activeCount":102},[],{"trials":25763,"activeCount":102},[],{"trials":25765,"activeCount":102},[],{"trials":25767,"activeCount":102},[25768],{"nctId":8252,"briefTitle":8253,"status":139,"phases":25769,"primaryCompletion":5724,"completion":5724,"start":8255,"enrollment":36,"conditions":25770,"interventions":25771},[],[8257,8258,8259],[8196,8261],{"intervention":25773,"totalTrials":180,"cells":25774},"VAXIGRIPPE",{"EARLY_PHASE1":25775,"PHASE1":25777,"PHASE2":25779,"PHASE3":25781,"PHASE4":25783,"NA":25785},{"trials":25776,"activeCount":102},[],{"trials":25778,"activeCount":102},[],{"trials":25780,"activeCount":102},[],{"trials":25782,"activeCount":102},[],{"trials":25784,"activeCount":102},[],{"trials":25786,"activeCount":102},[25787],{"nctId":25788,"briefTitle":25789,"status":241,"phases":25790,"completion":1708,"start":11197,"enrollment":25791,"conditions":25792,"interventions":25794},"NCT00359554","Influenza Vaccination of Nursing Home Workers.",[94],4000,[25793],"Influenza Disease",[25773],{"intervention":25796,"totalTrials":180,"cells":25797},"Inhaled Bronchodilators +\u002F- Inhaled Methacholine",{"EARLY_PHASE1":25798,"PHASE1":25800,"PHASE2":25802,"PHASE3":25804,"PHASE4":25806,"NA":25808},{"trials":25799,"activeCount":102},[],{"trials":25801,"activeCount":102},[],{"trials":25803,"activeCount":102},[],{"trials":25805,"activeCount":102},[],{"trials":25807,"activeCount":102},[],{"trials":25809,"activeCount":102},[25810],{"nctId":25811,"briefTitle":25812,"status":110,"phases":25813,"primaryCompletion":24828,"completion":24828,"start":21330,"enrollment":20807,"conditions":25814,"interventions":25816},"NCT03062904","Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects",[94],[25815],"Paradoxical Fall in Maximum Expiratory Flows",[25796],{"intervention":25818,"totalTrials":180,"cells":25819},"blood samples and skin biopsies",{"EARLY_PHASE1":25820,"PHASE1":25822,"PHASE2":25824,"PHASE3":25826,"PHASE4":25828,"NA":25830},{"trials":25821,"activeCount":102},[],{"trials":25823,"activeCount":102},[],{"trials":25825,"activeCount":102},[],{"trials":25827,"activeCount":102},[],{"trials":25829,"activeCount":102},[],{"trials":25831,"activeCount":102},[25832],{"nctId":25833,"briefTitle":25834,"status":139,"phases":25835,"primaryCompletion":9996,"completion":12380,"start":10260,"enrollment":1029,"conditions":25836,"interventions":25839},"NCT01114035","Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE)",[94],[25837,25838],"Intestinal Epithelial Dysplasia","Tufting Enteropathy",[25818,25840],"Skin biopsies",{"intervention":25840,"totalTrials":180,"cells":25842},{"EARLY_PHASE1":25843,"PHASE1":25845,"PHASE2":25847,"PHASE3":25849,"PHASE4":25851,"NA":25853},{"trials":25844,"activeCount":102},[],{"trials":25846,"activeCount":102},[],{"trials":25848,"activeCount":102},[],{"trials":25850,"activeCount":102},[],{"trials":25852,"activeCount":102},[],{"trials":25854,"activeCount":102},[25855],{"nctId":25833,"briefTitle":25834,"status":139,"phases":25856,"primaryCompletion":9996,"completion":12380,"start":10260,"enrollment":1029,"conditions":25857,"interventions":25858},[94],[25837,25838],[25818,25840],{"intervention":7978,"totalTrials":180,"cells":25860},{"EARLY_PHASE1":25861,"PHASE1":25863,"PHASE2":25865,"PHASE3":25867,"PHASE4":25869,"NA":25871},{"trials":25862,"activeCount":102},[],{"trials":25864,"activeCount":102},[],{"trials":25866,"activeCount":102},[],{"trials":25868,"activeCount":102},[],{"trials":25870,"activeCount":102},[],{"trials":25872,"activeCount":102},[25873],{"nctId":7969,"briefTitle":7970,"status":139,"phases":25874,"primaryCompletion":7972,"completion":7972,"start":7973,"enrollment":7974,"conditions":25875,"interventions":25876},[94],[7976],[7921,7978],{"intervention":25878,"totalTrials":180,"cells":25879},"Enalapril",{"EARLY_PHASE1":25880,"PHASE1":25882,"PHASE2":25884,"PHASE3":25886,"PHASE4":25888,"NA":25890},{"trials":25881,"activeCount":102},[],{"trials":25883,"activeCount":102},[],{"trials":25885,"activeCount":102},[],{"trials":25887,"activeCount":102},[],{"trials":25889,"activeCount":102},[],{"trials":25891,"activeCount":102},[25892],{"nctId":25893,"briefTitle":25894,"status":241,"phases":25895,"primaryCompletion":7961,"completion":5417,"start":14737,"enrollment":98,"conditions":25896,"interventions":25897},"NCT01096121","Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children",[94],[20],[25878],{"intervention":25899,"totalTrials":180,"cells":25900},"serum punction",{"EARLY_PHASE1":25901,"PHASE1":25903,"PHASE2":25905,"PHASE3":25907,"PHASE4":25909,"NA":25911},{"trials":25902,"activeCount":102},[],{"trials":25904,"activeCount":102},[],{"trials":25906,"activeCount":102},[],{"trials":25908,"activeCount":102},[],{"trials":25910,"activeCount":102},[],{"trials":25912,"activeCount":102},[25913],{"nctId":25914,"briefTitle":25915,"status":241,"phases":25916,"primaryCompletion":25917,"completion":25917,"start":25917,"enrollment":180,"conditions":25918,"interventions":25921},"NCT05247567","Quaternary Ammonium and Immunization in Hairdressers",[94],"2022-10-27",[25919,25920],"Quaternary Ammonium","Hypersensitivity",[25899,25922],"skin swab in elbow folds",{"intervention":25922,"totalTrials":180,"cells":25924},{"EARLY_PHASE1":25925,"PHASE1":25927,"PHASE2":25929,"PHASE3":25931,"PHASE4":25933,"NA":25935},{"trials":25926,"activeCount":102},[],{"trials":25928,"activeCount":102},[],{"trials":25930,"activeCount":102},[],{"trials":25932,"activeCount":102},[],{"trials":25934,"activeCount":102},[],{"trials":25936,"activeCount":102},[25937],{"nctId":25914,"briefTitle":25915,"status":241,"phases":25938,"primaryCompletion":25917,"completion":25917,"start":25917,"enrollment":180,"conditions":25939,"interventions":25940},[94],[25919,25920],[25899,25922],{"intervention":25942,"totalTrials":180,"cells":25943},"Biological testing on sequential blood sample",{"EARLY_PHASE1":25944,"PHASE1":25946,"PHASE2":25948,"PHASE3":25950,"PHASE4":25952,"NA":25954},{"trials":25945,"activeCount":102},[],{"trials":25947,"activeCount":102},[],{"trials":25949,"activeCount":102},[],{"trials":25951,"activeCount":102},[],{"trials":25953,"activeCount":102},[],{"trials":25955,"activeCount":102},[25956],{"nctId":25957,"briefTitle":25958,"status":139,"phases":25959,"primaryCompletion":25960,"completion":25960,"start":312,"enrollment":15216,"conditions":25961,"interventions":25963},"NCT04302246","Immune Function Following Liver Transplantation",[],"2019-12-17",[25962],"Liver Transplant; Complications",[25942],{"intervention":25965,"totalTrials":180,"cells":25966},"mRNAs encoding genes",{"EARLY_PHASE1":25967,"PHASE1":25969,"PHASE2":25971,"PHASE3":25973,"PHASE4":25975,"NA":25977},{"trials":25968,"activeCount":102},[],{"trials":25970,"activeCount":102},[],{"trials":25972,"activeCount":102},[],{"trials":25974,"activeCount":102},[],{"trials":25976,"activeCount":102},[],{"trials":25978,"activeCount":102},[25979],{"nctId":25980,"briefTitle":25981,"status":139,"phases":25982,"primaryCompletion":25983,"completion":25983,"start":1587,"enrollment":489,"conditions":25984,"interventions":25987},"NCT01380847","Prediction of Chronic Allograft Nephropathy",[],"2012-04-19",[7999,25985,25986],"Kidney Disease","Kidney Failure, Chronic",[25965],{"intervention":24047,"totalTrials":180,"cells":25989},{"EARLY_PHASE1":25990,"PHASE1":25992,"PHASE2":25994,"PHASE3":25996,"PHASE4":25998,"NA":26000},{"trials":25991,"activeCount":102},[],{"trials":25993,"activeCount":102},[],{"trials":25995,"activeCount":102},[],{"trials":25997,"activeCount":102},[],{"trials":25999,"activeCount":102},[],{"trials":26001,"activeCount":102},[26002],{"nctId":24037,"briefTitle":24038,"status":139,"phases":26003,"primaryCompletion":24040,"completion":24040,"start":24041,"enrollment":24042,"conditions":26004,"interventions":26005},[],[24044,24045],[24022,24047],{"intervention":26007,"totalTrials":180,"cells":26008},"sample",{"EARLY_PHASE1":26009,"PHASE1":26011,"PHASE2":26013,"PHASE3":26015,"PHASE4":26017,"NA":26019},{"trials":26010,"activeCount":102},[],{"trials":26012,"activeCount":102},[],{"trials":26014,"activeCount":102},[],{"trials":26016,"activeCount":102},[],{"trials":26018,"activeCount":102},[],{"trials":26020,"activeCount":102},[26021],{"nctId":26022,"briefTitle":26023,"status":139,"phases":26024,"primaryCompletion":11220,"completion":11220,"start":5163,"enrollment":291,"conditions":26025,"interventions":26027},"NCT02686359","Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)",[94],[26026],"Burning Mouth Syndrome",[26007],{"intervention":26029,"totalTrials":180,"cells":26030},"Fish oil",{"EARLY_PHASE1":26031,"PHASE1":26033,"PHASE2":26035,"PHASE3":26037,"PHASE4":26039,"NA":26041},{"trials":26032,"activeCount":102},[],{"trials":26034,"activeCount":102},[],{"trials":26036,"activeCount":102},[],{"trials":26038,"activeCount":102},[],{"trials":26040,"activeCount":102},[],{"trials":26042,"activeCount":102},[26043],{"nctId":26044,"briefTitle":26045,"status":241,"phases":26046,"completion":11837,"start":26047,"enrollment":27,"conditions":26048,"interventions":26049},"NCT00371982","Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women",[94],"2002-12",[3503],[26029],{"intervention":26051,"totalTrials":180,"cells":26052},"Intravenous Sodium Valproate",{"EARLY_PHASE1":26053,"PHASE1":26055,"PHASE2":26057,"PHASE3":26059,"PHASE4":26061,"NA":26063},{"trials":26054,"activeCount":102},[],{"trials":26056,"activeCount":102},[],{"trials":26058,"activeCount":102},[],{"trials":26060,"activeCount":102},[],{"trials":26062,"activeCount":102},[],{"trials":26064,"activeCount":102},[26065],{"nctId":26066,"briefTitle":26067,"status":139,"phases":26068,"primaryCompletion":1577,"completion":12696,"start":5162,"enrollment":26069,"conditions":26070,"interventions":26073},"NCT01791868","Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.",[94],245,[26071,26072],"Generalized Convulsive Status Epilepticus","Intensive Care Unit",[26051],{"intervention":26075,"totalTrials":180,"cells":26076},"Hydroxycarbamide, Hydroxyurea",{"EARLY_PHASE1":26077,"PHASE1":26079,"PHASE2":26081,"PHASE3":26083,"PHASE4":26085,"NA":26087},{"trials":26078,"activeCount":102},[],{"trials":26080,"activeCount":102},[],{"trials":26082,"activeCount":102},[],{"trials":26084,"activeCount":102},[],{"trials":26086,"activeCount":102},[],{"trials":26088,"activeCount":102},[26089],{"nctId":26090,"briefTitle":26091,"status":139,"phases":26092,"primaryCompletion":13760,"completion":12216,"start":17169,"enrollment":1202,"conditions":26093,"interventions":26094},"NCT00784082","Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease",[],[20],[26075],{"intervention":26096,"totalTrials":180,"cells":26097},"Gefitinib",{"EARLY_PHASE1":26098,"PHASE1":26100,"PHASE2":26102,"PHASE3":26104,"PHASE4":26106,"NA":26108},{"trials":26099,"activeCount":102},[],{"trials":26101,"activeCount":102},[],{"trials":26103,"activeCount":102},[],{"trials":26105,"activeCount":102},[],{"trials":26107,"activeCount":102},[],{"trials":26109,"activeCount":102},[26110],{"nctId":26111,"briefTitle":26112,"status":241,"phases":26113,"primaryCompletion":9910,"completion":5641,"start":535,"enrollment":180,"conditions":26114,"interventions":26117},"NCT01363557","Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis",[94],[26115,26116],"EGFR-mutated Lung Adenocarcinoma","Brain Metastasis",[26096],{"intervention":26119,"totalTrials":180,"cells":26120},"CF patients with a G551D mutation and treated with Ivacaftor",{"EARLY_PHASE1":26121,"PHASE1":26123,"PHASE2":26125,"PHASE3":26127,"PHASE4":26129,"NA":26131},{"trials":26122,"activeCount":102},[],{"trials":26124,"activeCount":102},[],{"trials":26126,"activeCount":102},[],{"trials":26128,"activeCount":102},[],{"trials":26130,"activeCount":102},[],{"trials":26132,"activeCount":102},[26133],{"nctId":26134,"briefTitle":26135,"status":139,"phases":26136,"primaryCompletion":8061,"completion":8062,"start":7960,"enrollment":19103,"conditions":26137,"interventions":26138},"NCT02194881","Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation",[],[23],[26119],{"intervention":26140,"totalTrials":180,"cells":26141},"A collection of maternal plasma and serum",{"EARLY_PHASE1":26142,"PHASE1":26144,"PHASE2":26146,"PHASE3":26148,"PHASE4":26150,"NA":26152},{"trials":26143,"activeCount":102},[],{"trials":26145,"activeCount":102},[],{"trials":26147,"activeCount":102},[],{"trials":26149,"activeCount":102},[],{"trials":26151,"activeCount":102},[],{"trials":26153,"activeCount":102},[26154],{"nctId":26155,"briefTitle":26156,"status":139,"phases":26157,"primaryCompletion":26158,"completion":26158,"start":26159,"enrollment":8869,"conditions":26160,"interventions":26161},"NCT03188900","Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia",[],"2019-06-12","2017-06-12",[8323],[26140],{"intervention":26163,"totalTrials":180,"cells":26164},"Cell line and virus",{"EARLY_PHASE1":26165,"PHASE1":26167,"PHASE2":26169,"PHASE3":26171,"PHASE4":26173,"NA":26175},{"trials":26166,"activeCount":102},[],{"trials":26168,"activeCount":102},[],{"trials":26170,"activeCount":102},[],{"trials":26172,"activeCount":102},[],{"trials":26174,"activeCount":102},[],{"trials":26176,"activeCount":102},[26177],{"nctId":26178,"briefTitle":26179,"status":110,"phases":26180,"primaryCompletion":26181,"completion":26181,"start":26182,"enrollment":280,"conditions":26183,"interventions":26185},"NCT05589012","Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model",[],"2024-04-01","2023-11-01",[26184],"Zika Virus Infection",[26163,26186,26187],"Infection of human placental culture explants","Determination of viral load in tissues by qRT-PCR",{"intervention":26186,"totalTrials":180,"cells":26189},{"EARLY_PHASE1":26190,"PHASE1":26192,"PHASE2":26194,"PHASE3":26196,"PHASE4":26198,"NA":26200},{"trials":26191,"activeCount":102},[],{"trials":26193,"activeCount":102},[],{"trials":26195,"activeCount":102},[],{"trials":26197,"activeCount":102},[],{"trials":26199,"activeCount":102},[],{"trials":26201,"activeCount":102},[26202],{"nctId":26178,"briefTitle":26179,"status":110,"phases":26203,"primaryCompletion":26181,"completion":26181,"start":26182,"enrollment":280,"conditions":26204,"interventions":26205},[],[26184],[26163,26186,26187],{"intervention":26187,"totalTrials":180,"cells":26207},{"EARLY_PHASE1":26208,"PHASE1":26210,"PHASE2":26212,"PHASE3":26214,"PHASE4":26216,"NA":26218},{"trials":26209,"activeCount":102},[],{"trials":26211,"activeCount":102},[],{"trials":26213,"activeCount":102},[],{"trials":26215,"activeCount":102},[],{"trials":26217,"activeCount":102},[],{"trials":26219,"activeCount":102},[26220],{"nctId":26178,"briefTitle":26179,"status":110,"phases":26221,"primaryCompletion":26181,"completion":26181,"start":26182,"enrollment":280,"conditions":26222,"interventions":26223},[],[26184],[26163,26186,26187],{"intervention":26225,"totalTrials":180,"cells":26226},"Riociguat",{"EARLY_PHASE1":26227,"PHASE1":26229,"PHASE2":26231,"PHASE3":26233,"PHASE4":26235,"NA":26237},{"trials":26228,"activeCount":102},[],{"trials":26230,"activeCount":102},[],{"trials":26232,"activeCount":102},[],{"trials":26234,"activeCount":102},[],{"trials":26236,"activeCount":102},[],{"trials":26238,"activeCount":102},[26239],{"nctId":26240,"briefTitle":26241,"status":139,"phases":26242,"primaryCompletion":26243,"completion":26243,"start":26244,"enrollment":15733,"conditions":26245,"interventions":26247},"NCT02634203","Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension",[94],"2020-01-27","2016-01-19",[26246],"Chronic Thromboembolic Pulmonary Hypertension",[26225],{"intervention":26249,"totalTrials":180,"cells":26250},"Ivacaftor+lumacaftor",{"EARLY_PHASE1":26251,"PHASE1":26253,"PHASE2":26255,"PHASE3":26257,"PHASE4":26259,"NA":26261},{"trials":26252,"activeCount":102},[],{"trials":26254,"activeCount":102},[],{"trials":26256,"activeCount":102},[],{"trials":26258,"activeCount":102},[],{"trials":26260,"activeCount":102},[],{"trials":26262,"activeCount":102},[26263],{"nctId":26264,"briefTitle":26265,"status":139,"phases":26266,"primaryCompletion":26267,"completion":26267,"start":26268,"enrollment":2318,"conditions":26269,"interventions":26270},"NCT03475381","Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)",[],"2018-12-31","2016-01-22",[23],[26249],{"intervention":26272,"totalTrials":180,"cells":26273},"biomarkers, MRI and CSF",{"EARLY_PHASE1":26274,"PHASE1":26276,"PHASE2":26278,"PHASE3":26280,"PHASE4":26282,"NA":26284},{"trials":26275,"activeCount":102},[],{"trials":26277,"activeCount":102},[],{"trials":26279,"activeCount":102},[],{"trials":26281,"activeCount":102},[],{"trials":26283,"activeCount":102},[],{"trials":26285,"activeCount":102},[26286],{"nctId":26287,"briefTitle":26288,"status":139,"phases":26289,"primaryCompletion":26290,"completion":26291,"start":26292,"enrollment":26293,"conditions":26294,"interventions":26297},"NCT01315639","New Biomarker for Alzheimer's Disease Diagnostic",[94],"2015-02-26","2018-03-16","2010-09-03",1067,[26295,26296],"Alzheimer's Disease","Mild Cognitive Impairment",[26272],{"intervention":26299,"totalTrials":180,"cells":26300},"Dolutegravir",{"EARLY_PHASE1":26301,"PHASE1":26303,"PHASE2":26305,"PHASE3":26307,"PHASE4":26309,"NA":26311},{"trials":26302,"activeCount":102},[],{"trials":26304,"activeCount":102},[],{"trials":26306,"activeCount":102},[],{"trials":26308,"activeCount":102},[],{"trials":26310,"activeCount":102},[],{"trials":26312,"activeCount":102},[26313],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26316,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26318,"interventions":26320},"NCT03194165","Population Pharmacokinetics of Antiretroviral in Children",[],"2017-06-16",[26319],"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed",[26299,26321,26322,26323,26324,26325,26326],"Raltegravir","Rilpivirine","Nevirapine","Atazanavir","Darunavir","Ritonavir",{"intervention":26321,"totalTrials":180,"cells":26328},{"EARLY_PHASE1":26329,"PHASE1":26331,"PHASE2":26333,"PHASE3":26335,"PHASE4":26337,"NA":26339},{"trials":26330,"activeCount":102},[],{"trials":26332,"activeCount":102},[],{"trials":26334,"activeCount":102},[],{"trials":26336,"activeCount":102},[],{"trials":26338,"activeCount":102},[],{"trials":26340,"activeCount":102},[26341],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26342,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26343,"interventions":26344},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26322,"totalTrials":180,"cells":26346},{"EARLY_PHASE1":26347,"PHASE1":26349,"PHASE2":26351,"PHASE3":26353,"PHASE4":26355,"NA":26357},{"trials":26348,"activeCount":102},[],{"trials":26350,"activeCount":102},[],{"trials":26352,"activeCount":102},[],{"trials":26354,"activeCount":102},[],{"trials":26356,"activeCount":102},[],{"trials":26358,"activeCount":102},[26359],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26360,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26361,"interventions":26362},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26323,"totalTrials":180,"cells":26364},{"EARLY_PHASE1":26365,"PHASE1":26367,"PHASE2":26369,"PHASE3":26371,"PHASE4":26373,"NA":26375},{"trials":26366,"activeCount":102},[],{"trials":26368,"activeCount":102},[],{"trials":26370,"activeCount":102},[],{"trials":26372,"activeCount":102},[],{"trials":26374,"activeCount":102},[],{"trials":26376,"activeCount":102},[26377],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26378,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26379,"interventions":26380},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26324,"totalTrials":180,"cells":26382},{"EARLY_PHASE1":26383,"PHASE1":26385,"PHASE2":26387,"PHASE3":26389,"PHASE4":26391,"NA":26393},{"trials":26384,"activeCount":102},[],{"trials":26386,"activeCount":102},[],{"trials":26388,"activeCount":102},[],{"trials":26390,"activeCount":102},[],{"trials":26392,"activeCount":102},[],{"trials":26394,"activeCount":102},[26395],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26396,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26397,"interventions":26398},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26325,"totalTrials":180,"cells":26400},{"EARLY_PHASE1":26401,"PHASE1":26403,"PHASE2":26405,"PHASE3":26407,"PHASE4":26409,"NA":26411},{"trials":26402,"activeCount":102},[],{"trials":26404,"activeCount":102},[],{"trials":26406,"activeCount":102},[],{"trials":26408,"activeCount":102},[],{"trials":26410,"activeCount":102},[],{"trials":26412,"activeCount":102},[26413],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26414,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26415,"interventions":26416},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26326,"totalTrials":180,"cells":26418},{"EARLY_PHASE1":26419,"PHASE1":26421,"PHASE2":26423,"PHASE3":26425,"PHASE4":26427,"NA":26429},{"trials":26420,"activeCount":102},[],{"trials":26422,"activeCount":102},[],{"trials":26424,"activeCount":102},[],{"trials":26426,"activeCount":102},[],{"trials":26428,"activeCount":102},[],{"trials":26430,"activeCount":102},[26431],{"nctId":26314,"briefTitle":26315,"status":139,"phases":26432,"primaryCompletion":21105,"completion":21105,"start":26317,"enrollment":20807,"conditions":26433,"interventions":26434},[],[26319],[26299,26321,26322,26323,26324,26325,26326],{"intervention":26436,"totalTrials":180,"cells":26437},"association of RIFAMPIN + CLINDAMYCIN",{"EARLY_PHASE1":26438,"PHASE1":26440,"PHASE2":26442,"PHASE3":26444,"PHASE4":26446,"NA":26448},{"trials":26439,"activeCount":102},[],{"trials":26441,"activeCount":102},[],{"trials":26443,"activeCount":102},[],{"trials":26445,"activeCount":102},[],{"trials":26447,"activeCount":102},[],{"trials":26449,"activeCount":102},[26450],{"nctId":26451,"briefTitle":26452,"status":139,"phases":26453,"primaryCompletion":956,"completion":956,"start":1833,"enrollment":30,"conditions":26454,"interventions":26456},"NCT01500837","Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)",[94],[26455],"Osteoarticular Infection",[26436,26457],"association of LEVOFLOXACIN+ CLINDAMYCIN",{"intervention":26457,"totalTrials":180,"cells":26459},{"EARLY_PHASE1":26460,"PHASE1":26462,"PHASE2":26464,"PHASE3":26466,"PHASE4":26468,"NA":26470},{"trials":26461,"activeCount":102},[],{"trials":26463,"activeCount":102},[],{"trials":26465,"activeCount":102},[],{"trials":26467,"activeCount":102},[],{"trials":26469,"activeCount":102},[],{"trials":26471,"activeCount":102},[26472],{"nctId":26451,"briefTitle":26452,"status":139,"phases":26473,"primaryCompletion":956,"completion":956,"start":1833,"enrollment":30,"conditions":26474,"interventions":26475},[94],[26455],[26436,26457],{"intervention":26477,"totalTrials":180,"cells":26478},"exhaled breath collection",{"EARLY_PHASE1":26479,"PHASE1":26481,"PHASE2":26483,"PHASE3":26485,"PHASE4":26487,"NA":26489},{"trials":26480,"activeCount":102},[],{"trials":26482,"activeCount":102},[],{"trials":26484,"activeCount":102},[],{"trials":26486,"activeCount":102},[],{"trials":26488,"activeCount":102},[],{"trials":26490,"activeCount":102},[26491],{"nctId":26492,"briefTitle":26493,"status":110,"phases":26494,"primaryCompletion":26495,"completion":26496,"start":26497,"enrollment":36,"conditions":26498,"interventions":26499},"NCT05726994","Volatilomic Approaches for the Study of CFTR Modulators (VOLATIL-CF)",[],"2024-02","2024-08","2023-02-06",[23],[26477],{"intervention":26501,"totalTrials":180,"cells":26502},"Drug selected in the study",{"EARLY_PHASE1":26503,"PHASE1":26505,"PHASE2":26507,"PHASE3":26509,"PHASE4":26511,"NA":26513},{"trials":26504,"activeCount":102},[],{"trials":26506,"activeCount":102},[],{"trials":26508,"activeCount":102},[],{"trials":26510,"activeCount":102},[],{"trials":26512,"activeCount":102},[],{"trials":26514,"activeCount":102},[26515],{"nctId":26516,"briefTitle":26517,"status":5932,"phases":26518,"primaryCompletion":497,"completion":497,"start":10963,"enrollment":102,"conditions":26519,"interventions":26520},"NCT02458040","Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs",[],[12262],[26501],{"intervention":26522,"totalTrials":180,"cells":26523},"B vaccination",{"EARLY_PHASE1":26524,"PHASE1":26526,"PHASE2":26528,"PHASE3":26530,"PHASE4":26532,"NA":26534},{"trials":26525,"activeCount":102},[],{"trials":26527,"activeCount":102},[],{"trials":26529,"activeCount":102},[],{"trials":26531,"activeCount":102},[],{"trials":26533,"activeCount":102},[],{"trials":26535,"activeCount":102},[26536],{"nctId":26537,"briefTitle":26538,"status":139,"phases":26539,"primaryCompletion":26540,"completion":26540,"start":26541,"enrollment":1931,"conditions":26542,"interventions":26545},"NCT03509051","Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation",[94],"2020-03-13","2019-06-01",[26543,26544],"Hematopoietic Stem Cell Transplant","Meningococcal Vaccine",[26522],{"intervention":26547,"totalTrials":180,"cells":26548},"DNA chip dedicated to the pharmacogenetic of steroids",{"EARLY_PHASE1":26549,"PHASE1":26551,"PHASE2":26553,"PHASE3":26555,"PHASE4":26557,"NA":26559},{"trials":26550,"activeCount":102},[],{"trials":26552,"activeCount":102},[],{"trials":26554,"activeCount":102},[],{"trials":26556,"activeCount":102},[],{"trials":26558,"activeCount":102},[],{"trials":26560,"activeCount":102},[26561],{"nctId":26562,"briefTitle":26563,"status":139,"phases":26564,"primaryCompletion":5701,"completion":5701,"start":8053,"enrollment":9998,"conditions":26565,"interventions":26566},"NCT01609426","Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome",[],[1942],[26547],{"intervention":26568,"totalTrials":180,"cells":26569},"specific treatment",{"EARLY_PHASE1":26570,"PHASE1":26572,"PHASE2":26574,"PHASE3":26576,"PHASE4":26578,"NA":26580},{"trials":26571,"activeCount":102},[],{"trials":26573,"activeCount":102},[],{"trials":26575,"activeCount":102},[],{"trials":26577,"activeCount":102},[],{"trials":26579,"activeCount":102},[],{"trials":26581,"activeCount":102},[26582],{"nctId":26583,"briefTitle":26584,"status":139,"phases":26585,"primaryCompletion":21897,"completion":3967,"start":26586,"enrollment":7834,"conditions":26587,"interventions":26589},"NCT02262117","Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates",[94],"2015-10-30",[26588],"Reproductive Medicine",[26568],{"intervention":26591,"totalTrials":180,"cells":26592},"new antiviral therapy",{"EARLY_PHASE1":26593,"PHASE1":26595,"PHASE2":26597,"PHASE3":26599,"PHASE4":26601,"NA":26603},{"trials":26594,"activeCount":102},[],{"trials":26596,"activeCount":102},[],{"trials":26598,"activeCount":102},[],{"trials":26600,"activeCount":102},[],{"trials":26602,"activeCount":102},[],{"trials":26604,"activeCount":102},[26605],{"nctId":26606,"briefTitle":26607,"status":110,"phases":26608,"primaryCompletion":497,"start":20619,"enrollment":1277,"conditions":26609,"interventions":26611},"NCT02856243","Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis",[],[5913,247,26610],"Hepatitis C",[26591],{"intervention":26613,"totalTrials":180,"cells":26614},"Blood assays",{"EARLY_PHASE1":26615,"PHASE1":26617,"PHASE2":26619,"PHASE3":26621,"PHASE4":26623,"NA":26625},{"trials":26616,"activeCount":102},[],{"trials":26618,"activeCount":102},[],{"trials":26620,"activeCount":102},[],{"trials":26622,"activeCount":102},[],{"trials":26624,"activeCount":102},[],{"trials":26626,"activeCount":102},[26627],{"nctId":26628,"briefTitle":26629,"status":5932,"phases":26630,"primaryCompletion":3499,"completion":1311,"start":26631,"enrollment":102,"conditions":26632,"interventions":26633},"NCT05558813","Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP)",[94],"2024-11",[14961],[26613],{"intervention":26635,"totalTrials":180,"cells":26636},"Analysis of early immune modifications",{"EARLY_PHASE1":26637,"PHASE1":26639,"PHASE2":26641,"PHASE3":26643,"PHASE4":26645,"NA":26647},{"trials":26638,"activeCount":102},[],{"trials":26640,"activeCount":102},[],{"trials":26642,"activeCount":102},[],{"trials":26644,"activeCount":102},[],{"trials":26646,"activeCount":102},[],{"trials":26648,"activeCount":102},[26649],{"nctId":26650,"briefTitle":26651,"status":139,"phases":26652,"primaryCompletion":26653,"completion":26653,"start":26654,"enrollment":26655,"conditions":26656,"interventions":26657},"NCT02184676","T1D Risk Assessment in Kids With Relatives",[94],"2019-05-17","2015-05-28",512,[1522],[26635],{"intervention":26659,"totalTrials":180,"cells":26660},"Administration of 131 iodine",{"EARLY_PHASE1":26661,"PHASE1":26663,"PHASE2":26665,"PHASE3":26667,"PHASE4":26669,"NA":26671},{"trials":26662,"activeCount":102},[],{"trials":26664,"activeCount":102},[],{"trials":26666,"activeCount":102},[],{"trials":26668,"activeCount":102},[],{"trials":26670,"activeCount":102},[],{"trials":26672,"activeCount":102},[26673],{"nctId":26674,"briefTitle":26675,"status":139,"phases":26676,"primaryCompletion":14737,"completion":14737,"start":5682,"enrollment":5911,"conditions":26677,"interventions":26679},"NCT01150318","Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients",[94],[26678],"Thyroid Neoplasms",[26659],{"intervention":26681,"totalTrials":180,"cells":26682},"platinum chemotherapy",{"EARLY_PHASE1":26683,"PHASE1":26685,"PHASE2":26687,"PHASE3":26689,"PHASE4":26691,"NA":26693},{"trials":26684,"activeCount":102},[],{"trials":26686,"activeCount":102},[],{"trials":26688,"activeCount":102},[],{"trials":26690,"activeCount":102},[],{"trials":26692,"activeCount":102},[],{"trials":26694,"activeCount":102},[26695],{"nctId":26696,"briefTitle":26697,"status":139,"phases":26698,"primaryCompletion":26699,"completion":26699,"start":26700,"enrollment":26701,"conditions":26702,"interventions":26703},"NCT04365023","Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors",[],"2023-05-25","2020-07-02",168,[19295],[26681],{"intervention":26705,"totalTrials":180,"cells":26706},"amoxicillin\u002Fclavulanate potassium",{"EARLY_PHASE1":26707,"PHASE1":26709,"PHASE2":26711,"PHASE3":26713,"PHASE4":26715,"NA":26717},{"trials":26708,"activeCount":102},[],{"trials":26710,"activeCount":102},[],{"trials":26712,"activeCount":102},[],{"trials":26714,"activeCount":102},[],{"trials":26716,"activeCount":102},[],{"trials":26718,"activeCount":102},[26719],{"nctId":26720,"briefTitle":26721,"status":139,"phases":26722,"primaryCompletion":14851,"completion":5301,"start":24671,"enrollment":26723,"conditions":26724,"interventions":26726},"NCT00135603","Antibiotic Therapy Versus Appendectomy for Acute Appendicitis",[94],243,[26725],"Appendicitis",[26705],{"intervention":23804,"totalTrials":180,"cells":26728},{"EARLY_PHASE1":26729,"PHASE1":26731,"PHASE2":26733,"PHASE3":26735,"PHASE4":26737,"NA":26739},{"trials":26730,"activeCount":102},[],{"trials":26732,"activeCount":102},[],{"trials":26734,"activeCount":102},[],{"trials":26736,"activeCount":102},[],{"trials":26738,"activeCount":102},[],{"trials":26740,"activeCount":102},[26741],{"nctId":23797,"briefTitle":23798,"status":139,"phases":26742,"primaryCompletion":19366,"completion":19366,"start":23800,"enrollment":5575,"conditions":26743,"interventions":26744},[94],[23802],[23804,23782],{"intervention":26746,"totalTrials":180,"cells":26747},"Serology SARS-CoV2",{"EARLY_PHASE1":26748,"PHASE1":26750,"PHASE2":26752,"PHASE3":26754,"PHASE4":26756,"NA":26758},{"trials":26749,"activeCount":102},[],{"trials":26751,"activeCount":102},[],{"trials":26753,"activeCount":102},[],{"trials":26755,"activeCount":102},[],{"trials":26757,"activeCount":102},[],{"trials":26759,"activeCount":102},[26760],{"nctId":26761,"briefTitle":26762,"status":139,"phases":26763,"primaryCompletion":26764,"completion":26764,"start":26765,"enrollment":26766,"conditions":26767,"interventions":26769},"NCT04442087","Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP",[94],"2021-04-30","2020-06-19",563,[26768],"SARS-CoV2",[26746],{"intervention":26771,"totalTrials":180,"cells":26772},"Standard management of patients suspected of thrombopathy",{"EARLY_PHASE1":26773,"PHASE1":26775,"PHASE2":26777,"PHASE3":26779,"PHASE4":26781,"NA":26783},{"trials":26774,"activeCount":102},[],{"trials":26776,"activeCount":102},[],{"trials":26778,"activeCount":102},[],{"trials":26780,"activeCount":102},[],{"trials":26782,"activeCount":102},[],{"trials":26784,"activeCount":102},[26785],{"nctId":26786,"briefTitle":26787,"status":139,"phases":26788,"primaryCompletion":26789,"completion":26789,"start":26790,"enrollment":333,"conditions":26791,"interventions":26793},"NCT04095715","Anomalies of Dense Platelet Granules",[],"2023-02-21","2019-12-09",[26792],"Spontaneous Induced Unexplained Haemorrhagic",[26771],{"intervention":26795,"totalTrials":180,"cells":26796},"Rapid optimized analgesic strategy",{"EARLY_PHASE1":26797,"PHASE1":26799,"PHASE2":26801,"PHASE3":26803,"PHASE4":26805,"NA":26807},{"trials":26798,"activeCount":102},[],{"trials":26800,"activeCount":102},[],{"trials":26802,"activeCount":102},[],{"trials":26804,"activeCount":102},[],{"trials":26806,"activeCount":102},[],{"trials":26808,"activeCount":102},[26809],{"nctId":26810,"briefTitle":26811,"status":139,"phases":26812,"primaryCompletion":13760,"completion":12216,"start":990,"enrollment":1984,"conditions":26813,"interventions":26815},"NCT00874172","Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy",[94],[26814],"Sickle Cell Anemia",[26795,26816],"current analgesic strategy",{"intervention":26816,"totalTrials":180,"cells":26818},{"EARLY_PHASE1":26819,"PHASE1":26821,"PHASE2":26823,"PHASE3":26825,"PHASE4":26827,"NA":26829},{"trials":26820,"activeCount":102},[],{"trials":26822,"activeCount":102},[],{"trials":26824,"activeCount":102},[],{"trials":26826,"activeCount":102},[],{"trials":26828,"activeCount":102},[],{"trials":26830,"activeCount":102},[26831],{"nctId":26810,"briefTitle":26811,"status":139,"phases":26832,"primaryCompletion":13760,"completion":12216,"start":990,"enrollment":1984,"conditions":26833,"interventions":26834},[94],[26814],[26795,26816],{"intervention":26836,"totalTrials":180,"cells":26837},"omics identity card",{"EARLY_PHASE1":26838,"PHASE1":26840,"PHASE2":26842,"PHASE3":26844,"PHASE4":26846,"NA":26848},{"trials":26839,"activeCount":102},[],{"trials":26841,"activeCount":102},[],{"trials":26843,"activeCount":102},[],{"trials":26845,"activeCount":102},[],{"trials":26847,"activeCount":102},[],{"trials":26849,"activeCount":102},[26850],{"nctId":26851,"briefTitle":26852,"status":139,"phases":26853,"primaryCompletion":26854,"completion":26854,"start":5469,"enrollment":26855,"conditions":26856,"interventions":26858},"NCT02672020","Towards an Easy-to-use Adrenal Cancer\u002FTumor Identity Card",[94],"2019-03-26",448,[26857],"Adrenal Gland Neoplasms",[26836],{"intervention":26860,"totalTrials":180,"cells":26861},"Blood volume collected specifically for this study",{"EARLY_PHASE1":26862,"PHASE1":26864,"PHASE2":26866,"PHASE3":26868,"PHASE4":26870,"NA":26872},{"trials":26863,"activeCount":102},[],{"trials":26865,"activeCount":102},[],{"trials":26867,"activeCount":102},[],{"trials":26869,"activeCount":102},[],{"trials":26871,"activeCount":102},[],{"trials":26873,"activeCount":102},[26874],{"nctId":26875,"briefTitle":26876,"status":139,"phases":26877,"primaryCompletion":10532,"completion":977,"start":9910,"enrollment":1015,"conditions":26878,"interventions":26880},"NCT01637220","Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents",[],[26879],"Anaphylactic Shock to Neuro-Muscular Blocking Agents (NMBA)",[26860],{"intervention":26882,"totalTrials":180,"cells":26883},"Cannabis (THC) in cigarettes of 30mg, 10mg and placebo",{"EARLY_PHASE1":26884,"PHASE1":26886,"PHASE2":26888,"PHASE3":26890,"PHASE4":26892,"NA":26894},{"trials":26885,"activeCount":102},[],{"trials":26887,"activeCount":102},[],{"trials":26889,"activeCount":102},[],{"trials":26891,"activeCount":102},[],{"trials":26893,"activeCount":102},[],{"trials":26895,"activeCount":102},[26896],{"nctId":26897,"briefTitle":26898,"status":139,"phases":26899,"primaryCompletion":10532,"completion":12093,"start":12765,"enrollment":26900,"conditions":26901,"interventions":26903},"NCT02061020","Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users",[94],37,[26902],"Occasional (1-2 Joints Per Week) and Chronic (1-2 Joints Per Day) Cannabis Users",[26882],{"intervention":26905,"totalTrials":180,"cells":26906},"Molecular detection of antibiotic resistance",{"EARLY_PHASE1":26907,"PHASE1":26909,"PHASE2":26911,"PHASE3":26913,"PHASE4":26915,"NA":26917},{"trials":26908,"activeCount":102},[],{"trials":26910,"activeCount":102},[],{"trials":26912,"activeCount":102},[],{"trials":26914,"activeCount":102},[],{"trials":26916,"activeCount":102},[],{"trials":26918,"activeCount":102},[26919],{"nctId":26920,"briefTitle":26921,"status":139,"phases":26922,"primaryCompletion":535,"completion":385,"start":5418,"enrollment":26923,"conditions":26924,"interventions":26926},"NCT01168063","Molecular Detection of Antibiotic Resistance and H Pylori Eradication",[94],1386,[26925],"Helicobacter Pylori Infection",[26905,26927],"standard triple therapy",{"intervention":26927,"totalTrials":180,"cells":26929},{"EARLY_PHASE1":26930,"PHASE1":26932,"PHASE2":26934,"PHASE3":26936,"PHASE4":26938,"NA":26940},{"trials":26931,"activeCount":102},[],{"trials":26933,"activeCount":102},[],{"trials":26935,"activeCount":102},[],{"trials":26937,"activeCount":102},[],{"trials":26939,"activeCount":102},[],{"trials":26941,"activeCount":102},[26942],{"nctId":26920,"briefTitle":26921,"status":139,"phases":26943,"primaryCompletion":535,"completion":385,"start":5418,"enrollment":26923,"conditions":26944,"interventions":26945},[94],[26925],[26905,26927],{"intervention":26947,"totalTrials":180,"cells":26948},"Genetic sample",{"EARLY_PHASE1":26949,"PHASE1":26951,"PHASE2":26953,"PHASE3":26955,"PHASE4":26957,"NA":26959},{"trials":26950,"activeCount":102},[],{"trials":26952,"activeCount":102},[],{"trials":26954,"activeCount":102},[],{"trials":26956,"activeCount":102},[],{"trials":26958,"activeCount":102},[],{"trials":26960,"activeCount":102},[26961],{"nctId":26962,"briefTitle":26963,"status":110,"phases":26964,"primaryCompletion":14779,"completion":12094,"start":267,"enrollment":12114,"conditions":26965,"interventions":26967},"NCT02572674","Study of Predictor of Mood Relapse in Bipolar Disorders",[94],[608,26966],"Euthymic State",[26947],{"intervention":26969,"totalTrials":180,"cells":26970},"Coagulation assay",{"EARLY_PHASE1":26971,"PHASE1":26973,"PHASE2":26975,"PHASE3":26977,"PHASE4":26979,"NA":26981},{"trials":26972,"activeCount":102},[],{"trials":26974,"activeCount":102},[],{"trials":26976,"activeCount":102},[],{"trials":26978,"activeCount":102},[],{"trials":26980,"activeCount":102},[],{"trials":26982,"activeCount":102},[26983],{"nctId":26984,"briefTitle":26985,"status":139,"phases":26986,"primaryCompletion":26987,"completion":26988,"start":26989,"enrollment":19103,"conditions":26990,"interventions":26991},"NCT03560570","Study of Hemostasis in Patients With Congenital Disorder of Glycosylation",[],"2017-01-31","2017-12-31","2014-01-01",[25343],[26969],{"intervention":26993,"totalTrials":180,"cells":26994},"Blood sample for nutritional assessment",{"EARLY_PHASE1":26995,"PHASE1":26997,"PHASE2":26999,"PHASE3":27001,"PHASE4":27003,"NA":27005},{"trials":26996,"activeCount":102},[],{"trials":26998,"activeCount":102},[],{"trials":27000,"activeCount":102},[],{"trials":27002,"activeCount":102},[],{"trials":27004,"activeCount":102},[],{"trials":27006,"activeCount":102},[27007],{"nctId":27008,"briefTitle":27009,"status":110,"phases":27010,"primaryCompletion":5236,"completion":27011,"start":23038,"enrollment":1277,"conditions":27012,"interventions":27014},"NCT06068088","Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)",[],"2025-02",[27013],"Carcinoma, Non-Small-Cell Lung",[26993],{"intervention":27016,"totalTrials":180,"cells":27017},"Pharmacokinetic",{"EARLY_PHASE1":27018,"PHASE1":27020,"PHASE2":27022,"PHASE3":27024,"PHASE4":27026,"NA":27028},{"trials":27019,"activeCount":102},[],{"trials":27021,"activeCount":102},[],{"trials":27023,"activeCount":102},[],{"trials":27025,"activeCount":102},[],{"trials":27027,"activeCount":102},[],{"trials":27029,"activeCount":102},[27030],{"nctId":27031,"briefTitle":27032,"status":139,"phases":27033,"primaryCompletion":3003,"completion":3003,"start":27034,"enrollment":3993,"conditions":27035,"interventions":27037},"NCT02252237","Pharmacokinetics of Glucocorticoids in Children (GLUCOPED)",[],"2014-12-03",[27036],"Children Receiving Prednisone or Prednisolone or Methylprednisolone or Hydrocortisone",[27016],{"intervention":27039,"totalTrials":180,"cells":27040},"methylprednisolone bolus IV 15 mg\u002Fkg\u002Fd for 3 days.",{"EARLY_PHASE1":27041,"PHASE1":27043,"PHASE2":27045,"PHASE3":27047,"PHASE4":27049,"NA":27051},{"trials":27042,"activeCount":102},[],{"trials":27044,"activeCount":102},[],{"trials":27046,"activeCount":102},[],{"trials":27048,"activeCount":102},[],{"trials":27050,"activeCount":102},[],{"trials":27052,"activeCount":102},[27053],{"nctId":27054,"briefTitle":27055,"status":241,"phases":27056,"primaryCompletion":5469,"completion":5469,"start":13760,"enrollment":1931,"conditions":27057,"interventions":27059},"NCT01652417","Treatment of Renal Sarcoidosis by Methylprednisolone Bolus",[94],[27058],"Renal Sarcoidosis",[27039],{"intervention":27061,"totalTrials":180,"cells":27062},"Genotyping",{"EARLY_PHASE1":27063,"PHASE1":27065,"PHASE2":27067,"PHASE3":27069,"PHASE4":27071,"NA":27073},{"trials":27064,"activeCount":102},[],{"trials":27066,"activeCount":102},[],{"trials":27068,"activeCount":102},[],{"trials":27070,"activeCount":102},[],{"trials":27072,"activeCount":102},[],{"trials":27074,"activeCount":102},[27075],{"nctId":27076,"briefTitle":27077,"status":139,"phases":27078,"primaryCompletion":1052,"completion":1052,"start":523,"enrollment":27079,"conditions":27080,"interventions":27082},"NCT00832962","Routine Fetal RhD Genotyping for RhD- Pregnant Women",[],2532,[27081],"Rhesus Negative Pregnant Women",[27061],{"intervention":27084,"totalTrials":180,"cells":27085},"Anastrozole",{"EARLY_PHASE1":27086,"PHASE1":27088,"PHASE2":27090,"PHASE3":27092,"PHASE4":27094,"NA":27096},{"trials":27087,"activeCount":102},[],{"trials":27089,"activeCount":102},[],{"trials":27091,"activeCount":102},[],{"trials":27093,"activeCount":102},[],{"trials":27095,"activeCount":102},[],{"trials":27097,"activeCount":102},[27098],{"nctId":27099,"briefTitle":27100,"status":110,"phases":27101,"primaryCompletion":12697,"completion":1051,"start":5660,"enrollment":6268,"conditions":27102,"interventions":27104},"NCT01520467","Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome",[94],[27103,23845],"Silver Russell Syndrome",[27084],{"intervention":5315,"totalTrials":180,"cells":27106},{"EARLY_PHASE1":27107,"PHASE1":27109,"PHASE2":27111,"PHASE3":27113,"PHASE4":27115,"NA":27117},{"trials":27108,"activeCount":102},[],{"trials":27110,"activeCount":102},[],{"trials":27112,"activeCount":102},[],{"trials":27114,"activeCount":102},[],{"trials":27116,"activeCount":102},[],{"trials":27118,"activeCount":102},[27119],{"nctId":5310,"briefTitle":5311,"status":241,"phases":27120,"completion":5144,"start":5171,"enrollment":24,"conditions":27121,"interventions":27122},[94],[3503],[5315,5274],{"intervention":27124,"totalTrials":180,"cells":27125},"Heart and spleen tissue",{"EARLY_PHASE1":27126,"PHASE1":27128,"PHASE2":27130,"PHASE3":27132,"PHASE4":27134,"NA":27136},{"trials":27127,"activeCount":102},[],{"trials":27129,"activeCount":102},[],{"trials":27131,"activeCount":102},[],{"trials":27133,"activeCount":102},[],{"trials":27135,"activeCount":102},[],{"trials":27137,"activeCount":102},[27138],{"nctId":27139,"briefTitle":27140,"status":110,"phases":27141,"primaryCompletion":1129,"completion":1730,"start":18191,"enrollment":489,"conditions":27142,"interventions":27144},"NCT02920203","Genetic Autopsy and Sudden Death",[],[27143],"Sudden Death",[27124],{"intervention":27146,"totalTrials":180,"cells":27147},"8 days of effective antibiotic treatment",{"EARLY_PHASE1":27148,"PHASE1":27150,"PHASE2":27152,"PHASE3":27154,"PHASE4":27156,"NA":27158},{"trials":27149,"activeCount":102},[],{"trials":27151,"activeCount":102},[],{"trials":27153,"activeCount":102},[],{"trials":27155,"activeCount":102},[],{"trials":27157,"activeCount":102},[],{"trials":27159,"activeCount":102},[27160],{"nctId":27161,"briefTitle":27162,"status":139,"phases":27163,"primaryCompletion":342,"completion":342,"start":27164,"enrollment":16801,"conditions":27165,"interventions":27167},"NCT02634411","Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)",[94],"2016-06-03",[27166],"Ventilator-Associated Pneumonia",[27146,27168],"15 days of effective antibiotic treatment",{"intervention":27168,"totalTrials":180,"cells":27170},{"EARLY_PHASE1":27171,"PHASE1":27173,"PHASE2":27175,"PHASE3":27177,"PHASE4":27179,"NA":27181},{"trials":27172,"activeCount":102},[],{"trials":27174,"activeCount":102},[],{"trials":27176,"activeCount":102},[],{"trials":27178,"activeCount":102},[],{"trials":27180,"activeCount":102},[],{"trials":27182,"activeCount":102},[27183],{"nctId":27161,"briefTitle":27162,"status":139,"phases":27184,"primaryCompletion":342,"completion":342,"start":27164,"enrollment":16801,"conditions":27185,"interventions":27186},[94],[27166],[27146,27168],{"intervention":27188,"totalTrials":180,"cells":27189},"Genetic analysis on tumor kept in tumor bank",{"EARLY_PHASE1":27190,"PHASE1":27192,"PHASE2":27194,"PHASE3":27196,"PHASE4":27198,"NA":27200},{"trials":27191,"activeCount":102},[],{"trials":27193,"activeCount":102},[],{"trials":27195,"activeCount":102},[],{"trials":27197,"activeCount":102},[],{"trials":27199,"activeCount":102},[],{"trials":27201,"activeCount":102},[27202],{"nctId":27203,"briefTitle":27204,"status":110,"phases":27205,"primaryCompletion":18330,"completion":18330,"start":20619,"enrollment":27206,"conditions":27207,"interventions":27210},"NCT02458664","BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer",[],597,[27208,27209],"Rectum Cancer","Cancer of Colon",[27188],{"intervention":24196,"totalTrials":180,"cells":27212},{"EARLY_PHASE1":27213,"PHASE1":27215,"PHASE2":27217,"PHASE3":27219,"PHASE4":27221,"NA":27223},{"trials":27214,"activeCount":102},[],{"trials":27216,"activeCount":102},[],{"trials":27218,"activeCount":102},[],{"trials":27220,"activeCount":102},[],{"trials":27222,"activeCount":102},[],{"trials":27224,"activeCount":102},[27225],{"nctId":24189,"briefTitle":24190,"status":110,"phases":27226,"primaryCompletion":8411,"completion":8411,"start":14556,"enrollment":1108,"conditions":27227,"interventions":27228},[94],[17126,24193],[24195,24196,24197],{"intervention":24197,"totalTrials":180,"cells":27230},{"EARLY_PHASE1":27231,"PHASE1":27233,"PHASE2":27235,"PHASE3":27237,"PHASE4":27239,"NA":27241},{"trials":27232,"activeCount":102},[],{"trials":27234,"activeCount":102},[],{"trials":27236,"activeCount":102},[],{"trials":27238,"activeCount":102},[],{"trials":27240,"activeCount":102},[],{"trials":27242,"activeCount":102},[27243],{"nctId":24189,"briefTitle":24190,"status":110,"phases":27244,"primaryCompletion":8411,"completion":8411,"start":14556,"enrollment":1108,"conditions":27245,"interventions":27246},[94],[17126,24193],[24195,24196,24197],{"intervention":27248,"totalTrials":180,"cells":27249},"Blood draw",{"EARLY_PHASE1":27250,"PHASE1":27252,"PHASE2":27254,"PHASE3":27256,"PHASE4":27258,"NA":27260},{"trials":27251,"activeCount":102},[],{"trials":27253,"activeCount":102},[],{"trials":27255,"activeCount":102},[],{"trials":27257,"activeCount":102},[],{"trials":27259,"activeCount":102},[],{"trials":27261,"activeCount":102},[27262],{"nctId":27263,"briefTitle":27264,"status":139,"phases":27265,"primaryCompletion":15494,"completion":15494,"start":23818,"enrollment":27266,"conditions":27267,"interventions":27268},"NCT04516512","Assessment of SARS-CoV-2 Seroprevalence in Detention",[94],1044,[15],[27248],{"intervention":27270,"totalTrials":180,"cells":27271},"Bio collection",{"EARLY_PHASE1":27272,"PHASE1":27274,"PHASE2":27276,"PHASE3":27278,"PHASE4":27280,"NA":27282},{"trials":27273,"activeCount":102},[],{"trials":27275,"activeCount":102},[],{"trials":27277,"activeCount":102},[],{"trials":27279,"activeCount":102},[],{"trials":27281,"activeCount":102},[],{"trials":27283,"activeCount":102},[27284],{"nctId":27285,"briefTitle":27286,"status":139,"phases":27287,"primaryCompletion":27288,"completion":27288,"start":27289,"enrollment":27290,"conditions":27291,"interventions":27295},"NCT04353869","Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications",[],"2024-01-10","2020-11-16",995,[27292,27293,27294],"Glutamine","Diabetic","Cardiovascular Complications",[27270],{"intervention":27297,"totalTrials":180,"cells":27298},"Imatinib treatment",{"EARLY_PHASE1":27299,"PHASE1":27301,"PHASE2":27303,"PHASE3":27305,"PHASE4":27307,"NA":27309},{"trials":27300,"activeCount":102},[],{"trials":27302,"activeCount":102},[],{"trials":27304,"activeCount":102},[],{"trials":27306,"activeCount":102},[],{"trials":27308,"activeCount":102},[],{"trials":27310,"activeCount":102},[27311],{"nctId":27312,"briefTitle":27313,"status":139,"phases":27314,"primaryCompletion":17169,"completion":17169,"start":387,"enrollment":163,"conditions":27315,"interventions":27318},"NCT01114087","Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility",[94],[27316,27317],"Chronic Myeloid Leukemia","Gastrointestinal Stromal Tumors",[27297],{"intervention":27320,"totalTrials":180,"cells":27321},"Blood samples and buccal swabs",{"EARLY_PHASE1":27322,"PHASE1":27324,"PHASE2":27326,"PHASE3":27328,"PHASE4":27330,"NA":27332},{"trials":27323,"activeCount":102},[],{"trials":27325,"activeCount":102},[],{"trials":27327,"activeCount":102},[],{"trials":27329,"activeCount":102},[],{"trials":27331,"activeCount":102},[],{"trials":27333,"activeCount":102},[27334],{"nctId":27335,"briefTitle":27336,"status":139,"phases":27337,"primaryCompletion":1402,"completion":8053,"start":8235,"enrollment":567,"conditions":27338,"interventions":27340},"NCT00873574","JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders",[],[27339],"Myeloproliferative Disorders",[27320],{"intervention":27342,"totalTrials":180,"cells":27343},"sFlt-1 \u002F PlGF ratio",{"EARLY_PHASE1":27344,"PHASE1":27346,"PHASE2":27348,"PHASE3":27350,"PHASE4":27352,"NA":27354},{"trials":27345,"activeCount":102},[],{"trials":27347,"activeCount":102},[],{"trials":27349,"activeCount":102},[],{"trials":27351,"activeCount":102},[],{"trials":27353,"activeCount":102},[],{"trials":27355,"activeCount":102},[27356],{"nctId":27357,"briefTitle":27358,"status":139,"phases":27359,"primaryCompletion":27360,"completion":27360,"start":27361,"enrollment":1474,"conditions":27362,"interventions":27363},"NCT03289611","Preeclampsia Ratio (sFlt-1\u002FPlGF)",[94],"2020-08-27","2018-04-26",[8323],[27342],{"intervention":27365,"totalTrials":180,"cells":27366},"BNP",{"EARLY_PHASE1":27367,"PHASE1":27369,"PHASE2":27371,"PHASE3":27373,"PHASE4":27375,"NA":27377},{"trials":27368,"activeCount":102},[],{"trials":27370,"activeCount":102},[],{"trials":27372,"activeCount":102},[],{"trials":27374,"activeCount":102},[],{"trials":27376,"activeCount":102},[],{"trials":27378,"activeCount":102},[27379],{"nctId":27380,"briefTitle":27381,"status":139,"phases":27382,"primaryCompletion":2225,"completion":2225,"start":27383,"enrollment":5557,"conditions":27384,"interventions":27387},"NCT02041663","Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis",[94],"2012-03-05",[27385,2462,27386],"Meningococcal Infections","Severe Sepsis",[27365],{"intervention":27389,"totalTrials":180,"cells":27390},"COMT polymorphism",{"EARLY_PHASE1":27391,"PHASE1":27393,"PHASE2":27395,"PHASE3":27397,"PHASE4":27399,"NA":27401},{"trials":27392,"activeCount":102},[],{"trials":27394,"activeCount":102},[],{"trials":27396,"activeCount":102},[],{"trials":27398,"activeCount":102},[],{"trials":27400,"activeCount":102},[],{"trials":27402,"activeCount":102},[27403],{"nctId":27404,"briefTitle":27405,"status":139,"phases":27406,"primaryCompletion":5701,"completion":5701,"start":11220,"enrollment":27407,"conditions":27408,"interventions":27413},"NCT01570699","Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients",[],87,[27409,27410,27411,27412],"Opioid-related Disorders","Opiate Dependence","Opiate Addiction","Opiate Abuse",[27389],{"intervention":27415,"totalTrials":180,"cells":27416},"intravenous morphine titration",{"EARLY_PHASE1":27417,"PHASE1":27419,"PHASE2":27421,"PHASE3":27423,"PHASE4":27425,"NA":27427},{"trials":27418,"activeCount":102},[],{"trials":27420,"activeCount":102},[],{"trials":27422,"activeCount":102},[],{"trials":27424,"activeCount":102},[],{"trials":27426,"activeCount":102},[],{"trials":27428,"activeCount":102},[27429],{"nctId":27430,"briefTitle":27431,"status":139,"phases":27432,"primaryCompletion":13261,"completion":13261,"start":11197,"enrollment":27433,"conditions":27434,"interventions":27436},"NCT00822549","Pharmacokinetic, Pharmacodynamic and Pharmacogenetic of Morphine After Surgery",[],438,[27435],"Orthopaedic Surgery",[27415],{"intervention":27438,"totalTrials":180,"cells":27439},"PET with 11C-Flumazenil",{"EARLY_PHASE1":27440,"PHASE1":27442,"PHASE2":27444,"PHASE3":27446,"PHASE4":27448,"NA":27450},{"trials":27441,"activeCount":102},[],{"trials":27443,"activeCount":102},[],{"trials":27445,"activeCount":102},[],{"trials":27447,"activeCount":102},[],{"trials":27449,"activeCount":102},[],{"trials":27451,"activeCount":102},[27452],{"nctId":27453,"briefTitle":27454,"status":110,"phases":27455,"primaryCompletion":19186,"completion":19186,"start":386,"enrollment":303,"conditions":27456,"interventions":27457},"NCT01651520","Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis",[94],[6488],[27438],{"intervention":27459,"totalTrials":180,"cells":27460},"COL4A1 genetic testing",{"EARLY_PHASE1":27461,"PHASE1":27463,"PHASE2":27465,"PHASE3":27467,"PHASE4":27469,"NA":27471},{"trials":27462,"activeCount":102},[],{"trials":27464,"activeCount":102},[],{"trials":27466,"activeCount":102},[],{"trials":27468,"activeCount":102},[],{"trials":27470,"activeCount":102},[],{"trials":27472,"activeCount":102},[27473],{"nctId":27474,"briefTitle":27475,"status":139,"phases":27476,"primaryCompletion":8005,"completion":8005,"start":5418,"enrollment":4073,"conditions":27477,"interventions":27479},"NCT01097564","COL4A1 Gene Related Cerebra-retinal Angiopathy",[],[27478],"Cerebra-retinal Angiopathy",[27459],{"intervention":27481,"totalTrials":180,"cells":27482},"Bio-specimen collected",{"EARLY_PHASE1":27483,"PHASE1":27485,"PHASE2":27487,"PHASE3":27489,"PHASE4":27491,"NA":27493},{"trials":27484,"activeCount":102},[],{"trials":27486,"activeCount":102},[],{"trials":27488,"activeCount":102},[],{"trials":27490,"activeCount":102},[],{"trials":27492,"activeCount":102},[],{"trials":27494,"activeCount":102},[27495],{"nctId":27496,"briefTitle":27497,"status":110,"phases":27498,"primaryCompletion":12911,"completion":7933,"start":497,"enrollment":1732,"conditions":27499,"interventions":27501},"NCT03090841","Biomarkers of Cytomegalovirus Fetal Infection and Disease",[],[27500],"Cytomegalovirus Congenital",[27481],{"intervention":27503,"totalTrials":180,"cells":27504},"lidocaine \u002F Prilocaine",{"EARLY_PHASE1":27505,"PHASE1":27507,"PHASE2":27509,"PHASE3":27511,"PHASE4":27513,"NA":27515},{"trials":27506,"activeCount":102},[],{"trials":27508,"activeCount":102},[],{"trials":27510,"activeCount":102},[],{"trials":27512,"activeCount":102},[],{"trials":27514,"activeCount":102},[],{"trials":27516,"activeCount":102},[27517],{"nctId":27518,"briefTitle":27519,"status":110,"phases":27520,"enrollment":303,"conditions":27521,"interventions":27522},"NCT00309673","Local Anesthesia and Tuberculin Skin Test in Infants and Children",[94],[6995],[27503],{"intervention":27524,"totalTrials":180,"cells":27525},"with severe malaria hospitalized in ICU",{"EARLY_PHASE1":27526,"PHASE1":27528,"PHASE2":27530,"PHASE3":27532,"PHASE4":27534,"NA":27536},{"trials":27527,"activeCount":102},[],{"trials":27529,"activeCount":102},[],{"trials":27531,"activeCount":102},[],{"trials":27533,"activeCount":102},[],{"trials":27535,"activeCount":102},[],{"trials":27537,"activeCount":102},[27538],{"nctId":27539,"briefTitle":27540,"status":139,"phases":27541,"primaryCompletion":5900,"completion":5900,"start":11197,"enrollment":27542,"conditions":27543,"interventions":27544},"NCT00372684","PALUREA: Severe Imported Malaria in Adults",[],302,[11644],[27524,27545],"with uncomplicated malaria",{"intervention":27545,"totalTrials":180,"cells":27547},{"EARLY_PHASE1":27548,"PHASE1":27550,"PHASE2":27552,"PHASE3":27554,"PHASE4":27556,"NA":27558},{"trials":27549,"activeCount":102},[],{"trials":27551,"activeCount":102},[],{"trials":27553,"activeCount":102},[],{"trials":27555,"activeCount":102},[],{"trials":27557,"activeCount":102},[],{"trials":27559,"activeCount":102},[27560],{"nctId":27539,"briefTitle":27540,"status":139,"phases":27561,"primaryCompletion":5900,"completion":5900,"start":11197,"enrollment":27542,"conditions":27562,"interventions":27563},[],[11644],[27524,27545],{"intervention":27565,"totalTrials":180,"cells":27566},"Clindamycin and rifampicin dosages",{"EARLY_PHASE1":27567,"PHASE1":27569,"PHASE2":27571,"PHASE3":27573,"PHASE4":27575,"NA":27577},{"trials":27568,"activeCount":102},[],{"trials":27570,"activeCount":102},[],{"trials":27572,"activeCount":102},[],{"trials":27574,"activeCount":102},[],{"trials":27576,"activeCount":102},[],{"trials":27578,"activeCount":102},[27579],{"nctId":27580,"briefTitle":27581,"status":139,"phases":27582,"primaryCompletion":27583,"completion":27584,"start":27585,"enrollment":36,"conditions":27586,"interventions":27588},"NCT02782078","Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections",[94],"2018-12-12","2019-01-03","2017-03-06",[27587],"Staphylococcal Infections",[27565],{"intervention":27590,"totalTrials":180,"cells":27591},"Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban",{"EARLY_PHASE1":27592,"PHASE1":27594,"PHASE2":27596,"PHASE3":27598,"PHASE4":27600,"NA":27602},{"trials":27593,"activeCount":102},[],{"trials":27595,"activeCount":102},[],{"trials":27597,"activeCount":102},[],{"trials":27599,"activeCount":102},[],{"trials":27601,"activeCount":102},[],{"trials":27603,"activeCount":102},[27604],{"nctId":27605,"briefTitle":27606,"status":139,"phases":27607,"primaryCompletion":27608,"completion":27608,"start":1939,"enrollment":12651,"conditions":27609,"interventions":27610},"NCT02286414","Benefit\u002FRisk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over",[],"2021-11",[467],[27590,27611],"Vitamin K antagonist: warfarin, fluindione, acenocoumarol",{"intervention":27611,"totalTrials":180,"cells":27613},{"EARLY_PHASE1":27614,"PHASE1":27616,"PHASE2":27618,"PHASE3":27620,"PHASE4":27622,"NA":27624},{"trials":27615,"activeCount":102},[],{"trials":27617,"activeCount":102},[],{"trials":27619,"activeCount":102},[],{"trials":27621,"activeCount":102},[],{"trials":27623,"activeCount":102},[],{"trials":27625,"activeCount":102},[27626],{"nctId":27605,"briefTitle":27606,"status":139,"phases":27627,"primaryCompletion":27608,"completion":27608,"start":1939,"enrollment":12651,"conditions":27628,"interventions":27629},[],[467],[27590,27611],{"intervention":27631,"totalTrials":180,"cells":27632},"biomarker-guided strategy",{"EARLY_PHASE1":27633,"PHASE1":27635,"PHASE2":27637,"PHASE3":27639,"PHASE4":27641,"NA":27643},{"trials":27634,"activeCount":102},[],{"trials":27636,"activeCount":102},[],{"trials":27638,"activeCount":102},[],{"trials":27640,"activeCount":102},[],{"trials":27642,"activeCount":102},[],{"trials":27644,"activeCount":102},[27645],{"nctId":27646,"briefTitle":27647,"status":139,"phases":27648,"primaryCompletion":27649,"completion":27649,"start":27650,"enrollment":489,"conditions":27651,"interventions":27652},"NCT04774575","Quantify the Benefits of Biomarkers in Routine Patient Care in Kidney Transplant Recipients",[94],"2024-05-29","2021-12-15",[945],[27631],{"intervention":1838,"totalTrials":180,"cells":27654},{"EARLY_PHASE1":27655,"PHASE1":27657,"PHASE2":27659,"PHASE3":27661,"PHASE4":27663,"NA":27665},{"trials":27656,"activeCount":102},[],{"trials":27658,"activeCount":102},[],{"trials":27660,"activeCount":102},[],{"trials":27662,"activeCount":102},[],{"trials":27664,"activeCount":102},[],{"trials":27666,"activeCount":102},[27667],{"nctId":1830,"briefTitle":1831,"status":139,"phases":27668,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1225,"conditions":27669,"interventions":27670},[94],[1836],[1838,1795,1839],{"intervention":1839,"totalTrials":180,"cells":27672},{"EARLY_PHASE1":27673,"PHASE1":27675,"PHASE2":27677,"PHASE3":27679,"PHASE4":27681,"NA":27683},{"trials":27674,"activeCount":102},[],{"trials":27676,"activeCount":102},[],{"trials":27678,"activeCount":102},[],{"trials":27680,"activeCount":102},[],{"trials":27682,"activeCount":102},[],{"trials":27684,"activeCount":102},[27685],{"nctId":1830,"briefTitle":1831,"status":139,"phases":27686,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1225,"conditions":27687,"interventions":27688},[94],[1836],[1838,1795,1839],{"intervention":27690,"totalTrials":180,"cells":27691},"Liquid biopsies (blood, gastric fluid).",{"EARLY_PHASE1":27692,"PHASE1":27694,"PHASE2":27696,"PHASE3":27698,"PHASE4":27700,"NA":27702},{"trials":27693,"activeCount":102},[],{"trials":27695,"activeCount":102},[],{"trials":27697,"activeCount":102},[],{"trials":27699,"activeCount":102},[],{"trials":27701,"activeCount":102},[],{"trials":27703,"activeCount":102},[27704],{"nctId":27705,"briefTitle":27706,"status":139,"phases":27707,"primaryCompletion":15493,"completion":15493,"start":27708,"enrollment":1258,"conditions":27709,"interventions":27711},"NCT04253106","Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer",[94],"2020-11-26",[27710],"Hereditary Diffuse Gastric Cancer",[27690],{"intervention":27713,"totalTrials":180,"cells":27714},"Whole blood sample",{"EARLY_PHASE1":27715,"PHASE1":27717,"PHASE2":27719,"PHASE3":27721,"PHASE4":27723,"NA":27725},{"trials":27716,"activeCount":102},[],{"trials":27718,"activeCount":102},[],{"trials":27720,"activeCount":102},[],{"trials":27722,"activeCount":102},[],{"trials":27724,"activeCount":102},[],{"trials":27726,"activeCount":102},[27727],{"nctId":27728,"briefTitle":27729,"status":139,"phases":27730,"primaryCompletion":301,"completion":301,"start":12268,"enrollment":1108,"conditions":27731,"interventions":27734},"NCT00873678","Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome",[],[27732,27733],"Joubert Syndrome","Cerebello-oculo-renal Syndromes",[27713],{"intervention":27736,"totalTrials":180,"cells":27737},"Recipients",{"EARLY_PHASE1":27738,"PHASE1":27740,"PHASE2":27742,"PHASE3":27744,"PHASE4":27746,"NA":27748},{"trials":27739,"activeCount":102},[],{"trials":27741,"activeCount":102},[],{"trials":27743,"activeCount":102},[],{"trials":27745,"activeCount":102},[],{"trials":27747,"activeCount":102},[],{"trials":27749,"activeCount":102},[27750],{"nctId":27751,"briefTitle":27752,"status":139,"phases":27753,"primaryCompletion":27754,"completion":27754,"start":11949,"enrollment":19103,"conditions":27755,"interventions":27757},"NCT02194868","Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)",[],"2022-01-18",[27756],"Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies",[27736,27758],"Donors",{"intervention":27758,"totalTrials":180,"cells":27760},{"EARLY_PHASE1":27761,"PHASE1":27763,"PHASE2":27765,"PHASE3":27767,"PHASE4":27769,"NA":27771},{"trials":27762,"activeCount":102},[],{"trials":27764,"activeCount":102},[],{"trials":27766,"activeCount":102},[],{"trials":27768,"activeCount":102},[],{"trials":27770,"activeCount":102},[],{"trials":27772,"activeCount":102},[27773],{"nctId":27751,"briefTitle":27752,"status":139,"phases":27774,"primaryCompletion":27754,"completion":27754,"start":11949,"enrollment":19103,"conditions":27775,"interventions":27776},[],[27756],[27736,27758],{"intervention":27778,"totalTrials":180,"cells":27779},"collection of sample of perilymphatic fluid during cochlear implantation",{"EARLY_PHASE1":27780,"PHASE1":27782,"PHASE2":27784,"PHASE3":27786,"PHASE4":27788,"NA":27790},{"trials":27781,"activeCount":102},[],{"trials":27783,"activeCount":102},[],{"trials":27785,"activeCount":102},[],{"trials":27787,"activeCount":102},[],{"trials":27789,"activeCount":102},[],{"trials":27791,"activeCount":102},[27792],{"nctId":27793,"briefTitle":27794,"status":110,"phases":27795,"primaryCompletion":27796,"completion":27796,"start":27797,"enrollment":1015,"conditions":27798,"interventions":27800},"NCT04724265","Cytomegalovirus (CMV) Perilymphatic Fluid",[94],"2022-12-10","2020-12-10",[27799,27500],"Hearing Loss, Cochlear",[27778],{"intervention":27802,"totalTrials":180,"cells":27803},"Remdesivir",{"EARLY_PHASE1":27804,"PHASE1":27806,"PHASE2":27808,"PHASE3":27810,"PHASE4":27812,"NA":27814},{"trials":27805,"activeCount":102},[],{"trials":27807,"activeCount":102},[],{"trials":27809,"activeCount":102},[],{"trials":27811,"activeCount":102},[],{"trials":27813,"activeCount":102},[],{"trials":27815,"activeCount":102},[27816],{"nctId":27817,"briefTitle":27818,"status":139,"phases":27819,"primaryCompletion":27820,"completion":27820,"start":22437,"enrollment":1474,"conditions":27821,"interventions":27822},"NCT04365725","Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",[],"2020-06-12",[15],[27802],{"intervention":27824,"totalTrials":180,"cells":27825},"18F-DPA-714 and 18F-FDG",{"EARLY_PHASE1":27826,"PHASE1":27828,"PHASE2":27830,"PHASE3":27832,"PHASE4":27834,"NA":27836},{"trials":27827,"activeCount":102},[],{"trials":27829,"activeCount":102},[],{"trials":27831,"activeCount":102},[],{"trials":27833,"activeCount":102},[],{"trials":27835,"activeCount":102},[],{"trials":27837,"activeCount":102},[27838],{"nctId":27839,"briefTitle":27840,"status":139,"phases":27841,"primaryCompletion":27842,"completion":27842,"start":27843,"enrollment":15216,"conditions":27844,"interventions":27848},"NCT02305264","Imaging of Intracerebral Inflammation in MS",[94],"2018-09-10","2012-03-19",[27845,27846,27847],"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Secondary Progressive","Multiple Sclerosis, Primary Progressive",[27824],{"intervention":27850,"totalTrials":180,"cells":27851},"Fibrinogen concentration by the qLabs®FIB Monitoring system",{"EARLY_PHASE1":27852,"PHASE1":27854,"PHASE2":27856,"PHASE3":27858,"PHASE4":27860,"NA":27862},{"trials":27853,"activeCount":102},[],{"trials":27855,"activeCount":102},[],{"trials":27857,"activeCount":102},[],{"trials":27859,"activeCount":102},[],{"trials":27861,"activeCount":102},[],{"trials":27863,"activeCount":102},[27864],{"nctId":27865,"briefTitle":27866,"status":139,"phases":27867,"primaryCompletion":27868,"completion":27868,"start":27869,"enrollment":400,"conditions":27870,"interventions":27872},"NCT06255002","Concordance Between the Measurement of Whole Blood Fibrinogen by the qLabs®FIB Analyzer and Its Measurement by Conventional Method (Clauss Fibrinogen) in the Context of Severe Postpartum Haemorrhage",[],"2026-03-02","2024-06-03",[27871],"Postpartum Hemorrhage",[27850],{"intervention":27874,"totalTrials":180,"cells":27875},"sampling",{"EARLY_PHASE1":27876,"PHASE1":27878,"PHASE2":27880,"PHASE3":27882,"PHASE4":27884,"NA":27886},{"trials":27877,"activeCount":102},[],{"trials":27879,"activeCount":102},[],{"trials":27881,"activeCount":102},[],{"trials":27883,"activeCount":102},[],{"trials":27885,"activeCount":102},[],{"trials":27887,"activeCount":102},[27888],{"nctId":27889,"briefTitle":27890,"status":110,"phases":27891,"primaryCompletion":9934,"completion":17682,"start":8061,"enrollment":303,"conditions":27892,"interventions":27894},"NCT02693340","Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease",[],[27893],"Inflammatory Bowel Disease",[27874],{"intervention":27896,"totalTrials":180,"cells":27897},"Dexamethasone + ondansetron + Placebo",{"EARLY_PHASE1":27898,"PHASE1":27900,"PHASE2":27902,"PHASE3":27904,"PHASE4":27906,"NA":27908},{"trials":27899,"activeCount":102},[],{"trials":27901,"activeCount":102},[],{"trials":27903,"activeCount":102},[],{"trials":27905,"activeCount":102},[],{"trials":27907,"activeCount":102},[],{"trials":27909,"activeCount":102},[27910],{"nctId":27911,"briefTitle":27912,"status":139,"phases":27913,"primaryCompletion":12380,"completion":13563,"start":13261,"enrollment":27914,"conditions":27915,"interventions":27917},"NCT01739985","Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis",[94],322,[27916],"Postoperative Vomiting",[27896,27918],"Dexamethasone + ondansetron + Droperidol",{"intervention":27918,"totalTrials":180,"cells":27920},{"EARLY_PHASE1":27921,"PHASE1":27923,"PHASE2":27925,"PHASE3":27927,"PHASE4":27929,"NA":27931},{"trials":27922,"activeCount":102},[],{"trials":27924,"activeCount":102},[],{"trials":27926,"activeCount":102},[],{"trials":27928,"activeCount":102},[],{"trials":27930,"activeCount":102},[],{"trials":27932,"activeCount":102},[27933],{"nctId":27911,"briefTitle":27912,"status":139,"phases":27934,"primaryCompletion":12380,"completion":13563,"start":13261,"enrollment":27914,"conditions":27935,"interventions":27936},[94],[27916],[27896,27918],{"intervention":27938,"totalTrials":180,"cells":27939},"Genetic blood collection",{"EARLY_PHASE1":27940,"PHASE1":27942,"PHASE2":27944,"PHASE3":27946,"PHASE4":27948,"NA":27950},{"trials":27941,"activeCount":102},[],{"trials":27943,"activeCount":102},[],{"trials":27945,"activeCount":102},[],{"trials":27947,"activeCount":102},[],{"trials":27949,"activeCount":102},[],{"trials":27951,"activeCount":102},[27952],{"nctId":27953,"briefTitle":27954,"status":139,"phases":27955,"primaryCompletion":13873,"completion":13873,"start":17564,"enrollment":19103,"conditions":27956,"interventions":27957},"NCT04703114","Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV)",[94],[26,19266],[27938],{"intervention":27959,"totalTrials":180,"cells":27960},"Urine and stoll samples",{"EARLY_PHASE1":27961,"PHASE1":27963,"PHASE2":27965,"PHASE3":27967,"PHASE4":27969,"NA":27971},{"trials":27962,"activeCount":102},[],{"trials":27964,"activeCount":102},[],{"trials":27966,"activeCount":102},[],{"trials":27968,"activeCount":102},[],{"trials":27970,"activeCount":102},[],{"trials":27972,"activeCount":102},[27973],{"nctId":27974,"briefTitle":27975,"status":139,"phases":27976,"primaryCompletion":27977,"completion":27977,"start":27978,"enrollment":27979,"conditions":27980,"interventions":27982},"NCT05171452","Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease",[],"2020-10-19","2019-10-03",101,[27981],"Inflammatory Bowel Diseases",[27959],{"intervention":27984,"totalTrials":180,"cells":27985},"Genetic screening",{"EARLY_PHASE1":27986,"PHASE1":27988,"PHASE2":27990,"PHASE3":27992,"PHASE4":27994,"NA":27996},{"trials":27987,"activeCount":102},[],{"trials":27989,"activeCount":102},[],{"trials":27991,"activeCount":102},[],{"trials":27993,"activeCount":102},[],{"trials":27995,"activeCount":102},[],{"trials":27997,"activeCount":102},[27998],{"nctId":27999,"briefTitle":28000,"status":110,"phases":28001,"primaryCompletion":9933,"completion":8411,"start":535,"enrollment":28002,"conditions":28003,"interventions":28005},"NCT02297035","Characterisation of Primary Progressives Aphasias",[94],155,[28004],"Aphasia Primary Progressive",[27984],{"intervention":28007,"totalTrials":180,"cells":28008},"Iohexol",{"EARLY_PHASE1":28009,"PHASE1":28011,"PHASE2":28013,"PHASE3":28015,"PHASE4":28017,"NA":28019},{"trials":28010,"activeCount":102},[],{"trials":28012,"activeCount":102},[],{"trials":28014,"activeCount":102},[],{"trials":28016,"activeCount":102},[],{"trials":28018,"activeCount":102},[],{"trials":28020,"activeCount":102},[28021],{"nctId":28022,"briefTitle":28023,"status":139,"phases":28024,"primaryCompletion":28025,"completion":28025,"start":15080,"enrollment":5804,"conditions":28026,"interventions":28028},"NCT04776486","Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance",[94],"2026-01-29",[28027,10942],"Augmented Renal Clearance",[28007],{"intervention":28030,"totalTrials":180,"cells":28031},"Instillation of cyclopentolate",{"EARLY_PHASE1":28032,"PHASE1":28034,"PHASE2":28036,"PHASE3":28038,"PHASE4":28040,"NA":28042},{"trials":28033,"activeCount":102},[],{"trials":28035,"activeCount":102},[],{"trials":28037,"activeCount":102},[],{"trials":28039,"activeCount":102},[],{"trials":28041,"activeCount":102},[],{"trials":28043,"activeCount":102},[28044],{"nctId":28045,"briefTitle":28046,"status":139,"phases":28047,"primaryCompletion":28048,"completion":28048,"start":20408,"enrollment":5419,"conditions":28049,"interventions":28053},"NCT05204069","Screening for 3-D Visual Disorders in Preschool Children",[94],"2021-09-01",[28050,28051,28052],"Amblyopia","Strabismus","Anisometropia",[28030],{"intervention":28055,"totalTrials":180,"cells":28056},"Regular serum screening",{"EARLY_PHASE1":28057,"PHASE1":28059,"PHASE2":28061,"PHASE3":28063,"PHASE4":28065,"NA":28067},{"trials":28058,"activeCount":102},[],{"trials":28060,"activeCount":102},[],{"trials":28062,"activeCount":102},[],{"trials":28064,"activeCount":102},[],{"trials":28066,"activeCount":102},[],{"trials":28068,"activeCount":102},[28069],{"nctId":28070,"briefTitle":28071,"status":139,"phases":28072,"primaryCompletion":14556,"completion":17238,"start":989,"enrollment":28073,"conditions":28074,"interventions":28076},"NCT02424474","T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients",[94],933,[28075],"Trisomy 21, 18 and 13 Screening",[28055],{"intervention":28078,"totalTrials":180,"cells":28079},"mutation",{"EARLY_PHASE1":28080,"PHASE1":28082,"PHASE2":28084,"PHASE3":28086,"PHASE4":28088,"NA":28090},{"trials":28081,"activeCount":102},[],{"trials":28083,"activeCount":102},[],{"trials":28085,"activeCount":102},[],{"trials":28087,"activeCount":102},[],{"trials":28089,"activeCount":102},[],{"trials":28091,"activeCount":102},[28092],{"nctId":28093,"briefTitle":28094,"status":139,"phases":28095,"primaryCompletion":7866,"completion":7866,"start":1708,"enrollment":28096,"conditions":28097,"interventions":28099},"NCT00541060","Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype",[94],390,[28098],"Dental Caries",[28078],{"intervention":28101,"totalTrials":180,"cells":28102},"Orkambi",{"EARLY_PHASE1":28103,"PHASE1":28105,"PHASE2":28107,"PHASE3":28109,"PHASE4":28111,"NA":28113},{"trials":28104,"activeCount":102},[],{"trials":28106,"activeCount":102},[],{"trials":28108,"activeCount":102},[],{"trials":28110,"activeCount":102},[],{"trials":28112,"activeCount":102},[],{"trials":28114,"activeCount":102},[28115],{"nctId":28116,"briefTitle":28117,"status":139,"phases":28118,"primaryCompletion":28119,"completion":2251,"start":28120,"enrollment":17793,"conditions":28121,"interventions":28123},"NCT03894657","Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.",[94],"2021-11-25","2019-12-18",[23,28122],"Homozygous F508del Mutation",[28101],{"intervention":28125,"totalTrials":180,"cells":28126},"immunogenetics",{"EARLY_PHASE1":28127,"PHASE1":28129,"PHASE2":28131,"PHASE3":28133,"PHASE4":28135,"NA":28137},{"trials":28128,"activeCount":102},[],{"trials":28130,"activeCount":102},[],{"trials":28132,"activeCount":102},[],{"trials":28134,"activeCount":102},[],{"trials":28136,"activeCount":102},[],{"trials":28138,"activeCount":102},[28139],{"nctId":28140,"briefTitle":28141,"status":110,"phases":28142,"primaryCompletion":28143,"completion":28144,"start":28145,"enrollment":3299,"conditions":28146,"interventions":28149},"NCT04236349","Tuberculosis Cohort in the North of Paris",[],"2020-01-31","2021-01-31","2018-05-01",[28147,28148],"Pulmonary Tuberculosis","Extra Pulmonary Tuberculosis",[28125],{"intervention":28151,"totalTrials":180,"cells":28152},"Identification of biological markers",{"EARLY_PHASE1":28153,"PHASE1":28155,"PHASE2":28157,"PHASE3":28159,"PHASE4":28161,"NA":28163},{"trials":28154,"activeCount":102},[],{"trials":28156,"activeCount":102},[],{"trials":28158,"activeCount":102},[],{"trials":28160,"activeCount":102},[],{"trials":28162,"activeCount":102},[],{"trials":28164,"activeCount":102},[28165],{"nctId":28166,"briefTitle":28167,"status":139,"phases":28168,"primaryCompletion":5518,"completion":28169,"start":301,"enrollment":941,"conditions":28170,"interventions":28172},"NCT02113917","Children and Adult Hemophagocytic Syndrome (HLHa)",[],"2017-01-12",[28171],"Hemophagocytic Syndrome",[28151],{"intervention":7908,"totalTrials":180,"cells":28174},{"EARLY_PHASE1":28175,"PHASE1":28177,"PHASE2":28179,"PHASE3":28181,"PHASE4":28183,"NA":28185},{"trials":28176,"activeCount":102},[],{"trials":28178,"activeCount":102},[],{"trials":28180,"activeCount":102},[],{"trials":28182,"activeCount":102},[],{"trials":28184,"activeCount":102},[],{"trials":28186,"activeCount":102},[28187],{"nctId":7902,"briefTitle":7903,"status":139,"phases":28188,"primaryCompletion":7905,"completion":7905,"start":1749,"enrollment":21,"conditions":28189,"interventions":28190},[],[1534],[7804,7908],{"intervention":28192,"totalTrials":180,"cells":28193},"Oil special 107 and MYGLIOL 810",{"EARLY_PHASE1":28194,"PHASE1":28196,"PHASE2":28198,"PHASE3":28200,"PHASE4":28202,"NA":28204},{"trials":28195,"activeCount":102},[],{"trials":28197,"activeCount":102},[],{"trials":28199,"activeCount":102},[],{"trials":28201,"activeCount":102},[],{"trials":28203,"activeCount":102},[],{"trials":28205,"activeCount":102},[28206],{"nctId":28207,"briefTitle":28208,"status":139,"phases":28209,"primaryCompletion":14737,"completion":14737,"start":11813,"enrollment":36,"conditions":28210,"interventions":28212},"NCT00328159","Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids",[94],[28211],"Inborn Errors of Metabolism",[28192],{"intervention":28214,"totalTrials":180,"cells":28215},"Dupilumab",{"EARLY_PHASE1":28216,"PHASE1":28218,"PHASE2":28220,"PHASE3":28222,"PHASE4":28224,"NA":28226},{"trials":28217,"activeCount":102},[],{"trials":28219,"activeCount":102},[],{"trials":28221,"activeCount":102},[],{"trials":28223,"activeCount":102},[],{"trials":28225,"activeCount":102},[],{"trials":28227,"activeCount":102},[28228],{"nctId":28229,"briefTitle":28230,"status":139,"phases":28231,"primaryCompletion":20010,"completion":20010,"start":28232,"enrollment":157,"conditions":28233,"interventions":28234},"NCT04022447","Dupilumab for Severe Asthma in a Real Life Setting",[],"2018-08-10",[8217],[28214],{"intervention":28236,"totalTrials":180,"cells":28237},"collection of biological samples",{"EARLY_PHASE1":28238,"PHASE1":28240,"PHASE2":28242,"PHASE3":28244,"PHASE4":28246,"NA":28248},{"trials":28239,"activeCount":102},[],{"trials":28241,"activeCount":102},[],{"trials":28243,"activeCount":102},[],{"trials":28245,"activeCount":102},[],{"trials":28247,"activeCount":102},[],{"trials":28249,"activeCount":102},[28250],{"nctId":28251,"briefTitle":28252,"status":139,"phases":28253,"primaryCompletion":8014,"completion":8014,"start":1116,"enrollment":28254,"conditions":28255,"interventions":28256},"NCT04355234","Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns",[94],2446,[4410],[28236],{"intervention":28258,"totalTrials":180,"cells":28259},"\"Collection of additional blood tubes; Biobanking (plasma, liver tissue).",{"EARLY_PHASE1":28260,"PHASE1":28262,"PHASE2":28264,"PHASE3":28266,"PHASE4":28268,"NA":28270},{"trials":28261,"activeCount":102},[],{"trials":28263,"activeCount":102},[],{"trials":28265,"activeCount":102},[],{"trials":28267,"activeCount":102},[],{"trials":28269,"activeCount":102},[],{"trials":28271,"activeCount":102},[28272],{"nctId":28273,"briefTitle":28274,"status":110,"phases":28275,"primaryCompletion":28276,"completion":5939,"start":14804,"enrollment":1130,"conditions":28277,"interventions":28281},"NCT03968354","NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)",[],"2021-06",[28278,28279,28280],"Diabetes type2","NASH - Nonalcoholic Steatohepatitis","NAFLD",[28258],{"intervention":28283,"totalTrials":180,"cells":28284},"genetic diagnosis",{"EARLY_PHASE1":28285,"PHASE1":28287,"PHASE2":28289,"PHASE3":28291,"PHASE4":28293,"NA":28295},{"trials":28286,"activeCount":102},[],{"trials":28288,"activeCount":102},[],{"trials":28290,"activeCount":102},[],{"trials":28292,"activeCount":102},[],{"trials":28294,"activeCount":102},[],{"trials":28296,"activeCount":102},[28297],{"nctId":28298,"briefTitle":28299,"status":139,"phases":28300,"primaryCompletion":301,"completion":301,"start":9997,"enrollment":1330,"conditions":28301,"interventions":28303},"NCT01022957","Nephronophthisis : Clinical and Genetic Study",[94],[28302],"Nephronophthisis",[28283],{"intervention":28305,"totalTrials":180,"cells":28306},"Plasma determination of iron, transferrin and ferritin",{"EARLY_PHASE1":28307,"PHASE1":28309,"PHASE2":28311,"PHASE3":28313,"PHASE4":28315,"NA":28317},{"trials":28308,"activeCount":102},[],{"trials":28310,"activeCount":102},[],{"trials":28312,"activeCount":102},[],{"trials":28314,"activeCount":102},[],{"trials":28316,"activeCount":102},[],{"trials":28318,"activeCount":102},[28319],{"nctId":28320,"briefTitle":28321,"status":139,"phases":28322,"primaryCompletion":28323,"completion":28323,"start":28324,"enrollment":28325,"conditions":28326,"interventions":28328},"NCT05133999","Iron and Retinopathy of Prematurity (ROP)",[],"2025-08-18","2022-04-28",175,[28327],"Retinopathy of Prematurity",[28305],{"intervention":28330,"totalTrials":180,"cells":28331},"Predetermined treatment duration",{"EARLY_PHASE1":28332,"PHASE1":28334,"PHASE2":28336,"PHASE3":28338,"PHASE4":28340,"NA":28342},{"trials":28333,"activeCount":102},[],{"trials":28335,"activeCount":102},[],{"trials":28337,"activeCount":102},[],{"trials":28339,"activeCount":102},[],{"trials":28341,"activeCount":102},[],{"trials":28343,"activeCount":102},[28344],{"nctId":28345,"briefTitle":28346,"status":110,"phases":28347,"primaryCompletion":1731,"completion":1731,"start":1128,"enrollment":10508,"conditions":28348,"interventions":28349},"NCT04166110","Antibiotic Therapy In Respiratory Tract Infections",[94],[4382],[28330,28350],"Variable treatment duration",{"intervention":28350,"totalTrials":180,"cells":28352},{"EARLY_PHASE1":28353,"PHASE1":28355,"PHASE2":28357,"PHASE3":28359,"PHASE4":28361,"NA":28363},{"trials":28354,"activeCount":102},[],{"trials":28356,"activeCount":102},[],{"trials":28358,"activeCount":102},[],{"trials":28360,"activeCount":102},[],{"trials":28362,"activeCount":102},[],{"trials":28364,"activeCount":102},[28365],{"nctId":28345,"briefTitle":28346,"status":110,"phases":28366,"primaryCompletion":1731,"completion":1731,"start":1128,"enrollment":10508,"conditions":28367,"interventions":28368},[94],[4382],[28330,28350],{"intervention":28370,"totalTrials":180,"cells":28371},"lithium treatment",{"EARLY_PHASE1":28372,"PHASE1":28374,"PHASE2":28376,"PHASE3":28378,"PHASE4":28380,"NA":28382},{"trials":28373,"activeCount":102},[],{"trials":28375,"activeCount":102},[],{"trials":28377,"activeCount":102},[],{"trials":28379,"activeCount":102},[],{"trials":28381,"activeCount":102},[],{"trials":28383,"activeCount":102},[28384],{"nctId":28385,"briefTitle":28386,"status":110,"phases":28387,"primaryCompletion":61,"completion":61,"start":28388,"enrollment":19187,"conditions":28389,"interventions":28391},"NCT04209140","Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative",[],"2020-01-10",[28390],"Bipolar I Disorder",[28370],{"intervention":28393,"totalTrials":180,"cells":28394},"Bacteriological analyses on clinical samples performed with Eswabs",{"EARLY_PHASE1":28395,"PHASE1":28397,"PHASE2":28399,"PHASE3":28401,"PHASE4":28403,"NA":28405},{"trials":28396,"activeCount":102},[],{"trials":28398,"activeCount":102},[],{"trials":28400,"activeCount":102},[],{"trials":28402,"activeCount":102},[],{"trials":28404,"activeCount":102},[],{"trials":28406,"activeCount":102},[28407],{"nctId":28408,"briefTitle":28409,"status":139,"phases":28410,"primaryCompletion":28411,"completion":28411,"start":28412,"enrollment":28413,"conditions":28414,"interventions":28416},"NCT02471937","Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection",[94],"2016-04-28","2015-06-01",151,[28415],"Vaginal Colonization With GBS",[28393],{"intervention":28418,"totalTrials":180,"cells":28419},"Mass spectrometry",{"EARLY_PHASE1":28420,"PHASE1":28422,"PHASE2":28424,"PHASE3":28426,"PHASE4":28428,"NA":28430},{"trials":28421,"activeCount":102},[],{"trials":28423,"activeCount":102},[],{"trials":28425,"activeCount":102},[],{"trials":28427,"activeCount":102},[],{"trials":28429,"activeCount":102},[],{"trials":28431,"activeCount":102},[28432],{"nctId":28433,"briefTitle":28434,"status":139,"phases":28435,"primaryCompletion":8868,"completion":8868,"start":28436,"enrollment":3922,"conditions":28437,"interventions":28438},"NCT04868799","Finding New Targets by Proteomic Approaches (InnovRT1)",[],"2022-08-12",[24943],[28418],{"intervention":28440,"totalTrials":180,"cells":28441},"Deep nasopharyngeal swab",{"EARLY_PHASE1":28442,"PHASE1":28444,"PHASE2":28446,"PHASE3":28448,"PHASE4":28450,"NA":28452},{"trials":28443,"activeCount":102},[],{"trials":28445,"activeCount":102},[],{"trials":28447,"activeCount":102},[],{"trials":28449,"activeCount":102},[],{"trials":28451,"activeCount":102},[],{"trials":28453,"activeCount":102},[28454],{"nctId":28455,"briefTitle":28456,"status":110,"phases":28457,"primaryCompletion":28458,"completion":28459,"start":28460,"enrollment":8227,"conditions":28461,"interventions":28463},"NCT05113836","LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2",[],"2022-01-05","2022-07-01","2020-12-19",[28462],"SARS-CoV2 Infection",[28440,28464],"Blood sample at D1, D3 and D7",{"intervention":28464,"totalTrials":180,"cells":28466},{"EARLY_PHASE1":28467,"PHASE1":28469,"PHASE2":28471,"PHASE3":28473,"PHASE4":28475,"NA":28477},{"trials":28468,"activeCount":102},[],{"trials":28470,"activeCount":102},[],{"trials":28472,"activeCount":102},[],{"trials":28474,"activeCount":102},[],{"trials":28476,"activeCount":102},[],{"trials":28478,"activeCount":102},[28479],{"nctId":28455,"briefTitle":28456,"status":110,"phases":28480,"primaryCompletion":28458,"completion":28459,"start":28460,"enrollment":8227,"conditions":28481,"interventions":28482},[],[28462],[28440,28464],{"intervention":28484,"totalTrials":180,"cells":28485},"Remifentanil",{"EARLY_PHASE1":28486,"PHASE1":28488,"PHASE2":28490,"PHASE3":28492,"PHASE4":28494,"NA":28496},{"trials":28487,"activeCount":102},[],{"trials":28489,"activeCount":102},[],{"trials":28491,"activeCount":102},[],{"trials":28493,"activeCount":102},[],{"trials":28495,"activeCount":102},[],{"trials":28497,"activeCount":102},[28498],{"nctId":28499,"briefTitle":28500,"status":139,"phases":28501,"primaryCompletion":28502,"completion":26540,"start":28503,"enrollment":1108,"conditions":28504,"interventions":28506},"NCT03498820","Analgesia-Nociception Index Guided Intraoperative Remifentanil Administration Versus Standard Practice:Evaluation of Perioperative Opioid Use",[94],"2019-12-19","2018-11-19",[5146,28505],"Anesthesia",[28484],{"intervention":7688,"totalTrials":180,"cells":28508},{"EARLY_PHASE1":28509,"PHASE1":28511,"PHASE2":28513,"PHASE3":28515,"PHASE4":28517,"NA":28519},{"trials":28510,"activeCount":102},[],{"trials":28512,"activeCount":102},[],{"trials":28514,"activeCount":102},[],{"trials":28516,"activeCount":102},[],{"trials":28518,"activeCount":102},[],{"trials":28520,"activeCount":102},[28521],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28522,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28523,"interventions":28524},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7689,"totalTrials":180,"cells":28526},{"EARLY_PHASE1":28527,"PHASE1":28529,"PHASE2":28531,"PHASE3":28533,"PHASE4":28535,"NA":28537},{"trials":28528,"activeCount":102},[],{"trials":28530,"activeCount":102},[],{"trials":28532,"activeCount":102},[],{"trials":28534,"activeCount":102},[],{"trials":28536,"activeCount":102},[],{"trials":28538,"activeCount":102},[28539],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28540,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28541,"interventions":28542},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7690,"totalTrials":180,"cells":28544},{"EARLY_PHASE1":28545,"PHASE1":28547,"PHASE2":28549,"PHASE3":28551,"PHASE4":28553,"NA":28555},{"trials":28546,"activeCount":102},[],{"trials":28548,"activeCount":102},[],{"trials":28550,"activeCount":102},[],{"trials":28552,"activeCount":102},[],{"trials":28554,"activeCount":102},[],{"trials":28556,"activeCount":102},[28557],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28558,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28559,"interventions":28560},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7691,"totalTrials":180,"cells":28562},{"EARLY_PHASE1":28563,"PHASE1":28565,"PHASE2":28567,"PHASE3":28569,"PHASE4":28571,"NA":28573},{"trials":28564,"activeCount":102},[],{"trials":28566,"activeCount":102},[],{"trials":28568,"activeCount":102},[],{"trials":28570,"activeCount":102},[],{"trials":28572,"activeCount":102},[],{"trials":28574,"activeCount":102},[28575],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28576,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28577,"interventions":28578},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7692,"totalTrials":180,"cells":28580},{"EARLY_PHASE1":28581,"PHASE1":28583,"PHASE2":28585,"PHASE3":28587,"PHASE4":28589,"NA":28591},{"trials":28582,"activeCount":102},[],{"trials":28584,"activeCount":102},[],{"trials":28586,"activeCount":102},[],{"trials":28588,"activeCount":102},[],{"trials":28590,"activeCount":102},[],{"trials":28592,"activeCount":102},[28593],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28594,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28595,"interventions":28596},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7693,"totalTrials":180,"cells":28598},{"EARLY_PHASE1":28599,"PHASE1":28601,"PHASE2":28603,"PHASE3":28605,"PHASE4":28607,"NA":28609},{"trials":28600,"activeCount":102},[],{"trials":28602,"activeCount":102},[],{"trials":28604,"activeCount":102},[],{"trials":28606,"activeCount":102},[],{"trials":28608,"activeCount":102},[],{"trials":28610,"activeCount":102},[28611],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28612,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28613,"interventions":28614},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7695,"totalTrials":180,"cells":28616},{"EARLY_PHASE1":28617,"PHASE1":28619,"PHASE2":28621,"PHASE3":28623,"PHASE4":28625,"NA":28627},{"trials":28618,"activeCount":102},[],{"trials":28620,"activeCount":102},[],{"trials":28622,"activeCount":102},[],{"trials":28624,"activeCount":102},[],{"trials":28626,"activeCount":102},[],{"trials":28628,"activeCount":102},[28629],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28630,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28631,"interventions":28632},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7696,"totalTrials":180,"cells":28634},{"EARLY_PHASE1":28635,"PHASE1":28637,"PHASE2":28639,"PHASE3":28641,"PHASE4":28643,"NA":28645},{"trials":28636,"activeCount":102},[],{"trials":28638,"activeCount":102},[],{"trials":28640,"activeCount":102},[],{"trials":28642,"activeCount":102},[],{"trials":28644,"activeCount":102},[],{"trials":28646,"activeCount":102},[28647],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28648,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28649,"interventions":28650},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7697,"totalTrials":180,"cells":28652},{"EARLY_PHASE1":28653,"PHASE1":28655,"PHASE2":28657,"PHASE3":28659,"PHASE4":28661,"NA":28663},{"trials":28654,"activeCount":102},[],{"trials":28656,"activeCount":102},[],{"trials":28658,"activeCount":102},[],{"trials":28660,"activeCount":102},[],{"trials":28662,"activeCount":102},[],{"trials":28664,"activeCount":102},[28665],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28666,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28667,"interventions":28668},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7698,"totalTrials":180,"cells":28670},{"EARLY_PHASE1":28671,"PHASE1":28673,"PHASE2":28675,"PHASE3":28677,"PHASE4":28679,"NA":28681},{"trials":28672,"activeCount":102},[],{"trials":28674,"activeCount":102},[],{"trials":28676,"activeCount":102},[],{"trials":28678,"activeCount":102},[],{"trials":28680,"activeCount":102},[],{"trials":28682,"activeCount":102},[28683],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28684,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28685,"interventions":28686},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7699,"totalTrials":180,"cells":28688},{"EARLY_PHASE1":28689,"PHASE1":28691,"PHASE2":28693,"PHASE3":28695,"PHASE4":28697,"NA":28699},{"trials":28690,"activeCount":102},[],{"trials":28692,"activeCount":102},[],{"trials":28694,"activeCount":102},[],{"trials":28696,"activeCount":102},[],{"trials":28698,"activeCount":102},[],{"trials":28700,"activeCount":102},[28701],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28702,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28703,"interventions":28704},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7700,"totalTrials":180,"cells":28706},{"EARLY_PHASE1":28707,"PHASE1":28709,"PHASE2":28711,"PHASE3":28713,"PHASE4":28715,"NA":28717},{"trials":28708,"activeCount":102},[],{"trials":28710,"activeCount":102},[],{"trials":28712,"activeCount":102},[],{"trials":28714,"activeCount":102},[],{"trials":28716,"activeCount":102},[],{"trials":28718,"activeCount":102},[28719],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28720,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28721,"interventions":28722},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7701,"totalTrials":180,"cells":28724},{"EARLY_PHASE1":28725,"PHASE1":28727,"PHASE2":28729,"PHASE3":28731,"PHASE4":28733,"NA":28735},{"trials":28726,"activeCount":102},[],{"trials":28728,"activeCount":102},[],{"trials":28730,"activeCount":102},[],{"trials":28732,"activeCount":102},[],{"trials":28734,"activeCount":102},[],{"trials":28736,"activeCount":102},[28737],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28738,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28739,"interventions":28740},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7702,"totalTrials":180,"cells":28742},{"EARLY_PHASE1":28743,"PHASE1":28745,"PHASE2":28747,"PHASE3":28749,"PHASE4":28751,"NA":28753},{"trials":28744,"activeCount":102},[],{"trials":28746,"activeCount":102},[],{"trials":28748,"activeCount":102},[],{"trials":28750,"activeCount":102},[],{"trials":28752,"activeCount":102},[],{"trials":28754,"activeCount":102},[28755],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28756,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28757,"interventions":28758},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7703,"totalTrials":180,"cells":28760},{"EARLY_PHASE1":28761,"PHASE1":28763,"PHASE2":28765,"PHASE3":28767,"PHASE4":28769,"NA":28771},{"trials":28762,"activeCount":102},[],{"trials":28764,"activeCount":102},[],{"trials":28766,"activeCount":102},[],{"trials":28768,"activeCount":102},[],{"trials":28770,"activeCount":102},[],{"trials":28772,"activeCount":102},[28773],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28774,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28775,"interventions":28776},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7704,"totalTrials":180,"cells":28778},{"EARLY_PHASE1":28779,"PHASE1":28781,"PHASE2":28783,"PHASE3":28785,"PHASE4":28787,"NA":28789},{"trials":28780,"activeCount":102},[],{"trials":28782,"activeCount":102},[],{"trials":28784,"activeCount":102},[],{"trials":28786,"activeCount":102},[],{"trials":28788,"activeCount":102},[],{"trials":28790,"activeCount":102},[28791],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28792,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28793,"interventions":28794},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7705,"totalTrials":180,"cells":28796},{"EARLY_PHASE1":28797,"PHASE1":28799,"PHASE2":28801,"PHASE3":28803,"PHASE4":28805,"NA":28807},{"trials":28798,"activeCount":102},[],{"trials":28800,"activeCount":102},[],{"trials":28802,"activeCount":102},[],{"trials":28804,"activeCount":102},[],{"trials":28806,"activeCount":102},[],{"trials":28808,"activeCount":102},[28809],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28810,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28811,"interventions":28812},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7706,"totalTrials":180,"cells":28814},{"EARLY_PHASE1":28815,"PHASE1":28817,"PHASE2":28819,"PHASE3":28821,"PHASE4":28823,"NA":28825},{"trials":28816,"activeCount":102},[],{"trials":28818,"activeCount":102},[],{"trials":28820,"activeCount":102},[],{"trials":28822,"activeCount":102},[],{"trials":28824,"activeCount":102},[],{"trials":28826,"activeCount":102},[28827],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28828,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28829,"interventions":28830},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7707,"totalTrials":180,"cells":28832},{"EARLY_PHASE1":28833,"PHASE1":28835,"PHASE2":28837,"PHASE3":28839,"PHASE4":28841,"NA":28843},{"trials":28834,"activeCount":102},[],{"trials":28836,"activeCount":102},[],{"trials":28838,"activeCount":102},[],{"trials":28840,"activeCount":102},[],{"trials":28842,"activeCount":102},[],{"trials":28844,"activeCount":102},[28845],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28846,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28847,"interventions":28848},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7708,"totalTrials":180,"cells":28850},{"EARLY_PHASE1":28851,"PHASE1":28853,"PHASE2":28855,"PHASE3":28857,"PHASE4":28859,"NA":28861},{"trials":28852,"activeCount":102},[],{"trials":28854,"activeCount":102},[],{"trials":28856,"activeCount":102},[],{"trials":28858,"activeCount":102},[],{"trials":28860,"activeCount":102},[],{"trials":28862,"activeCount":102},[28863],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28864,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28865,"interventions":28866},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7710,"totalTrials":180,"cells":28868},{"EARLY_PHASE1":28869,"PHASE1":28871,"PHASE2":28873,"PHASE3":28875,"PHASE4":28877,"NA":28879},{"trials":28870,"activeCount":102},[],{"trials":28872,"activeCount":102},[],{"trials":28874,"activeCount":102},[],{"trials":28876,"activeCount":102},[],{"trials":28878,"activeCount":102},[],{"trials":28880,"activeCount":102},[28881],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28882,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28883,"interventions":28884},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":7711,"totalTrials":180,"cells":28886},{"EARLY_PHASE1":28887,"PHASE1":28889,"PHASE2":28891,"PHASE3":28893,"PHASE4":28895,"NA":28897},{"trials":28888,"activeCount":102},[],{"trials":28890,"activeCount":102},[],{"trials":28892,"activeCount":102},[],{"trials":28894,"activeCount":102},[],{"trials":28896,"activeCount":102},[],{"trials":28898,"activeCount":102},[28899],{"nctId":7679,"briefTitle":7680,"status":139,"phases":28900,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":7684,"conditions":28901,"interventions":28902},[],[7686],[7688,7689,7690,7691,7692,7693,7694,7695,7696,7697,7698,7699,7700,7701,7702,7703,7704,7705,7706,7707,7708,7709,7710,7711,7712],{"intervention":28904,"totalTrials":180,"cells":28905},"Gadolinium",{"EARLY_PHASE1":28906,"PHASE1":28908,"PHASE2":28910,"PHASE3":28912,"PHASE4":28914,"NA":28916},{"trials":28907,"activeCount":102},[],{"trials":28909,"activeCount":102},[],{"trials":28911,"activeCount":102},[],{"trials":28913,"activeCount":102},[],{"trials":28915,"activeCount":102},[],{"trials":28917,"activeCount":102},[28918],{"nctId":28919,"briefTitle":28920,"status":139,"phases":28921,"primaryCompletion":28922,"completion":28923,"start":8413,"enrollment":24,"conditions":28924,"interventions":28925},"NCT02948322","Cardiac (CMRI) Assessment of Acromegaly",[94],"2017-06-09","2019-02-28",[23958],[28904],{"intervention":28927,"totalTrials":180,"cells":28928},"cholecalciferol",{"EARLY_PHASE1":28929,"PHASE1":28931,"PHASE2":28933,"PHASE3":28935,"PHASE4":28937,"NA":28939},{"trials":28930,"activeCount":102},[],{"trials":28932,"activeCount":102},[],{"trials":28934,"activeCount":102},[],{"trials":28936,"activeCount":102},[],{"trials":28938,"activeCount":102},[],{"trials":28940,"activeCount":102},[28941],{"nctId":28942,"briefTitle":28943,"status":139,"phases":28944,"primaryCompletion":10067,"completion":10067,"start":301,"enrollment":36,"conditions":28945,"interventions":28947},"NCT01413230","Vitamin D Supplementation in Systemic Lupus Erythematosus",[],[28946],"Vitamin D Deficiency",[28927],{"intervention":28949,"totalTrials":180,"cells":28950},"AUC of MPA measure",{"EARLY_PHASE1":28951,"PHASE1":28953,"PHASE2":28955,"PHASE3":28957,"PHASE4":28959,"NA":28961},{"trials":28952,"activeCount":102},[],{"trials":28954,"activeCount":102},[],{"trials":28956,"activeCount":102},[],{"trials":28958,"activeCount":102},[],{"trials":28960,"activeCount":102},[],{"trials":28962,"activeCount":102},[28963],{"nctId":28964,"briefTitle":28965,"status":241,"phases":28966,"primaryCompletion":4923,"completion":4923,"start":28967,"enrollment":163,"conditions":28968,"interventions":28969},"NCT04244916","MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis",[],"2020-05-25",[325],[28949],{"intervention":28971,"totalTrials":180,"cells":28972},"Pfizer",{"EARLY_PHASE1":28973,"PHASE1":28975,"PHASE2":28977,"PHASE3":28979,"PHASE4":28981,"NA":28983},{"trials":28974,"activeCount":102},[],{"trials":28976,"activeCount":102},[],{"trials":28978,"activeCount":102},[],{"trials":28980,"activeCount":102},[],{"trials":28982,"activeCount":102},[],{"trials":28984,"activeCount":102},[28985],{"nctId":28986,"briefTitle":28987,"status":110,"phases":28988,"primaryCompletion":28989,"completion":24894,"start":12054,"enrollment":28990,"conditions":28991,"interventions":28993},"NCT04900467","Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine",[94],"2021-07-02",418,[28992],"Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose",[28971,28994],"Moderna",{"intervention":28994,"totalTrials":180,"cells":28996},{"EARLY_PHASE1":28997,"PHASE1":28999,"PHASE2":29001,"PHASE3":29003,"PHASE4":29005,"NA":29007},{"trials":28998,"activeCount":102},[],{"trials":29000,"activeCount":102},[],{"trials":29002,"activeCount":102},[],{"trials":29004,"activeCount":102},[],{"trials":29006,"activeCount":102},[],{"trials":29008,"activeCount":102},[29009],{"nctId":28986,"briefTitle":28987,"status":110,"phases":29010,"primaryCompletion":28989,"completion":24894,"start":12054,"enrollment":28990,"conditions":29011,"interventions":29012},[94],[28992],[28971,28994],{"intervention":24055,"totalTrials":180,"cells":29014},{"EARLY_PHASE1":29015,"PHASE1":29017,"PHASE2":29019,"PHASE3":29021,"PHASE4":29023,"NA":29025},{"trials":29016,"activeCount":102},[],{"trials":29018,"activeCount":102},[],{"trials":29020,"activeCount":102},[],{"trials":29022,"activeCount":102},[],{"trials":29024,"activeCount":102},[],{"trials":29026,"activeCount":102},[29027],{"nctId":24049,"briefTitle":24050,"status":139,"phases":29028,"primaryCompletion":17616,"completion":17616,"start":24052,"enrollment":13040,"conditions":29029,"interventions":29030},[],[24050],[24055,24022]]